aid,aidtype,aidname,aiddesc,aidsrcid,aidsrcname,aidextid,aidmdate,cids,sids,geneids,aidcategories,protacxns,depcatg,pmids,rnai,dois,ecs,repacxns,annotation
445,2,IkB Signaling,NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_NCGC Assay Overview:_|_Nuclear factor kappa-B (NF-kappa-B) plays an important role in normal B cell development and survival. Diffuse large B cell lymphoma (DLBCL) is the most commonly observed type of non-Hodgkin's lymphoma. Gene expression analysis has identified an activated B cell-like subtype of DLBCL (ABC-DLBCL) which expresses known NF-kappa-B target genes. In ABC-DLBCL cell lines this is due to high ,2,National Center for Advancing Translational Sciences (NCATS),ikb-signaling,20070412,"11,13,51,66,108,119,138,174,177,178,180,196,199,227,239,240,241,243,244,248,249,261,263,286,289,299,300,305,311,323,335,339,370,379,398,403,447,460,500,525,527,535,546,547,564,612,650,660,681,700,701,702,713,750,753,774,785,787,795,864,887,896,903,904,912,931,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1049,1052,1054,1057,1066,1102,1103,1123,1140,1150,1176,1183,1214,1309,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,1390,1433,1449,1456,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",4792,NULL,NP_065390,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P25963,NULL
901,2,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,"NCGC IMPase Assay Overview_|__|_Lithium has been widely used for the treatment of bipolar disorder. But lithium has a narrow therapeutic index and it can cause side effects such as thirst, weight gain, tremor, polyuria and memory problems. Although the mechanism for lithium action in treatment of bipolar disorder is still not fully understood, inhibition of inositol monophosphatase (IMPase) and the subsequent depletion of the inositol pool in living cells have been implicated as the primary therapeutic bene",2,National Center for Advancing Translational Sciences (NCATS),IMPE496,20100706,"119,138,178,199,239,248,249,253,275,286,289,304,305,366,408,471,525,535,546,547,564,610,636,650,681,698,750,774,785,787,846,847,864,896,903,912,932,938,1045,1046,1050,1054,1066,1072,1102,1103,1123,1150,1183,1214,1309,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,1390,1400,1433,1449,1456,1474,1518,1533,1574,1598,1607,1609,1645,1647,1649,1663,1669,1676,1678,1681,1694,1697,1701,1720,1725,1727,1730,1734,1738,1742,1745,1748,1756,1774,1775,1779,1793,1794,1795,1797,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",83523,NULL,P97697,Governmental Organizations|NIH Initiatives,"16864780,20161830",0,10.1073/pnas.0604348103|10.2174/1875397300801010070,"3.1.3.25,3.1.3.94",P97697,NULL
662,2,Cell signaling CRE-BLA (Fsk stim),"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLSCN Grant: 1X01MH079867-01_|_Assay Provider: Marshall W. Nirenberg, U.S. National heart lung & blood institute_|__|_NCGC Assay Overview_|__|_Memories persist for different lengths of time, from seconds or minutes to a lifetime. There are two kinds of memory: short-term memory (STM) and long-term memory (LTM). STM lasts for minutes to hours, which maybe mediated by modifications of molecules involved in syn",2,National Center for Advancing Translational Sciences (NCATS),FSK-CRE,20070412,"11,13,51,66,108,119,138,174,177,178,180,196,199,227,239,240,241,243,244,248,249,261,263,286,289,299,300,305,311,323,335,339,370,379,398,403,447,460,500,525,527,535,546,547,564,612,650,660,681,700,701,702,713,750,753,774,785,787,795,864,887,896,903,904,912,931,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1049,1052,1054,1057,1066,1102,1103,1123,1140,1150,1176,1183,1214,1309,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,1390,1433,1449,1456,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
880,2,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),"Assay Submitter: Siderovski, David P, University of North Carolina at Chapel Hill_|_Screening Center PI: Austin, C.P._|_Screening Center: NIH Chemical Genomics Center [NCGC]_|_NIH Grant: NS053754-01_|__|_G-protein-coupled receptors (GPCRs) are major targets for drug discovery. The regulator of G-protein signaling (RGS)-protein family has important roles in GPCR signal transduction. RGS proteins contain a conserved RGS-box, which is often accompanied by other signaling regulatory elements. RGS proteins accel",2,National Center for Advancing Translational Sciences (NCATS),RGSP682,20090805,"11,13,51,66,72,108,119,174,177,178,180,185,187,190,191,196,199,204,205,206,224,227,239,240,241,243,244,253,261,263,275,289,298,299,300,304,311,323,335,338,339,342,359,366,370,379,398,401,403,408,412,447,453,460,462,464,471,500,525,527,535,546,547,564,588,594,595,596,607,610,612,636,650,660,681,698,700,701,702,710,713,727,736,750,753,774,785,795,803,827,830,836,846,847,853,863,864,866,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,985,991,992,995,996,999,1001,1004,1017,1018,1023,1030,1046,10","842121,842122,842123,842124,842125,842126,842127,842128,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842166,842167,842168,842169,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842201,8","2770,6002",NULL,"AAC39835,NP_002060",Governmental Organizations|NIH Initiatives,"12120503,15313559,16864780,18537560",0,10.1016/s0076-6879(04)89004-9|10.1038/nrd747|10.1073/pnas.0604348103|10.2174/138620708784534770,NULL,"AAC39835,P63096",NULL
912,2,qHTS Assay for Anthrax Lethal Toxin Internalization,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLSCN Grant: 1 X01 MH082337-01_|_PI Name:  Dr. Thomas Bugge_|__|_NCGC Assay Overview:_|__|_Lethal factor (LF, 83 kDa), edema factor (98 kDa) and protective antigen (PA, 83 kDa) are lethal toxins produced by bacillus anthracis, a Gram-positive and spore-forming bacterium responsible for anthrax. While LF and EF contribute the cytotoxic activity of anthrax bacteria, PA is required for internalization of LF an ",2,National Center for Advancing Translational Sciences (NCATS),ANTX642,20100712,"11,13,51,66,108,119,138,174,177,178,180,196,199,227,239,240,241,243,244,248,249,261,263,286,289,299,300,305,311,323,335,339,370,379,398,403,447,460,500,525,527,535,546,547,564,612,650,660,681,700,701,702,713,750,753,774,785,787,795,864,887,896,903,904,912,931,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1049,1052,1054,1057,1066,1102,1103,1123,1140,1150,1176,1183,1214,1309,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,1390,1433,1449,1456,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,NP_652928,Governmental Organizations|NIH Initiatives,"16444249,16554829,16864780,19540764",0,10.1016/j.bmc.2009.05.054|10.1038/ng0206-137|10.1038/nmeth862|10.1073/pnas.0604348103,NULL,NP_652928,NULL
940,1,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: Dr. Raymond Dingledine, Emory University_|_MLSCN Grant: 5-U01NS058158-02_|__|_Assay Overview:_|_Injury of the brain is a major cause of death and morbidity after the prolonged seizures termed status epilepticus (SE). Studies in rodents have demonstrated that cyclooxygenase 2 (COX2) activation by ischemia and SE generally contributes to neuronal injury, but multiple downstream COX2 s",16,Emory University Molecular Libraries Screening Center,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,20081030,"51,72,108,119,178,190,191,204,253,289,298,323,338,339,366,370,401,471,500,525,535,546,547,564,588,607,650,681,727,774,785,803,827,830,846,864,896,903,904,914,932,936,938,992,1023,1046,1047,1052,1066,1123,1148,1150,1176,1201,1209,1216,1222,1228,1232,1233,1239,1242,1245,1256,1317,1318,1328,1329,1330,1340,1345,1359,1365,1367,1390,1400,1456,1474,1480,1482,1486,1487,1488,1489,1490,1492,1493,1539,1564,1598,1607,1609,1639,1641,1645,1646,1649,1676,1678,1683,1688,1720,1727,1730,1732,1738,1742,1752,1756,1774,1775,177","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",5732,NULL,NP_000947,Legacy Depositors|NIH Initiatives,"12821374,15191797",0,10.1016/j.expneurol.2004.03.019|10.1016/s0014-4886(03)00086-4,NULL,P43116,NULL
781,1,uHTS for 14-3-3/Bad interaction inhibitors,"Ultra-High Throughput Screening for 14-3-3/Bad interaction inhibitors_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: Dr. Haian Fu, Emory University_|_MLSCN Grant: 1R03MH76385-1_|__|_Assay Overview_|__|_14-3-3 proteins are a family of phosphoserine/threonine binding proteins, which consists of seven isoforms in mammalian cells (Fu et al, Ann Rev of Pharm & Tox  40:617-47; 2000).  These isoforms are encoded by genes in different",16,Emory University Molecular Libraries Screening Center,uHTS for 14-3-3/Bad interaction inhibitors,20070723,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",287022,NULL,NP_777239,Legacy Depositors|NIH Initiatives,"10836149,11723239,8460141",0,10.1073/pnas.90.6.2320|10.1124/mol.60.6.1325|10.1146/annurev.pharmtox.40.1.617,NULL,P63103,NULL
782,1,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,"Screening for Small Molecule Inhibitors of Eukaryotic Translation Initiation_|__|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: Dr. Jerry Pelletier, McGill UNIVERSITY_|_MLSCN Grant: 1 R03 MH081216-01_|__|_Title: uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation_|__|_Assay Overview_|_The recruitment of the 40S ribosomal subunit and associated factors (43S pre-initiation_|_complex) to the mRNA during transla",16,Emory University Molecular Libraries Screening Center,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,20110304,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8","1981,13684",NULL,"NP_004944,NP_031943",Legacy Depositors|NIH Initiatives,"10394359,10872469,9124320,9268293",0,10.1016/s1097-2765(01)80003-4|10.1074/jbc.272.35.21677|10.1146/annurev.biochem.68.1.913|10.1152/ajpcell.1997.272.2.c754,NULL,"P63073,Q04637",NULL
926,2,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|_MLSCN Grant: 1 X01 MH080680-01_|_PI Name: Dr. Marvin Gershengorn, NIH_|__|_NCGC Assay Overview:_|__|_Thyroid Stimulating Hormone Receptor _|__|_TSH is an alpha/beta heterodimeric glycoprotein hormone secreted from the anterior pituitary gland which belongs to the glycoprotein hormone family. The actions of TSH are mediated by a seven-transmembrane receptor, which upon TSH binding couples preferentially to the G",2,National Center for Advancing Translational Sciences (NCATS),TSHR742,20100706,"11,13,51,66,108,119,138,174,177,178,180,196,199,227,239,240,241,243,244,248,249,261,263,286,289,299,300,305,311,323,335,339,370,379,398,403,447,460,500,525,527,535,546,547,564,612,650,660,681,700,701,702,713,750,753,774,785,787,795,864,887,896,903,904,912,931,936,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1047,1049,1052,1054,1057,1066,1102,1103,1123,1140,1150,1176,1183,1199,1214,1309,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,1390,14","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",7253,NULL,AAR07906,Governmental Organizations|NIH Initiatives,"16488885,16864780,18216391,18669595,19592511,20427476",0,10.1073/pnas.0604348103|10.1073/pnas.0904506106|10.1074/jbc.c600014200|10.1177/1087057107313786|10.1210/en.2008-0836|10.1210/en.2010-0199,NULL,P16473,NULL
902,2,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|__|_MLSCN Grant: 1 X01 MH079844-01_|_Assay Submitter (PI): Dr. SUN, YI, University of Michigan_|__|_NCGC Assay Overview:_|__|_Synthetic Lethal Screen for Compounds to Kill Cancer Cells with p53 Mutation. _|__|_Tumor suppressor gene p53 serves as a major cellular barrier against tumorigenesis. It has been reported that p53 mutations occurs in half of all tumors, and the other half possess alterations in the p53 p",2,National Center for Advancing Translational Sciences (NCATS),P53T796.2,20100706,"11,13,51,66,108,119,138,174,177,178,180,185,190,191,196,199,204,224,227,239,240,241,243,244,248,249,253,261,263,275,286,289,298,299,300,304,305,311,323,335,339,370,379,398,401,403,408,447,460,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,713,727,736,750,753,774,785,787,795,827,830,836,846,847,853,864,887,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1047,1049,1050,1052,1054,1057,1064,1066,1072,1102,1103,1123,1140,1148,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",7157,Toxicity,NP_000537,Governmental Organizations|NIH Initiatives,"16652354,16864780,19679550",0,10.1002/mc.20231|10.1073/pnas.0604348103|10.1158/0008-5472.can-09-0891,NULL,P04637,NULL
924,2,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|__|_MLSCN Grant: 1 X01 MH079844-01_|_Assay Submitter (PI): Dr. SUN, YI, University of Michigan_|__|_NCGC Assay Overview:_|__|_Synthetic Lethal Screen for Compounds to Kill Cancer Cells with p53 Mutation. _|__|_Tumor suppressor gene p53 serves as a major cellular barrier against tumorigenesis. It has been reported that p53 mutations occurs in half of all tumors, and the other half possess alterations in the p53 p",2,National Center for Advancing Translational Sciences (NCATS),P53T796.1,20100706,"11,13,51,66,108,119,138,174,177,178,180,185,190,191,196,199,204,224,227,239,240,241,243,244,248,249,253,261,263,275,286,289,298,299,300,304,305,311,323,335,339,370,379,398,401,403,408,447,460,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,713,727,736,750,753,774,785,787,795,827,830,836,846,847,853,864,887,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1047,1049,1050,1052,1054,1057,1064,1066,1072,1102,1103,1123,1140,1148,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",7157,Toxicity,NP_000537,Governmental Organizations|NIH Initiatives,"16652354,16864780,19679550",0,10.1002/mc.20231|10.1073/pnas.0604348103|10.1158/0008-5472.can-09-0891,NULL,P04637,NULL
900,2,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLSCN Grant: 1 X01 MH078950-01_|_PI Name: Dr. James Wells, _|_Dr. Enrique Perez-Paya, Dr.Janice Williams, Dr. Dennis Wolan, Mr. Brandon Butler_|__|_NCGC Assay Overview:_|__|_The caspases (Cysteine Aspartyl Protease) comprise a related family of 14 dimeric proteases that are critical mediators of apoptosis (programmed cell death) and inflammation. The caspases represent an important class of drug targets for ",2,National Center for Advancing Translational Sciences (NCATS),CASP120,20100712,"11,13,51,66,108,119,138,174,177,178,180,185,190,191,196,199,204,224,227,239,240,241,243,244,248,249,253,261,263,275,286,289,298,299,300,304,305,311,323,335,339,370,379,398,401,403,408,447,460,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,713,727,736,750,753,774,785,787,795,827,830,836,846,847,853,864,887,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1047,1049,1050,1052,1054,1057,1064,1066,1072,1102,1103,1123,1140,1148,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",834,NULL,NP_150634,Governmental Organizations|NIH Initiatives,"15314233,16682620,16864780,20229566",0,10.1002/cmdc.200900531|10.1073/pnas.0404781101|10.1073/pnas.0602571103|10.1073/pnas.0604348103,3.4.22.36,P29466,NULL
889,2,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLSCN Grant: 1 X01 MH078950-01_|_PI Name: Dr. James Wells, _|_Dr. Enrique Perez-Paya, Dr.Janice Williams, Dr. Dennis Wolan, Mr. Brandon Butler_|__|_NCGC Assay Overview:_|__|_The caspases (Cysteine Aspartyl Protease) comprise a related family of 14 dimeric proteases that are critical mediators of apoptosis (programmed cell death) and inflammation. The caspases represent an important class of drug targets for ",2,National Center for Advancing Translational Sciences (NCATS),CASP513,20100712,"11,13,51,66,108,119,138,174,177,178,180,185,190,191,196,199,204,224,227,239,240,241,243,244,248,249,253,261,263,275,286,289,298,299,300,304,305,311,323,335,339,370,379,398,401,403,408,447,460,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,713,727,736,750,753,774,785,787,795,827,830,836,846,847,853,864,887,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1047,1049,1050,1052,1054,1057,1064,1066,1072,1102,1103,1123,1140,1148,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",840,NULL,P55210,Governmental Organizations|NIH Initiatives,"15314233,16682620,16864780",0,10.1073/pnas.0404781101|10.1073/pnas.0602571103|10.1073/pnas.0604348103,3.4.22.60,P55210,NULL
881,2,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),"Assay Overview:_|__|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|_MLSCN Grant: MH081283-01A1_|_PI Name: Holman, T.R., University of California, Santa Cruz_|__|_Human lipoxygenase 15hLO-2 is a member of the closely related lipoxygenase family of enzymes which catalyze the site-specific oxidation of arachidonic acid to various hormone precursor molecules and as such is a candidate for drug development in a variety of disease areas, such as cancer and inflam",2,National Center for Advancing Translational Sciences (NCATS),LPOX575,20110304,"11,13,51,66,108,119,138,174,177,178,180,185,190,191,196,199,204,206,224,227,239,240,241,243,244,248,249,253,261,263,275,286,289,298,299,300,304,305,311,323,335,338,339,342,366,370,379,398,401,403,408,447,453,460,464,471,500,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,710,713,727,736,750,753,774,785,787,795,827,830,836,846,847,853,864,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,999,1004,1017,1023,1030,1045,1046,1049,1050,1052,1054,1057,1064,1066","842121,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",247,NULL,O15296,Governmental Organizations|NIH Initiatives,"16500106,16864780,17826100,17869117",0,10.1016/j.bmc.2006.01.057|10.1016/j.bmc.2007.07.036|10.1016/j.bmc.2007.08.015|10.1073/pnas.0604348103,"1.13.11.-,1.13.11.33",O15296,NULL
894,2,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),"Human 15-Hydroxyprostaglandin dehydrogenase (HPGD) catalyzes the inactivation of prostaglandin E2, and plays a major role in cancer biology by antagonizing the oncogenic potential of cyclooxygenase type 2 (COX2). Assays are available, based on absorbance/fluorescence increase of NADH with the substrate 15-OH prostaglandin E2.  _|__|_References _|_1. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D, Markowitz SD. 1",2,National Center for Advancing Translational Sciences (NCATS),HPGD335,20100301,"11,13,51,66,108,119,174,177,178,180,185,190,191,196,199,204,206,224,227,239,240,241,243,244,253,261,263,275,289,298,299,300,304,311,323,335,338,339,342,366,370,379,398,401,403,408,447,453,460,464,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,710,713,727,736,750,753,774,785,795,803,827,830,836,846,847,853,864,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,999,1004,1017,1023,1030,1046,1047,1049,1050,1052,1054,1057,1064,1066,1072,1080,1102,","842121,842122,842123,842124,842125,842126,842127,842128,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842166,842167,842168,842169,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842201,8",3248,NULL,NP_000851,Governmental Organizations|NIH Initiatives,"15574495,16864780,16880406,17575121",0,10.1073/pnas.0406142101|10.1073/pnas.0603235103|10.1073/pnas.0604348103|10.1158/0008-5472.can-06-2287,1.1.1.141,P15428,NULL
995,2,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,"_|_qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay _|__|_NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|__|_MLSCN Grant: 1X01MH082406-01_|_Assay Submitter (PI): Dr. Wei Zheng, NCGC/NIH_|__|_NCGC Assay Overview:_|__|_The Ras/extracellular-signal-regulated kinase (ERK) mitogen activated protein (MAP) kinase signaling pathway  (ERK1/2 cascade) plays is a  key role in transmitting  signals from the cell surface to the n",2,National Center for Advancing Translational Sciences (NCATS),ERKS579,20100706,"11,13,51,66,108,119,138,174,177,178,180,185,190,191,196,199,204,224,227,239,240,241,243,244,248,249,253,261,263,275,286,289,298,299,300,304,305,311,323,335,339,370,379,398,401,403,408,447,460,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,713,727,736,750,753,774,785,787,795,827,830,836,846,847,853,864,887,896,903,904,912,914,931,932,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1049,1050,1052,1054,1057,1064,1066,1072,1102,1103,1123,1140,1148,1150,1176","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",5594,NULL,NP_002736,Governmental Organizations|NIH Initiatives,"11242034,15573115,16864780,8388132",0,10.1016/0968-0004(93)90019-j|10.1038/35065000|10.1038/nrc1503|10.1073/pnas.0604348103,2.7.11.24,P28482,NULL
938,2,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|_MLSCN Grant: 1 X01 MH080680-01_|_PI Name: Dr. Marvin Gershengorn_|__|_NCGC Assay Overview:_|__|_This cell based assay utilized a cyclic nucleotide gated ion channel (CNG) as a biosensor for cAMP induction. HEK 293 cells stably expressing the modified CNG were purchased from BD biosciences (http://www.atto.com/products/actone/features_benefits.shtml) . Stimulation of cAMP production causes the CNG to open and su,2,National Center for Advancing Translational Sciences (NCATS),TSHR742.2,20100706,"11,13,51,66,108,119,138,174,177,178,180,196,199,227,239,240,241,243,244,248,249,261,263,286,289,299,300,305,311,323,335,339,370,379,398,403,447,460,500,525,527,535,546,547,564,612,650,660,681,700,701,702,713,750,753,774,785,787,795,864,887,896,903,904,912,931,936,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1047,1049,1052,1054,1057,1066,1102,1103,1123,1140,1150,1176,1183,1199,1214,1309,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,1390,14","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",7253,NULL,AAR07906,Governmental Organizations|NIH Initiatives,"16488885,16864780,18216391,18669595,19592511,20427476",0,10.1073/pnas.0604348103|10.1073/pnas.0904506106|10.1074/jbc.c600014200|10.1177/1087057107313786|10.1210/en.2008-0836|10.1210/en.2010-0199,NULL,P16473,NULL
878,1,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,"Hydrogen peroxide (H2O2) can modulate (activate or inhibit) the activity of a variety of proteins including protein kinases, protein phosphatases, transcription factors, phospholipases, ion channels and G proteins.  H2O2 is capable of oxidizing the cysteine residues of proteins that may be crucial for their catalytic and/or structural function. Many proteins, including a significant number of the targets screened by the MLSCN, contain an active site cysteine that is required for biological activity e.g. the",9,University of Pittsburgh Molecular Library Screening Center,NIH Compound Library Profiling: Redox Cycling H2O2 Generation,20080225,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,32","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",NULL,NULL,NULL,NIH Initiatives,14711389,0,10.1177/1087057103258285,NULL,NULL,NULL
797,1,Fluorescence polarization assay for PKD inhibitors,"The PKD HTS assay was developed and run at the University of Pittsburgh Molecular Screening Center (PMLSC) as part of the Molecular Library Screening Center Network (MLSCN)(1R03DA24898-01). _|__|_Protein kinase D (PKD) is a novel family of serine/threonine kinases targeted by diacylglycerol. It regulates many fundamental cell functions including cell proliferation, survival, differentiation and protein trafficking, and plays important roles in pathological conditions such as cardiac hypertrophy and cancer i",9,University of Pittsburgh Molecular Library Screening Center,1R03DA024898-01,20070910,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,32","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",5587,NULL,NP_002733,NIH Initiatives,NULL,0,NULL,2.7.11.13,Q15139,NULL
898,1,YopH  HTS,"Grant number: none._|__|_Yersinia pestis is the causal agent of the bubonic plague and, although modern antibiotics are extremely effective against the malady, the plague remains a threat in many areas in the world.  Outbreaks of hundreds of cases still occur in Asia, Africa and South America and, in the United States cases are reported sporadically, mainly because of people handling infected animals or by being bitten by infected wild rodent fleas (http://www.cdc.gov).  YopH (Yersinia outer protein H) is a",9,University of Pittsburgh Molecular Library Screening Center,YopH HTS,20071218,"119,253,323,338,366,525,546,774,803,932,936,938,1046,1047,1150,1318,1329,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1833,1893,1922,1967,1985,1986,2000,2007,2015,2082,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2708,2720,2727,2732,2733,2754,2756,2762,2771,2788,2804,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,3279,3295,3308,3331,3332,3333,3334,3335,3339,3366,3371,3373,3374,3385","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",1239205,NULL,NP_783699,NIH Initiatives,"15847602,9077521",0,10.1146/annurev.micro.59.030804.121320|10.1172/jci119270,NULL,NP_783699,NULL
893,2,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4","Assay Overview:_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|_Structural Genomics Consortium [SGC]_|_Grant number: None_|__|_HADH2: Hydroxyacyl-Coenzyme A dehydrogenase, type II, was supplied by researchers at the Structural Genomics Consortium, Oxford University lab (PI Udo Oppermann). The mitochondrial enzyme 17-hydroxysteroid dehydrogenase type 10 (HSD17-10) previously classified as type II hydroxyacyl-CoA dehydrogenase (HADH2) catalyzes the NAD+ depe",2,National Center for Advancing Translational Sciences (NCATS),HSDB130,20100706,"11,13,51,66,108,119,138,174,177,178,180,185,190,191,196,199,204,224,227,239,240,241,243,244,248,249,253,261,263,275,286,289,298,299,300,304,305,311,323,335,339,370,379,398,401,403,408,447,460,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,713,727,736,750,753,774,785,787,795,827,830,836,846,847,853,864,887,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1047,1049,1050,1052,1054,1057,1064,1066,1072,1102,1103,1123,1140,1148,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,"2O23_A,2O23_B",Governmental Organizations|NIH Initiatives,"10371197,12696021,12917011,16864780,9338779",0,10.1016/s0014-5793(99)00586-4|10.1038/39522|10.1042/bj20030877|10.1073/pnas.0604348103|10.1086/375116,NULL,2O23_A,NULL
923,2,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLSCN Grant: 1 X01 MH078950-01_|_PI Name: Dr. James Wells, _|_Dr. Enrique Perez-Paya, Dr.Janice Williams, Dr. Dennis Wolan, Mr. Brandon Butler_|__|_NCGC Assay Overview:_|__|_The rate of false hits is dramatically reduced by the qHTS approach (Inglese et al, PNAS, 103, 1147 (2006)) as spurious high- or low-response wells are quickly revealed when plotted in the context of concentration response. Occasionally,",2,National Center for Advancing Translational Sciences (NCATS),CASP120.2,20100712,"11,13,51,66,108,119,138,174,177,178,180,185,190,191,196,199,204,224,227,239,240,241,243,244,248,249,253,261,263,275,286,289,298,299,300,304,305,311,323,335,339,370,379,398,401,403,408,447,460,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,713,727,736,750,753,774,785,787,795,827,830,836,846,847,853,864,887,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1047,1049,1050,1052,1054,1057,1064,1066,1072,1102,1103,1123,1140,1148,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"15314233,16682620,16864780",0,10.1073/pnas.0404781101|10.1073/pnas.0602571103|10.1073/pnas.0604348103,NULL,NULL,NULL
886,2,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)","Assay Overview:_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|_Structural Genomics Consortium [SGC]_|_Grant Number: None_|__|__|_HADH2: Hydroxyacyl-Coenzyme A dehydrogenase, type II, was supplied by researchers at the Structural Genomics Consortium, Oxford University lab (PI Udo Oppermann). The mitochondrial enzyme 17-hydroxysteroid dehydrogenase type 10 (HSD17-10) previously classified as type II hydroxyacyl-CoA dehydrogenase (HADH2) catalyzes the NAD+ d",2,National Center for Advancing Translational Sciences (NCATS),HADH560,20100712,"11,13,51,66,108,119,138,174,177,178,180,196,199,227,239,240,241,243,244,248,249,261,263,275,286,289,299,300,305,311,323,335,339,370,379,398,403,447,460,500,525,527,535,546,547,564,612,650,660,681,700,701,702,713,750,753,774,785,787,795,864,887,896,903,904,912,931,936,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1047,1049,1052,1054,1057,1066,1102,1103,1123,1140,1150,1176,1183,1199,1214,1309,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,139","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,"2O23_A,2O23_B",Governmental Organizations|NIH Initiatives,16864780,0,10.1073/pnas.0604348103,NULL,2O23_A,NULL
887,2,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),"Assay Overview:_|__|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|_MLSCN Grant: MH081283-01A1_|_PI Name: Holman, T.R., University of California, Santa Cruz_|__|_Human lipoxygenase 15hLO-1 is a member of the closely related lipoxygenase family of enzymes which catalyze the site-specific oxidation of arachidonic acid to various hormone precursor molecules and as such is a candidate for drug development in a variety of disease areas, such as cancer and inflam",2,National Center for Advancing Translational Sciences (NCATS),LPOX955,20100706,"11,13,51,66,108,119,138,174,177,178,180,185,190,191,196,199,204,224,227,239,240,241,243,244,248,249,253,261,263,275,286,289,298,299,300,304,305,311,323,335,339,370,379,398,401,403,408,447,460,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,713,727,736,750,753,774,785,787,795,827,830,836,846,847,853,864,887,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1047,1049,1050,1052,1054,1057,1064,1066,1072,1102,1103,1123,1140,1148,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",246,NULL,AAC52118,Governmental Organizations|NIH Initiatives,"16500106,16864780,17826100,17869117",0,10.1016/j.bmc.2006.01.057|10.1016/j.bmc.2007.07.036|10.1016/j.bmc.2007.08.015|10.1073/pnas.0604348103,NULL,AAC52118,NULL
584,2,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLSCN Grant: 1 X01 MH079825-01_|_PI Name: Shoichet, Brian K._|__|_NCGC Assay Overview:_|_This aggregation profiling approach exploits the sensitivity of aggregate formation to detergent. Inhibition of b-lactamase is measured in the presence and absence of 0.01% Triton X-100. This particular assay had the prescence of 0.01% Triton X-100. See Pubchem assay ""Promiscuous and Specific Inhibitors of AmpC Beta-Lact",2,National Center for Advancing Translational Sciences (NCATS),AMPC374,20071101,"11,13,51,66,108,119,138,174,177,178,180,196,199,227,239,240,241,243,244,248,249,261,263,286,289,299,300,305,311,323,335,339,370,379,398,403,447,460,500,525,527,535,546,547,564,612,650,660,681,700,701,702,713,750,753,774,785,787,795,864,887,896,903,904,912,931,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1049,1052,1054,1057,1066,1102,1103,1123,1140,1150,1176,1183,1214,1309,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,1390,1433,1449,1456,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,2HDS_A,Governmental Organizations|NIH Initiatives,"13678405,16408018,16570910,17149857,17191086",0,10.1021/jm030266r|10.1021/jm060029z|10.1021/jm061103g|10.1038/nchembio718|10.1038/nprot.2006.77,NULL,1C3B_A,NULL
892,2,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),"Assay Overview:_|__|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|_MLSCN Grant: MH081227-01_|_PI Name: Natarajan, Amarnath; University of Texas_|_ _|_Inhibitors of the BRCT:pBACH1 interaction should prove useful in studies of BRCA1's tumor suppression role and to potentially sensitive tumors to chemotherapeutic agents. A complex of BRCT (C-terminal portion of BRCA1, MW ~35 kDa, His-tagged) and fluorescently labeled pBACH1 phosphorylated 10 aa peptide fragm",2,National Center for Advancing Translational Sciences (NCATS),BRCA738,20100712,"11,13,51,66,108,119,138,174,177,178,180,185,190,191,196,199,204,224,227,239,240,241,243,244,248,249,253,261,263,275,286,289,298,299,300,304,305,311,323,335,339,370,379,398,401,403,408,447,460,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,713,727,736,750,753,774,785,787,795,827,830,836,846,847,853,864,887,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1047,1049,1050,1052,1054,1057,1064,1066,1072,1102,1103,1123,1140,1148,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,1OQA_A,Governmental Organizations|NIH Initiatives,"16500609,16864780,17685618,18158907",0,10.1016/j.ab.2006.01.025|10.1016/j.ab.2007.11.039|10.1021/ja0739178|10.1073/pnas.0604348103,NULL,1OQA_A,NULL
875,2,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|_MLSCN Grant: MH081227-01_|_PI Name: Natarajan, Amarnath; University of Texas_|_ _|_Inhibitors of the BRCT:pBACH1 interaction should prove useful in studies of BRCA1's tumor suppression role and to potentially sensitive tumors to chemotherapeutic agents. A complex of BRCT (C-terminal portion of BRCA1, MW ~35 kDa, His-tagged) and fluorescently labeled pBACH1 phosphorylated 10 aa peptide fragment of BACH1, a helic",2,National Center for Advancing Translational Sciences (NCATS),BRCA737,20100712,"11,13,51,66,108,119,138,174,177,178,180,185,190,191,196,199,204,224,227,239,240,241,243,244,248,249,253,261,263,275,286,289,298,299,300,304,305,311,323,335,339,370,379,398,401,403,408,447,460,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,713,727,736,750,753,774,785,787,795,827,830,836,846,847,853,864,887,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1047,1049,1050,1052,1054,1057,1064,1066,1072,1102,1103,1123,1140,1148,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,1OQA_A,Governmental Organizations|NIH Initiatives,"16500609,16864780,17685618,18158907",0,10.1016/j.ab.2006.01.025|10.1016/j.ab.2007.11.039|10.1021/ja0739178|10.1073/pnas.0604348103,NULL,1OQA_A,NULL
817,0,Identification and characterization of compounds for addressing human bone marrow failure,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: Dr. Paul De Figueiredo, Texas A&M University System_|_MLSCN Grant: 1 X01 MH079865-01 _|__|_Assay Overview:_|_Shwachman-Diamond Syndrome (SDS) is an autosomal recessive genetic syndrome that results in hematopoietic defects as well as impaired pancreatic function and skeletal development (1, 2).  Presently, therapeutic options are limited to supportive care or bone marrow transplant,",16,Emory University Molecular Libraries Screening Center,Identification and characterization of compounds for addressing human bone marrow failure,20071003,"119,253,323,338,366,525,546,774,803,932,936,938,1046,1047,1150,1318,1329,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1833,1893,1922,1967,1985,1986,2000,2007,2015,2082,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2708,2720,2727,2732,2733,2754,2756,2762,2771,2788,2804,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,3279,3295,3308,3331,3332,3333,3334,3335,3339,3366,3371,3373,3374,3385","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",NULL,NULL,CAA97545,Legacy Depositors|NIH Initiatives,"14158482,14221166,17353896,17475909",0,10.1016/s0022-3476(64)80150-5|10.1038/ng1994|10.1111/j.1651-2227.1964.tb07237.x|10.1182/blood-2007-02-075184,NULL,CAA97545,NULL
800,1,Factor XIIa 1536 HTS,"Molecular Library Screening Center Network (MLSCN)_|_Penn Center for Molecular Discovery (PCMD)_|_Assay Provider:  Scott L. Diamond, University of Pennsylvania  _|_MLSCN Grant:  X01-MH076406-01_|__|_Target_|__|_Factor XII (FXII) is a 80 kDa zymogen found at a concentration of 0.375 uM in plasma, and upon activation by kallikrein at R353, a disulfide-linked two chain molecule called factor XIIa alpha (FXIIa) is generated.  FXIIa is also capable of autoactivation by binding to negatively charged surfaces (1).",10,PCMD,FXIIA_1536,20110304,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2181,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2866,2890,2904,2950,2955,2972,3003,3012,3019,3025,3","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",2161,NULL,P00748,Legacy Depositors|NIH Initiatives,"14529397,14806439,15124772,16009717,1652157,2019570,2578463,3278905,3639874,4118185,4473201,501286,632748,6782101,690132,8488686,893417,9371304,947956",0,10.1021/bi00719a006|10.1038/167233a0|10.1084/jem.147.3.719|10.1084/jem.150.5.1122|10.1084/jem.20050664|10.1111/j.1432-1033.1988.tb13849.x|10.1111/j.1749-6632.1972.tb16323.x|10.1126/science.1652157|10.1172/jci108361|10.1191/1352458504ms999xx|10.2174/1381612033453938,3.4.21.38,P00748,NULL
798,1,Factor XIa 1536 HTS,"Molecular Library Screening Center Network (MLSCN)_|_Penn Center for Molecular Discovery (PCMD)_|_Assay Provider:  Scott L. Diamond, University of Pennsylvania_|_MLSCN Grant:  X01-MH076406-01_|__|_Target_|__|_Factor XI (FXI) circulates as a complex with high molecular weight kininogen (HK) in the plasma at a concentration of 5 ug/ml (equivalent to 31.3 nM, dimeric concentration) as a homodimeric glycosylated blood plasma zymogen of approximately 160 kDa, containing monomeric subunits of 80 kDa each (1).  Th",10,PCMD,FXIA_1536,20081007,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2181,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2866,2890,2904,2950,2955,2972,3003,3012,3019,3025,3","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",NULL,NULL,AAA51985,Legacy Depositors|NIH Initiatives,"11159184,12689935,14529397,14806439,15733058,1652157,16880142,1998667,2019570,3278905,3636155,4118185,4473201,6604052,6782101,690132,876353,893417",0,10.1016/s0002-9440(10)63989-2|10.1021/bi00222a008|10.1021/bi00357a018|10.1021/bi00719a006|10.1038/167233a0|10.1038/266729a0|10.1111/j.1432-1033.1988.tb13849.x|10.1111/j.1538-7836.2005.01236.x|10.1111/j.1749-6632.1972.tb16323.x|10.1126/science.1652157|10.1182/blood-2003-01-0324|10.1309/qc259f09unmkvp0r|10.2174/1381612033453938,NULL,AAA51985,NULL
927,2,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLSCN Grant: XO1-MH079852-01_|_PI Name: Nicholson, Ben. Progenra Inc, Malvern, PA_|__|_NCGC Assay Overview:_|__|_Homeostasis of cellular proteins is maintained through a combination of synthesis and degradation. The pathway that accounts for the majority of protein degradation is the ubiquitin-proteasomal pathway. Ubiquitin (Ub) is highly conserved in all cells and the generation of a multi-Ub chain typicall",2,National Center for Advancing Translational Sciences (NCATS),UBPA427,20080603,"119,138,178,185,190,191,199,204,224,248,249,253,275,286,289,298,305,323,370,401,408,525,535,546,547,564,588,596,607,636,650,681,727,736,774,785,787,827,830,836,846,853,864,896,903,904,914,932,938,992,1045,1046,1054,1064,1066,1072,1102,1103,1123,1148,1150,1176,1203,1249,1256,1287,1302,1309,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1354,1355,1359,1365,1366,1367,1390,1433,1456,1474,1480,1482,1486,1487,1488,1489,1490,1493,1518,1574,1598,1607,1609,1639,1645,1646,1647,1649,1663,1669,1676,1678,1681,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842132,842133,842134,842135,842136,842138,842139,842140,842141,842142,842143,842144,842145,842148,842150,842151,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842201,842202,842203,8",9099,NULL,NP_004196,Governmental Organizations|NIH Initiatives,"15050917,15571815,16325574,16951176,17290220,17381419",0,10.1016/j.bbamcr.2004.10.003|10.1016/j.cell.2005.11.007|10.1016/s1535-6108(04)00055-8|10.1038/sj.emboj.7601567|10.1158/0008-5472.can-06-1374|10.2217/14796694.3.2.191,3.4.19.12,O75604,NULL
873,1,Kallikrein 5 1536 HTS,"Molecular Library Screening Center Network (MLSCN)_|_Penn Center for Molecular Discovery (PCMD)_|_Assay Provider:  Scott L. Diamond, University of Pennsylvania_|_MLSCN Grant:  X01-MH076406-01_|__|_Target_|__|_Human kallikrein 5 (hK5) is a member of the human tissue kallikrein family, which contains 15 kallikrein-like serine proteases (1).  It is synthesized as a 293 amino acid zymogen, and loses a 29 amino acid signal peptide upon secretion, followed by cleavage at the Arg66-Ile67 bond, which releases a 37 ",10,PCMD,hK5_1536,20081119,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2181,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2866,2890,2904,2950,2955,2972,3003,3012,3019,3025,3","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",25818,NULL,NP_036559,Legacy Depositors|NIH Initiatives,"10514489,11067830,12873991,15004490,15675955,15713679,16517595,16740631,17676051,7537777",0,10.1038/nm1616|10.1074/jbc.274.42.30033|10.1074/jbc.m408132200|10.1074/jbc.m600326200|10.1074/jbc.m602372200|10.1111/1523-1747.ep12607007|10.1111/j.0022-202x.2004.23583.x|10.1159/000076462,3.4.21.-,Q9Y337,NULL
411,2,qHTS Assay for Inhibitors of Firefly Luciferase,"To aid in the interpretation of high-throughput screening (HTS) results derived from luciferase-based assays, we used quantitative HTS, an approach that defines the concentration-response behavior of each library sample, to profile the ATP-dependent luciferase from Photinus pyralis against more than 72 000 samples._|__|_Luciferase (PKLight, Cambrex Corporation) was assayed for its ability to generate light using ATP and luciferin as substrates.  The ATP concentration in the assay (10 uM) was within the line",2,National Center for Advancing Translational Sciences (NCATS),luciferase_pklight,20100303,"51,108,119,138,178,199,239,248,249,286,289,305,339,500,525,535,546,547,564,650,681,750,774,785,787,896,903,912,938,1023,1045,1046,1052,1054,1066,1102,1103,1123,1150,1214,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,1390,1433,1449,1456,1474,1518,1533,1574,1598,1607,1609,1645,1647,1649,1663,1669,1676,1678,1681,1688,1701,1720,1725,1727,1730,1734,1738,1742,1745,1748,1756,1774,1775,1779,1780,1793,1794,1795,1797,1809,1820,1826,1832,1833,1845,1853,1858,1864,1868,18","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,AAA29795,Governmental Organizations|NIH Initiatives,"16864780,18363348,18590332,19208811,19215089",0,10.1021/cb8000793|10.1021/jm701302v|10.1021/jm8014525|10.1073/pnas.0604348103|10.1073/pnas.0813345106,NULL,P08659,NULL
595,2,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|__|_NCGC Assay Overview:_|_Hsp90 (heat shock protein 90) is the essential molecular chaperone and it accounts for 1-2% of all cytosolic proteins and is critical for the activity of diverse cellular proteins that are involved in a variety of cellular processes, including development, cell cycle, and steroid hormone signaling. Its client proteins include signaling kinases such as IGF1R, Akt, v-Src, Raf-1; regulato",2,National Center for Advancing Translational Sciences (NCATS),HSPT775,20071019,"11,13,51,66,108,119,138,174,177,178,180,196,199,227,239,240,241,243,244,248,249,261,263,286,289,299,300,305,311,323,335,339,370,379,398,403,447,460,500,525,527,535,546,547,564,612,650,660,681,700,701,702,713,750,753,774,785,787,795,864,887,896,903,904,912,931,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1049,1052,1054,1057,1066,1102,1103,1123,1140,1150,1176,1183,1214,1309,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,1390,1433,1449,1456,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
871,1,Primary cell-based high throughput screening assay to measure STAT3 activation,"Source (MLSCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider:  David Frank, Dana Farber Cancer Institute_|_Network: Molecular Library Screening Center Network (MLSCN)_|_Grant Proposal Number: 1 X01 MH079826-01 _|_Grant Proposal PI: David Frank_|__|_External Assay ID:  STAT3_POT_LUC_1536_%ACT_|__|_Name:_|_Primary cell-based high throughput screening assay to measure STAT3 activation._|__|_Description:_|__|_T",5,The Scripps Research Institute Molecular Screening Center,STAT3_POT_LUC_1536_%ACT,20080911,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,3279,3295,33","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",6774,Cell-based,AAK17196,NIH Initiatives,"12209125,12796382,12842895,15958548,17502367,17908954,9794394",0,10.1038/nrm909|10.1074/jbc.m301629200|10.1074/jbc.r700016200|10.1158/0008-5472.can-04-4281|10.1158/1078-0432.ccr-06-2491,NULL,AAK17196,NULL
861,1,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,"Source (MLSCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Center Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Peter Tobias, TSRI_|_Network: Molecular Library Screening Center Network (MLSCN)_|_Grant Proposal Number: 1 X01 MH079857-01_|_Grant Proposal PI: Peter Tobias_|__|_External Assay ID: TLR4-MyD88 _INH_ BLA_1536_%INH_|__|_Name:_|__|_Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding_|__|_Description:_|__|_In athero",5,The Scripps Research Institute Molecular Screening Center,TLR4-MyD88 _INH_ BLA_1536_%INH,20071121,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,32","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",NULL,Cell-based,CAH72619,NIH Initiatives,"10075645,17275323",0,10.1016/j.smim.2006.12.004|10.1074/jbc.274.12.7611,NULL,CAH72619,NULL
925,2,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|_MLSCN Grant: 1 X01 MH080684-01_|_PI Name:  Dr. Ryszard Kole_|__|_NCGC Assay Overview:_|__|_Modulation of Alternative Splicing as Therapy_|__|_Abnormal splicing is associated with a number of diseases, including cancer and genetic diseases such as cystic fibrosis, muscular dystrophy and beta-thalassemia. Alteration of disease associated splicing patterns provides a promising target for treatment. Work in the Kol",2,National Center for Advancing Translational Sciences (NCATS),THAL594,20100706,"11,13,51,66,108,119,138,174,177,178,180,196,199,227,240,241,243,244,248,249,261,263,286,289,299,300,305,311,323,335,339,370,379,398,403,447,460,500,525,527,535,546,547,564,612,650,660,681,700,701,702,713,753,774,785,787,795,864,887,896,903,904,931,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1049,1052,1054,1057,1066,1102,1103,1123,1140,1150,1176,1183,1214,1309,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1354,1355,1359,1365,1366,1367,1390,1433,1456,1474,1483,1486,1491,1493,151","842123,842124,842125,842128,842131,842133,842134,842137,842138,842146,842147,842149,842150,842151,842152,842154,842158,842159,842161,842162,842166,842171,842172,842175,842178,842179,842180,842182,842184,842189,842190,842191,842192,842193,842194,842195,842196,842199,842200,842202,842203,842205,842206,842208,842212,842217,842219,842221,842224,842226,842227,842228,842231,842234,842235,842236,842237,842239,842241,842242,842245,842246,842249,842251,842252,842253,842256,842258,842259,842260,842262,842263,842264,8",3043,NULL,NP_000509,Governmental Organizations|NIH Initiatives,"12498768,16864780",0,10.1006/mthe.2002.0805|10.1073/pnas.0604348103,NULL,P68871,NULL
920,1,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Source (MLSCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: David Frank _|_Network: Molecular Library Screening Center Network (MLSCN)_|_Grant Proposal Number: 1 X01 MH079826-01 _|_Grant Proposal PI: David Frank_|__|_External Assay ID:  STAT1_INH_LUMI_1536_%INH   _|__|_Name: Primary cell-based high throughput screening assay to identify inhibitors of STAT1_|__|_Description:_|__|_The signal transducer and ,5,The Scripps Research Institute Molecular Screening Center,STAT1_INH_LUMI_1536_%INH,20080911,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,32","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",6772,Cell-based,NP_009330,NIH Initiatives,"12209125,12796382,15958548,17283162,17502367,17908954,8676625",0,10.1016/s0140-6736(96)91681-5|10.1038/nrm909|10.1074/jbc.r700016200|10.1158/0008-5472.can-04-4281|10.1158/0008-5472.can-06-2439|10.1158/1078-0432.ccr-06-2491,NULL,P42224,NULL
932,1,Primary cell-based high throughput screening assay to measure STAT1 activation,Source (MLSCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: David Frank_|_Network: Molecular Library Screening Center Network (MLSCN)_|_Grant Proposal Number: 1 X01 MH079826-01 _|_Grant Proposal PI: David Frank_|_External Assay ID: STAT1_POT_LUMI_1536_%ACT_|__|_Name: Primary cell-based high throughput screening assay to measure STAT1 activation._|__|_Description:_|__|_The signal transducer and activator o,5,The Scripps Research Institute Molecular Screening Center,STAT1_POT_LUMI_1536_%ACT,20110926,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,32","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",6772,Cell-based,NP_009330,NIH Initiatives,"12209125,12796382,15958548,17283162,17502367,17908954,8676625",0,10.1016/s0140-6736(96)91681-5|10.1038/nrm909|10.1074/jbc.r700016200|10.1158/0008-5472.can-04-4281|10.1158/0008-5472.can-06-2439|10.1158/1078-0432.ccr-06-2491,NULL,P42224,NULL
731,1,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),"Source (MLSCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Center Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Scripps Florida_|_Network: Molecular Library Screening Center Network (MLSCN)_|_Proposal Number: 1 X01 MH079861-01_|_PI: Patrick Griffin_|__|_External Assay ID: PPARgSRC3_AG_TRFRET_1536_%ACT_|__|_Name:_|_Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome prol",5,The Scripps Research Institute Molecular Screening Center,PPARgSRC3_AG_TRFRET_1536_%ACT,20100616,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2187,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3016,3019,3025,30","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8","5468,8202",Biochemical,"NP_056953,NP_858045",NIH Initiatives,"11729302,12169646,15057233,15860371,16511591,9171241,9808609",0,10.1016/j.tips.2005.03.003|10.1038/nm1025|10.1126/science.294.5548.1866|10.1161/01.cir.98.19.2088|10.1161/01.res.0000029080.15742.85|10.1172/jci27955|10.1210/mend.11.6.0007,2.3.1.48,"P37231,Q9Y6Q9",NULL
904,2,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|__|_MLSCN Grant: 1 X01 MH079844-01_|_Assay Submitter (PI): Dr. SUN, YI, University of Michigan_|__|_NCGC Assay Overview:_|__|_Synthetic Lethal Screen for Compounds to Kill Cancer Cells with p53 Mutation. _|__|_Tumor suppressor gene p53 serves as a major cellular barrier against tumorigenesis. It has been reported that p53 mutations occurs in half of all tumors, and the other half possess alterations in the p53 p",2,National Center for Advancing Translational Sciences (NCATS),P53T796.4,20100706,"5155,7337,10816,12109,14399,16175,16484,21924,22860,26629,27211,27775,30897,31840,33462,38661,39685,42607,55656,57491,60290,66532,67869,70557,71602,73239,78251,79437,79878,80185,83258,85814,87418,88976,89047,91401,94777,95028,95139,95446,97806,98466,98771,100319,103958,104452,111488,115936,118752,121025,121034,123450,127053,127522,130606,134450,137903,139410,142164,145454,149270,151814,152215,154096,167520,176015,181679,200946,202725,205085,205489,207452,209293,212810,213226,213321,215605,219761,221091,2217","842122,842249,842251,842280,842298,842322,842323,842325,842369,842380,842414,842426,842442,842463,842471,842475,842490,842529,842568,842571,842585,842626,842692,842702,842719,842725,842770,842773,842826,842844,842859,842864,842966,843010,843033,843042,843070,843079,843085,843164,843193,843230,843274,843307,843336,843407,843429,843432,843437,843442,843444,843506,843554,843586,843589,843614,843623,843634,843651,843652,843667,843711,843712,843736,843751,843759,843763,843773,843851,843853,843870,843874,843881,8",7157,Toxicity,NP_000537,Governmental Organizations|NIH Initiatives,"16652354,16864780,19679550",0,10.1002/mc.20231|10.1073/pnas.0604348103|10.1158/0008-5472.can-09-0891,NULL,P04637,NULL
526,2,Ubiquitin-GFP Assay,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|__|_NCGC Assay Overview:_|_The ubiquitin-proteasome pathway is present within all eukaryotic cells and plays roles in normal cellular functions and disease-related dysfunction. Proteins are tagged with a poly-ubiquitin chain that targets them for the proteasome, a multimeric protease, that degrades the protein into peptides and free ubiquitin. The proteasome has a key role in regulating cell cycle and growth and",2,National Center for Advancing Translational Sciences (NCATS),Ubiquitin-GFP Assay,20061109,"51,108,119,138,178,199,239,248,249,286,289,305,339,500,525,535,546,547,564,650,681,750,774,785,787,896,903,912,938,1023,1045,1046,1052,1054,1066,1102,1103,1123,1150,1214,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,1390,1433,1449,1456,1474,1518,1533,1574,1598,1607,1609,1645,1647,1649,1663,1669,1676,1678,1681,1701,1720,1725,1727,1730,1734,1738,1742,1745,1748,1756,1774,1775,1779,1793,1794,1795,1797,1809,1820,1826,1832,1833,1845,1853,1858,1864,1868,1871,1884,18","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
862,1,Primary cell-based high throughput screening assay to measure STAT3 inhibition,"Source (MLSCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider:  David Frank, Dana-Farber Cancer Institute_|_Network: Molecular Library Screening Center Network (MLSCN)_|_Grant Proposal Number: 1 X01 MH079826-01 _|_Grant Proposal PI: David Frank_|__|_External Assay ID:  STAT3_INH_LUMI_1536_%INH   _|__|_Name:_|__|_Primary cell-based high throughput screening assay to identify inhibitors of STAT3_|__|_Descripti",5,The Scripps Research Institute Molecular Screening Center,STAT3_INH_LUMI_1536_%INH,20080911,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,3279,3295,33","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",6774,Cell-based,AAK17196,NIH Initiatives,"12209125,12796382,12842895,15958548,17502367,17908954,9794394",0,10.1038/nrm909|10.1074/jbc.m301629200|10.1074/jbc.r700016200|10.1158/0008-5472.can-04-4281|10.1158/1078-0432.ccr-06-2491,NULL,AAK17196,NULL
868,1,Screen for Chemicals that Inhibit the RAM Network,"Southern Research Molecular Libraries Screening Center (SRMLSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Screening Centers Network (MLSCN)_|_Assay Provider: Dr. Eric Weiss, Northwestern University_|_Award: 1R21NS056968-01_|__|_A screen for inhibitors of the budding yeast RAM network_|__|_The RAM network is a novel and highly conserved signaling pathway involved in maintenance of polarized growth, cell proliferation, and control of gene expression. The pathway is well con",11,SRMLSC,Yeast RAM SD FS,20080603,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,32","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",NULL,NULL,NULL,NIH Initiatives,"11014197,12196508,12972564",0,10.1038/35030148|10.1083/jcb.200203094|10.1091/mbc.e03-01-0018,NULL,NULL,NULL
841,1,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),"Emory Chemistry-Biology Discovery Center Assay Overview:_|_Grant number: none_|__|_Paramyxoviruses comprise several major human pathogens. Although a live-attenuated vaccine protects against measles virus (MV), a member of the paramyxovirus family, the virus remains a principal cause of worldwide mortality and accounts for approximately 21 million cases and 300,000 to 400,000 deaths annually. The development of novel antivirals that allow improved case management of severe measles and silence viral outbreak",16,Emory University Molecular Libraries Screening Center,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),20071106,"119,253,323,338,366,525,546,774,803,932,936,938,1046,1047,1150,1318,1329,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1833,1893,1922,1967,1985,1986,2000,2007,2015,2082,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2708,2720,2727,2732,2733,2754,2756,2762,2771,2788,2804,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,3279,3295,3308,3331,3332,3333,3334,3335,3339,3366,3371,3373,3374,3385","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842143,842144,842145,842146,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,8",NULL,NULL,NULL,Legacy Depositors|NIH Initiatives,17470652,0,10.1128/aac.00289-07,NULL,NULL,NULL
631,1,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),"Source (MLSCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Center Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider:  Scripps Florida_|_Network: Molecular Library Screening Center Network (MLSCN)_|_Grant Proposal Number: 1 X01 MH079861-01, Patrick Griffin, PI_|__|__|_External Assay ID: PPARgSRC1_AG_HTRF_1536_%ACT_|__|_Name:_|__|_Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the perox",5,The Scripps Research Institute Molecular Screening Center,PPARgSRC1_AG_HTRF_1536_%ACT,20080125,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2187,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3016,3019,3025,30","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8","5468,8648",Biochemical,"NP_003734,NP_056953",NIH Initiatives,"11729302,12169646,15057233,15860371,16511591,9171241,9808609",0,10.1016/j.tips.2005.03.003|10.1038/nm1025|10.1126/science.294.5548.1866|10.1161/01.cir.98.19.2088|10.1161/01.res.0000029080.15742.85|10.1172/jci27955|10.1210/mend.11.6.0007,2.3.1.48,"P37231,Q15788",NULL
903,2,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|__|_MLSCN Grant: 1 X01 MH079844-01_|_Assay Submitter (PI): Dr. SUN, YI, University of Michigan_|__|_NCGC Assay Overview:_|__|_Synthetic Lethal Screen for Compounds to Kill Cancer Cells with p53 Mutation. _|__|_Tumor suppressor gene p53 serves as a major cellular barrier against tumorigenesis. It has been reported that p53 mutations occurs in half of all tumors, and the other half possess alterations in the p53 p",2,National Center for Advancing Translational Sciences (NCATS),P53T796.3,20100706,"5155,10816,12109,14399,16175,16484,20992,21924,22860,26629,27211,27775,30897,31840,33462,38661,39685,39687,42607,55656,57491,60290,67869,70557,71602,73239,76293,78251,79437,79878,80185,83258,85814,87418,88976,89047,91401,94777,95028,95139,95446,97806,98466,98771,100319,103958,104452,111488,115936,118752,121025,121034,123450,127053,127522,130606,134450,137903,139410,142164,145454,147560,149270,149654,151814,152215,154096,167520,176015,181679,200946,202725,205085,205489,207452,209293,212810,213226,213321,2156","842122,842249,842251,842280,842298,842322,842323,842325,842369,842380,842414,842426,842442,842463,842471,842475,842490,842529,842568,842571,842585,842626,842692,842702,842719,842725,842770,842773,842826,842844,842859,842864,842966,843010,843033,843042,843070,843079,843085,843164,843193,843230,843274,843307,843336,843407,843429,843432,843437,843442,843444,843506,843554,843586,843589,843614,843623,843634,843651,843652,843667,843711,843712,843736,843751,843759,843763,843773,843851,843853,843870,843874,843881,8",7157,Toxicity,NP_000537,Governmental Organizations|NIH Initiatives,"16652354,16864780,19679550",0,10.1002/mc.20231|10.1073/pnas.0604348103|10.1158/0008-5472.can-09-0891,NULL,P04637,NULL
585,2,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLSCN Grant: 1 X01 MH079825-01_|_PI Name: Shoichet, Brian K._|__|_NCGC Assay Overview:_|_This aggregation profiling approach exploits the sensitivity of aggregate formation to detergent. Inhibition of b-lactamase is measured in the presence and absence of 0.01% Triton X-100. See Pubchem assay ""Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent)"" for related screen. Compounds tha",2,National Center for Advancing Translational Sciences (NCATS),AMPC188,20070430,"11,13,51,66,108,119,138,174,177,178,180,196,199,227,239,240,241,243,244,248,249,261,263,286,289,299,300,305,311,323,335,339,370,379,398,403,447,460,500,525,527,535,546,547,564,612,650,660,681,700,701,702,713,750,753,774,785,787,795,864,887,896,903,904,912,931,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1049,1052,1054,1057,1066,1102,1103,1123,1140,1150,1176,1183,1214,1309,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,1390,1433,1449,1456,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,2HDS_A,Governmental Organizations|NIH Initiatives,"13678405,16408018,16570910,17149857,17191086",0,10.1021/jm030266r|10.1021/jm060029z|10.1021/jm061103g|10.1038/nchembio718|10.1038/nprot.2006.77,NULL,1C3B_A,NULL
422,1,HTS for 14-3-3 protein interaction modulators,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_MLSCN Grant: 1 X01MH78953-01_|__|_The 14-3-3 proteins are the prototype for a novel class of protein modules that can recognize phosphoserine/threonine (pS/T)-containing motifs in a variety of signaling proteins. To date, 14-3-3 proteins have been reported to bind more than 200 client proteins. Through these interactions, 14-3-3 proteins play important roles in a wide range of vital regulatory proc",16,Emory University Molecular Libraries Screening Center,"Emory 14-3-3 Screening May 19, 2006",20080812,"108,119,127,178,289,366,401,471,525,546,547,564,640,650,785,802,896,903,1027,1046,1052,1066,1123,1153,1177,1209,1216,1222,1228,1232,1233,1239,1245,1256,1317,1318,1328,1329,1330,1340,1345,1359,1365,1367,1390,1456,1474,1539,1564,1607,1609,1641,1645,1649,1676,1678,1683,1688,1720,1727,1730,1738,1742,1756,1774,1775,1779,1780,1794,1795,1802,1820,1826,1832,1833,1845,1853,1858,1864,1868,1871,1884,1892,1893,1908,1917,1922,1935,1967,1981,1986,1989,1995,2000,2005,2046,2051,2052,2061,2063,2071,2082,2083,2123,2137,2141,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842167,842168,842169,842170,842172,842174,842175,842176,842177,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",7532,NULL,NP_036611,Legacy Depositors|NIH Initiatives,"10836149,8460141",0,10.1073/pnas.90.6.2320|10.1146/annurev.pharmtox.40.1.617,NULL,P61981,NULL
819,1,Primary HTS assay for chemical potentiators of IL-1B stimulated NFkB nuclear translocation,"Inflammatory disease requires that endothelial cells detect and amplify a pro-inflammatory signal. This results in the adherence, activation, and ultimately transmigration of lymphocytes at the site of damage (Pober, 2002). This assay detects an early event in this process, the nuclear translocation of the transcription factor, NFkappaB (Senftleben, et al., 2002).  Chronic inflammatory disease is believed to pose a tremendous medical burden in the developed world, not only in terms of patient suffering but ",19,Columbia University Molecular Screening Center,NFkB_PS_Signaling_InCell3000_384_TRF2_Activation_100507,20090326,"253,366,525,1400,2000,2804,2890,3279,3786,3787,3945,4114,4235,4463,4632,4740,4878,4879,4928,5155,5325,5382,5383,5531,5578,5595,5610,5707,5775,6048,6320,6763,6821,6825,6872,7031,7064,7153,7204,7564,7578,8570,8588,8660,8694,8743,9013,9340,10145,10365,10367,10737,10752,10788,11257,11332,11352,11371,11373,11394,11741,12109,12543,12612,12856,12884,12888,12897,12901,12914,13067,13451,14399,14562,15049,15139,15548,15629,15630,15680,15718,15723,15807,15882,16124,16175,16179,16484,16559,16803,17335,17471,20118,20231","842121,842122,842124,842125,842126,842127,842129,842130,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842145,842146,842148,842150,842151,842152,842153,842155,842156,842157,842158,842159,842160,842161,842163,842164,842165,842166,842167,842168,842170,842172,842173,842174,842175,842176,842177,842178,842179,842181,842182,842183,842184,842185,842186,842187,842188,842189,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,842205,842207,8",NULL,NULL,NULL,Legacy Depositors|NIH Initiatives,"11891403,11937262,12110129,12424381,12949498,8675211,8691131,9786892",0,10.1016/s0301-472x(02)00777-4|10.1038/nri1184|10.1046/j.1365-2567.1996.511581.x|10.1074/jbc.273.44.28897|10.1084/jem.184.1.173|10.1126/science.1071914|10.1186/ar576,NULL,NULL,NULL
757,1,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,"University of New Mexico Assay Overview:_|_Assay Support: NIH I RO3 MH081231-01 _|_HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases_|_PI: Angela Wandinger-Ness, Ph.D._|_Co-PI: Larry Sklar, Ph.D._|_Assay Development: Zurab Surviladze, Ph.D._|_Assay Implementation: Zurab Surviladze, Danuta Wlodek, Terry Foutz, Mark Carter, Anna Waller_|_Target Team Leader for the Center: Larry Sklar (lsklar@salud.unm.edu)_|__|_Assay Background and Significance:_|__|_Ras and related small molec",6,NMMLSC,UNM_GTPase_Rac_wt,20091026,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,32","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",5879,NULL,CAB53579,NIH Initiatives,"10961859,11152757,11309812,12142347,12531900,12545426,12701132,15128949,15455439,15731001,16505163,16732721,16831938,16842149,1899358,2195986,6318112,7177195,8342602",0,10.1002/ana.20281|10.1002/cyto.a.10035|10.1016/0092-8674(91)90246-u|10.1038/300762a0|10.1038/306658a0|10.1073/pnas.0307512101|10.1074/jbc.m211996200|10.1083/jcb.200512057|10.1086/367847|10.1152/physrev.2001.81.1.153|10.1161/01.res.0000028149.15986.4c|10.1196/annals.1346.041|10.1242/jcs.01660|10.1517/13543784.15.6.709|10.2174/156802606777812095,NULL,P63000,NULL
596,2,qHTS Assay for Tau Filament Binding,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLSCN Grant: 1 X01 MH079825-01_|_Assay Provider: Jeffrey A. Kuret, Ohio State University_|__|__|_NCGC Assay Overview:_|_Tau monomers form filaments in vitro in the presence of anionic detergents or fatty acids. The dye Thioflavine S (ThS) binds to tau filaments and upon binding, increases in fluorescence several fold. Small molecules that displace ThS binding or prevent filament binding are identified by a r",2,National Center for Advancing Translational Sciences (NCATS),TAUP555,20071220,"11,13,51,66,108,119,138,174,177,178,180,196,199,227,239,240,241,243,244,248,249,261,263,286,289,299,300,305,311,323,335,339,370,379,398,403,447,460,500,525,527,535,546,547,564,612,650,660,681,700,701,702,713,750,753,774,785,787,795,864,887,896,903,904,912,931,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1049,1052,1054,1057,1066,1102,1103,1123,1140,1150,1176,1183,1214,1309,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,1390,1433,1449,1456,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",4137,NULL,AAI14949,Governmental Organizations|NIH Initiatives,"15005623,16042400",0,10.1021/bi036094h|10.1021/bi050387o,NULL,AAI14949,NULL
758,1,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,"University of New Mexico Assay Overview:_|_Assay Support: NIH I RO3 MH081231-01 _|_HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases_|_PI: Angela Wandinger-Ness, Ph.D._|_Co-PI: Larry Sklar, Ph.D._|_Assay Development: Zurab Surviladze, Ph.D._|_Assay Implementation: Zurab Surviladze, Danuta Wlodek, Terry Foutz, Mark Carter, Anna Waller_|_Target Team Leader for the Center: Larry Sklar (lsklar@salud.unm.edu)_|__|_Assay Background and Significance:_|__|_Ras and related small molec",6,NMMLSC,UNM_GTPase_Rab7_wt,20091026,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,32","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",404007,NULL,AAA30890,NIH Initiatives,"10961859,11152757,11309812,12142347,12531900,12545426,12701132,15128949,15455439,15731001,16505163,16732721,16831938,16842149,1899358,2195986,6318112,7177195,8342602,8607022",0,10.1002/ana.20281|10.1002/cyto.a.10035|10.1016/0092-8674(91)90246-u|10.1038/300762a0|10.1038/306658a0|10.1073/pnas.0307512101|10.1074/jbc.m211996200|10.1083/jcb.200512057|10.1086/367847|10.1152/physrev.2001.81.1.153|10.1161/01.res.0000028149.15986.4c|10.1196/annals.1346.041|10.1242/jcs.01660|10.1517/13543784.15.6.709|10.2174/156802606777812095,NULL,P18067,NULL
761,1,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,"University of New Mexico Assay Overview:_|_Assay Support: NIH I RO3 MH081231-01 _|_HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases_|_PI: Angela Wandinger-Ness, Ph.D._|_Co-PI: Larry Sklar, Ph.D._|_Assay Development: Zurab Surviladze, Ph.D._|_Assay Implementation: Zurab Surviladze, Danuta Wlodek, Terry Foutz, Mark Carter, Anna Waller_|_Target Team Leader for the Center: Larry Sklar (lsklar@salud.unm.edu)_|__|_Assay Background and Significance:_|__|_Ras and related small molec",6,NMMLSC,UNM_GTPase_cdc42_wt,20091025,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,32","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",NULL,NULL,CAI19851,NIH Initiatives,"10961859,11152757,11309812,12142347,12531900,12545426,12701132,15128949,15455439,15731001,16505163,16732721,16831938,16842149,1899358,2195986,6318112,7177195,8342602,8607022",0,10.1002/ana.20281|10.1002/cyto.a.10035|10.1016/0092-8674(91)90246-u|10.1038/300762a0|10.1038/306658a0|10.1073/pnas.0307512101|10.1074/jbc.m211996200|10.1083/jcb.200512057|10.1086/367847|10.1152/physrev.2001.81.1.153|10.1161/01.res.0000028149.15986.4c|10.1196/annals.1346.041|10.1242/jcs.01660|10.1517/13543784.15.6.709|10.2174/156802606777812095,NULL,CAI19851,NULL
760,1,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,"University of New Mexico Assay Overview:_|_Assay Support: NIH I RO3 MH081231-01 _|_HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases_|_PI: Angela Wandinger-Ness, Ph.D._|_Co-PI: Larry Sklar, Ph.D._|_Assay Development: Zurab Surviladze, Ph.D._|_Assay Implementation: Zurab Surviladze, Danuta Wlodek, Terry Foutz, Mark Carter, Anna Waller_|_Target Team Leader for the Center: Larry Sklar (lsklar@salud.unm.edu)_|__|_Assay Background and Significance:_|__|_Ras and related small molec",6,NMMLSC,UNM_GTPase_Rab2_wt,20091025,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,32","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",404009,NULL,P61105,NIH Initiatives,"10961859,11152757,11309812,12142347,12531900,12545426,12701132,15128949,15455439,15731001,16505163,16732721,16831938,16842149,1899358,2195986,6318112,7177195,8342602,8607022",0,10.1002/ana.20281|10.1002/cyto.a.10035|10.1016/0092-8674(91)90246-u|10.1038/300762a0|10.1038/306658a0|10.1073/pnas.0307512101|10.1074/jbc.m211996200|10.1083/jcb.200512057|10.1086/367847|10.1152/physrev.2001.81.1.153|10.1161/01.res.0000028149.15986.4c|10.1196/annals.1346.041|10.1242/jcs.01660|10.1517/13543784.15.6.709|10.2174/156802606777812095,NULL,P61105,NULL
759,1,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,"University of New Mexico Assay Overview:_|_Assay Support: NIH I RO3 MH081231-01 _|_HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases_|_PI: Angela Wandinger-Ness, Ph.D._|_Co-PI: Larry Sklar, Ph.D._|_Assay Development: Zurab Surviladze, Ph.D._|_Assay Implementation: Zurab Surviladze, Danuta Wlodek, Terry Foutz, Mark Carter, Anna Waller_|_Target Team Leader for the Center: Larry Sklar (lsklar@salud.unm.edu)_|__|_Assay Background and Significance:_|__|_Ras and related small molec",6,NMMLSC,UNM_GTPase_Ras_wt,20091026,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,32","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",3265,NULL,AAA36557,NIH Initiatives,"10961859,11152757,11309812,12142347,12531900,12545426,12701132,15128949,15455439,15731001,16505163,16732721,16831938,16842149,1899358,2195986,6318112,7177195,8342602,8607022",0,10.1002/ana.20281|10.1002/cyto.a.10035|10.1016/0092-8674(91)90246-u|10.1038/300762a0|10.1038/306658a0|10.1073/pnas.0307512101|10.1074/jbc.m211996200|10.1083/jcb.200512057|10.1086/367847|10.1152/physrev.2001.81.1.153|10.1161/01.res.0000028149.15986.4c|10.1196/annals.1346.041|10.1242/jcs.01660|10.1517/13543784.15.6.709|10.2174/156802606777812095,NULL,AAA36557,NULL
485,1,Primary HTS Assay for S1P3 Antagonists,"Source (MLSCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Hugh Rosen, TSRI_|_Network: Molecular Library Screening Center Network (MLSCN)_|_Grant Proposal Number: 1 R03 MH076533-01_|_Grant Proposal PI: Germana Sanna, TSRI_|__|_External Assay ID: S1P3_ANT_BLA_1536_%INH_|__|_Name: Primary Cell-Based High Throughput Assay for Antagonists of the Sphingosine 1-Phosphate Receptor 3 (S1P3)_|__|_Description:_|_T",5,The Scripps Research Institute Molecular Screening Center,S1P3_ANT_BLA_1536_%INH,20100611,"72,119,191,204,253,298,323,338,525,546,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2812,2890,2904,2950,2955,2972,3003","842122,842123,842124,842125,842126,842127,842128,842129,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842151,842152,842153,842155,842156,842160,842161,842162,842163,842164,842165,842167,842168,842169,842170,842172,842174,842175,842176,842177,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,8",1903,NULL,NP_005217,NIH Initiatives,"11923495,12941420,14732717,14747617,15578083,15968000,15975516,16099402,16273098,16342326,18305483,18590333",0,10.1002/eji.200535127|10.1016/j.chembiol.2005.04.019|10.1016/j.prostaglandins.2004.09.011|10.1016/s1367-5931(03)00085-1|10.1021/cb800051m|10.1038/nature06663|10.1038/ni1269|10.1073/pnas.0501997102|10.1074/jbc.m311743200|10.1124/jpet.103.062828|10.1126/science.1070238|10.1172/jci23704,NULL,Q99500,NULL
764,1,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,"University of New Mexico Assay Overview:_|_Assay Support: NIH I RO3 MH081231-01 _|_HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases_|_PI: Angela Wandinger-Ness, Ph.D._|_Co-PI: Larry Sklar, Ph.D._|_Assay Development: Zurab Surviladze, Ph.D._|_Assay Implementation: Zurab Surviladze, Danuta Wlodek, Terry Foutz, Mark Carter, Anna Waller_|_Target Team Leader for the Center: Larry Sklar (lsklar@salud.unm.edu)_|__|_Assay Background and Significance:_|__|_Ras and related small molec",6,NMMLSC,UNM_GTPase_Rac_act,20091025,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,32","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",5879,NULL,CAB53579,NIH Initiatives,"10961859,11152757,11309812,12142347,12531900,12545426,12701132,15128949,15455439,15731001,16505163,16732721,16831938,16842149,1899358,2195986,6318112,7177195,8342602,8607022",0,10.1002/ana.20281|10.1002/cyto.a.10035|10.1016/0092-8674(91)90246-u|10.1038/300762a0|10.1038/306658a0|10.1073/pnas.0307512101|10.1074/jbc.m211996200|10.1083/jcb.200512057|10.1086/367847|10.1152/physrev.2001.81.1.153|10.1161/01.res.0000028149.15986.4c|10.1196/annals.1346.041|10.1242/jcs.01660|10.1517/13543784.15.6.709|10.2174/156802606777812095,NULL,P63000,NULL
951,1,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.","University of New Mexico Assay Overview:_|_Assay Support: NIH 1X01 MH079850-01   _|_HTS to identify small molecule regulators of Bcl-2 family protein interactions _|_PI: Larry Sklar, Ph.D._|_Assay Implementatiion:  Peter Simons Ph.D, Susan Young MS, Anna Waller Ph.D,  Mark Carter MS_|__|_Assay Background and Significance:_|__|_One arm of apoptosis is regulated by the balance of anti-apoptotic and pro-apoptotic Bcl-2 family members.  In humans, six genes have been identified that encode anti-apoptotic protei",6,NMMLSC,UNM_Bcl_Bim-Bcl-B,20071221,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2187,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3016,3019,3025,30","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",10017,NULL,Q9HD36,NIH Initiatives,"10224090,10766760,11309812,11689480,15226512,15353804,17726463",0,10.1038/sj.bjc.6603951|10.1074/jbc.274.19.13298|10.1074/jbc.m909572199|10.1093/hmg/10.21.2329|10.1126/science.1099191|10.1126/stke.2392004re9,NULL,Q9HD36,NULL
950,1,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.","University of New Mexico Assay Overview:_|_Assay Support: NIH 1X01 MH079850-01   _|_HTS to identify small molecule regulators of Bcl-2 family protein interactions _|_PI: Larry Sklar, Ph.D._|_Assay Implementatiion:  Peter Simons Ph.D, Susan Young MS, Anna Waller Ph.D, Mark Carter MS_|__|_Assay Background and Significance:_|__|_One arm of apoptosis is regulated by the balance of anti-apoptotic and pro-apoptotic Bcl-2 family members.  In humans, six genes have been identified that encode anti-apoptotic protein",6,NMMLSC,UNM_Bcl_Bim-Bcl-2,20071221,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2187,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3016,3019,3025,30","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",596,NULL,P10415,NIH Initiatives,"10224090,10766760,11309812,11689480,15226512,15353804,17726463,3523487,8358789,8761287",0,10.1016/0092-8674(93)90508-n|10.1038/sj.bjc.6603951|10.1073/pnas.83.14.5214|10.1074/jbc.274.19.13298|10.1074/jbc.m909572199|10.1093/hmg/10.21.2329|10.1126/science.1099191|10.1126/stke.2392004re9,NULL,P10415,NULL
952,1,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.","University of New Mexico Assay Overview:_|_Assay Support: NIH 1X01 MH079850-01   _|_HTS to identify small molecule regulators of Bcl-2 family protein interactions _|_PI: Larry Sklar, Ph.D._|_Assay Implementatiion:  Peter Simons Ph.D, Susan Young MS, Anna Waller Ph.D,  Mark Carter MS_|__|_Assay Background and Significance:_|__|_One arm of apoptosis is regulated by the balance of anti-apoptotic and pro-apoptotic Bcl-2 family members.  In humans, six genes have been identified that encode anti-apoptotic protei",6,NMMLSC,UNM_Bcl_Bim-Bcl-W,20071221,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2187,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3016,3019,3025,30","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",599,NULL,AAB09055,NIH Initiatives,"10224090,10766760,11309812,11689480,15226512,15353804,17726463,8761287",0,10.1038/sj.bjc.6603951|10.1074/jbc.274.19.13298|10.1074/jbc.m909572199|10.1093/hmg/10.21.2329|10.1126/science.1099191|10.1126/stke.2392004re9,NULL,NP_004041,NULL
693,1,High throughput fluorescence polarization-based assay to screen for small molecule inhibitors of the Polo box domain (PBD) of Plk1.,"Extracted from the MH078944 proposal submitted by Dr. Michael Yaffe of MIT._|__|_The Polo-like kinases (Plks) play important roles in many cell cycle-related events including the initiation of mitosis, chromosome segregation, centrosome maturation, bipolar spindle formation, regulation of anaphase-promoting complex and execution of cytokinesis. The prototypic Polo kinase was originally identified in flies, in which mutants resulted in abnormal spindle poles. A single Polo family member is found in flies, bu",9,University of Pittsburgh Molecular Library Screening Center,MH078944 HTS FP Assay for Inhibitors of PLK-1-PBD,20070423,"253,366,525,1400,2000,2804,2890,3279,3786,3787,3945,4114,4235,4463,4632,4740,4878,4879,4928,5155,5325,5382,5383,5531,5578,5595,5610,5707,5775,6048,6320,6763,6821,6825,6872,7031,7064,7153,7204,7564,7578,8570,8588,8660,8694,8743,9013,9340,10145,10365,10367,10737,10752,10788,11257,11332,11352,11371,11373,11394,11741,12109,12543,12612,12856,12884,12888,12897,12901,12914,13067,13451,14399,14562,15049,15139,15163,15548,15629,15630,15680,15718,15723,15807,15882,16054,16124,16175,16179,16484,16559,16803,17335,17471","842121,842122,842124,842125,842126,842127,842129,842130,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842145,842146,842148,842150,842151,842152,842153,842155,842156,842157,842158,842159,842160,842161,842163,842164,842165,842166,842167,842168,842170,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",5347,NULL,NP_005021,NIH Initiatives,14711389,0,10.1177/1087057103258285,2.7.11.21,P53350,NULL
796,1,IL-1B Induced NFkB Translocation - Primary Screen,"Inflammatory disease requires that endothelial cells detect and amplify a pro-inflammatory signal. This results in the adherence, activation, and ultimately transmigration of lymphocytes at the site of damage (Pober, 2002). Drugs that block this process would significantly alleviate the symptoms of inflammation. Our assay detects an early event in this process, the nuclear translocation of the transcription factor, NFkappaB (Senftleben, et al., 2002)._|_Chronic inflammatory disease is believed to pose a tre",19,Columbia University Molecular Screening Center,NFkB_PS_Signaling_InCell3000_384_TRF2_08242007,20090326,"253,366,525,1400,2000,2804,2890,3279,3786,3787,3945,4114,4235,4463,4632,4740,4878,4879,4928,5155,5325,5382,5383,5531,5578,5595,5610,5707,5775,6048,6320,6763,6821,6825,6872,7031,7064,7153,7204,7564,7578,8570,8588,8660,8694,8743,9013,9340,10145,10365,10367,10737,10752,10788,11257,11332,11352,11371,11373,11394,11741,12109,12543,12612,12856,12884,12888,12897,12901,12914,13067,13451,14399,14562,15049,15139,15548,15629,15630,15680,15718,15723,15807,15882,16124,16175,16179,16484,16559,16803,17335,17471,20118,20231","842121,842122,842124,842125,842126,842127,842129,842130,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842145,842146,842148,842150,842151,842152,842153,842155,842156,842157,842158,842159,842160,842161,842163,842164,842165,842166,842167,842168,842170,842172,842173,842174,842175,842176,842177,842178,842179,842181,842182,842183,842184,842185,842186,842187,842188,842189,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,842205,842207,8",NULL,NULL,NULL,Legacy Depositors|NIH Initiatives,"11891403,11937262,12110129,12424381,12949498,8675211,8691131,9786892",0,10.1016/s0301-472x(02)00777-4|10.1038/nri1184|10.1046/j.1365-2567.1996.511581.x|10.1074/jbc.273.44.28897|10.1084/jem.184.1.173|10.1126/science.1071914|10.1186/ar576,NULL,NULL,NULL
684,1,Factor XIIa Mixture HTS,"Target_|__|_Factor XII (FXII) is a 80 kDa zymogen found at a concentration of 0.375 uM in plasma, and upon activation by kallikrein at R353, a disulfide-linked two chain molecule called factor XIIa alpha (FXIIa) is generated.  FXIIa is also capable of autoactivation by binding to negatively charged surfaces (1).  Kallikrein can also cleave other scissile bonds in FXIIa alpha outside of the catalytic domain at R334, R343, and R353, generating FXIIa beta, a 30 kDa enzyme that is no longer able to bind to surf",10,PCMD,FXIIA_MIXHTS,20110304,"525,1329,1676,1688,1780,1820,1832,1892,1893,1967,1981,1986,2000,2082,2123,2153,2170,2196,2247,2249,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2794,2890,2955,3012,3019,3025,3059,3108,3126,3151,3168,3169,3182,3194,3213,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3371,3374,3394,3446,3463,3478,3488,3512,3542,3559,3616,3639,3647,3672,3676,3702,3715,3728,3747,3767,3786,3787,3793,3825,3828,3830,3878,3883,3899,3957,3969,4021,4030,4038,4044,4100,4107,411","842121,842122,842123,842124,842125,842126,842127,842128,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",2161,NULL,P00748,Legacy Depositors|NIH Initiatives,"14529397,14806439,15124772,16009717,1652157,2019570,2578463,3278905,3639874,4118185,4473201,501286,632748,6782101,690132,8488686,893417,9371304,947956",0,10.1021/bi00719a006|10.1038/167233a0|10.1084/jem.147.3.719|10.1084/jem.150.5.1122|10.1084/jem.20050664|10.1111/j.1432-1033.1988.tb13849.x|10.1111/j.1749-6632.1972.tb16323.x|10.1126/science.1652157|10.1172/jci108361|10.1191/1352458504ms999xx|10.2174/1381612033453938,3.4.21.38,P00748,NULL
633,1,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: John A. Katzenellenbogen, University of Illinois Urbana-Champaign_|_MLSCN Grant: 1 X01MH78953-01_|__|_Assay Overview_|_      Estrogens, which are responsible for the growth of many breast cancers, act through the estrogen receptors, ER-alpha and ER-beta, which are ligand-modulated transcription factors and members of the nuclear receptor gene superfamily. ER-alpha and ER-beta are we",16,Emory University Molecular Libraries Screening Center,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,20070604,"119,253,338,366,525,938,1329,1646,1676,1688,1820,1832,1892,1893,1922,1967,1981,1985,1986,2000,2007,2082,2118,2123,2153,2170,2196,2247,2249,2266,2284,2315,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2804,2890,2950,2955,3012,3019,3025,3059,3108,3125,3151,3168,3169,3182,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3366,3371,3374,3385,3394,3446,3463,3478,3488,3503,3512,3542,3559,3598,3616,3639,3647,3672,3676,3702,3715,3747,3767,3787,3793,3825,3828,3830,3878,3883,389","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",2100,NULL,NP_001428,Legacy Depositors|NIH Initiatives,"11384865,14668813,14736241",0,10.1016/s0960-0760(00)00193-x|10.1021/jm030404c|10.1038/nrc1211,NULL,Q92731,NULL
629,1,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: John A. Katzenellenbogen, University of Illinois at Urbana-Champaign_|_MLSCN Grant: 1 X01MH78953-01_|__|_Title: HTS for Estrogen Receptor-alpha Coactivator Binding inhibitors_|__|_Assay Overview_|_      Estrogens, which are responsible for the growth of many breast cancers, act through the estrogen receptors, ER-alpha and ER-beta, which are ligand-modulated transcription factors and",16,Emory University Molecular Libraries Screening Center,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors to Block Estrogen Action,20070423,"119,253,338,366,525,938,1329,1646,1676,1688,1820,1832,1892,1893,1922,1967,1981,1985,1986,2000,2007,2082,2118,2123,2153,2170,2196,2247,2249,2266,2284,2315,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2804,2890,2950,2955,3012,3019,3025,3059,3108,3125,3151,3168,3169,3182,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3366,3371,3374,3385,3394,3446,3463,3478,3488,3503,3512,3542,3559,3598,3616,3639,3647,3672,3676,3702,3715,3747,3767,3787,3793,3825,3828,3830,3878,3883,389","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",2099,NULL,AAI28575,Legacy Depositors|NIH Initiatives,"11384865,14668813,14736241",0,10.1016/s0960-0760(00)00193-x|10.1021/jm030404c|10.1038/nrc1211,NULL,P03372,NULL
583,2,High Throughput Screening Assay for Hsp70 Inhibitors,"Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Sanford-Burnham Medical Research Institute (San Diego, CA)_|_NIH Molecular Libraries Screening Centers Network (MLSCN)_|_MLSCN Grant: XO1 MH079863-01_|__|_Over-expression of molecular chaperones occurs commonly in cancers and provides protection from a wide variety of cellular stresses, both endogenous and iatrogenic. Molecular chaperones also play important roles in maintaining the activity of several signal-transducing proteins and transcriptions fact",14,Burnham Center for Chemical Genomics,SDCCG-A013-Hsp70,20100830,"119,253,338,366,525,936,938,1046,1047,1329,1474,1492,1646,1675,1676,1686,1688,1832,1893,1922,1967,1981,1985,1986,2000,2007,2082,2118,2123,2153,2170,2247,2249,2266,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2733,2754,2762,2771,2788,2794,2804,2890,2950,2955,3012,3019,3025,3037,3059,3108,3125,3126,3151,3168,3169,3182,3194,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3366,3371,3374,3385,3446,3463,3478,3488,3503,3512,3542,3559,3598,3616,3639,3647,3672,3702,3715,3747,3767","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,CAM24989,NIH Initiatives,"11584289,15770419,9083109,9563820",0,10.1007/s00018-004-4464-6|10.1016/s0969-2126(97)00197-4|10.1038/ncb1001-e237,NULL,CAM24989,NULL
501,1,Cathepsin S,"Molecular Library Screening Center Network (MLSCN)_|_Penn Center for Molecular Discovery (PCMD)_|_Assay Provider: Dr. Scott L. Diamond, University of Pennsylvania_|_MLSCN Grant: X01-MH076406-01_|__|_Human cathepsin S (EC 3.4.22.27) is a lysosomal cysteine protease that is expressed in antigen-presenting cells, especially dendritic cells, B-cells and macrophages. Cathepsin S plays a key role in the processing of antigenic peptides for presentation by MHC Class II molecules on the surface of antigen-presentin",10,PCMD,CATS,20081007,"525,1329,1676,1780,1820,1832,1892,1893,1967,1981,1986,2000,2082,2123,2153,2170,2196,2247,2249,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2794,2890,2955,3012,3019,3025,3059,3108,3126,3151,3168,3169,3182,3194,3213,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3371,3374,3394,3446,3463,3478,3488,3512,3542,3559,3616,3639,3647,3672,3676,3702,3715,3728,3747,3767,3786,3787,3793,3825,3828,3830,3878,3883,3899,3957,3969,4021,4030,4038,4044,4100,4107,4114,417","842121,842122,842123,842124,842125,842126,842127,842128,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",1520,NULL,NP_004070,Legacy Depositors|NIH Initiatives,NULL,0,NULL,3.4.22.27,P25774,NULL
619,1,Fluorescence polarization assay for PLK1 inhibitors,"The PLK1 HTS assay was developed and run at the University of Pittsburgh Molecular Screening Center (PMLSC) as part of the Molecular Library Screening Center Network (MLSCN)(1 X01 MH76330).   _|__|_Polo-like kinase 1 (Plk1) is a serine-threonine protein kinase that functions as a key regulator of mitosis/meiosis and cytokinesis (Barr et al., 2004).  Numerous research studies have demonstrated that Plk1 gene expression is frequently up regulated in human cancers and carcinoma-derived cell lines (Simizu and O",9,University of Pittsburgh Molecular Library Screening Center,1 X01 MH077611-01,20070808,"253,366,525,1400,2000,2804,2890,3279,3786,3787,3945,4114,4235,4463,4632,4740,4878,4879,4928,5155,5325,5382,5383,5531,5578,5595,5610,5707,5775,6048,6320,6763,6821,6825,6872,7031,7064,7153,7204,7564,7578,8570,8588,8660,8694,8743,9013,9340,10145,10365,10367,10737,10752,10788,11257,11332,11352,11371,11373,11394,11741,12109,12543,12612,12856,12884,12888,12897,12901,12914,13067,13451,14399,14562,15049,15139,15163,15548,15629,15630,15680,15718,15723,15807,15882,16054,16124,16175,16179,16484,16559,16803,17335,17471","842121,842122,842124,842125,842126,842127,842129,842130,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842145,842146,842148,842150,842151,842152,842153,842155,842156,842157,842158,842159,842160,842161,842163,842164,842165,842166,842167,842168,842170,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",5347,NULL,NP_005021,NIH Initiatives,"11056542,12488480,15173270,15173822,15805268",0,10.1038/35041102|10.1038/nrm1401|10.1093/jnci/94.24.1863|10.1093/jnci/djh146|10.1158/0008-5472.can-04-2131,2.7.11.21,P53350,NULL
680,1,Factor XIa Mixture HTS,"Molecular Library Screening Center Network (MLSCN)_|_Penn Center for Molecular Discovery (PCMD)_|_Assay Provider:  Scott L. Diamond, University of Pennsylvania_|_MLSCN Grant:  X01-MH076406-01_|__|_Target_|__|_Factor XI (FXI) circulates as a complex with high molecular weight kininogen (HK) in the plasma at a concentration of 5 ug/ml (equivalent to 31.3 nM, dimeric concentration) as a homodimeric glycosylated blood plasma zymogen of approximately 160 kDa, containing monomeric subunits of 80 kDa each (1).  Th",10,PCMD,FXIA_MIXHTS,20081007,"525,1329,1676,1688,1780,1820,1832,1892,1893,1967,1981,1986,2000,2082,2123,2153,2170,2196,2247,2249,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2794,2890,2955,3012,3019,3025,3059,3108,3126,3151,3168,3169,3182,3194,3213,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3371,3374,3394,3446,3463,3478,3488,3512,3542,3559,3616,3639,3647,3672,3676,3702,3715,3728,3747,3767,3786,3787,3793,3825,3828,3830,3878,3883,3899,3957,3969,4021,4030,4038,4044,4100,4107,411","842121,842122,842123,842124,842125,842126,842127,842128,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",NULL,NULL,AAA51985,Legacy Depositors|NIH Initiatives,"11159184,12689935,14529397,14806439,15733058,1652157,16880142,1998667,2019570,3278905,3636155,4118185,4473201,6604052,6782101,690132,876353,893417",0,10.1016/s0002-9440(10)63989-2|10.1021/bi00222a008|10.1021/bi00357a018|10.1021/bi00719a006|10.1038/167233a0|10.1038/266729a0|10.1111/j.1432-1033.1988.tb13849.x|10.1111/j.1538-7836.2005.01236.x|10.1111/j.1749-6632.1972.tb16323.x|10.1126/science.1652157|10.1182/blood-2003-01-0324|10.1309/qc259f09unmkvp0r|10.2174/1381612033453938,NULL,AAA51985,NULL
538,1,Complement factor C1s,"Molecular Library Screening Center Network (MLSCN)_|_Penn Center for Molecular Discovery (PCMD)_|_Assay Provider: Scott L. Diamond, University of Pennsylvania _|_MLSCN Grant: X01-MH076406-01_|__|_Target_|__|_Complement factor C1s (EC 3.4.21.42) is a trypsin-like serine protease that is activated in one of the first steps in the classical complement cascade. Despite the essential role for the complement cascade in immune defense, unregulated activation leading to acute inflammation and tissue damage has been",10,PCMD,COMPLEMENT C1s,20081007,"525,1329,1676,1688,1780,1820,1832,1892,1893,1967,1981,1986,2000,2082,2123,2153,2170,2196,2247,2249,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2794,2890,2955,3012,3019,3025,3059,3108,3126,3151,3168,3169,3182,3194,3213,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3371,3374,3394,3446,3463,3478,3488,3512,3542,3559,3616,3639,3647,3672,3676,3702,3715,3728,3747,3767,3786,3787,3793,3825,3828,3830,3878,3883,3899,3957,3969,4021,4030,4038,4044,4100,4107,411","842121,842122,842123,842124,842125,842126,842127,842128,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",716,NULL,NP_001725,Legacy Depositors|NIH Initiatives,NULL,0,NULL,3.4.21.42,P09871,NULL
639,1,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: John A. Katzenellenbogen, University of Illinois Urbana-Champaign_|_MLSCN Grant: 1 X01MH78953-01_|__|_Assay Overview_|_   Menopause is associated with the onset of hot flashes, night sweats, mood changes, and urogenital atrophy, which many women find distressing enough to seek medical management for relief. Estrogens in the form of hormone therapy (HT) have been the standard treatme",16,Emory University Molecular Libraries Screening Center,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,20070423,"119,253,338,366,525,938,1329,1646,1676,1688,1820,1832,1892,1893,1922,1967,1981,1985,1986,2000,2007,2082,2118,2123,2153,2170,2196,2247,2249,2266,2284,2315,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2804,2890,2950,2955,3012,3019,3025,3059,3108,3125,3151,3168,3169,3182,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3366,3371,3374,3385,3394,3446,3463,3478,3488,3503,3512,3542,3559,3598,3616,3639,3647,3672,3676,3702,3715,3747,3767,3787,3793,3825,3828,3830,3878,3883,389","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",2099,NULL,AAI28575,Legacy Depositors|NIH Initiatives,"11459850,12642637",0,10.1056/nejmoa030311|10.1074/jbc.r100029200,NULL,P03372,NULL
581,1,Cathepsin G,"Molecular Library Screening Center Network (MLSCN)_|_Penn Center for Molecular Discovery (PCMD)_|_Assay Provider: Dr. Scott L. Diamond, University of Pennsylvania_|_MLSCN Grant: X01-MH076406-01_|__|_Cathepsin G (EC 3.4.21.20) is a chymotrypsin-like serine protease that is secreted from neutrophils.  Disregulated cathepsin G activity is implicated in the progression of various chronic inflammatory diseases such as asthma and chronic pulmonary obstructive disease. Thus cathepsin G inhibitors represent useful ",10,PCMD,CAT G,20081007,"525,1329,1676,1688,1780,1820,1832,1892,1893,1967,1981,1986,2000,2082,2123,2153,2170,2196,2247,2249,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2794,2890,2955,3012,3019,3025,3059,3108,3126,3151,3168,3169,3182,3194,3213,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3371,3374,3394,3446,3463,3478,3488,3512,3542,3559,3616,3639,3647,3672,3676,3702,3715,3728,3747,3767,3786,3787,3793,3825,3828,3830,3878,3883,3899,3957,3969,4021,4030,4038,4044,4100,4107,411","842121,842122,842123,842124,842125,842126,842127,842128,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",1511,NULL,AAH14460,Legacy Depositors|NIH Initiatives,NULL,0,NULL,NULL,P08311,NULL
630,1,HTS of Smad transcription factor inhibitors,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: F.M. Hoffmann, University of Wisconsin-Madison_|_MLSCN Grant: 1R21NS057002-01_|__|_Assay Overview:_|_    Transforming growth factor beta (TGF-Beta) regulates a variety of processes in mammalian cells, including proliferation, apoptosis, cell migration and extracellular matrix production. Aberrant increases in TGF-Beta signaling have been implicated in several pathological conditions",16,Emory University Molecular Libraries Screening Center,HTS of Smad transcription factor inhibitors,20070323,"51,108,119,253,338,339,366,500,525,546,938,1023,1052,1318,1329,1646,1676,1688,1820,1832,1892,1893,1922,1967,1981,1985,1986,2000,2007,2082,2118,2123,2153,2170,2196,2247,2249,2266,2284,2315,2333,2343,2378,2391,2392,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2804,2890,2895,2915,2950,2955,3012,3019,3025,3059,3108,3125,3151,3168,3169,3182,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3366,3371,3374,3385,3394,3446,3463,3478,3488,3496,3503,3512,3542,3559,3598,3616,3639,3647,3672,3676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",4088,NULL,NP_005893,Legacy Depositors|NIH Initiatives,15750622,0,10.1038/sj.onc.1208556,NULL,P84022,NULL
818,1,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,"Southern Research Molecular Libraries Screening Center (SRMLSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Screening Centers Network (MLSCN)_|_Submitted by Dr. Todd Waldman (Lombardi Cancer Center, Georgetown University School of Medicine)_|_Award: R03-NS053741_|__|_Numerous genes have been identified which participate, either through activation (oncogenes) or inactivation (tumor suppressors), in the multifactorial process of carcinogenesis (Vogelstein B and Kinzler KW, 20",11,SRMLSC,Beta Catenin SD 140K,20071016,"119,253,323,338,366,525,546,774,803,932,936,938,1046,1047,1150,1318,1329,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1833,1893,1922,1967,1985,1986,2000,2007,2015,2082,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2708,2720,2727,2732,2733,2754,2756,2762,2771,2788,2804,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,3279,3295,3308,3331,3332,3333,3334,3335,3339,3366,3371,3373,3374,3385","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",NULL,NULL,NULL,NIH Initiatives,"12019147,14749129,15286780,15466180,17143293",0,10.1016/s1535-6108(03)00334-9|10.1038/nm1087|10.1038/sj.onc.1210056|10.1158/0008-5472.can-04-1767,NULL,NULL,NULL
827,1,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,"Southern Research Molecular Libraries Screening Center (SRMLSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Screening Centers Network (MLSCN)_|_Submitted by Dr. Todd Waldman (Lombardi Cancer Center, Georgetown University School of Medicine)_|_Award: 1R03NS050857-01_|__|_Numerous genes have been identified which participate, either through activation (oncogenes) or inactivation (tumor suppressors), in the multifactorial process of carcinogenesis (Vogelstein B and Kinzler KW,",11,SRMLSC,PTEN SD 140K,20071016,"119,253,323,338,366,525,546,774,803,932,936,938,1046,1047,1150,1318,1329,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1833,1893,1922,1967,1985,1986,2000,2007,2015,2082,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2708,2720,2727,2732,2733,2754,2756,2762,2771,2788,2804,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,3279,3295,3308,3331,3332,3333,3334,3335,3339,3366,3371,3373,3374,3385","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",NULL,NULL,NULL,NIH Initiatives,"12946627,15286780,15466180,15950905,17060456",0,10.1016/j.ccr.2005.05.014|10.1016/s0962-8924(03)00175-2|10.1038/nm1087|10.1128/mcb.00537-06|10.1158/0008-5472.can-04-1767,NULL,NULL,NULL
488,1,Cathepsin B compound mixture screening,"One of our goals at the Penn Center for Molecular Discovery (PCMD) is to develop capabilities for screening multiple members of target classes, for example cysteine and serine proteases. Many HTS labs focus effort on one target of interest within a class due to resource and time constraints. A few compounds are then tested for selectivity against additional target class members during the hit-to-lead process. Our goal is to test the entire MLSCN compound library against multiple cysteine and serine protease",10,PCMD,CATB MIXTURES,20071011,"525,1329,1676,1688,1780,1820,1832,1892,1893,1967,1981,1986,2000,2082,2123,2153,2170,2196,2247,2249,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2794,2890,2955,3012,3019,3025,3059,3108,3126,3151,3168,3169,3182,3194,3213,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3371,3374,3394,3446,3463,3478,3488,3512,3542,3559,3616,3639,3647,3672,3676,3702,3715,3728,3747,3767,3786,3787,3793,3825,3828,3830,3878,3883,3899,3957,3969,4021,4030,4038,4044,4100,4107,411","842121,842122,842123,842124,842125,842126,842127,842128,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",1508,NULL,AAH95408,Legacy Depositors|NIH Initiatives,NULL,0,NULL,NULL,P07858,NULL
804,1,Screen for Chemicals that Shorten Yeast Lifespan,"Southern Research Molecular Libraries Screening Center (SRMLSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Screening Centers Network (MLSCN)_|_Assay Provider: Dr. David S. Goldfarb, University of Rochester_|_Award: R03 MH076395-01_|__|_There is now solid evidence for the existence of conserved pathways that regulate cell aging and senescence. These pathways may have evolved to allow eukaryotic cells and animals to remain reproductively viable for long periods during unfavo",11,SRMLSC,Yeast Lifespan Shortening 138K SD,20071116,"119,253,323,338,366,525,546,774,803,932,936,938,1046,1047,1150,1318,1329,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1833,1893,1922,1967,1985,1986,2000,2007,2015,2082,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2708,2720,2727,2732,2733,2754,2756,2762,2771,2788,2804,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,3279,3295,3308,3331,3332,3333,3334,3335,3339,3366,3371,3373,3374,3385","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",NULL,NULL,NULL,NIH Initiatives,"12297502,15489200,17129213",0,10.1016/j.femsyr.2004.06.015|10.1074/jbc.m205670200|10.1111/j.1474-9726.2006.00240.x,NULL,NULL,NULL
628,1,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen,Assay Provider: P. Jeffrey Conn_|_Assay Provider Affiliation: Vanderbilt University_|_Grant Title: Discovery of novel allosteric modulators of the M1 muscarinic receptor_|_Grant Number: 1 R03 MH077606-01_|__|_The M1 muscarinic receptor is thought to be an important therapeutic target in schizophrenia. A cell-based fluorometric calcium assay was developed for high throughput screening. This assay was used to identify compounds with high selectivity for the M1 receptor subtype that act at an allosteric site o,23,Vanderbilt High Throughput Screening Facility,VMLSCN00000007,20101029,"525,1329,1676,1688,1780,1820,1832,1892,1893,1967,1981,1986,2000,2082,2123,2153,2170,2196,2247,2249,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2794,2890,2955,3012,3019,3025,3059,3108,3126,3151,3168,3169,3182,3194,3213,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3371,3374,3394,3446,3463,3478,3488,3512,3542,3559,3616,3639,3647,3672,3676,3702,3715,3728,3747,3767,3786,3787,3793,3825,3828,3830,3878,3883,3899,3957,3969,4021,4030,4038,4044,4100,4107,411","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",25229,NULL,P08482,NIH Initiatives,"11786307,12021390,14559102,14595031,16465162",0,10.1016/s1471-4892(01)00119-9|10.1016/s1471-4892(03)00107-3|10.1038/nbt1186|10.1073/pnas.1835612100|10.1124/mol.61.6.1297,NULL,P08482,NULL
828,1,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),"Source (MLSCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Florida Research Institute, TSRI_|_Assay Provider: Steven Brown, TSRI_|_Network: Molecular Library Screening Center Network (MLSCN)_|_Grant Proposal Number: 1 R21 NS057101-01_|_PI: Steven Brown_|__|_External Assay ID: GALR2_ANT_BLA_1536_%INH_|__|_Name: Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2)_|__|__|_Description:_|__|_Galanin, a 29 a",5,The Scripps Research Institute Molecular Screening Center,GALR2_ANT_BLA_1536_%INH,20100616,"119,253,323,338,366,525,546,774,803,932,936,938,1046,1047,1150,1318,1329,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1833,1893,1922,1967,1985,1986,2000,2007,2015,2082,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2708,2720,2727,2732,2733,2754,2756,2762,2771,2788,2804,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,3279,3295,3308,3331,3332,3333,3334,3335,3339,3366,3371,3373,3374,3385","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",8811,Cell-based,O43603,NIH Initiatives,"10980593,14993421,15041741,17002216,17160146,17511615",0,10.1038/sj.onc.1203777|10.1073/pnas.0304823101|10.1124/mi.3.3.137|10.1358/dnp.2006.19.8.1043963|10.2174/187152707780619335,NULL,O43603,NULL
803,1,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),"Source (MLSCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Florida Research Institute, TSRI_|_Assay Provider: Steven Brown, TSRI_|_Network: Molecular Library Screening Center Network (MLSCN)_|_Grant Proposal Number: 1 R21 NS057101-01_|_PI: Steven Brown_|__|_External Assay ID: GALR2_AG_BLA_1536_%ACT_|__|_Name: Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2)_|__|_Description:_|__|_Galanin, a 29 amino ac",5,The Scripps Research Institute Molecular Screening Center,GALR2_AG_BLA_1536_%ACT,20100616,"119,253,323,338,366,525,546,774,803,932,936,938,1046,1047,1150,1318,1329,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1833,1893,1922,1967,1985,1986,2000,2007,2015,2082,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2708,2720,2727,2732,2733,2754,2756,2762,2771,2788,2804,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,3279,3295,3308,3331,3332,3333,3334,3335,3339,3366,3371,3373,3374,3385","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",8811,Cell-based,O43603,NIH Initiatives,"10980593,14993421,15041741,17002216,17160146,17511615",0,10.1038/sj.onc.1203777|10.1073/pnas.0304823101|10.1124/mi.3.3.137|10.1358/dnp.2006.19.8.1043963|10.2174/187152707780619335,NULL,O43603,NULL
793,1,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),"Source (MLSCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Scripps Florida_|_Network: Molecular Library Screening Center Network (MLSCN)_|_Grant Proposal Number 1 R21 NS056950-01 (Fast Track)_|_PI: Claes Wahlestedt_|_External Assay ID: NPY-Y2_ANT_CNGC_1536_%INH_|_Name: Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2)_|__|_Description:_|__|_Neuropeptide Y (",5,The Scripps Research Institute Molecular Screening Center,NPY-Y2_ANT_CNGC_1536_%INH,20100616,"119,253,323,338,366,525,546,774,803,932,936,938,1046,1047,1150,1318,1329,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1833,1893,1922,1967,1985,1986,2000,2007,2015,2082,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2708,2720,2727,2732,2733,2754,2756,2762,2771,2788,2804,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,3279,3295,3308,3331,3332,3333,3334,3335,3339,3366,3371,3373,3374,3385","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",4887,Cell-based,NP_000901,NIH Initiatives,"12384178,12742262,14617685,15670655,2664885,3010387",0,10.1016/0167-0115(86)90048-0|10.1016/0278-5846(89)90003-1|10.1016/j.neulet.2004.10.084|10.1016/s0024-3205(02)02159-8|10.1016/s0166-4328(02)00374-1|10.1124/jpet.103.060459,NULL,P49146,NULL
603,2,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLSCN Grant: 1 X01 MH077636-01_|_Assay Provider: Charles McHenry, University of Colorado_|__|_NCGC Assay Overview:_|_E. coli DNA polymerase III holoenzyme complex was assayed for DNA production by fluorescent detection of the double-stranded DNA product with PicoGreen dye. The holoenzyme complex was reconstituted from the following purified protein components: DNA Polymerase III, beta subunit processivity fa",2,National Center for Advancing Translational Sciences (NCATS),DNAR301,20070301,"11,13,51,66,108,119,138,174,177,178,180,196,199,227,239,240,241,243,244,248,249,261,263,286,289,299,300,305,311,323,335,339,370,379,398,403,447,460,500,525,527,535,546,547,564,612,650,660,681,700,701,702,713,750,753,774,785,787,795,864,887,896,903,904,912,931,938,949,957,967,978,991,992,995,996,1004,1017,1023,1030,1045,1046,1049,1052,1054,1057,1066,1102,1103,1123,1140,1150,1176,1183,1214,1309,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,1390,1433,1449,1456,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,16864780,0,10.1073/pnas.0604348103,NULL,NULL,NULL
799,1,Identification of Molecular Probes that Activate MRP-1,"Southern Research Molecular Libraries Screening Center (SRMLSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Screening Centers Network (MLSCN)_|_Submitted by Dr. Gary A. Piazza (Southern Research Institute) in collaboration with Sharon Terry (Genetic Alliance)_|_Proposal number 1X01-MH077620-01_|__|_Pseudoxanthoma elasticum (PXE) is a rare genetic disorder, which involves damage to connective tissues that result in multiple manifestations including skin abnormalities, blindn",11,SRMLSC,MRP Activation SD,20071120,"119,253,323,338,366,525,546,774,803,932,936,938,1046,1047,1150,1318,1329,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1833,1893,1922,1967,1985,1986,2000,2007,2015,2082,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2708,2720,2727,2732,2733,2754,2756,2762,2771,2788,2804,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,3279,3295,3308,3331,3332,3333,3334,3335,3339,3366,3371,3373,3374,3385","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",4363,NULL,NP_004987,NIH Initiatives,NULL,0,NULL,"7.6.2.2,7.6.2.3",P33527,NULL
775,1,Screen for Chemicals that Extend Yeast Lifespan,"Southern Research Molecular Libraries Screening Center (SRMLSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Screening Centers Network (MLSCN)_|_Assay Provider: Dr. David S. Goldfarb, University of Rochester_|_Award: R03 MH076395-01_|__|_There is now solid evidence for the existence of conserved pathways that regulate cell aging and senescence. These pathways may have evolved to allow eukaryotic cells and animals to remain reproductively viable for long periods during unfavo",11,SRMLSC,Yeast Lifespan - restrictive,20071116,"119,253,323,338,366,525,546,774,803,932,936,938,1046,1047,1150,1318,1329,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1833,1893,1922,1967,1985,1986,2000,2007,2015,2082,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2708,2720,2727,2732,2733,2754,2756,2762,2771,2788,2804,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,3279,3295,3308,3331,3332,3333,3334,3335,3339,3366,3371,3373,3374,3385","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",NULL,NULL,NULL,NIH Initiatives,"12297502,15489200,17129213",0,10.1016/j.femsyr.2004.06.015|10.1074/jbc.m205670200|10.1111/j.1474-9726.2006.00240.x,NULL,NULL,NULL
521,2,"HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target","Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Screening Centers Network (MLSCN)_|_Grant Number: XO1 MH077603-01_|_Assay Provider: Dr. Tomas Mustelin, Sanford-Burnham Medical Research Institute_|__|__|_Protein tyrosine phosphatases (PTPs), working with protein tyrosine kinases (PTKs), control the phosphorylation state of many proteins in the signal transduction pathwa",14,Burnham Center for Chemical Genomics,SDCCG-A010-HePTP,20100830,"525,1329,1492,1675,1676,1686,1688,1780,1820,1832,1892,1893,1967,1981,1986,2000,2082,2123,2153,2170,2196,2247,2249,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2794,2890,2955,3012,3019,3025,3059,3108,3126,3151,3168,3169,3182,3194,3213,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3371,3374,3394,3446,3463,3478,3488,3512,3542,3559,3616,3639,3647,3672,3676,3702,3715,3728,3747,3767,3786,3787,3793,3825,3828,3830,3858,3878,3883,3899,3928,3957,3969,4021,403","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",5778,NULL,NP_542155,NIH Initiatives,"10940933,12614357,1510684,15615724,15630428,16226275,6246487",0,10.1002/1521-4141(2000)30:8&lt;2412::aid-immu2412&gt;3.0.co;2-j|10.1016/j.jmb.2005.09.049|10.1016/s0006-291x(05)81592-x|10.1034/j.1600-065x.2003.00014.x|10.1038/nri1530|10.1073/pnas.77.3.1311|10.1074/jbc.m413122200,3.1.3.48,P35236,NULL
425,2,MKP-3 in vitro HTS assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Screening Centers Network (MLSCN)_|_Grant Number: XO1 MH076390-01_|_Assay Provider: Dr. John Lazo, University of Pittsburg_|__|__|_MKP-3 (mitogen-activated protein kinase phosphatase-3; EC 3.1.3.48, EC 3.1.3.16), a dual specificity phosphatase negatively regulates ERK1/2 by catalyzing the removal of a phosphoryl group fro",14,Burnham Center for Chemical Genomics,SDCCG-A002-MKP3,20100825,"525,1329,1492,1675,1676,1686,1688,1780,1820,1832,1892,1893,1967,1981,1986,2000,2082,2123,2153,2170,2196,2247,2249,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2794,2890,2955,3012,3019,3025,3059,3108,3126,3151,3168,3169,3182,3194,3213,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3371,3374,3394,3446,3463,3478,3488,3512,3542,3559,3616,3639,3647,3672,3676,3702,3715,3728,3747,3767,3786,3787,3793,3825,3828,3830,3858,3878,3883,3899,3928,3957,3969,4021,403","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",116663,In vitro,NP_446335,NIH Initiatives,"10209154,12809524,15115656",0,10.1016/j.cellsig.2003.12.008|10.1016/s0955-0674(99)80028-3|10.1021/ar020122r,"3.1.3.16,3.1.3.48",Q64346,NULL
748,2,High Throughput Fluorescence Polarization Screen for Bcl-B Phenotype Converters,"Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Sanford-Burnham Medical Research Institute (San Diego, CA)_|_NIH Molecular Libraries Screening Centers Network (MLSCN)_|__|_Bcl-B is an anti-apoptotic member of the Bcl-2 family that is prominently expressed in plasma and multiple myeloma cells. TR3 (NR4A1; HMR; NP10; GFRP1; NAK1; NUR77; NGFIB) is an orphan member of the steroid/thyroid/retinoid nuclear receptor superfamily that translocates from cellular nuclei to mitochondria upon exposure to various ",14,Burnham Center for Chemical Genomics,SDCCG-A021-Bcl-B,20110119,"253,366,525,1400,2000,2804,2890,3279,3786,3787,3825,3830,3945,4114,4235,4463,4544,4632,4740,4878,4879,4928,5325,5382,5383,5408,5531,5578,5595,5610,5707,5775,6048,6320,6731,6763,6821,6825,6872,7031,7064,7135,7153,7204,7564,7578,7619,8096,8570,8588,8660,8694,8743,9013,9340,10145,10365,10367,10737,10752,10788,11257,11332,11352,11371,11373,11394,11741,12117,12543,12612,12856,12884,12888,12897,12901,12914,13067,13451,14562,14569,15049,15139,15163,15548,15629,15630,15680,15718,15723,15807,15882,16054,16124,16179,","842121,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",3164,NULL,NP_775180,NIH Initiatives,"10947977,11278245,14980220,16892086,17227826",0,10.1016/s0092-8674(04)00162-x|10.1038/sj.onc.1209601|10.1074/jbc.c000871200|10.1126/science.289.5482.1159|10.1182/blood-2006-11-056879,NULL,P22736,NULL
602,1,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,"Southern Research Molecular Libraries Screening Center (SRMLSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Screening Centers Network (MLSCN)_|_(Proposal number 1X01-MH077620-01) Submitted by Dr. Gary A. Piazza of Southern Research Institute._|__|_Drug resistance, whether intrinsic or acquired, is a major clinical obstacle, which limits the efficacy of cancer chemotherapy.  Multi-drug resistance (MDR) is a phenomenon by which tumor cells display or develop resistance to a n",11,SRMLSC,MRP Inhibition,20071116,"119,253,338,366,938,1329,1646,1676,1688,1820,1832,1892,1893,1922,1967,1981,1985,1986,2000,2007,2082,2118,2123,2153,2170,2196,2247,2249,2266,2284,2315,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2804,2890,2950,2955,3012,3019,3025,3059,3108,3125,3151,3168,3169,3182,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3366,3371,3374,3385,3394,3446,3463,3478,3488,3503,3512,3542,3559,3598,3616,3639,3647,3672,3676,3702,3715,3747,3767,3787,3793,3825,3828,3830,3878,3883,3899,39","842121,842122,842123,842124,842125,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842191,842192,842193,842194,842196,842197,842198,8",NULL,NULL,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
802,1,Primary HTS assay for chemical inhibitors of TNF alpha stimulated VCAM1 expression,"Cytokines such as TNF alpha and IL-1B activate a pro-inflammatory response in endothelial cells by nuclear translocation of the NFkB transcription factor (1).  This response induces the transcription of pro-inflammatory genes including, at late times, the cell adhesion molecule, VCAM-1 (Vascular Cell Adhesion Molecule - 1) (2).  The resulting cell surface expression of VCAM-1 upon stimulation with cytokines in primary human umbilical vein cells (HUVEC cells) provides a read-out to study the effects of bioac",19,Columbia University Molecular Screening Center,VCAM1_PS_Signaling_InCell3000_384_VGS0_Inh_09202007,20071119,"253,366,525,1400,2804,3279,3786,3787,3945,4114,4235,4463,4740,4878,4879,4928,5155,5325,5382,5383,5531,5578,5595,5610,5707,5775,6048,6320,6763,6821,6825,6872,7031,7064,7153,7204,7564,7578,8570,8588,8660,8694,8743,9013,9340,10145,10365,10367,10737,10752,10788,11257,11332,11352,11371,11373,11394,11741,12109,12543,12612,12856,12884,12888,12897,12901,12914,13067,13451,14399,14562,15049,15139,15548,15629,15630,15680,15718,15723,15807,15882,16054,16124,16175,16179,16484,16559,16803,17335,17471,20118,20231,20415,20","842121,842122,842124,842125,842126,842127,842129,842130,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842145,842146,842148,842150,842151,842152,842153,842155,842156,842157,842158,842159,842160,842161,842163,842164,842165,842166,842167,842168,842170,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842189,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,842205,842207,8",NULL,NULL,NULL,Legacy Depositors|NIH Initiatives,"11937262,12110129,17292586",0,10.1016/j.cellsig.2006.12.013|10.1016/s0301-472x(02)00777-4|10.1186/ar576,NULL,NULL,NULL
360,2,Glucocerebrosidase,"NCGC Assay Overview:_|__|_Beta-glucocerebrosidase catalyzes the hydrolysis of beta-glucocerebroside to glucose and ceramide. The inherited deficiency of beta-glucocerebrosidase results in Gaucher disease, which is characterized by a wide variety of symptoms including hepatosplenomegaly, anemia, thrombocytopenia, bony lesions and bone marrow infiltration with characteristic storage cells, known as Gaucher cells. There are also forms of the disorder affecting the central nervous system. Patients with the same",2,National Center for Advancing Translational Sciences (NCATS),glucocerebrosidase,20070218,"525,1820,2000,2196,3279,3394,3786,3825,4114,4235,4463,4632,4740,4879,5155,5344,5379,5430,5578,5595,5610,5707,5735,5775,6821,7064,7153,7204,7619,8570,8588,8593,8743,9013,10367,10648,11257,11332,11373,11741,12856,13067,14562,14569,15163,15548,15629,15718,15882,16054,16124,16175,16559,16803,16834,20415,20557,21184,21307,21600,22780,22883,25711,25712,26033,26731,26880,28777,28912,30627,31898,32238,34312,34611,34632,36316,36339,38115,39854,40146,40230,40672,41368,41567,42023,42999,43000,43247,44008,44383,44827,4","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,1Y7V_A,Governmental Organizations|NIH Initiatives,"12434014,12587096,8163674,9331372",0,10.1073/pnas.192582899|10.1086/367850|10.1101/gr.7.10.1020|10.1172/jci117160,NULL,1Y7V_A,NULL
592,0,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|_MLSCN Grant number: none_|__|_NCGC Assay Overview:_|_The rate of false hits is dramatically reduced by the qHTS approach (Inglese et al, PNAS, 103, 1147 (2006)) as spurious high- or low-response wells are quickly revealed when plotted in the context of concentration response. Occasionally, the artifactual effect may originate from the compounds own spectral or other biophysical properties which generally tend t",2,National Center for Advancing Translational Sciences (NCATS),SPEC115,20070719,"51,108,119,138,178,199,248,249,286,289,305,339,500,525,535,546,547,564,650,681,774,785,787,896,903,938,1023,1045,1046,1052,1054,1066,1102,1103,1123,1150,1316,1317,1318,1328,1329,1330,1331,1337,1340,1342,1346,1354,1355,1359,1365,1366,1367,1390,1433,1456,1474,1518,1574,1607,1609,1645,1647,1649,1663,1669,1676,1678,1681,1688,1701,1720,1725,1727,1730,1734,1738,1742,1745,1748,1756,1774,1775,1779,1780,1793,1794,1795,1809,1820,1826,1832,1833,1845,1853,1858,1864,1868,1871,1884,1892,1893,1908,1917,1922,1935,1967,1981","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,16864780,0,10.1073/pnas.0604348103,NULL,NULL,NULL
808,1,Primary HTS assay for chemical potentiators of TNFalpha stimulated VCAM1 expression,"Cytokines such as TNF alpha and IL-1B activate a pro-inflammatory response in endothelial cells by nuclear translocation of the NFkB transcription factor (1).  This response induces the transcription of pro-inflammatory genes including, at late times, the cell adhesion molecule, VCAM-1 (Vascular Cell Adhesion Molecule - 1) (2).  The resulting cell surface expression of VCAM-1 upon stimulation with cytokines in primary human umbilical vein cells (HUVEC cells) provides a read-out to study the effects of bioac",19,Columbia University Molecular Screening Center,VCAM1_PS_Signaling_InCell3000_384_VGS0_Activation_09262007,20071119,"253,366,525,1400,2804,3279,3786,3787,3945,4114,4235,4463,4740,4878,4879,4928,5155,5325,5382,5383,5531,5578,5595,5610,5707,5775,6048,6320,6763,6821,6825,6872,7031,7064,7153,7204,7564,7578,8570,8588,8660,8694,8743,9013,9340,10145,10365,10367,10737,10752,10788,11257,11332,11352,11371,11373,11394,11741,12109,12543,12612,12856,12884,12888,12897,12901,12914,13067,13451,14399,14562,15049,15139,15548,15629,15630,15680,15718,15723,15807,15882,16054,16124,16175,16179,16484,16559,16803,17335,17471,20118,20231,20415,20","842121,842122,842124,842125,842126,842127,842129,842130,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842145,842146,842148,842150,842151,842152,842153,842155,842156,842157,842158,842159,842160,842161,842163,842164,842165,842166,842167,842168,842170,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842189,842191,842192,842193,842194,842196,842197,842198,842199,842200,842201,842202,842203,842204,842205,842207,842208,8",NULL,NULL,NULL,Legacy Depositors|NIH Initiatives,"11937262,12110129,17292586",0,10.1016/j.cellsig.2006.12.013|10.1016/s0301-472x(02)00777-4|10.1186/ar576,NULL,NULL,NULL
436,1,HTS for BAP1 Enzyme inhibitors,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: Keith D. Wilkinson, Emory University_|_MLSCN Grant: 1 R03 MH076382-01_|__|_Assay Overview:_|_ _|_     BAP1 (BRCA1 associated protein 1) is a member of the Ubiquitin carboxy-terminal hydrolase (UCH) family of deubiquitinating enzymes(DUB). These proteases reverse the conjugation of ubiquitin to_|_targeted proteins. The importance of ubiquitin conjugation in many_|_cellular processes ",16,Emory University Molecular Libraries Screening Center,HTS for BAP1 Enzyme inhibitors,20080103,"119,178,289,401,471,525,546,547,564,650,785,896,903,1046,1066,1123,1209,1216,1222,1228,1232,1233,1239,1245,1256,1317,1318,1328,1329,1330,1340,1345,1359,1365,1367,1390,1456,1474,1564,1607,1609,1641,1645,1649,1676,1678,1683,1688,1720,1727,1730,1738,1742,1756,1774,1775,1779,1780,1794,1795,1820,1826,1832,1845,1853,1858,1864,1868,1871,1884,1892,1893,1908,1917,1922,1967,1981,1986,1989,2000,2046,2051,2052,2061,2063,2071,2082,2083,2123,2137,2141,2143,2145,2151,2153,2154,2170,2196,2207,2244,2247,2249,2252,2259,2265,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842167,842168,842169,842170,842172,842174,842175,842176,842177,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",8314,NULL,Q92560,Legacy Depositors|NIH Initiatives,9528852,0,10.1038/sj.onc.1201861,3.4.19.12,Q92560,NULL
568,2,High Throughput Screening Assay for Hsc70 Inhibitors,"Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Sanford-Burnham Medical Research Institute (San Diego, CA)_|_NIH Molecular Libraries Screening Centers Network (MLSCN)_|__|_Over-expression of molecular chaperones occurs commonly in cancers and provides protection from a wide variety of cellular stresses, both endogenous and iatrogenic. Molecular chaperones also play important roles in maintaining the activity of several signal-transducing proteins and transcriptions factors involved in malignant trans",14,Burnham Center for Chemical Genomics,SDCCG-A012-Hsc70,20100830,"119,253,338,366,525,936,938,1046,1047,1329,1474,1646,1676,1688,1832,1893,1922,1967,1981,1985,1986,2000,2007,2082,2118,2123,2153,2170,2247,2249,2266,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2733,2754,2762,2771,2788,2794,2804,2890,2950,2955,3012,3019,3025,3037,3059,3108,3125,3126,3151,3168,3169,3182,3194,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3366,3371,3374,3385,3446,3463,3478,3488,3503,3512,3542,3559,3598,3616,3639,3647,3672,3702,3715,3747,3767,3773,3786,3787","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",3312,NULL,"NP_006588,NP_694881",NIH Initiatives,NULL,0,NULL,NULL,P11142,NULL
836,1,Primary HTS assay for chemical modifiers of cytoskeleton assembly,"Data Source: Columbia University Molecular Screening Center_|_Source (MLSCN Center Name): Columbia University Molecular Screening Center_|_Center Affiliation: Columbia University Molecular Screening Center_|_Assay Provider: Thomas Mayer, Columbia University Molecular Screening Center_|_Network: Molecular Library Screening Center Network (MLSCN)_|_Grant Proposal Number: 1R03 MH076343-01  _|__|_During inflammation, cytokine activation of the NFkB signaling pathway results in, among others, VCAM-1 (Vascular Ce",19,Columbia University Molecular Screening Center,Cytoskeleton_PS_Signaling_InCell3000_384_VGS0_10202007,20071023,"253,366,1400,2804,3279,3786,3787,3945,4114,4235,4463,4740,4878,4879,4928,5155,5325,5382,5383,5531,5578,5595,5610,5707,5775,6048,6763,6821,6825,6872,7031,7064,7153,7204,7564,7578,8570,8588,8694,8743,9013,9340,10145,10365,10367,10737,10752,10788,11257,11332,11352,11371,11373,11741,12109,12612,12856,12884,12888,12897,12901,12914,13067,13451,14399,14562,15049,15139,15629,15630,15718,15723,15807,15882,16054,16124,16175,16484,16559,16803,17335,17471,20118,20231,20415,20557,20612,20926,21107,21184,21307,21600,2162","842121,842122,842124,842125,842126,842127,842129,842130,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842145,842146,842148,842150,842151,842152,842153,842155,842156,842157,842158,842159,842160,842161,842163,842164,842165,842166,842167,842168,842170,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,842205,842207,8",NULL,NULL,NULL,Legacy Depositors|NIH Initiatives,"11937262,16956370,16973154,17292586",0,10.1016/j.cellsig.2006.12.013|10.1016/j.ejphar.2006.08.003|10.1016/s0301-472x(02)00777-4|10.1111/j.1742-4658.2006.05440.x,NULL,NULL,NULL
690,2,Luminescent assay for HTS discovery of chemical inhibitors of placental alkaline phosphatase,"Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_NIH Molecular Libraries Screening Centers Network (MLSCN)_|__|_Alkaline phosphatase (EC 3.1.3.1) (APs) catalyze the hydrolysis of phosphomonoesters, releasing phosphate and alcohol. APs are dimeric enzymes found in most organisms. In human, four isozymes of APs have been identified: three isozymes are tissue-specific and the fourth one is tissue-nonspecific. Placental alkaline phosphata",14,Burnham Center for Chemical Genomics,SDCCG-A022-PLAP-inhibitors,20100830,"253,366,525,1400,2804,2890,3279,3786,3787,3825,3830,3945,4114,4235,4463,4544,4632,4740,4878,4879,4928,5325,5382,5383,5408,5531,5578,5595,5610,5707,5775,6048,6320,6731,6763,6821,6825,6872,7031,7064,7135,7153,7204,7564,7578,7619,8096,8570,8588,8660,8694,8743,9013,9340,10145,10365,10367,10737,10752,10788,11257,11332,11352,11371,11373,11394,11741,12117,12543,12612,12856,12884,12888,12897,12901,12914,13067,13451,14562,14569,15049,15139,15163,15548,15629,15630,15680,15718,15723,15807,15882,16054,16124,16179,16246","842121,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",251,NULL,NP_112603,NIH Initiatives,"12372831,15039209,15946677",0,10.1016/j.jmb.2005.04.068|10.1016/s0002-9440(10)63208-7|10.1074/jbc.m207394200,3.1.3.1,P10696,NULL
361,2,Pyruvate Kinase,"NCGC Assay Overview:_|__|_Pyruvate kinase (partially purified from Bacillus stearothermophilus) was assayed for its ability to generate ATP from ADP using phosphoenolpyruvate (PEP) as a substrate.  ATP generation was detected in a coupled reaction by luciferase-mediated luminescence, an ATP-dependent process.  Pyruvate kinase substrates, PEP and ADP, were present in the assay at Km and 10-fold below Km respectively.  The enzyme was assayed at an intermediate level of activity to screen for inhibitors and ac",2,National Center for Advancing Translational Sciences (NCATS),pyruvatekinase,20061031,"525,1329,1676,1688,1780,1820,1832,1892,1893,1967,1981,1986,2000,2082,2123,2153,2170,2196,2247,2249,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2794,2955,3012,3019,3025,3059,3108,3126,3151,3168,3169,3182,3194,3213,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3371,3374,3394,3446,3463,3478,3488,3512,3542,3559,3616,3639,3647,3672,3676,3702,3715,3728,3747,3767,3786,3793,3825,3828,3878,3883,3899,3957,3969,4021,4030,4038,4044,4100,4107,4114,4173,4201,423","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,BAA02406,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,Q02499,NULL
368,1,Cdc25B Catalytic Domain protein tyrosine phosphatase  HTS,"Cdc25B HTS Developed and Run at the University of Pittsburgh Molecular Screening Center (PMLSC) part of the Molecular Library Screening Center Network (MLSCN). XO1 submission  MH078959 Cdc25B catalytic domain in vitro assay, Assay Provider Dr. Marni Brisson, Department of Pharmacology at the University of Pittsburgh._|_ _|_Cdc25 is a protein tyrosine phosphatase that plays a pivotal role in the regulation of the cell cycle.  Of the three isoforms that exist (Cdc25A, B, and C), Cdc25A and Cdc25B have been fo",9,University of Pittsburgh Molecular Library Screening Center,Cdc25B-CD,20070508,"525,936,1046,1047,1329,1474,1676,1688,1780,1820,1832,1892,1893,1967,1981,1986,2000,2082,2123,2153,2170,2196,2247,2249,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2733,2754,2762,2771,2788,2794,2890,2955,3012,3019,3025,3037,3059,3108,3126,3151,3168,3169,3182,3194,3213,3229,3278,3279,3295,3308,3331,3332,3333,3334,3339,3371,3374,3394,3446,3463,3478,3488,3512,3542,3559,3616,3639,3647,3672,3676,3702,3715,3728,3747,3767,3773,3786,3787,3793,3825,3828,3830,3878,3883,3899,3957,3969","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",994,NULL,NP_004349,NIH Initiatives,NULL,0,NULL,3.1.3.48,P30305,NULL
777,1,CYP2C9 Assay,"Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_NIH Molecular Libraries Screening Centers Network (MLSCN)_|__|_The cytochrome P450 enzymes represent a diverse superfamily of hemoproteins present in eukaryotic, bacterial, and archaean systems. The primary function of these enzymes is in the metabolism and clearance of both endogenous and exogenous (xenobiotic) compounds due to their propensity to metabolize multiple substrates through",14,Burnham Center for Chemical Genomics,SDCCG-A027-CYP2C9,20100827,"253,366,525,1400,2804,2890,3279,3786,3787,3825,3830,3945,4114,4235,4463,4544,4632,4740,4878,4879,4928,5325,5382,5383,5408,5531,5578,5595,5610,5707,5775,6048,6320,6731,6763,6821,6825,6872,7031,7064,7135,7153,7204,7564,7578,7619,8096,8570,8588,8660,8694,8743,9013,9340,10145,10365,10367,10737,10752,10788,11257,11332,11352,11371,11373,11394,11741,12117,12543,12612,12856,12884,12888,12897,12901,12914,13067,13451,14562,14569,15049,15139,15163,15548,15629,15630,15680,15718,15723,15807,15882,16054,16124,16179,16246","842121,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",1559,NULL,NP_000762,NIH Initiatives,NULL,0,NULL,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1487,2,qHTS Assay for Modulators of Lamin A Splicing,NCGC Assay Overview:_|__|_Hutchinson-Gilford Progeria Syndrome (HGPS) is a pediatric premature aging disease caused by a spontaneous mutation in the lamin A/C (LMNA) gene. The mutation activates a cryptic splice site in the LMNA pre-mRNA which results in production of a pre-lamin A protein that cannot be processed properly. The mutant protein accumulates in the nucleus and negatively affects numerous cellular functions. Correction of the splicing defect in HGPS patient cells using a targeted oligonucleotide,2,National Center for Advancing Translational Sciences (NCATS),LMNA453,20090107,"51,119,178,180,190,191,196,205,206,227,244,253,263,275,289,298,323,338,359,366,370,379,401,408,453,460,464,471,525,535,546,547,564,588,594,595,596,612,636,650,681,710,727,736,753,774,785,803,827,846,863,864,866,876,887,892,896,903,904,932,936,938,967,978,985,992,1004,1018,1023,1030,1046,1047,1050,1051,1052,1054,1057,1064,1066,1072,1080,1110,1123,1132,1140,1150,1176,1203,1216,1222,1228,1232,1233,1234,1245,1254,1256,1287,1292,1309,1317,1318,1328,1329,1330,1340,1345,1359,1365,1367,1390,1400,1456,1474,1480,1482","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",4000,NULL,NP_733822,Governmental Organizations|NIH Initiatives,"15750600,16712425",0,10.1038/nm1204|10.1089/adt.2006.4.209,NULL,P02545,NULL
1766,2,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,"qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias_|_NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Centers Network [MLPCN]_|__|_MLPCN Grant: MH084875-01A1_|_Assay Submitter (PI): Jolanta Grembecka, Tomasz Cierpicki, University of Virginia_|__|_Translocations of the MLL (Mixed Lineage Leukemia) gene are frequently found in human leukemias affecting both children and adults. Fusion of MLL to one of more than 60 genes results in generation of oncogenic ",2,National Center for Advancing Translational Sciences (NCATS),MENN9465,20090515,"51,72,119,135,178,180,185,187,190,191,196,199,204,205,206,224,227,239,244,253,263,273,275,277,289,298,303,304,323,338,342,359,366,370,379,401,408,450,453,460,464,471,499,525,535,546,547,564,588,594,595,596,607,610,612,614,636,637,650,681,698,710,727,736,750,753,757,774,785,791,798,803,827,830,836,846,847,853,863,864,866,876,887,892,896,903,904,912,914,931,932,936,938,967,978,985,992,999,1004,1018,1023,1030,1046,1047,1050,1051,1052,1053,1054,1057,1060,1064,1066,1072,1080,1101,1102,1103,1110,1123,1131,1132,11","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8","4221,4297",NULL,"NP_000235,NP_005924",Governmental Organizations|NIH Initiatives,16239140,0,10.1016/j.cell.2005.09.025,2.1.1.354,"O00255,Q03164",NULL
1768,2,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,"qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias_|_NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Centers Network [MLPCN]_|__|_MLPCN Grant: MH084875-01A1_|_Assay Submitter (PI): Jolanta Grembecka, Tomasz Cierpicki, University of Virginia_|__|_Translocations of the MLL (Mixed Lineage Leukemia) gene are frequently found in human leukemias affecting both children and adults. Fusion of MLL to one of more than 60 genes results in generation of oncogenic ",2,National Center for Advancing Translational Sciences (NCATS),MENN9466,20090515,"51,119,135,178,180,185,187,190,191,196,199,204,205,206,224,227,239,244,253,263,273,275,277,289,298,303,304,323,338,342,359,366,370,379,401,408,450,453,460,464,471,499,525,535,546,547,564,588,594,595,596,607,610,612,614,636,637,650,681,698,710,727,736,750,753,757,774,785,791,798,803,827,830,836,846,847,853,863,864,866,876,887,892,896,903,904,912,914,931,932,936,938,967,978,985,992,999,1004,1018,1023,1030,1046,1047,1050,1051,1052,1053,1054,1057,1060,1064,1066,1072,1080,1101,1102,1103,1110,1123,1131,1132,1134,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8","4221,4297",NULL,"NP_000235,NP_005924",Governmental Organizations|NIH Initiatives,16239140,0,10.1016/j.cell.2005.09.025,2.1.1.354,"O00255,Q03164",NULL
1961,2,Image-based HTS for Selective Agonists of GPR55,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1X01 DA026205-01 _|_Assay Provider: Dr. Mary Abood, California Pacific Medical Center Research Institute (currently Temple University)_|__|_The cannabinoid and endocannabinoid system has been implicated in the pathophysiology of drug dependence and addictio",14,Burnham Center for Chemical Genomics,BCCG-A221-GPR55-Agonist-Assay,20101230,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",9290,NULL,NP_005674,NIH Initiatives,"17765871,17876302,17906678,18263782,19233486,19723626,9931487",0,10.1016/j.bbrc.2007.08.078|10.1016/j.tips.2008.12.004|10.1016/s0169-328x(98)00277-0|10.1038/sj.bjp.0707460|10.1038/sj.bjp.0707481|10.1074/jbc.m109.050187|10.1104/pp.107.111443,NULL,Q9Y2T6,NULL
1460,2,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding","NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: X01 MH083262-01_|_Assay Provider: Carlo Ballatore, University of Pennsylvania_|__|__|_NCGC Assay Overview:_|_The microtubule-associated protein tau is an abundant protein in the axons of neurons that stabilizes microtubules. With its ability to modulate microtubule dynamics, tau contributes directly or indirectly, to key structural and regulatory cellular functions. Particularly important is the ",2,National Center for Advancing Translational Sciences (NCATS),TAU2241,20081230,"72,119,178,185,187,190,191,199,204,206,224,239,253,275,289,298,304,323,338,342,366,370,401,408,412,453,462,464,471,525,535,546,547,564,588,596,607,610,636,650,681,698,710,727,736,750,774,785,803,827,830,836,846,847,853,864,876,892,896,903,904,912,914,932,936,938,992,999,1001,1046,1047,1050,1064,1066,1072,1080,1102,1103,1110,1123,1148,1150,1176,1182,1183,1201,1203,1204,1212,1214,1216,1217,1218,1219,1220,1222,1225,1228,1232,1233,1234,1235,1236,1240,1242,1243,1245,1249,1253,1254,1256,1257,1287,1302,1309,1316,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",4137,NULL,AAI14949,Governmental Organizations|NIH Initiatives,"11606569,17176091,8068626,9836646",0,10.1021/bi00198a017|10.1021/bi061422+|10.1074/jbc.m105196200|10.1126/science.282.5395.1914,NULL,AAI14949,NULL
1721,2,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),"NIH Chemical Genomics Center [NCGC]_|_Malcolm Walkinshaw, Hugh Morgan, Linda Gilmore_|_University of Edinburgh, UK_|_MLPCN Grant: 1 R03 MH085697-01_|__|_NCGC Assay Overview:_|_Pyruvate kinase (L. Mexicana) (LmPK) enzyme was supplied as a highly purified (>95% pure) sulphate-free preparation from University of Edinburgh, UK and assayed for its ability to generate ATP from ADP using phosphoenolpyruvate (PEP) as a substrate. ATP generation was detected in a coupled reaction by luciferase-mediated luminescence,",2,National Center for Advancing Translational Sciences (NCATS),PYKL835i,20100316,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,CAA52898,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,CAA52898,NULL
1722,2,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),"NIH Chemical Genomics Center [NCGC]_|_Malcolm Walkinshaw, Hugh Morgan, Linda Gilmore_|_University of Edinburgh, UK_|_MLPCN Grant: 1 R03 MH085697-01_|__|_NCGC Assay Overview:_|_Pyruvate kinase (L. Mexicana) (LmPK) enzyme was supplied as a highly purified (>95% pure) sulphate-free preparation from University of Edinburgh, UK and assayed for its ability to generate ATP from ADP using phosphoenolpyruvate (PEP) as a substrate. ATP generation was detected in a coupled reaction by luciferase-mediated luminescence,",2,National Center for Advancing Translational Sciences (NCATS),PYKL731a,20100316,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,CAA52898,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,CAA52898,NULL
1030,2,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),"Aldehyde dehydrogenase 1 (ALDH1A1) catalyzes the NAD+ dependent oxidation of a variety of endogenous and exogenous aldehydes to the corresponding carboxylic acids. The enzyme is the critical step in the metabolic activation of retinoic acid, which plays essential roles as nuclear receptor ligand. Furthermore, the precursor, retinaldehyde has recently been shown to play a fundamental role in adipogenesis and obesity, which makes inhibitor development a possible target in metabolic diseases. See [1] through [",2,National Center for Advancing Translational Sciences (NCATS),ALDH101,20100315,"11,13,51,66,72,108,119,174,177,178,180,185,187,190,191,196,199,204,206,224,227,239,240,241,243,244,253,261,263,275,289,298,299,300,304,311,323,335,338,339,342,366,370,379,398,401,403,408,412,447,453,460,462,464,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,710,713,727,736,750,753,774,785,795,803,827,830,836,846,847,853,864,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,999,1001,1004,1017,1023,1030,1046,1047,1049,1050,1052,1054,1057,1064,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",216,NULL,AAP35567,Governmental Organizations|NIH Initiatives,"12851412,12941160,16864780,17175089,17529981",0,10.1016/j.biochi.2006.11.005|10.1038/nm1587|10.1073/pnas.0604348103|10.1074/jbc.m303709200|10.1089/104454903322216671,NULL,P00352,NULL
1463,2,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization","NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: X01 MH083262-01_|_Assay Provider: Carlo Ballatore, University of Pennsylvania_|__|__|_NCGC Assay Overview:_|_The microtubule-associated protein tau is an abundant protein in the axons of neurons that stabilizes microtubules. With its ability to modulate microtubule dynamics, tau contributes directly or indirectly, to key structural and regulatory cellular functions. Particularly important is the ",2,National Center for Advancing Translational Sciences (NCATS),TAU2304,20081229,"72,119,178,185,187,190,191,199,204,206,224,239,253,275,289,298,304,323,338,342,366,370,401,408,412,453,462,464,471,525,535,546,547,564,588,596,607,610,636,650,681,698,710,727,736,750,774,785,803,827,830,836,846,847,853,864,876,892,896,903,904,912,914,932,936,938,992,999,1001,1046,1047,1050,1064,1066,1072,1080,1102,1103,1110,1123,1148,1150,1176,1182,1183,1201,1203,1204,1212,1214,1216,1217,1218,1219,1220,1222,1225,1228,1232,1233,1234,1235,1236,1240,1242,1243,1245,1249,1253,1254,1256,1257,1287,1302,1309,1316,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"11606569,17176091,8068626,9836646",0,10.1021/bi00198a017|10.1021/bi061422+|10.1074/jbc.m105196200|10.1126/science.282.5395.1914,NULL,NULL,NULL
1468,2,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization","NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: X01 MH083262-01_|_Assay Provider: Carlo Ballatore, University of Pennsylvania_|__|__|_NCGC Assay Overview:_|_The microtubule-associated protein tau is an abundant protein in the axons of neurons that stabilizes microtubules. With its ability to modulate microtubule dynamics, tau contributes directly or indirectly, to key structural and regulatory cellular functions. Particularly important is the ",2,National Center for Advancing Translational Sciences (NCATS),TAU2591,20081230,"72,119,178,185,187,190,191,199,204,206,224,239,253,275,289,298,304,323,338,342,366,370,401,408,412,453,462,464,471,525,535,546,547,564,588,596,607,610,636,650,681,698,710,727,736,750,774,785,803,827,830,836,846,847,853,864,876,892,896,903,904,912,914,932,936,938,992,999,1001,1046,1047,1050,1064,1066,1072,1080,1102,1103,1110,1123,1148,1150,1176,1182,1183,1201,1203,1204,1212,1214,1216,1217,1218,1219,1220,1222,1225,1228,1232,1233,1234,1235,1236,1240,1242,1243,1245,1249,1253,1254,1256,1257,1287,1302,1309,1316,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",4137,NULL,AAI14949,Governmental Organizations|NIH Initiatives,"11606569,17176091,8068626,9836646",0,10.1021/bi00198a017|10.1021/bi061422+|10.1074/jbc.m105196200|10.1126/science.282.5395.1914,NULL,AAI14949,NULL
1469,2,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: DK058080_|_Assay Provider: R. Kip Guy, St. Jude Children's Research Hospital_|__|_NCGC Assay Overview:_|_Thyroid receptor (TR) regulates many homeostatic processes including basal metabolism, cardiovascular function, body weight, and lipid trafficking. TR modulators are potential therapeutics for obesity and hyperlipidemias but current thyroid analogs have undesirable side effects, particularly c",2,National Center for Advancing Translational Sciences (NCATS),TR778,20081231,"6,11,13,51,66,72,119,135,174,177,178,180,185,187,190,191,196,199,204,205,206,224,227,239,240,241,243,244,253,261,263,273,275,277,289,298,299,300,304,311,323,335,338,342,359,366,370,379,398,401,403,408,412,447,450,453,460,462,464,471,525,527,535,546,547,564,568,588,594,595,596,607,610,612,614,636,650,660,671,679,681,698,700,701,702,710,713,727,736,750,753,757,774,785,795,803,827,830,836,846,847,853,863,864,866,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,985,991,992,995,996,999,1001,1004,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",7068,NULL,NP_001121649,Governmental Organizations|NIH Initiatives,16804159,0,10.1126/stke.3412006pl3,NULL,P10828,NULL
1904,100,siRNA Circadian Assay,"Description:_|__|_To identify additional clock genes and modifiers, we conducted a genome-wide screen of ~90,000 siRNAs (QIAGEN Inc) in a human cellular model of clock function. Knockdown of nearly a thousand genes reduced_|_rhythm amplitude; these are presumably due to toxic effects on cells. Hundreds of genes potently modified period length or increased amplitude.",37,The Genomics Institute of the Novartis Research Foundation (GNF),siRNA_circadian,20100701,NULL,"85098869,85098870,85098871,85098872,85098873,85098874,85098875,85098876,85098877,85098878,85098879,85098880,85098881,85098882,85098883,85098884,85098885,85098886,85098887,85098888,85098889,85098890,85098891,85098892,85098893,85098894,85098895,85098896,85098897,85098898,85098899,85098900,85098901,85098902,85098903,85098904,85098905,85098906,85098907,85098908,85098909,85098910,85098911,85098912,85098913,85098914,85098915,85098916,85098917,85098918,85098919,85098920,85098921,85098922,85098923,85098924,85098925","1,2,9,10,12,13,14,15,16,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,43,47,48,49,50,51,52,53,54,55,56,58,59,60,70,71,72,81,86,87,88,89,90,91,92,93,94,95,97,98,100,101,102,103,104,105,107,108,109,111,112,113,114,115,116,117,118,119,120,123,124,125,126,127,128,130,131,132,133,134,135,136,140,141,142,143,146,147,148,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,172,173,174,175,176,177,178,181,182,183,185,186,187,189,190,191,196,197,199,203,204,205,207,208,21",RNAi,NULL,Legacy Depositors|Research and Development,19765810,1,10.1016/j.cell.2009.08.031,NULL,NULL,NULL
1479,2,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: DK058080_|_Assay Provider: R. Kip Guy, St. Jude Children's Research Hospital_|__|__|_NCGC Assay Overview:_|_Thyroid receptor (TR) regulates many homeostatic processes including basal metabolism, cardiovascular function, body weight, and lipid trafficking. TR modulators are potential therapeutics for obesity and hyperlipidemias but current thyroid analogs have undesirable side effects, particularl",2,National Center for Advancing Translational Sciences (NCATS),TR852,20090107,"6,11,13,51,66,72,119,135,174,177,178,180,185,187,190,191,196,199,204,205,206,224,227,239,240,241,243,244,253,261,263,273,275,277,289,298,299,300,304,311,323,335,338,342,359,366,370,379,398,401,403,408,412,447,450,453,460,462,464,471,525,527,535,546,547,564,568,588,594,595,596,607,610,612,614,636,650,660,671,679,681,698,700,701,702,710,713,727,736,750,753,757,774,785,795,803,827,830,836,846,847,853,863,864,866,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,985,991,992,995,996,999,1001,1004,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",7068,NULL,NP_001121649,Governmental Organizations|NIH Initiatives,16804159,0,10.1126/stke.3412006pl3,NULL,P10828,NULL
1381,1,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,"Excerpts from the R21NS057026 Application - Dr. Billy Day University of Pittsburgh._|__|_Cytoplasmic dynein is the molecular motor that carries cargo to the minus ends of microtubules (MTs) (e.g., from the cytoplasm to the nucleus), and provides the mechancial force for many other important fuctions, including nuclear envelope breakdown and sister chromatid exchange at mitosis. Unlike the numerous MT plus end-directed molecular motors, the kinesins, no specific small molecule inhibitors of dynein are known.",9,University of Pittsburgh Molecular Library Screening Center,R21NS057026: Primary Glucocorticoid Nuclear Hormone Receptor Translocation HCS Assay to Identify Inhibitors of Dynein Mediated Cargo Transport towards the Minus Ends of Microtubules.,20080818,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2181,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2866,2890,2904,2950,2955,2972,3003,3012,3019,3025,3","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",NULL,NULL,NULL,NIH Initiatives,"14978266,15213337",0,10.1073/pnas.0400116101|10.1126/stke.2382004pl10,NULL,NULL,NULL
1458,2,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|__|_MLPCN Grant: R03 MH084179-01_|_Assay Submitter (PI): Elliot Androphy_|__|_NCGC Assay Overview:_|__|_Spinal muscular atrophy (SMA) is caused by insufficient levels of the survival motor neuron protein SMN. The SMN locus on chromosome 5q13 contains two inverted copies of SMN called SMN1 and SMN2 which are 99% identical at the amino acid level. SMN1 is a fully functional protein and SMN2 skips exon 7 90%,2,National Center for Advancing Translational Sciences (NCATS),SMN2002,20081223,"11,13,51,66,108,119,174,177,178,180,185,187,190,191,196,199,204,224,227,239,240,241,243,244,253,261,263,275,289,298,299,300,311,323,335,338,339,366,370,379,398,401,403,408,412,447,460,462,471,500,525,527,535,546,547,564,588,596,607,612,636,650,660,681,700,701,702,713,727,736,753,774,785,795,803,827,830,836,846,853,864,887,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,1001,1004,1017,1023,1030,1046,1047,1049,1052,1054,1057,1064,1066,1072,1123,1140,1148,1150,1176,1182,1183,1203,1204,1212,","842121,842122,842123,842124,842125,842126,842127,842128,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842166,842167,842168,842169,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842201,8",6607,NULL,NP_059107,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,Q16637,NULL
1631,2,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,"NIH Chemical Genomics Center [NCGC]_|_Matthew G. Vander Heiden, M.D., Ph.D. [Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115]_|_MLPCN Grant: 1 R03 MH085679-01_|__|_NCGC Assay Overview:_|_Human pyruvate kinase muscle 2 (hPK-M2) enzyme was supplied as a highly purified (>95% pure) preparation from Harvard Medical School and assayed for its ability to generate ATP from ADP using phosphoenolpyruvate (PEP) as a substrate. ATP generation was detected in a coupled reaction by luciferase-mediated ",2,National Center for Advancing Translational Sciences (NCATS),PYKH221a,20090619,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1214,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1677,1688,1694,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2359,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",5315,NULL,NP_002645,Governmental Organizations|NIH Initiatives,NULL,0,NULL,2.7.1.40,P14618,NULL
1634,2,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,"NIH Chemical Genomics Center [NCGC]_|_Matthew G. Vander Heiden, M.D., Ph.D. [Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115]_|_MLPCN Grant: 1 R03 MH085679-01_|__|_NCGC Assay Overview:_|_Human pyruvate kinase muscle 2 (hPK-M2) enzyme was supplied as a highly purified (>95% pure) preparation from Harvard Medical School and assayed for its ability to generate ATP from ADP using phosphoenolpyruvate (PEP) as a substrate. ATP generation was detected in a coupled reaction by luciferase-mediated ",2,National Center for Advancing Translational Sciences (NCATS),PYKH162i,20090619,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1214,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1677,1688,1694,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2359,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",5315,NULL,NP_002645,Governmental Organizations|NIH Initiatives,NULL,0,NULL,2.7.1.40,P14618,NULL
1471,2,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|_ _|_MLPCN Grant: R03MH084839-01A1_|_Assay Submitter (PI): Wei Zheng_|_ _|_NCGC Assay Overview:_|__|_Huntington's disease is a neurodegenerative disorder caused by a trinucleotide repeat expansion in Exon 1 of the Huntingtin gene. The CAG trinucleotide encodes glutamine and polyglutamine expansions cause cell death in selective areas of the brain. Huntington polyglutamine repeats have the tendency to form,2,National Center for Advancing Translational Sciences (NCATS),HTT0008,20090320,"11,13,51,66,72,108,119,138,174,177,178,180,185,187,190,191,196,199,204,205,206,224,227,239,240,241,243,244,248,249,253,261,263,275,286,289,298,299,300,304,305,311,323,335,338,339,342,359,366,370,379,398,401,403,408,412,447,453,460,462,464,471,500,525,527,535,546,547,564,588,594,595,596,607,610,612,636,650,660,681,698,700,701,702,710,713,727,736,750,753,774,785,787,791,795,798,827,830,836,846,847,853,863,864,866,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,985,991,992,995,996,999,1001,1004","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",3064,NULL,NP_002102,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P42858,NULL
1656,1,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH083261-01A1_|_Assay Provider: Dr. Patrick M. McDonough, Vala Sciences Inc._|__|_Medical researchers world-wide now use the term ""epidemic"" or ""pandemic"" to describe the alarming incidence of obesity in modern society, which is estimated to occur in ",14,Burnham Center for Chemical Genomics,BCCG-A181-Lipid-Droplet-Imaging-Assay,20101230,"72,119,191,204,253,298,303,323,338,366,460,499,546,547,588,637,774,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1401,1474,1492,1539,1646,1676,1688,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2082,2092,2108,2118,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2482,2519,2554,2576,2581,2585,2618,2662,2690,2692,2708,2720,2722,2727","842121,842122,842126,842128,842131,842137,842138,842139,842142,842143,842149,842150,842153,842155,842156,842157,842159,842161,842164,842168,842169,842174,842176,842182,842183,842185,842186,842187,842191,842193,842195,842196,842197,842198,842210,842211,842215,842217,842219,842220,842222,842225,842228,842236,842237,842239,842249,842251,842252,842257,842258,842259,842260,842266,842269,842274,842277,842279,842280,842282,842283,842284,842288,842291,842292,842298,842299,842300,842303,842308,842315,842322,842323,8",NULL,NULL,NULL,NIH Initiatives,"18093937,18304679,18408709,19067489,7904757",0,10.1016/j.jhep.2008.01.009|10.1038/nature06928|10.1073/pnas.0704154104|10.1073/pnas.91.2.674|10.1371/journal.pbio.0060292,NULL,NULL,NULL
1868,2,qHTS Assay for Inhibitors of Human Galactokinase (GALK),"NIH Molecular Libraries Probe Production Centers Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|_MLPCN Grant: R03 MH085689-01_|_Assay Submitter (PI): Kent Lai (University of Utah School of Medicine, 50 N Mario Capecchi Drive, Salt Lake City, UT 84132)_|__|_NCGC Assay Overview:_|_Inherited deficiency of galactose-1-phosphate uridyltransferase (GALT) can result in a potentially lethal disorder called Classic Galactosemia (OMIM 230400). Several lines of evidence indicate that an elevated level of galac",2,National Center for Advancing Translational Sciences (NCATS),GALK663,20091026,"72,119,191,204,253,298,323,338,366,525,546,547,774,864,932,936,938,1046,1047,1201,1309,1318,1329,1345,1367,1400,1474,1492,1539,1688,1727,1738,1775,1780,1820,1832,1853,1882,1890,1892,1893,1967,1981,1985,1986,2000,2002,2018,2048,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2435,2466,2471,2480,2482,2519,2554,2576,2585,2690,2692,2708,2722,2727,2732,2733,2741,2754,2756,2762,2804,2812,2866,2890,2904,2955,2972,2999,3003,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",2584,NULL,NP_000145,Governmental Organizations|NIH Initiatives,"18490662,19215089",0,10.1021/jm8014525|10.1177/1087057108318331,2.7.1.6,P51570,NULL
1832,1,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,"Broad Institute: MLPCN maternal gene expression_|__|_Project ID: 2024_|__|_Keywords: Zinc finger, C. elegans, maternal gene expression, RNA-protein interaction, gene regulation, MEX-5, POS-1, embryonic development_|__|_Primary Collaborators: Sean Ryder, U. Mass Medical School, sean.ryder@umassmed.edu_|__|_Project Overview: _|_In most organisms, the body axes and founding tissue types are formed prior to the onset of zygotic transcription. Thus, post-transcriptional regulation of maternal transcripts by mate",31,Broad Institute,2024-01-A,20090929,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",178296,NULL,Q9XUB2,NIH Initiatives,17264081,0,10.1074/jbc.m700079200,NULL,Q9XUB2,NULL
1379,2,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,"NCGC Assay Overview:_|__|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|_NIH Chemical Genomics Center [NCGC]_|_MLSCN Grant: None_|__|_Luciferase (Kinase-Glo, Promega Corporation) was assayed for its ability to generate light using ATP and luciferin as substrates. The ATP concentration in the assay (10 uM) was within the linear range of enzyme activity for the assay conditions used.",2,National Center for Advancing Translational Sciences (NCATS),LUCKG089,20100706,"51,108,119,178,185,190,191,199,204,206,224,239,253,275,289,298,304,323,338,339,342,366,370,401,408,453,464,471,500,525,535,546,547,564,588,596,607,610,636,650,681,698,710,727,736,750,774,785,803,827,830,836,846,847,853,864,876,892,896,903,904,912,914,932,936,938,992,999,1023,1046,1047,1050,1052,1054,1064,1066,1072,1080,1102,1103,1110,1123,1148,1150,1176,1183,1199,1203,1204,1214,1216,1222,1228,1232,1233,1242,1245,1249,1254,1256,1287,1302,1309,1317,1318,1321,1328,1329,1330,1340,1345,1348,1354,1355,1359,1365,1","842121,842122,842123,842124,842125,842126,842127,842128,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842166,842167,842168,842169,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842201,8",NULL,NULL,BAA05005,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,BAA05005,NULL
1477,2,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|_ _|_MLPCN Grant: X01MH083259-01_|_Assay Submitter (PI): Paul Liu_|_ _|_NCGC Assay Overview:_|_ _|_Core Binding Factor (CBF) abnormalities are associated with 20-25% of all acute myeloid leukemias (AML), of which 5-10% are further sub classified as acute myelomonocytic leukemia with eosinophilia,  also known as M4Eo in the FAB classification scheme.  This subtype of leukemia is usually associated with chr",2,National Center for Advancing Translational Sciences (NCATS),CBFB001,20090102,"11,13,51,66,72,119,135,174,177,178,180,185,187,190,191,196,199,204,206,224,227,239,240,241,243,244,253,261,263,273,275,277,289,298,299,300,304,311,323,335,338,342,366,370,379,398,401,403,408,412,447,450,453,460,462,464,471,525,527,535,546,547,564,595,596,607,610,612,614,636,650,660,698,700,701,702,710,713,727,736,750,753,757,774,785,795,803,827,830,846,847,853,864,866,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,999,1001,1004,1017,1030,1046,1047,1049,1050,1054,1060,1066,10","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
1461,2,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|__|_MLPCN Grant: X01-DA026210-01_|_Assay Submitter (PI): Heilig, Markus Alexander_|__|_NCGC Assay Overview:_|__|_Neuropeptide S receptor (NPSR), previously known as GPR154, is a recently de-orphanized G protein coupled receptor. Its endogenous ligand is the 20 amino acids peptide Neuropeptide S (NPS). Activation of NPSR induces transient increases in intracellular calcium and cAMP, suggesting coupling of ",2,National Center for Advancing Translational Sciences (NCATS),NPSR003,20090610,"72,119,178,191,204,253,275,289,298,323,338,366,401,408,471,525,546,547,564,650,774,785,803,864,896,903,932,936,938,1046,1047,1066,1123,1150,1201,1216,1222,1228,1232,1233,1245,1256,1309,1317,1318,1328,1329,1330,1340,1345,1359,1365,1367,1390,1400,1456,1474,1492,1539,1564,1607,1609,1641,1645,1646,1649,1676,1678,1683,1688,1694,1697,1720,1727,1730,1738,1742,1756,1774,1775,1779,1780,1794,1795,1820,1826,1832,1833,1845,1853,1858,1864,1868,1871,1882,1884,1892,1893,1908,1917,1922,1967,1981,1985,1986,1989,2000,2002,20","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",387129,NULL,NP_997055,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,Q6W5P4,NULL
1875,1,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,"Keywords: mRNA maturation, polyadenylation, reporter gene assay, yeast, gene expression_|__|_Assay:  Yeast which harbor a reporter construct will be screened for elevated levels of beta-galactosidase activity using the luminescent signal from the GalScreen assay.  Briefly, cells are lysed after incubation with compounds using the GalScreen reagent and then the luminescent signal is read on a plate reader._|__|_Expected Outcome:  Compounds which perturb polyadenylation will produce an elevated level of lumin",31,Broad Institute,2015-01-INHIBITORS-SINGLE_POINT-MLPCN_HTS,20090916,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",NULL,Cell-based,NULL,NIH Initiatives,"12391290,18461935,19147347,2005893",0,10.1016/j.bmcl.2008.12.081|10.1021/ja711209p|10.1073/pnas.222222699|10.1128/mcb.11.4.2004,NULL,NULL,NULL
1662,1,MLPCN Streptokinase Expression Inhibition,"Broad Institute MLPCN Streptokinase Expression Inhibition Project_|__|_Project ID: 2014_|_ _|_Keywords: Streptokinase, inhibition, growth, bacterial, group A streptococcus, virulence_|__|_Primary Collaborators: Hongmin Sun, University of Missouri-Columbia, sunh@health.missouri.edu_|_ _|_Project Overview:_|_The goal of the project is to identify and develop novel antibiotic small molecules through inhibiting streptokinase (SK) expression in group A streptococcus (GAS). Based on the critical role of SK in GAS",31,Broad Institute,2014-01,20090409,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",901648,NULL,NP_269944,NIH Initiatives,15333838,0,10.1126/science.1101245,NULL,P10520,NULL
1663,1,MLPCN Platelet Activation -Dense Granule Release,"Broad Institute MLPCN Platelet Activation Project_|__|_Project ID: 2016_|__|_Keywords: Platelet, activation, granule, secretion, arterial thrombosis, PAR1, SFLLRN, thrombin receptor_|__|_Primary Collaborators:_|__|_Robert Flaumenhaft, Beth Israel Deaconess Medical Center, rflaumen@bidmc.harvard.edu_|__|_John Thomas, NHLBI, ThomasJ@nhlbi.nih.gov_|__|_Project Overview:_|__|_The goal of this project is to identify small molecules that inhibit the activation of platelets by measuring the secretion of ATP-rich d",31,Broad Institute,2016-01,20090409,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,8",NULL,NULL,NULL,NIH Initiatives,"1313429,14645013",0,10.1182/blood-2003-04-1133,NULL,NULL,NULL
1865,2,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,"NIH Molecular Libraries Screening Centers Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLSCN Grant: 1 X01 MH079860-01_|_Assay Provider: Elisabeth D. Martinez, University of Texas SW Medical Center_|__|_NCGC Assay Overview:_|_The Locus Derepression (LDR) assay detects the derepression or induction of a GFP reporter that is stably integrated in a genomic region of murine cells that is presumably silenced. Transcription of the GFP reporter is controlled by a CMV promoter, which normally is consti",2,National Center for Advancing Translational Sciences (NCATS),LDR883,20090710,"72,119,178,185,187,190,191,199,204,206,224,239,253,275,289,298,304,323,338,342,366,370,401,408,412,453,462,464,471,525,535,546,547,564,588,596,607,610,636,650,681,698,710,727,736,750,774,785,803,827,830,836,846,847,853,864,876,892,896,903,904,912,914,932,936,938,992,999,1001,1046,1047,1050,1054,1064,1066,1072,1080,1102,1103,1110,1123,1148,1150,1176,1182,1183,1199,1201,1203,1204,1212,1214,1216,1217,1218,1219,1220,1222,1225,1228,1232,1233,1234,1235,1236,1240,1242,1243,1245,1249,1253,1254,1256,1257,1287,1302,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"17110184,17110211,18211814",0,10.1016/j.ab.2007.12.028|10.1016/s0076-6879(06)14002-1|10.1016/s0076-6879(06)14029-x,NULL,NULL,NULL
1688,2,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|__|_MLPCN Grant: R03MH084839-01A1_|_Assay Submitter (PI): Wei Zheng_|__|_NCGC Assay Overview:_|__|_Huntington's disease is a neurodegenerative disorder caused by a trinucleotide repeat expansion in Exon 1 of the Huntingtin gene. The CAG trinucleotide encodes glutamine and polyglutamine expansions cause cell death in selective areas of the brain. Huntington polyglutamine repeats have the tendency to form a,2,National Center for Advancing Translational Sciences (NCATS),HTT010,20090421,"51,72,119,180,190,191,196,204,205,206,227,244,253,263,298,323,338,359,366,370,379,408,453,460,464,525,546,547,564,588,594,595,612,681,710,727,736,753,774,785,791,798,803,827,830,863,864,866,876,887,892,896,904,931,932,936,938,967,978,985,1004,1018,1023,1030,1046,1047,1050,1051,1052,1053,1057,1072,1080,1110,1123,1131,1132,1140,1150,1174,1176,1201,1203,1234,1236,1254,1257,1292,1309,1318,1329,1345,1355,1359,1367,1400,1474,1483,1492,1539,1646,1676,1683,1687,1688,1727,1732,1738,1775,1780,1820,1832,1833,1853,1882","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",3064,NULL,NP_002102,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P42858,NULL
1885,1,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,"Keywords: Trypanosoma cruzi, Chagas disease_|__|_Assay Overview: The assay detects intracellular trypanosomes that are replicating inside host cells.  NIH3T3 cells are trypsinized, counted, and plated in 384-well tissue culture plates.  After plating the NIH3T3 cells, compounds are added to the wells.  T. cruzi that are genetically modified to express b-galactosidase are then harvested and active Trypomastigotes form  are counted and co-cultured with the NIH3T3 cells.  After 90 hours of co-culture, all cell",31,Broad Institute,2017-01-INHIBITORS-SINGLE_POINT-MLPCN_HTS,20090929,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",NULL,"Cell-based,Organism-based",NULL,NIH Initiatives,"19238193,8913471",0,10.1371/journal.pntd.0000384,NULL,NULL,NULL
1814,1,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,"Broad Institute MLPCN Alpha-Synuclein 5'UTR Project_|__|_Project ID: 2023_|__|_Keywords:_|_alpha-synuclein, Parkinson's disease, translation, RNA stem-loop, 5'-untranslated region _|__|_Primary Collaborators:_|_Jack T. Rogers, Mass General Hospital, jtrogers@rics.bwh.harvard.edu, 617-726-8838, Charlestown, MA_|__|_Project Overview:_|__|_The goal of this project is to identify novel small molecule probes that increase alpha-synuclein translational expression in dopaminergic neurons by targeting the 5'-untran",31,Broad Institute,2023-01-B,20091214,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,","842121,842122,842123,842125,842126,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,8",NULL,NULL,NULL,NIH Initiatives,"16928984,19399246,9765156",0,10.1126/science.282.5387.296|10.1177/1087057106287271|10.3390/ijms10031226,NULL,NULL,NULL
1813,1,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,"Broad Institute MLPCN Alpha-Synuclein 5'UTR Project_|__|_Project ID: 2023_|__|_Keywords: alpha-synuclein, Parkinson's disease, translation, RNA stem-loop, 5'-untranslated region_|__|_Primary Collaborators:_|__|_Jack T. Rogers, Massachusetts General Hospital, jtrogers@rics.bwh.harvard.edu, 617-726-8838, Charlestown, MA_|__|_Project Overview:_|__|_The goal of this project is to identify novel small molecule probes that inhibit alpha-synuclein translational expression in dopaminergic neurons by targeting the 5",31,Broad Institute,2023-01,20091214,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,","842121,842122,842123,842125,842126,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,8",NULL,NULL,NULL,NIH Initiatives,"16928984,19399246,9765156",0,10.1126/science.282.5387.296|10.1177/1087057106287271|10.3390/ijms10031226,NULL,NULL,NULL
1554,1,MLPCN Ras selective lethality-BJeLR viability,"Broad Institute MLPCN Ras Selective Lethality Project_|__|_Project ID: 2013_|__|_Keywords: Ras, apoptosis, cancer, VDAC, oxidative cell death_|__|_Primary Collaborators:_|__|_Brent Stockwell, Columbia University, 614 Fairchild Center, MC 2406, 1212 Amesterdam Ave, New York, NY 10027, bs2189@columbia.edu, 212.854.2948_|__|_Dan Zaharevitz, NCI Science Officer, zaharevd@mail.nih.gov_|__|_Project Overview:_|__|_The goal of the project is to identify small molecules in the MLSMR and related compound synthesized ",31,Broad Institute,2013-01,20090317,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",NULL,NULL,NULL,NIH Initiatives,"12676586,17174591,17568748,18355723,18704666",0,10.1007/s10863-008-9158-6|10.1016/j.cbpa.2006.11.033|10.1016/j.chembiol.2008.02.010|10.1016/s1535-6108(03)00050-3|10.1038/nature05859,NULL,NULL,NULL
1467,2,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|__|_MLPCN Grant: 1R03MH084842-01_|_Assay Submitter (PI): Wei Zheng_|__|_NCGC Assay Overview:_|__|_Alpha-galactosidase is a homodimeric glycoprotein that hydrolyzes the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. Deficiency of this enzyme results in Fabry Disease with progressive accumulation of globotriaosylceramide and other glycosphingolipids in vascular endothelial cells that,2,National Center for Advancing Translational Sciences (NCATS),AGAL005,20130104,"72,119,178,185,190,191,199,204,206,224,239,253,275,289,298,304,323,338,342,366,370,401,408,453,464,471,525,535,546,547,564,588,596,607,610,636,650,681,698,710,727,736,750,785,803,827,830,836,846,847,853,864,876,892,896,903,904,912,914,932,936,938,992,999,1046,1050,1054,1064,1066,1072,1080,1102,1103,1110,1123,1148,1150,1176,1183,1201,1203,1204,1214,1216,1222,1228,1232,1233,1242,1245,1249,1254,1256,1287,1302,1309,1317,1318,1321,1328,1329,1330,1340,1345,1348,1354,1355,1359,1365,1367,1370,1377,1379,1380,1390,14","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",2717,NULL,CAA29232,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P06280,NULL
1910,1,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,"Keywords: Hypoxia, Hypoxia Inducible Factor (HIF), Hypoxia Responsive Element (HRE), luciferase, transcriptional activation, tissue regeneration, ischemia_|__|_Assay Overview: Luciferase assay (Steady-Glo, Promega)._|_Primary screen using human osteosarcoma U2OS cells stably over-expressing a plasmid containing 3 copies of the Hypoxia Responsive Element  linked to luciferase gene (U2OS HRE-luciferase cells) to identify small molecules inducing an increased luciferase activity in these cells. The small molec",31,Broad Institute,2030-01-ACTIVATORS-SINGLE_POINT-MLPCN_HTS,20091008,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",NULL,Cell-based,NULL,NIH Initiatives,"16778202,18184809,19338032,19502547",0,10.1002/jor.20886|10.1073/pnas.0708474105|10.1093/toxsci/kfp123|10.1158/0008-5472.can-05-2519,NULL,NULL,NULL
1979,1,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,"Broad Institute: Reversing Antifungal Drug Resistance_|__|_Project ID: 2037_|__|_Keywords: Candida albicans, drug resistance, fluconazole, Hsp90, Calcineurin, stress response_|__|_Primary Collaborators: Susan Lindquist, Whitehead Institute for Biomedical Research, sll@wi.mit.edu_|__|_Assay Overview: The basic assay strategy will consist of fluconazole-resistant C. albicans clinical isolate cultured in 1536-well format in the presence of a sub-toxic concentration of fluconazole. Test compounds that inhibit s",31,Broad Institute,2037-01_INHIBITORS_SINGLE-POINT_MLPCN-HTS,20091014,"72,109,119,127,190,191,204,229,253,311,323,338,366,412,444,460,499,525,547,588,597,637,774,802,803,892,896,899,932,938,942,978,1001,1174,1201,1309,1340,1367,1369,1401,1486,1492,1539,1546,1639,1646,1662,1676,1688,1775,1780,1795,1826,1853,1864,1882,1889,1890,1917,1923,1985,1986,1988,2000,2002,2015,2018,2048,2092,2108,2123,2159,2161,2162,2170,2181,2187,2240,2256,2265,2266,2345,2348,2374,2375,2391,2466,2471,2482,2519,2554,2585,2618,2662,2690,2692,2708,2720,2722,2723,2733,2741,2756,2758,2762,2833,2866,2890,2904,","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",NULL,Cell-based,CAA56931,NIH Initiatives,8161633,0,10.1093/clinids/18.2.240,NULL,CAA56931,NULL
1665,2,High Throughput Imaging Assay for Beta-Catenin,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Screening Centers Network (MLSCN)_|_Grant Proposal Number: 1 R03 MH082378-01_|_Assay Provider: Dr. Patrick M. McDonough, Vala Sciences Inc._|__|_Cancer is one of the most tragic afflictions in modern society, and often results from alterations in the mitotic process. In normal cells, beta-catenin is found predominantly as",14,Burnham Center for Chemical Genomics,BCCG-A186-Beta-Catenin-Imaging-Assay,20101230,"72,191,204,253,298,323,338,366,546,547,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1492,1539,1676,1688,1738,1775,1780,1832,1833,1853,1882,1892,1981,1985,2002,2007,2015,2018,2092,2108,2118,2123,2125,2159,2161,2170,2181,2187,2247,2249,2256,2265,2315,2331,2333,2348,2375,2378,2391,2466,2471,2482,2519,2554,2576,2585,2690,2692,2708,2720,2722,2727,2754,2756,2762,2771,2788,2804,2812,2866,2890,2904,2955,2972,3003,3012,3016,3019,3037,3059,3108,3117,3126,3151,3168,3182,3194,3213,3242,3278,3279,3295,330","842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842151,842152,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842185,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",1499,NULL,NP_001895,NIH Initiatives,"16204054,16567498,17208432",0,10.1016/j.gde.2006.12.007|10.1083/jcb.200601018|10.1158/0008-5472.can-05-0718,NULL,P35222,NULL
1466,2,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|__|_MLPCN Grant: 1R03MH084841-01_|_Assay Submitter (PI): Wei Zheng_|__|_NCGC Assay Overview:_|__|_Alpha-glucosidase is responsible for hydrolysis of terminal, non-reducing 1,4-linked alpha-D-glucose residues with release of alpha-D-glucose. It is a lysosomal hydrolase that is required for the degradation of a small percentage (1-3%) of cellular glycogen in human. Deficiency of this enzyme results in glyco",2,National Center for Advancing Translational Sciences (NCATS),ALGU004,20100112,"72,119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2585,2690,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3016,3019","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",2548,NULL,NP_000143,Governmental Organizations|NIH Initiatives,NULL,0,NULL,3.2.1.20,P10253,NULL
1457,2,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|__|_MLPCN Grant: X01 MH082413-01_|_Assay Submitter (PI): Wei Zheng_|__|_NCGC Assay Overview:_|__|_Lithium has been widely used for the treatment of bipolar disorder. But lithium has a narrow therapeutic index and it can cause side effects such as thirst, weight gain, tremor, polyuria and memory problems. Although the mechanism for lithium action in treatment of bipolar disorder is still not fully understo",2,National Center for Advancing Translational Sciences (NCATS),IMPE497,20081223,"11,13,51,66,108,119,174,177,178,180,185,187,190,191,196,199,204,206,224,227,239,240,241,243,244,253,261,263,275,289,298,299,300,304,311,323,335,338,339,342,366,370,379,398,401,403,408,412,447,453,460,462,464,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,710,713,727,736,750,753,774,785,795,803,827,830,836,846,847,853,864,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,999,1001,1004,1017,1023,1030,1046,1047,1049,1050,1052,1054,1057,1064,106","842121,842122,842123,842124,842125,842126,842127,842128,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842166,842167,842168,842169,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842201,8",83523,NULL,P97697,Governmental Organizations|NIH Initiatives,10445037,0,10.3109/14756369909036548,"3.1.3.25,3.1.3.94",P97697,NULL
1452,2,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),"Assay Provider: Holman, T.R., University of California, Santa Cruz_|_Screening Center PI: Austin, C.P._|_Screening Center: NIH Chemical Genomics Center [NCGC]_|__|_Human lipoxygenase 12hLO is a member of the closely related lipoxygenase family of enzymes which catalyze the site-specific oxidation of arachidonic acid to various hormone precursor molecules and as such is a candidate for drug development in a variety of disease areas, such as cancer and inflammation._|_Inhibition of 12hLO activity was screened",2,National Center for Advancing Translational Sciences (NCATS),LPOX867,20081219,"11,13,51,66,108,119,138,174,177,178,180,185,190,191,196,199,204,206,224,227,239,240,241,243,244,248,249,253,261,263,275,286,289,298,299,300,304,305,311,323,335,338,339,342,366,370,379,398,401,403,408,447,453,460,464,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,710,713,727,736,750,753,774,785,787,795,803,827,830,836,846,847,853,864,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,999,1004,1017,1023,1030,1045,1046,1047,1049,1050,1052,1054,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",239,NULL,NP_000688,Governmental Organizations|NIH Initiatives,"16500106,16864780,17826100,17869117",0,10.1016/j.bmc.2006.01.057|10.1016/j.bmc.2007.07.036|10.1016/j.bmc.2007.08.015|10.1073/pnas.0604348103,"1.13.11.-,1.13.11.31,1.13.11.33,3.3.2.-",P18054,NULL
1422,1,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: Dr. Raymond Dingledine, Emory University_|_MLSCN Grant: 5-U01NS058158-02_|__|_Assay Overview:_|__|_Prostaglandin E2 that is produced by COX2 in response to cellular injury is involved in a multimodal inflammatory response in many tissues, including the brain.  Studies in rodents have demonstrated that cyclooxygenase 2 (COX2) activation following ischemia and status epilepticus gener",16,Emory University Molecular Libraries Screening Center,A30 EP2 Inhibitors Primary Screen,20081031,"19,51,72,86,108,109,119,178,190,191,204,253,289,298,311,323,338,339,366,370,401,403,412,444,471,500,525,535,546,547,564,588,607,650,681,727,774,785,802,803,827,830,846,864,896,903,904,914,932,936,938,942,978,992,1001,1023,1046,1047,1052,1057,1066,1123,1148,1150,1176,1201,1209,1216,1222,1228,1232,1233,1239,1242,1245,1256,1317,1318,1328,1329,1330,1340,1345,1359,1365,1367,1390,1400,1456,1474,1480,1482,1486,1487,1488,1489,1490,1492,1493,1539,1564,1598,1607,1609,1639,1641,1645,1646,1649,1662,1676,1678,1683,1688,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842159,842160,842161,842162,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,8",5732,NULL,NP_000947,Legacy Depositors|NIH Initiatives,"12821374,15191797",0,10.1016/j.expneurol.2004.03.019|10.1016/s0014-4886(03)00086-4,NULL,P43116,NULL
1490,2,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),"Assay Submitter: Michael Burkart, University of California, San Diego_|_Screening Center PI: Austin, C.P._|_Screening Center: NIH Chemical Genomics Center [NCGC]_|__|_The covalent attachment of a phosphopantetheinyl (4'-PP) arm to a variety of synthases and other proteins is a key posttranslational protein modification. The 4'-PP is installed on the proteins post-translationally from coenzyme A (CoA) on a conserved serine residue by action of phosphopantetheinyl transferase (PPTase) enzymes. Phosphopantethe",2,National Center for Advancing Translational Sciences (NCATS),PPTA101,20100126,"51,72,119,135,180,185,187,190,191,196,199,204,205,206,224,227,239,244,253,263,273,275,277,298,303,304,323,338,342,359,366,370,379,401,408,412,450,453,460,462,464,471,499,525,535,546,547,564,588,594,595,596,607,610,612,614,636,637,681,698,710,727,736,750,753,757,774,785,791,798,803,827,830,836,846,847,853,863,864,866,876,887,892,896,903,904,912,914,931,932,936,938,967,978,985,992,999,1001,1004,1018,1023,1030,1046,1047,1050,1051,1052,1053,1054,1057,1060,1064,1066,1072,1080,1101,1102,1103,1110,1123,1131,1132,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,AAG24257,Governmental Organizations|NIH Initiatives,"15123281,16089439,16967968,8939709",0,10.1016/j.chembiol.2004.02.010|10.1016/s1074-5521(96)90181-7|10.1021/ja052911k|10.1021/ja063217n,NULL,Q9F4F7,NULL
1511,1,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,"Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Assay Provider: Dr. Sabina Kupershmidt, Vanderbilt University Medical Center_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R03MH084820-01_|_Grant Proposal PI: Dr. Sabina Kupershmidt, Vanderbilt University Medical Center_|_Assay Implementation: Beiyan Zou Ph.D., Shunyou Long M.S., Amy Scott M.S., Haibo Yu Ph.D., Meng Wu P",27,Johns Hopkins Ion Channel Center,JHICC_hERG,20100327,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",3757,Cell-based,AAA62473,Legacy Depositors|NIH Initiatives,"10636190,10648647,10838414,11723241,12552182,14525949,1501123,15574182,15634793,16474415,16633353,17189275,17218666,7736582,7978420,8649354,8700146,8921803",0,10.1016/0092-8674(95)90340-2|10.1038/sj.bjp.0706678|10.1038/sj.bjp.0706744|10.1046/j.1540-8167.2004.04099.x|10.1074/jbc.m605976200|10.1096/fj.02-1057fje|10.1097/00000542-200302000-00002|10.1111/j.1540-8167.1999.tb00224.x|10.1124/mol.60.6.1343|10.1161/01.cir.94.10.2572|10.1177/1087057104268749|10.1177/1087057106296498|10.1177/108705719900400206|10.1213/00000539-199411000-00028,NULL,Q12809,NULL
1625,2,HCS for Compounds that Up-Regulate Insulin Promoter Activity in MIN6 Cells,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Screening Centers Network (MLSCN)_|_Grant Proposal Number: 1X01MH077631-01_|_Assay Provider: Drs. Mark Mercola and Fred Levine, Sanford-Burnham Medical Research Institute and University of CA San Diego_|__|_The cardinal property of beta-cells, shared by no other cell in the body, is high level expression of the insulin ge",14,Burnham Center for Chemical Genomics,BCCG-A164-MIN6-UP-Regulate-Assay,20101230,"72,191,204,253,298,547,803,864,1150,1201,1345,1367,1492,1539,1738,1832,1833,1853,1882,1892,1981,1985,2002,2015,2018,2092,2108,2118,2125,2159,2161,2181,2187,2256,2265,2331,2348,2375,2378,2519,2585,2690,2692,2754,2804,2812,2866,2890,2904,2972,3003,3016,3059,3168,3279,3324,3357,3366,3373,3396,3397,3431,3516,3611,3616,3686,3747,3749,3758,3784,3786,3787,3793,3830,3878,3883,3902,3945,3951,3957,3969,4049,4066,4114,4140,4173,4197,4235,4236,4409,4418,4463,4487,4496,4507,4544,4563,4612,4614,4619,4630,4632,4723,4728,4","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842195,842196,842197,842198,842199,8",NULL,NULL,NULL,NIH Initiatives,"10966856,14711389,8567638,9857028",0,10.1006/scdb.2000.0171|10.1074/jbc.271.4.1909|10.1074/jbc.273.52.34970|10.1177/1087057103258285,NULL,NULL,NULL
1628,2,HCS for Compounds that Down-Regulate Insulin Promoter Activity in MIN6 Cells,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Screening Centers Network (MLSCN)_|_Grant Proposal Number: 1X01MH077631-01_|_Assay Provider: Drs. Mark Mercola and Fred Levine, Sanford-Burnham Medical Research Institute and University of CA San Diego_|__|_The cardinal property of beta-cells, shared by no other cell in the body, is high level expression of the insulin ge",14,Burnham Center for Chemical Genomics,BCCG-A167-MIN6-Down-Regulate-Assay,20101230,"72,191,204,253,298,547,803,864,1150,1201,1345,1367,1492,1539,1738,1832,1833,1853,1882,1892,1981,1985,2002,2015,2018,2092,2108,2118,2125,2159,2161,2181,2187,2256,2265,2331,2348,2375,2378,2519,2585,2690,2692,2754,2804,2812,2866,2890,2904,2972,3003,3016,3059,3168,3279,3324,3357,3366,3373,3396,3397,3431,3516,3611,3616,3686,3747,3749,3758,3784,3786,3787,3793,3830,3878,3883,3902,3945,3951,3957,3969,4049,4066,4114,4140,4173,4197,4235,4236,4409,4418,4463,4487,4496,4507,4544,4563,4612,4614,4619,4630,4632,4723,4728,4","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842188,842189,842190,842191,842192,842193,842195,842196,842197,842198,842199,842200,8",NULL,NULL,NULL,NIH Initiatives,"10966856,14711389,8567638,9857028",0,10.1006/scdb.2000.0171|10.1074/jbc.271.4.1909|10.1074/jbc.273.52.34970|10.1177/1087057103258285,NULL,NULL,NULL
1984,2,Fluorescence for the identification of compounds that decrease p/CIP protein stability,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number:  1 R03 MH084852-01_|_Assay Provider: Zhiyong Wang PhD, The Salk Institute for biological studies, San Diego CA_|_ _|_Genetic studies have demonstrated that loss of the transcriptional co-activator p/CIP leads to resistance to obesity and diabetes, especially in extreme mo",14,Burnham Center for Chemical Genomics,BCCG-A215-p/CIP-Inhibitors,20101230,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",17979,NULL,NP_032705,NIH Initiatives,"16439211,16456540,16459312,16751179,17574025",0,10.1016/j.cell.2005.11.037|10.1016/j.cell.2007.04.039|10.1016/j.cmet.2006.01.002|10.1038/sj.emboj.7600981|10.1101/gad.1424806,NULL,NP_032705,NULL
1578,2,uHTS luminescence assay for the identification of compounds that inhibit NOD1,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1 R03 MH084844-01_|_Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_ The modulation of immune response activity is one of the major goals in the development of novel therapeutics for auto-immune and inflammatory disea",14,Burnham Center for Chemical Genomics,BCCG-A153-NOD1-Primary-Luminescent-Assay,20101230,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",10392,NULL,NP_006083,NIH Initiatives,"14711389,15198989,15215247,15692052,15790594,16446438,16493424,16819970,17133080,18031249,18261938,18574154,18585455",0,10.1016/j.coi.2008.06.001|10.1016/j.immuni.2007.12.012|10.1038/nri1747|10.1042/bst0351479|10.1073/pnas.0509228103|10.1073/pnas.0710445105|10.1074/jbc.m403861200|10.1093/hmg/ddh182|10.1093/hmg/ddi135|10.1097/mog.0b013e32801182b0|10.1111/j.1462-5822.2006.00701.x|10.1126/science.1103685|10.1177/1087057103258285,NULL,Q9Y239,NULL
1903,2,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,"A biochemical assay using the ADP-Hunter methodology, purified TAg, and ATP to identify compounds that inhibit the ATPase activity of Tag_|_Southern Research's Specialized Biocontainment Screening Center (SRSBSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Probe Centers Network (MLPCN)_|_Assay Provider: Dr. Jeffery Brodsky, University of Pittsburgh_|_Grant number: 1R03MH084077-01 _|__|_Assay Rationale and Summary: The oncogenic virus Simian Virus 40 (SV40) is a well-charact",33,Southern Research Specialized Biocontainment Screening Center,SV40_SD_DR,20110304,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,727,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1018,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1486,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1761,1775,1780,1794,1795,1820,1826,1832,1833,1853,1858,1864,1868,1882,1889,1890","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",29031019,NULL,YP_003708382,NIH Initiatives,"10432461,18164205,19200446,6169844",0,10.1016/j.bmc.2007.12.014|10.1016/j.virusres.2008.12.018|10.1016/s0076-6879(99)06019-x,3.6.4.-,P03070,NULL
1817,2,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number:  1 R03 MH086475-01_|_Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_Proteasomal degradation typically requires post-translational modification of target proteins with K48-linked polyubiquitin chains. This process of protein",14,Burnham Center for Chemical Genomics,BCCG-A208-Siah-Antagonist-Assay,20110103,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",5339,NULL,AAR95677,NIH Initiatives,"11389839,12626763",0,10.1016/s1097-2765(01)00242-8|10.1073/pnas.0534783100,NULL,AAR95677,NULL
1430,1,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,"Excerpt from MH0882340 application (Dr. James Morris, Clemson University)_|__|_Trypanosoma brucei, the digenic protozoan parasite that causes African sleeping sickness in man, annually infects ~500,000 people in sub-Saharan Africa, leading to 50,000-70,000 deaths per year.  Glucose metabolism is essential for the parasite, with the pathogenic lifestage of the parasite, the bloodstream form (BSF), acquiring energy exclusively through glycolysis.  _|__|_Hexokinase (HK), the first enzyme in glycolysis, catalys",9,University of Pittsburgh Molecular Library Screening Center,MH082340,20081110,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2181,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2866,2890,2904,2950,2955,2972,3003,3012,3019,3025,3","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",3663016,NULL,EAN77629,NIH Initiatives,"11334933,12144928,15955817,8634823",0,10.1016/0968-0896(95)00129-5|10.1016/s0020-7519(01)00155-2|10.1016/s1074-5521(02)00169-2|10.1074/jbc.m502403200,NULL,EAN77629,NULL
1672,1,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,"Name: Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1_|_Data Source: Johns Hopkins Ion Channel Center (JHICC)_|_BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed _|__|_Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Elena Makhina Ph.D.,",27,Johns Hopkins Ion Channel Center,JHICC_KIR2.1_Primary,20100329,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",16518,Cell-based,NP_032451,Legacy Depositors|NIH Initiatives,"10838414,11273717,14722253,15087421,15634793,16174819,16407206,16465162,18171729,18411331,19279215,7973666",0,10.1006/jmcc.2001.1344|10.1038/nbt1186|10.1073/pnas.0812756106|10.1074/jbc.m600072200|10.1085/jgp.200709946|10.1124/mol.107.041053|10.1124/mol.65.1.214|10.1126/science.7973666|10.1126/stke.stke.3022005pe46|10.1161/01.res.0000128408.66946.67|10.1177/1087057104268749|10.1177/108705719900400206,NULL,P35561,NULL
1440,1,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.","University of New Mexico Assay Overview:_|_Assay Support: NIH R21NS057014  _|_HTS to identify small molecule regulators of RGS family protein interactions _|_PI: Richard Neubig, Ph.D._|_Assay Implementation: Yang Wu Ph.D., Mark Haynes Ph.D., Anna Waller Ph.D., Mark Carter MS_|_Target Team Leader for the Center: Larry Sklar, Ph.D., (lsklar@salud.unm.edu)_|__|_Assay Background and Significance:_|__|_Regulators of G protein signaling (RGS) proteins are a diverse set of intracellular proteins that modulate G pr",6,NMMLSC,UNM_RGS19_PrimaryScreen,20081201,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2754,2756,2762,2771,2788,2804,2812,2866,2890,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8","2775,10287",NULL,"NP_001034556,NP_066268",NIH Initiatives,"10449728,10942773,11309812,11356902,12120503,14671004,16647283,17012620,3113327",0,10.1016/j.semcdb.2006.03.002|10.1038/nrd747|10.1073/pnas.96.17.9539|10.1074/jbc.m005785200|10.1124/mol.106.028670|10.1146/annurev.bi.56.070187.003151|10.1210/er.2000-0026,NULL,"P09471,P49795",NULL
1850,2,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,"Southern Research's Specialized Biocontainment Screening Center (SRSBSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Probe Centers Network (MLPCN)_|_Assay Provider: Dr. Jason Harris, Massachusetts General Hospital _|__|_Assay Rationale and Summary: Salmonella is a genus of rod-shaped Gram-negative enterobacteria that causes typhoid fever, paratyphoid fever, and foodborne illness. Salmonella enterica, serovar Typhimurium, is a leading cause of human gastroenteritis (acute in",33,Southern Research Specialized Biocontainment Screening Center,PhoP_Typhi,20100217,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,727,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1018,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1486,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1761,1775,1780,1794,1795,1820,1826,1832,1833,1853,1858,1864,1868,1882,1889,1890","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,8",NULL,NULL,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
1863,2,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,"A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium._|_Southern Research's Specialized Biocontainment Screening Center (SRSBSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Probe Centers Network (MLPCN)_|_Assay Provider: Dr. Jason Harris, Massachusetts General Hospital Grant number: 1R21-NS059429-01 _|__|_Assay Rationale and Summary: Salmonella is a genus of rod-shaped Gram-negative enterobacteria that causes typhoid fever, paratyphoid fever,",33,Southern Research Specialized Biocontainment Screening Center,Pho_Typhimurium,20100222,"6,19,72,86,109,119,137,190,191,204,229,253,289,298,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,727,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1018,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1400,1401,1474,1492,1493,1539,1546,1570,1609,1646,1662,1676,1678,1688,1727,1730,1738,1761,1775,1780,1794,1795,1820,1826,1832,1833,1853,1858,1864,1868,1882,1889,1890,1892,1893,1917,192","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",NULL,NULL,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
1441,1,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.","University of New Mexico Assay Overview:_|_Assay Support: NIH R21NS057014  _|_HTS to identify small molecule regulators of RGS family protein interactions _|_PI: Richard Neubig, Ph.D._|_Assay Implementation: Yang Wu Ph.D., Mark Haynes Ph.D., Anna Waller Ph.D., Mark Carter MS_|_Target Team Leader for the Center: Larry Sklar, Ph.D., (lsklar@salud.unm.edu)_|__|_Assay Background and Significance:_|__|_Regulators of G protein signaling (RGS) proteins are a diverse set of intracellular proteins that modulate G pr",6,NMMLSC,UNM_RGS16_PrimaryScreen,20081201,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2754,2756,2762,2771,2788,2804,2812,2866,2890,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8","2775,6004",NULL,"NP_002919,NP_066268",NIH Initiatives,"10449728,10942773,11309812,11356902,12120503,14671004,16647283,17012620,3113327",0,10.1016/j.semcdb.2006.03.002|10.1038/nrd747|10.1073/pnas.96.17.9539|10.1074/jbc.m005785200|10.1124/mol.106.028670|10.1146/annurev.bi.56.070187.003151|10.1210/er.2000-0026,NULL,"O15492,P09471",NULL
1439,1,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.","University of New Mexico Assay Overview:_|_Assay Support: NIH R21NS057014  _|_HTS to identify small molecule regulators of RGS family protein interactions _|_PI: Richard Neubig, Ph.D._|_Assay Implementation: Yang Wu Ph.D., Mark Haynes Ph.D., Anna Waller Ph.D., Mark Carter MS_|_Target Team Leader for the Center: Larry Sklar, Ph.D., (lsklar@salud.unm.edu)_|__|_Assay Background and Significance:_|__|_Regulators of G protein signaling (RGS) proteins are a diverse set of intracellular proteins that modulate G pr",6,NMMLSC,UNM_RGS7_PrimaryScreen,20081201,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2754,2756,2762,2771,2788,2804,2812,2866,2890,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8","2775,6000",NULL,"AAC50351,NP_066268",NIH Initiatives,"10449728,10942773,11309812,11356902,12120503,14671004,16647283,17012620,3113327",0,10.1016/j.semcdb.2006.03.002|10.1038/nrd747|10.1073/pnas.96.17.9539|10.1074/jbc.m005785200|10.1124/mol.106.028670|10.1146/annurev.bi.56.070187.003151|10.1210/er.2000-0026,NULL,"AAC50351,P09471",NULL
1423,1,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.","University of New Mexico Assay Overview:_|_Assay Support: NIH R21NS057014  _|_HTS to identify small molecule regulators of RGS family protein interactions _|_PI: Richard Neubig, Ph.D._|_Assay Implementation: Yang Wu Ph.D., Mark Haynes Ph.D., Anna Waller Ph.D., Mark Carter MS_|_Target Team Leader for the Center: Larry Sklar, Ph.D., (lsklar@salud.unm.edu)_|__|_Assay Background and Significance:_|__|_Regulators of G protein signaling (RGS) proteins are a diverse set of intracellular proteins that modulate G pr",6,NMMLSC,UNM_RGS8_PrimaryScreen,20081201,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2754,2756,2762,2771,2788,2804,2812,2866,2890,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8","2775,85397",NULL,"AAI03867,NP_066268",NIH Initiatives,"10449728,10942773,11309812,11356902,12120503,14671004,16647283,17012620,3113327",0,10.1016/j.semcdb.2006.03.002|10.1038/nrd747|10.1073/pnas.96.17.9539|10.1074/jbc.m005785200|10.1124/mol.106.028670|10.1146/annurev.bi.56.070187.003151|10.1210/er.2000-0026,NULL,"P09471,P57771",NULL
1415,1,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.","University of New Mexico Assay Overview:_|_Assay Support: NIH R21NS057014  _|_HTS to identify small molecule regulators of RGS family protein interactions _|_PI: Richard Neubig, Ph.D._|_Assay Implementation: Yang Wu Ph.D., Mark Haynes Ph.D., Anna Waller Ph.D., Mark Carter MS_|_Target Team Leader for the Center: Larry Sklar, Ph.D., (lsklar@salud.unm.edu)_|__|_Assay Background and Significance:_|__|_Regulators of G protein signaling (RGS) proteins are a diverse set of intracellular proteins that modulate G pr",6,NMMLSC,UNM_RGS4_PrimaryScreen,20081201,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2754,2756,2762,2771,2788,2804,2812,2866,2890,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8","2775,5999",NULL,"ABC94590,NP_066268",NIH Initiatives,"10449728,10942773,11309812,11356902,12120503,14671004,16647283,17012620,3113327",0,10.1016/j.semcdb.2006.03.002|10.1038/nrd747|10.1073/pnas.96.17.9539|10.1074/jbc.m005785200|10.1124/mol.106.028670|10.1146/annurev.bi.56.070187.003151|10.1210/er.2000-0026,NULL,"ABC94590,P09471",NULL
1778,2,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number:  1X01DA026208-01_|_Assay Provider: Dr. Lawrance Barak , Duke University, Durham NC_|__|_Drug addiction is a disease originating in the central nervous system that produces compulsive behaviors despite the negative consequences that may result. Major addictive drugs of abu",14,Burnham Center for Chemical Genomics,BCCG-A203-KOR-Antagonist-Assay,20101230,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",4986,NULL,NP_000903,NIH Initiatives,"12954747,15090153,15090178,15289816,15525797,15542743,15935455,16213533,16353938,16353947,16483675,1664548,16924269,17105950,17702750,18660457,19149644,7483322,7592342,7649270,7890732,8137953,8574585,8585130,9022829,9346876",0,10.1016/0014-5793(94)80472-9|10.1016/0014-5793(95)00765-2|10.1016/0968-0004(91)90157-q|10.1016/j.lfs.2005.09.008|10.1016/j.pbb.2005.01.024|10.1016/j.tins.2006.01.008|10.1016/s0083-6729(08)61039-0|10.1016/s0168-9525(00)89090-3|10.1016/s0960-9822(95)00254-5|10.1038/sj.mp.4001560|10.1038/sj.mp.4001882|10.1056/nejmra023160|10.1074/jbc.270.11.6010|10.1074/jbc.272.44.27497|10.1074/jbc.m705540200|10.1089/154065802761001275|10.1089/154065803322163722|10.1124/jpet.104.077974|10.1128/jb.177.20.5906-5911.1995|10.1139/,NULL,P41145,NULL
1566,2,uHTS luminescence assay for the identification of compounds that inhibit NOD2,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH084844-01_|_Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_The modulation of immune response activity is one of the major goals in the development of novel therapeutics for auto-immune and inflammatory disease",14,Burnham Center for Chemical Genomics,BCCG-A154-NOD2-Primary-Luminescent-Assay,20101230,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",64127,NULL,NP_071445,NIH Initiatives,"15198989,15215247,15692052,15790594,16446438,16493424,16819970,17133080,18031249,18261938,18574154,18585455",0,10.1016/j.coi.2008.06.001|10.1016/j.immuni.2007.12.012|10.1038/nri1747|10.1042/bst0351479|10.1073/pnas.0509228103|10.1073/pnas.0710445105|10.1074/jbc.m403861200|10.1093/hmg/ddh182|10.1093/hmg/ddi135|10.1097/mog.0b013e32801182b0|10.1111/j.1462-5822.2006.00701.x|10.1126/science.1103685,NULL,Q9HC29,NULL
1063,1,Leishmania major promastigote HTS,"No grant number_|__|_Infection with Leishmania represents a major health concern in the developing world, with approximately 1.2 to 1.5 million cases reported annually and 350 million people (globally) at risk of infection.   The limited number of available leishmaniasis treatments is complicated by (1) serious (toxic) side effects; and (2) an increase in chemoresistance.  Therefore, the identification of new small molecules for the treatment of leishmaniasis is a critical.  A simple, inexpensive and HTS am",9,University of Pittsburgh Molecular Library Screening Center,Leishmania major promastigote HTS,20080229,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,32","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",NULL,NULL,NULL,NIH Initiatives,15142618,0,10.1016/j.resmic.2004.01.001,NULL,NULL,NULL
1948,2,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,"qHTS Assay for Compounds that Induce Erasure of Genomic Imprints_|__|_NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|__|_Assay Submitter (PI): JEFFRIES, SEAN, NCGC, University of Cambridge_|__|_NCGC Peg3 Imprinting Assay Overview_|__|_Genomic imprinting is the epigenetic process whereby genes are expressed in a parent of origin fashion. Imprinted genes exhibit monoallelic expression exclusively from either the paternal or maternal allele. Unlike some forms o",2,National Center for Advancing Translational Sciences (NCATS),IMPR274,20090915,"11,13,51,66,108,119,174,177,178,180,185,190,191,196,199,204,206,224,227,239,240,241,243,244,253,261,263,275,289,298,299,300,304,311,323,335,338,339,342,370,379,398,401,403,408,447,453,460,464,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,710,713,727,736,750,753,785,795,827,830,836,846,847,853,864,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,999,1004,1017,1023,1030,1046,1049,1050,1052,1054,1057,1064,1066,1072,1080,1102,1103,1110,1123,11","842121,842122,842123,842124,842125,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842141,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842161,842162,842163,842165,842166,842167,842168,842169,842170,842171,842172,842173,842175,842176,842177,842178,842179,842180,842182,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
1362,1,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,"Southern Research Molecular Libraries Screening Center (SRMLSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Screening Centers Network (MLSCN)_|_Assay Provider: Dr. Jodi M. Nunnari, University of California, Davis_|_Award: R03 MH081279-01_|__|__|_Screening for compounds that inhibit mitochondrial fusion using a yeast model system as a primary screening tool_|__|_Mitochondria are essential, double-membraned organelles that perform a myriad of tasks within cells. Unlike their ",11,SRMLSC,YMitoFus_SD,20080717,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2187,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3016,3019,3025,30","842121,842122,842123,842124,842125,842126,842127,842128,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",NULL,NULL,NULL,NIH Initiatives,"17362197,18267088",0,10.1016/j.devcel.2007.11.019|10.1146/annurev.biochem.76.071905.090048,NULL,NULL,NULL
1986,2,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number:  1R21NS059403-01_|_Assay Provider: Dr. Miriam Gochin, Touro University-California, Vallejo, CA_|__|_The fusion-active conformation of the envelope protein gp41 of HIV-1 consists of an N-terminal trimeric alpha-helical coiled coil domain, and three anti-parallel C-terminal",14,Burnham Center for Chemical Genomics,BCCG-A227-GP41-Inhibitors,20101230,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,AAS58777,NIH Initiatives,"17452484,19206471,19364877",0,10.1021/ja8094558|10.1128/aac.00150-07|10.1128/aac.00150-09,NULL,AAS58777,NULL
1779,2,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number:  1R21NS056945-01_|_Assay Provider: Dr. Nunzio Bottini, San Diego Institute for Allergy and Immunology CA_|__|_LYP, is a lymphocyte specific protein tyrosine phosphatase that plays a critical regulatory role in T cell receptor signaling. The PTPN22 gene encodes this phosph",14,Burnham Center for Chemical Genomics,BCCG-A204-LYP-Inhibitor-Assay,20101230,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",26191,NULL,NP_057051,NIH Initiatives,"15004560,15208781,15273934,15504986,15641066,16273109,16314859,16614815,16642008,17237219,17878369,17934143,18056643,18305142,18821667,18981062,19265110,19299707,19371084",0,10.1002/art.20771|10.1002/art.23900|10.1007/s00125-006-0225-4|10.1021/bi900166y|10.1038/ng0506-499|10.1038/ng1205-1300|10.1038/ng1323|10.1038/ng1673|10.1073/pnas.0610250104|10.1073/pnas.0706233104|10.1086/422827|10.1086/423790|10.1093/hmg/ddn363|10.2337/db07-0289|10.2337/db07-1131|10.2337/diabetes.53.11.3020|10.4049/jimmunol.0713370|10.4049/jimmunol.0803317|10.4049/jimmunol.179.7.4704,3.1.3.48,Q9Y2R2,NULL
1456,0,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,"Vanderbilt Screening Center for GPCRs, Ion Channels and Transporters_|_Assay Provider: Eric Delpire_|_Assay Provider Affliation: Vanderbilt University_|_Grant Title: Identification of Novel Modulators of Cl- dependent Transport Process via HTS_|_Grant Number: R21NS053658-01_|__|_Cation-chloride cotransporters such as K-Cl cotransport and Na-K-2Cl cotransport play major roles in a variety of physiological settings, including the modulation of GABAergic synaptic transmission. For instance, KCC2, a neuronal-sp",23,Vanderbilt High Throughput Screening Facility,ED001,20081223,"72,119,204,253,298,323,338,366,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2866","842121,842122,842123,842124,842126,842127,842128,842129,842130,842131,842132,842133,842134,842137,842138,842139,842140,842142,842143,842144,842145,842146,842148,842149,842150,842153,842154,842155,842156,842159,842160,842162,842163,842164,842165,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842179,842184,842185,842186,842187,842189,842191,842192,842193,842194,842195,842196,842198,842199,842200,842201,842203,842204,842205,842206,842207,842208,842209,842210,842211,842213,842215,842216,8",57468,NULL,AAG43493,NIH Initiatives,16465162,0,10.1038/nbt1186,NULL,AAG43493,NULL
1654,2,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1 R03 MH084230-01A1_|_Assay Provider: Dr. Lutz Tautz, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_Protein tyrosine phosphatases (PTPs) play vital roles in numerous cellular processes and are implicated in a growing number of human diseases, rangin",14,Burnham Center for Chemical Genomics,BCCG-A179-VHR1-Absorbance-Assay,20101230,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2662,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",1845,NULL,NP_004081,NIH Initiatives,17532512,0,10.1016/j.ymeth.2007.02.014,"3.1.3.16,3.1.3.48",P51452,NULL
1851,0,Cytochrome panel assay with activity outcomes,"NCGC Assay Overview:_|__|_The P450 gene superfamily is involved in the metabolism and clearance of xenobiotics. This assay used various human CYP P450 isozymes to measure the dealkylation of various pro-luciferin substrates to luciferin. The luciferin is then measured by luminescence after the addition of a luciferase detection reagent. Pro-luciferin substrate concentration in the assay was equal to its KM for its CYP P450 isozyme. Inhibitors and some substrates limit the production of luciferin, and decrea",2,National Center for Advancing Translational Sciences (NCATS),Cytochrome panel assay,20090714,"108,119,138,178,199,239,248,249,286,305,339,500,525,535,546,547,564,681,750,774,787,896,903,912,938,1023,1045,1052,1054,1066,1102,1103,1123,1150,1214,1316,1317,1328,1329,1330,1331,1337,1340,1342,1346,1348,1354,1355,1359,1365,1366,1367,1370,1390,1433,1449,1456,1474,1518,1533,1574,1598,1609,1645,1647,1649,1663,1669,1678,1681,1701,1720,1725,1727,1734,1738,1742,1745,1748,1756,1774,1775,1779,1793,1794,1795,1797,1809,1826,1832,1833,1845,1853,1858,1864,1868,1871,1884,1892,1893,1908,1917,1922,1935,1960,1981,1983,19","842238,842250,842319,842408,842584,842618,842697,842789,842891,842953,842968,843048,843170,843289,843293,843295,843298,843422,843526,843611,843632,843662,843808,843813,843859,843987,844035,844042,844043,844085,844118,844156,844203,844275,844373,844442,844455,844570,844622,844690,844782,844835,844873,844932,844963,845093,845164,845245,845384,845406,845417,845577,845581,845632,845641,845652,845706,845813,845859,845879,845912,846035,846056,846109,846135,846155,846175,846256,846286,846322,846376,846379,846448,8","1544,1557,1559,1565,1576",NULL,"NP_000752,NP_000760,NP_000762,NP_001020332,NP_059488",Governmental Organizations|NIH Initiatives,NULL,0,NULL,"1.14.14.-,1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.55,1.14.14.56,1.14.14.73,1.14.14.75,4.2.1.152","P05177,P08684,P10635,P11712,P33261",NULL
1565,2,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number:  1 R03 MH084086-01_|_Assay Provider: Dr. Jose Luis Milan, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_Mineralization of cartilage and bone occurs by a series of physicochemical and biochemical processes that together facilitate the deposition of hydroxya",14,Burnham Center for Chemical Genomics,BCCG-A152-Phospho1-Absorbance-Assay,20101230,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2662,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",162466,NULL,NP_001137276,NIH Initiatives,"12464021,14983068,15050893,15175005,16054448,17227223,18471996",0,10.1016/j.bbapap.2005.06.009|10.1016/j.bbrc.2008.04.163|10.1016/j.bone.2003.12.023|10.1042/bj20040511|10.1046/j.1365-2052.2002.00900.x|10.1093/protein/gzg126|10.1359/jbmr.070108,3.1.3.75,Q8TCT1,NULL
1021,1,uHTS of Mcl-1/Bid interaction inhibitors,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: Nikolovska-Coleska, University of Michigan_|_MLSCN Grant: R21NS057014_|__|_The Bcl-2 protein family includes anti-apoptotic proteins such as Bcl-2, Bcl-xL and Mcl-1 and pro-apoptotic proteins such as Bak, Bax, Bim, Bid and Bad. All members of the Bcl-2 protein family contain at least one conserved Bcl-2 homology (BH) domain. These domains have been demonstrated to be involved in the",16,Emory University Molecular Libraries Screening Center,uHTS of Mcl-1/Bid interaction inhibitors,20080108,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",4170,NULL,AAF64255,Legacy Depositors|NIH Initiatives,15325294,0,10.1016/j.ab.2004.05.055,NULL,AAF64255,NULL
1377,1,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,"A HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells performed by the PMLSC in the University of Pittsburgh Drug Discovery Institute._|_Excerpts from the MH81266 Application - Dr. Junying Yuan, Harvard University._|_Necrosis in physiological and pathological conditions._|_Necrosis is a caspase-independent cell death marked by a rapid loss of plasma membrane integrity, organelle swelling and mitochondrial dysfunction, and lacking typical features of apoptosis such as internucleosomal DNA cle",9,University of Pittsburgh Molecular Library Screening Center,MH081226: Primary HTS for Inhibitors of a Novel Necrotic Cell Death Pathway L929 Model.,20080811,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2181,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2866,2890,2904,2950,2955,2972,3003,3012,3019,3025,3","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",NULL,NULL,NULL,NIH Initiatives,16408008,0,10.1038/nchembio711,NULL,NULL,NULL
1022,1,uHTS of Mcl-1/Noxa interaction inhibitors,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: Nikolovska-Coleska, University of Michigan_|_MLSCN Grant: R21NS057014_|__|_The Bcl-2 protein family includes anti-apoptotic proteins such as Bcl-2, Bcl-xL and Mcl-1 and pro-apoptotic proteins such as Bak, Bax, Bim, Bid and Bad. All members of the Bcl-2 protein family contain at least one conserved Bcl-2 homology (BH) domain. These domains have been demonstrated to be involved in the",16,Emory University Molecular Libraries Screening Center,uHTS of Mcl-1/Noxa interaction inhibitors,20080108,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,8",4170,NULL,AAF64255,Legacy Depositors|NIH Initiatives,15325294,0,10.1016/j.ab.2004.05.055,NULL,AAF64255,NULL
1777,2,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number:  1X01DA026208-01_|_Assay Provider: Dr. Lawrance Barak , Duke University, Durham NC_|__|_Drug addiction is a disease originating in the central nervous system that produces compulsive behaviors despite the negative consequences that may result. Major addictive drugs of abu",14,Burnham Center for Chemical Genomics,BCCG-A202-KOR-Agonist-Assay,20101230,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",4986,NULL,NP_000903,NIH Initiatives,"12954747,15090153,15090178,15289816,15525797,15542743,15935455,16213533,16353938,16353947,16483675,1664548,16924269,17105950,17702750,18660457,19149644,7483322,7592342,7649270,7890732,8137953,8574585,8585130,9022829,9346876",0,10.1016/0014-5793(94)80472-9|10.1016/0014-5793(95)00765-2|10.1016/0968-0004(91)90157-q|10.1016/j.lfs.2005.09.008|10.1016/j.pbb.2005.01.024|10.1016/j.tins.2006.01.008|10.1016/s0083-6729(08)61039-0|10.1016/s0168-9525(00)89090-3|10.1016/s0960-9822(95)00254-5|10.1038/sj.mp.4001560|10.1038/sj.mp.4001882|10.1056/nejmra023160|10.1074/jbc.270.11.6010|10.1074/jbc.272.44.27497|10.1074/jbc.m705540200|10.1089/154065802761001275|10.1089/154065803322163722|10.1124/jpet.104.077974|10.1128/jb.177.20.5906-5911.1995|10.1139/,NULL,P41145,NULL
1236,1,uHTS for Calpain Inhibitors,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: Jonathan Glass, MD, Emory University School of Medicine_|_MLSCN Grant: R03DA024890-01_|__|_Calpains are ubiquitous, calcium-activated cysteine proteases involved in both physiological and pathological cellular functions.  The two major forms, u-calpain (calpain I) and m-calpain (calpain II), are activated by micromolar and millimolar calcium concentrations, respectively.  A current ",16,Emory University Molecular Libraries Screening Center,A22 Calpain HTS,20080314,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",397393,NULL,AAB17381,Legacy Depositors|NIH Initiatives,"11959150,14761904,2057527,7477738,7855906",0,10.1016/0165-6147(94)90090-6|10.1016/s0022-510x(02)00013-8|10.1080/01616412.1995.11740322|10.1093/brain/awh078|10.1152/physrev.1991.71.3.813,NULL,AAB17381,NULL
1987,1,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Richard Honkanen, University of South Alabama_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH085702-01A1_|_Grant Proposal PI: Richard Honkanen, University of South Alabama_|_External Assay ID: PP5_INH_FLINT_1536_1X%INH_|__|_Name: Fluorescence-based primary biochemical high through",5,The Scripps Research Institute Molecular Screening Center,PP5_INH_FLINT_1536_1X%INH,20100615,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,182","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",5536,Biochemical,AAH00750,NIH Initiatives,"11137038,17084641,18253812,9195923,9278397,9575175",0,10.1007/s10555-008-9125-z|10.1016/j.tem.2006.10.013|10.1016/s1043-2760(00)00335-0|10.1074/jbc.272.26.16224|10.1074/jbc.272.36.22464|10.1074/jbc.273.20.12250,NULL,AAH00750,NULL
1899,1,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: A.D. Strosberg, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1-X01-MH085709-01_|_Grant Proposal PI: A.D. Strosberg, TSRI_|_External Assay ID: HCVCORE_INH_HTRF_1536_1X%INH_|__|_Name: TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) cor",5,The Scripps Research Institute Molecular Screening Center,HCVCORE_INH_HTRF_1536_1X%INH,20100615,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,727,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1018,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1486,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1761,1775,1780,1794,1795,1820,1826,1832,1833,1853,1858,1864,1868,1882,1889,1890","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",NULL,Biochemical,ABC47431,NIH Initiatives,"10233931,12407573,15039539,15566499,19009270,19264632,7518529,8676467,9916717",0,10.1007/978-1-59745-394-3_22|10.1053/jhep.2002.36227|10.1099/vir.0.008565-0|10.1099/vir.0.79775-0|10.1111/j.1478-3231.2004.0965.x,NULL,ABC47431,NULL
1974,1,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Benjamin Cravatt, TSRI_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R01 CA087660-05 Fast Track_|_Grant Proposal PI: Benjamin Cravatt, TSRI_|_External Assay ID: GSTO1-1_INH_FP_1536_1X%INH_|__|_Name: Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical",5,The Scripps Research Institute Molecular Screening Center,GSTO1-1_INH_FP_1536_1X%INH,20100616,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,727,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1018,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1486,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1761,1775,1780,1794,1795,1820,1826,1832,1833,1853,1858,1864,1868,1882,1889,1890","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",9446,Biochemical,NP_004823,NIH Initiatives,"10449909,12296629,1411535,16272168,19004028,9697699",0,10.1002/prot.22278|10.1023/a:1019886918029|10.1038/1258|10.1093/carcin/bgi261|10.1126/science.1411535|10.1159/000015304,"1.20.4.2,1.8.5.1,2.5.1.18",P78417,NULL
1950,1,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Paul Lieberman, Wistar Institute_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: I R21 NS063906-01_|_Grant Proposal PI: Paul Lieberman, Wistar Institute_|_External Assay ID: EBNA1_INH_FP_1536_1X%INH_|__|_Name: Fluorescence polarization-based primary biochemical high throughput screening as",5,The Scripps Research Institute Molecular Screening Center,EBNA1_INH_FP_1536_1X%INH,20100616,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,727,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1018,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1486,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1761,1775,1780,1794,1795,1820,1826,1832,1833,1853,1858,1864,1868,1882,1889,1890","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",3783709,Biochemical,CAD53427,NIH Initiatives,"10530796,12450729,15242681,15541197,17153849,17459939,18515742,18946490,19139406,19211802,9032305",0,10.1016/j.molmed.2004.05.006|10.1016/s0024-3205(99)00214-3|10.1016/s1044579x0200086x|10.1017/s1462399404008440|10.1038/emboj.2008.221|10.1073/pnas.0810619106|10.1073/pnas.0812575106|10.1128/jvi.00153-07|10.1177/0961203306070009|10.1634/theoncologist.2008-0036,NULL,CAD53427,NULL
1906,1,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: John Dalton and Donald Gardiner, Queensland Institute of Medical Research, Australia_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number 1 R03 MH084103-01_|_Grant Proposal PI: John Dalton and Donald Gardiner, Queensland Institute of Medical Research, Australia_|_External Assay ID: CTSL1_INH_FLINT_1536_1X%INH_|__|",5,The Scripps Research Institute Molecular Screening Center,CTSL1_INH_FLINT_1536_1X%INH,20100616,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,727,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1018,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1486,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1761,1775,1780,1794,1795,1820,1826,1832,1833,1853,1858,1864,1868,1882,1889,1890","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",NULL,Biochemical,CAI16307,NIH Initiatives,"14743975,15320788,16597508,16611071,16913833,16983082,17073736,17094048,17107951,17720817,18721457,6363922,7048089,9632644,9694371",0,10.1007/s004360050447|10.1016/0166-6851(82)90034-2|10.1016/0166-6851(84)90017-3|10.1016/j.pbi.2006.03.009|10.1042/bst0340997|10.1073/pnas.0604101103|10.1074/jbc.273.26.15961|10.1074/jbc.m609251200|10.1074/jbc.m704938200|10.1186/1475-2875-7-161|10.1515/bc.2006.107|10.2174/092986706776361085|10.2174/1568016043356264|10.3317/jraas.2006.021,NULL,CAI16307,NULL
1947,1,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Benjamin Cravatt, TSRI_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R01 CA087660-05 Fast Track_|_Grant Proposal PI: Benjamin Cravatt, TSRI_|_External Assay ID: FAM108B_INH_FP_1536_1X%INH_|__|_Name: Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical",5,The Scripps Research Institute Molecular Screening Center,FAM108B_INH_FP_1536_1X%INH,20100615,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,727,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1018,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1486,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1761,1775,1780,1794,1795,1820,1826,1832,1833,1853,1858,1864,1868,1882,1889,1890","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",226016,Biochemical,AAH32261,NIH Initiatives,"10449909,12296629,1411535,16272168,19004028,9697699",0,10.1002/prot.22278|10.1023/a:1019886918029|10.1038/1258|10.1093/carcin/bgi261|10.1126/science.1411535|10.1159/000015304,NULL,AAH32261,NULL
1700,1,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Vincent Yang, Emory University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number 1-R03-DA026215-01_|_Grant Proposal PI: Vincent Yang_|__|_External Assay ID: KLF5_INH_Lumi_1536_%INH_|__|_Name: Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)_|__|_Descripti",5,The Scripps Research Institute Molecular Screening Center,KLF5_INH_LUMI_1536_%INH,20090629,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1400,1401,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2581,2585,2618,2662,2690,2692,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",688,Cell-based,ABM97548,NIH Initiatives,"11152667,15077182,15581624,15740636,15950866,17395897,17508399,18450752,18620093",0,10.1002/bies.20581|10.1016/j.febslet.2004.10.079|10.1016/j.tibs.2005.04.003|10.1016/s0065-230x(08)00003-1|10.1038/sj.cr.7290271|10.1038/sj.onc.1207397|10.1074/jbc.c000870200|10.1074/jbc.m801384200|10.1152/ajpgi.00541.2006,NULL,ABM97548,NULL
1621,2,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,"Southern Research's Specialized Biocontainment Screening Center (SRSBSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Assay Provider: Dr. Marintha Heil, Southern Research Institute_|_Award: 1R03 MH084847-01_|__|_West Nile virus (WNV) is a mosquito borne infectious agent that causes febrile illness and occasionally encephalitis.  Outbreaks had been reported in Africa, Asia, and Europe since 1937.  In 1999, the first case of WNV was d",33,Southern Research Specialized Biocontainment Screening Center,WNV,20100226,"19,72,86,109,119,190,191,204,253,298,303,311,323,338,366,403,412,444,460,499,525,546,547,588,637,774,785,802,803,864,896,903,932,936,938,942,978,992,1001,1046,1047,1057,1123,1150,1176,1201,1309,1318,1329,1340,1345,1365,1367,1400,1401,1474,1492,1493,1539,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1833,1853,1864,1882,1889,1890,1893,1917,1922,1923,1967,1981,1985,1986,1990,2000,2002,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161,2162,2165,2170,2176,2181,2187,2196,219","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842159,842160,842161,842162,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
1962,1,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Heather Harding, New York University School of Medicine_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1-R03-DA026554-01_|_Grant Proposal PI: Heather Harding, New York University School of Medicine_|_External Assay ID: TPT1_INH_FP_1536_1X%INH_|__|_Name: Fluorescence polarization-based pri",5,The Scripps Research Institute Molecular Screening Center,TPT1_INH_FP_1536_1X%INH,20100616,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,727,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1018,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1486,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1761,1775,1780,1794,1795,1820,1826,1832,1833,1853,1858,1864,1868,1882,1889,1890","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",NULL,Biochemical,XP_717710,NIH Initiatives,"11705403,14504659,1537841,15611301,18094117,18217203,18372167,18479253,18776460,373120,8392224,9404890,9582290",0,10.1007/s00018-003-3107-7|10.1007/s00018-008-7393-y|10.1016/j.gde.2008.01.006|10.1021/bi011388t|10.1042/bc20070143|10.1074/jbc.273.21.12685|10.1093/nass/nrn241|10.1126/science.373120|10.1126/science.8392224|10.1261/rna.7193705|10.1261/rna.859908,NULL,XP_717710,NULL
1800,1,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: David Frick, New York Medical College_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH085690-01_|_Grant Proposal PI: David Frick, New York Medical College_|_External Assay ID: NS3HCVDNA_INH_FLINT_1536_%INH_|__|_Name: Fluorescence-based primary biochemical high throughput screening ",5,The Scripps Research Institute Molecular Screening Center,NS3HCVDNA_INH_FLINT_1536_%INH,20100615,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1400,1401,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2581,2585,2618,2662,2690,2692,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",NULL,Biochemical,ABN45876,NIH Initiatives,"10644352,12206878,12407573,17263143,19009270,9493270,9614113",0,10.1007/978-1-59745-394-3_22|10.1016/s0166-3542(02)00096-7|10.1016/s0969-2126(98)00010-0|10.1053/jhep.2002.36227|10.1074/jbc.273.24.15045|10.1128/jvi.74.4.1794-1800.2000,NULL,ABN45876,NULL
1845,1,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: David Frick, New York Medical College_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH085690-01_|_Grant Proposal PI: David Frick, New York Medical College_|__|_External Assay ID: DNAETBR_INH_FLINT_1536_%FID_|__|_Name:_|__|_Fluorescence-based counterscreen assay for HCV NS3 helicase",5,The Scripps Research Institute Molecular Screening Center,DNAETBR_INH_FLINT_1536_%FID,20100615,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1400,1401,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2581,2585,2618,2662,2690,2692,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",NULL,Biochemical,ABN45876,NIH Initiatives,"10644352,12206878,12407573,17263143,19009270,9493270,9614113",0,10.1007/978-1-59745-394-3_22|10.1016/s0166-3542(02)00096-7|10.1016/s0969-2126(98)00010-0|10.1053/jhep.2002.36227|10.1074/jbc.273.24.15045|10.1128/jvi.74.4.1794-1800.2000,NULL,ABN45876,NULL
1476,2,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),"Cruzain is a cysteine protease from the tropical parasite Trypanosoma cruzi. Dual qHTS experiment was performed against the NCGC compound collection in order to 1) identify novel inhibitors of the enzyme and 2) profile the compound collection for promiscuous inhibitors operating via colloidal aggregation (by performing detergent-free and detergent-containing comparison screens). Cruzain was assayed by the use of fluorogenic coumarin-based substrate Z-FR-AMC: proteolytic cleavage releases AMC, whose fluoresc",2,National Center for Advancing Translational Sciences (NCATS),CRUZ188,20100219,"11,13,51,66,108,119,174,177,178,180,185,190,191,196,199,204,206,224,227,239,240,241,243,244,253,261,263,275,289,298,299,300,304,311,323,335,338,339,342,366,370,379,398,401,403,408,447,453,460,464,471,500,525,527,535,546,547,564,588,596,607,610,612,636,650,660,681,698,700,701,702,710,713,727,736,750,753,774,785,795,803,827,830,836,846,847,853,864,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,999,1004,1017,1023,1030,1046,1047,1049,1050,1052,1054,1057,1064,1066,1072,1080,1102,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,3I06_A,Governmental Organizations|NIH Initiatives,"10725218,16864780,17447748,17698625,18223646,19908840,19908842,9705954",0,10.1021/jm061317y|10.1021/jm901069a|10.1021/jm901070c|10.1038/nchembio.65|10.1073/pnas.0604348103|10.1084/jem.188.4.725|10.1128/aac.00436-07,NULL,1ME3_A,NULL
1822,1,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: John Dalton and Donald Gardiner, Queensland Institute of Medical Research, Australia_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number 1 R03 MH084103-01_|_Grant Proposal PI: John Dalton and Donald Gardiner, Queensland Institute of Medical Research, Australia_|_External Assay ID: PFM18AAP_INH_FLINT_1536_%INH_|__",5,The Scripps Research Institute Molecular Screening Center,PFM18AAP_INH_FLINT_1536_%INH,20100615,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1400,1401,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2581,2585,2618,2662,2690,2692,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",813594,Biochemical,CAD52000,NIH Initiatives,"14743975,15320788,16597508,16611071,16913833,16983082,17073736,17094048,17107951,17720817,18721457,6363922,7048089,9632644,9694371",0,10.1007/s004360050447|10.1016/0166-6851(82)90034-2|10.1016/0166-6851(84)90017-3|10.1016/j.pbi.2006.03.009|10.1042/bst0340997|10.1073/pnas.0604101103|10.1074/jbc.273.26.15961|10.1074/jbc.m609251200|10.1074/jbc.m704938200|10.1186/1475-2875-7-161|10.1515/bc.2006.107|10.2174/092986706776361085|10.2174/1568016043356264|10.3317/jraas.2006.021,NULL,XP_001352189,NULL
1531,1,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype","University of New Mexico Assay Overview:_|_Assay Support:  1R03MH084830-01   _|_Project Title:  TR-FRET HTS Assay for Inhibitors of MEKK2-MEK5 PB1 Domain Interaction  _|_PI: Kazuhiro Nakamura, Ph.D_|_Center PI:  Larry Sklar, Ph.D_|_Assay Implementatiion:  Zurab Surviladze Ph.D, Mark Haynes Ph.D, Anna Waller Ph.D, Mark Carter MS_|__|_Assay Background and Significance:_|_PB1 (Phox/Bem1p) domains function as protein-protein interaction sites by forming PB1-PB1 domain heterodimers (Moscat, et al. 2006). There a",6,NMMLSC,UNM_MEK5_MEK_Kinase_2_WildType,20090302,"19,72,86,109,119,190,191,204,253,298,303,311,323,338,366,403,412,444,460,499,525,546,547,588,637,774,785,802,803,864,896,903,932,936,938,942,978,992,1001,1046,1047,1057,1123,1150,1176,1201,1309,1318,1329,1340,1345,1365,1367,1400,1401,1474,1492,1493,1539,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1833,1853,1864,1882,1889,1890,1892,1893,1917,1922,1923,1967,1981,1985,1986,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2143,2145,2153,2159,2161,2162,2165,2170,2176,218","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842159,842160,842161,842162,842164,842165,842166,842167,842168,842169,842170,842171,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",5871,NULL,NP_004570,NIH Initiatives,"11309812,12912994,15085193,16949360,17452462",0,10.1016/j.molcel.2006.08.002|10.1074/jbc.c300313200|10.1128/mcb.00125-07|10.1172/jci19890,2.7.11.1,Q12851,NULL
1861,1,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Olivier Civelli, University of California, Irvine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number 1-R03-DA026557-01_|_Grant Proposal PI: Olivier Civelli_|_External Assay ID: GPR7_ANT_FLUO8_1536_1X%INH_|__|_Name: Fluorescence-based primary cell-based high throughput screening assay to identify antagon",5,The Scripps Research Institute Molecular Screening Center,GPR7_ANT_FLUO8_1536_1X%INH,20090720,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1400,1401,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2581,2585,2618,2662,2690,2692,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",2831,Cell-based,EAW86722,NIH Initiatives,"10407191,12118011,12401809,12719537,12925742,15261118,15607941,15983370,17629964,17959251,18370232,18382464,7590751",0,10.1006/geno.1995.1109|10.1007/978-1-59745-205-2_6|10.1016/j.brainres.2004.03.079|10.1016/j.mcn.2004.08.010|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2007.06.001|10.1016/s0169-328x(99)00171-0|10.1038/nrd2518|10.1073/pnas.0503795102|10.1073/pnas.0837789100|10.1073/pnas.1334189100|10.1074/jbc.m205883200|10.1074/jbc.m206396200,NULL,P48145,NULL
1454,2,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|__|_MLSCN Grant: 1X01MH082406-01_|_Assay Submitter (PI): Dr. Wei Zheng, NCGC/NIH_|__|_NCGC Assay Overview:_|__|_The Ras/extracellular-signal-regulated kinase (ERK) mitogen activated protein (MAP) kinase signaling pathway  (ERK1/2 cascade) plays a key role in transmitting signals from the cell surface to the nucleus (Nishida and Gotoh 1993; Chang and Karin, 2001). The cascade is initiated by the small G-protein R",2,National Center for Advancing Translational Sciences (NCATS),ERKS580,20081219,"72,119,178,185,190,191,199,204,224,239,253,275,289,298,304,323,338,370,401,408,471,525,535,546,547,564,588,596,607,610,636,650,681,698,727,736,750,774,785,803,827,830,836,846,847,853,864,896,903,904,912,914,932,936,938,992,1046,1050,1054,1064,1066,1072,1102,1103,1123,1148,1150,1176,1183,1201,1203,1214,1216,1222,1228,1232,1233,1242,1245,1249,1256,1287,1302,1309,1317,1318,1321,1328,1329,1330,1340,1345,1348,1354,1355,1359,1365,1367,1370,1377,1379,1380,1390,1420,1433,1449,1456,1474,1480,1482,1486,1487,1488,1489","842122,842249,842251,842280,842298,842322,842323,842325,842369,842380,842414,842426,842442,842463,842471,842475,842529,842558,842560,842568,842571,842585,842588,842626,842629,842688,842692,842702,842719,842725,842770,842773,842826,842844,842859,842864,842883,842966,842997,843010,843033,843042,843070,843079,843085,843110,843164,843193,843230,843274,843307,843314,843336,843407,843429,843432,843437,843442,843444,843479,843506,843530,843554,843568,843586,843589,843614,843617,843623,843634,843651,843652,843667,8",5594,NULL,NP_002736,Governmental Organizations|NIH Initiatives,NULL,0,NULL,2.7.11.24,P28482,NULL
1706,1,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Valerie Tokars and Andrew Mesecar, University of Illinois at Chicago (UIC)_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1-R03-MH084162-01A1_|_Grant Proposal PI: Valerie Tokars and Andrew Mesecar, UIC_|__|_External Assay ID: 3CLPRO_INH_QFRET_1536_%INH_|__|_Name: QFRET-based primary bioch",5,The Scripps Research Institute Molecular Screening Center,3CLPRO_INH_QFRET_1536_%INH,20100615,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1400,1401,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2581,2585,2618,2662,2690,2692,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",NULL,Biochemical,AAZ82016,NIH Initiatives,"12690091,12690092,14561748,15358261,17168761,17168763",0,10.1016/j.mib.2004.06.007|10.1056/nejmoa030747|10.1056/nejmoa030781|10.1074/jbc.m310875200|10.2174/138161206779010369|10.2174/138161206779010396,NULL,AAZ82016,"COVID-19, COVID19, Coronavirus, Corona-virus, SARS, SARS2, SARS-CoV, SARS-CoV-2 [as per BioAssay]"
1529,1,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype","University of New Mexico Assay Overview:_|_Assay Support:  1R03MH084830-01   _|_Project Title:  TR-FRET HTS Assay for Inhibitors of MEKK2-MEK5 PB1 Domain Interaction  _|_PI: Kazuhiro Nakamura, Ph.D_|_Center PI:  Larry Sklar, Ph.D_|_Assay Implementatiion:  Zurab Surviladze Ph.D, Mark Haynes Ph.D, Anna Waller Ph.D, Mark Carter MS_|__|_Assay Background and Significance:_|_PB1 (Phox/Bem1p) domains function as protein-protein interaction sites by forming PB1-PB1 domain heterodimers (Moscat, et al. 2006). There a",6,NMMLSC,UNM_MEK5_MEK_Kinase_3_WildType,20090302,"19,72,86,109,119,190,191,204,253,298,303,311,323,338,366,403,412,444,460,499,525,546,547,588,637,774,785,802,803,864,896,903,932,936,938,942,978,992,1001,1046,1047,1057,1123,1150,1176,1201,1309,1318,1329,1340,1345,1365,1367,1400,1401,1474,1492,1493,1539,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1833,1853,1864,1882,1889,1890,1892,1893,1917,1922,1923,1967,1981,1985,1986,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2143,2145,2153,2159,2161,2162,2165,2170,2176,218","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842159,842160,842161,842162,842164,842165,842166,842167,842168,842169,842170,842171,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",4215,NULL,NP_976226,NIH Initiatives,"11309812,12912994,15085193,16949360,17452462",0,10.1016/j.molcel.2006.08.002|10.1074/jbc.c300313200|10.1128/mcb.00125-07|10.1172/jci19890,2.7.11.25,Q99759,NULL
1789,1,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Robert Matts, Oklahoma State University_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 X01 MH083240-01_|_Grant Proposal PI: Robert Matts, Oklahoma State University_|_External Assay ID: HSP90_INH_LUMI_1536_%INH_|__|_Name: Luminescence-based primary biochemical high throughput screening a",5,The Scripps Research Institute Molecular Screening Center,HSP90_INH_LUMI_1536_%INH,20100615,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1400,1401,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2581,2585,2618,2662,2690,2692,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",3320,Biochemical,AAI08696,NIH Initiatives,"10471810,11868271,12563018,14508491,16460658,18190862,8144534,8873613",0,10.1016/j.ab.2005.12.023|10.1016/j.drudis.2007.10.007|10.1016/s0014-5793(99)01056-x|10.1016/s0065-3233(01)59005-1|10.1021/bi9615396|10.1038/nature01913|10.1177/153537020322800201,NULL,AAI08696,NULL
1527,1,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Peter Hodder, TSRI_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS059451-01 Fast Track_|_Grant Proposal PI: Peter Hodder, TSRI_|__|_External Assay ID: VIM-2_INH_EPIABS_1536_%INH_|__|_Name: Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-",5,The Scripps Research Institute Molecular Screening Center,VIM-2_INH_EPIABS_1536_%INH,20121226,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1400,1401,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2581,2585,2618,2662,2690,2692,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",14678525,Biochemical,AAF61483,NIH Initiatives,"10390207,10508665,1158579,14557293,15187432,15831827,15949786,16476803,18160745,18364060,18519228,18754746,9687398",0,10.1016/j.ab.2005.04.029|10.1016/s1367-5931(99)00017-4|10.1099/jmm.0.46126-0|10.1128/cmr.16.4.673-687.2003|10.1128/cmr.18.2.306-325.2005|10.1248/bpb.27.851|10.1517/17425247.5.9.931|10.2478/v10042-008-0020-9,NULL,AAF61483,NULL
1556,1,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Peter Hodder, TSRI_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS059451-01 Fast Track_|_Grant Proposal PI: Peter Hodder, TSRI_|_External Assay ID: IMP-1_INH_EPIABS_1536_%INH_|_Name: Fluorescence primary biochemical high throughput screening assay to identify inhibitors of IMP-1 m",5,The Scripps Research Institute Molecular Screening Center,IMP-1_INH_EPIABS_1536_%INH,20130104,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1400,1401,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2581,2585,2618,2662,2690,2692,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",NULL,Biochemical,AAN87168,NIH Initiatives,"10390207,10508665,11585791,14557293,15187432,15831827,15949786,16476803,18160745,18364060,18519228,18754746,9687398",0,10.1016/j.ab.2005.04.029|10.1016/s1367-5931(99)00017-4|10.1099/jmm.0.46126-0|10.1128/cmr.14.4.933-951.2001|10.1128/cmr.16.4.673-687.2003|10.1128/cmr.18.2.306-325.2005|10.1248/bpb.27.851|10.1517/17425247.5.9.931|10.2478/v10042-008-0020-9,NULL,AAN87168,NULL
1825,1,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Vincent Yang, Emory University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number 1-R03-DA026215-01_|_Grant Proposal PI: Vincent Yang_|__|_External Assay ID: IEC6CYTOX_INH_LUMI_1536_%INH_|__|_Name: Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify ",5,The Scripps Research Institute Molecular Screening Center,IEC6CYTOX_INH_LUMI_1536_%INH,20090618,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1400,1401,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2581,2585,2618,2662,2690,2692,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",NULL,Cell-based,NULL,NIH Initiatives,"11152667,15077182,15581624,15740636,15950866,17395897,17508399,18450752,18620093",0,10.1002/bies.20581|10.1016/j.febslet.2004.10.079|10.1016/j.tibs.2005.04.003|10.1016/s0065-230x(08)00003-1|10.1038/sj.cr.7290271|10.1038/sj.onc.1207397|10.1074/jbc.c000870200|10.1074/jbc.m801384200|10.1152/ajpgi.00541.2006,NULL,NULL,NULL
1085,1,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: Theodore Jardetzky; Northwestern University_|_MLSCN Grant: 1R21NS059415-01_|__|_Epstein-Barr virus (EBV), or human herpes virus 4 (HHV-4), is a member of the larger herpesvirus family that consists of three subfamilies (&#945;, &#946;, &#947;). Epstein-Barr virus (EBV) is an extremely prevalent human herpesvirus. Disease syndromes in humans caused by EBV reflect the cell types that ",16,Emory University Molecular Libraries Screening Center,A27 EBV HTS,20080303,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",5176170,NULL,YP_001129466,Legacy Depositors|NIH Initiatives,"17581996,17655906",0,10.1016/j.virol.2007.06.031|10.1128/jvi.00575-07,NULL,Q1HVG2,NULL
1274,1,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)","NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: Susan Smith, Emory University_|_MLSCN Grant: MH083234-01_|__|_Oxidative stress (the excess production of cellular oxidizing substances) is a central component in many diseases. Reactive oxygen species (ROS) produce oxidative stress that plays a central role in inflammation in general, and in the tissue damage and abnormal cell growth and fibrosis associated with many diseases. ROS-a",16,Emory University Molecular Libraries Screening Center,A26,20080603,"72,119,191,204,253,298,323,338,366,525,546,547,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1367,1400,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2585,2690,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",653361,NULL,NP_000256,Legacy Depositors|NIH Initiatives,"17900370,18398843",0,10.1002/ijc.23423|10.1186/1471-2148-7-178,NULL,P14598,NULL
1626,2,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,"Southern Research Molecular Libraries Screening Center (SRMLSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Screening Centers Network (MLSCN)_|_Assay Provider Lucile White, Southern Research Institute, Birmingham, AL_|_Award: N01-AI-15449_|__|_Mycobacterium tuberculosis (Mtb) is a notorious pathogen whose increasing resistance to antibiotics and heightened lethality in combination with AIDS makes it a major health concern worldwide. The World Health Organization (WHO) estim",11,SRMLSC,H37Rv,20091002,"19,72,86,109,119,190,191,204,253,298,311,323,338,366,403,412,444,525,546,547,774,785,802,803,864,896,903,932,936,938,942,978,992,1001,1046,1047,1057,1123,1150,1176,1201,1318,1329,1340,1345,1365,1367,1400,1474,1492,1493,1539,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1833,1853,1864,1882,1889,1892,1893,1917,1922,1967,1981,1985,1986,1990,2000,2002,2015,2018,2082,2092,2108,2118,2123,2125,2143,2145,2153,2159,2161,2162,2170,2176,2181,2187,2196,2197,2244,2247,2249,2256,2265,2266,2303,2315,233","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842159,842160,842161,842162,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,8",NULL,NULL,NULL,NIH Initiatives,"19783214,9145860",0,10.1016/j.tube.2009.07.006,NULL,NULL,NULL
1530,1,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant","University of New Mexico Assay Overview:_|_Assay Support:  1R03MH084830-01   _|_Project Title:  TR-FRET HTS Assay for Inhibitors of MEKK2-MEK5 PB1 Domain Interaction  _|_PI: Kazuhiro Nakamura, Ph.D_|_Center PI:  Larry Sklar, Ph.D_|_Assay Implementatiion:  Zurab Surviladze Ph.D, Mark Haynes Ph.D, Anna Waller Ph.D, Mark Carter MS_|__|_Assay Background and Significance:_|_PB1 (Phox/Bem1p) domains function as protein-protein interaction sites by forming PB1-PB1 domain heterodimers (Moscat, et al. 2006). There a",6,NMMLSC,UNM_MEK_5_MEK_Kinase_2_Mutant,20090302,"19,72,86,109,119,190,191,204,253,298,303,311,323,338,366,403,412,444,460,499,525,546,547,588,637,774,785,802,803,864,896,903,932,936,938,942,978,992,1001,1046,1047,1057,1123,1150,1176,1201,1309,1318,1329,1345,1365,1367,1400,1401,1474,1492,1493,1539,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1833,1853,1864,1882,1889,1890,1892,1893,1917,1922,1923,1967,1981,1985,1986,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2143,2145,2153,2159,2161,2162,2165,2170,2176,2181,218","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842159,842160,842161,842162,842164,842165,842166,842167,842168,842169,842170,842171,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",5871,NULL,NP_004570,NIH Initiatives,"11309812,12912994,15085193,16949360,17452462",0,10.1016/j.molcel.2006.08.002|10.1074/jbc.c300313200|10.1128/mcb.00125-07|10.1172/jci19890,2.7.11.1,Q12851,NULL
2685,2,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,"NIH Molecular Libraries Probe Production Centers Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|_MLPCN Grant:  1 R03 MH085686-01_|_Assay Submitter (PI): Beller, Mathias; Max-Planck-Institut fur Biophysikalische Chemie_|__|_NCGC Assay Overview: _|_Storing lipids as a reservoir for energy or the anabolism of elementary metabolites is a common feature of probably all cells and is conserved from bacteria to humans. The universal cellular lipid storage organelle is the so-called lipid storage droplet (LD",2,National Center for Advancing Translational Sciences (NCATS),LDSA001,20100325,"6,72,119,137,191,204,229,253,289,298,299,303,323,338,366,441,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,803,864,892,899,931,932,936,938,957,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2002,2007,2015,2018,2020,2048,2052,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,19067489,0,10.1371/journal.pbio.0060292,NULL,NULL,NULL
2517,2,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),"The apurinic/apyrimidinic endonuclease APE1 is the primary mammalian enzyme responsible for the removal of abasic (or AP) sites in DNA and functions centrally in the base excision DNA repair (BER) pathway. Recent studies suggested a link between an overexpression of APE1 in many cancers and resistance of these tumor cells to radio- and chemotherapy. Thus, targeting APE1 could improve the efficacy of current treatment paradigms by promoting selective sensitization or protection of diseased and normal cells, ",2,National Center for Advancing Translational Sciences (NCATS),APE1917,20130716,"6,11,13,51,66,72,119,135,137,174,177,178,180,185,187,190,191,196,199,204,224,227,229,239,240,241,243,244,253,261,263,273,275,277,289,298,299,300,303,304,311,323,335,338,342,366,370,379,398,401,403,408,412,441,447,450,453,460,462,464,471,487,499,525,527,535,546,547,564,588,595,596,597,610,612,614,636,637,650,660,681,698,700,701,702,713,727,750,753,757,774,785,795,803,827,830,836,846,847,853,864,866,876,887,892,896,899,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,999,1001,1004,1017,1018,103","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,1DE9_A,Governmental Organizations|NIH Initiatives,"11585362,16864780,17112792,17259346,19484131",0,10.1016/j.dnarep.2006.10.017|10.1016/s0921-8777(01)00063-5|10.1073/pnas.0604348103|10.1158/1541-7786.mcr-06-0329|10.1371/journal.pone.0005740,NULL,1DE9_A,NULL
2675,2,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production Centers Network [MLPCN]_|__|_MLPCN Grant: R03 MH087421-01_|_Assay Submitter (PI): Charles Thornton_|__|_NCGC Assay Overview:_|__|_Expanded CTG repeats in the 3' untranslated region of the DM protein kinase (DMPK) gene causes type I myotonic dystrophy (DM1). DM1 is a multi-systemic disease with a prevalence of 1/7000. Clinical features include myotonia, progressive muscle weakness and wasting, cardiac arrhythmia, insulin resistanc",2,National Center for Advancing Translational Sciences (NCATS),MBNL923,20100325,"119,178,191,204,253,275,289,298,303,323,338,366,401,408,460,471,499,525,546,547,564,588,637,650,774,785,803,864,896,903,932,936,938,1046,1047,1066,1123,1150,1201,1216,1222,1228,1232,1233,1245,1256,1309,1317,1318,1328,1329,1330,1340,1345,1359,1365,1367,1390,1400,1401,1456,1474,1539,1564,1607,1609,1641,1645,1646,1649,1676,1678,1683,1688,1694,1697,1720,1727,1730,1738,1742,1756,1774,1775,1779,1780,1794,1795,1820,1826,1832,1833,1845,1853,1858,1864,1868,1871,1882,1884,1890,1892,1893,1908,1917,1922,1923,1967,1981,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",4154,NULL,NP_066368,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,Q9NR56,NULL
2662,2,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|__|_MLPCN Grant: DA027717-01A1_|_Assay Submitter (PI): John Bushweller_|__|_NCGC Assay Overview:_|__|_The MLL (Mixed Lineage Luekemia) gene is involved in chromosomal translocation that results in either acute lymphoid leukemia (ALL) or acute myeloid leukemia (AML). Chromasomal  translocation of MLL gene is responsible for the fusion of N-terminal MLL to more than 60 different partner genes in frame. Many,2,National Center for Advancing Translational Sciences (NCATS),MLLD723,20100928,"51,72,119,178,180,190,191,196,204,205,206,227,244,253,263,275,289,298,303,323,338,359,366,370,379,401,408,453,460,464,471,499,525,546,547,564,588,594,595,612,637,650,710,736,753,774,785,791,798,803,827,863,864,866,876,887,892,896,903,904,931,932,936,938,967,978,985,1004,1018,1023,1030,1046,1047,1050,1051,1052,1053,1057,1066,1080,1110,1123,1131,1132,1140,1150,1174,1176,1201,1216,1222,1228,1232,1233,1236,1245,1254,1256,1292,1309,1317,1318,1328,1329,1330,1340,1345,1359,1365,1367,1390,1400,1401,1456,1474,1483,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",4297,NULL,NP_005924,Governmental Organizations|NIH Initiatives,NULL,0,NULL,2.1.1.354,Q03164,NULL
2013,2,Image-Based HTS for Selective Antagonists for GPR55,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1X01 DA026205-01 _|_Assay Provider: Dr. Mary Abood, California Pacific Medical Center Research Institute_|__|_The cannabinoid and endocannabinoid system has been implicated in the pathophysiology of drug dependence and addiction disorders.  GPR55, an orphan",14,Burnham Center for Chemical Genomics,BCCG-A240-GPR55-Antagonist-Assay,20110112,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",9290,NULL,NP_005674,NIH Initiatives,"17765871,17876302,17906678,18263782,19233486,9931487",0,10.1016/j.bbrc.2007.08.078|10.1016/j.tips.2008.12.004|10.1016/s0169-328x(98)00277-0|10.1038/sj.bjp.0707460|10.1038/sj.bjp.0707481|10.1104/pp.107.111443,NULL,Q9Y2T6,NULL
2551,2,qHTS for inhibitors of ROR gamma transcriptional activity,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: R03 DA026211-01_|_Assay Provider: Dan Littman, New York University_|__|_Assay Overview:_|__|_The retinoic acid-related orphan receptor (ROR) gamma is a transcription factor that has a central role in the differentiation of Th17 cells, a subset of T helper cells that secrete the inflammatory cytokines IL-17, IL-17F, and IL-22. Th17 cells have been implicated in graft versus host disease, autoimmun",2,National Center for Advancing Translational Sciences (NCATS),RORG318,20100315,"11,13,51,66,72,119,135,174,177,180,185,187,190,191,196,199,204,205,206,224,227,239,240,241,243,244,253,261,263,273,275,277,289,298,299,300,303,304,311,323,335,338,342,359,366,370,379,398,401,403,408,447,450,453,460,464,471,499,525,527,535,546,547,564,588,594,595,596,607,610,612,614,636,637,650,660,681,698,700,701,702,710,713,727,736,750,753,757,774,785,791,795,798,803,827,830,836,846,847,853,863,864,866,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,985,991,992,995,996,999,1004,1017,1018,10","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",19885,NULL,NP_035411,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P51450,NULL
2058,2,Image-Based HTS for Selective Antagonists of GPR35,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1X01MH085708-01_|_Assay Provider: Dr. Lawrence Barak, Duke University_|__|_Addictive behavior stems from abnormal signaling activities in the brain. Thus identification of compounds blocking this modified signaling activity may lead to treatments for addict",14,Burnham Center for Chemical Genomics,BCCG-A245-GPR35-Antagonist-Assay,20110119,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",2859,NULL,NP_005292,NIH Initiatives,"16934253,17906678,17940199,17996730,9479505",0,10.1006/geno.1998.5095|10.1016/j.bbrc.2007.10.197|10.1016/j.febslet.2006.08.015|10.1038/sj.bjp.0707481|10.1124/jpet.107.127266,NULL,Q9HC97,NULL
2546,2,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: R03 DA026211-01_|_Assay Provider: Dan Littman, New York University_|__|_Assay Overview:_|__|_The retinoic acid-related orphan receptor (ROR) gamma is a transcription factor that has a central role in the differentiation of Th17 cells, a subset of T helper cells that secrete the inflammatory cytokines IL-17, IL-17F, and IL-22. Th17 cells have been implicated in graft versus host disease, autoimmun",2,National Center for Advancing Translational Sciences (NCATS),RORG919,20100313,"11,13,51,66,72,119,135,174,177,180,185,187,190,191,196,199,204,205,206,224,227,239,240,241,243,244,253,261,263,273,275,277,289,298,299,300,303,304,311,323,335,338,342,359,366,370,379,398,401,403,408,447,450,453,460,464,471,499,525,527,535,546,547,564,588,594,595,596,607,610,612,614,636,637,650,660,681,698,700,701,702,710,713,727,736,750,753,757,774,785,791,795,798,803,827,830,836,846,847,853,863,864,866,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,985,991,992,995,996,999,1004,1017,1018,10","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",19885,NULL,NP_035411,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P51450,NULL
2289,2,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,"MLSCN Grant: 1 R21 NS059478-01_|__|_Assay Provider: Qihong Huang, The Wistar Institute_|__|_NCGC Assay Overview:_|__|_MicroRNAs (miRNAs) are endogenously encoded small (~20-25 nucleotides), nonprotein-coding RNAs that are involved in post-transcriptional repression of target messenger RNAs (mRNAs) (Le and Hannon, 2004). Estimated to be involved in the regulation of 30% of all protein-coding mRNAs (Filipowicz et al., 2008), miRNAs play a significant role in many biological processes including cellular differ",2,National Center for Advancing Translational Sciences (NCATS),MIRNA828i,20100125,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"15211354,16024602,16557279,17622355,18197166,18369380,19148191",0,10.1038/cgt.2008.8|10.1038/nrc1840|10.1038/nrg1379|10.1038/nrg2290|10.1038/nrg2504|10.1158/0008-5472.can-05-0137|10.1371/journal.pone.0000610,NULL,NULL,NULL
2288,2,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,"MLSCN Grant: 1 R21 NS059478-01_|__|_Assay Provider: Qihong Huang, The Wistar Institute_|__|_NCGC Assay Overview:_|__|_MicroRNAs (miRNAs) are endogenously encoded small (~20-25 nucleotides), nonprotein-coding RNAs that are involved in post-transcriptional repression of target messenger RNAs (mRNAs) (Le and Hannon, 2004). Estimated to be involved in the regulation of 30% of all protein-coding mRNAs (Filipowicz et al., 2008), miRNAs play a significant role in many biological processes including cellular differ",2,National Center for Advancing Translational Sciences (NCATS),MIRNA828a,20100125,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"15211354,16024602,16557279,17622355,18197166,18369380,19148191",0,10.1038/cgt.2008.8|10.1038/nrc1840|10.1038/nrg1379|10.1038/nrg2290|10.1038/nrg2504|10.1158/0008-5472.can-05-0137|10.1371/journal.pone.0000610,NULL,NULL,NULL
2528,2,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),"Survival of cells and the faithful propagation of the genome depend on elaborate mechanisms of detecting and repairing DNA damage. Treatment of advanced cancer relies on radiation therapy or chemotherapy, which kill cancer cells by causing extensive DNA damage. It is often found, that cancer cells develop resistance to therapy through enhanced activity of DNA repair functions; this has led to an increased interest in developing drugs that interfere with DNA repair, which could sensitize cancer cells to conv",2,National Center for Advancing Translational Sciences (NCATS),BLMA518,20100315,"51,72,119,135,178,180,185,187,190,191,196,199,204,205,206,224,227,239,244,253,263,273,275,277,289,298,303,304,323,338,342,359,366,370,379,401,408,450,453,460,464,471,499,525,535,546,547,564,588,594,595,596,607,610,612,614,636,637,650,681,698,710,727,736,750,753,757,774,785,791,798,803,827,830,836,846,847,853,863,864,866,876,887,892,896,903,904,912,914,931,932,936,938,967,978,985,992,999,1004,1018,1023,1030,1046,1047,1050,1051,1052,1053,1054,1057,1060,1064,1066,1072,1080,1101,1102,1103,1110,1123,1131,1132,11","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",641,NULL,NP_000048,Governmental Organizations|NIH Initiatives,"16864780,18188578,18448429,19442250,19657341,20071248,9388193",0,10.1007/s00412-007-0142-4|10.1016/j.dnarep.2009.12.007|10.1038/nrc2682|10.1042/bst0370553|10.1073/pnas.0604348103|10.1074/jbc.272.49.30611|10.1074/jbc.m709749200,3.6.4.12,P54132,NULL
2101,2,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production Centers Network [MLPCN]_|__|_MLPCN Grant: MH086442-01_|_Assay Submitter (PI): Wei Zheng_|__|_Glucocerebrosidase (GC) catalyzes the hydrolysis of beta-glucocerebroside to glucose and ceramide in lysosomes. Mutations in the glucocerebrosidase gene result in Gaucher disease, an autosomal recessive lysosomal storage disorder. Many of the mutations encountered in patients with Gaucher disease are missense alterations that may cause mi",2,National Center for Advancing Translational Sciences (NCATS),GCNS623,20091105,"6,11,13,51,66,72,119,135,137,174,177,178,180,185,187,190,191,196,199,204,206,224,227,229,239,240,241,243,244,253,261,263,273,275,277,289,298,299,300,303,304,311,323,335,338,342,366,370,379,398,401,403,408,412,441,447,450,453,460,462,464,471,487,499,525,527,535,546,547,564,588,595,596,597,607,610,612,614,636,637,650,660,681,698,700,701,702,710,713,727,736,750,753,757,774,785,795,803,827,830,836,846,847,853,864,866,876,887,892,896,899,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,999,1001,10","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",2629,NULL,BAA02545,Governmental Organizations|NIH Initiatives,8294033,0,10.1016/0378-1119(93)90497-q,NULL,P04062,NULL
2451,2,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia","MLPCN Grant: MH085699-01_|__|_Assay Provider: Osnat Herzberg, University of Maryland_|__|_NCGC Assay Overview:_|__|_The objective of this project is to obtain compounds that inhibit Giardia lamblia growth. G. lamblia is a human pathogen which afflicts impoverished nations; it is the most common cause of outbreaks of diarrhea in the United States. During the course of our study of potential drug targets in Giardia, we have identified the Class II (Zn2+ functions in electrophilic catalysis) fructose-1,6-bisph",2,National Center for Advancing Translational Sciences (NCATS),FBPA821,20100428,"72,119,135,178,185,187,190,191,199,204,206,224,239,253,273,275,277,289,298,303,304,323,338,342,366,370,401,408,450,453,460,464,471,499,525,535,546,547,564,588,595,596,607,610,614,636,637,650,681,698,710,727,736,750,757,774,785,803,827,830,836,846,847,853,864,866,876,892,896,903,904,912,914,932,936,938,992,999,1046,1047,1050,1054,1060,1064,1066,1072,1080,1101,1102,1103,1110,1123,1132,1134,1148,1150,1176,1183,1201,1203,1204,1214,1216,1222,1228,1232,1233,1242,1245,1248,1249,1254,1256,1287,1292,1301,1302,1309,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,2ISV_A,Governmental Organizations|NIH Initiatives,"17166851,19236002",0,10.1021/bi9001166|10.1074/jbc.m609534200,NULL,2ISV_A,NULL
2147,2,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),"Assay Provider: Structural Genomics Consortium [SGC]_|_Screening Center PI: Austin, C.P._|_Screening Center: NIH Chemical Genomics Center [NCGC]_|__|_The fine interplay among methylation states of several lysine residues on the tails of histone proteins is a major determinant of the transcriptional state of the associated DNA coding regions and is commonly referred to as the histone code. Histone lysine demethylases catalyze the removal of methyl groups from methylated lysine sidechains on histones H3 and H",2,National Center for Advancing Translational Sciences (NCATS),JMJD2E,20091119,"72,119,178,185,190,191,199,204,224,239,253,275,289,298,304,323,338,366,370,401,408,471,525,535,546,547,564,588,596,607,610,636,650,681,698,727,736,750,774,785,803,827,830,836,846,847,853,864,896,903,904,912,914,932,936,938,992,1046,1047,1050,1054,1064,1066,1072,1102,1103,1123,1148,1150,1176,1183,1201,1203,1214,1216,1222,1228,1232,1233,1242,1245,1249,1256,1287,1302,1309,1317,1318,1321,1328,1329,1330,1340,1345,1348,1354,1355,1359,1365,1367,1370,1377,1379,1380,1390,1400,1420,1433,1449,1456,1474,1480,1482,1486,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,2W2I_A,Governmental Organizations|NIH Initiatives,"16864780,18942826,19035846",0,10.1021/jm800936s|10.1073/pnas.0604348103|10.1089/adt.2008.150,NULL,2W2I_A,NULL
2676,2,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production Centers Network [MLPCN]_|__|_MLPCN Grant: R03 MH085705-01A1_|_Assay Submitter (PI): Alexander Agoulnik_|__|_NCGC Assay Overview:_|__|_The relaxin hormone is involved in the variety of biological functions in normal tissues and diseases. The role of relaxin is well-established in female reproduction and parturition, mammary gland and endometrial development, maintenance of myometrial quiescence during pregnancy. Relaxin signaling ",2,National Center for Advancing Translational Sciences (NCATS),RXFP145,20180315,"6,72,119,137,191,204,229,253,289,298,299,303,323,338,366,441,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,803,864,892,899,931,932,936,938,957,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2002,2007,2015,2018,2020,2048,2052,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",59350,NULL,NP_067647,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,Q9HBX9,NULL
2100,2,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production Centers Network [MLPCN]_|__|_MLPCN Grant: R03 MH084841-01_|_Assay Submitter (PI): Wei Zheng_|__|_NCGC Assay Overview:_|__|_Alpha-glucosidase is responsible for the hydrolysis of terminal, non-reducing 1,4-linked alpha-D-glucose residues, which releases alpha-D-glucose. It is a lysosomal hydrolase that is required for the degradation of a small percentage (1-3%) of cellular glycogen in humans. Deficiency of this enzyme results in ",2,National Center for Advancing Translational Sciences (NCATS),AGLU007,20091105,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",2548,NULL,NP_000143,Governmental Organizations|NIH Initiatives,NULL,0,NULL,3.2.1.20,P10253,NULL
2326,2,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Centers Network [MLPCN]_|__|_MLPCN Grant: MH084878-01A1_|_Assay Submitter (PI): Daniel Engel_|__|_Influenza is a world-wide public health problem and emerging forms of the virus have the potential to cause a pandemic of equal or greater magnitude to the outbreaks recorded in 1918, 1957 or 1968. Vaccine development is proceeding and there also exist two classes of anti-influenza compounds. However these therapeutic modalities are neither ful",2,National Center for Advancing Translational Sciences (NCATS),NS100050,20100201,"51,72,108,119,178,191,204,253,275,289,298,303,323,338,339,366,401,408,460,471,499,500,525,546,547,564,588,637,650,774,785,803,864,896,903,932,936,938,1023,1046,1047,1052,1066,1123,1150,1201,1216,1222,1228,1232,1233,1245,1256,1309,1317,1318,1328,1329,1330,1340,1345,1359,1365,1367,1390,1400,1401,1456,1474,1492,1539,1564,1607,1609,1641,1645,1646,1649,1676,1678,1683,1688,1694,1697,1720,1727,1730,1738,1742,1756,1774,1775,1779,1780,1794,1795,1820,1826,1832,1833,1845,1853,1858,1864,1868,1871,1882,1884,1890,1892,18","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,8",NULL,NULL,ACF54603,Governmental Organizations|NIH Initiatives,19052087,0,10.1128/jvi.01805-08,NULL,ACF54603,NULL
2107,2,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production Centers Network [MLPCN]_|__|_MLPCN Grant: R03 MH084842-01_|_Assay Submitter (PI): Wei Zheng_|__|_NCGC Assay Overview:_|__|_Alpha-galactosidase is a homodimeric glycoprotein that hydrolyzes the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. Deficiency of this enzyme results in Fabry Disease with progressive accumulation of globotriaosylceramide and other glycosphingolipids in vascular endothelial cells that,2,National Center for Advancing Translational Sciences (NCATS),AGAL007,20091105,"11,13,51,66,72,119,135,174,177,178,180,185,187,190,191,196,199,204,206,224,227,239,240,241,243,244,253,261,263,273,275,277,289,298,299,300,304,311,323,335,338,342,366,370,379,398,401,403,408,412,447,450,453,460,462,464,471,525,527,535,546,547,564,588,595,596,607,610,612,614,636,650,660,681,698,700,701,702,710,713,727,736,750,753,757,774,785,795,803,827,830,836,846,847,853,864,866,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,999,1001,1004,1017,1030,1046,1047,1049,1050,1054,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",2717,NULL,CAA29232,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P06280,NULL
2112,2,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production Centers Network [MLPCN]_|__|_MLPCN Grant: R03 MH084841-01_|_Assay Submitter (PI): Wei Zheng_|__|_NCGC Assay Overview:_|__|_Alpha-glucosidase is responsible for the hydrolysis of terminal, non-reducing 1,4-linked alpha-D-glucose residues, which releases alpha-D-glucose. It is a lysosomal hydrolase that is required for the degradation of a small percentage (1-3%) of cellular glycogen in humans. Deficiency of this enzyme results in ",2,National Center for Advancing Translational Sciences (NCATS),AGLU006,20091106,"11,13,51,66,72,119,135,174,177,178,180,185,187,190,191,196,199,204,206,224,227,239,240,241,243,244,253,261,263,273,275,277,289,298,299,300,304,311,323,335,338,342,366,370,379,398,401,403,408,412,447,450,453,460,462,464,471,525,527,535,546,547,564,588,595,596,607,610,612,614,636,650,660,681,698,700,701,702,710,713,727,736,750,753,757,774,785,795,803,827,830,836,846,847,853,864,866,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,999,1001,1004,1017,1030,1046,1047,1049,1050,1054,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",2548,NULL,NP_000143,Governmental Organizations|NIH Initiatives,NULL,0,NULL,3.2.1.20,P10253,NULL
2549,2,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),"Survival of cells and the faithful propagation of the genome depend on elaborate mechanisms of detecting and repairing DNA damage. Treatment of advanced cancer relies on radiation therapy or chemotherapy, which kill cancer cells by causing extensive DNA damage. It is often found, that cancer cells develop resistance to therapy through enhanced activity of DNA repair functions; this has led to an increased interest in developing drugs that interfere with DNA repair, which could sensitize cancer cells to conv",2,National Center for Advancing Translational Sciences (NCATS),RECQ151,20100315,"11,13,51,66,72,119,135,174,177,178,180,185,187,190,191,196,199,204,206,224,227,239,240,241,243,244,253,261,263,273,275,277,289,298,299,300,304,311,323,335,338,342,366,370,379,398,401,403,408,412,447,450,453,460,462,464,471,525,527,535,546,547,564,588,595,596,607,610,612,614,636,650,660,681,698,700,701,702,710,713,727,736,750,753,757,774,785,795,803,827,830,836,846,847,853,864,866,876,887,892,896,903,904,912,914,931,932,936,938,949,957,967,978,991,992,995,996,999,1001,1004,1017,1030,1046,1047,1049,1050,1054,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,2WWY_A,Governmental Organizations|NIH Initiatives,"16864780,18448429,19151156",0,10.1073/pnas.0604348103|10.1073/pnas.0806908106|10.1074/jbc.m709749200,NULL,2WWY_A,NULL
2716,1,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,"Keywords: SUMO, Ubiquitin  _|__|_Primary Collaborators:_|_Gregory Prelich, Albert Einstein College of Medicine of Yeshiva University, gregory.prelich@einstein.ny.edu, 718-430-2181_|__|_Assay Overview: Luciferase assay (Bactiter-Glo, Promega)._|_Primary screen using a yeast (S.Cerevisiae) temperature-sensitive mutant of the transcription factor MOT1 (Mot1-301) to selectively identify small molecules inhibitors of the SUMO pathway.  The small molecules induce yeast growth at high temperature (38.5C) by interf",31,Broad Institute,2059-01_INHIBITORS_SINGLE-POINT_MLPCN-HTS,20100329,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,182","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,8",NULL,Organism-based,NULL,NIH Initiatives,"16387868,19139279",0,10.1128/mcb.01470-08|10.1534/genetics.105.052811,NULL,NULL,NULL
2629,1,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,"Primary Collaborators:_|_Kenneth Kaye,Brigham & Womens,Boston MA,kkaye@rics.bwh.harvard.edu,617-525-4256_|_Chantal Beauchemin,Brigham & Womens,Boston MA,cbeauchemin@rics.bwh.harvard.edu,617-525-4256_|__|_Keywords: KSHV, LANA, fluorescence polarization, nucleosomes, viral persistence_|__|_Assay Overview:_|_Screening for inhibitors that reduce or prevent the binding of LANA to the acidic region of the H2A/H2B histone dimer interface.  Synthetic LANA peptide is labeled with an amino terminal FITC fluorophore l",31,Broad Institute,2053-01_INHIBITORS_SINGLE-POINT_MLPCN-HTS,20100322,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,182","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,8",4961527,NULL,YP_001129431,NIH Initiatives,16469929,0,10.1126/science.1120541,NULL,Q9QR71,NULL
2718,1,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,"Keywords:  histone deacetylase, HDAC3, epigenetics_|__|_Assay Overview: HDAC3 is incubated with compounds for 10 minutes before addition of a coumarin-linked tripeptide substrate containing a terminal acetylated lysine, and trypsin. If HDAC3 is not inhibited it will deacetylate the substrate, which renders the peptide a substrate for trypsin. Trypsin can then liberate the coumarin, increasing fluorescence_|__|__|_Expected Outcome: HDAC3 inhibitors will prevent deacetylation of the peptide substrate, renderi",31,Broad Institute,2062-01_INHIBITORS_SINGLE-POINT_MLPCN-HTS,20100329,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1794,1795,1814,1820,1826,1832,1833,1853,1858,18","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,8",8841,NULL,NP_003874,NIH Initiatives,20139990,0,10.1038/nchembio.313,3.5.1.98,O15379,NULL
2094,1,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,"Keywords: Quorum Sensing, Auto-inducer 2 (AI-2), Vibrio harveyi, LuxS, LuxPQ, Luminescense_|__|_Assay Overview:  A modified strain of Vibrio harveyi with only the AI-2 quorum sensing system intact will be exposed to small molecules.  Growth of the organism post exposure will be followed using optical density and disruption of quorum sensing will be observed  based on decreased luminescent signal._|__|_Expected Outcome: Identification of AI-2 quorum sensing system inhibitors with modes of action which either",31,Broad Institute,2035-01_MODULATORS_SINGLE-POINT_MLPCN-HTS,20091104,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",NULL,Organism-based,"1ZHH_A,1ZHH_B,ABY84639",NIH Initiatives,"11544353,15916958,7984107,8231809",0,10.1016/j.molcel.2005.04.020|10.1111/j.1365-2958.1993.tb01737.x|10.1111/j.1365-2958.1994.tb00422.x|10.1146/annurev.micro.55.1.165,NULL,"1ZHH_A,1ZHH_B,ABY84639",NULL
2462,1,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,"Keywords: apoptosis, BH3 domain, Bcl2-A1, BIM, caspase, cancer_|_ _|_Primary Collaborator: Todd Golub, Broad Institute, golub@broadinstitute.org_|_ _|_Assay Overview: _|_The fate of cell survival versus apoptosis is determined by the balance of anti and pro-apoptotic proteins. Expression of activator BH3-only proteins, such as BIM or tBID, leads to downstream caspase activation and apoptosis. A1 can functionally bind to and sequester BIM or tBID. In this assay, the parental control cells do not depend on A1",31,Broad Institute,2045-01_INHIBITORS_SINGLE-POINT_MLPCN-HTS,20100303,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1794,1795,1814,1820,1826,1832,1833,1853,18","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",10018,Cell-based,"2VM6_A,NP_619527",NIH Initiatives,NULL,0,NULL,NULL,"2VM6_A,O43521",NULL
2717,1,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Keywords: Breast Cancer Stem Cells_|__|_Assay Overview: The objective of the experiments in this proposal is to identify compounds that can selectively kill breast cancer stem cells (CSCs). The HMLE cell line suppressing E-Cadherin expression (HMLE_sh_ECad) is a stable cell line that has been induced into epithelial-to-mesenchymal transdifferentiation (EMT).  This cell line was used to represent a uniform population of  CSCs.  Two thousand HMLE_sh_ECAD were plated in 50 uL of media in each well and cells we,31,Broad Institute,2058-01_INHIBITORS_SINGLE-POINT_MLPCN-HTS,20110301,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1794,1795,1814,1820,1826,1832,1833,1853,18","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842137,842138,842140,842141,842142,842143,842145,842147,842148,842149,842150,842151,842152,842154,842155,842156,842157,842161,842162,842163,842164,842165,842166,842167,842169,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842191,842192,842193,842194,842195,842197,842198,842199,842200,842201,842202,842203,842205,842207,842208,842209,842210,842211,842213,8",NULL,Cell-based,NULL,NIH Initiatives,19682730,0,10.1016/j.cell.2009.06.034,NULL,NULL,NULL
2098,1,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,"Keywords: Heat Shock Factor-1 (HSF-1), Stress Response, MG132, NIH3T3, Luminescence_|__|_Assay Overview: Modified NIH3T3, transformed to express firefly luciferase under the control of a HSF-1 response element, will be exposed to small molecules.  After 30min exposure to small molecules, proteasome inhibitor MG132 is added to elicit a stress response. After 8hr incubation in the presence of this stressor, the amount of HSF-1 mediated luciferase expression is measured using a luminescence detection reagent. ",31,Broad Institute,2038-01_INHIBITORS_SINGLE-POINT_MLPCN-HTS,20091104,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",15499,Cell-based,AAH94064,NIH Initiatives,"10955818,18434519,19335068,9083035",0,10.1074/jbc.272.14.9086|10.1517/14728220902832697|10.1523/jneurosci.0296-08.2008,NULL,AAH94064,NULL
2216,1,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,"Broad Institute MLPCN RanGTP Inhibitor Screening_|__|_Project ID: 2041_|__|_Keywords: FRET assay, HTS, RanGTP-Importin-beta complex, small molecule inhibitor, Cell division, Cancer_|__|_Primary Collaborators: Rebecca Heald, UC Berkley, bheald@berkeley.edu_|_Karsten Weis,UC Berkley,kweis@berkeley.edu_|__|_Project Overview: _|_Mitosis in eukaryotic cells is characterized by a series of discrete steps that ultimately lead to the equal segregation of the duplicated genome into daughter cells The structural rear",31,Broad Institute,2041-01_INHIBITORS_SINGLE-POINT_MLPCN-HTS,20091223,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",NULL,NULL,NULL,NIH Initiatives,"10367892,16572176,18366719,19641022",0,10.1016/s0092-8674(00)80774-6|10.1038/nature04589|10.1091/mbc.e09-02-0152|10.1186/1471-2121-9-14,NULL,NULL,NULL
2205,1,HCS assay for microtubule stabilizers,"Agents that perturb the dynamics of cellular microtubules (MTs) are proven cell biology tools, antitumor agents, and antifungal agents. Some have also shown promise as inhibitors of angiogenesis. Microtubule dynamics can be altered by small molecules through a variety of mechanisms, including direct interaction with tubulin (typically leading to inhibition of proliferation into microtubules -- aka tubulin polymerization inhibitors; e.g., colchicinoids and vinca alkaloids), direct interaction with microtubul",9,University of Pittsburgh Molecular Library Screening Center,MH081275,20091215,"119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1893,1922,1967,1981,1985,1986,2000,2002,2007,2015,2082,2108,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2692,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,32","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842158,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842175,842176,842177,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,8",203068,NULL,NP_821133,NIH Initiatives,"14711389,16274252,17683369,18073274",0,10.1021/bi050685l|10.1111/j.1747-0285.2007.00541.x|10.1124/mol.107.042598|10.1177/1087057103258285,NULL,P07437,NULL
2242,2,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|__|_MLPCN Grant: 1R03MH084841-01_|_Assay Submitter (PI): Wei Zheng_|__|_NCGC Assay Overview:_|__|_Alpha-glucosidase is responsible for hydrolysis of terminal, non-reducing 1,4-linked alpha-D-glucose residues with release of alpha-D-glucose. It is a lysosomal hydrolase that is required for the degradation of a small percentage (1-3%) of cellular glycogen in human. Deficiency of this enzyme results in glyco",2,National Center for Advancing Translational Sciences (NCATS),AGLU004b,20100112,"72,119,191,253,298,323,338,366,525,546,774,803,864,932,936,938,1046,1047,1150,1201,1318,1329,1345,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1832,1833,1853,1882,1892,1893,1922,1967,1981,1985,1986,2000,2007,2015,2018,2082,2092,2108,2118,2123,2125,2153,2159,2161,2170,2181,2187,2196,2197,2247,2249,2256,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2585,2690,2708,2720,2722,2727,2732,2733,2754,2756,2762,2771,2788,2804,2812,2890,2950,2955,2972,3012,3016,3019","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",2548,NULL,NP_000143,Governmental Organizations|NIH Initiatives,NULL,0,NULL,3.2.1.20,P10253,NULL
2052,1,HTS for developing T Cell Immune Modulators,"University of New Mexico Assay Overview_|_Assay Support:  1 X01 MH085707-01   _|_Project Title:  HTS for developing T Cell Immune Modulators  _|_PI:  Inkyu Hwang,PhD The Scripps Research Institute (La Jolla) _|_Assay Implementation:  Mark K. Haynes PhD, Chelin Hu MS, Anna Waller PhD, Mark Carter MS_|_University of New Mexico Center for Molecular Discovery  PI: Larry Sklar PhD_|__|_Assay Background and Significance:_|_When naive T cells encounter antigen presenting cells (APC) displaying cognate MHC-peptide ",6,NMMLSC,UNM_LFA-1_T-Cell_Immune_Modulators_MLPCN,20100302,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,179","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",16408,NULL,NP_032426,NIH Initiatives,"12732350,12734401,12743365,14500982,16855047,17073678,17624950,17624952,19258452",0,10.1016/s0196-9781(03)00083-4|10.1073/pnas.0603466103|10.1073/pnas.0810844106|10.1073/pnas.1131852100|10.1111/j.1600-065x.2007.00526.x|10.1111/j.1600-065x.2007.00537.x|10.1126/science.1084174|10.1242/jcs.00465|10.2174/138161206778559696,NULL,NP_032426,NULL
2520,1,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute(SBMRI, San Diego)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R21NS059422-01_|_Assay Provider: Dr. Layton Smith, Sanford-Burnham Medical Research Institute_|__|_Currently there are no small molecule tools to investigate the biological functions of apelin and its receptor. Apelin is the endogenous peptide ligand for the G-protein c",14,Burnham Center for Chemical Genomics,BCCG-A318-APJ-Agonist-Primary-Assay,20110113,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,412,441,460,464,487,499,525,546,547,564,597,637,660,698,701,727,802,803,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1609,1639,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,1826,1832","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",187,NULL,NP_005152,NIH Initiatives,"10617103,14645236,15621035,17129829,19829178",0,10.1016/j.cardiores.2004.08.018|10.1016/j.drudis.2006.10.011|10.1046/j.1471-4159.2000.0740034.x|10.1074/jbc.m306377200|10.1097/crd.0b013e3181b3fe0d,NULL,P35414,NULL
2099,1,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,"Broad Institute MLPCN GASC-1 Project_|__|_Project ID: 2043_|__|_Keywords:_|_GASC-1 (gene amplified in squamous cell carcinoma-1), histone demethylase, DELFIA_|__|_Primary Collaborators: _|_Stefan Kubicek, Broad Institute, skubicek@broadinstitute.org, Cambridge, MA._|_Robert Gould, Broad Institute, rgould@broadinstitute.org, Cambridge, MA._|__|_Project Overview: _|_The goal of this project is to identify inhibitors of the histone demethylase GASC-1 (gene amplified in squamous cell carcinoma-1).  GASC-1 has r",31,Broad Institute,2043-01_INHIBITORS_SINGLE-POINT _MLPCN-HTS,20091105,"19,72,86,109,119,127,137,190,191,204,229,253,298,299,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,701,774,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1030,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1775,1780,1794,1795,1814,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",NULL,Biochemical,NULL,NIH Initiatives,16732293,0,10.1038/nature04837,NULL,NULL,NULL
2521,1,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute(SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R21NS059422-01_|_Assay Provider: Dr. Layton Smith, Sanford-Burnham Medical Research Institute_|__|_Currently there are no small molecule tools to investigate the biological functions of apelin and its receptor. Apelin is the endogenous peptide ligand for the G-prote",14,Burnham Center for Chemical Genomics,BCCG-A319-APJ-Antagonist-Primary-Assay,20110113,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,412,441,460,464,487,499,525,546,547,564,597,637,660,698,701,727,802,803,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1609,1639,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,1826,1832","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",187,NULL,NP_005152,NIH Initiatives,"10617103,14645236,15621035,17129829,19829178",0,10.1016/j.cardiores.2004.08.018|10.1016/j.drudis.2006.10.011|10.1046/j.1471-4159.2000.0740034.x|10.1074/jbc.m306377200|10.1097/crd.0b013e3181b3fe0d,NULL,P35414,NULL
2380,1,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number: 1R21NS057001-01_|_Assay Provider: Dr. Fred Levine, Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|__|_Identifying compounds from HTS that may affect b-cell replication has a potential to increase our understanding of the fundamental processes regulatio",14,Burnham Center for Chemical Genomics,BCCG-A277-bCell-MIN6-Agonist-Assay,20110113,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,412,441,460,464,487,499,525,546,547,564,597,637,660,698,701,727,802,803,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1609,1639,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,1826,1832","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",NULL,NULL,NULL,NIH Initiatives,"16195383,16638909,17404238,19136653,19265026",0,10.1073/pnas.0503484102|10.1073/pnas.0701509104|10.1210/er.2006-0004|10.2337/db08-0631|10.2337/db08-1198,NULL,NULL,NULL
2825,1,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1 U01 AI078048_|_Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute, San Diego, CA_|__|_NLR family proteins are an important component of the innate immune system of vertebrates.  These proteins possess a nucleotide-binding oligomerization",14,Burnham Center for Chemical Genomics,BCCG-A358-Yeast_NALP3_Inhibitor-Primary-Assay,20110113,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,412,441,460,464,487,499,525,546,547,564,597,637,660,698,701,727,802,803,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1609,1639,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,1826,1832","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",114548,NULL,AAI43360,NIH Initiatives,"10399008,11879630,12094217,12191486,15353551,15967716,17082814,17349957,17418785,18172447,9092497,9922454",0,10.1016/j.cell.2007.01.045|10.1016/j.it.2005.06.004|10.1016/j.molcel.2007.01.032|10.1016/s0065-2776(08)60788-9|10.1016/s1097-2765(02)00599-3|10.1016/s1534-5807(02)00137-5|10.1038/ncprheum0681|10.1038/nrm858|10.1038/sj.cdd.4402059|10.1074/jbc.272.15.9677|10.1083/jcb.144.2.281|10.1084/jem.20032234,NULL,AAI43360,NULL
2805,1,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLSPN)_|_Grant Proposal Number: X01-MH077602-01_|_Assay Provider: Dr. Jose Luis Millan, Sanford-Sanford-Burnham Medical Research Institute, San Diego, CA._|__|_Alkaline phosphatase (EC 3.1.3.1) (APs) catalyze the hydrolysis of phosphomonoesters, releasing inorganic phosphate and alcohol. ",14,Burnham Center for Chemical Genomics,BCCG-A349-Mouse_IAP_Activator-Primary-Assay,20110112,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,412,441,460,464,487,499,525,546,547,564,597,637,660,698,701,727,802,803,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1609,1639,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,1826,1832","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",76768,NULL,NP_001074551,NIH Initiatives,"5023163,5139211,5911626,6950431",0,10.1073/pnas.79.3.879|10.1177/20.5.336,NULL,NP_001074551,NULL
2661,1,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,"Primary Collaborators:_|_Robert Gould,Broad Institute,Cambridge, MA,rgould@broainstitute.org,617.714.7220,_|__|_Keywords: STK33 Kinase, Non-ATP Competitive Inhibitor_|__|_Assay Overview: Purified STK33 Kinase is pre-incubated with potential inhibitors and allowed to phosphorylate MBP at ~ 1.5 Km ATP.  Kinase activity is measured using the ADP Glo Kit (Promega) which converts ADP reaction product into a luminescent signal._|__|_Expected Outcome: Inhibitors of STK33 Kinase will cause a decreased luminescent r",31,Broad Institute,2052-01_INHIBITORS_SINGLE-POINT_MLPCN-HTS,20100324,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1794,1795,1814,1820,1826,1832,1833,1853,18","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842161,842162,842163,842164,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842205,8",65975,NULL,NP_112168,NIH Initiatives,19490892,0,10.1016/j.cell.2009.03.017,2.7.11.1,Q9BYT3,NULL
2315,1,A qHTS for Small Molecule Inhibitors of Shiga Toxin,"Shiga toxin (Stx) is released by certain strains of E. coli and is associated with food-borne gastroenteritis. In some patients, especially children, the toxin enters the bloodstream and causes hemolytic uremic syndrome, a condition that results in kidney, heart, and occasionally brain injury. The pathogenic effects of Stx arise by the toxin entering cells and inhibiting protein synthesis. To identify inhibitors of Stx activity and transport, a cell-based assay was used that employed luciferase activity as ",2,National Center for Advancing Translational Sciences (NCATS),STX001,20100204,"72,119,135,191,204,206,253,273,277,298,303,323,338,342,366,450,453,460,464,499,525,546,547,588,595,614,637,710,750,757,774,803,864,866,876,892,912,932,936,938,999,1046,1047,1050,1060,1080,1101,1110,1132,1134,1150,1201,1204,1248,1254,1292,1301,1309,1318,1329,1345,1367,1370,1400,1401,1464,1474,1492,1539,1646,1676,1688,1697,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1949,1960,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2072,2082,2088,2092,2108,2117,2118,2123,2125,2132,2153,2159","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,"BAC78637,BAC78638",Governmental Organizations|NIH Initiatives,"16192432,17576758",0,10.1099/jmm.0.46143-0|10.1128/iai.00442-07,NULL,"BAC78637,BAC78638",NULL
2097,1,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,"Keywords: GSK3beta, kinase, inhibition, HTS_|__|_Assay Overview:_|_The glycogen synthase kinase-3 beta (GSK-3b) is a known master regulator for several cellular pathways and plays a critical role in metabolism, transcription, development, cell survival, and neuronal functions.  The overall objective is to identify one or multiple series of inhibitors of GSK-3beta with micromolar potency.  Such compounds will become probe(s) with demonstrated kinase-selectivity (&#8805;10-fold IC50) and activation of Wnt sig",31,Broad Institute,2046-01_INHIBITORS_SINGLE-POINT_MLPCN-HTS,20100526,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",2932,NULL,NP_002084,NIH Initiatives,NULL,0,NULL,"2.7.11.1,2.7.11.26",P49841,NULL
2650,1,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,"Keywords: Glycogen synthase kinase-3 alpha (GSK-3 alpha), kinase, acute myeloblastic leukemia (AML), multiple myeloma (MM), cancer, high-throughput screening (HTS)_|__|_Assay Overview: _|_GSK-3 alpha has emerged as a target for acute myeloblastic leukemia (AML) and multiple myeloma (MM) in both RNAi-based and chemical genomic-based high-throughput screening.  The overall objective is to identify one or more specific inhibitors of GSK-3 alpha with micromolar potency. Such compounds will become probes with de",31,Broad Institute,2063-01_INHIBITORS_SINGLE-POINT_MLPCN-HTS,20100331,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1794,1795,1814,1820,1826,1832,1833,1853,18","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842205,842207,8",2931,NULL,NP_063937,NIH Initiatives,NULL,0,NULL,"2.7.11.1,2.7.11.26",P49840,NULL
2806,1,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: X01-MH077602-01_|_Assay Provider: Dr. Jose Luis Millan, Sanford-Burnham Medical Research Institute, San Diego, CA._|__|_Alkaline phosphatase (EC 3.1.3.1) (APs) catalyze the hydrolysis of phosphomonoesters, releasing inorganic phosphate and alcohol. APs are ",14,Burnham Center for Chemical Genomics,BCCG-A350-Mouse_IAP_Inhibitor-Primary-Assay,20110112,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,412,441,460,464,487,499,525,546,547,564,597,637,660,698,701,727,802,803,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1609,1639,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,1826,1832","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",76768,NULL,NP_001074551,NIH Initiatives,"5023163,5139211,5911626,6950431",0,10.1073/pnas.79.3.879|10.1177/20.5.336,NULL,NP_001074551,NULL
2540,1,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R21 NS061758-01 fast track_|_Assay Provider: Dr. Guy Salvesen, Sanford-Burnham Medical Research Institute, San Diego, CA._|__|_Modification of proteins by SUMO is a dynamic and reversible process. SUMOylation/deSUMOylation cycle regulates SUMOs function. S",14,Burnham Center for Chemical Genomics,BCCG-A320-SENP8-Primary-Assay,20110113,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,412,441,460,464,487,499,525,546,547,564,597,637,660,698,701,727,802,803,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1609,1639,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,1826,1832","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",123228,NULL,NP_660205,NIH Initiatives,"17591783,17916063,18799455",0,10.1042/bj20070940|10.1074/jbc.m702444200|10.1074/jbc.m805655200,3.4.22.-,Q96LD8,NULL
2221,1,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,"Broad Institute: Intein TB_|__|_Project ID: 2047_|__|_Keywords: GFP-RecA intein, refolding, reducing reagent, GFP fluorescence, protein splicing_|__|_Primary Collaborators: Henry Paulus,Boston Biomedical Research Institute,paulus@bbri.org_|__|_Project Overview: _|_Tuberculosis (TB) is globally the most widespread infectious disease. Two billion people, one third of the world's population, are infected with Mycobacterium tuberculosis and 5-10% of these suffer active disease, leading to nearly 3 million death",31,Broad Institute,2047-01_INHIBITORS_SINGLE-POINT_MLPCN-HTS,20100608,"19,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1967,1981,1985,1986,1988,1990,2000,2002,2007,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161,2162,216","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,8",888371,NULL,NP_217253,NIH Initiatives,12957838,0,10.2741/1195,3.1.-.-,P9WHJ3,NULL
2563,1,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,"Keywords: Ras Converting Enzyme, Inhibitor, Protease, HTS_|__|_Primary Collaborators:_|_Walter Schmidt,University of Georgia,120 Green St, Athens GA 30602,wschmidt@bmb.uga.edu,706.583.8241,_|__|_Assay Overview: The assay that was run for the High Throughput Screen was an in vitro biochemical assay monitoring the endoprotease cleavage of a quenched isoprenylated peptide.  Cleavage of the peptide substrate caused an increase in fluorescence intensity that could be read at 320/430nM. The enzyme activity was pr",31,Broad Institute,2034-01_INHIBITORS_SINGLE-POINT_MLPCN-HTS,20100316,"19,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1967,1981,1985,1986,1988,1990,2000,2002,2007,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161,2162,216","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,8",855317,NULL,NP_014001,NIH Initiatives,"11038283,11739732,17942791,20162532,9736709",0,10.1002/yea.1756|10.1006/abio.2000.4795|10.1073/pnas.95.19.11175|10.1128/mcb.22.1.171-181.2002|10.1177/1087057107307226,3.4.22.-,Q03530,NULL
2524,1,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: X01-MH077602-01_|_Assay Provider: Dr. Jose Luis Millan, Sanford-Burnham Medical Research Institute, San Diego, CA_|__|_Alkaline phosphatase (EC 3.1.3.1) (APs) catalyze the hydrolysis of phosphomonoesters, releasing inorganic phosphate and alcohol. APs are d",14,Burnham Center for Chemical Genomics,BCCG-A321-Human_IAP_Activator-Primary-Assay,20110113,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,412,441,460,464,487,499,525,546,547,564,597,637,660,698,701,727,802,803,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1609,1639,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,1826,1832","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",248,NULL,AAI32679,NIH Initiatives,"5023163,5139211,5911626,6950431",0,10.1073/pnas.79.3.879|10.1177/20.5.336,NULL,P09923,NULL
2314,1,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,"Shiga toxin (Stx) is released by certain strains of E. coli and is associated with food-borne gastroenteritis. In some patients, especially children, the toxin enters the bloodstream and causes hemolytic uremic syndrome, a condition that results in kidney, heart, and occasionally brain injury. The pathogenic effects of Stx arise by the toxin entering cells and inhibiting protein synthesis. To identify inhibitors of Stx activity and transport, a cell-based assay was used that employed luciferase activity as ",2,National Center for Advancing Translational Sciences (NCATS),CHX001,20100204,"72,119,135,191,204,206,253,273,277,298,303,323,338,342,366,450,453,460,464,499,525,546,547,588,595,614,637,710,750,757,774,803,864,866,876,892,912,932,936,938,999,1046,1047,1050,1060,1080,1101,1110,1132,1134,1150,1201,1204,1248,1254,1292,1301,1309,1318,1329,1345,1367,1370,1400,1401,1464,1474,1492,1539,1646,1676,1688,1697,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1949,1960,1967,1981,1985,1986,2000,2002,2007,2015,2018,2048,2072,2082,2088,2092,2108,2117,2118,2123,2125,2132,2153,2159","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,"BAC78637,BAC78638",Governmental Organizations|NIH Initiatives,"16192432,17576758",0,10.1099/jmm.0.46143-0|10.1128/iai.00442-07,NULL,"BAC78637,BAC78638",NULL
2599,1,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation:Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLSCN)_|_Grant Proposal Number: 1R21 NS061758-01 fast track_|_Assay Provider: Dr. Guy Salvesen, Sanford-Burnham Medical Research Institute, San Diego, CA._|__|_Modification of proteins by SUMO is a dynamic and reversible process. SUMOylation/deSUMOylation cycle regulates SUMOs function. Se",14,Burnham Center for Chemical Genomics,BCCG-A328-SENP6-Primary-Assay,20110112,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,412,441,460,464,487,499,525,546,547,564,597,637,660,698,701,727,802,803,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1609,1639,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,1826,1832","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",26054,NULL,AAF04852,NIH Initiatives,"17591783,17916063,18799455",0,10.1042/bj20070940|10.1074/jbc.m702444200|10.1074/jbc.m805655200,NULL,AAF04852,NULL
2071,1,Colorimetric  Assay for Inhibitors for NALP1,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number:  1 R03 MH086463-01_|_Assay Provider: Dr. John C. Reed, Sanford-Burham Medical Research Institute, San Diego CA_|__|_NLR family proteins are an important component of the innate immune system of vertebrates.  These proteins possess a nucleotide-binding oligomerization doma",14,Burnham Center for Chemical Genomics,BCCG-A249-NALP1-Inhibitors-Assay,20110113,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",22861,NULL,NP_127497,NIH Initiatives,"10399008,11879630,12094217,12191486,15353551,15967716,17082814,17349957,17418785,18172447,9092497,9922454",0,10.1016/j.cell.2007.01.045|10.1016/j.it.2005.06.004|10.1016/j.molcel.2007.01.032|10.1016/s0065-2776(08)60788-9|10.1016/s1097-2765(02)00599-3|10.1016/s1534-5807(02)00137-5|10.1038/ncprheum0681|10.1038/nrm858|10.1038/sj.cdd.4402059|10.1074/jbc.272.15.9677|10.1083/jcb.144.2.281|10.1084/jem.20032234,NULL,Q9C000,NULL
2073,2,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,"Data Source: Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH085675-01_|_Assay Provider: Dr Ilya Bezprozvanny, UT Southwestern Medical Center , Dallas, TX_|__|_Chronic pain (neuropathic pain, inflammatory pain, cancer pain) is a major health problem. Opiate-based drugs, such as morphine and morphine derivatives, are the primary stand",14,Burnham Center for Chemical Genomics,BCCG-A238-Mint1-PDZ-TR-FRET-Assay,20101008,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8","774,83589",NULL,"AAC05303,NP_000709",NIH Initiatives,"10455105,12177192,7715945,8046458",0,10.1016/0304-3959(94)00094-u|10.1074/jbc.274.35.24453|20026688,NULL,"O35430,Q00975",NULL
2006,2,uHTS HTRF assay for identification of inhibitors of SUMOylation,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH084862-01_|_Assay Provider: Dr. Yuan Chen, Beckman Research Institute, City Of Hope, CA_|__|_Protein modification by the SUMO (Small Ubiquitin-like MOdifier) family of proteins is an important post-translational modification that plays an essential role in m",14,Burnham Center for Chemical Genomics,BCCG-A235-SUMO-HTRF-Assay,20110113,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8","7329,10054,10055",NULL,"AAH03153,AAH18271,NP_003336",NIH Initiatives,"10070749,12924945,14506472,15189146,15292183,15542864,15590687,17643372,18154725,9357313,9425343",0,10.1016/j.ab.2007.11.024|10.1016/j.molcel.2007.05.023|10.1016/s0955-0674(97)80079-8|10.1016/s0968-0004(97)01122-5|10.1021/bi0345283|10.1023/a:1008364314328|10.1038/nrm1200|10.1074/jbc.m407950200|10.1074/jbc.m413209200|10.1074/mcp.m400154-mcp200|10.1146/annurev.biochem.73.011303.074118,2.3.2.-,"P63279,Q9UBE0,Q9UBT2",NULL
2012,2,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number:  1R03MH084835-01_|_Assay Provider: Jerry Pelletier, Ph.D, McGill University, Montreal, Canada_|__|_Translation is an essential cellular process whose deregulation is associated with alterations in cell growth, cell cycle progression, and cell death responses. The initiati",14,Burnham Center for Chemical Genomics,BCCG-A237-eIF4H-FP-Assay,20110112,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",7458,NULL,AAH66928,NIH Initiatives,"10872469,15193258,15314020,15630022,17923239,18926791",0,10.1016/j.ab.2008.09.037|10.1016/j.ccr.2004.05.024|10.1016/s0076-6879(07)31013-6|10.1101/gad.1212704|10.1101/gad.1262905|10.1146/annurev.biochem.68.1.913,NULL,AAH66928,NULL
2014,2,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number:  1R03MH084835-01_|_Assay Provider: Jerry Pelletier, Ph.D, McGill University, Montreal, Canada_|__|_Translation is an essential cellular process whose deregulation is associated with alterations in cell growth, cell cycle progression, and cell death responses. The initiati",14,Burnham Center for Chemical Genomics,BCCG-A235-PABP-FP-Assay,20110112,"72,119,191,204,253,298,303,323,338,366,460,499,525,546,547,588,637,774,803,864,932,936,938,1046,1047,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1492,1539,1646,1676,1688,1727,1738,1775,1780,1820,1832,1833,1853,1882,1890,1892,1893,1922,1923,1967,1981,1985,1986,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2159,2161,2165,2170,2181,2187,2196,2197,2215,2240,2247,2249,2256,2265,2266,2303,2315,2331,2333,2343,2348,2375,2378,2391,2406,2435,2466,2471,2480,2482,2519,2554,2576,2581,2585,2618,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",26986,NULL,NP_002559,NIH Initiatives,"10872469,15193258,15314020,15630022,17923239,18926791",0,10.1016/j.ab.2008.09.037|10.1016/j.ccr.2004.05.024|10.1016/s0076-6879(07)31013-6|10.1101/gad.1212704|10.1101/gad.1262905|10.1146/annurev.biochem.68.1.913,NULL,P11940,NULL
2544,1,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: X01-MH077602-01_|_Assay Provider: Dr. Jose Luis Millan, Sanford-Burnham Medical Research Institute, San Diego, CA_|__|_Alkaline phosphatase (EC 3.1.3.1) (APs) catalyze the hydrolysis of phosphomonoesters, releasing inorganic phosphate and alcohol. APs are d",14,Burnham Center for Chemical Genomics,BCCG-A322-Human_IAP_Inhibitor-Primary-Assay,20110113,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,412,441,460,464,487,499,525,546,547,564,597,637,660,698,701,727,802,803,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1609,1639,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,1826,1832","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",248,NULL,AAI32679,NIH Initiatives,"5023163,5135237,5139211,5911626,6950431",0,10.1042/bj1240509|10.1073/pnas.79.3.879|10.1177/20.5.336,NULL,P09923,NULL
2066,1,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,"University of New Mexico Assay Overview:_|_Assay Support: 1R03 MH086450-01   _|_Project Title:  Chemical Screen of TOR pathway GFP fusion proteins in S. cerevisiae _|_PI: Maggie Werner-Washburne_|__|_Center PI: Larry Sklar_|__|_Assay Implementation: Jun Chen, Chris Allen, Susan Young, Anna Waller, Mark Carter_|__|_Assay Background and Significance:_|__|_The target of rapamycin, TOR, is a ser/thr protein_|_kinase evolutionarily conserved from yeast to man [Wullschleger, et al. 2006]. TOR functions in two dis",6,NMMLSC,UNM_TOR_Pathway_HTS_in_Saccharomyces_cerevisiae_specifically_AGP1_MLPCN,20110405,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842205,8",850333,NULL,NP_009905,NIH Initiatives,"11309812,16219781,16469695,16647875,17041625,7528205,8387896,8413204,9811607",0,10.1016/0092-8674(93)90144-f|10.1016/j.biocel.2006.02.013|10.1016/j.cell.2006.01.016|10.1016/s0960-9822(07)00511-8|10.1038/sj.onc.1209884|10.1128/mcb.13.10.6012|10.1534/genetics.105.051979,NULL,P25376,NULL
2025,1,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,"University of New Mexico Assay Overview:_|_Assay Support: 1R03 MH086450-01   _|_Project Title:  Chemical Screen of TOR pathway GFP fusion proteins in S. cerevisiae _|_PI: Maggie Werner-Washburne_|__|_Center PI: Larry Sklar_|__|_Assay Implementation: Jun Chen, Chris Allen, Susan Young, Anna Waller, Mark Carter_|__|_Assay Background and Significance:_|__|_The target of rapamycin, TOR, is a ser/thr protein_|_kinase evolutionarily conserved from yeast to man [Wullschleger, et al. 2006]. TOR functions in two dis",6,NMMLSC,UNM_TOR_Pathway_HTS_in_Saccharomyces_cerevisiae_specifically_RPL19A_MLPCN,20110405,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",NULL,NULL,CAA84846,NIH Initiatives,"11309812,16219781,16469695,16647875,17041625,7528205,8387896,8413204,9811607",0,10.1016/0092-8674(93)90144-f|10.1016/j.biocel.2006.02.013|10.1016/j.cell.2006.01.016|10.1016/s0960-9822(07)00511-8|10.1038/sj.onc.1209884|10.1128/mcb.13.10.6012|10.1534/genetics.105.051979,NULL,CAA84846,NULL
2023,1,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,"University of New Mexico Assay Overview:_|_Assay Support: 1R03 MH086450-01   _|_Project Title:  Chemical Screen of TOR pathway GFP fusion proteins in S. cerevisiae _|_PI: Maggie Werner-Washburne_|__|_Center PI: Larry Sklar_|__|_Assay Implementation: Jun Chen, Chris Allen, Susan Young, Anna Waller, Mark Carter_|__|_Assay Background and Significance:_|__|_The target of rapamycin, TOR, is a ser/thr protein_|_kinase evolutionarily conserved from yeast to man [Wullschleger, et al. 2006]. TOR functions in two dis",6,NMMLSC,UNM_TOR_Pathway_HTS_in_Saccharomyces_cerevisiae_specifically_LAP4_MLPCN,20110405,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",NULL,NULL,CAA81943,NIH Initiatives,"11309812,16219781,16469695,16647875,17041625,7528205,8387896,8413204,9811607",0,10.1016/0092-8674(93)90144-f|10.1016/j.biocel.2006.02.013|10.1016/j.cell.2006.01.016|10.1016/s0960-9822(07)00511-8|10.1038/sj.onc.1209884|10.1128/mcb.13.10.6012|10.1534/genetics.105.051979,NULL,CAA81943,NULL
2029,1,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,"University of New Mexico Assay Overview:_|_Assay Support: 1R03 MH086450-01   _|_Project Title:  Chemical Screen of TOR pathway GFP fusion proteins in S. cerevisiae _|_PI: Maggie Werner-Washburne_|__|_Center PI: Larry Sklar_|__|_Assay Implementation: Jun Chen, Chris Allen, Susan Young, Anna Waller, Mark Carter_|__|_Assay Background and Significance:_|__|_The target of rapamycin, TOR, is a ser/thr protein_|_kinase evolutionarily conserved from yeast to man [Wullschleger, et al. 2006]. TOR functions in two dis",6,NMMLSC,UNM_TOR_Pathway_HTS_in_Saccharomyces_cerevisiae_specifically_CIT2_MLPCN,20110405,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842125,842126,842127,842128,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842156,842157,842159,842162,842163,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842180,842181,842182,842183,842184,842186,842187,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842205,842207,842208,842209,842210,842211,8",NULL,NULL,AAA34498,NIH Initiatives,"11309812,16219781,16469695,16647875,17041625,7528205,8387896,8413204,9811607",0,10.1016/0092-8674(93)90144-f|10.1016/j.biocel.2006.02.013|10.1016/j.cell.2006.01.016|10.1016/s0960-9822(07)00511-8|10.1038/sj.onc.1209884|10.1128/mcb.13.10.6012|10.1534/genetics.105.051979,NULL,AAA34498,NULL
2016,1,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,"University of New Mexico Assay Overview:_|_Assay Support: 1R03 MH086450-01   _|_Project Title:  Chemical Screen of TOR pathway GFP fusion proteins in S. cerevisiae _|_PI: Maggie Werner-Washburne_|__|_Center PI: Larry Sklar_|__|_Assay Implementation: Jun Chen, Chris Allen, Susan Young, Anna Waller, Mark Carter_|__|_Assay Background and Significance:_|__|_The target of rapamycin, TOR, is a ser/thr protein_|_kinase evolutionarily conserved from yeast to man [Wullschleger, et al. 2006]. TOR functions in two dis",6,NMMLSC,UNM_TOR_Pathway_HTS_in_Saccharomyces_cerevisiae_specifically_MEP2_MLPCN,20110405,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",NULL,NULL,CAA96025,NIH Initiatives,"11309812,16219781,16469695,16647875,17041625,7528205,8387896,8413204,9811607",0,10.1016/0092-8674(93)90144-f|10.1016/j.biocel.2006.02.013|10.1016/j.cell.2006.01.016|10.1016/s0960-9822(07)00511-8|10.1038/sj.onc.1209884|10.1128/mcb.13.10.6012|10.1534/genetics.105.051979,NULL,CAA96025,NULL
2239,1,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,"Data Source: Johns Hopkins Ion Channel Center (JHICC)_|_BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed _|__|_Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Min Li, Ph.D._|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number:  1 R03 DA027716-01_|_Grant Proposal PI: Min Li, Ph.D., Johns Hopki",27,Johns Hopkins Ion Channel Center,JHICC_KCNQ2_potentiator_HTS,20100330,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",170848,Cell-based,NP_579856,Legacy Depositors|NIH Initiatives,"10025409,10816588,10838414,14640909,14657415,15634793,16465162,18171729,18238816,19279215,6965523,8528244,8739124,8813562,9074774,9425895,9425900",0,10.1016/0014-2999(96)00073-8|10.1016/0920-1211(95)00101-8|10.1016/s0092-8674(00)80556-5|10.1038/283673a0|10.1038/nbt1186|10.1038/ng0196-17|10.1038/ng0198-25|10.1038/ng0198-53|10.1073/pnas.0812756106|10.1074/jbc.m003245200|10.1113/jphysiol.2008.150656|10.1124/mol.107.041053|10.1124/pr.55.4.9|10.1146/annurev.physiol.59.1.483|10.1177/1087057104268749|10.1177/108705719900400206|10.1517/14728222.7.6.737,NULL,O88943,NULL
2690,1,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,"University of New Mexico Assay Overview:_|_Assay Support:  1 R03 MH087439-01  _|_Project Title: A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide _|_PI: William C. Burhans, Ph.D. _|__|_Assay Implementation: Catherine Prudom Ph.D., Chris Allen Ph.D., Anna Waller Ph.D, Mark Carter MS_|_Assay technical support:  Travis Houston, Keon Ahghar, Stephanie Sedillo_|__|_Assay Background and Significance:_|__|_Reactive oxygen species (ROS) and activation of growth signaling pathways are ",6,NMMLSC,UNMCMD_HTS_Yeast_Senescence,20100519,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",NULL,NULL,NULL,NIH Initiatives,"11689102,16873059,17710147,18055498,18282568,18323444",0,10.1016/j.cell.2006.07.002|10.1016/j.yexcr.2008.01.011|10.1093/nar/gkm1059|10.1126/science.1140735|10.1177/108705710100600204|10.1371/journal.pone.0000748,NULL,NULL,NULL
2557,1,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,"University of New Mexico Assay Overview:_|_Assay Support   _|_Project Title:HTS for Identification of VLA-4 Allosteric Modulators 1 R01 HL081062-01  _|_PI:Larry Sklar PhD and Alex Chigaev PhD _|__|_Assay Implementation:  Peter Simons PhD, Susan Young MS, Yang Wu PhD, Terry Foutz, Stephanie Sedillo, Anna Waller PhD, Mark Carter MS_|__|_Assay Background and Significance:_|__|_We have developed a novel ligand induced binding site (LIBS) mAb assay for integrin HTS using phycoerythrin (PE) labeled HUTS-21 mAb. T",6,NMMLSC,UNMCMD_VLA4_LIBS_HTS,20100723,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",3676,NULL,NP_000876,NIH Initiatives,"11170109,11641394,12844491,14645084,15166232,16507218,16989599,17513731,18345706,18534032,19251697",0,10.1002/1097-0320(20010301)43:3&lt;211::aid-cyto1052&gt;3.0.co;2-3|10.1007/s11912-006-0043-3|10.1016/s0006-3495(03)74809-7|10.1074/jbc.m103194200|10.1074/jbc.m210472200|10.1074/jbc.m404387200|10.1074/jbc.m901178200|10.1186/1471-2172-9-26|10.1517/13543784.15.10.1235|10.2165/00063030-200822020-00002|10.4049/jimmunol.178.11.6828,NULL,P13612,NULL
2391,2,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),"Southern Research's Specialized Biocontainment Screening Center (SRSBSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Probe Centers Network (MLPCN)_|_Assay Provider: Dr. William Severson, Southern Research Institute _|_Grant number:  1 R03 MH082403-01A1_|__|_Assay Rationale and Summary:  Currently, there are no commercially available vaccines to protect humans against Respiratory syncytial virus (RSV). RSV is associated with substantial morbidity and mortality and is the mos",33,Southern Research Specialized Biocontainment Screening Center,RSV,20100222,"6,19,72,86,109,119,127,137,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,785,864,892,896,899,903,931,932,936,938,942,957,992,1001,1017,1018,1030,1046,1047,1066,1088,1101,1123,1174,1176,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,1826,1832,1853,1858,1864,1882,1889,1890","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
2751,1,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Alan Saghatelian, Harvard University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 DP2 OD002374-01 Fast Track_|_Grant Proposal PI: Alan Saghatelian, Harvard University_|_External Assay ID: PREPL_INH_FP_1536_1X%INH_|__|_Name: Fluorescence polarization-based primary biochemical high throughput scr",5,The Scripps Research Institute Molecular Screening Center,PREPL_INH_FP_1536_1X%INH,20100615,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",9581,Biochemical,AAI51237,NIH Initiatives,"10611275,12740587,15533037,16385448,17052608,17579669,19011639,19329999",0,10.1016/j.chembiol.2006.08.008|10.1021/bi0480335|10.1038/nbt.1531|10.1038/nbt826|10.1038/nchembio.126|10.1038/sj.ejhg.5201881|10.1073/pnas.96.26.14694|10.1086/498852,NULL,AAI51237,NULL
2796,1,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Michael Denison, University of California, Davis_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1-X01-DA026558-01_|_Grant Proposal PI: Michael Denison_|_External Assay ID: AHR_ACT_LUMI_1X%INH_|__|_Name: Luminescence-based primary cell-based high throughput screening assay to identify acti",5,The Scripps Research Institute Molecular Screening Center,AHR_ACT_LUMI_1X%INH,20100805,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",196,Cell-based,NP_001612,NIH Initiatives,"12107286,12213383,12540743,12774124,15096657,15627472,15950866,16301529,16545780,16788953,17119250,17535977,18270326,18762178,7598497,8812265",0,10.1002/biof.5520200102|10.1002/jbt.20126|10.1006/faat.1996.0056|10.1016/j.bcp.2004.06.043|10.1016/j.bcp.2006.01.017|10.1016/j.cbi.2008.07.013|10.1016/j.tibs.2005.04.003|10.1016/s0009-2797(02)00064-9|10.1038/nature01606|10.1073/pnas.0504757102|10.1073/pnas.152706299|10.1124/mol.107.037259|10.1146/annurev.pa.35.040195.001515|10.1146/annurev.pharmtox.43.100901.135828|10.1182/blood-2007-08-109645|10.1196/annals.1371.045,NULL,P35869,NULL
2445,1,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Michael Jarstfer, University of North Carolina at Chapel Hill (UNC)_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH085678-01A1_|_Grant Proposal PI: Michael Jarstfer, UNC_|_External Assay ID: OTR_POT_FLUO8_1536_1X%ACT PRUNS_|__|_Name: Fluorescence-based primary cell-based high thro",5,The Scripps Research Institute Molecular Screening Center,OTR_POT_FLUO8_1536_1X%ACT PRUNS,20100615,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",5021,Cell-based,NP_000907,NIH Initiatives,"16249339,17629964,17893705,17959251,18370232,18382464,18655883,19015103,7895660,9176188",0,10.1007/978-1-59745-205-2_6|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2007.06.001|10.1016/s0079-6123(08)00417-2|10.1038/nrd2518|10.1038/sj.mp.4002087|10.1073/pnas.0505312102|10.1093/scan/nsn004|10.1152/ajpendo.1997.272.5.e870|10.1210/endo.136.4.7895660,NULL,P30559,NULL
2606,1,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Sabine Ehrt, Weill Cornell Medical College_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R01 AI081725-01 Fast Track_|_Grant Proposal PI: Sabine Ehrt_|_External Assay ID: RV3671C_INH_FP_1536_1X%INH_|__|_Name: Fluorescence polarization-based primary biochemical high throughput screening assay to ide",5,The Scripps Research Institute Molecular Screening Center,RV3671C_INH_FP_1536_1X%INH,20100615,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",885176,Biochemical,NP_218188,NIH Initiatives,"10611275,12149457,12740587,15035039,15036157,15748242,16161994,17280904,18606844,18641659,18645410,19170587,19329999,19465648,19519739,19601856",0,10.1016/j.cbpa.2003.11.004|10.1016/s0079-6468(06)45504-1|10.1021/jm050101d|10.1038/nbt.1531|10.1038/nbt826|10.1038/nm.1795|10.1038/nrmicro749|10.1073/pnas.162187599|10.1073/pnas.96.26.14694|10.1097/fjc.0b013e31817e9b9e|10.1111/j.1538-7836.2005.01166.x|10.1111/j.1747-0285.2009.00836.x|10.1128/aac.01508-07|10.1128/jb.00305-09|10.1592/phco.29.2.167|10.2174/157016109788340785,3.4.21.-,P9WHR9,NULL
2280,1,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: James R. Williamson, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS056951-01_|_Grant Proposal PI: James R. Williamson_|_External Assay ID: GLD1_INH_FP_1536_1X%INH_|__|_Name: Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of G",5,The Scripps Research Institute Molecular Screening Center,GLD1_INH_FP_1536_1X%INH,20110510,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",172532,Biochemical,NP_492143,NIH Initiatives,"12709531,12897774,14511482,16198329,16857580,7601353,7713419,7713420,8948583,9433137",0,10.1006/dbio.1996.0293|10.1016/j.molcel.2006.07.003|10.1016/j.ydbio.2005.08.038|10.1016/s0168-9525(97)01269-9|10.1038/nrg1125|10.1098/rstb.2003.1333|10.1101/gad.9.12.1491|10.1126/stke.2003.179.re6,NULL,Q17339,NULL
2472,1,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen","MLPCN Grant: MH085699-01_|__|_Assay Provider: Osnat Herzberg, University of Maryland_|__|_NCGC Assay Overview:_|__|_The objective of this project is to obtain compounds that inhibit Giardia lamblia growth. G. lamblia is a human pathogen which afflicts impoverished nations; it is the most common cause of outbreaks of diarrhea in the United States. During the course of our study of potential drug targets in Giardia, we have identified the Class II (Zn2+ functions in electrophilic catalysis) fructose-1,6-bisph",2,National Center for Advancing Translational Sciences (NCATS),FBPA823,20100428,"72,119,135,185,187,190,191,199,204,206,224,239,253,273,275,277,298,303,304,323,338,342,366,370,401,408,450,453,460,464,471,499,525,535,546,547,564,588,595,596,607,610,614,636,637,681,698,710,727,736,750,757,774,785,803,827,830,836,846,847,853,864,866,876,892,896,903,904,912,914,932,936,938,992,999,1046,1047,1050,1054,1060,1064,1066,1072,1080,1101,1102,1103,1110,1123,1132,1134,1148,1150,1176,1183,1201,1203,1204,1214,1242,1248,1249,1254,1256,1287,1292,1301,1302,1309,1318,1321,1329,1345,1348,1354,1355,1359,136","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",2597,NULL,NP_002037,Governmental Organizations|NIH Initiatives,"17166851,19236002",0,10.1021/bi9001166|10.1074/jbc.m609534200,"1.2.1.12,2.6.99.-",P04406,NULL
2234,1,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Paul Lieberman, Wistar Institute_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: I R21 NS063906-01_|_Grant Proposal PI: Paul Lieberman, Wistar Institute_|_External Assay ID: ZTA_INH_FP_1536_1X%INH_|__|_Name: Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemica",5,The Scripps Research Institute Molecular Screening Center,ZTA_INH_FP_1536_1X%INH,20100615,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,182","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",3783744,Biochemical,YP_401673,NIH Initiatives,"10530796,12450729,15242681,15541197,17153849,17459939,18515742,18946490,19139406,19211802,2154599,9032305",0,10.1016/j.molmed.2004.05.006|10.1016/s0024-3205(99)00214-3|10.1016/s1044579x0200086x|10.1017/s1462399404008440|10.1038/emboj.2008.221|10.1073/pnas.0810619106|10.1073/pnas.0812575106|10.1128/jvi.00153-07|10.1177/0961203306070009|10.1634/theoncologist.2008-0036,NULL,P03206,NULL
2057,1,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Michael Cardone, Eutropics_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number 1 R43 CA135915-01 Fast Track_|_Grant Proposal PI: Michael Cardone, Eutropics_|_External Assay ID: MCL-1BIM_INH_FP_1536_1X%INH_|__|_Name: Fluorescence polarization-based primary biochemical high throughput screening assay to identify in",5,The Scripps Research Institute Molecular Screening Center,MCL-1BIM_INH_FP_1536_1X%INH,20100615,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,182","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",4170,Biochemical,AAI07736,NIH Initiatives,"12070027,14996493,15718471,15902208,16023593,16200198,16826219,18534118,18818117,7682708",0,10.1016/j.bbamcr.2003.08.012|10.1016/j.ccr.2005.06.012|10.1016/j.drup.2008.08.002|10.1038/nature03579|10.1038/ncponc0538|10.1073/pnas.90.8.3516|10.1126/science.1106114|10.1172/jci26250|10.1177/147323000803600301|10.1182/blood.v100.1.194,NULL,Q07820,NULL
2177,1,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Ben Cravatt, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number 1 R01 CA132630 Fast Track_|_Grant Proposal PI: Ben Cravatt, TSRI_|_External Assay ID: LYPLA2_INH_FP_1536_1X%INH_|__|_Name: Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to",5,The Scripps Research Institute Molecular Screening Center,LYPLA2_INH_FP_1536_1X%INH,20100615,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,182","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",NULL,Biochemical,CAB40158,NIH Initiatives,"10611275,11060018,11171037,11300781,12740587,1325671,15661531,18596935,19293187,8206937,8650216,9727084",0,10.1016/j.gde.2004.12.004|10.1021/bi002579j|10.1038/nbt826|10.1042/0264-6021:3530417|10.1073/pnas.93.12.6043|10.1073/pnas.96.26.14694|10.1093/emboj/19.21.5672|10.1126/science.1325671|10.1158/0008-5472.can-08-2760|10.1371/journal.pone.0002486|10.2741/a336,NULL,O95372,NULL
2129,1,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Michael Cardone, Eutropics_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number 1 R43 CA135915-01 Fast Track_|_Grant Proposal PI: Michael Cardone, Eutropics_|_External Assay ID: BCLXLBIM_INH_FP_1536_1X%INH_|__|_Name: Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein",5,The Scripps Research Institute Molecular Screening Center,BCLXLBIM_INH_FP_1536_1X%INH,20100615,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,182","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",598,Biochemical,CAA80661,NIH Initiatives,"12070027,14996493,15718471,15902208,16023593,16200198,16826219,18534118,18818117,7682708",0,10.1016/j.bbamcr.2003.08.012|10.1016/j.ccr.2005.06.012|10.1016/j.drup.2008.08.002|10.1038/nature03579|10.1038/ncponc0538|10.1073/pnas.90.8.3516|10.1126/science.1106114|10.1172/jci26250|10.1177/147323000803600301|10.1182/blood.v100.1.194,NULL,CAA80661,NULL
2130,1,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Ben Cravatt, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number 1 R01 CA132630 Fast Track_|_Grant Proposal PI: Ben Cravatt, TSRI_|_External Assay ID: PME1_INH_FP_1536_1X%INH_|__|_Name: Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosp",5,The Scripps Research Institute Molecular Screening Center,PME1_INH_FP_1536_1X%INH,20100615,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,182","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",51400,Biochemical,NP_057231,NIH Initiatives,"10611275,11060018,11171037,11300781,12740587,1325671,15661531,18596935,19293187,8206937,8650216,9727084",0,10.1016/j.gde.2004.12.004|10.1021/bi002579j|10.1038/nbt826|10.1042/0264-6021:3530417|10.1073/pnas.93.12.6043|10.1073/pnas.96.26.14694|10.1093/emboj/19.21.5672|10.1126/science.1325671|10.1158/0008-5472.can-08-2760|10.1371/journal.pone.0002486|10.2741/a336,3.1.1.89,Q9Y570,NULL
2435,1,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Michael Jarstfer, University of North Carolina at Chapel Hill (UNC)_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH085678-01A1_|_Grant Proposal PI: Michael Jarstfer, UNC_|_External Assay ID: OTR_AG_FLUO8_1X%INH_|__|_Name: Fluorescence-based primary cell-based high throughput scree",5,The Scripps Research Institute Molecular Screening Center,OTR_AG_FLUO8_1X%ACT,20100615,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",5021,Cell-based,NP_000907,NIH Initiatives,"16249339,17629964,17893705,17959251,18370232,18382464,18655883,19015103,7895660,9176188",0,10.1007/978-1-59745-205-2_6|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2007.06.001|10.1016/s0079-6123(08)00417-2|10.1038/nrd2518|10.1038/sj.mp.4002087|10.1073/pnas.0505312102|10.1093/scan/nsn004|10.1152/ajpendo.1997.272.5.e870|10.1210/endo.136.4.7895660,NULL,P30559,NULL
2235,1,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Richard Honkanen, University of South Alabama_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH085702-01A1_|_Grant Proposal PI: Richard Honkanen, University of South Alabama_|_External Assay ID: PP1_INH_FLINT_1536_1X%INH_|__|_Name: Counterscreen for inhibitors of PP5: fluorescence-b",5,The Scripps Research Institute Molecular Screening Center,PP1_INH_FLINT_1536_1X%INH,20100615,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,182","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",5499,Biochemical,NP_001008709,NIH Initiatives,"11137038,17084641,18253812,9195923,9278397,9575175",0,10.1007/s10555-008-9125-z|10.1016/j.tem.2006.10.013|10.1016/s1043-2760(00)00335-0|10.1074/jbc.272.26.16224|10.1074/jbc.272.36.22464|10.1074/jbc.273.20.12250,3.1.3.16,P62136,NULL
2797,1,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Michael Jarstfer, University of North Carolina at Chapel Hill (UNC)_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH085678-01A1_|_Grant Proposal PI: Michael Jarstfer, UNC_|_External Assay ID: V1R_AG_FLUO8_1536_1X%ACT OXTR CSRUN_|__|_Name: Counterscreen for Oxytocin Receptor (OXTR) ",5,The Scripps Research Institute Molecular Screening Center,V1R_AG_FLUO8_1536_1X%ACT OXTR CSRUN,20100615,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",552,Cell-based,NP_000697,NIH Initiatives,"16249339,17629964,17893705,17959251,18370232,18382464,18655883,19015103,7895660,9176188",0,10.1007/978-1-59745-205-2_6|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2007.06.001|10.1016/s0079-6123(08)00417-2|10.1038/nrd2518|10.1038/sj.mp.4002087|10.1073/pnas.0505312102|10.1093/scan/nsn004|10.1152/ajpendo.1997.272.5.e870|10.1210/endo.136.4.7895660,NULL,P37288,NULL
2300,1,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Konstantin Petrukhin, Columbia University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS061718-01 Fast Track_|_Grant Proposal PI: Konstantin Petrukhin, Columbia University_|_External Assay ID: NR2E3_AG_TR-FRET_1536_1X%INH_|__|_Name: TR-FRET-based primary biochemical high throughput screening assay ",5,The Scripps Research Institute Molecular Screening Center,NR2E3_AG_TR-FRET_1536_1X%INH,20100615,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,182","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",10002,Biochemical,BAH02301,NIH Initiatives,"10221899,10805811,11071390,11487564,12842037,12963616,15190009,15634773,15914712,16834531,17255935,17564971,17982421,18294254,18592265",0,10.1001/archopht.121.9.1316|10.1007/s00427-008-0232-1|10.1007/s004390000350|10.1016/s0969-2126(03)00133-3|10.1038/sj.emboj.7601548|10.1073/pnas.97.10.5551|10.1086/518426|10.1089/adt.2006.4.253|10.1093/hmg/10.16.1619|10.1093/hmg/ddh173|10.1111/j.1399-0004.2008.00963.x|10.1126/science.284.5415.757|10.1210/me.2005-0046|10.1523/jneurosci.3571-04.2005,NULL,Q9Y5X4,NULL
2174,1,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Ben Cravatt, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number 1 R01 CA132630 Fast Track_|_Grant Proposal PI: Ben Cravatt, TSRI_|_External Assay ID: LYPLA1_INH_FP_1536_1X%INH_|__|_Name: Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to",5,The Scripps Research Institute Molecular Screening Center,LYPLA1_INH_FP_1536_1X%INH,20100615,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,182","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",10434,Biochemical,NP_006321,NIH Initiatives,"10611275,11060018,11171037,11300781,12740587,1325671,15661531,18596935,19293187,8206937,8650216,9727084",0,10.1016/j.gde.2004.12.004|10.1021/bi002579j|10.1038/nbt826|10.1042/0264-6021:3530417|10.1073/pnas.93.12.6043|10.1073/pnas.96.26.14694|10.1093/emboj/19.21.5672|10.1126/science.1325671|10.1158/0008-5472.can-08-2760|10.1371/journal.pone.0002486|10.2741/a336,3.1.2.-,O75608,NULL
2732,1,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,"NIH Molecular Libraries Screening Centers Network [MLSCN]_|_Emory Chemical Biology Discovery Center in MLSCN_|_Assay provider: Dr. Randal Kaufman, University of Michigan_|_MLSCN Grant: R03MH084182-01, U54HG003918_|__|_Many genetic and environmental diseases result from defective protein folding within the secretory pathway so that aberrantly folded proteins are recognized by the cellular surveillance system and retained within the endoplasmic reticulum (ER). Under conditions of malfolded protein accumulatio",16,Emory University Molecular Libraries Screening Center,A28 - Inhibitors of ER stress-induced CHOP promoter activation primary screen,20100331,"72,119,178,191,204,253,289,298,323,338,366,401,471,525,546,547,564,650,774,785,803,864,896,903,932,936,938,1046,1047,1066,1123,1150,1201,1209,1216,1222,1228,1232,1233,1239,1245,1256,1317,1318,1328,1329,1330,1340,1345,1359,1365,1367,1390,1400,1456,1474,1492,1539,1564,1607,1609,1641,1645,1646,1649,1676,1678,1683,1688,1720,1727,1730,1738,1742,1756,1774,1775,1779,1780,1794,1795,1820,1826,1832,1833,1845,1853,1858,1864,1868,1871,1882,1884,1892,1893,1908,1917,1922,1967,1981,1985,1986,1989,2000,2002,2007,2015,2018,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842141,842142,842143,842144,842145,842146,842148,842149,842150,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,8",13198,NULL,NP_031863,Legacy Depositors|NIH Initiatives,NULL,0,NULL,NULL,P35639,NULL
2156,1,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,"Data Source: Johns Hopkins Ion Channel Center (JHICC_KCNQ2)_|_BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed _|__|__|_Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Min Li, Ph.D._|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number:  1 R03 DA027716-01_|_Grant Proposal PI: Min Li, Ph.D., Jo",27,Johns Hopkins Ion Channel Center,JHICC_KCNQ2_HTS_1,20100330,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",170848,Cell-based,NP_579856,Legacy Depositors|NIH Initiatives,"10025409,10816588,10838414,14657415,15634793,16465162,18171729,18238816,19279215,6965523,8528244,9074774,9425895,9425900",0,10.1016/s0092-8674(00)80556-5|10.1038/283673a0|10.1038/nbt1186|10.1038/ng0196-17|10.1038/ng0198-25|10.1038/ng0198-53|10.1073/pnas.0812756106|10.1074/jbc.m003245200|10.1113/jphysiol.2008.150656|10.1124/mol.107.041053|10.1124/pr.55.4.9|10.1146/annurev.physiol.59.1.483|10.1177/1087057104268749|10.1177/108705719900400206,NULL,O88943,NULL
2237,1,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,"Data Source: Johns Hopkins Ion Channel Center (JHICC)_|_BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed _|__|_Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Michael Zhu, Ph.D., Ohio State University_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number:  1 R21 NS056942-01_|_Grant Proposal PI",27,Johns Hopkins Ion Channel Center,JHICC_TRPC4_AG,20100330,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",22066,Cell-based,AAC05178,Legacy Depositors|NIH Initiatives,"10838414,16234348,16382100,16465162,17233605,17298296,17368864,17579562,18940894,19116627,19234573,19546862,8646775",0,10.1016/j.bbadis.2007.02.002|10.1016/s0092-8674(00)81233-7|10.1038/nbt1186|10.1038/nrd2757|10.1038/nrneph.2009.100|10.1042/bst0350077|10.1096/fj.08-119495|10.1124/pr.57.4.6|10.1139/y08-112|10.1146/annurev.biochem.75.103004.142819|10.1177/1087057105279493|10.1177/108705719900400206|10.1517/14728222.11.3.391,NULL,AAC05178,NULL
2227,1,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),"Data Source: Johns Hopkins Ion Channel Center (JHICC)_|_BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed _|__|_Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Michael Zhu, Ph.D., Ohio State University_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number:  1 R21 NS056942-01_|_Grant Proposal PI",27,Johns Hopkins Ion Channel Center,JHICC_TRPC4_Allo,20100330,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",22066,Cell-based,AAC05178,Legacy Depositors|NIH Initiatives,"10838414,16234348,16465162,17233605,17298296,17368864,17579562,18940894,19116627,19234573,19546862,8646775",0,10.1016/j.bbadis.2007.02.002|10.1016/s0092-8674(00)81233-7|10.1038/nbt1186|10.1038/nrd2757|10.1038/nrneph.2009.100|10.1042/bst0350077|10.1096/fj.08-119495|10.1139/y08-112|10.1146/annurev.biochem.75.103004.142819|10.1177/1087057105279493|10.1177/108705719900400206|10.1517/14728222.11.3.391,NULL,AAC05178,NULL
2247,1,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,"Data Source: Johns Hopkins Ion Channel Center (JHICC)_|_BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed _|__|_Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Michael Zhu, Ph.D., Ohio State University_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number:  1 R21 NS056942-01_|_Grant Proposal PI",27,Johns Hopkins Ion Channel Center,JHICC_TRPC4_Inh,20100330,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",22066,Cell-based,AAC05178,Legacy Depositors|NIH Initiatives,"10838414,16234348,16382100,16465162,17233605,17298296,17368864,17579562,18940894,19116627,19234573,19546862,8646775",0,10.1016/j.bbadis.2007.02.002|10.1016/s0092-8674(00)81233-7|10.1038/nbt1186|10.1038/nrd2757|10.1038/nrneph.2009.100|10.1042/bst0350077|10.1096/fj.08-119495|10.1124/pr.57.4.6|10.1139/y08-112|10.1146/annurev.biochem.75.103004.142819|10.1177/1087057105279493|10.1177/108705719900400206|10.1517/14728222.11.3.391,NULL,AAC05178,NULL
2553,1,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),"Name: High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6) _|_Data Source: Johns Hopkins Ion Channel Center _|_BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed_|__|_Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Mike Zhu Ph.D., Ohio State University_|_Network: Molecular Libraries Probe Pro",27,Johns Hopkins Ion Channel Center,TRPC6_Inhibitor_MPD,20100321,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",22068,NULL,NP_038866,Legacy Depositors|NIH Initiatives,"10838414,11897058,15879175,16465162,17056714,17298296,18812089,19362736,19936226,20127491,9351965",0,10.1007/s00424-010-0788-2|10.1016/j.ceca.2009.03.005|10.1016/j.cub.2008.07.063|10.1038/nbt1186|10.1073/pnas.0606894103|10.1124/mol.52.5.755|10.1126/science.1106215|10.1177/108705710200700110|10.1177/108705719900400206|10.1371/journal.pone.0007771|10.1517/14728222.11.3.391,NULL,Q61143,NULL
2642,1,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,"Data Source: Johns Hopkins Ion Channel Center (JHICC)_|_BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed _|__|_Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Meng Wu, Ph.D._|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number:  1 R03 MH090837-01_|_Grant Proposal PI: Meng Wu, Ph.D., Johns Hop",27,Johns Hopkins Ion Channel Center,JHICC_KCNQ1_Inh_Tl_HTS,20101118,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",3784,Cell-based,NP_000209,Legacy Depositors|NIH Initiatives,"10646604,10654932,10825393,10838414,11448722,12191600,15634793,16261179,16287990,16382104,16465162,17305705,17347319,17395127,18171729,18174212,18238808,18238816,18264812,18476673,18663467,1868484,18836841,18989792,19113860,19279215,19298256,19342611,19364771,19439185,19584308",0,10.1007/s00232-008-9093-9|10.1007/s00424-008-0557-7|10.1007/s11481-008-9130-6|10.1007/s12013-008-9032-5|10.1016/j.nurt.2007.01.015|10.1016/j.vascn.2009.04.197|10.1016/s0163-7258(01)00116-4|10.1016/s0163-7258(02)00201-2|10.1021/bi8018515|10.1021/cr078234p|10.1038/35003200|10.1038/nbt1186|10.1038/nrn1785|10.1073/pnas.0812756106|10.1074/jbc.m808021200|10.1093/emboj/19.3.332|10.1111/j.1476-5381.2009.00111.x|10.1111/j.1748-1716.2006.01646.x|10.1113/jphysiol.2007.148254|10.1113/jphysiol.2007.148304|10.1113/jphysi,NULL,P51787,NULL
2648,1,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,"Data Source: Johns Hopkins Ion Channel Center (JHICC_KCNQ1_Pot_Tl_HTS)_|_BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed _|__|_Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Meng Wu, Ph.D._|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number:  1 R03 MH090837-01_|_Grant Proposal PI: Meng Wu,",27,Johns Hopkins Ion Channel Center,JHICC_KCNQ1_Pot_Tl_HTS,20101118,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",3784,Cell-based,NP_000209,Legacy Depositors|NIH Initiatives,"10646604,10654932,10838414,11448722,12191600,15634793,16261179,16287990,16382104,16465162,17305705,17395127,18171729,18174212,18238808,18238816,18264812,18476673,18663467,18684841,18836841,18989792,19113860,19279215,19298256,19342611,19364771,19439185,19584308",0,10.1007/s00232-008-9093-9|10.1007/s00424-008-0557-7|10.1007/s11481-008-9130-6|10.1007/s12013-008-9032-5|10.1016/j.nurt.2007.01.015|10.1016/j.vascn.2009.04.197|10.1016/s0163-7258(01)00116-4|10.1016/s0163-7258(02)00201-2|10.1021/bi8018515|10.1021/cr078234p|10.1038/35003200|10.1038/nbt1186|10.1038/nrn1785|10.1073/pnas.0812756106|10.1074/jbc.m808021200|10.1093/emboj/19.3.332|10.1111/j.1476-5381.2009.00111.x|10.1111/j.1748-1716.2006.01646.x|10.1113/jphysiol.2007.148254|10.1113/jphysiol.2007.148304|10.1113/jphysi,NULL,P51787,NULL
2550,1,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),"Data Source: Johns Hopkins Ion Channel Center (TRPC6_Activator_MPD)_|_BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed_|__|_Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Mike Zhu Ph.D., Ohio State University_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS056942-01 _|_Grant Pr",27,Johns Hopkins Ion Channel Center,TRPC6_Activator_MPD,20101025,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,2161","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",22068,NULL,NP_038866,Legacy Depositors|NIH Initiatives,"10838414,11897058,12765700,15879175,16465162,17056714,17298296,17433435,18812089,19103233,19362736,9351965",0,10.1016/j.bbamcr.2008.11.010|10.1016/j.ceca.2007.02.009|10.1016/j.ceca.2009.03.005|10.1016/j.cub.2008.07.063|10.1016/s0143-4160(03)00060-5|10.1038/nbt1186|10.1073/pnas.0606894103|10.1124/mol.52.5.755|10.1126/science.1106215|10.1177/108705710200700110|10.1177/108705719900400206|10.1517/14728222.11.3.391,NULL,Q61143,NULL
2417,1,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,"High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment _|_NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Centers Network [MLPCN]_|__|_MLPCN Grant: MH082371-01A2_|_Assay Submitter (PI): Sui Huang, Northwestern University, Feinberg School of Medicine, Cell and Molecular Biology, Chicago, Illinois._|__|_The perinucleolar compartment (PNC) is a non-membrane-bound nuclear subdomain that is associated with but structurally distinct from the nucleolus. The ",2,National Center for Advancing Translational Sciences (NCATS),PNC5466,20100224,"119,253,323,338,366,525,546,774,803,932,936,938,1046,1047,1150,1318,1329,1400,1474,1492,1539,1646,1676,1688,1727,1775,1780,1820,1833,1893,1922,1967,1985,1986,2000,2007,2015,2082,2123,2153,2170,2196,2197,2247,2249,2256,2266,2303,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2482,2554,2576,2708,2720,2727,2732,2733,2754,2756,2762,2771,2788,2804,2890,2950,2955,2972,3012,3019,3025,3037,3108,3117,3126,3151,3168,3169,3182,3194,3213,3242,3278,3279,3295,3308,3331,3332,3333,3334,3335,3339,3366,3371,3373,3374,3385","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",5725,NULL,NP_002810,Governmental Organizations|NIH Initiatives,19288520,0,10.1002/jcb.22107,NULL,P26599,NULL
2240,1,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,"This data was generated through collaboration with the National Cancer Institute's Initiative for Chemical Genetics_|__|_Internal Project ID: 2007_|__|_Keywords: MITF, Microphthalmia-associated transcription factor, TRPM1 gene, melanocyte proliferation_|__|_Assay:  To identify broad suppressors of MITF activity - either by suppression of MITF expression or by inhibition of MITF activity (without affecting expression)._|__|_Expected Outcome: Active wells will show a reduced luminescence intensity due to fewe",31,Broad Institute,2007-01_INHIBITORS_SINGLE-POINT_BROAD-HTS,20100112,"86,237,323,444,861,863,896,903,932,992,1002,1203,1204,1219,1220,1225,1234,1236,1240,1242,1302,1329,1342,1345,1346,1348,1354,1355,1359,1370,1400,1464,1480,1486,1493,1533,1609,1649,1663,1674,1683,1694,1713,1720,1733,1775,1779,1820,1830,1833,1845,1853,1863,1880,1882,1884,1892,1893,1917,1923,1935,1960,1978,1979,1981,1988,1989,2004,2031,2044,2048,2049,2051,2052,2061,2063,2064,2078,2082,2083,2092,2119,2120,2122,2123,2125,2126,2129,2132,2145,2153,2160,2162,2170,2196,2200,2203,2206,2230,2247,2249,2256,2264,2265,226","85787078,85787079,85787080,85787081,85787082,85787083,85787084,85787085,85787086,85787087,85787088,85787089,85787090,85787091,85787092,85787093,85787094,85787095,85787096,85787097,85787098,85787099,85787100,85787101,85787102,85787103,85787104,85787105,85787106,85787107,85787108,85787109,85787110,85787111,85787112,85787113,85787114,85787115,85787116,85787117,85787118,85787119,85787120,85787121,85787122,85787123,85787124,85787125,85787126,85787127,85787128,85787129,85787130,85787131,85787132,85787133,85787134",4286,Cell-based,NP_937802,NIH Initiatives,"19147347,2005893",0,10.1016/j.bmcl.2008.12.081|10.1128/mcb.11.4.2004,NULL,O75030,NULL
2330,1,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,"This data was generated through collaboration with the National Cancer Institute's Initiative for Chemical Genetics._|__|_Primary Collaborators: Gary Gilliland, Brigham and Women's Hospital, ggilliland@rics.bwh.harvard.edu_|__|_Keywords: Serine/Threonine Kinase, Cell Titre Glo,_|__|_Assay Overview:The NOMO-1 cell line is a non-adherent acute myeloid leukemia (AML) cell line.  This cell line is KRAS dependent and the serine/threonine kinase 33 (STK33) was identified as being synthetically lethal using an RNA",31,Broad Institute,2021-01_INHIBITORS_SINGLE-POINT_BROAD-HTS,20100203,"86,237,323,444,861,863,896,903,932,992,1002,1203,1204,1219,1220,1225,1234,1236,1240,1242,1302,1329,1342,1345,1346,1348,1354,1355,1359,1370,1400,1464,1480,1486,1493,1533,1609,1649,1663,1674,1683,1694,1713,1720,1733,1775,1779,1820,1830,1833,1845,1853,1863,1880,1882,1884,1892,1893,1917,1923,1935,1960,1978,1979,1981,1988,1989,2004,2031,2044,2048,2049,2051,2052,2061,2063,2064,2078,2082,2083,2092,2119,2120,2122,2123,2125,2126,2129,2132,2145,2153,2160,2162,2170,2196,2200,2203,2206,2230,2247,2249,2256,2264,2265,226","85787078,85787079,85787080,85787081,85787082,85787083,85787084,85787085,85787086,85787087,85787088,85787089,85787090,85787091,85787092,85787093,85787094,85787095,85787096,85787097,85787098,85787099,85787100,85787101,85787102,85787103,85787104,85787105,85787106,85787107,85787108,85787109,85787110,85787111,85787112,85787113,85787114,85787115,85787116,85787117,85787118,85787119,85787120,85787121,85787122,85787123,85787124,85787125,85787126,85787127,85787128,85787129,85787130,85787131,85787132,85787133,85787134",65975,Cell-based,CAC29064,NIH Initiatives,NULL,0,NULL,NULL,Q9BYT3,NULL
2275,1,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,"This data was generated through collaboration with the National Cancer Institute's Initiative for Chemical Genetics_|__|_Internal Project ID: 2013_|__|_Keywords: Ras, apoptosis, cancer, VDAC, oxidative cell death_|__|_Assay: Cell viability of BJeLR (BJ fibroblasts transformed with hTERT, genomic SV40 LT and ST oncoproteins, and oncogenic HRASV12).  Using CellTiterGlo, which measures the amount of intracellular ATP from living cells, the total amount of viable cells can be measured by luminescence readout.  ",31,Broad Institute,2013-01_SELECTIVELYCYTOTOXIC_SINGLE-POINT_BROAD-HTS,20100121,"86,237,323,444,861,863,896,903,932,992,1002,1203,1204,1219,1220,1225,1234,1236,1240,1242,1302,1329,1342,1345,1346,1348,1354,1355,1359,1370,1400,1464,1480,1486,1493,1533,1599,1609,1649,1663,1674,1683,1694,1713,1720,1733,1775,1779,1820,1830,1833,1845,1853,1863,1880,1882,1884,1892,1893,1917,1923,1935,1960,1978,1979,1981,1988,1989,2004,2031,2044,2048,2049,2051,2052,2061,2063,2064,2078,2082,2083,2092,2119,2120,2122,2123,2125,2126,2129,2132,2145,2153,2160,2162,2170,2196,2200,2203,2206,2230,2247,2249,2256,2264,226","85787078,85787079,85787080,85787081,85787082,85787083,85787084,85787085,85787086,85787087,85787088,85787089,85787090,85787091,85787092,85787093,85787094,85787095,85787096,85787097,85787098,85787099,85787100,85787101,85787102,85787103,85787104,85787105,85787106,85787107,85787108,85787109,85787110,85787111,85787112,85787113,85787114,85787115,85787116,85787117,85787118,85787119,85787120,85787121,85787122,85787123,85787124,85787125,85787126,85787127,85787128,85787129,85787130,85787131,85787132,85787133,85787134",NULL,Cell-based,NULL,NIH Initiatives,"12676586,17174591,17568748,18355723,18704666",0,10.1007/s10863-008-9158-6|10.1016/j.cbpa.2006.11.033|10.1016/j.chembiol.2008.02.010|10.1016/s1535-6108(03)00050-3|10.1038/nature05859,NULL,NULL,NULL
2322,1,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,"This data was generated through collaboration with the National Cancer Institute's Initiative for Chemical Genetics._|__|_Keywords: STK33, KRAS, RAS, kinase, cancer_|__|_Assay Overview: The ADP-Glo (Promega) primary screen will be run under conditions that are expected to provide competitive, uncompetitive and non-competitive hits, by screening with an ATP concentration (100uM) that is above the Km (36uM) under the assay conditions. Compounds to be screened at 12.5uM._|_ _|_Expected Outcome: Compounds that ",31,Broad Institute,2029-01_ INHIBITORS_SINGLE-POINT_BROAD-HTS,20100201,"86,237,323,444,861,863,896,903,932,992,1203,1204,1219,1220,1225,1234,1236,1240,1242,1302,1329,1342,1345,1346,1348,1354,1355,1359,1370,1400,1464,1480,1486,1493,1533,1609,1649,1663,1674,1683,1694,1713,1720,1733,1775,1779,1820,1830,1833,1845,1853,1863,1880,1882,1884,1892,1893,1917,1923,1935,1960,1978,1979,1981,1988,1989,2002,2004,2031,2044,2048,2049,2051,2052,2061,2063,2064,2078,2082,2083,2092,2119,2120,2122,2123,2125,2126,2129,2132,2145,2153,2160,2162,2170,2196,2200,2203,2206,2230,2247,2249,2256,2264,2265,226","85787078,85787079,85787080,85787081,85787082,85787083,85787084,85787085,85787086,85787087,85787088,85787089,85787090,85787091,85787092,85787093,85787094,85787095,85787096,85787097,85787098,85787099,85787100,85787101,85787102,85787103,85787104,85787105,85787106,85787107,85787108,85787109,85787110,85787111,85787112,85787113,85787114,85787115,85787116,85787117,85787118,85787119,85787120,85787121,85787122,85787123,85787124,85787125,85787126,85787127,85787128,85787129,85787130,85787131,85787132,85787133,85787134",NULL,NULL,NULL,NIH Initiatives,19490892,0,10.1016/j.cell.2009.03.017,NULL,NULL,NULL
2316,1,Luminescence Cell-Based Primary HTS to Identify Activators of the Reversal of PD-1 Mediated Inhibitors of T-Cell Inhibition,"This data was generated through collaboration with the National Cancer Institute's Initiative for Chemical Genetics._|__|_Keywords:  T cell, PD-1, cancer, viral infection_|__|_Assay Overview: _|_We will use primary human CD4 T cells as the cell source because they are more representative of in vivo biology than cell lines.  Our screen will be aimed at identifying compounds that can reverse PD-1-mediated inhibition of T cell activation.  To recapitulate PD-1 signaling in vitro, we have established a bead-bas",31,Broad Institute,2020-01_ACTIVATORS_SINGLE-POINT_BROAD-HTS,20100201,"86,863,1002,1203,1204,1220,1234,1348,1354,1370,1533,1649,1683,1694,1713,1733,1779,1833,1845,1853,1892,1960,1978,1989,2044,2048,2049,2051,2052,2061,2064,2120,2123,2153,2160,2170,2196,2203,2247,2264,2265,2303,2310,2343,2353,2356,2366,2400,2422,2426,2427,2428,2448,2471,2477,2480,2520,2554,2688,2689,2703,2725,2733,2753,2764,2771,2776,2788,2803,2832,2856,2910,2913,2948,2984,3012,3019,3033,3038,3092,3100,3101,3105,3117,3157,3185,3194,3213,3277,3280,3291,3330,3331,3356,3371,3386,3394,3397,3475,3476,3478,3488,3501,","85787078,85787079,85787080,85787081,85787082,85787083,85787084,85787085,85787086,85787087,85787088,85787089,85787090,85787091,85787092,85787093,85787094,85787095,85787096,85787097,85787098,85787099,85787100,85787101,85787102,85787103,85787104,85787105,85787106,85787107,85787108,85787109,85787110,85787111,85787112,85787113,85787114,85787115,85787116,85787117,85787118,85787119,85787120,85787121,85787122,85787123,85787124,85787125,85787126,85787127,85787128,85787129,85787130,85787131,85787132,85787133,85787134",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
2313,1,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,"This data was generated through collaboration with the National Cancer Institute's Initiative for Chemical Genetics_|__|_Internal Project ID: 2018_|__|_Keywords: Sonic Hedgehog Signaling, Inhibition, Reporter Assay_|__|_Assay: The Hh pathway involves the binding of one of the Hh ligands to its 7-pass trans-membrane receptor, Patched (Ptc, Ptch-1 in mammals), which then releases its inhibitory effect on the pseudo-G-coupled protein receptor Smoothened (Smo). This leads to the liberation of the transcription ",31,Broad Institute,2018-01_INHIBITORS_SINGLE-POINT_BROAD-HTS,20100129,"86,237,323,444,861,863,896,903,932,992,1002,1203,1204,1219,1220,1225,1234,1236,1240,1242,1302,1329,1342,1345,1346,1348,1354,1355,1359,1370,1400,1464,1480,1486,1493,1533,1609,1649,1663,1674,1683,1694,1713,1720,1733,1775,1779,1820,1830,1833,1845,1853,1863,1880,1882,1884,1892,1893,1917,1923,1935,1960,1978,1979,1981,1988,1989,2002,2004,2031,2044,2048,2049,2051,2052,2061,2063,2064,2078,2082,2083,2092,2119,2120,2122,2123,2125,2126,2129,2132,2145,2153,2160,2162,2170,2196,2200,2203,2206,2230,2247,2249,2256,2264,226","85787078,85787079,85787080,85787081,85787082,85787083,85787084,85787085,85787086,85787087,85787088,85787089,85787090,85787091,85787092,85787093,85787094,85787095,85787096,85787097,85787098,85787099,85787100,85787101,85787102,85787103,85787104,85787105,85787106,85787107,85787108,85787109,85787110,85787111,85787112,85787113,85787114,85787115,85787116,85787117,85787118,85787119,85787120,85787121,85787122,85787123,85787124,85787125,85787126,85787127,85787128,85787129,85787130,85787131,85787132,85787133,85787134",NULL,Cell-based,NULL,NIH Initiatives,"10984056,12391318",0,10.1038/35023008|10.1073/pnas.182542899,NULL,NULL,NULL
2465,1,Luminescence Cell-Based Primary HTS to Identify Compounds which Inhibit A1 Apoptosis,"This data was generated through collaboration with the National Cancer Institute's Initiative for Chemical Genetics._|__|_Keywords: apoptosis, BH3 domain, Bcl2-A1, BIM, caspase, cancer_|_ _|_Primary Collaborator: Todd Golub, Broad Institute, golub@broadinstitute.org_|_ _|_Assay Overview: _|_The fate of cell survival versus apoptosis is determined by the balance of anti and pro-apoptotic proteins. Expression of activator BH3-only proteins, such as BIM or tBID, leads to downstream caspase activation and apopt",31,Broad Institute,2045-01_INHIBITORS_SINGLE-POINT_HTS_BROAD,20100303,"2674,2876,10204,12543,17534,98327,100018,216239,220662,353147,353423,402949,453385,585329,602051,617686,626461,641294,641298,693172,730768,736269,840245,1051842,1522030,1526786,1526852,1560402,1569268,2032097,2795556,2844802,2844804,3144930,3360305,3616421,4158809,4228863,4455627,5293655,5316606,5331525,5332009,5332016,5332204,5332576,5333026,5333884,5333947,5334465,5334616,5334689,5334948,5340131,5340562,5341081,5348511,5388518,5706767,6566094,6667077,6667131,6667324,6668231,6668384,6668425,6668481,6668510","85789756,85789757,85789759,85789763,85789765,85789767,85789768,85789770,85789772,85789773,85789774,85789775,85789776,85789777,85789778,85789779,85789780,85789783,85789784,85789785,85789786,85789787,85789788,85789789,85789790,85789793,85789795,85789796,85789797,85789798,85789799,85789803,85789804,85789805,85789810,85789813,85789814,85789816,85789819,85789820,85789821,85789822,85789824,85789826,85789827,85789829,85789830,85789831,85789834,85789835,85789836,85789837,85789838,85789839,85789842,85789843,85789844",10018,Cell-based,"2VM6_A,NP_619527",NIH Initiatives,NULL,0,NULL,NULL,"2VM6_A,O43521",NULL
2842,2,High Throughput Screen of a Putative Kinase Compound Library to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,"Mycobacterium tuberculosis (Mtb) is a notorious pathogen whose increasing resistance to antibiotics and heightened lethality in combination with AIDS makes it a major health concern worldwide. The World Health Organization (WHO) estimates that one-third of the world's population is infected with Mtb; eight million people worldwide develop tuberculosis annually while nearly two million die. Mtb causes more deaths than any other infectious agent in the world. Immunocompromised individuals, particularly those ",26,Southern Research Institute,H37Rv_Kinase,20100519,"675,1188,2265,3687,5155,5778,7023,8593,9221,9822,17561,18046,21652,24067,51998,55970,62389,65280,65708,70660,71029,73239,75526,79515,79516,80525,82316,82634,87127,89649,90260,93558,94960,95108,99051,115990,121025,124293,134684,151480,151533,165348,209466,210031,218692,219752,219757,219769,220711,220762,220875,222599,228615,228633,230460,230890,232191,236838,237111,247444,251576,253823,255290,257211,262499,264060,272051,272110,273249,279219,292744,296187,296188,296858,297061,304853,305038,305303,307505,30930","92093460,92093461,92093462,92093463,92093464,92093465,92093466,92093467,92093468,92093469,92093470,92093471,92093472,92093473,92093474,92093475,92093476,92093477,92093478,92093479,92093480,92093481,92093482,92093483,92093484,92093485,92093486,92093487,92093488,92093489,92093490,92093491,92093492,92093493,92093494,92093495,92093496,92093497,92093498,92093499,92093500,92093501,92093502,92093503,92093504,92093505,92093506,92093507,92093508,92093509,92093510,92093511,92093512,92093513,92093514,92093515,92093516",NULL,NULL,NULL,Research and Development,"19716767,19758845,9145860",0,10.1016/j.tube.2009.05.008|10.1016/j.tube.2009.07.007,NULL,NULL,NULL
2241,1,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,"This data was generated through collaboration with the National Cancer Institute's Initiative for Chemical Genetics._|__|_Keywords: _|_apoptosis, BH3 domain, Bcl2-A1, BIM, caspase, cancer_|__|_Primary Collaborators:_|_Todd Golub, Broad Institute, golub@broadinstitute.org_|__|_Project Overview:_|_The bcl family protein A1 is an anti-apoptotic factor that works in a manner similar to other proteins such as Bcl2 and BclXL, binding to and inhibiting pro-apoptotic factors such as BIM and tBid.  Many cancers are ",31,Broad Institute,2011-01_INHIBITORS_SINGLE-POINT_BROAD-HTS,20100112,"86,237,323,444,861,863,896,903,932,992,1002,1203,1204,1219,1220,1225,1234,1236,1240,1242,1302,1329,1342,1345,1346,1348,1354,1355,1359,1370,1400,1464,1480,1486,1493,1533,1599,1609,1649,1663,1674,1683,1694,1713,1720,1733,1775,1779,1820,1830,1833,1845,1853,1863,1880,1882,1884,1892,1893,1917,1923,1935,1960,1978,1979,1981,1988,1989,2004,2031,2044,2048,2049,2051,2052,2061,2063,2064,2078,2082,2083,2092,2119,2120,2122,2123,2125,2126,2129,2132,2145,2153,2160,2162,2170,2196,2200,2203,2206,2230,2247,2249,2256,2264,226","85787078,85787079,85787080,85787081,85787082,85787083,85787084,85787085,85787086,85787087,85787088,85787089,85787090,85787091,85787092,85787093,85787094,85787095,85787096,85787097,85787098,85787099,85787100,85787101,85787102,85787103,85787104,85787105,85787106,85787107,85787108,85787109,85787110,85787111,85787112,85787113,85787114,85787115,85787116,85787117,85787118,85787119,85787120,85787121,85787122,85787123,85787124,85787125,85787126,85787127,85787128,85787129,85787130,85787131,85787132,85787133,85787134",NULL,Cell-based,2VM6_A,NIH Initiatives,NULL,0,NULL,NULL,2VM6_A,NULL
2291,1,Fluorescence polarization-based Maybridge primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Ben Cravatt, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R01 CA132630 Fast Track_|_Grant Proposal PI: Ben Cravatt, TSRI_|_External Assay ID: PME1_INH_FP_384_1X%INH Maybridge_|__|_Name: Fluorescence polarization-based Maybridge primary biochemical high throughput screening assay to identify inhibit",5,The Scripps Research Institute Molecular Screening Center,PME1_INH_FP_384_1X%INH_Maybridge,20100615,"203,298,802,863,1002,1072,1474,2002,2051,2192,2197,2242,2455,2797,2833,3182,3195,3330,3488,3647,3830,4421,4487,4614,4661,4740,4781,4895,4994,5315,5386,5480,5503,5802,5899,5932,6084,6088,6129,6253,6688,6711,6730,6796,6825,6890,7082,7105,7156,7168,7226,7560,7594,7598,8342,8417,8515,8709,8739,8742,9154,9190,9200,9217,9301,9923,10184,10210,10221,10366,10367,10737,10752,10788,11043,11082,11100,11107,11155,11493,11855,11958,12011,12147,12446,12867,13099,13220,13225,13263,13494,13625,14041,14322,14566,15079,15165,","26527673,26527674,26527675,26527676,26527677,26527678,26527679,26527680,26527681,26527682,26527683,26527684,26527685,26527686,26527687,26527688,26527689,26527690,26527691,26527692,26527693,26527694,26527695,26527696,26527697,26527698,26527699,26527700,26527701,26527702,26527703,26527704,26527705,26527706,26527707,26527708,26527709,26527710,26527711,26527712,26527713,26527714,26527715,26527716,26527717,26527718,26527719,26527720,26527721,26527722,26527723,26527724,26527725,26527726,26527727,26527728,26527729",51400,Biochemical,NP_057231,NIH Initiatives,"10611275,12070027,12740587,14996493,15718471,15902208,16023593,16200198,16826219,18534118,18818117,7682708",0,10.1016/j.bbamcr.2003.08.012|10.1016/j.ccr.2005.06.012|10.1016/j.drup.2008.08.002|10.1038/nature03579|10.1038/nbt826|10.1038/ncponc0538|10.1073/pnas.90.8.3516|10.1073/pnas.96.26.14694|10.1126/science.1106114|10.1172/jci26250|10.1177/147323000803600301|10.1182/blood.v100.1.194,3.1.1.89,Q9Y570,NULL
2120,2,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Screening Centers Network [MLSCN]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_MLSCN Grant: None_|__|_NCGC Assay Overview_|__|_Hypoxia-inducible factor-1 (HIF-1) is the major hypoxia-regulated transcription factor that controls cellular responses to low oxygen concentration.  HIF-1 is composed of two subunits: hypoxia responsive HIF-1a and constitutively expressed HIF-1b, which is also kn",2,National Center for Advancing Translational Sciences (NCATS),HRE953,20091109,"11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,370,379,398,403,447,460,527,612,650,660,700,701,702,713,753,785,795,864,887,896,904,931,949,957,967,978,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1309,1318,1483,1486,1491,1493,1732,1752,1775,1923,1983,1988,1989,2078,2087,2153,2155,2202,2244,2256,2265,2268,2272,2286,2331,2347,2355,2365,2391,2406,2478,2482,2519,2537,2554,2576,2662,2708,2720,2727,2730,2756,2758,2767,2788,2879,2950,2955,2969,3017,3026,3035,30","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",3091,NULL,AAP88778,Governmental Organizations|NIH Initiatives,19502547,0,10.1093/toxsci/kfp123,NULL,Q16665,NULL
485364,2,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,"Schistosomiasis is a major neglected tropical disease that currently affects over 200 million.  It is caused by different species of flatworms, such as Schistosoma mansoni.  Over the last century, drugs to treat the disease have evolved from potassium antimonyl tartrate, artemisinin, oxamniquine, to praziquantel, with praziquantel remaining the universally-used single drug of choice over the past three decades.  However, transmission rates have changed little with praziquantel, and there is evidence for the",2,National Center for Advancing Translational Sciences (NCATS),TGR5001,20101006,"6,72,119,137,191,204,229,253,289,298,299,303,323,338,366,441,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,803,864,892,899,931,932,936,938,957,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2002,2007,2015,2018,2020,2048,2052,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",8345881,NULL,AAK85233,Governmental Organizations|NIH Initiatives,"18235848,18345010,18665782,19761212",0,10.1021/jm901021k|10.1038/nm1737|10.1089/adt.2008.149|10.1371/journal.pntd.0000127,NULL,AAK85233,NULL
485294,2,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|_Assay Provider: Professor Brian Shoichet, UCSF_|__|_Assay Overview:_|_This aggregation profiling approach exploits the sensitivity of aggregate formation to detergent. Inhibition of b-lactamase is measured in the presence and absence of 0.01% Triton X-100. This particular assay had the prescence of 0.01% Triton X-100. See Pubchem assay ""Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without de",2,National Center for Advancing Translational Sciences (NCATS),AMPC379,20100929,"6,72,119,137,191,204,229,253,289,298,299,303,323,338,366,441,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,803,864,892,899,931,932,936,938,957,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2002,2007,2015,2018,2020,2048,2052,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,2HDS_A,Governmental Organizations|NIH Initiatives,"13678405,16408018,16570910,17149857,17191086,17447748,18333608,63767",0,10.1016/s0140-6736(76)92058-4|10.1021/jm030266r|10.1021/jm060029z|10.1021/jm061103g|10.1021/jm061317y|10.1021/jm701500e|10.1038/nchembio718|10.1038/nprot.2006.77,NULL,1C3B_A,NULL
485314,2,qHTS Assay for Inhibitors of DNA Polymerase Beta,The base excision repair system in human cells is a target for therapeutic modulation of the response to irradiation treatment and DNA-damaging drugs. A key enzyme in this system is the bi-functional DNA polymerase known as DNA polymerase Beta (Pol Beta)._|__|_The following is a homogeneous kinetic assay to study the primer extension and strand-displacement reaction catalyzed by pol beta.,2,National Center for Advancing Translational Sciences (NCATS),POLB201,20100929,"72,119,178,191,204,253,275,289,298,303,323,338,366,401,408,460,471,499,525,546,547,564,588,637,650,774,785,803,864,896,903,932,936,938,1046,1047,1066,1123,1150,1201,1216,1222,1228,1232,1233,1245,1256,1309,1317,1318,1328,1329,1330,1340,1345,1359,1365,1367,1390,1400,1401,1456,1474,1492,1539,1564,1607,1609,1641,1645,1646,1649,1676,1678,1683,1688,1694,1697,1720,1727,1730,1738,1742,1756,1774,1775,1779,1780,1794,1795,1820,1826,1832,1833,1845,1853,1858,1864,1868,1871,1882,1884,1890,1892,1893,1908,1917,1922,1923,19","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",5423,NULL,NP_002681,Governmental Organizations|NIH Initiatives,"15258144,16464010,18343122",0,10.1016/j.bmc.2008.02.071|10.1021/cr0404904|10.1074/jbc.m402842200,"2.7.7.7,4.2.99.-",P06746,NULL
485281,2,qHTS Assay for Identification of Novel General Anesthetics,"Source: NIH Chemical Genomics Center [NCGC]_|_Assay Submitter: Roderic Eckenhoff, University of Pennsylvania_|_Screening Center PI: Christopher P. Austin, NIH_|_Probe Development: NIH Chemical Genomics Center [NCGC]_|_NIH Grant Number: MH084836-01_|__|_Anesthetic development has remained a largely empirical process. There are growing concerns about the cognitive effects of known general anesthetics [1] and acceleration of the onset of neurodegenerative disease [2]. The compounds' toxicity [3] and multiple s",2,National Center for Advancing Translational Sciences (NCATS),APOF102,20100927,"72,119,135,185,187,190,191,204,206,224,239,253,273,277,298,303,323,338,342,366,370,408,412,450,453,460,464,499,525,546,547,564,588,595,607,614,636,637,710,727,736,750,757,774,803,827,853,864,866,876,892,896,904,912,914,932,936,938,992,999,1001,1046,1047,1050,1054,1060,1064,1080,1101,1110,1132,1134,1150,1176,1182,1201,1204,1212,1214,1217,1218,1236,1243,1248,1249,1253,1254,1287,1292,1301,1309,1316,1318,1321,1329,1345,1348,1367,1370,1377,1379,1380,1400,1401,1420,1449,1464,1474,1480,1482,1486,1487,1488,1489,149","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,3F32_A,Governmental Organizations|NIH Initiatives,"11752113,17287498,17346857,19346473,19777064,8875327",0,10.1002/(sici)1097-4547(19960901)45:5&lt;631::aid-jnr12&gt;3.0.co;2-1|10.1016/j.neurobiolaging.2007.02.009|10.1073/pnas.0810590106|10.1124/jpet.300.1.172|10.1371/journal.pone.0007150|10.1523/jneurosci.5320-06.2007,NULL,3F32_A,NULL
485290,2,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|_Assay Provider: Yves Pommier and Christophe Marchand, National Cancer Institute_|_Assay Title: qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1)_|__|_Assay Overview:_|__|_Human tyrosyl-DNA phosphodiesterase I (Tdp1) is a rational anticancer target because this enzyme is involved in the repair of DNA lesions created by the trapping of human DNA topoisomerase I (Top1) following treatment by antican",2,National Center for Advancing Translational Sciences (NCATS),TDP1826,20100928,"11,13,51,66,72,119,135,174,177,178,180,185,187,190,191,196,199,204,205,206,224,227,239,240,241,243,244,253,261,263,273,275,277,289,298,299,300,304,311,323,335,338,342,359,366,370,379,398,401,403,408,412,447,450,453,460,462,464,471,525,527,535,546,547,564,588,594,595,596,607,610,612,614,636,650,660,681,698,700,701,702,710,713,727,736,750,753,757,774,785,795,803,827,830,836,846,847,853,863,864,866,876,887,892,896,903,904,912,914,931,932,936,938,942,949,957,967,978,985,991,992,995,996,999,1001,1004,1017,1018,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,1JY1_A,Governmental Organizations|NIH Initiatives,"16618796,16864780,17576665,18473723,19139134",0,10.1073/pnas.0604348103|10.1093/nar/gkm463|10.1124/mol.105.021865|10.1158/1535-7163.mct-08-0878|10.2174/187152008784220357,NULL,1JY1_A,NULL
485367,2,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_Grant: 1 R03 MH092153-01_|_PI Name: Malcolm Walkinshaw, University of Edinburgh_|__|_NCGC Assay Overview:_|__|_Various species of the protozoan family Trypanosomatidae are responsible for a range of serious human diseases in tropical and subtropical areas of the world. The subspecies Trypanosoma brucei is one of three known to cause sleeping sickness in sub-Saharan Africa, significantly contributing to the mi",2,National Center for Advancing Translational Sciences (NCATS),PFK002,20101105,"6,72,119,137,174,191,204,229,243,253,289,298,299,303,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,803,864,892,899,904,931,932,936,938,957,995,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2002,20","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",3656265,NULL,XP_843920,Governmental Organizations|NIH Initiatives,"11512153,15955817,19084537",0,10.1016/j.jmb.2008.11.047|10.1054/drup.2000.0177|10.1074/jbc.m502403200,NULL,XP_843920,NULL
485341,2,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|_Assay Provider: Professor Brian Shoichet, UCSF_|__|_Assay Overview:_|_This aggregation profiling approach exploits the sensitivity of aggregate formation to detergent. Inhibition of b-lactamase is measured in the presence and absence of 0.01% Triton X-100. This particular assay had the prescence of 0.01% Triton X-100. See Pubchem assay ""Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without de",2,National Center for Advancing Translational Sciences (NCATS),AMPC203,20101004,"6,72,119,137,174,191,204,229,243,253,289,298,299,303,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,803,864,892,899,904,931,932,936,938,957,995,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2002,20","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",NULL,NULL,2HDS_A,Governmental Organizations|NIH Initiatives,"13678405,16408018,16570910,17149857,17191086,17447748,18333608,63767",0,10.1016/s0140-6736(76)92058-4|10.1021/jm030266r|10.1021/jm060029z|10.1021/jm061103g|10.1021/jm061317y|10.1021/jm701500e|10.1038/nchembio718|10.1038/nprot.2006.77,NULL,1C3B_A,NULL
485353,2,qHTS of Yeast-based Assay for SARS-CoV PLP,NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Centers Network [MLPCN]_|__|_MLPCN Grant: NS063854-01_|_Assay Submitter (PI): Daniel Engel_|__|_PLP is a viral protease from SARS-CoV that is important in virus maturation. We have developed an assay for high-throughput chemical screens for inhibitors of the SARS-coronavirus (SARS-CoV) protein PLP. The basic format of the assays involves expression of the viral proteins in budding yeast S. cerevisiae. We showed previously that expression of,2,National Center for Advancing Translational Sciences (NCATS),PLP5122,20101112,"72,119,137,174,191,204,243,253,298,299,303,323,335,338,366,379,441,460,464,499,525,546,547,564,588,637,660,701,774,803,864,904,931,932,936,938,957,995,1017,1030,1046,1047,1066,1101,1150,1201,1309,1318,1329,1345,1367,1400,1401,1474,1483,1491,1492,1539,1646,1676,1688,1727,1730,1738,1742,1775,1780,1814,1820,1832,1833,1853,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1986,1988,2000,2002,2007,2015,2018,2048,2082,2092,2108,2118,2123,2125,2132,2153,2154,2159,2161,2165,2170,2181,2187,2196,2197,2202,2203,2","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",1489680,NULL,NP_828849,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P0C6X7,"COVID-19, COVID19, Coronavirus, Corona-virus, SARS, SARS2, SARS-CoV, SARS-CoV-2 [as per BioAssay]"
485297,2,qHTS Assay for Rab9 Promoter Activators,NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|__|_MLPCN Grant: MH089537-01_|_Assay Submitter (PI): Yiannis A. Ioannou_|__|_NCGC Assay Overview:_|_Niemann Pick Type C (NPC) is a rare neurodegenerative lipidosis that is characterized by lipid storage in the endosomal/lysosomal system.  Treatment modalities for this devastating disease are currently non-existent due to the severe obstacles associated with accessing the central nervous system with protei,2,National Center for Advancing Translational Sciences (NCATS),RAB9542,20100929,"6,72,119,137,138,178,191,199,204,229,237,248,249,253,275,286,289,298,299,303,305,323,338,366,401,441,444,460,462,464,471,487,499,525,535,546,547,564,588,597,637,650,681,698,701,727,774,785,787,803,838,864,892,896,899,903,931,932,936,938,951,957,1017,1018,1030,1045,1046,1047,1066,1088,1101,1102,1103,1123,1150,1174,1201,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1292,1302,1309,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,13","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",9367,NULL,NP_004242,Governmental Organizations|NIH Initiatives,"11001808,15465421",0,10.1006/mgme.2000.3061|10.1016/j.bbalip.2004.08.006,NULL,P51151,NULL
485313,2,qHTS Assay for NPC1 Promoter Activators,NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|__|_MLPCN Grant: MH089375-01A1_|_Assay Submitter (PI): Yiannis A. Ioannou_|__|_NCGC Assay Overview:_|_Niemann Pick Type C (NPC) is a rare neurodegenerative lipidosis that is characterized by lipid storage in the endosomal/lysosomal system.  Treatment modalities for this devastating disease are currently non-existent due to the severe obstacles associated with accessing the central nervous system with prot,2,National Center for Advancing Translational Sciences (NCATS),NPC1542,20101004,"6,72,119,137,138,178,191,199,204,229,237,248,249,253,275,286,289,298,299,303,305,323,338,366,401,441,444,460,462,464,471,487,499,525,535,546,547,564,588,597,637,650,681,698,701,727,774,785,787,803,838,864,892,896,899,903,931,932,936,938,951,957,1017,1018,1030,1045,1046,1047,1066,1088,1101,1102,1103,1123,1150,1174,1201,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1292,1302,1309,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,13","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",4864,NULL,NP_000262,Governmental Organizations|NIH Initiatives,"11001808,15465421",0,10.1006/mgme.2000.3061|10.1016/j.bbalip.2004.08.006,NULL,O15118,NULL
485298,2,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|__|_MLPCN Grant: MH081279-01_|_Assay Submitter (PI): Jodi M. Nunnari_|__|_NCGC Assay Overview:_|__|_The budding yeast S. cerevisiae is a powerful system to study mitochondrial fusion. Unlike other organisms, yeast cells without functional mitochondrial DNA (mtDNA) can be propagated and studied as long as they maintain a mitochondrial compartment and are provided with a fermentable carbon source. When mito",2,National Center for Advancing Translational Sciences (NCATS),MITO372,20100929,"6,72,119,137,138,178,191,199,204,229,237,248,249,253,275,286,289,298,299,303,305,323,338,366,401,441,444,460,462,464,471,487,499,525,535,546,547,564,588,597,637,650,681,698,701,727,774,785,787,803,838,864,892,896,899,903,931,932,936,938,951,957,1017,1018,1030,1045,1046,1047,1066,1088,1101,1102,1103,1123,1150,1174,1201,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1292,1302,1309,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,13","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
485349,2,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Centers Network [MLPCN]_|__|_MLPCN Grant: MH089030-01_|_Assay Submitter (PI): Wei Zheng and Yosef Shiloh_|__|_Ataxia-telangiectasia (A-T) is a devastating and progressive disease for which, there is no cure. Although A-T is a multisystem disease, it is stereotyped characterized by its neurological symptoms such as truncal ataxia, due to cerebellar cortical degeneration of the Purkinje and granule cells. Other symptoms of A-T are telangiecta",2,National Center for Advancing Translational Sciences (NCATS),ATM5035,20101004,"6,72,119,137,174,191,204,229,243,253,289,298,299,303,323,335,338,366,379,441,460,464,487,499,525,547,564,588,597,637,660,698,701,727,774,803,864,892,899,904,931,932,936,938,957,995,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2002,2007,2015,2","842121,842122,842123,842124,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842160,842161,842162,842163,842164,842165,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,8",472,NULL,NP_000042,Governmental Organizations|NIH Initiatives,NULL,0,NULL,2.7.11.1,Q13315,NULL
485273,1,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number:  1R03 MH085677-01_|_Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_Tumor Necrosis Factor Receptor-Associated Factors (TRAFs) are a family of adapter proteins that bind an unusual ubiquitin-conjugating enzyme, Ubc13, which pr",14,Burnham Center for Chemical Genomics,SBCCG-A429-UBC13-Primary-TR-FRET-Assay,20101004,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,412,441,460,464,487,499,525,546,547,564,597,637,660,698,701,727,802,803,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1609,1639,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,1826,1832","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",7334,NULL,NP_003339,NIH Initiatives,"10837071,11057907,11477402,12834344,14579250,15147900,16056267,16862162,16893187,17114420,17404240",0,10.1002/bies.10352|10.1016/j.febslet.2004.04.038|10.1016/s0092-8674(00)00126-4|10.1021/bi034480t|10.1021/bi060631r|10.1038/90609|10.1038/ncb0805-758|10.1038/ni1367|10.1073/pnas.0700548104|10.1146/annurev.immunol.18.1.621|10.4049/jimmunol.177.11.7520,2.3.2.23,P61088,NULL
485360,2,qHTS Assay for the Inhibitors of L3MBTL1,The histone code is comprised of many post-translational modifications that occur mainly in histone tail peptides. The identity and location of these marks are read by a variety of histone binding proteins that are emerging as important regulators of cellular differentiation and development and are increasingly being implicated in numerous disease states.  Small molecule probes that disrupt the interaction between histone binding proteins and chromatin would enable a systematic chemical biology study of pro,2,National Center for Advancing Translational Sciences (NCATS),L3MB101,20101005,"6,72,119,137,174,191,204,229,243,253,289,298,299,323,335,338,379,441,464,487,525,546,564,597,660,698,701,727,774,803,864,892,899,904,931,932,936,938,957,995,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1400,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1893,1922,1967,1981,1983,1985,1986,1988,1989,2000,2002,2007,2015,2020,2052,2082,2108,2117,2122,2123,2148,2151,2153,","842122,842123,842124,842125,842126,842127,842129,842130,842131,842132,842133,842134,842135,842136,842138,842140,842141,842144,842145,842146,842147,842148,842150,842151,842152,842154,842157,842160,842161,842162,842163,842164,842165,842166,842167,842170,842171,842172,842173,842176,842178,842179,842180,842181,842183,842184,842185,842186,842188,842189,842190,842192,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842207,842208,842209,842210,842212,842213,842214,842215,842216,8",26013,NULL,NP_056293,Governmental Organizations|NIH Initiatives,"18026117,20008125",0,10.1038/nsmb1340|10.1177/1087057109352902,NULL,Q9Y468,NULL
485346,1,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number: R03 MH089489-01_|_Assay Provider: Dr. Geoffrey M. Wahl, Salk Institute for Biological Studies, La Jolla, CA_|__|_A wild type but attenuated p53 is retained in approximately 50% of human tumors, and reactivation of p53 in such tumors is an attractive chemotherapeutic strate",14,Burnham Center for Chemical Genomics,SBCCG-A439-Mdm2-MdmX-Primary-Assay,20101004,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,412,441,460,464,487,499,525,546,547,564,597,637,660,698,701,727,802,803,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1609,1639,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1780,1794,1795,1814,1820,1826,1832","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8","4193,4194",NULL,"NP_002383,NP_002384",NIH Initiatives,"10722742,10827196,11403293,11528400,11917093,15284440,16204450,16540668,16905541,16905769,17616658,18219319,18677113,7477326",0,10.1021/ac0013296|10.1038/378203a0|10.1038/ng714|10.1038/sj.cdd.4402309|10.1073/pnas.0404041101|10.1074/jbc.275.12.8945|10.1074/jbc.c600147200|10.1074/jbc.m003496200|10.1074/jbc.m605405200|10.1093/nar/gni145|10.1152/physrev.00027.2001|10.1158/0008-5472.can-05-3832|10.1158/0008-5472.can-07-1313|10.4161/cc.6365,2.3.2.27,"O15151,Q00987",NULL
485317,1,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,"Keywords: Mitochondria, biogenesis, protein import, intermembrane space, FAD, sulfhydryl oxidase, ALR, Erv1_|__|_Assay Overview:_|_Screen for inhibitors of purified, recombinant ALR to oxidize the generic substrate DTT.  Oxidation of DTT by ALR produces hydrogen peroxide, which was detected using horseradish peroxidase (HRP) and luminol.  A solution of ALR and HRP was added to plates containing compounds, followed by the addition of DTT.  The plates were incubated for 2 hours prior to the addition of the lu",31,Broad Institute,2036-02_Inhibitor_SinglePoint_HTS,20101018,"6,19,72,86,109,119,127,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,487,499,525,546,547,588,597,637,698,701,727,802,803,864,892,896,899,903,931,932,938,942,957,978,992,1001,1017,1018,1030,1047,1057,1066,1088,1123,1150,1174,1176,1201,1233,1245,1292,1302,1330,1340,1359,1365,1367,1369,1401,1474,1483,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1727,1730,1738,1742,1761,1775,1794,1795,1826,1833,1853,1858,1864,1868,1882,1889,1890,1892,1893,1917,1923,1983,1985,1986,1989,19","842121,842122,842123,842124,842125,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842150,842151,842152,842153,842154,842155,842156,842157,842162,842163,842164,842166,842167,842168,842169,842170,842171,842172,842174,842178,842179,842180,842181,842182,842183,842184,842186,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842203,842205,842207,842208,842209,842210,842211,842213,8",2671,Biochemical,NP_005253,NIH Initiatives,NULL,0,NULL,1.8.3.2,P55789,NULL
485347,1,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Centers Network [MLPCN]_|__|_MLPCN Grant: NS064831-01_|_Assay Submitter (PI): David Sibley_|__|_Dopamine receptors (DARs) are involved in the etiology and/or therapy of a number of neuropsychiatric and endocrine disorders. For instance, all receptor-based antiparkinsonian drugs work via stimulating the D2 DAR subtype whereas all FDA-approved antipsychotic agents are antagonists of this receptor. Most drugs targeting the D2 DAR are problemat",2,National Center for Advancing Translational Sciences (NCATS),DOP2201,20101005,"6,72,119,137,191,204,229,253,289,298,299,303,323,338,366,441,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,803,892,899,931,932,936,938,957,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1988,1989,2000,2002,2007,2015,2018,2020,2048,2052,2082,2092","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842192,842193,842195,842196,842197,842198,8",1813,NULL,NP_000786,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P14416,NULL
485344,1,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Centers Network [MLPCN]_|__|_MLPCN Grant: NS064831-01_|_Assay Submitter (PI): David Sibley_|__|_Dopamine receptors (DARs) are involved in the etiology and/or therapy of a number of neuropsychiatric and endocrine disorders. For instance, all receptor-based antiparkinsonian drugs work via stimulating the D2 DAR subtype whereas all FDA-approved antipsychotic agents are antagonists of this receptor. Most drugs targeting the D2 DAR are problemat",2,National Center for Advancing Translational Sciences (NCATS),DOP2301,20101004,"6,72,119,137,191,204,229,253,298,299,303,323,338,366,441,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,803,892,899,931,932,936,938,957,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1988,1989,2000,2002,2007,2015,2018,2020,2048,2052,2082,2092,210","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842192,842193,842197,842198,842199,842200,842202,842203,8",1813,NULL,NP_000786,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P14416,NULL
485275,1,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,"UNM CMD Assay Overview:_|_Assay Support:  1 R03 MH087406-01A1    _|_Project Title:  Identification of broad-spectrum antifungal efflux pump inhibitors  _|_PI:  Richard Cannon_|_Screening Center PI:  Larry Sklar_|_Chemistry Center PI:  Craig Lindsley _|__|_Assay Implementation:  J Jacob Strouse, Susan Young, Stephanie Chavez, Dominique Perez, Matthew Garcia, Travis Houston, Keon Ahghar, Terry Foutz, Anna Waller, Annette Evangelisti, Mark Carter, Virginia Salas_|__|_Assay Background and Significance:_|__|_Fun",6,NMMLSC,UNM_CMD_phenotypic_multiplex_HTS_for_antifungal efflux_pump_inhibitors,20120309,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",NULL,NULL,NULL,NIH Initiatives,"15486081,1718242,19366916,20717788,3378546",0,10.1007/978-1-60761-820-1_15|10.1093/jac/dkh456|10.1128/cmr.00051-08,NULL,NULL,NULL
485358,1,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Centers Network [MLPCN]_|__|_MLPCN Grant: NS064831-01_|_Assay Submitter (PI): David Sibley_|__|_Dopamine receptors (DARs) are involved in the etiology and/or therapy of a number of neuropsychiatric and endocrine disorders. For instance, all receptor-based antiparkinsonian drugs work via stimulating the D2 DAR subtype whereas all FDA-approved antipsychotic agents are antagonists of this receptor. Most drugs targeting the D2 DAR are problemat",2,National Center for Advancing Translational Sciences (NCATS),DOP2101,20101005,"6,72,119,137,191,204,229,253,298,299,303,323,338,366,441,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,803,892,899,931,932,936,938,957,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1988,1989,2000,2002,2007,2015,2018,2020,2048,2052,2082,2092,210","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842192,842193,842195,842197,842198,842199,842200,8",1813,NULL,NP_000786,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P14416,NULL
485270,1,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Patricia McDonald, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R01 DA023915-02_|_Grant Proposal PI: Patricia McDonald_|_External Assay ID: OX1R_ANT_FRET_1536_1X%INH PRUN IP-ONE_|__|_Name: FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 r",5,The Scripps Research Institute Molecular Screening Center,OX1R_ANT_FRET_1536_1X%INH PRUN IP-ONE,20100924,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",3061,Cell-based,NP_001516,NIH Initiatives,"10485925,10860858,11394998,15217328,17629964,17959251,18370232,18382464,18423425,19207823,19363060,19596018,19656173,9419374,9491897",0,10.1006/bbrc.2000.2880|10.1007/978-1-59745-205-2_6|10.1016/j.biopsych.2008.03.006|10.1016/j.neuropharm.2009.07.008|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2007.06.001|10.1016/s0092-8674(00)80949-6|10.1016/s0896-6273(01)00293-8|10.1038/nrd2518|10.1073/pnas.95.1.322|10.1073/pnas.96.19.10911|10.1111/j.1365-2826.2009.01824.x|10.1111/j.1460-9568.2009.06844.x|10.1124/jpet.109.152009|10.1146/annurev.neuro.27.070203.144206,NULL,O43613,NULL
485272,1,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Paul Thompson, University of South Carolina_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R01 GM079357-01_|_Grant Proposal PI: Paul Thompson_|_External Assay ID: PAD4_INH_FP_1536_1X%INH PRUN_|__|_Name: Fluorescence polarization-based primary biochemical high throughput screening assay to identify ",5,The Scripps Research Institute Molecular Screening Center,PAD4_INH_FP_1536_1X%INH PRUN,20100924,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,253,289,298,299,303,311,323,335,338,366,379,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",23569,Biochemical,NP_036519,NIH Initiatives,"12776222,14579251,15020330,15899032",0,10.1002/bies.10357|10.1038/nrd1109|10.1136/ard.2003.012211|10.1186/ar1697,3.5.3.15,Q9UM07,NULL
485350,1,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,"Aryl acid adenylating enzymes (AAAEs) are involved in siderophore biosynthesis in Mycobacterium tuberculosis, Yersinia pestis, Escherichia coli, Vibrio cholerae, Bacillus subtilis, and Acinetobacter baumannii.  The design and synthesis of a fluorescent probe Fl-Sal-AMS 6 based on the tight-binding inhibitor 5'-O-[N-(salicyl)sulfamoyl]adenosine (Sal-AMS) enabled the performance of a 384-well format high-throughput screen against BasE, an AAAE from A. baumannii involved in production of the siderophore acinet",46,"ICCB-Longwood Screening Facility, Harvard Medical School",HMS800,20161019,"89,108,119,127,190,204,253,303,311,323,325,340,346,370,397,437,564,675,727,774,782,785,830,863,864,873,896,904,914,932,938,994,1002,1046,1066,1072,1134,1148,1150,1176,1188,1203,1204,1234,1236,1309,1321,1348,1359,1366,1377,1379,1380,1400,1420,1433,1449,1464,1493,1539,1560,1563,1570,1609,1645,1646,1649,1720,1727,1732,1754,1756,1775,1780,1781,1825,1830,1833,1853,1863,1880,1890,1892,1960,1967,1981,1983,1984,1985,1986,1989,1990,1995,2004,2005,2046,2049,2051,2063,2075,2081,2082,2083,2092,2116,2117,2120,2122,2123,","92117389,92117390,92117391,92117392,92117393,92117394,92117395,92117396,92117397,92117398,92117399,92117400,92117401,92117402,92117403,92117404,92117405,92117406,92117407,92117408,92117409,92117410,92117411,92117412,92117413,92117414,92117415,92117416,92117417,92117418,92117419,92117420,92117421,92117422,92117423,92117424,92117425,92117426,92117427,92117428,92117429,92117430,92117431,92117432,92117433,92117434,92117435,92117436,92117437,92117438,92117439,92117440,92117441,92117442,92117443,92117444,92117445",NULL,NULL,YP_001085402,Research and Development,"18690677,18928302",0,10.1021/bi801625b|10.1021/jm800567v,NULL,YP_001085402,NULL
485395,0,A screen for compounds that inhibit the activity of Staphylococcus aureus DNA helicase,"Antibacterial compounds with new mechanisms of action are needed for effective therapy against drug-resistant pathogens in the clinic and in biodefense. Inhibitors of the essential replicative helicase of Staphylococcus aureus were identified using an assay based on the helicase-mediated dissociation of two annealed oligonucleotides, one with a fluorescent label, the other bearing a quencher moiety.  Two complementary annealed 60-mer oligonucleotides with noncomplementary 30-mer ends were labeled, respectiv",46,"ICCB-Longwood Screening Facility, Harvard Medical School",HMS661,20161019,"108,127,303,311,325,340,346,366,397,437,464,675,782,873,896,994,1134,1148,1188,1203,1309,1366,1539,1570,1599,1775,1802,1814,1833,1890,1892,1995,2048,2123,2193,2240,2678,2788,2877,3157,3195,3306,3512,3712,3778,3789,3798,3845,3858,3913,4030,4133,4237,4411,4436,4653,4782,4990,5010,5070,5071,5155,5213,5280,5386,5418,5531,5595,5792,5827,5861,5899,5931,6009,6018,6035,6043,6096,6142,6168,6637,6661,6748,6808,6813,6821,6837,6844,6855,6862,6885,6890,6918,6942,6993,7026,7036,7038,7050,7053,7058,7060,7064,7075,7083,709","92117389,92117390,92117391,92117392,92117393,92117394,92117395,92117396,92117397,92117398,92117399,92117400,92117401,92117402,92117403,92117404,92117405,92117406,92117407,92117408,92117409,92117410,92117411,92117412,92117413,92117414,92117415,92117416,92117417,92117418,92117419,92117420,92117421,92117422,92117423,92117424,92117425,92117426,92117427,92117428,92117429,92117430,92117431,92117432,92117433,92117434,92117435,92117436,92117437,92117438,92117439,92117440,92117441,92117442,92117443,92117444,92117445",NULL,NULL,YP_001315171,Research and Development,19477652,0,10.1016/j.bmc.2009.05.014,NULL,YP_001315171,NULL
485345,2,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLSCN Grant: 1 R03 DA031086-01A1_|_PI Name: Dr. R. Eric Davis_|__|_NCGC Assay Overview:_|__|_Diffuse large B-cell lymphoma (DLBCL) is the most common category of non-Hodgkin lymphoma, with ~20,000 new cases per year in the United States. DLBCL should be regarded as a collection of different neoplasms. Microarray gene expression analysis has defined two principal types of DLBCL, named for their similarity to n",2,National Center for Advancing Translational Sciences (NCATS),TMD8001,20101223,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"11748286,16572121,17355202,20054396",0,10.1038/nature04687|10.1038/nature08638|10.1084/jem.194.12.1861|10.1089/adt.2006.048,NULL,NULL,NULL
485342,2,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLSCN Grant: 1 R03 MH087464-01A1_|_PI Name: Dr. Eric Freed, NCI_|__|_NCGC Assay Overview:_|__|_Stages of the HIV-1 replication cycle, specifically virus assembly and release, provide underexploited targets for the development of novel antiviral inhibitors.  The late stages of HIV-1 replication are mediated by the Gag precursor protein, Pr55Gag.  Expression of Pr55Gag is both necessary and sufficient for the p",2,National Center for Advancing Translational Sciences (NCATS),TSG001,20101105,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",7251,NULL,NP_006283,Governmental Organizations|NIH Initiatives,18083557,0,10.1016/j.bmcl.2007.12.003,NULL,Q99816,NULL
485318,2,Histone deacetylase 3 counterscreen for GASC1 inhibitors Measured in Biochemical System Using Plate Reader - 2043-03_Inhibitor_Dose_CherryPick,"Keywords:  histone deacetylase, HDAC3, epigenetics_|__|_Assay Overview: Histone deacetylase 3 (HDAC3) is a metal-dependent chromatin modifying enzyme, as is the primary target in this project, JMJD2C histone demethylase.  There are also reports of passive relationships between histone demethylation and histone deacetylation.  To eliminate non-specific compound such as metal chelators, active compound from the primary demethylase screen are counterscreened against HDAC3 in this assay.  HDAC3 is incubated wit",31,Broad Institute,2043-03_Inhibitor_Dose_CherryPick,20100929,"2052,5712,10365,66541,70262,85511,91440,91458,92123,135728,147514,193147,197690,256659,268524,271643,288131,360404,404524,444913,460747,518566,535921,548037,548573,562880,570654,576784,581119,601428,604485,607443,611070,612869,625794,644603,644638,644839,645508,645628,645747,645763,645968,646129,646148,646170,646330,646531,646859,646912,647339,647341,647739,647873,647977,648090,648292,648314,648319,648482,648575,648694,648794,648879,649212,649299,649861,649926,649950,650034,650046,650162,650194,650253,65057","842345,842370,842570,843224,843337,843451,843468,843824,843843,843866,844019,844020,844219,844532,844585,845001,845396,845524,845622,845728,845924,845946,845951,846110,846193,846308,846403,846604,846730,846819,846906,847132,847456,847521,847632,847753,847778,847839,848143,848534,848662,848893,848914,849079,849117,849871,850026,850066,850083,850153,850256,850699,850701,850773,850986,851213,851220,851247,851255,851357,851400,851718,851796,851914,852326,852585,852991,853122,853675,856727,856901,857016,857088,8",8841,Biochemical,NP_003874,NIH Initiatives,"16732293,19234612",0,10.1038/nature04837|10.1371/journal.pone.0004556,3.5.1.98,O15379,NULL
485295,2,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,"B Subtilis DNA polymerase III holoenzyme complex was assayed for DNA production by fluorescent detection of the double-stranded DNA product with PicoGreen dye. The holoenzyme complex was reconstituted from the following purified protein components: DNA Polymerase III, beta subunit processivity factor, SSB single-stranded DNA binding protein, and Primase. Single-stranded, circular M13Gori was used as a substrate with dNTPs and NTPs also supplied to the substrate reagent. Compounds from the NCGC collection we",2,National Center for Advancing Translational Sciences (NCATS),POL3001,20110419,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",NULL,NULL,AAP13898,Governmental Organizations|NIH Initiatives,"11439188,16864780,8891218",0,10.1016/s0092-8674(01)00400-7|10.1073/pnas.0604348103|10.2144/96214st04,NULL,AAP13898,NULL
485366,2,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|_MLSCN Grant: Fast-track/HHSN271700800025C_|_PI: Bryan Roth and Bob Lefkowitz_|__|_The concept of biased agonism [1] is an emerging concept of molecular pharmacology which proposes that seven transmembrane receptors (7TMRs) or G protein-coupled receptors (GPCRs), exist in multiple signaling conformations and complexes and that ligands (either agonists or antagonists) can induce signaling biased responses for dist",2,National Center for Advancing Translational Sciences (NCATS),TANGO001,20101104,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",154,NULL,NP_000015,Governmental Organizations|NIH Initiatives,"17305471,17644195,17925438,18165312",0,10.1016/j.tips.2007.06.006|10.1073/pnas.0707936104|10.1073/pnas.0710487105|10.1146/annurev.physiol.69.022405.154749,NULL,P07550,NULL
485368,2,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_Grant: 1 R03 MH092153-01_|_PI Name: Malcolm Walkinshaw, University of Edinburgh_|__|_NCGC Assay Overview:_|__|_Various species of the protozoan family Trypanosomatidae are responsible for a range of serious human diseases in tropical and subtropical areas of the world. The subspecies Trypanosoma brucei is one of three known to cause sleeping sickness in sub-Saharan Africa, significantly contributing to the mi",2,National Center for Advancing Translational Sciences (NCATS),PFK001,20101025,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",3656265,NULL,XP_843920,Governmental Organizations|NIH Initiatives,"11512153,15955817,19084537",0,10.1016/j.jmb.2008.11.047|10.1054/drup.2000.0177|10.1074/jbc.m502403200,NULL,XP_843920,NULL
485351,2,SAR analysis of Ubc13-Ubiquitination selectivity in a TR-FRET assay for In Vitro dose response studies - set 2,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Institute for Medical Research (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH084862-01_|_Assay Provider: Dr. Yuan Chen, Beckman Research Institute, City Of Hope, CA_|__|_Protein modification by the SUMO (Small Ubiquitin-like MOdifier) family of proteins is an important post-translational modification that plays an essential role ",14,Burnham Center for Chemical Genomics,SBCCG-A442-SUMO-UBC13-DryPowder-Assay-2,20101005,"658797,658849,658861,665380,987585,1348924,1666392,1886648,1892578,1902320,1902331,1906557,1909175,1910302,1912891,1925988,1930124,1934962,1942142,1951332,1964696,2309497,2316932,2323827,3159328,5441539,5973446,8057317,8073461,16127219,16456927,17580184,17583801,17585522,46835069,46835070,46835071,46835072,46835073,46835074,46835075,46835076,46835077,46835078,46835079,46835080,46835081,46835082,46835083,46835084,46835085,46835086,46835087,46835088,46835089,46835090,46835091,46835092,46835093,46835095,468350","87544572,87544573,87544576,87544577,89650182,89650183,89650184,89650185,89650186,89650187,89650188,89650189,92310254,92310255,92310256,92310257,92310258,92310259,92310260,92310261,92310262,92310263,92310264,92310265,92310268,92310269,92310270,92310271,92310272,92310273,92310274,92310275,92310276,99212953,99212954,99212955,99212956,99212957,99212958,99212959,99212960,99212961,99212962,99212963,99212964,99212965,99212966,99212967,99212968,99212969,99212970,99212971,99212972,99212973,99212974,99212975,99212976","7317,7334,7335",In vitro,"NP_003325,NP_003339,NP_068823",NIH Initiatives,"10070749,12924945,14506472,15189146,15292183,15542864,15590687,17643372,18154725,9357313,9425343",0,10.1016/j.ab.2007.11.024|10.1016/j.molcel.2007.05.023|10.1016/s0955-0674(97)80079-8|10.1016/s0968-0004(97)01122-5|10.1021/bi0345283|10.1023/a:1008364314328|10.1038/nrm1200|10.1074/jbc.m407950200|10.1074/jbc.m413209200|10.1074/mcp.m400154-mcp200|10.1146/annurev.biochem.73.011303.074118,"2.3.2.23,6.2.1.45","P22314,P61088,Q13404",NULL
485299,1,Single concentration confirmation of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH089782-01_|_Assay Provider: Dr. Randal J Kaufman, University of Michigan_|__|_Tremendous advances in our understanding of pathologic mechanisms have recently revealed that defective protein processing within the secretory pathway is an integral component of many genet",14,Burnham Center for Chemical Genomics,SBCCG-A438-UPR-XBP1-Agonist-CP-Assay,20100929,"13436,64945,66479,67239,73549,94381,95168,100640,114429,228632,255326,289745,292872,301935,373127,375148,375151,441336,542139,586278,638276,646458,646464,647216,650327,650361,650979,653178,653187,653473,654937,655186,657803,658849,659124,659524,662276,662393,662572,663138,663955,665504,665518,665525,665537,665954,666419,666713,667046,667299,677881,690744,698133,710309,727631,729707,732046,732049,750915,751869,774089,781102,797378,800081,800400,802672,802888,803804,825248,826728,826945,830119,839482,843346,8","842142,844142,844148,845907,847943,848530,850491,850648,850657,851602,851635,852129,852322,852563,856443,857500,857769,858172,858893,861006,861129,861321,861678,861913,862723,864257,864271,864278,864290,864713,865169,865459,865786,3711668,3712622,3715031,3716906,3717872,4240481,4241660,4241737,4242633,4243044,4243914,4244003,4244359,4244892,4244949,4245394,4245529,4245708,4246481,4246534,4246752,4246816,4247498,4247863,4247896,4248505,4249974,4251907,4255388,4256964,4258072,4259550,4260375,4260674,4261094,4",NULL,NULL,NULL,NIH Initiatives,"10383835,17638893,18559534,19239892,9247311",0,10.1006/jsre.1999.5653|10.1016/j.cell.2009.01.042|10.1038/sj.onc.1201216|10.1158/0008-5472.can-07-0752|10.1158/0008-5472.can-08-0074,NULL,NULL,NULL
485391,2,SAR analysis of small molecule inhibitors of SUMOylation in an AlphaScreen assay in the presence of BSA,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Institute for Medical Research (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH084862-01_|_Assay Provider: Dr. Yuan Chen, Beckman Research Institute, City Of Hope, CA_|__|_Protein modification by the SUMO (Small Ubiquitin-like MOdifier) family of proteins is an important post-translational modification that plays an essential role ",14,Burnham Center for Chemical Genomics,SBCCG-A448-SUMO-AlphaScreen-BSA-DryPowder-Assay,20101007,"658797,658849,658861,665380,987585,1348924,1666392,1886648,1892578,1902320,1902331,1906557,1909175,1910302,1912891,1925988,1930124,1934962,1942142,1951332,1964696,2309497,2316932,2323827,3159328,5441539,5973446,8057317,8073461,16127219,16456927,17580184,17583801,17585522,46835069,46835070,46835071,46835072,46835073,46835074,46835075,46835076,46835077,46835078,46835079,46835080,46835081,46835082,46835083,46835084,46835085,46835086,46835087,46835088,46835089,46835090,46835091,46835092,46835093,46835095,468350","87544572,87544573,87544576,87544577,89650182,89650183,89650184,89650185,89650186,89650187,89650188,89650189,92310254,92310255,92310256,92310257,92310258,92310259,92310260,92310261,92310262,92310263,92310264,92310265,92310268,92310269,92310270,92310271,92310272,92310273,92310274,92310275,92310276,99212953,99212954,99212955,99212956,99212957,99212958,99212959,99212960,99212961,99212962,99212963,99212964,99212965,99212966,99212967,99212968,99212969,99212970,99212971,99212972,99212973,99212974,99212975,99212976","7334,10054,10055",NULL,"AAH03153,AAH18271,NP_003339",NIH Initiatives,"10070749,12924945,14506472,15189146,15292183,15542864,15590687,17643372,18154725,9357313,9425343",0,10.1016/j.ab.2007.11.024|10.1016/j.molcel.2007.05.023|10.1016/s0955-0674(97)80079-8|10.1016/s0968-0004(97)01122-5|10.1021/bi0345283|10.1023/a:1008364314328|10.1038/nrm1200|10.1074/jbc.m407950200|10.1074/jbc.m413209200|10.1074/mcp.m400154-mcp200|10.1146/annurev.biochem.73.011303.074118,2.3.2.23,"P61088,Q9UBE0,Q9UBT2",NULL
485285,2,SAR analysis of antagonists of the Cannabinoid Receptor 1 using an Image-Based Assay - Set 4,"Data Source: Sanford-Burnham Center for Chemical Genomics _|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego) _|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1X01 DA026205-01_|_Assay Provider: Dr. Mary Abood, Temple University, formerly at California Pacific Medical Center Research Institute_|_Drug addiction is a disease that involves the G-protein coupled receptors in the central nervous system resulting in compulsive or abnormal",14,Burnham Center for Chemical Genomics,SBCCG-A435-CB1-Antagonist-DryPowder-4,20110401,"651615,706463,797608,888780,939600,944642,944814,1011349,1050206,1050207,1077534,1077536,1077539,1077540,1077547,1214651,1214658,1214667,1214672,1261822,1261894,1306259,1358622,1434956,1434957,1434959,1434960,1434989,1468079,1582687,2164452,2308203,2330731,2332853,2333197,2385808,3151382,3151386,3151387,3193014,3193015,3193022,3197465,3392313,3785326,4623233,4803470,4877555,5143845,5188035,15359842,17446092,23612541,23612542,23612543,23612544,23612548,23612550,23612553,23612554,42600928,45917985,45917986,46","87225742,87225746,87225762,99303126,99303127,99303128,99303129,99303130,99303131,99303132,99303133,99303134,99303135,99303136,99303137,99303138,99303139,99303140,99303141,99303142,99303143,99303144,99303145,99303146,99303147,99303148,99303149,99303150,99303151,99303152,99303153,99303154,99303155,99303156,99303157,99303158,99303159,99303160,99303161,99303162,99303163,99303164,99303165,99303166,99303167,99303168,99303169,99303170,99303171,99303172,99303173,99303174,99303175,99303176,99303177,99303178,99303179",1268,NULL,AAI00969,NIH Initiatives,18584858,0,10.1016/j.pbb.2008.05.010,NULL,P21554,NULL
485352,2,"HTS Dose response counterscreen for assays utilizing the enzyme, beta-galactosidase - Set 2","Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research  Institute(SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1X01DA026208-01_|_Assay Provider: Dr. Lawrance Barak , Duke University, Durham, NC_|__|_b-galactosidase (b-gal), a hydrolase enzyme that catalyzes the hydrolysis of b-galactosides to monosaccharides is utilized in many different screening technologies involving enz",14,Burnham Center for Chemical Genomics,SBCCG-A440-beta-GAL-Assay-2,20110726,"3117,11100,23205,43001,82533,100520,130606,161167,200953,324450,330973,379337,379338,387104,441314,442142,568849,579121,583493,645440,659124,659805,664920,665535,665597,666884,666914,679337,718402,730662,742856,750420,761850,768313,768473,773605,780062,780302,788408,788410,788411,788612,788616,788618,788619,793621,793994,800048,801741,804442,824082,852940,854200,869765,877472,878847,878879,888488,889369,890649,902793,917183,921731,929469,930382,933895,935971,936147,938458,938551,972880,973504,977006,991372,","843162,857769,858026,858494,863665,864288,864349,865625,865656,3711096,3711949,3713089,3713364,3715849,3717466,4240645,4241083,4244630,4250780,4251553,4259886,4260021,4262714,4263281,4263860,7972392,7973186,7973917,7975274,7975750,7977964,14719042,14721057,14725477,14726207,14726352,14726414,14726422,14727957,14728334,14728505,14728719,14729216,14729228,14729238,14734078,14734290,14734519,14734630,14735144,14737257,14738788,14740656,14741408,14742588,14743166,14743666,14745104,14745782,14746294,14746760,169",NULL,NULL,CAC87491,NIH Initiatives,"15950161,18660457,19171920",0,10.1016/j.crvi.2005.03.006|10.1177/1087057108321531|10.1177/1087057108327329,NULL,Q8VNN2,NULL
485374,2,SAR analysis of small molecule inhibitors of SUMOylation in an AlphaScreen assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Institute for Medical Research (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH084862-01_|_Assay Provider: Dr. Yuan Chen, Beckman Research Institute, City Of Hope, CA_|__|_Protein modification by the SUMO (Small Ubiquitin-like MOdifier) family of proteins is an important post-translational modification that plays an essential role ",14,Burnham Center for Chemical Genomics,SBCCG-A447-SUMO-AlphaScreen-DryPowder-Assay,20101007,"658797,658861,665380,987585,1348924,1666392,1886648,1892578,1902320,1902331,1906557,1909175,1910302,1912891,1925988,1934962,1951332,1964696,2068085,2309497,2316932,2323827,3159328,5441539,5973446,8057317,8073461,16127219,16456927,17580184,17583801,17585522,44640139,46835069,46835070,46835071,46835072,46835073,46835074,46835075,46835077,46835078,46835079,46835080,46835081,46835082,46835083,46835084,46835085,46835086,46835087,46835088,46835090,46835091,46835092,46835093,46835095,46835096,46835097,46835099,468","87544582,87544856,89650182,89650183,89650184,89650185,89650186,89650187,89650188,89650189,92310254,92310255,92310256,92310257,92310258,92310259,92310260,92310261,92310262,92310263,92310264,92310265,92310268,92310269,92310270,92310271,92310272,92310273,92310274,92310275,92310276,99212953,99212954,99212955,99212956,99212957,99212958,99212959,99212960,99212961,99212962,99212963,99212964,99212965,99212966,99212967,99212968,99212969,99212970,99212971,99212972,99212973,99212974,99212975,99212976,99212977,99212978","7334,10054,10055",NULL,"AAH03153,AAH18271,NP_003339",NIH Initiatives,"10070749,12924945,14506472,15189146,15292183,15542864,15590687,17643372,18154725,9357313,9425343",0,10.1016/j.ab.2007.11.024|10.1016/j.molcel.2007.05.023|10.1016/s0955-0674(97)80079-8|10.1016/s0968-0004(97)01122-5|10.1021/bi0345283|10.1023/a:1008364314328|10.1038/nrm1200|10.1074/jbc.m407950200|10.1074/jbc.m413209200|10.1074/mcp.m400154-mcp200|10.1146/annurev.biochem.73.011303.074118,2.3.2.23,"P61088,Q9UBE0,Q9UBT2",NULL
485287,2,SAR Analysis of Selective Antagonists of GPR55 using an Image-Based Assay - Set 4,"Data Source: Sanford-Burnham Center for Chemical Genomics(SBCCG) _|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA) _|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1X01 DA026205-01_|_Assay Provider: Dr. Mary Abood, (Temple University,  formerly at California Pacific Medical Center Research Institute)_|_ _|_The cannabinoid and endocannabinoid system has been implicated in the pathophysiology of drug dependence and addiction di",14,Burnham Center for Chemical Genomics,SBCCG-A430-GPR55-Antagonist-DryPowder-Assay-4,20110401,"651615,706463,797608,888780,939600,944642,944814,1011349,1050206,1050207,1077534,1077536,1077539,1077540,1077547,1214651,1214658,1214667,1214672,1261822,1261894,1306259,1358622,1434956,1434957,1434959,1434960,1434989,1468079,1582687,2164452,2308203,2330731,2332853,2333197,2385808,3151382,3151386,3151387,3193014,3193015,3193022,3197465,3392313,3785326,4623233,4803470,4877555,5143845,5188035,15359842,17446092,23612541,23612542,23612543,23612544,23612548,23612550,23612553,23612554,42600928,45917985,45917986,46","87225742,87225746,87225762,99303126,99303127,99303128,99303129,99303130,99303131,99303132,99303133,99303134,99303135,99303136,99303137,99303138,99303139,99303140,99303141,99303142,99303143,99303144,99303145,99303146,99303147,99303148,99303149,99303150,99303151,99303152,99303153,99303154,99303155,99303156,99303157,99303158,99303159,99303160,99303161,99303162,99303163,99303164,99303165,99303166,99303167,99303168,99303169,99303170,99303171,99303172,99303173,99303174,99303175,99303176,99303177,99303178,99303179",9290,NULL,NP_005674,NIH Initiatives,"17876302,17906678,18263782,19233486,9931487",0,10.1016/j.tips.2008.12.004|10.1016/s0169-328x(98)00277-0|10.1038/sj.bjp.0707460|10.1038/sj.bjp.0707481|10.1104/pp.107.111443,NULL,Q9Y2T6,NULL
485278,2,SAR analysis of antagonists of the Cannabinoid Receptor 2 using an Image-Based Assay - Set 3,"Data Source: Sanford-Burnham Center for Chemical Genomics _|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1X01 DA026205-01_|_Assay Provider: Dr. Mary Abood, Temple University, formerly at California Pacific Medical Center Research Institute _|__|_Drug addiction is a disease that involves the G-protein coupled receptors in the central nervous system resulting in compulsive or a",14,Burnham Center for Chemical Genomics,SBCCG-A436-CB2-Antagonist-DryPowder-3,20110401,"651615,706463,797608,888780,939600,944642,944814,1011349,1050206,1050207,1077534,1077536,1077539,1077540,1077547,1214651,1214658,1214667,1214672,1261822,1261894,1306259,1358622,1434956,1434957,1434959,1434960,1434989,1468079,1582687,2164452,2308203,2330731,2332853,2333197,2385808,3151382,3151386,3151387,3193014,3193015,3193022,3197465,3392313,3785326,4623233,4803470,4877555,5143845,5188035,15359842,17446092,23612541,23612542,23612543,23612544,23612548,23612550,23612553,23612554,42600928,45917985,45917986,46","87225742,87225746,87225762,99303126,99303127,99303128,99303129,99303130,99303131,99303132,99303133,99303134,99303135,99303136,99303137,99303138,99303139,99303140,99303141,99303142,99303143,99303144,99303145,99303146,99303147,99303148,99303149,99303150,99303151,99303152,99303153,99303154,99303155,99303156,99303157,99303158,99303159,99303160,99303161,99303162,99303163,99303164,99303165,99303166,99303167,99303168,99303169,99303170,99303171,99303172,99303173,99303174,99303175,99303176,99303177,99303178,99303179",1269,NULL,NP_001832,NIH Initiatives,NULL,0,NULL,NULL,P34972,NULL
485277,2,SAR analysis of agonists of the Cannabinoid Receptor 2 using an Image-Based Assay - Set 3,"Data Source: Sanford-Burnham Center for Chemical Genomics _|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1X01 DA026205-01_|_Assay Provider: Dr. Mary Abood, Temple University, formerly at California Pacific Medical Center Research Institute _|__|_Drug addiction is a disease that involves the G-protein coupled receptors in the central nervous system resulting in compulsive or a",14,Burnham Center for Chemical Genomics,SBCCG-A433-CB2-Agonist-DryPowder-3,20110401,"651615,706463,797608,888780,939600,944642,944814,1011349,1050206,1050207,1077534,1077536,1077539,1077540,1077547,1214651,1214658,1214667,1214672,1261822,1261894,1306259,1358622,1434956,1434957,1434959,1434960,1434989,1468079,1582687,2164452,2308203,2330731,2332853,2333197,2385808,3151382,3151386,3151387,3193014,3193015,3193022,3197465,3392313,3785326,4623233,4803470,4877555,5143845,5188035,15359842,17446092,23612541,23612542,23612543,23612544,23612548,23612550,23612553,23612554,42600928,45917985,45917986,46","87225742,87225746,87225762,99303126,99303127,99303128,99303129,99303130,99303131,99303132,99303133,99303134,99303135,99303136,99303137,99303138,99303139,99303140,99303141,99303142,99303143,99303144,99303145,99303146,99303147,99303148,99303149,99303150,99303151,99303152,99303153,99303154,99303155,99303156,99303157,99303158,99303159,99303160,99303161,99303162,99303163,99303164,99303165,99303166,99303167,99303168,99303169,99303170,99303171,99303172,99303173,99303174,99303175,99303176,99303177,99303178,99303179",1269,NULL,NP_001832,NIH Initiatives,NULL,0,NULL,NULL,P34972,NULL
485283,2,SAR analysis of Antagonists of the GPR35 Receptor using an Image-Based Assay - Set 6,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1X01 DA026205-01_|_Assay Provider: Dr. Mary Abood, (Temple University, formerly at California Pacific Medical Center Research Institute)_|_ _|_Addictive behavior stems from abnormal signaling activities in the brain. Thus identification of compounds blocking this mo",14,Burnham Center for Chemical Genomics,SBCCG-A434-GPR35-Antagonist-DryPowder-6,20110401,"706463,797608,888780,939600,944642,944814,1011349,1050206,1050207,1077534,1077536,1077539,1077540,1077547,1214651,1214658,1214667,1214672,1261894,1306259,1358622,1434956,1434957,1434959,1434960,1434989,1468079,1582687,2164452,2308203,2330731,2332853,2333197,2385808,3151382,3151386,3151387,3193015,3193022,3197465,3392313,3785326,4623233,4803470,4877555,5143845,5188035,15359842,17446092,23612541,23612542,23612543,23612544,23612548,23612550,23612553,23612554,42600928,45917985,45917986,46864267,135656418,135656","99303126,99303127,99303128,99303129,99303130,99303131,99303132,99303133,99303134,99303135,99303136,99303137,99303138,99303139,99303140,99303141,99303142,99303143,99303144,99303145,99303146,99303147,99303148,99303149,99303150,99303151,99303152,99303153,99303154,99303155,99303156,99303157,99303158,99303159,99303160,99303161,99303162,99303163,99303164,99303165,99303166,99303167,99303168,99303169,99303170,99303171,99303172,99303173,99303174,99303175,99303176,99303177,99303178,99303179,99303180,99303181,99303182",2859,NULL,NP_005292,NIH Initiatives,"16934253,17906678,17940199,17996730,9479505",0,10.1006/geno.1998.5095|10.1016/j.bbrc.2007.10.197|10.1016/j.febslet.2006.08.015|10.1038/sj.bjp.0707481|10.1124/jpet.107.127266,NULL,Q9HC97,NULL
485286,2,SAR analysis of Agonists of the GPR35 Receptor using an Image-Based Assay - Set 4,"Data Source: Sanford-Burnham Center for Chemical Genomics _|_Source Affiliation: Sanford-Burnham Medical Research Institute_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1X01 DA026205-01_|_Assay Provider: Dr. Mary Abood, (Temple University, formerly at California Pacific Medical Center Research Institute)_|__|_Addictive behavior stems from abnormal signaling activities in the brain. Thus identification of compounds blocking this modified signaling activity may l",14,Burnham Center for Chemical Genomics,SBCCG-A431-GPR35-Agonist-DryPowder-4,20110401,"706463,797608,888780,939600,944642,944814,1011349,1050206,1050207,1077534,1077536,1077539,1077540,1077547,1214651,1214658,1214667,1214672,1261894,1306259,1358622,1434956,1434957,1434959,1434960,1434989,1468079,1582687,2164452,2308203,2330731,2332853,2333197,2385808,3151382,3151386,3151387,3193015,3193022,3197465,3392313,3785326,4623233,4803470,4877555,5143845,5188035,15359842,17446092,23612541,23612542,23612543,23612544,23612548,23612550,23612553,23612554,42600928,45917985,45917986,46864267,135656418,135656","99303126,99303127,99303128,99303129,99303130,99303131,99303132,99303133,99303134,99303135,99303136,99303137,99303138,99303139,99303140,99303141,99303142,99303143,99303144,99303145,99303146,99303147,99303148,99303149,99303150,99303151,99303152,99303153,99303154,99303155,99303156,99303157,99303158,99303159,99303160,99303161,99303162,99303163,99303164,99303165,99303166,99303167,99303168,99303169,99303170,99303171,99303172,99303173,99303174,99303175,99303176,99303177,99303178,99303179,99303180,99303181,99303182",2859,NULL,NP_005292,NIH Initiatives,"16934253,17906678,17940199,17996730,9479505",0,10.1006/geno.1998.5095|10.1016/j.bbrc.2007.10.197|10.1016/j.febslet.2006.08.015|10.1038/sj.bjp.0707481|10.1124/jpet.107.127266,NULL,Q9HC97,NULL
485282,2,SAR analysis of agonists of the Cannabinoid Receptor 1 using an Image-Based Assay - Set 4,"Data Source: Sanford-Burnham Center for Chemical Genomics _|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego) _|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1X01 DA026205-01_|_Assay Provider: Dr. Mary Abood, Temple University, formerly at California Pacific Medical Center Research Institute_|__|_Drug addiction is a disease that involves the G-protein coupled receptors in the central nervous system resulting in compulsive or abnor",14,Burnham Center for Chemical Genomics,SBCCG-A432-CB1-Agonist-DryPowder-4,20110401,"706463,797608,888780,939600,944642,944814,1011349,1050206,1050207,1077534,1077536,1077539,1077540,1077547,1214651,1214658,1214667,1214672,1261894,1306259,1358622,1434956,1434957,1434959,1434960,1434989,1468079,1582687,2164452,2308203,2330731,2332853,2333197,2385808,3151382,3151386,3151387,3193015,3193022,3197465,3392313,3785326,4623233,4803470,4877555,5143845,5188035,15359842,17446092,23612541,23612542,23612543,23612544,23612548,23612550,23612553,23612554,42600928,45917985,45917986,46864267,135656418,135656","99303126,99303127,99303128,99303129,99303130,99303131,99303132,99303133,99303134,99303135,99303136,99303137,99303138,99303139,99303140,99303141,99303142,99303143,99303144,99303145,99303146,99303147,99303148,99303149,99303150,99303151,99303152,99303153,99303154,99303155,99303156,99303157,99303158,99303159,99303160,99303161,99303162,99303163,99303164,99303165,99303166,99303167,99303168,99303169,99303170,99303171,99303172,99303173,99303174,99303175,99303176,99303177,99303178,99303179,99303180,99303181,99303182",1268,NULL,AAI00969,NIH Initiatives,18584858,0,10.1016/j.pbb.2008.05.010,NULL,P21554,NULL
485393,2,SAR analysis of the MOA of E2 SUMOylation inhibitors in an HTRF format,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH084862-01_|_Assay Provider: Dr. Yuan Chen, Beckman Research Institute, City Of Hope, CA_|__|_Protein modification by the SUMO (Small Ubiquitin-like MOdifier) family of proteins is an important post-translational modification that plays an essential role in many fun",14,Burnham Center for Chemical Genomics,SBCCG-A449-SUMO-HTRF-MOA-DryPowder-Assay,20101007,"4413,658797,658849,1080172,1098340,1098382,1098386,1098417,1177253,1226487,1358388,1399898,1564382,1909242,1930124,1942142,2068085,2092254,2096377,2096417,2142225,2364467,2384768,2435766,2553264,2587706,2868855,2972836,2972936,2975144,2978460,3151565,3152411,3154412,3612347,3753586,3901625,4008175,4082798,4240943,4321047,4360168,4502965,5013593,5130755,6874905,6875023,9549553,17608985,24761147,24761173,44640139","26513988,48410245,56373551,56373553,56373714,56373716,56373801,56373802,56373835,56373846,56405557,85176738,85256229,85285633,85285647,85285648,85285650,85285651,85285655,87544543,87544545,87544547,87544548,87544549,87544550,87544551,87544552,87544555,87544556,87544558,87544559,87544561,87544565,87544566,87544568,87544570,87544572,87544573,87544574,87544576,87544577,87544579,87544580,87544582,87544584,87544589,87544598,87544600,87544602,87544843,87544852,87544853,87544856,89650190","7329,10054,10055",NULL,"AAH03153,AAH18271,NP_003336",NIH Initiatives,"10070749,12924945,14506472,15189146,15292183,15542864,15590687,17643372,18154725,7329,9357313,9425343",0,10.1016/j.ab.2007.11.024|10.1016/j.molcel.2007.05.023|10.1016/s0955-0674(97)80079-8|10.1016/s0968-0004(97)01122-5|10.1021/bi0345283|10.1023/a:1008364314328|10.1038/nrm1200|10.1074/jbc.m407950200|10.1074/jbc.m413209200|10.1074/mcp.m400154-mcp200|10.1146/annurev.biochem.73.011303.074118,2.3.2.-,"P63279,Q9UBE0,Q9UBT2",NULL
485284,2,HTS for developing T Cell Immune Modulators: Dose-Response Assay,"University of New Mexico Assay Overview:_|_Assay Support:  1 X01 MH085707-01   _|_Project Title:  HTS for developing T Cell Immune Modulators  _|_PI:  Inkyu Hwang, PhD The Scripps Research Institute (La Jolla) _|__|_Assay Implementation:  Mark K. Haynes PhD, Chelin Hu MS, Anna Waller PhD, Mark Carter MS_|_UNM CMD PI: Larry Sklar PhD_|__|_Assay Background and Significance:_|__|_When naive T cells encounter antigen presenting cells (APC) displaying cognate MHC-peptide complexes (pMHCs), the T cell and the APC",6,NMMLSC,UNM_LFA-1_T-Cell_Microvesicle_Binding_DR,20101112,"19646,91649,223613,619952,628013,648494,650648,651491,652940,656205,659809,661364,666520,684085,687167,688679,691379,698250,700599,702175,707191,715211,726602,739039,752372,772528,802474,845536,864614,870743,897374,947664,972317,977839,1017208,1072843,1072886,1087723,1091486,1105480,1114147,1178532,1262873,1304167,1305730,1327626,1339945,1416331,1451421,1460022,1477390,1484365,1489664,1490992,1504703,1849030,1918453,1971650,2041313,2082712,2121446,2125737,2128353,2137938,2197124,2201629,2334577,2386733,2396","844740,846123,848221,849025,850250,850419,853546,856319,858498,860058,863767,865266,3711167,3713689,3713987,3715513,4241715,4243865,4244816,4247430,4249440,4250290,4250681,4251886,4254500,4254636,4255737,4262021,4262376,4262816,4264072,4264314,4264738,7965435,7966250,7966979,7967220,7967436,7969296,7969486,7969877,7970224,7972724,7972914,7973223,7974422,14722554,14722998,14723003,14729276,14729755,14730059,14732957,14735154,14736582,14737490,14737587,14737622,14738122,14742902,14743040,14744781,17403172,174",NULL,NULL,NULL,NIH Initiatives,"12732350,12734401,12743365,14500982,16855047,17073678,17624950,17624952,19258452",0,10.1016/s0196-9781(03)00083-4|10.1073/pnas.0603466103|10.1073/pnas.0810844106|10.1073/pnas.1131852100|10.1111/j.1600-065x.2007.00526.x|10.1111/j.1600-065x.2007.00537.x|10.1126/science.1084174|10.1242/jcs.00465|10.2174/138161206778559696,NULL,NULL,NULL
485337,2,SAR analysis of SUMOylation using HTRF in an in-Vitro dose response assay - Set 2,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH084862-01_|_Assay Provider: Dr. Yuan Chen, Beckman Research Institute, City Of Hope, CA_|__|_Protein modification by the SUMO (Small Ubiquitin-like MOdifier) family of proteins is an important post-translational modification that plays an essential role in many fun",14,Burnham Center for Chemical Genomics,SBCCG-A441-SUMO-HTRF-DryPowder-Assay-2,20101001,"658861,665380,987585,1348924,1886648,1892578,1902320,1902331,1906557,1909175,1910302,1912891,1925988,1934962,1951332,1964696,2068085,2309497,2316932,3159328,5441539,5973446,8057317,8073461,16456927,17580184,17583801,17585522,44640139,135603927","87544582,87544856,89650182,89650183,89650184,89650185,89650186,89650187,89650188,89650189,92310254,92310255,92310256,92310257,92310258,92310259,92310260,92310261,92310262,92310263,92310264,92310265,92310268,92310269,92310270,92310271,92310272,92310273,92310274,92310275,92310276","7329,10054,10055",In vitro,"AAH03153,AAH18271,NP_003336",NIH Initiatives,"10070749,12924945,14506472,15189146,15292183,15542864,15590687,17643372,18154725,9357313,9425343",0,10.1016/j.ab.2007.11.024|10.1016/j.molcel.2007.05.023|10.1016/s0955-0674(97)80079-8|10.1016/s0968-0004(97)01122-5|10.1021/bi0345283|10.1023/a:1008364314328|10.1038/nrm1200|10.1074/jbc.m407950200|10.1074/jbc.m413209200|10.1074/mcp.m400154-mcp200|10.1146/annurev.biochem.73.011303.074118,2.3.2.-,"P63279,Q9UBE0,Q9UBT2",NULL
485340,2,Secondary Screen to Confirm Synergistic Effect of Compounds with Meropenem Against Mycobacterium Tuberculosis,"Southern Research's Specialized Biocontainment Screening Center (SRSBSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Assay Provider: Dr. William Bishai, Johns Hopkins University Tuberculosis Research Center_|_Award: 1 R03 MH084877-01A1_|__|_With approximately two billion people who have been exposed to Mycobacterium tuberculosis (M.tb) world-wide, tuberculosis has been declared a global health emergency by the WHO.  In 2008, there ",33,Southern Research Specialized Biocontainment Screening Center,TB_SL_DRMatrix,20101004,"70851,621402,624794,645654,655450,664371,665108,665499,665533,718487,732047,746058,828292,851756,879266,923383,930568,940424,947436,977742,978413,1051125,1121022,1266538,1591203,1994587,2088873,2114488,2207970,2219004,2242335,2562875,2572918,2583301,2583326,2583844,2731492,2810295,2813497,2815322,2850229,2998208,2999074,3122100,3237314,3564277,3912518,4235031,4492340,4579365,4774211,5145454,5219869,5331443,5346284,5378081,5411492,5775469,6251331,6884156,6894877,6901840,7120754,7161819,7254391,9551976,955594","843364,847929,850069,852810,863134,863855,864252,864286,3712911,3715082,3715744,4242456,4254477,4254844,4263606,14727655,14729380,14732338,14740668,14743483,14743642,14744191,14745321,14745486,14746393,16953649,17385895,17401381,17407052,17408456,17412396,17414224,17414690,17415127,17416262,17505139,17506098,17506612,17511038,17511970,17514917,17515983,22400801,22408299,22409522,22414106,22414297,24779105,24779857,24788158,24790683,24794044,24798898,24807061,24815255,24815860,24822496,24823913,24830541,2483",NULL,NULL,NULL,NIH Initiatives,"19716767,19758845,9145860",0,10.1016/j.tube.2009.05.008|10.1016/j.tube.2009.07.007,NULL,NULL,NULL
485980,2,Inhibition of CETP in rabbit serum after 1 hr by fluorescent cholesteryl esters transfer assay,Title: Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration._|__|_Abstract: Cholesteryl ester transfer protein (CETP) is involved in trafficking lipoprotein particles and neutral lipids between HDL and LDL and therefore is considered a valid target for treating dyslipidemic conditions and complications. Pharmacophore modeling and quantitative structure-activity relationship (QSAR) analysis were combined to ,43,ChEMBL,636763,20180913,"3488,259534,302384,6918520,9806102,9806610,9828869,9829416,9870704,9894320,9916392,9935853,9936855,9970068,10050438,10073382,10073471,10116967,10119293,10120284,10142885,10144277,10162638,10164805,10165968,10186806,10187358,10188926,10208920,10229629,10229808,10231557,10232095,10281896,10434530,10498920,10619814,10648591,10692165,10763332,10766781,10790582,10805120,10806097,10864218,10875144,10884510,10895866,10896230,10907408,10918359,10928074,10940086,10940406,10940802,10948829,10951775,10973830,10984622,","103168790,103221337,103221377,103221485,103221663,103221664,103221860,103221861,103221921,103221952,103222355,103222394,103222397,103222446,103222451,103222454,103222487,103263016,103263052,103263090,103263175,103263240,103263250,103263320,103263323,103263348,103263378,103263404,103263411,103263415,103263440,103263463,103263472,103263500,103263576,103263579,103263581,103263612,103263663,103263665,103263668,103263670,103263680,103263707,103263716,103263778,103263787,103263793,103263837,103263879,103263894,10",100327267,NULL,P22687,Curation Efforts|Research and Development,20116902,0,10.1016/j.ejmech.2009.12.070,NULL,P22687,NULL
485348,0,Center Based Initiative to identify novel inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based primary assay to identify LRH1 inhibitors (3X%INH),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRISMC)_|_Center Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Patrick Griffin, TSRI_|_Network: Molecular Library Probe Production Center Network (MLPCN)_|_Grant Proposal Number: U54 MH084512_|_Grant Proposal PI: Patrick Griffin, TSRI_|_External Assay ID: LRH1_IAG_LUMI_0384_3X%INH PRUN Round 0_|__|_Name: Center Based Initiative to identify novel inverse agonists of the liver receptor homolog-1 (LRH-1",5,The Scripps Research Institute Molecular Screening Center,LRH1_IAG_LUMI_0384_3X%INH PRUN Round 0,20101004,"1479244,1484049,3237172,3238389,3239085,3240644,3241826,3242688,3244825,3245522,3571734,3571735,4141058,4621936,5310579,6623965,7080816,7080823,7080827,7080829,7080831,7080833,44825215,44825216,44825217,44825219,44825223,44825226,44825230,44825240,45100430,45100432,45100433,45100438,45100439,45100448,45100453,45100455,45100460,45100462,45382268,45382269,45382271,45382272,45382275,45382276,45382277,45382279,45382280,45382282,45382283,45382284,45382285,45480133,45480134,45480135,45480136,45480137,45480138,454","85786757,85786758,85786759,85786760,85786761,85786762,89649715,89649733,89649734,89649735,89649736,89649737,89649738,89649739,89650164,89650166,92092823,92092824,92092825,92092826,92092827,92092828,92092829,92092830,92092831,92092832,92092833,92092834,92092835,92092836,92092837,92092838,92092839,92092840,92092841,92092842,92092843,92092844,92092845,93375297,93375298,93375299,93375300,93375301,93375302,93375303,93375304,93375305,93375306,93375307,93375308,93375309,93577916,93577917,93577918,93577919,93577920",2494,NULL,NP_003813,NIH Initiatives,"10078197,11108279,15130581,15707893,15721253,16289203,1709303,8139576,8187173,8668203,9332374",0,10.1016/0092-8674(94)90211-9|10.1016/j.cell.2005.01.024|10.1016/j.jmb.2005.10.009|10.1016/j.molcel.2005.02.002|10.1016/j.tcb.2004.03.008|10.1016/s0378-1119(97)00270-9|10.1016/s1097-2765(00)80305-6|10.1126/science.1709303|10.1128/mcb.14.4.2786|10.1128/mcb.16.7.3853|10.1210/endo.141.12.7808,NULL,O00482,NULL
485941,100,Induction of alpha-secretase-mediated reduction in amyloid beta secretion in human H4 cells expressing wild type betaAPP695 at 10 uM after 24 hrs by Western blot relative to control,"Title: Synthesis and biological evaluation of analogues of a novel inhibitor of beta-amyloid secretion._|__|_Abstract: A drug library of 17,200 compounds was screened to select small molecules that inhibit the secretion of amyloid beta peptide (Abeta), the major component of Alzheimer disease senile plaques, from a human neuronal cell line. Twenty-nine hits were validated that decreased Abeta secretion by >40% at 10 microM, for a 0.17% hit rate. A lead hit was selected for further study based on its activit",43,ChEMBL,636724,20180913,"891370,898317,1488789,1581465,1733677,1743633,1752604,1754338,1769722,2200701,2222859,2243462,2261915,2262495,2281508,2284259,2284473,2284706,2284949,2285605,2289325,2742028,2742079,2742085,2850950,3900808,46867668,46867669,46867670,46867671,46867672,46867673,46867813,46867814,46867815,46867816,46867817,46867818,46867819,46867954,46867955,46867956,46867957,46867958,46867959,46867960,46868091,46868092,46868093,46868094,46868095,46868096,46868097,46868098,46868221,46868222,46868223,46868224,46868225,46868226,","103764908,103764909,103764910,103764911,103764912,103764913,103764964,103764965,103764966,103764967,103764968,103764969,103764970,103765031,103765032,103765033,103765034,103765035,103765036,103765097,103765098,103765099,103765100,103765101,103765102,103765167,103765168,103765169,103765170,103765171,103765172,103765230,103765231,103765232,103765233,103765234,103765235,103765282,103765283,103765284,103765285,103765286,103765287,103765375,103765376,103765377,103765378,103765379,103765380,103765441,103765442,10",NULL,NULL,NULL,Curation Efforts|Research and Development,20568779,0,10.1021/jm100308g,NULL,NULL,NULL
485336,2,Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of KLF5 protein levels,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Vincent Yang, Emory University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1-R03-DA026215-01_|_Grant Proposal PI: Vincent Yang_|_External Assay ID: KLF5-WESTERN-BLOT_INH_LUMI_3XIC50 MDCSRUN SAR_Round 1_|__|_Name: Late stage assay provider counterscreen results from the probe development effort to identif",5,The Scripps Research Institute Molecular Screening Center,KLF5-WESTERN-BLOT_INH_LUMI_3XIC50 MDCSRUN SAR_Round 1,20101020,"439501,776240,2567894,4283428,4877095,5951923,12006093","88443007,88443009,88443010,88443015,88443016,88443019,92092794",688,NULL,ABM97548,NIH Initiatives,"11152667,15077182,15581624,15740636,15950866,17395897,17508399,18450752,18620093",0,10.1002/bies.20581|10.1016/j.febslet.2004.10.079|10.1016/j.tibs.2005.04.003|10.1016/s0065-230x(08)00003-1|10.1038/sj.cr.7290271|10.1038/sj.onc.1207397|10.1074/jbc.c000870200|10.1074/jbc.m801384200|10.1152/ajpgi.00541.2006,NULL,ABM97548,NULL
485979,100,Inhibition of CETP in rabbit serum at 10 uM after 1 hr by fluorescent cholesteryl esters transfer assay,Title: Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration._|__|_Abstract: Cholesteryl ester transfer protein (CETP) is involved in trafficking lipoprotein particles and neutral lipids between HDL and LDL and therefore is considered a valid target for treating dyslipidemic conditions and complications. Pharmacophore modeling and quantitative structure-activity relationship (QSAR) analysis were combined to ,43,ChEMBL,636762,20180913,"2247,2769,3348,3488,3739,4932,5152,5405,31101,65651,72749,104741,184789,235001,245862,254258,259534,269343,269833,274239,277043,279604,286383,293781,302384,306547,309125,309134,309548,309552,311610,327052,329045,339422,339423,340951,340972,372593,392954,411883,5282226,5311221,5357968,5840563,9555477,16051921,46848006,46907314,46907315,46907316,46907425,46907460,46907575,46907576,46907577,46907578,46907607,46907608,46907609,46907610,54680085,90665172,135998846","103168790,103170197,103181781,103188808,103224052,103238871,103286209,103389223,103447197,103611411,103764769,103764770,103764771,103764773,103764774,103764855,103764916,103764917,103764971,103764973,103764974,103764975,103765037,103765038,103765040,103765041,103765103,103765104,103765105,103765106,103765107,103765173,103765174,103765175,103765176,103765177,103765236,103765237,103765238,103765239,103765288,103765289,103765290,103765382,103765383,103765449,103765450,103765452,103765453,103765509,103765510,10",100327267,NULL,P22687,Curation Efforts|Research and Development,20116902,0,10.1016/j.ejmech.2009.12.070,NULL,P22687,NULL
485279,0,SAR analysis of Agonists of GPR55 using MAPK Activation Assay,"Data Source: Dr. Mary Abood_|_Source Affiliation: Temple University_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1X01 DA026205-01 _|_Assay Provider: Dr. Mary Abood, California Pacific Medical Center Research Institute (currently Temple University)_|__|_Phosphorylation of ERK1/2 occurs as a result of GPCR activation. The western-blot analysis utilizes a cell line permanently expressing a beta-arrestin GFP biosensor and human GPR55 receptor.  This wester",14,Burnham Center for Chemical Genomics,SBCCG-A437-GPR55-Agonist-pERK-DryPowder-Assay,20110331,"800833,1172084,1374043,1792197,2440433,4103947,4832119,15945391,24816860","85285580,85285581,87225722,87225724,87225728,87225729,87225730,87225731,87225737",9290,NULL,NP_005674,NIH Initiatives,"17765871,17876302,17906678,18263782,19233486,19723626,9931487",0,10.1016/j.bbrc.2007.08.078|10.1016/j.tips.2008.12.004|10.1016/s0169-328x(98)00277-0|10.1038/sj.bjp.0707460|10.1038/sj.bjp.0707481|10.1074/jbc.m109.050187|10.1104/pp.107.111443,NULL,Q9Y2T6,NULL
485338,2,Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): luminescence-based cell-based dose response assay for cytotoxic compounds using the DLD-1 cell line (Round 1),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Vincent Yang, Emory University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1-R03-DA026215-01_|_Grant Proposal PI: Vincent Yang_|_External Assay ID: DLD1CYTOX_INH_LUMI_3XIC50 CSDRUN SAR_Round 1_|__|_Name: Late stage assay provider counterscreen results from the probe development effort to identify inhibit",5,The Scripps Research Institute Molecular Screening Center,DLD1CYTOX_INH_LUMI_3XIC50 CSDRUN SAR_Round 1,20101020,"439501,776240,2567894,4283428,4877095,5951923,12006093","88443007,88443009,88443010,88443015,88443016,88443019,92092794",NULL,Cell-based,NULL,NIH Initiatives,"11152667,15077182,15581624,15740636,15950866,17395897,17508399,18450752,18620093",0,10.1002/bies.20581|10.1016/j.febslet.2004.10.079|10.1016/j.tibs.2005.04.003|10.1016/s0065-230x(08)00003-1|10.1038/sj.cr.7290271|10.1038/sj.onc.1207397|10.1074/jbc.c000870200|10.1074/jbc.m801384200|10.1152/ajpgi.00541.2006,NULL,NULL,NULL
485523,2,Anticancer activity against human MCF7 cells after 24 hrs by MTT assay,"Title: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli._|__|_Abstract: A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC(50) growth inhibitory ones, accounting, at least partly, for their cytostatic effects ",43,ChEMBL,636306,20180913,"8468,19844,226355,5281767,13468795,13468796,20612718,22895394,45257222,45376005,45376139,45376140,45376141,45376142,45376143,45376411,45376415,45376416,46906970,46906971,46906972,46907000,46907001,46907030,46907031,46907032,46907066,46907067,46907101,46907102,46907103,46907130,46907131,46907132,46907133,46907167","103340697,103347186,103582394,103764164,103764165,103764166,103764167,103764227,103764228,103764229,103764230,103764269,103764270,103764271,103764272,103764327,103764328,103764329,103764330,103764389,103764390,103764391,103764392,103764393,103764453,103764454,103764455,103764456,103764513,103764514,103764515,103764516,103764517,103764518,103764519,103764576",NULL,NULL,NULL,Curation Efforts|Research and Development,20466556,0,10.1016/j.bmc.2010.04.047,NULL,NULL,NULL
485528,2,Anticancer activity against human U373 cells after 24 hrs by MTT assay,"Title: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli._|__|_Abstract: A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC(50) growth inhibitory ones, accounting, at least partly, for their cytostatic effects ",43,ChEMBL,636311,20200702,"8468,19844,226355,5281767,13468795,13468796,20612718,22895394,45257222,45376005,45376139,45376140,45376141,45376142,45376143,45376411,45376415,45376416,46906970,46906971,46906972,46907000,46907001,46907030,46907031,46907032,46907066,46907067,46907101,46907102,46907103,46907130,46907131,46907132,46907133,46907167","103340697,103347186,103582394,103764164,103764165,103764166,103764167,103764227,103764228,103764229,103764230,103764269,103764270,103764271,103764272,103764327,103764328,103764329,103764330,103764389,103764390,103764391,103764392,103764393,103764453,103764454,103764455,103764456,103764513,103764514,103764515,103764516,103764517,103764518,103764519,103764576",NULL,NULL,NULL,Curation Efforts|Research and Development,20466556,0,10.1016/j.bmc.2010.04.047,NULL,NULL,NULL
485522,2,Anticancer activity against human PC3 cells after 24 hrs by MTT assay,"Title: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli._|__|_Abstract: A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC(50) growth inhibitory ones, accounting, at least partly, for their cytostatic effects ",43,ChEMBL,636305,20180913,"8468,19844,226355,5281767,13468795,13468796,20612718,22895394,45257222,45376005,45376139,45376140,45376141,45376142,45376143,45376411,45376415,45376416,46906970,46906971,46906972,46907000,46907001,46907030,46907031,46907032,46907066,46907067,46907101,46907102,46907103,46907130,46907131,46907132,46907133,46907167","103340697,103347186,103582394,103764164,103764165,103764166,103764167,103764227,103764228,103764229,103764230,103764269,103764270,103764271,103764272,103764327,103764328,103764329,103764330,103764389,103764390,103764391,103764392,103764393,103764453,103764454,103764455,103764456,103764513,103764514,103764515,103764516,103764517,103764518,103764519,103764576",NULL,NULL,NULL,Curation Efforts|Research and Development,20466556,0,10.1016/j.bmc.2010.04.047,NULL,NULL,NULL
485525,2,Anticancer activity against human LoVo cells after 24 hrs by MTT assay,"Title: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli._|__|_Abstract: A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC(50) growth inhibitory ones, accounting, at least partly, for their cytostatic effects ",43,ChEMBL,636308,20180913,"8468,19844,226355,5281767,13468795,13468796,20612718,22895394,45257222,45376005,45376139,45376140,45376141,45376142,45376143,45376411,45376415,45376416,46906970,46906971,46906972,46907000,46907001,46907030,46907031,46907032,46907066,46907067,46907101,46907102,46907103,46907130,46907131,46907132,46907133,46907167","103340697,103347186,103582394,103764164,103764165,103764166,103764167,103764227,103764228,103764229,103764230,103764269,103764270,103764271,103764272,103764327,103764328,103764329,103764330,103764389,103764390,103764391,103764392,103764393,103764453,103764454,103764455,103764456,103764513,103764514,103764515,103764516,103764517,103764518,103764519,103764576",NULL,NULL,NULL,Curation Efforts|Research and Development,20466556,0,10.1016/j.bmc.2010.04.047,NULL,NULL,NULL
485519,2,Anticancer activity against mouse B16F10 cells after 24 hrs by MTT assay,"Title: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli._|__|_Abstract: A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC(50) growth inhibitory ones, accounting, at least partly, for their cytostatic effects ",43,ChEMBL,636302,20180913,"8468,19844,226355,5281767,13468795,13468796,20612718,22895394,45257222,45376005,45376139,45376140,45376141,45376142,45376143,45376411,45376415,45376416,46906970,46906971,46906972,46907000,46907001,46907030,46907031,46907032,46907066,46907067,46907101,46907102,46907103,46907130,46907131,46907132,46907133,46907167","103340697,103347186,103582394,103764164,103764165,103764166,103764167,103764227,103764228,103764229,103764230,103764269,103764270,103764271,103764272,103764327,103764328,103764329,103764330,103764389,103764390,103764391,103764392,103764393,103764453,103764454,103764455,103764456,103764513,103764514,103764515,103764516,103764517,103764518,103764519,103764576",NULL,NULL,NULL,Curation Efforts|Research and Development,20466556,0,10.1016/j.bmc.2010.04.047,NULL,NULL,NULL
485524,2,Anticancer activity against human A549 cells after 24 hrs by MTT assay,"Title: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli._|__|_Abstract: A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC(50) growth inhibitory ones, accounting, at least partly, for their cytostatic effects ",43,ChEMBL,636307,20180913,"8468,19844,226355,5281767,13468795,13468796,20612718,22895394,45257222,45376005,45376139,45376140,45376141,45376142,45376143,45376411,45376415,45376416,46906970,46906971,46906972,46907000,46907001,46907030,46907031,46907032,46907066,46907067,46907101,46907102,46907103,46907130,46907131,46907132,46907133,46907167","103340697,103347186,103582394,103764164,103764165,103764166,103764167,103764227,103764228,103764229,103764230,103764269,103764270,103764271,103764272,103764327,103764328,103764329,103764330,103764389,103764390,103764391,103764392,103764393,103764453,103764454,103764455,103764456,103764513,103764514,103764515,103764516,103764517,103764518,103764519,103764576",NULL,NULL,NULL,Curation Efforts|Research and Development,20466556,0,10.1016/j.bmc.2010.04.047,NULL,NULL,NULL
485527,2,Anticancer activity against human T98G cells after 24 hrs by MTT assay,"Title: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli._|__|_Abstract: A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC(50) growth inhibitory ones, accounting, at least partly, for their cytostatic effects ",43,ChEMBL,636310,20180913,"8468,19844,226355,5281767,13468795,13468796,20612718,22895394,45257222,45376005,45376139,45376140,45376141,45376142,45376143,45376411,45376415,45376416,46906970,46906971,46906972,46907000,46907001,46907030,46907031,46907032,46907066,46907067,46907101,46907102,46907103,46907130,46907131,46907132,46907133,46907167","103340697,103347186,103582394,103764164,103764165,103764166,103764167,103764227,103764228,103764229,103764230,103764269,103764270,103764271,103764272,103764327,103764328,103764329,103764330,103764389,103764390,103764391,103764392,103764393,103764453,103764454,103764455,103764456,103764513,103764514,103764515,103764516,103764517,103764518,103764519,103764576",NULL,NULL,NULL,Curation Efforts|Research and Development,20466556,0,10.1016/j.bmc.2010.04.047,NULL,NULL,NULL
485526,2,Anticancer activity against human Hs683 cells after 24 hrs by MTT assay,"Title: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli._|__|_Abstract: A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC(50) growth inhibitory ones, accounting, at least partly, for their cytostatic effects ",43,ChEMBL,636309,20200702,"8468,19844,226355,5281767,13468795,13468796,20612718,22895394,45257222,45376005,45376139,45376140,45376141,45376142,45376143,45376411,45376415,45376416,46906970,46906971,46906972,46907000,46907001,46907030,46907031,46907032,46907066,46907067,46907101,46907102,46907103,46907130,46907131,46907132,46907133,46907167","103340697,103347186,103582394,103764164,103764165,103764166,103764167,103764227,103764228,103764229,103764230,103764269,103764270,103764271,103764272,103764327,103764328,103764329,103764330,103764389,103764390,103764391,103764392,103764393,103764453,103764454,103764455,103764456,103764513,103764514,103764515,103764516,103764517,103764518,103764519,103764576",NULL,NULL,NULL,Curation Efforts|Research and Development,20466556,0,10.1016/j.bmc.2010.04.047,NULL,NULL,NULL
485520,2,Anticancer activity against human OE33 cells after 24 hrs by MTT assay,"Title: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli._|__|_Abstract: A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC(50) growth inhibitory ones, accounting, at least partly, for their cytostatic effects ",43,ChEMBL,636303,20180913,"8468,19844,226355,5281767,13468795,13468796,20612718,22895394,45257222,45376005,45376139,45376140,45376141,45376142,45376143,45376411,45376415,45376416,46906970,46906971,46906972,46907000,46907001,46907030,46907031,46907032,46907066,46907067,46907101,46907102,46907103,46907130,46907131,46907132,46907133,46907167","103340697,103347186,103582394,103764164,103764165,103764166,103764167,103764227,103764228,103764229,103764230,103764269,103764270,103764271,103764272,103764327,103764328,103764329,103764330,103764389,103764390,103764391,103764392,103764393,103764453,103764454,103764455,103764456,103764513,103764514,103764515,103764516,103764517,103764518,103764519,103764576",NULL,NULL,NULL,Curation Efforts|Research and Development,20466556,0,10.1016/j.bmc.2010.04.047,NULL,NULL,NULL
485521,2,Anticancer activity against human OE21 cells after 24 hrs by MTT assay,"Title: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli._|__|_Abstract: A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC(50) growth inhibitory ones, accounting, at least partly, for their cytostatic effects ",43,ChEMBL,636304,20200702,"8468,19844,226355,5281767,13468795,13468796,20612718,22895394,45257222,45376005,45376139,45376140,45376141,45376142,45376143,45376411,45376415,45376416,46906970,46906971,46906972,46907000,46907001,46907030,46907031,46907032,46907066,46907067,46907101,46907102,46907103,46907130,46907131,46907132,46907133,46907167","103340697,103347186,103582394,103764164,103764165,103764166,103764167,103764227,103764228,103764229,103764230,103764269,103764270,103764271,103764272,103764327,103764328,103764329,103764330,103764389,103764390,103764391,103764392,103764393,103764453,103764454,103764455,103764456,103764513,103764514,103764515,103764516,103764517,103764518,103764519,103764576",NULL,NULL,NULL,Curation Efforts|Research and Development,20466556,0,10.1016/j.bmc.2010.04.047,NULL,NULL,NULL
485535,2,Binding affinity to mouse recombinant HSP47 expressed in Escherichia coli JM109 after 10 mins by surface plasmon resonance assay,"Title: A structure-activity relationship study elucidating the mechanism of sequence-specific collagen recognition by the chaperone HSP47._|__|_Abstract: Heat-shock protein 47 (HSP47) is a chaperone that facilitates the proper folding of procollagen. Our previous studies showed that the high-affinity HSP47-binding motif in the collagen triple helix is Xaa-(Thr/Pro)-Gly-Xaa-Arg-Gly. In this study, we further investigated structural requirements for the HSP47-binding motif, using synthetic triple-helical coll",43,ChEMBL,636318,20180913,"46907205,46907206,46907207,46907208,46907209,46907210,46907211,46907212,46907213,46907215,46907216,46907217,46907218,46907219,46907220,46907221,46907222,46907223,46907224,46907225,46907226,46907227,46907229,46907230,46907231,46907232,46907234,46907235,46907236,46907237,46907238,46907239,46907240,46907241,46907242,46907243,46907244,46907245,46907246,73347203,73348711,73354784","103764636,103764637,103764638,103764639,103764640,103764641,103764642,103764643,103764644,103764646,103764647,103764648,103764649,103764650,103764651,103764652,103764653,103764654,103764655,103764656,103764657,103764658,103764660,103764661,103764662,103764663,103764665,103764666,103764667,103764668,103764669,103764670,103764671,103764672,103764673,103764674,103764675,103764676,103764677,174490305,174495327,174516038",12406,NULL,P19324,Curation Efforts|Research and Development,20471275,0,10.1016/j.bmc.2010.04.054,NULL,P19324,NULL
485288,2,"A confirmatory biochemical assay using the ADP-Hunter methodology, purified TAg, and ATP to quantify activity of synthesized compounds that inhibit the ATPase activity of Tag (3)","Southern Research's Specialized Biocontainment Screening Center (SRSBSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Probe Centers Network (MLPCN)_|_Assay Provider: Dr. Jeffery Brodsky, University of Pittsburgh_|_Grant number: 1R03MH084077-01 _|__|_The oncogenic virus Simian Virus 40 (SV40) is a well-characterized model system to examine the underlying mechanisms of growth control and cancer. SV40 is also closely related to two viruses, JC and BK virus, which infect humans,",33,Southern Research Specialized Biocontainment Screening Center,SV40_DR_4,20110304,"2406,3037,3598,6620,11742,12111,16069,66802,75575,228537,1992009,6611846,46829345,46829346,46829347,46829348,46829349","99206560,99206561,99206562,99206563,99206564,99206565,99206566,99206567,99206568,99206569,99234228,99234229,99234230,99234231,99234232,99234233,99234234",29031019,Biochemical,YP_003708382,NIH Initiatives,"10432461,18164205,19200446,6169844",0,10.1016/j.bmc.2007.12.014|10.1016/j.virusres.2008.12.018|10.1016/s0076-6879(99)06019-x,3.6.4.-,P03070,NULL
485370,0,SAR analysis of the effect of Antagonists of IAP-family anti-apoptotic proteins on rhTRAIL in HeLa cells,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Proposal Number: MH081277-01_|_Assay Provider: John C. Reed, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_This XIAP dose response assay is developed and performed to confirm hits originally identified in the XIAP HTS binding assay (AID 1018) and to study the struc",14,Burnham Center for Chemical Genomics,SBCCG-A445-XIAP-Dry-Powder-HeLa-Assay,20101006,44176340,85164169,NULL,NULL,CAB95312,NIH Initiatives,"11257232,14749124,19258513,9393848,9545235,9721092",0,10.1016/s0092-8674(00)80442-0|10.1016/s0092-8674(01)00274-4|10.1016/s1535-6108(03)00332-5|10.1093/emboj/17.8.2215|10.1126/science.281.5381.1309|10.1158/0008-5472.can-08-2436,NULL,P98170,NULL
485276,2,Identification of SV40 T antigen inhibitors: A Secondary Screen for the Cytotoxicity and Efficacy using BSC cells (3),"Southern Research's Specialized Biocontainment Screening Center (SRSBSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Assay Provider: Dr. Jeffery Brodsky, University of Pittsburgh, Pittsburgh, PA_|_Award: R03MH084077-01_|__|_Rationale and Summary: The oncogenic virus Simian Virus 40 (SV40) is a well-characterized model system to examine the underlying mechanisms of growth control and cancer. SV40 is also closely related to two virus",33,Southern Research Specialized Biocontainment Screening Center,SV40_BSC_Sec3,20101025,"2406,3037,6623,12111,16069,66802,228537,1289594,1992009,18365740","92277586,92277587,96022079,99206561,99206566,99234228,99234230,99234232,99234233,99234234",NULL,Toxicity,NULL,NIH Initiatives,"18164205,19200446",0,10.1016/j.bmc.2007.12.014|10.1016/j.virusres.2008.12.018,NULL,NULL,NULL
485301,2,Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): real-time florescence-based biochemical assay to determine whether compounds inhibit the helicase encoded by one or more HCV strain,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: David Frick, New York Medical College_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH085690-01_|_Grant Proposal PI: David Frick, New York Medical College_|_External Assay ID: HCV NS3_INH_QFRET_96_1XIC50_|__|_Name: Late stage probe development counterscreen for inhibitors of the He",5,The Scripps Research Institute Molecular Screening Center,HCV NS3_INH_QFRET_96_1XIC50,20100929,"3291242,3496625,4051948,4371917,4611776,4675220,4872167,5691857,9682118","87241476,87241477,87241478,87241479,87241480,87241481,87241482,87241483,92126116,92126117,92126118,92126119,92126120,92126121,92126122,92126123",NULL,Biochemical,"AAC15722,ACM69038,CAB46913",NIH Initiatives,"10644352,12206878,12407573,17263143,19009270,9493270,9614113",0,10.1007/978-1-59745-394-3_22|10.1016/s0166-3542(02)00096-7|10.1016/s0969-2126(98)00010-0|10.1053/jhep.2002.36227|10.1074/jbc.273.24.15045|10.1128/jvi.74.4.1794-1800.2000,NULL,"AAC15722,ACM69038,CAB46913",NULL
485369,0,SAR analysis of the effect of Antagonists of IAP-family anti-apoptotic proteins on rhTRAIL in MDA-MB-231 cells,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Proposal Number: MH081277-01_|_Assay Provider: John C. Reed, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_This XIAP dose response assay is developed and performed to confirm hits originally identified in the XIAP HTS binding assay (AID 1018) and to study the struc",14,Burnham Center for Chemical Genomics,SBCCG-A444-XIAP-Dry-Powder-MDA-Assay,20101006,44176340,85164169,NULL,NULL,CAB95312,NIH Initiatives,"11257232,14749124,19258513,9393848,9545235,9721092",0,10.1016/s0092-8674(00)80442-0|10.1016/s0092-8674(01)00274-4|10.1016/s1535-6108(03)00332-5|10.1093/emboj/17.8.2215|10.1126/science.281.5381.1309|10.1158/0008-5472.can-08-2436,NULL,P98170,NULL
485942,100,Induction of alpha-secretase-mediated reduction in amyloid beta secretion in human H4 cells expressing wild type betaAPP695 at 30 uM after 24 hrs by Western blot relative to control,"Title: Synthesis and biological evaluation of analogues of a novel inhibitor of beta-amyloid secretion._|__|_Abstract: A drug library of 17,200 compounds was screened to select small molecules that inhibit the secretion of amyloid beta peptide (Abeta), the major component of Alzheimer disease senile plaques, from a human neuronal cell line. Twenty-nine hits were validated that decreased Abeta secretion by >40% at 10 microM, for a 0.17% hit rate. A lead hit was selected for further study based on its activit",43,ChEMBL,636725,20180913,"2284259,46867668,46867669,46867670,46867671,46867672,46867673,46867813,46867814,46867815,46867816,46867817,46867818,46867819,46867954,46867955,46867956,46867957,46867958,46867959,46867960,46868091,46868092,46868093,46868094,46868095,46868096,46868097,46868098,46868221,46868222,46868223,46868224,46868225,46868226,46868227,46868228,46868359,46868360,46868361,46868362,46868363,46868364,46868365,46868514,46868515,46868516,46868517,46868518,46868519,46868520,46868659,46868660","103765167,103765168,103765169,103765170,103765171,103765172,103765230,103765231,103765232,103765233,103765234,103765235,103765282,103765283,103765284,103765285,103765286,103765287,103765375,103765376,103765377,103765378,103765379,103765380,103765441,103765442,103765443,103765444,103765445,103765446,103765503,103765504,103765505,103765506,103765507,103765508,103765563,103765564,103765565,103765566,103765567,103765568,103765624,103765625,103765626,103765627,103765628,103765629,103765702,103765703,103765704,10",NULL,NULL,NULL,Curation Efforts|Research and Development,20568779,0,10.1021/jm100308g,NULL,NULL,NULL
485280,2,Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: Absorbance-based cell-based assay to identify compounds that are cytotoxic to Huh-7.5 cells,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: A.D. Strosberg, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1-X01-MH085709-01_|_Grant Proposal PI: A.D. Strosberg, TSRI_|_External Assay ID: HUH7.5-CYTOX_INH_ABS_0096_3XIC50 MDCSRUN_|__|_Name: Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of ",5,The Scripps Research Institute Molecular Screening Center,HUH7.5-CYTOX_INH_ABS_0096_3XIC50 MDCSRUN,20101026,"1780,694792,1557339,5280489,9426403,22422906,24979394,24979772,135857758","87219207,87219208,87219209,87219210,87219211,87219212,87219213,87219214,87219215",NULL,Cell-based,NULL,NIH Initiatives,"10233931,12407573,15039539,15566499,19009270,19264632,7518529,8676467,9916717",0,10.1007/978-1-59745-394-3_22|10.1053/jhep.2002.36227|10.1099/vir.0.008565-0|10.1099/vir.0.79775-0|10.1111/j.1478-3231.2004.0965.x,NULL,NULL,NULL
485943,100,Cytotoxicity against human H4 cells expressing wild type betaAPP695 assessed as decrease in cell protein at 10 uM after 24 hrs,"Title: Synthesis and biological evaluation of analogues of a novel inhibitor of beta-amyloid secretion._|__|_Abstract: A drug library of 17,200 compounds was screened to select small molecules that inhibit the secretion of amyloid beta peptide (Abeta), the major component of Alzheimer disease senile plaques, from a human neuronal cell line. Twenty-nine hits were validated that decreased Abeta secretion by >40% at 10 microM, for a 0.17% hit rate. A lead hit was selected for further study based on its activit",43,ChEMBL,636726,20200702,"2284259,46867668,46867669,46867670,46867671,46867672,46867673,46867813,46867814,46867815,46867816,46867817,46867818,46867819,46867954,46867955,46867956,46867957,46867958,46867959,46867960,46868091,46868092,46868093,46868094,46868095,46868096,46868097,46868098,46868221,46868222,46868223,46868224,46868225,46868226,46868227,46868228,46868359,46868360,46868361,46868362,46868363,46868364,46868365,46868514,46868515,46868516,46868517,46868518,46868519,46868520,46868659,46868660","103765167,103765168,103765169,103765170,103765171,103765172,103765230,103765231,103765232,103765233,103765234,103765235,103765282,103765283,103765284,103765285,103765286,103765287,103765375,103765376,103765377,103765378,103765379,103765380,103765441,103765442,103765443,103765444,103765445,103765446,103765503,103765504,103765505,103765506,103765507,103765508,103765563,103765564,103765565,103765566,103765567,103765568,103765624,103765625,103765626,103765627,103765628,103765629,103765702,103765703,103765704,10",NULL,NULL,NULL,Curation Efforts|Research and Development,20568779,0,10.1021/jm100308g,NULL,NULL,NULL
485944,100,Cytotoxicity against human H4 cells expressing wild type betaAPP695 assessed as decrease in cell protein at 30 uM after 24 hrs,"Title: Synthesis and biological evaluation of analogues of a novel inhibitor of beta-amyloid secretion._|__|_Abstract: A drug library of 17,200 compounds was screened to select small molecules that inhibit the secretion of amyloid beta peptide (Abeta), the major component of Alzheimer disease senile plaques, from a human neuronal cell line. Twenty-nine hits were validated that decreased Abeta secretion by >40% at 10 microM, for a 0.17% hit rate. A lead hit was selected for further study based on its activit",43,ChEMBL,636727,20200702,"2284259,46867668,46867669,46867670,46867671,46867672,46867673,46867813,46867814,46867815,46867816,46867817,46867818,46867819,46867954,46867955,46867956,46867957,46867958,46867959,46867960,46868091,46868092,46868093,46868094,46868095,46868096,46868097,46868098,46868221,46868222,46868223,46868224,46868225,46868226,46868227,46868228,46868359,46868360,46868361,46868362,46868363,46868364,46868365,46868514,46868515,46868516,46868517,46868518,46868519,46868520,46868659,46868660","103765167,103765168,103765169,103765170,103765171,103765172,103765230,103765231,103765232,103765233,103765234,103765235,103765282,103765283,103765284,103765285,103765286,103765287,103765375,103765376,103765377,103765378,103765379,103765380,103765441,103765442,103765443,103765444,103765445,103765446,103765503,103765504,103765505,103765506,103765507,103765508,103765563,103765564,103765565,103765566,103765567,103765568,103765624,103765625,103765626,103765627,103765628,103765629,103765702,103765703,103765704,10",NULL,NULL,NULL,Curation Efforts|Research and Development,20568779,0,10.1021/jm100308g,NULL,NULL,NULL
485271,2,Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization: fluorescence-based cell-based quantitative PCR assay to identify inhibitors of HCV infectivity,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: A.D. Strosberg, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1-X01-MH085709-01_|_Grant Proposal PI: A.D. Strosberg, TSRI_|_External Assay ID: CORE_INH_FLUOR_0096_FOLD-CHANGE QPCR SAR_ROUND_0 MDCSRUN_|__|_Name: Late stage assay provider counterscreen results for the probe development effort to identif",5,The Scripps Research Institute Molecular Screening Center,CORE_INH_FLUOR_0096_FOLD-CHANGE QPCR SAR_ROUND_0 MDCSRUN,20101012,22422906,87219211,NULL,Cell-based,"ABC47431,ABC47431,ABC47431",NIH Initiatives,"10233931,12407573,15039539,15566499,19009270,19264632,7518529,8676467,9916717",0,10.1007/978-1-59745-394-3_22|10.1053/jhep.2002.36227|10.1099/vir.0.008565-0|10.1099/vir.0.79775-0|10.1111/j.1478-3231.2004.0965.x,NULL,ABC47431,NULL
485963,2,Agonist activity at rat urotensin 2 receptor expressed in CHO cells assessed as calcium mobilization by FLIPR,Title: Urotensin-II receptor modulators as potential drugs._|_,43,ChEMBL,636746,20180913,"10865905,10898288,10898324,10898540,10909326,10920221,10920324,10930952,10974939,10985981,11006017,11007453,11125778,11714850,11829013,11829173,12111224,16150418,16150656,44206680,44206682,46907603,46907604,46907606","103501549,103708451,103708483,103764851,103765838,103765839,103765840,103765841,103765842,103765843,103765844,103765845,103765847,103765848,103765849,103765850,103765851,103765853,103765855,103765857,103765858,103765860,103765861,103765862",57305,NULL,P49684,Curation Efforts|Research and Development,20043680,0,10.1021/jm901294u,NULL,P49684,NULL
485550,100,Inhibition of glycogen phosphorylase assessed as inositol phosphate release at 100 uM after 30 mins,"Title: Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents._|__|_Abstract: A series of 2,4-disubstituted polyhydroquinoline were synthesized and evaluated for their in vivo antihyperglycemic as well as antidyslipidemic activities. Several synthesized compounds have exhibited promising in vivo antihyperglycemic in SLM, STZ-S, and db/db mice model along with significant lipid and TG modulating activity. All these compounds were evaluated i",43,ChEMBL,636333,20180913,"10914479,11110678,11132236,14494718,14532695,14532696,14532699,46845036,46845037,46906758,46906759,46906760,46906761,46906827,46906828,46906829,46906830,46906831,46906933,46906934,46906973,46906974,46906975,46907002,46907003,46907004,46907005,46907006,46907033,46907034,46907035,46907036","103763873,103763987,103763988,103763989,103763990,103763991,103764066,103764067,103764068,103764069,103764070,103764071,103764121,103764168,103764169,103764170,103764171,103764172,103764231,103764232,103764233,103764234,103764235,103764273,103764274,103764275,103764276,103764277,103764331,103764332,103764333,103764334",NULL,NULL,NULL,Curation Efforts|Research and Development,20471838,0,10.1016/j.bmc.2009.11.061,NULL,NULL,NULL
485559,100,"Antihyperglycemic activity in Charles Foster-Wistar albino rat sucrose loaded model assessed as decrease of blood glucose level at 100 mg/kg, po administered 30 mins before glucose challenge measured up to 120 mins by glucometer","Title: Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents._|__|_Abstract: A series of 2,4-disubstituted polyhydroquinoline were synthesized and evaluated for their in vivo antihyperglycemic as well as antidyslipidemic activities. Several synthesized compounds have exhibited promising in vivo antihyperglycemic in SLM, STZ-S, and db/db mice model along with significant lipid and TG modulating activity. All these compounds were evaluated i",43,ChEMBL,636342,20180913,"3488,4091,10914479,11110678,11132236,14494718,14532695,14532696,14532699,46845036,46845037,46906758,46906759,46906760,46906761,46906827,46906828,46906829,46906830,46906831,46906933,46906934,46906973,46906974,46906975,46907002,46907003,46907004,46907005,46907006,46907033,46907034,46907035,46907036","103168790,103508547,103763873,103763987,103763988,103763989,103763990,103763991,103764066,103764067,103764068,103764069,103764070,103764071,103764121,103764168,103764169,103764170,103764171,103764172,103764231,103764232,103764233,103764234,103764235,103764273,103764274,103764275,103764276,103764277,103764331,103764332,103764333,103764334",NULL,NULL,NULL,Curation Efforts|Research and Development,20471838,0,10.1016/j.bmc.2009.11.061,NULL,NULL,NULL
485557,100,"Antihyperglycemic activity in Sprague-Dawley albino rat streptozotocin-induced beta-cell damaged diabetic model assessed as decrease of blood glucose level at 100 mg/kg, po administered 30 mins before glucose challenge measured after 24 hrs by glucometer","Title: Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents._|__|_Abstract: A series of 2,4-disubstituted polyhydroquinoline were synthesized and evaluated for their in vivo antihyperglycemic as well as antidyslipidemic activities. Several synthesized compounds have exhibited promising in vivo antihyperglycemic in SLM, STZ-S, and db/db mice model along with significant lipid and TG modulating activity. All these compounds were evaluated i",43,ChEMBL,636340,20180913,"3488,4091,10914479,11110678,11132236,14532695,14532696,14532699,46845036,46845037,46906758,46906759,46906760,46906761,46906827,46906828,46906829,46906830,46906831,46906933,46906934,46906973,46906974,46906975,46907002,46907003,46907004,46907005,46907006,46907033,46907034,46907035,46907036","103168790,103508547,103763873,103763987,103763988,103763989,103763990,103763991,103764066,103764067,103764068,103764069,103764070,103764071,103764168,103764169,103764170,103764171,103764172,103764231,103764232,103764233,103764234,103764235,103764273,103764274,103764275,103764276,103764277,103764331,103764332,103764333,103764334",NULL,NULL,NULL,Curation Efforts|Research and Development,20471838,0,10.1016/j.bmc.2009.11.061,NULL,NULL,NULL
485558,100,"Antihyperglycemic activity in Sprague-Dawley albino rat streptozotocin-induced beta-cell damaged diabetic model assessed as decrease of blood glucose level at 100 mg/kg, po administered 30 mins before glucose challenge measured after 5 hrs by glucometer","Title: Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents._|__|_Abstract: A series of 2,4-disubstituted polyhydroquinoline were synthesized and evaluated for their in vivo antihyperglycemic as well as antidyslipidemic activities. Several synthesized compounds have exhibited promising in vivo antihyperglycemic in SLM, STZ-S, and db/db mice model along with significant lipid and TG modulating activity. All these compounds were evaluated i",43,ChEMBL,636341,20180913,"3488,4091,10914479,11110678,11132236,14532695,14532696,14532699,46845036,46845037,46906758,46906759,46906760,46906761,46906827,46906828,46906829,46906830,46906831,46906933,46906934,46906973,46906974,46906975,46907002,46907003,46907004,46907005,46907006,46907033,46907034,46907035,46907036","103168790,103508547,103763873,103763987,103763988,103763989,103763990,103763991,103764066,103764067,103764068,103764069,103764070,103764071,103764168,103764169,103764170,103764171,103764172,103764231,103764232,103764233,103764234,103764235,103764273,103764274,103764275,103764276,103764277,103764331,103764332,103764333,103764334",NULL,NULL,NULL,Curation Efforts|Research and Development,20471838,0,10.1016/j.bmc.2009.11.061,NULL,NULL,NULL
485551,100,Inhibition of glucose-6-phosphatase assessed as inositol phosphate release at 100 uM after 30 mins,"Title: Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents._|__|_Abstract: A series of 2,4-disubstituted polyhydroquinoline were synthesized and evaluated for their in vivo antihyperglycemic as well as antidyslipidemic activities. Several synthesized compounds have exhibited promising in vivo antihyperglycemic in SLM, STZ-S, and db/db mice model along with significant lipid and TG modulating activity. All these compounds were evaluated i",43,ChEMBL,636334,20180913,"10914479,11110678,11132236,14494718,14532695,14532696,14532699,46845036,46845037,46906758,46906759,46906760,46906761,46906827,46906828,46906829,46906830,46906831,46906933,46906934,46906973,46906974,46906975,46907002,46907003,46907004,46907005,46907006,46907033,46907034,46907035,46907036","103763873,103763987,103763988,103763989,103763990,103763991,103764066,103764067,103764068,103764069,103764070,103764071,103764121,103764168,103764169,103764170,103764171,103764172,103764231,103764232,103764233,103764234,103764235,103764273,103764274,103764275,103764276,103764277,103764331,103764332,103764333,103764334",2538,NULL,P35575,Curation Efforts|Research and Development,20471838,0,10.1016/j.bmc.2009.11.061,3.1.3.9,P35575,NULL
485548,100,Inhibition of DPP4 at 100 uM after 15 mins by spectrofluorimeter,"Title: Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents._|__|_Abstract: A series of 2,4-disubstituted polyhydroquinoline were synthesized and evaluated for their in vivo antihyperglycemic as well as antidyslipidemic activities. Several synthesized compounds have exhibited promising in vivo antihyperglycemic in SLM, STZ-S, and db/db mice model along with significant lipid and TG modulating activity. All these compounds were evaluated i",43,ChEMBL,636331,20180913,"61671,10914479,11110678,11132236,14494718,14532695,14532696,14532699,46845036,46845037,46906758,46906759,46906760,46906761,46906827,46906828,46906829,46906830,46906831,46906933,46906934,46906973,46906974,46906975,46907002,46907003,46907004,46907005,46907006,46907033,46907034,46907035,46907036","103444098,103763873,103763987,103763988,103763989,103763990,103763991,103764066,103764067,103764068,103764069,103764070,103764071,103764121,103764168,103764169,103764170,103764171,103764172,103764231,103764232,103764233,103764234,103764235,103764273,103764274,103764275,103764276,103764277,103764331,103764332,103764333,103764334",1803,NULL,P27487,Curation Efforts|Research and Development,20471838,0,10.1016/j.bmc.2009.11.061,3.4.14.5,P27487,NULL
485407,2,Inhibition of ALK by time-resolved fluorescence assay,"Title: Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase._|__|_Abstract: Dysregulation of the anaplastic lymphoma kinase (ALK) is implicated in a variety of cancers. A series of tetrahydropyrido[2,3-b]pyrazines was constructed as ring-constrained analogs of a known aminopyridine kinase scaffold. Chemistry was developed to rapidly elaborate the SAR, structural elements impacting ALK inhibitory activi",43,ChEMBL,636190,20180913,"24852349,24853018,24853225,24853329,46871637,46871638,46871653,46906623,46906624,46906669,46906670,46906671,46906672,46906715,46906716,46906717,46906718,46906792,46906793,46906794,46907265,46907305,49859980","103763831,103763832,103763833,103763834,103763887,103763888,103763889,103763890,103763938,103763939,103763940,103763941,103764027,103764028,103764029,103764030,103764031,103764698,103764699,103764754,103764755,103764756,104234635",238,NULL,Q9UM73,Curation Efforts|Research and Development,20483621,0,10.1016/j.bmc.2010.04.087,2.7.10.1,Q9UM73,NULL
485339,2,Late-stage fluorescence-based dose response cell-based screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7): Intracellular calcium release,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Olivier Civelli, University of California, Irvine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1-R03-DA026557-01_|_Grant Proposal PI: Olivier Civelli_|_External Assay ID: GPR7_ANT_FLUO8_96_IC50_|__|_Name: Late-stage fluorescence-based dose response cell-based screening assay to identify antagonis",5,The Scripps Research Institute Molecular Screening Center,GPR7_ANT_FLUO8_96_IC50,20110414,46172919,96021160,2831,Cell-based,EAW86722,NIH Initiatives,"10407191,12118011,12401809,12719537,12925742,15261118,15607941,15983370,17629964,17959251,18370232,18382464,7590751",0,10.1006/geno.1995.1109|10.1007/978-1-59745-205-2_6|10.1016/j.brainres.2004.03.079|10.1016/j.mcn.2004.08.010|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2007.06.001|10.1016/s0169-328x(99)00171-0|10.1038/nrd2518|10.1073/pnas.0503795102|10.1073/pnas.0837789100|10.1073/pnas.1334189100|10.1074/jbc.m205883200|10.1074/jbc.m206396200,NULL,P48145,NULL
485549,100,Inhibition of alpha-glucosidase at 100 uM after 3 mins,"Title: Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents._|__|_Abstract: A series of 2,4-disubstituted polyhydroquinoline were synthesized and evaluated for their in vivo antihyperglycemic as well as antidyslipidemic activities. Several synthesized compounds have exhibited promising in vivo antihyperglycemic in SLM, STZ-S, and db/db mice model along with significant lipid and TG modulating activity. All these compounds were evaluated i",43,ChEMBL,636332,20180913,"10914479,11110678,11132236,14494718,14532695,14532696,14532699,46845036,46845037,46906758,46906759,46906760,46906761,46906827,46906828,46906829,46906830,46906831,46906933,46906934,46906973,46906974,46906975,46907002,46907003,46907004,46907005,46907006,46907033,46907034,46907035,46907036","103763873,103763987,103763988,103763989,103763990,103763991,103764066,103764067,103764068,103764069,103764070,103764071,103764121,103764168,103764169,103764170,103764171,103764172,103764231,103764232,103764233,103764234,103764235,103764273,103764274,103764275,103764276,103764277,103764331,103764332,103764333,103764334",NULL,NULL,NULL,Curation Efforts|Research and Development,20471838,0,10.1016/j.bmc.2009.11.061,NULL,NULL,NULL
485547,100,Inhibition of PTP1B assessed as p-nitrophenolate ion production at 100 uM pretreated for 10 mins measured after 30 mins,"Title: Design and synthesis of 2,4-disubstituted polyhydroquinolines as prospective antihyperglycemic and lipid modulating agents._|__|_Abstract: A series of 2,4-disubstituted polyhydroquinoline were synthesized and evaluated for their in vivo antihyperglycemic as well as antidyslipidemic activities. Several synthesized compounds have exhibited promising in vivo antihyperglycemic in SLM, STZ-S, and db/db mice model along with significant lipid and TG modulating activity. All these compounds were evaluated i",43,ChEMBL,636330,20180913,"10914479,11110678,11132236,14494718,14532695,14532696,14532699,46845036,46845037,46906758,46906759,46906760,46906761,46906827,46906828,46906829,46906830,46906831,46906933,46906934,46906973,46906974,46906975,46907002,46907003,46907004,46907005,46907006,46907033,46907034,46907035,46907036","103763873,103763987,103763988,103763989,103763990,103763991,103764066,103764067,103764068,103764069,103764070,103764071,103764121,103764168,103764169,103764170,103764171,103764172,103764231,103764232,103764233,103764234,103764235,103764273,103764274,103764275,103764276,103764277,103764331,103764332,103764333,103764334",5770,NULL,P18031,Curation Efforts|Research and Development,20471838,0,10.1016/j.bmc.2009.11.061,3.1.3.48,P18031,NULL
485529,100,Chemical stability after 7 days by HPLC,"Title: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli._|__|_Abstract: A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC(50) growth inhibitory ones, accounting, at least partly, for their cytostatic effects ",43,ChEMBL,636312,20180913,"8468,19844,226355,5281767,13468795,13468796,20612718,22895394,45257222,45376005,45376139,45376140,45376141,45376142,45376143,45376411,45376415,45376416,46906970,46906971,46906972,46907000,46907001,46907030,46907031,46907032,46907066,46907067,46907101,46907102,46907103,46907130,46907131,46907132,46907133,46907167","103340697,103347186,103582394,103764164,103764165,103764166,103764167,103764227,103764228,103764229,103764230,103764269,103764270,103764271,103764272,103764327,103764328,103764329,103764330,103764389,103764390,103764391,103764392,103764393,103764453,103764454,103764455,103764456,103764513,103764514,103764515,103764516,103764517,103764518,103764519,103764576",NULL,NULL,NULL,Curation Efforts|Research and Development,20466556,0,10.1016/j.bmc.2010.04.047,NULL,NULL,NULL
485540,2,Cytotoxicity against human K562 cells after 72 hrs by MTS assay,"Title: Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents._|__|_Abstract: Anticancer drugs that bind to DNA and inhibit DNA-processing enzymes represent an important class of anticancer drugs. Combilexin molecules, which combine DNA minor groove binding and intercalating functionalities, have the potential for increased DNA binding affinity and increased selectivity due to their dual mode of DNA binding. ",43,ChEMBL,636323,20180913,"4461,31703,46906605,46906606,46906607,46906608,46906609,46906652,46906653,46906654,46906655,46907247,46907248,46907249,46907250,46907286,46907287,46907288,46907289","103270249,103763810,103763811,103763812,103763813,103763814,103763869,103763870,103763871,103763872,103764678,103764679,103764680,103764681,103764733,103764734,103764735,103764736,123097261",NULL,Toxicity,NULL,Curation Efforts|Research and Development,20471276,0,10.1016/j.bmc.2010.04.028,NULL,NULL,NULL
485541,2,Cytotoxicity against human K/VP.5 cells after 72 hrs by MTS assay,"Title: Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents._|__|_Abstract: Anticancer drugs that bind to DNA and inhibit DNA-processing enzymes represent an important class of anticancer drugs. Combilexin molecules, which combine DNA minor groove binding and intercalating functionalities, have the potential for increased DNA binding affinity and increased selectivity due to their dual mode of DNA binding. ",43,ChEMBL,636324,20200702,"4461,31703,46906605,46906606,46906607,46906608,46906609,46906652,46906653,46906654,46906655,46907247,46907248,46907249,46907250,46907286,46907287,46907288,46907289","103270249,103763810,103763811,103763812,103763813,103763814,103763869,103763870,103763871,103763872,103764678,103764679,103764680,103764681,103764733,103764734,103764735,103764736,123097261",NULL,NULL,NULL,Curation Efforts|Research and Development,20471276,0,10.1016/j.bmc.2010.04.028,NULL,NULL,NULL
485950,2,Inhibition of human reticulocyte N-terminal His6-tagged 15-lipoxygenase by UV-vis spectrometry,"Title: Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes._|__|_Abstract: Enzyme screening of crude sponge extracts prioritized a 2005 Papua New Guinea collection of Hyrtios sp. for further study. The MeOH extract contained puupehenone and four puupehenone analogues (1, 2, 3, 5, and 7) along with a new diastereomer, 20-epi-hydroxyhaterumadienone (4), and a new analogue, 15-oxo-puupehenoic acid (6). The drimane terpene core of 4 and 6 was rapidly dereplicated, and th",43,ChEMBL,636733,20180913,"4534,72536,460087,10110469,10179787,10220327,44557858,46907572,46907602","103167143,103405661,103444183,103444317,103765768,103765769,103765770,103765836,103765837",246,NULL,P16050,Curation Efforts|Research and Development,19848434,0,10.1021/np900465e,"1.13.11.-,1.13.11.12,1.13.11.31,1.13.11.33",P16050,NULL
485949,2,Inhibition of human platelet N-terminal His6-tagged 12-lipoxygenase by UV-vis spectrometry,"Title: Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes._|__|_Abstract: Enzyme screening of crude sponge extracts prioritized a 2005 Papua New Guinea collection of Hyrtios sp. for further study. The MeOH extract contained puupehenone and four puupehenone analogues (1, 2, 3, 5, and 7) along with a new diastereomer, 20-epi-hydroxyhaterumadienone (4), and a new analogue, 15-oxo-puupehenoic acid (6). The drimane terpene core of 4 and 6 was rapidly dereplicated, and th",43,ChEMBL,636732,20180913,"4534,72536,460087,10110469,10179787,10220327,44557858,46907572,46907602","103167143,103405661,103444183,103444317,103765768,103765769,103765770,103765836,103765837",239,NULL,P18054,Curation Efforts|Research and Development,19848434,0,10.1021/np900465e,"1.13.11.-,1.13.11.31,1.13.11.33,3.3.2.-",P18054,NULL
485968,2,Displacement of [125I]U2 from rat urotensin 2 receptor expressed in CHO cells,Title: Urotensin-II receptor modulators as potential drugs._|_,43,ChEMBL,636751,20180913,"9846574,10865905,10887289,10898288,10930952,10974939,10985299,10996572,11006017,11007453,11040237,11125778,11829013,12111224,16150418,16150656","103460958,103708451,103765838,103765850,103765851,103765852,103765853,103765854,103765855,103765856,103765857,103765858,103765859,103765860,103765861,103765862",57305,NULL,P49684,Curation Efforts|Research and Development,20043680,0,10.1021/jm901294u,NULL,P49684,NULL
485951,2,Inhibition of human N-terminal His6-tagged 5-lipoxygenase arachidonic acid by UV-vis spectrometry,"Title: Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes._|__|_Abstract: Enzyme screening of crude sponge extracts prioritized a 2005 Papua New Guinea collection of Hyrtios sp. for further study. The MeOH extract contained puupehenone and four puupehenone analogues (1, 2, 3, 5, and 7) along with a new diastereomer, 20-epi-hydroxyhaterumadienone (4), and a new analogue, 15-oxo-puupehenoic acid (6). The drimane terpene core of 4 and 6 was rapidly dereplicated, and th",43,ChEMBL,636734,20180913,"4534,72536,460087,10110469,10179787,10220327,44557858,46907572,46907602","103167143,103405661,103444183,103444317,103765768,103765769,103765770,103765836,103765837",240,NULL,P09917,Curation Efforts|Research and Development,19848434,0,10.1021/np900465e,"1.13.11.-,1.13.11.34",P09917,NULL
485517,2,Cytotoxicity against human NHDF cells by MTT assay,"Title: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli._|__|_Abstract: A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC(50) growth inhibitory ones, accounting, at least partly, for their cytostatic effects ",43,ChEMBL,636300,20180913,"226355,13468795,13468796,22895394,45257222,45376005,45376139,45376140,46906970,46906971,46906972,46907031,46907032,46907067,46907131,46907132","103764164,103764165,103764166,103764167,103764227,103764228,103764229,103764230,103764269,103764329,103764330,103764390,103764391,103764516,103764517,103764518",NULL,Toxicity,NULL,Curation Efforts|Research and Development,20466556,0,10.1016/j.bmc.2010.04.047,NULL,NULL,NULL
485952,2,Selectivity ratio of IC50 for human platelet 12-lipoxygenase to IC50 for human 5-lipoxygenase,"Title: Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes._|__|_Abstract: Enzyme screening of crude sponge extracts prioritized a 2005 Papua New Guinea collection of Hyrtios sp. for further study. The MeOH extract contained puupehenone and four puupehenone analogues (1, 2, 3, 5, and 7) along with a new diastereomer, 20-epi-hydroxyhaterumadienone (4), and a new analogue, 15-oxo-puupehenoic acid (6). The drimane terpene core of 4 and 6 was rapidly dereplicated, and th",43,ChEMBL,636735,20180913,"4534,72536,460087,10110469,10179787,10220327,46907572,46907602","103167143,103405661,103444183,103444317,103765768,103765769,103765836,103765837",NULL,NULL,NULL,Curation Efforts|Research and Development,19848434,0,10.1021/np900465e,NULL,NULL,NULL
485983,2,Growth inhibition of human HCT116 cells by sulforhodamine B assay,"Title: New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges._|__|_Abstract: The goal of this study was to isolate and study additional jasplakinolide analogues from two taxonomically distinct marine sponges including two Auletta spp. and one Jaspis splendens. This led to the isolation of jasplakinolide (1) and eleven jasplakinolide analogues (3-13) including seven new analogues (6-10, 12, and 13). Structure elucidation of the new compounds was based on a comb",43,ChEMBL,636766,20180913,"9831636,10747466,23584823,25017462,45103599,45103600,46907532,46907533,46907534,46907535,46907536","103562376,103579559,103765631,103765632,103765633,103765634,103765635,103765636,103765637,103765638,103765639",NULL,NULL,NULL,Curation Efforts|Research and Development,20121114,0,10.1021/jm9013554,NULL,NULL,NULL
485953,2,Selectivity ratio of IC50 for human reticulocyte 15-lipoxygenase to IC50 for human 5-lipoxygenase,"Title: Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes._|__|_Abstract: Enzyme screening of crude sponge extracts prioritized a 2005 Papua New Guinea collection of Hyrtios sp. for further study. The MeOH extract contained puupehenone and four puupehenone analogues (1, 2, 3, 5, and 7) along with a new diastereomer, 20-epi-hydroxyhaterumadienone (4), and a new analogue, 15-oxo-puupehenoic acid (6). The drimane terpene core of 4 and 6 was rapidly dereplicated, and th",43,ChEMBL,636736,20180913,"4534,72536,460087,10110469,10179787,10220327,46907572,46907602","103167143,103405661,103444183,103444317,103765768,103765769,103765836,103765837",NULL,NULL,NULL,Curation Efforts|Research and Development,19848434,0,10.1021/np900465e,NULL,NULL,NULL
485518,2,Cytotoxicity against human WI38 cells after 24 hrs by MTT assay,"Title: Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli._|__|_Abstract: A series of 33 novel divanillates and trivanillates were synthesized and found to possess promising cytostatic rather than cytotoxic properties. Several compounds under study decreased by >50% the activity of Aurora A, B, and C, and WEE1 kinase activity at concentrations <10% of their IC(50) growth inhibitory ones, accounting, at least partly, for their cytostatic effects ",43,ChEMBL,636301,20180913,"226355,13468795,13468796,22895394,45257222,45376005,45376139,45376140,46906970,46906971,46906972,46907031,46907032,46907067,46907131,46907132","103764164,103764165,103764166,103764167,103764227,103764228,103764229,103764230,103764269,103764329,103764330,103764390,103764391,103764516,103764517,103764518",NULL,Toxicity,NULL,Curation Efforts|Research and Development,20466556,0,10.1016/j.bmc.2010.04.047,NULL,NULL,NULL
485989,2,Growth inhibition of human MCF7 cells by sulforhodamine B assay,"Title: New structures and bioactivity properties of jasplakinolide (jaspamide) analogues from marine sponges._|__|_Abstract: The goal of this study was to isolate and study additional jasplakinolide analogues from two taxonomically distinct marine sponges including two Auletta spp. and one Jaspis splendens. This led to the isolation of jasplakinolide (1) and eleven jasplakinolide analogues (3-13) including seven new analogues (6-10, 12, and 13). Structure elucidation of the new compounds was based on a comb",43,ChEMBL,636772,20180913,"9831636,10747466,23584823,25017462,45103599,45103600,46907532,46907533,46907534,46907535,46907536","103562376,103579559,103765631,103765632,103765633,103765634,103765635,103765636,103765637,103765638,103765639",NULL,NULL,NULL,Curation Efforts|Research and Development,20121114,0,10.1021/jm9013554,NULL,NULL,NULL
485536,100,Inhibition of topoisomerase 1-mediated relaxation of supercoiled pBR322 DNA at 20 uM after 20 mins using ethidium bromide staining by electrophoresis relative to control,"Title: Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents._|__|_Abstract: Anticancer drugs that bind to DNA and inhibit DNA-processing enzymes represent an important class of anticancer drugs. Combilexin molecules, which combine DNA minor groove binding and intercalating functionalities, have the potential for increased DNA binding affinity and increased selectivity due to their dual mode of DNA binding. ",43,ChEMBL,636319,20180913,"4461,31703,46906605,46906606,46906607,46906608,46906609,46906652,46906653,46906654,46906655,46907247,46907248,46907249,46907250,46907286,46907287,46907288,46907289","103270249,103763810,103763811,103763812,103763813,103763814,103763869,103763870,103763871,103763872,103764678,103764679,103764680,103764681,103764733,103764734,103764735,103764736,123097261",7150,NULL,P11387,Curation Efforts|Research and Development,20471276,0,10.1016/j.bmc.2010.04.028,5.6.2.1,P11387,NULL
485539,100,Inhibition of human recombinant topoisomerase 2 alpha assessed as stabilization of enzyme-PBR322 DNA complex at 100 uM relative to control,"Title: Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents._|__|_Abstract: Anticancer drugs that bind to DNA and inhibit DNA-processing enzymes represent an important class of anticancer drugs. Combilexin molecules, which combine DNA minor groove binding and intercalating functionalities, have the potential for increased DNA binding affinity and increased selectivity due to their dual mode of DNA binding. ",43,ChEMBL,636322,20180913,"4461,31703,46906605,46906606,46906607,46906608,46906609,46906652,46906653,46906654,46906655,46907247,46907248,46907249,46907250,46907286,46907287,46907288,46907289","103270249,103763810,103763811,103763812,103763813,103763814,103763869,103763870,103763871,103763872,103764678,103764679,103764680,103764681,103764733,103764734,103764735,103764736,123097261",7153,NULL,P11388,Curation Efforts|Research and Development,20471276,0,10.1016/j.bmc.2010.04.028,5.6.2.2,P11388,NULL
504891,2,qHTS Assay to Find Inhibitors of Pin1,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|_MLPCN Grant: 1 R03 DA031663-01_|_PI Name: Dr. Kun Ping Lu_|__|_NCGC Assay Overview:_|__|_Protein phosphorylation on certain serine or threonine residues preceding a proline (phos.Ser/Thr-Pro) is a major signaling mechanism in diverse cellular processes, and its deregulation contributes to human disease, notably cancer, Alzheimer's disease, aging, and asthma [1-2]. The unique chemical properties of Pro allow for ",2,National Center for Advancing Translational Sciences (NCATS),pin1002,20110701,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1189,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1677,1678,1688,1689,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",5300,NULL,NP_006212,Governmental Organizations|NIH Initiatives,"17410202,17876319,17878917",0,10.1038/nchembio.2007.35|10.1038/nrc2107|10.1038/nrm2261,5.2.1.8,Q13526,NULL
504444,2,Nrf2 qHTS screen for inhibitors,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: R03-MH092170-01_|_Assay Provider: Shyam Biswal, Johns Hopkins University_|__|_Assay Overview:_|_Nrf2 is a transcription factor that maintains cellular redox homoestasis and protects cells from xenobiotics [1,2]. Nrf2 binds to the antioxidant response element (ARE) to induce gene expression of a broad spectrum of genes that encode for antioxidants. Hence this Nrf2 pathway provides a first line of ",2,National Center for Advancing Translational Sciences (NCATS),NRF2002,20110315,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,379,403,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1189,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1677,1678,1688,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842150,842151,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842182,842183,842184,842186,842188,842189,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842205,842206,842207,842208,8",4780,NULL,NP_001138884,Governmental Organizations|NIH Initiatives,"16959974,18692501",0,10.1053/j.gastro.2008.06.082|10.1126/science.1133427,NULL,Q16236,NULL
504834,2,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation","The goal of this screen is to discover new antimalarial compounds that act by inhibiting the development of the apicoplast in the malarial parasite Plasmodium falciparum. The biochemical processes that make this organelle essential for erythrocytic stage parasites are not well understood. However, antibiotics such as azithromycin and tetracycline, which target the apicoplast translational machinery, have a potent antimalarial effect. The killing caused by these drugs is unusual in that it does not appear to",2,National Center for Advancing Translational Sciences (NCATS),DDP96HR,20110622,"6,51,72,119,137,180,190,191,196,204,205,206,227,229,244,253,263,289,298,299,303,323,338,359,366,370,379,408,441,453,460,464,487,499,525,546,547,564,588,594,595,597,612,637,681,698,701,710,727,736,753,774,785,791,798,803,827,830,863,864,866,876,887,892,896,899,904,931,932,936,938,957,967,978,985,1004,1017,1018,1023,1030,1046,1047,1050,1051,1052,1053,1057,1066,1072,1080,1088,1101,1110,1123,1131,1132,1140,1150,1174,1176,1201,1203,1233,1234,1236,1245,1254,1292,1302,1309,1318,1329,1330,1345,1355,1359,1367,1400,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
504648,2,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: R03-MH092170-01_|_Assay Provider: Shyam Biswal, Johns Hopkins University_|__|_Assay Overview:_|_Nrf2 is a transcription factor that maintains cellular redox homoestasis and protects cells from xenobiotics [1,2]. Nrf2 binds to the antioxidant response element (ARE) to induce gene expression of a broad spectrum of genes that encode for antioxidants. Hence this Nrf2 pathway provides a first line of ",2,National Center for Advancing Translational Sciences (NCATS),NRF2003,20110412,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,403,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1189,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1677,1678,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,8",NULL,Toxicity,NULL,Governmental Organizations|NIH Initiatives,"16959974,18692501",0,10.1053/j.gastro.2008.06.082|10.1126/science.1133427,NULL,NULL,NULL
504832,2,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation","The goal of this screen is to discover new antimalarial compounds that act by inhibiting the development of the apicoplast in the malarial parasite Plasmodium falciparum. The biochemical processes that make this organelle essential for erythrocytic stage parasites are not well understood. However, antibiotics such as azithromycin and tetracycline, which target the apicoplast translational machinery, have a potent antimalarial effect. The killing caused by these drugs is unusual in that it does not appear to",2,National Center for Advancing Translational Sciences (NCATS),DDP48HR,20110622,"6,51,72,119,137,180,190,191,196,204,205,206,227,229,244,253,263,289,298,299,303,323,338,359,366,370,379,408,441,453,460,464,487,499,525,546,547,564,588,594,595,597,612,637,681,698,701,710,727,736,753,774,785,791,798,803,827,830,863,864,866,876,887,892,896,899,904,931,932,936,938,957,967,978,985,1004,1017,1018,1023,1030,1046,1047,1050,1051,1052,1053,1057,1066,1072,1080,1088,1101,1110,1123,1131,1132,1140,1150,1174,1176,1201,1203,1233,1234,1236,1245,1254,1292,1302,1309,1318,1329,1330,1345,1355,1359,1367,1400,1","842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842152,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
504467,2,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: 1 R03 MH092164-01_|_Assay Provider: Kyungjae Myung, NHGRI, NIH_|__|_Keywords: MLPCN, qHTS, NCGC, genotoxicity, cancer_|__|_Assay Overview:_|__|_Cancer cells divide rapidly compared to normal cells in the body. During cell division, cancer cells need to duplicate their genome by DNA replication. The failure of genome duplication leads to cancer cells' death. Therefore, inhibitors of DNA replicatio",2,National Center for Advancing Translational Sciences (NCATS),ELG233,20110316,"6,72,119,137,174,191,204,229,243,253,289,298,299,303,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,803,864,892,899,904,931,932,936,938,957,995,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2002,2007,20","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",79915,NULL,AAH15051,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAH15051,NULL
504847,2,Inhibitors of the vitamin D receptor (VDR): qHTS,"The vitamin D receptor (VDR) is a ligand-activated transcription factor and is partially responsible for the regulation of the endocrine system. This includes the transcriptional regulation of genes involved in the production of the parathyroid hormone (PTH) and the regulation of the blood calcium level. High levels of PHT can cause hypercalcemia in the case of primary and tertiary hyperparathyroidism. The VDR-mediated gene regulation, activated by its ligand 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3), is gove",2,National Center for Advancing Translational Sciences (NCATS),VDR100,20110624,"6,19,40,51,72,86,109,119,127,135,137,138,174,178,180,185,187,190,191,196,199,204,205,206,224,227,229,237,239,243,244,248,249,253,255,263,273,275,277,286,289,298,299,303,304,305,311,314,323,335,338,342,359,366,370,379,401,403,408,412,441,444,450,453,460,462,464,471,487,499,525,535,546,547,564,588,594,595,597,607,610,612,614,636,637,650,660,681,698,701,710,727,736,745,750,753,757,774,785,787,791,798,802,803,827,830,838,847,853,863,864,866,876,887,892,896,899,903,904,912,914,931,932,936,938,942,951,957,967,978","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",7421,NULL,NP_001017535,Governmental Organizations|NIH Initiatives,10678179,0,10.1016/s1097-2765(00)80413-x,NULL,P11473,NULL
504466,2,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: 1 R03 MH092164-01_|_Assay Provider: Kyungjae Myung, NHGRI, NIH_|__|_Keywords: MLPCN, qHTS, NCGC, genotoxicity, cancer_|__|_Assay Overview:_|__|_Cancer cells divide rapidly compared to normal cells in the body. During cell division, cancer cells need to duplicate their genome by DNA replication. The failure of genome duplication leads to cancer cells' death. Therefore, inhibitors of DNA replicatio",2,National Center for Advancing Translational Sciences (NCATS),ELG908,20110316,"6,72,119,137,174,191,204,229,243,253,289,298,299,303,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,803,864,892,899,904,931,932,936,938,957,995,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2002,2007,20","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",79915,Toxicity,AAH15051,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAH15051,NULL
504332,2,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,"Methylated lysines, on the N-terminal tails of histone proteins serve as epigenetic markers to  recruit factors that can then modify local chromatin structure to lead to functional consequences.  G9a and other members of the SUV39 family of the SET domain-containing superfamily of histone lysine methyltransferases (HMT) have been identified to specifically methylate Lys9 of histone H3 (H3K9). G9a catalyzes the mono- and di-methylation of H3K9 in mammalian euchromatic regions, where the resulting H3K9me2 is ",2,National Center for Advancing Translational Sciences (NCATS),G9A502,20110222,"6,51,119,137,138,178,180,185,187,190,191,196,199,204,205,206,224,227,229,237,239,244,248,249,253,263,275,286,289,298,299,305,323,338,342,359,366,370,379,401,408,412,441,444,453,460,462,464,471,487,499,525,535,546,547,564,588,594,595,597,607,612,637,650,681,698,701,710,727,736,753,774,785,787,791,798,803,827,838,853,863,864,866,876,887,892,896,899,903,904,912,914,931,932,936,938,951,957,967,978,985,999,1001,1004,1017,1018,1023,1030,1045,1046,1047,1050,1051,1052,1053,1054,1057,1066,1080,1088,1101,1102,1103,11","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,CAQ07474,Governmental Organizations|NIH Initiatives,"16864780,18496600,19891491,20131845,20567762,20614940",0,10.1016/j.jala.2007.12.004|10.1021/jm100478y|10.1021/jm901137j|10.1021/jm901543m|10.1039/b921912a|10.1073/pnas.0604348103,NULL,CAQ07474,NULL
504845,2,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,"G-protein-coupled receptors (GPCRs) are well-established targets for drug discovery and development. Members of the ""regulator of G-protein signaling"" (RGS)-protein superfamily have recently emerged as critical modulators of specific GPCR signaling pathways. Via their conserved RGS domain that possesses ""GTPase-accelerating protein"" (GAP) activity, RGS proteins deactivate heterotrimeric G-protein alpha (G) subunits and thus attenuate GPCR signal transduction. Combining specific RGS domain inhibitors with ex",2,National Center for Advancing Translational Sciences (NCATS),RGS4001,20110623,"6,19,40,72,86,109,119,127,137,138,174,178,185,187,190,191,199,204,229,237,239,243,248,249,253,255,275,286,289,298,299,303,304,305,311,314,323,335,338,366,379,401,403,408,412,441,444,460,462,464,471,487,499,525,535,546,547,564,588,597,610,636,637,650,660,681,698,701,727,745,750,774,785,787,802,803,838,847,864,892,896,899,903,904,912,931,932,936,938,942,951,957,978,992,995,1001,1002,1017,1018,1030,1045,1046,1047,1050,1066,1088,1101,1102,1103,1123,1150,1174,1176,1182,1183,1189,1201,1204,1207,1212,1214,1215,121","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",5999,NULL,ABC94591,Governmental Organizations|NIH Initiatives,11326297,0,10.1038/sj.mp.4000866,NULL,P49798,NULL
504327,2,qHTS Assay for Inhibitors of GCN5L2,"Histone acetyltransferase (HAT) enzymes transfer a methyl group from acetyl-coenzyme A to the epsilon-amino group of conserved lysine residues of N-terminal histone tails. Acetylation results in charge neutralization of this positively charged amino acid, decreasing interactions with the positively charged DNA backbone and making the DNA more accessible for transcription. HATs have been recognized as an emerging drug target for treatment of cancer, diabetes, asthma, chronic obstructive pulmonary disease, ca",2,National Center for Advancing Translational Sciences (NCATS),GCN509,20110222,"6,51,72,119,135,137,138,174,178,180,185,187,190,191,196,199,204,205,206,224,227,229,237,239,243,244,248,249,253,263,273,275,277,286,289,298,299,303,304,305,323,335,338,342,359,366,370,379,401,408,412,441,444,450,453,460,462,464,471,487,499,525,535,546,547,564,588,594,595,597,607,610,612,614,636,637,650,660,681,698,701,710,727,736,750,753,757,774,785,787,791,798,803,827,838,847,853,863,864,866,876,887,892,896,899,903,904,912,914,931,932,936,938,951,957,967,978,985,992,995,999,1001,1004,1017,1018,1023,1030,10","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",2648,NULL,NP_066564,Governmental Organizations|NIH Initiatives,"16864780,18337604,18496600",0,10.1016/j.jala.2007.12.004|10.1056/nejmra072067|10.1073/pnas.0604348103,"2.3.1.-,2.3.1.48",Q92830,NULL
504339,2,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,"JMJD2A is a jumonji-domain-containing lysine demethylase that uses Fe(II) together with 2-OG to effect oxidative demethylation of histones. Methylation is one of many post-transcriptional modification that affect epigenetic transcription. Hence, cross-talk between histonemarks and histone modifying enzymes exists, whereby enzymes that transfer/remove histone marks also contain reader domains. JmjD2A has been shown to specifically bind to trimethyl H3K4 and H4K20 marks [1] It is proposed that the functions o",2,National Center for Advancing Translational Sciences (NCATS),JMJD2845,20110222,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,403,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1189,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1677,1678,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",NULL,NULL,2QQS_A,Governmental Organizations|NIH Initiatives,"16864780,18084306,18496600,19897549,20131845",0,10.1016/j.jala.2007.12.004|10.1021/jm901137j|10.1038/nsmb1326|10.1073/pnas.0604348103|10.1093/nar/gkp899,NULL,2QQS_A,NULL
504333,2,qHTS Assay for Inhibitors of BAZ2B,"BAZ2B (bromodomain adjacent to zinc finger domain, 2B) belongs to a family of ubiquitously expressed bromodomain containing proteins, which biological function has not yet been elucidated. However, it is suggested that BAZ2B has a similar function as the Drosophila Acf1 protein which regulates nucleosome mobilization through the ATP-dependent chromatin remodelling factor ISWI [1], resulting in alteration in the translational position of the histone and hence transcriptional regulation. The interaction of BA",2,National Center for Advancing Translational Sciences (NCATS),BAZ2722,20110222,"6,72,119,137,191,204,229,253,289,298,299,303,323,338,366,441,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,803,864,892,899,931,932,936,938,957,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2002,2007,2015,2018,2020,2048,2052,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842172,842173,842174,842176,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",29994,NULL,BAA89212,Governmental Organizations|NIH Initiatives,"10662543,15457208,16864780,18496600,19897549,20131845",0,10.1006/geno.1999.6071|10.1016/j.jala.2007.12.004|10.1021/jm901137j|10.1038/sj.emboj.7600382|10.1073/pnas.0604348103|10.1093/nar/gkp899,NULL,BAA89212,NULL
504706,2,qHTS assay for re-activators of p53 using a Luc reporter,"The p53 tumor suppressor plays a key role in suppression of tumorigenesis and in human carcinogenesis. It is frequently found inactivated in human cancers, mainly by point mutation. These point mutations are found in a wide variety of human cancers and a majority of them affect the DNA binding domain of the protein. The point mutations either alter native p53 conformation or abolish DNA contact. Additionally, cancer cells with p53 mutations are more resistant to chemo-radiation therapies._|__|_In order to f",2,National Center for Advancing Translational Sciences (NCATS),p53001,20110427,"6,72,119,137,174,191,204,229,243,253,289,298,299,303,323,335,338,366,379,441,460,464,487,525,546,547,564,597,660,698,701,727,774,803,864,892,899,904,931,932,936,938,957,995,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1893,1922,1967,1981,1983,1985,1986,1988,1989,2000,2002,2007,2015,2020,2048,2052,2082","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",7157,NULL,BAC16799,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,BAC16799,NULL
504937,2,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,"Atherosclerosis is the underlying process for cardiovascular disease and thus is a major contributor to disease burden in the population. The infiltration of LDL into the subendothelial space of the vessel wall, and more importantly its retention, has been shown to be the key factors in the initiation of atherosclerosis. Recently, it has been found that secretory acid sphingomyelinase (S-ASM) action on LDL promotes the retention of LDL by causing its aggregation and enhancing its uptake by macrophages. Thus",2,National Center for Advancing Translational Sciences (NCATS),ASM101,20120530,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",6609,NULL,AAA58377,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAA58377,NULL
504842,2,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,"The eukaryotic chaperonin TRiC (for TCP-1 ring complex) is an essential and conserved chaperone required for the folding and activation of 10-15% of the proteins encoded by the human genome.  TRiC is indispensable for cell survival, as folding of an essential subset of cytosolic proteins, including cytoskeletal components, cell cycle regulators and tumor suppressor proteins, exhibits a strict requirement for TRiC which cannot be substituted by other cytosolic chaperones. The TRiC complex consist of two stac",2,National Center for Advancing Translational Sciences (NCATS),TRiC001,20110623,"6,72,119,137,174,191,204,229,243,253,289,298,299,303,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,774,803,864,892,899,904,931,932,936,938,957,995,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2007,20","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",10576,NULL,AAC98906,Governmental Organizations|NIH Initiatives,20194787,0,10.1073/pnas.0913774107,NULL,P78371,NULL
504894,2,Activators of T cell receptors: qHTS campaign,"Normally activation of naive T cells requires two signals. 1. A signal through the T cell receptor (TCR) which provides antigen specificity to the response. 2. Signals through co-stimulatory molecules, which are necessary for proliferation, survival and cytokine production. In the absence of co-stimulatory signals T cells are not effectively activated, and may even be rendered anergic or unresponsive to subsequent signaling. This lack of costimulation has been shown in multiple model systems to be a major f",2,National Center for Advancing Translational Sciences (NCATS),Tcell001,20110701,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",NULL,NULL,AAA51534,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAA51534,NULL
504720,1,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 2R01 GM068385-06_|_Assay Provider: Dr. Paul Hergenrother, University of Illinois, Urbana, IL_|__|_Bacterial resistance to antibiotics is a worldwide health crisis.  Resistance typically occurs as a result of chromosomal mutation or acquisition of a mobile genetic el",14,Burnham Center for Chemical Genomics,SBCCG-A647-MazEF-Act-Primary-Assay,20110505,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",947252,NULL,NP_417262,NIH Initiatives,"11071896,17190821,17706586,18625335",0,10.1016/j.ab.2007.07.017|10.1016/j.cbpa.2008.06.015|10.1073/pnas.0601168104|10.1074/jbc.m008832200,3.1.27.-,P0AE70,NULL
504810,1,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,The thyroid-stimulating hormone receptor (TSHR) is a member of the 7 trans-membrane-spanning receptor (7TMR) family of cell surface receptors. TSHR-mediated hyperthyroidism is important in thyroid pathology. The development of small molecule antagonists of TSHR may lead to therapeutic approaches for TSHR-mediated hyperthyroidism caused by constitutively activating mutations or stimulating auto-antibodies associated with Graves' disease. Graves' disease is the leading cause of hyperthyroidism and is caused b,2,National Center for Advancing Translational Sciences (NCATS),TSH002,20110625,"6,72,119,137,138,174,178,191,199,204,229,237,243,248,249,253,275,286,289,298,299,303,305,323,335,338,366,379,401,441,444,460,462,464,471,487,499,525,535,546,547,564,588,597,637,650,660,681,698,701,727,774,785,787,803,838,864,892,896,899,903,904,931,932,936,938,951,957,995,1017,1018,1030,1045,1046,1047,1066,1088,1101,1102,1103,1123,1150,1201,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1292,1302,1309,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",7253,NULL,AAI27629,Governmental Organizations|NIH Initiatives,"18216391,19592511,20427476",0,10.1073/pnas.0904506106|10.1177/1087057107313786|10.1210/en.2010-0199,NULL,AAI27629,NULL
504812,1,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,The thyroid-stimulating hormone receptor (TSHR) is a member of the 7 trans-membrane-spanning receptor (7TMR) family of cell surface receptors. TSHR-mediated hyperthyroidism is important in thyroid pathology. The development of small molecule antagonists of TSHR may lead to therapeutic approaches for TSHR-mediated hyperthyroidism caused by constitutively activating mutations or stimulating auto-antibodies associated with Graves' disease. Graves' disease is the leading cause of hyperthyroidism and is caused b,2,National Center for Advancing Translational Sciences (NCATS),TSH001,20110627,"6,72,119,137,138,174,178,191,199,204,229,237,243,248,249,253,275,286,289,298,299,303,305,323,335,338,366,379,401,441,444,460,462,464,471,487,499,525,535,546,547,564,588,597,637,650,660,681,698,701,727,774,785,787,803,838,864,892,896,899,903,904,931,932,936,938,951,957,995,1017,1018,1030,1045,1046,1047,1066,1088,1101,1102,1103,1123,1150,1201,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1292,1302,1309,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,8",7253,NULL,AAI27629,Governmental Organizations|NIH Initiatives,"18216391,19592511,20427476",0,10.1073/pnas.0904506106|10.1177/1087057107313786|10.1210/en.2010-0199,NULL,AAI27629,NULL
504749,0,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,"NIH National Institute of Allergy and Infectious Diseases [NIAID]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: None_|_Assay Provider: Xinzhuan Su, NIAID_|__|_NCGC Assay Overview:_|__|_Plasmodium falciparum is a virulent malarial parasite that kills 1-2 million people worldwide each year. Transmitted by mosquitoes, the sporozoite form of the parasite enters the blood stream to infect hepatocytes, where they become merozoites that infect red blood cells (erythrocytes). Within erythrocytes, merozoit",2,National Center for Advancing Translational Sciences (NCATS),SYBR728,20110816,"51,119,180,190,196,205,206,227,244,263,298,323,359,370,379,408,453,460,464,546,564,588,594,595,612,681,710,727,736,753,774,785,791,798,827,830,863,864,866,876,887,892,896,904,931,936,938,967,978,985,1004,1018,1023,1030,1046,1050,1051,1052,1053,1057,1072,1080,1110,1123,1131,1132,1140,1174,1176,1203,1234,1236,1254,1257,1292,1309,1355,1359,1483,1546,1676,1683,1687,1727,1732,1775,1892,1935,1967,1979,1983,1984,1985,1986,1989,1990,2000,2005,2017,2018,2052,2061,2075,2081,2082,2083,2088,2099,2116,2118,2119,2120,212","855626,855750,855904,3714055,4252459,4252462,4252481,4252484,4252489,4252498,4252505,4252514,4252542,4252550,4252556,4252663,4252664,4252672,4252673,4252682,4252707,4252720,4252736,4252762,4252766,4252873,4252936,4252942,4253003,4253075,4253130,4253134,4253165,4253169,4253170,4253171,4253172,4253243,4253288,4253342,4253464,4253491,4253760,4253884,4253929,4253930,4253932,4253933,4253943,4253976,4254064,4254080,4254095,4254117,4254158,4254257,4254365,7972459,7975373,11110658,11110743,11110779,11110790,1111084",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"18579783,21817045",0,10.1073/pnas.0802982105|10.1126/science.1205216,NULL,NULL,NULL
504884,1,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords:_|_Y. pestis Topoisomerase I, oligonucleotide, Buffer, Mg2+, fluorescence_|__|_Assay Overview:_|_E. coli and Y. pestis accumulate topoisomerase I mutants which can lead to an increase in hydroxyl radicals and rapid bacterial cell death._|_Inhibitors that trap the covalent intermediate formed by bacterial type IA topoisomerases could be developed into novel therapeutics compounds for bacterial pathogens  including gram negatives. An oligo nucleotide substrate with a fluorescent reporter at the 5' en",31,Broad Institute,2123-01_Activator_SinglePoint_HTS_Activity,20111018,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",1175052,Biochemical,CAL20848,NIH Initiatives,NULL,0,NULL,NULL,CAL20848,NULL
504558,1,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: NF-kappaB, Epstein-Barr Virus, inhibitor, LMP1, Latent Membrane Protein 1, luciferase reporter, TES1, TES2_|__|_Assay Overview: Epstein-Barr Virus is a ubiquitous Herpesvirus that is an important cause of Hodgkin's Disease, other Lymphoproliferative Diseases, and Nasopharyngeal Carcinoma. EBV infection mimics NF-kB hyperactivation states present in many malignancies. The EBV oncoprotein LMP1 constitutively activates both canonical and noncanonical NF-kB pathways in a ligand-independent fashion.  L",31,Broad Institute,2122-01_Inhibitor_SinglePoint_HTS_Activity,20110324,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,172","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",3783750,Cell-based,CAD53472,NIH Initiatives,NULL,0,NULL,NULL,CAD53472,NULL
504775,1,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,"Keywords: HDL, Scavenger receptor, SR-BI, cholesterol_|__|_Assay Overview:_|_HDL particles are labeled with DiI and added to mSR-B1 cells at 10 ug/mL in black, 384 well plates.  Cells normally take up HDL via the SR-B1 scavenger receptor in 2 to 3 hours.  After significant uptake of the DiI-HDL, cells become fluorescent.  The level of fluorescence correlates with the amount of HDL uptake and can be measured with the Perkin Elmer Envision plate reader.  The uptake can be inhibited with the compound BLT-1 or ",31,Broad Institute,2085-01_Activator_SinglePoint_HTS_Activity,20110525,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,1738,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",20778,Cell-based,NP_058021,NIH Initiatives,12438696,0,10.1073/pnas.222421399,NULL,Q61009,NULL
504690,1,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R21AI082434-01 _|_Assay Provider: Lars Bode, Ph.D., University of California San Diego, San Diego, CA_|__|_Tropical malaria caused by the protozoan parasite Plasmodium falciparum is responsible for up to three million deaths annually. Due to increasing regional dist",14,Burnham Center for Chemical Genomics,SBCCG-A639-pfG6PDH-Primary-Assay,20110517,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",NULL,NULL,CAC24715,NIH Initiatives,"13682585,15331814,15353959,15672556,18177777,3887862,6337374,86896,9694435",0,10.1007/978-1-4615-9400-0_4|10.1007/s001090050253|10.1016/s0140-6736(08)60073-2|10.1016/s0140-6736(79)91857-9|10.1073/pnas.80.1.298|10.1097/00001432-200410000-00004|10.1136/bmj.1.5236.1346,NULL,CAC24715,NULL
504523,1,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: Keap1- Nrf2 complex, Kelch domain, Inhibitor screening, biochemical fluorescence polarization assay_|__|_Assay Overview:_|_The Keap1, an oxidative stress ""sensor"" protein, forms a complex with the transcription factor Nrf2 and keeps Nrf2 in the cytosol for ubiquitination and subsequent proteosomal degradation.  Under oxidative stress conditions, Keap1 liberates Nrf2 from its repression, resulting in an increased oxidative stress response.  This response may play a role in several diseases, includi",31,Broad Institute,2119-01_Inhibitor_SinglePoint_HTS_Activity,20110321,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8","4780,9817",Biochemical,"NP_001138884,NP_987096",NIH Initiatives,NULL,0,NULL,NULL,"Q14145,Q16236",NULL
504621,1,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,"Keywords: Plasmodium falciparum, malaria, Hsp90_|__|__|_Assay Overview: Approximately 2 million deaths a year result from infections with the malarial parasite Plasmodium falciparum, the most deadly human parasitic disease. Drug-resistant strains of this parasite have emerged and threaten the utility of conventional anti-malarial compounds used to fight this disease. In a variety of fungal species, it has been shown that HSP90 inhibitors can reverse drug resistance, and this may be true for other eukaryotic",31,Broad Institute,2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,20110330,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,1738,1742,17","842121,842122,842123,842124,842125,842126,842128,842129,842130,842131,842133,842134,842136,842137,842138,842140,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842167,842168,842169,842170,842171,842172,842173,842178,842179,842180,842181,842182,842183,842187,842188,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842204,842205,842206,842207,842209,842211,842213,842214,842216,842217,8",811999,Organism-based,XP_001348591,NIH Initiatives,NULL,0,NULL,NULL,XP_001348591,NULL
504406,1,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,"Keywords:_|_Uridine Diphosphate (UDP), UDP-Galactopyranose Mutase (UGM), Inhibitor Screening, Fluorescent Polarization (FP) assay, Mycobacterium tuberculosis_|__|_Assay Overview:_|_This is a FP assay to measure binding between UGM from M.tuberculosis and UDP. UGM is a recombinant protein with a N-terminal 6xHistidine tag expressed in and purified from E.coli bacteria. UDP is conjugated to a fluororescein for use as tracer in FP assay. Emission of UDP-Fluorescein after excitation with plane-polarized light i",31,Broad Institute,2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,20110302,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,299,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,701,727,785,802,803,864,892,896,899,903,931,932,936,938,942,957,978,992,1001,1017,1018,1030,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1742,1761,1775,1794,1795,1814,1820,1826,1832,1833,1853,18","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,8",886142,Biochemical,NP_218326,NIH Initiatives,NULL,0,NULL,5.4.99.9,P9WIQ1,NULL
504582,1,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: Heat shock proteins, malaria_|__|_Assay Overview:  During its life cycle in its human host P. falciparum infects and remodels red blood cells. Strikingly, P. falciparum also shows a marked expansion of the heat shock protein 40 (Hsp40) family of co-chaperones and it's been proposed that during this process the parasite relies on a greatly expanded class of Hsp40 co-chaperones to infect and kill cells.  In this screening project, the capacity of small molecules to block malaria HSP40-mediated yeast",31,Broad Institute,2120-01_Inhibitor_SinglePoint_HTS_Activity,20110331,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",811941,"Organism-based,Toxicity,In vivo",XP_001348533,NIH Initiatives,NULL,0,NULL,NULL,XP_001348533,NULL
504462,1,uHTS fluorescent assay for identification of inhibitors of ATG4B,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH090871-01_|_Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_Autophagy is an evolutionarily conserved process whereby cells catabolize damaged proteins and organelles for purposes of generating substrates for su",14,Burnham Center for Chemical Genomics,SBCCG-A593-ATG4B-Primary-Assay,20110316,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",23192,NULL,NP_037457,NIH Initiatives,"12446702,12967324,16183633,16728626,16843265,17957134,18196957,18305538",0,10.1016/j.ccr.2006.06.001|10.1038/nature06639|10.1042/bj20030826|10.1074/jbc.m208247200|10.1074/jbc.m509158200|10.1126/science.312.5777.1160|10.4161/auto.5172|10.4161/auto.5523,3.4.22.-,Q9Y4P1,NULL
504408,1,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,"Keywords: Heat Shock Factor-1 (HSF-1), Stress Response, MG132, NIH3T3, Luminescence_|__|_Assay Overview: Confirmation testing of small molecules identified as increasing expression of a firefly luciferase under the control of a HSF-1 response element in modified NIH3T3 cells. For consistency with the primary assay in which these compounds were identified, after 30min exposure to small molecules, proteasome inhibitor MG132 is added to elicit a stress response*. After an additional 8hr incubation, the amount ",31,Broad Institute,2038-01_Activator_SinglePoint_HTS_Activity,20110307,"19,72,86,109,119,127,137,190,191,204,229,253,298,303,311,323,338,366,403,412,444,460,464,499,525,546,547,588,597,637,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1046,1047,1123,1174,1176,1201,1309,1318,1329,1340,1345,1365,1367,1369,1401,1474,1486,1492,1493,1539,1546,1639,1646,1662,1676,1678,1688,1727,1738,1775,1780,1795,1820,1826,1832,1853,1864,1882,1889,1890,1892,1893,1917,1923,1967,1981,1985,1986,1988,1990,2000,2002,2007,2015,2018,2048,2082,2092,2108,2123,2125,2132,2143,2145,2153,2159,","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,8",NULL,Cell-based,NULL,NIH Initiatives,"10955818,18434519,9083035",0,10.1074/jbc.272.14.9086|10.1523/jneurosci.0296-08.2008,NULL,NULL,NULL
504423,1,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: KSHV, LANA, DNA-binding, latency, fluorescence polarization_|__|_Assay Overview:_|_C-terminal LANA self-associates to bind a specific 20 bp terminal repeat (TR) DNA sequence (Kd of 1.51+/- 0.16 nM) on the KSHV episome. LANA binding is essential for episome persistence since it tethers the KSHV DNA episome to host chromosomes and is essential for LANA to mediate replication of TR DNA. We developed a primary assay to detect the binding of LANA binding sequence (LBS) (a labeled DNA duplex containing ",31,Broad Institute,2117-01_Inhibitor_SinglePoint_HTS_Activity,20110307,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,Biochemical,ADQ57959,NIH Initiatives,11238851,0,10.1128/jvi.75.7.3250-3258.2001,NULL,ADQ57959,NULL
504652,1,Antagonist of Human D 1 Dopamine Receptor: qHTS,"Dopamine receptors (DARs) are involved in the etiology and/or therapy of a number of neuropsychiatric and endocrine disorders. For instance, all receptor-based antiparkinsonian drugs work via stimulating the D1 DAR subtype whereas all FDA-approved antipsychotic agents are antagonists of this receptor. Most drugs targeting the D1 DAR are problematic, however, either being less efficacious as desired or possessing limiting side effects, most of which are due to reactivity at other receptors. One approach towa",2,National Center for Advancing Translational Sciences (NCATS),DOP1002,20110412,"6,72,119,137,191,204,229,253,289,298,303,323,338,441,460,464,487,499,525,546,547,564,588,597,637,698,727,774,803,864,892,899,932,936,938,1018,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2002,2007,2015,2018,2020,2048,2052,2082,2092,2108,2117,2118,2122,2123,2125,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",1812,NULL,NP_000785,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P21728,NULL
504660,1,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Centers Network [MLPCN]_|__|_MLPCN Grant: NS064831-01_|_Assay Submitter (PI): David Sibley_|__|_Dopamine receptors (DARs) are involved in the etiology and/or therapy of a number of neuropsychiatric and endocrine disorders. For instance, all receptor-based antiparkinsonian drugs work via stimulating the D1 DAR subtype whereas all FDA-approved antipsychotic agents are antagonists of this receptor. Most drugs targeting the D1 DAR are problemat",2,National Center for Advancing Translational Sciences (NCATS),DOP1001,20110413,"6,72,119,137,191,204,229,253,289,298,299,303,323,338,366,441,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,803,864,892,899,931,932,936,938,957,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2002,2007,2015,2018,2020,2048,2052,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",1812,NULL,NP_000785,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P21728,NULL
504577,1,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,"University of New Mexico Assay Overview:  _|_Assay Support: 1 R03 DA031666-01A1_|_Project Title: Flow Cytometry HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast_|_Assay Provider: Karlett Parra Ph.D _|_Lead Biologist: Catherine Prudom Ph.D., Mark Carter MS_|_Chemistry Center/ PI:  _|_Specialized Chemistry Center:_|_Assay Implementation: Travis Houston, Keon Ahghar, Stephanie Chavez, Dominique Perez, Matthew Garcia, Sahba Charkhzarrin, Anna Waller Ph.D, Annette Evangelisti Ph.D_|__|_Ass",6,NMMLSC,UNMCMD_VA_PRIMARY_MLPCN,20120118,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,172","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",855842,NULL,NP_015090,NIH Initiatives,11689102,0,10.1177/108705710100600204,NULL,P32842,NULL
504329,2,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,"Influenza viruses are negative-sense, single-stranded RNA viruses that infect the upper, and occasionally the lower, respiratory tracts In the US. Illness from infections by influenza virus has caused an average of approximately 36,000 deaths from 1990-1999 and 226,000 hospitalizations during 1979-2001 (Thompson, W. W., et al. PMID: 15367555), (Thompson, W. W., et al. PMID:12517228). Influenza A viruses (IAV), which also infect a wide number of avian and mammalian species, pose a considerable public health ",33,Southern Research Specialized Biocontainment Screening Center,NS1A_H1N1,20110222,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",23308111,NULL,ACP44172,NIH Initiatives,"10202186,11226857,12517228,15367555,17426143,17970694,18089727,18813227,19390508,19465683",0,10.1001/jama.289.2.179|10.1001/jama.292.11.1333|10.1016/s1286-4579(00)01351-4|10.1038/cr.2008.288|10.1073/pnas.0701849104|10.1089/jir.2006.0176|10.1099/vir.0.83391-0|10.1126/science.1176225|10.3892/ijmm.3.5.527,NULL,ACP44172,NULL
504490,1,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,"University of New Mexico Assay Overview:  _|_Assay Support: 1 R03 DA031665-01A1_|_Project Title: MLP Assay for Arrestin-AP2 Inhibitors_|_Assay Provider: Eric Prossnitz Ph.D _|_Lead Biologist: Catherine Prudom Ph.D., Mark Carter MS, Anna Waller Ph.D, Annette Evangelisti Ph.D_|_Screening Operations Team: Mark Carter MS, Kristine Gouveia MS, J. Jacob Strouse Ph.D., Anna Waller Ph.D._|_Chemistry Center/ PI: Craig W. Lindsley_|_Specialized Chemistry Center: Vanderbilt Specialized Chemistry Center For Accelerated",6,NMMLSC,UNMCMD_AP2_PRIMARY_MLPCN,20110326,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",408,NULL,AAH03636,NIH Initiatives,"11689102,16903783,19602204",0,10.1111/j.1600-0854.2009.00957.x|10.1177/108705710100600204|10.1371/journal.pbio.0040262,NULL,P49407,NULL
504454,1,HTS for Beta-2AR agonists via FAP method,"University of New Mexico Assay Overview:  _|_Assay Support: R03 MH093192-01_|_Project Title: HTS for Non-Canonical Ligands for Beta 2 Adrenergic Receptor Internalization _|_Assay Provider: Jonathan Jarvik, Carnegie Mellon University _|_Screening Center/ PI:  UNMCMD/ Larry Sklar_|_Lead Biologist:  Yang Wu_|_Chemistry Center/ PI:  Vanderbilt Specialty Chemistry Center/Craig Lindsley                                                             Chemistry Center Lead:  Shaun Stauffer_|_Assay Implementation:  Yang",6,NMMLSC,UNMCMD_BA_PRIMARY_MLPCN,20110921,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",154,NULL,NP_000015,NIH Initiatives,"15181976,16289308,18071299",0,10.1016/j.pharmthera.2005.10.001|10.1038/sj.bjp.0707606|10.1080/07853890310024668,NULL,P07550,NULL
504734,1,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Peter S. Tobias, The Scripps Research Institute (TSRI)_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: RO1 AI078288_|_Grant Proposal PI: Peter S. Tobias, The Scripps Research Institute (TSRI)_|_External Assay ID: TLR9_INH_BLA_1536_1X%INH PRUN_|__|_Name: Fluorescence-based cell-based primary high thr",5,The Scripps Research Institute Molecular Screening Center,TLR9_INH_BLA_1536_1X%INH PRUN,20110509,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,172","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",54106,Cell-based,BAG55070,NIH Initiatives,"16832055,19574451",0,10.1073/pnas.0603804103|10.1073/pnas.0905441106,NULL,Q9NR96,NULL
504634,1,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Lakshmi A. Devi, Mount Sinai School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R03NS053751_|_Grant Proposal PI: Lakshmi A. Devi, Mount Sinai School of Medicine_|_External Assay ID: HTR5A_IAG_LUMI_1536_1X%INH_|__|_Name: Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimeriza",5,The Scripps Research Institute Molecular Screening Center,HTR5A_IAG_LUMI_1536_1X%INH,20110403,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",3361,Cell-based,NP_076917,NIH Initiatives,"11069979,16353937,20074870,20647592,8387705,8893006",0,10.1016/0165-6147(93)90068-u|10.1016/j.drugalcdep.2009.12.016|10.1038/383819a0|10.1126/scisignal.2000807|10.1208/aapsj070360,NULL,P47898,NULL
504700,1,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Susan Taylor, University of California, San Diego (UCSD)_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R01 GM34921_|_Grant Proposal PI: Susan Taylor, University of California, San Diego (UCSD)_|_External Assay ID: PKAR2B_ACT_FP_1536_1X%ACT PRUN_|__|_Name: Fluorescence polarization-based biochemica",5,The Scripps Research Institute Molecular Screening Center,PKAR2B_ACT_FP_1536_1X%ACT PRUN,20110422,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,172","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8","5567,5577",Biochemical,"NP_002727,NP_997461",NIH Initiatives,"11749372,12814432,16178799,17133108,17165815,17889648,17932298,1840296,19748511,20697156,4330492,8010741",0,10.1016/j.cell.2007.07.018|10.1016/j.jmb.2009.09.014|10.1021/ac061104g|10.1021/cr000226k|10.1046/j.1365-2184.2003.00267.x|10.1097/cco.0b013e32801195eb|10.1111/j.1749-6632.1971.tb45250.x|10.1126/science.1146447|10.1146/annurev.ph.56.030194.001321|10.1172/jci42391|10.2174/1389450054863644,2.7.11.11,"P22694,P31323",NULL
504707,1,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Susan Taylor, University of California, San Diego (UCSD)_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R01 GM34921_|_Grant Proposal PI: Susan Taylor, University of California, San Diego (UCSD)_|_External Assay ID: PKAR1A_ACT_FP_1536_1X%ACT PRUN_|__|_Name: Fluorescence polarization-based biochemica",5,The Scripps Research Institute Molecular Screening Center,PKAR1A_ACT_FP_1536_1X%ACT PRUN,20110427,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,172","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8","18749,615074",Biochemical,"NP_001069826,NP_035230",NIH Initiatives,"11749372,12814432,16178799,17133108,17165815,17889648,17932298,1840296,19748511,20697156,4330492,8010741",0,10.1016/j.cell.2007.07.018|10.1016/j.jmb.2009.09.014|10.1021/ac061104g|10.1021/cr000226k|10.1046/j.1365-2184.2003.00267.x|10.1097/cco.0b013e32801195eb|10.1111/j.1749-6632.1971.tb45250.x|10.1126/science.1146447|10.1146/annurev.ph.56.030194.001321|10.1172/jci42391|10.2174/1389450054863644,2.7.11.11,"P00514,P68181",NULL
504803,1,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),"Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Antonis S. Zervos, University of Central Florida_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: DK055734_|_Grant Proposal PI: Antonis S. Zervos, University of Central Florida_|_Grant Proposal PI: Antonis S. Zervos, University of Central Florida_|_External Assay ID: HTRA1_INH_FP_1536_1X%INH PRUN_|__|_Name: Fluorescence polarization-based primary biochemical high throughput screening assay to id",5,The Scripps Research Institute Molecular Screening Center,HTRA1_INH_FP_1536_1X%INH PRUN,20110608,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,172","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,Biochemical,Q05DJ8,NIH Initiatives,"12408815,14716297,15101818,15568990,15855271,15993670,16377621,16650464,17053109,17053121,18551132,20238298,9852107",0,10.1016/j.bone.2005.03.015|10.1016/j.ygyno.2006.03.006|10.1016/s1097-2765(02)00658-5|10.1038/cdd.2008.82|10.1038/sj.onc.1207271|10.1042/bj20040435|10.1073/pnas.0501823102|10.1074/jbc.273.51.34406|10.1074/jbc.m500361200|10.1126/science.1133811|10.1126/science.314.5798.405a|10.1146/annurev.genet.38.072902.093416|10.14670/hh-25.599,NULL,Q05DJ8,NULL
504357,1,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Lakshmi A. Devi, Mount Sinai School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R03NS053751_|_Grant Proposal PI: Lakshmi A. Devi, Mount Sinai School of Medicine_|_External Assay ID: OPRM1-OPRD1_IAG_LUMI_1536_1X%INH PRUN_|__|_Name: Luminescence-based cell-based primary high throughput",5,The Scripps Research Institute Molecular Screening Center,OPRM1-OPRD1_IAG_LUMI_1536_1X%INH PRUN,20110224,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8","4985,4988",Cell-based,"NP_000902,NP_000905",NIH Initiatives,"11069979,16353937,20074870,20647592,8387705,8893006",0,10.1016/0165-6147(93)90068-u|10.1016/j.drugalcdep.2009.12.016|10.1038/383819a0|10.1126/scisignal.2000807|10.1208/aapsj070360,NULL,"P35372,P41143",NULL
504651,1,Potentiators of Human D1 Dopamine Receptor: qHTS,"Dopamine receptors (DARs) are involved in the etiology and/or therapy of a number of neuropsychiatric and endocrine disorders. For instance, all receptor-based antiparkinsonian drugs work via stimulating the D1 DAR subtype whereas all FDA-approved antipsychotic agents are antagonists of this receptor. Most drugs targeting the D1 DAR are problematic, however, either being less efficacious as desired or possessing limiting side effects, most of which are due to reactivity at other receptors. One approach towa",2,National Center for Advancing Translational Sciences (NCATS),DOP1003,20110412,"6,72,119,137,191,204,229,253,289,298,299,303,323,338,366,441,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,803,864,892,899,931,932,936,938,957,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2002,2007,2015,2018,2020,2048,2052,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",1812,NULL,NP_000785,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P21728,NULL
504414,1,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: CFTR, CAL, PDZ domain, fluorescence polarization_|__|_Assay Overview: A purified CAL PDZ domain construct is allowed to interact with a tetramethylrhodamine (TMR) labeled fluorescent reporter peptide that binds in the canonical peptide-binding groove. The disruption of the interaction is monitored using fluorescence polarization (FP). Fluorescence is measured at 535 nM in the S and P planes with the Perkin-Elmer Viewlux plate reader after 1 hour incubation at room temperature and the fluorescence ",31,Broad Institute,2109-01_Inhibitor_SinglePoint_HTS_Activity,20110303,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842149,842150,842151,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842182,842183,842184,842187,842188,842189,842191,842192,842193,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,842205,842206,842207,842208,842209,8","1080,57120",Biochemical,"NP_000483,NP_065132",NIH Initiatives,"17158866,21105033",0,10.1002/anie.201005585|10.1074/jbc.m611049200,5.6.1.6,"P13569,Q9HD26",NULL
504411,1,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Benjamin Cravatt, The Scripps Research Institute (TSRI)_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R01 DA025285_|_Grant Proposal PI: Benjamin Cravatt, The Scripps Research Institute (TSRI)_|_External Assay ID: DAGLB_INH_QFRET_1536_1X%INH PRUN_|__|_Name: Fluorescence-based primary biochemical ",5,The Scripps Research Institute Molecular Screening Center,DAGLB_INH_QFRET_1536_1X%INH PRUN,20110303,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,172","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",221955,Biochemical,NP_631918,NIH Initiatives,"18429637,18446159,18657971,20147530,20159446",0,10.1016/j.bmcl.2008.06.091|10.1016/j.neuron.2010.01.021|10.1021/cr0782067|10.1038/nrd2553|10.1523/jneurosci.5693-09.2010,"3.1.1.-,3.1.1.3",Q8NCG7,NULL
504441,1,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: Dyrk-1 kinase, ADP-Glo Kinase Assay, Nuclear Factor Activated T-cells, NFAT_|__|_Assay Overview: The goal of this project is to develop small molecule modulators of the Nuclear Factor Activated T-cells (NFAT) signaling by identifying inhibitors of Dyrk1A kinase.  Using the Promega ADP-Glo Kinase Assay kit, a low volume, 1536-well assay will be used to screen the MLSMR.  Small-molecule inhibitors of Dyrk1A kinase activity will be identified and tested in the assay critical path.  Dyrk1 A kinase inh",31,Broad Institute,2124-01_Inhibitor_SinglePoint_HTS_Activity,20110310,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,932,936,938,942,978,992,995,1001,1018,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1486,1489,1492,1493,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1727,1730,1738,1742,1761,1775,1794,1795,1814,1820,1821,1826,1832,183","842121,842122,842123,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,842205,842206,8",25255,Biochemical,NP_036923,NIH Initiatives,NULL,0,NULL,2.7.12.1,Q63470,NULL
504692,1,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Lakshmi A. Devi, Mount Sinai School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R03NS053751_|_Grant Proposal PI: Lakshmi A. Devi, Mount Sinai School of Medicine_|_External Assay ID: HTR5A_AG_LUMI_1536_1X%ACT_|__|_Name: Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: lum",5,The Scripps Research Institute Molecular Screening Center,HTR5A_AG_LUMI_1536_1X%ACT,20110701,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",3361,Cell-based,NP_076917,NIH Initiatives,"11069979,16353937,20074870,20647592,8387705,8893006",0,10.1016/0165-6147(93)90068-u|10.1016/j.drugalcdep.2009.12.016|10.1038/383819a0|10.1126/scisignal.2000807|10.1208/aapsj070360,NULL,P47898,NULL
504766,1,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Enzo Lalli, CNRS_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R03 DA030558-01_|_Grant Proposal PI: Enzo Lalli, CNRS_|_External Assay ID: DAX1_INH_LUMI_1536_1X%INH PRUN_|__|_Name: Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear rec",5,The Scripps Research Institute Molecular Screening Center,DAX1_INH_LUMI_1536_1X%INH PRUN,20110620,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,172","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",190,Cell-based,NP_000466,NIH Initiatives,"10221899,12842037,15914712,16206264,19530134,7990953,9032275,9384387,9415399,9751505",0,10.1002/ijc.21578|10.1002/stem.78|10.1016/s0969-2126(03)00133-3|10.1038/36899|10.1038/372635a0|10.1126/science.284.5415.757|10.1128/mcb.17.3.1476|10.1210/endo.139.10.6217|10.1210/me.2005-0046|10.1210/mend.11.13.0038,NULL,P51843,NULL
504326,1,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Lakshmi A. Devi, Mount Sinai School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R03NS053751_|_Grant Proposal PI: Lakshmi A. Devi, Mount Sinai School of Medicine_|_External Assay ID: OPRM1-OPRD1_AG_LUMI_1536_1X%ACT PRUN_|__|_Name: Luminescence-based cell-based primary high throughput ",5,The Scripps Research Institute Molecular Screening Center,OPRM1-OPRD1_AG_LUMI_1536_1X%ACT PRUN,20110926,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8","4985,4988",Cell-based,"NP_000902,NP_000905",NIH Initiatives,"11069979,16353937,20074870,20647592,8387705,8893006",0,10.1016/0165-6147(93)90068-u|10.1016/j.drugalcdep.2009.12.016|10.1038/383819a0|10.1126/scisignal.2000807|10.1208/aapsj070360,NULL,"P35372,P41143",NULL
504784,1,Genes regulating lipid storage in Drosophila melanogaster,"Title: COPI Complex Is a Regulator of Lipid Homeostasis_|__|_Abstract: _|_Lipid droplets are ubiquitous triglyceride and sterol ester storage organelles required for energy storage homeostasis and biosynthesis. Although little is known about lipid droplet formation and regulation, it is clear that members of the PAT (perilipin, adipocyte differentiation related protein, tail interacting protein of 47 kDa) protein family coat the droplet surface and mediate interactions with lipases that remobilize the store",50,Drosophila RNAi Screening Center (DRSC),DRSC-P69,20110601,NULL,"104179795,104179796,104179799,104179803,104179804,104179805,104179809,104179822,104179824,104179825,104179830,104179831,104179832,104179838,104179841,104179848,104179851,104179864,104179866,104179868,104179870,104179873,104179880,104179881,104179884,104179886,104179887,104179893,104179894,104179899,104179902,104179910,104179913,104179916,104179919,104179926,104179936,104179937,104179940,104179941,104179943,104179948,104179949,104179950,104179951,104179952,104179959,104179961,104179963,104179983,104179987,10",NULL,RNAi,NULL,Research and Development,19067489,1,10.1371/journal.pbio.0060292,NULL,NULL,NULL
504774,1,Genetic modifiers of cell survival following exposure to DNA damaging agents,"Title: A Network of Conserved Damage Survival Pathways Revealed by a Genomic RNAi Screen_|__|_Abstract: _|_Damage initiates a pleiotropic cellular response aimed at cellular survival when appropriate. To identify genes required for damage survival, we used a cell-based RNAi screen against the Drosophila genome and the alkylating agent methyl methanesulphonate (MMS). Similar studies performed in other model organisms report that damage response may involve pleiotropic cellular processes other than the centra",50,Drosophila RNAi Screening Center (DRSC),DRSC-P44,20110525,NULL,"104179793,104179794,104179795,104179796,104179797,104179798,104179799,104179800,104179801,104179802,104179803,104179804,104179805,104179806,104179807,104179808,104179809,104179810,104179811,104179812,104179813,104179814,104179815,104179816,104179817,104179818,104179819,104179820,104179821,104179822,104179823,104179824,104179825,104179826,104179827,104179828,104179829,104179830,104179831,104179832,104179833,104179834,104179835,104179836,104179837,104179838,104179839,104179840,104179841,104179842,104179843,10",NULL,RNAi,NULL,Research and Development,19543366,1,10.1371/journal.pgen.1000527,NULL,NULL,NULL
504770,0,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,"The Vibrionaceae is comprised of numerous aquatic species and includes several human pathogens, such as Vibrio cholerae, the cause of cholera. All organisms in this family have two chromosomes, and replication of the smaller one depends on rctB, a gene that is restricted to the Vibrionaceae. Given the increasing prevalence of multi-drug resistance in pathogenic vibrios, there is a need for new targets and drugs to combat these pathogens. This high throughput cell-based screen was performed to identify small",46,"ICCB-Longwood Screening Facility, Harvard Medical School",HMS731,20161019,"108,119,127,190,204,253,303,311,323,325,340,346,366,370,397,437,464,564,675,727,782,785,830,863,864,873,896,904,914,938,994,1002,1046,1066,1134,1148,1150,1176,1188,1203,1309,1366,1474,1493,1539,1570,1599,1646,1727,1732,1775,1802,1814,1832,1833,1880,1890,1892,1981,1983,1984,1985,1986,1990,1995,2004,2005,2048,2075,2081,2082,2083,2092,2116,2117,2122,2123,2145,2148,2149,2151,2153,2154,2155,2193,2197,2202,2206,2240,2244,2247,2249,2265,2266,2272,2283,2284,2307,2315,2337,2343,2345,2346,2355,2365,2378,2391,2446,245","92117389,92117390,92117391,92117392,92117393,92117394,92117395,92117396,92117397,92117398,92117399,92117400,92117401,92117402,92117403,92117404,92117405,92117406,92117407,92117408,92117409,92117410,92117411,92117412,92117413,92117414,92117415,92117416,92117417,92117418,92117419,92117420,92117421,92117422,92117423,92117424,92117425,92117426,92117427,92117428,92117429,92117430,92117431,92117432,92117433,92117434,92117435,92117436,92117437,92117438,92117439,92117440,92117441,92117442,92117443,92117444,92117445",2612528,NULL,AAF95916,Research and Development,"18647828,19936046",0,10.1073/pnas.0803904105|10.1371/journal.ppat.1000663,NULL,AAF95916,NULL
504794,1,Identification of novel genes involved in light-dependent CRY degradation,"Title: Identification of novel genes involved in light-dependent CRY degradation through a genome-wide RNAi screen_|__|_Abstract: _|_Circadian clocks regulate many different physiological processes and synchronize these to environmental light:dark cycles. In Drosophila, light is transmitted to the clock by a circadian blue light photoreceptor CRYPTOCHROME (CRY). In response to light, CRY promotes the degradation of the circadian clock protein TIMELESS (TIM) and then is itself degraded. To identify novel gen",50,Drosophila RNAi Screening Center (DRSC),DRSC-P35,20110606,NULL,"104179793,104179794,104179795,104179796,104179797,104179798,104179799,104179800,104179801,104179802,104179803,104179804,104179805,104179806,104179807,104179808,104179809,104179810,104179811,104179812,104179813,104179814,104179815,104179816,104179817,104179818,104179819,104179820,104179821,104179822,104179823,104179824,104179825,104179826,104179827,104179828,104179829,104179830,104179831,104179832,104179833,104179834,104179835,104179836,104179837,104179838,104179839,104179840,104179841,104179842,104179843,10","30970,30971,30972,30973,30975,30976,30977,30978,30979,30980,30981,30982,30983,30984,30985,30986,30988,30990,30991,30994,30995,30996,30998,31000,31001,31002,31003,31004,31005,31006,31007,31009,31010,31011,31012,31013,31014,31015,31016,31017,31018,31019,31020,31021,31022,31023,31024,31025,31026,31027,31028,31029,31030,31031,31032,31033,31035,31036,31037,31038,31039,31042,31043,31044,31045,31046,31047,31048,31049,31050,31052,31054,31055,31056,31057,31059,31060,31061,31062,31063,31064,31065,31066,31067,31068,31",RNAi,NULL,Research and Development,18519643,1,10.1101/gad.1652308,NULL,NULL,NULL
504791,1,Identification and characterization of proteins required for MicroRNA and siRNA biogenesis and functioning,"Title: Comparative Analysis of Argonaute-Dependent Small RNA Pathways in Drosophila_|__|_Abstract: _|_The specificity of RNAi pathways is determined by several classes of small RNAs, which include siRNAs, piRNAs, endo-siRNAs, and microRNAs (miRNAs). These small RNAs are invariably incorporated into large Argonaute (Ago)-containing effector complexes known as RNA-induced silencing complexes (RISCs), which they guide to silencing targets. Both genetic and biochemical strategies have yielded conserved molecula",50,Drosophila RNAi Screening Center (DRSC),DRSC-P36,20110603,NULL,"104179793,104179794,104179795,104179796,104179797,104179798,104179799,104179800,104179801,104179802,104179803,104179804,104179805,104179806,104179807,104179808,104179809,104179810,104179811,104179812,104179813,104179814,104179815,104179816,104179817,104179818,104179819,104179820,104179821,104179822,104179823,104179824,104179825,104179826,104179827,104179828,104179829,104179830,104179831,104179832,104179833,104179834,104179835,104179836,104179837,104179838,104179839,104179840,104179841,104179842,104179843,10",NULL,RNAi,NULL,Research and Development,19026789,1,10.1016/j.molcel.2008.10.018,NULL,NULL,NULL
504716,1,General Secretion,"Title: A genome-wide RNA interference screen identifies two novel components of the metazoan secretory pathway_|__|_Abstract: Genetic screens in the yeast Saccharomyces cerevisiae have identified many proteins involved in the secretory pathway, most of which have orthologs in higher eukaryotes. To investigate whether there are additional proteins that are required for secretion in metazoans but are absent from yeast, we used genome-wide RNA interference (RNAi) to look for genes required for secretion of rec",50,Drosophila RNAi Screening Center (DRSC),DRSC-P59,20110504,NULL,"104179793,104179794,104179795,104179796,104179797,104179798,104179799,104179800,104179801,104179802,104179803,104179804,104179805,104179806,104179807,104179808,104179809,104179810,104179811,104179812,104179813,104179814,104179815,104179816,104179817,104179818,104179819,104179820,104179821,104179822,104179823,104179824,104179825,104179826,104179827,104179828,104179829,104179830,104179831,104179832,104179833,104179834,104179835,104179836,104179837,104179838,104179839,104179840,104179841,104179842,104179843,10",NULL,RNAi,NULL,Research and Development,14764878,1,10.1126/science.1091266,NULL,NULL,NULL
504761,1,Identification of Host Factors Required for Dengue Viral Growth,"Title: Discovery of insect and human dengue virus host factors._|__|_Abstract: Dengue fever is the most frequent arthropod-borne viral disease of humans, with almost half of the world's population at risk of infection. The high prevalence, lack of an effective vaccine, and absence of specific treatment conspire to make dengue fever a global public health threat. Given their compact genomes, dengue viruses (DENV-1-4) and other flaviviruses probably require an extensive number of host factors; however, only a",50,Drosophila RNAi Screening Center (DRSC),DRSC-P81,20110513,NULL,"104179793,104179796,104179799,104179803,104179804,104179805,104179809,104179822,104179824,104179825,104179830,104179831,104179832,104179841,104179848,104179851,104179864,104179866,104179868,104179870,104179873,104179880,104179881,104179884,104179886,104179887,104179893,104179894,104179899,104179902,104179910,104179913,104179916,104179919,104179926,104179936,104179937,104179940,104179943,104179948,104179949,104179950,104179951,104179952,104179959,104179961,104179963,104179983,104179987,104179993,104179996,10",NULL,RNAi,NULL,Research and Development,19396146,1,10.1038/nature07967,NULL,NULL,NULL
504721,1,Mitochondrial Ca Antiporter,"Title: Genome-Wide RNAi Screen Identifies Letm1 as a Mitochondrial Ca2+/H+ Antiporter_|__|_Abstract: Mitochondria are integral components of cellular calcium (Ca2+) signaling. Calcium stimulates mitochondrial adenosine 5 -triphosphate production, but can also initiate apoptosis. In turn, cytoplasmic Ca2+ concentrations are regulated by mitochondria. Although several transporter and ion-channel mechanisms have been measured in mitochondria, the molecules that govern Ca2+ movement across the inner mitochondri",50,Drosophila RNAi Screening Center (DRSC),DRSC-P77,20110505,NULL,"104179793,104179796,104179799,104179803,104179804,104179805,104179809,104179822,104179824,104179825,104179830,104179831,104179832,104179841,104179848,104179851,104179864,104179866,104179868,104179870,104179873,104179880,104179881,104179884,104179886,104179887,104179893,104179894,104179899,104179902,104179910,104179913,104179916,104179919,104179926,104179936,104179937,104179940,104179943,104179948,104179949,104179950,104179951,104179952,104179959,104179961,104179963,104179983,104179987,104179993,104179996,10",NULL,RNAi,NULL,Research and Development,"17853882,19797662",1,10.1038/nprot.2007.250|10.1126/science.1175145,NULL,NULL,NULL
504764,1,Modifiers of Notch Signalling,"Title: Modifiers of notch transcriptional activity identified by genome-wide RNAi._|__|_Abstract: _|_BACKGROUND:_|_The Notch signaling pathway regulates a diverse array of developmental processes, and aberrant Notch signaling can lead to diseases, including cancer. To obtain a more comprehensive understanding of the genetic network that integrates into Notch signaling, we performed a genome-wide RNAi screen in Drosophila cell culture to identify genes that modify Notch-dependent transcription._|__|_RESULTS:",50,Drosophila RNAi Screening Center (DRSC),DRSC-P4,20110516,NULL,"104179793,104179794,104179795,104179796,104179797,104179798,104179799,104179800,104179801,104179802,104179803,104179804,104179805,104179806,104179807,104179808,104179809,104179810,104179811,104179812,104179813,104179814,104179815,104179816,104179817,104179818,104179819,104179820,104179821,104179822,104179823,104179824,104179825,104179826,104179827,104179828,104179829,104179830,104179831,104179832,104179833,104179834,104179835,104179836,104179837,104179838,104179839,104179840,104179841,104179842,104179843,10",31293,RNAi,NULL,Research and Development,20959007,1,10.1186/1471-213x-10-107,NULL,NULL,NULL
504744,1,Insulin response,"Title: Dynamic switch of negative feedback regulation in Drosophila Akt-TOR signaling._|__|_Abstract: Akt represents a nodal point between the Insulin receptor and TOR signaling, and its activation by phosphorylation controls cell proliferation, cell size, and metabolism. The activity of Akt must be carefully balanced, as increased Akt signaling is frequently associated with cancer and as insufficient Akt signaling is linked to metabolic disease and diabetes mellitus. Using a genome-wide RNAi screen in Dros",50,Drosophila RNAi Screening Center (DRSC),DRSC-P24,20110511,NULL,"104179793,104179794,104179795,104179796,104179797,104179798,104179799,104179800,104179801,104179802,104179803,104179804,104179805,104179806,104179807,104179808,104179809,104179810,104179811,104179812,104179813,104179814,104179815,104179816,104179817,104179818,104179819,104179820,104179821,104179822,104179823,104179824,104179825,104179826,104179827,104179828,104179829,104179830,104179831,104179832,104179833,104179834,104179835,104179836,104179837,104179838,104179839,104179840,104179841,104179842,104179843,10",NULL,RNAi,NULL,Research and Development,20585550,1,10.1371/journal.pgen.1000990,NULL,NULL,NULL
504786,1,Transcriptional Response to Hypoxia,"Title: Drosophila Genome-Wide RNAi Screen Identifies Multiple Regulators of HIF-Dependent Transcription in Hypoxia_|__|_Abstract: _|_Hypoxia-inducible factors (HIFs) are a family of evolutionary conserved alpha-beta heterodimeric transcription factors that induce a wide range of genes in response to low oxygen tension. Molecular mechanisms that mediate oxygen-dependent HIF regulation operate at the level of the alpha subunit, controlling protein stability, subcellular localization, and transcriptional coact",50,Drosophila RNAi Screening Center (DRSC),DRSC-P38,20110601,NULL,"104179793,104179794,104179795,104179796,104179797,104179798,104179799,104179800,104179801,104179802,104179803,104179804,104179805,104179806,104179807,104179808,104179809,104179810,104179811,104179812,104179813,104179814,104179815,104179816,104179817,104179818,104179819,104179820,104179821,104179822,104179823,104179824,104179825,104179826,104179827,104179828,104179829,104179830,104179831,104179832,104179833,104179834,104179835,104179836,104179837,104179838,104179839,104179840,104179841,104179842,104179843,10",NULL,RNAi,NULL,Research and Development,20585616,1,10.1371/journal.pgen.1000994,NULL,NULL,NULL
504705,1,Manipulation of the host cell by Francisella tularensis,"Title: Host Factors Required for Modulation of Phagosome Biogenesis and Proliferation of Francisella tularensis within the Cytosol_|__|_Abstract: Francisella tularensis is a highly infectious facultative intracellular bacterium that can be transmitted between mammals by arthropod vectors. Similar to many other intracellular bacteria that replicate within the cytosol, such as Listeria, Shigella, Burkholderia, and Rickettsia, the virulence of F. tularensis depends on its ability to modulate biogenesis of its ",50,Drosophila RNAi Screening Center (DRSC),DRSC-P113,20110503,NULL,"104179793,104179796,104179799,104179803,104179804,104179805,104179809,104179822,104179824,104179825,104179830,104179831,104179832,104179841,104179848,104179851,104179864,104179866,104179868,104179870,104179873,104179880,104179881,104179884,104179886,104179887,104179893,104179894,104179899,104179902,104179910,104179913,104179916,104179919,104179926,104179936,104179937,104179940,104179943,104179948,104179949,104179950,104179951,104179952,104179959,104179961,104179963,104179983,104179987,104179993,104179996,10",NULL,RNAi,NULL,Research and Development,20552012,1,10.1371/journal.pone.0011025,NULL,NULL,NULL
504808,1,A genome-wide RNA interference screen identifies putative chromatin regulators essential for E2F repression,"Title: A genome-wide RNA interference screen identifies putative chromatin regulators essential for E2F repression_|__|_Abstract: _|_Regulation of chromatin structure is critical in many fundamental cellular processes. Previous studies have suggested that the Rb tumor suppressor may recruit multiple chromatin regulatory proteins to repress E2F, a key regulator of cell proliferation and differentiation. Taking advantage of the evolutionary conservation of the E2F pathway, we have conducted a genome-wide RNAi",50,Drosophila RNAi Screening Center (DRSC),DRSC-P18,20110610,NULL,"104179793,104179794,104179795,104179796,104179797,104179798,104179799,104179800,104179801,104179802,104179803,104179804,104179805,104179806,104179807,104179808,104179809,104179810,104179811,104179812,104179813,104179814,104179815,104179816,104179817,104179818,104179819,104179820,104179821,104179822,104179823,104179824,104179825,104179826,104179827,104179828,104179829,104179830,104179831,104179832,104179833,104179834,104179835,104179836,104179837,104179838,104179839,104179840,104179841,104179842,104179843,10","30970,30971,30972,30973,30975,30976,30977,30978,30979,30980,30981,30982,30983,30984,30985,30986,30988,30990,30991,30994,30995,30996,30998,31000,31001,31002,31003,31004,31005,31006,31007,31009,31010,31011,31012,31013,31014,31015,31016,31017,31018,31019,31020,31021,31022,31023,31024,31025,31026,31027,31028,31029,31030,31031,31032,31033,31035,31036,31037,31038,31039,31042,31043,31044,31045,31046,31047,31048,31049,31050,31052,31054,31055,31056,31057,31059,31060,31061,31062,31063,31064,31065,31066,31067,31068,31",RNAi,NULL,Research and Development,17517653,1,10.1073/pnas.0610279104,NULL,NULL,NULL
504865,2,Inhibitors of USP1/UAF1: Pilot qHTS,"Deubiquitinating enzymes (DUBs) are a class of enzymes that can cleave isopeptide bond formed between the C-terminal carboxylate of ubiquitin and a lysine side-chain amino group on the target protein. Among them, ubiquitin specific proteases (USPs) constitute the largest DUB family. Human USPs are emerging as promising targets for pharmacological intervention because of their connection to a number of human diseases, including prostate, colon and breast cancer (1, 2), pediatric acute lymphoblastic leukemia ",2,National Center for Advancing Translational Sciences (NCATS),USP1001,20110628,"51,119,138,178,180,185,190,196,199,204,205,206,224,227,237,239,244,248,249,253,263,275,286,289,298,304,305,323,359,370,379,401,408,444,453,460,462,464,471,535,546,547,564,588,594,595,607,610,612,636,650,681,710,727,736,750,753,774,785,787,791,798,827,830,838,847,853,863,864,866,876,887,892,896,903,904,912,914,931,936,938,951,967,978,985,992,1004,1018,1023,1030,1045,1046,1050,1051,1052,1053,1054,1057,1064,1066,1072,1080,1102,1103,1110,1123,1131,1132,1140,1150,1174,1176,1183,1203,1207,1214,1215,1216,1218,1219","3714055,4237471,4237472,4237474,4237475,4237478,4237479,4237480,4237482,4237483,4237484,4237485,4237486,4237487,4237489,4237491,4237492,4237493,4237494,4237495,4237497,4237498,4237500,4237506,4237508,4237510,4237511,4237514,4237518,4237519,4237521,4237522,4237523,4237524,4237526,4237529,4237530,4237532,4237533,4237534,4237537,4237538,4237540,4237541,4237542,4237544,4237550,4237551,4237553,4237555,4237557,4237558,4237559,4237562,4237563,4237564,4237567,4237569,4237572,4237574,4237575,4237578,4237579,4237580,",7398,NULL,AAH18745,Governmental Organizations|NIH Initiatives,"12917691,15996926,16951176,17558397",0,10.1038/nature01802|10.1038/ncb1601|10.1158/0008-5472.can-06-1374,NULL,AAH18745,NULL
504804,1,A genome-wide RNAi screen reveals multiple regulators of caspase activation,"Title: A genome-wide RNAi screen reveals multiple regulators of caspase activation_|__|_Abstract: _|_Apoptosis is an evolutionally conserved cellular suicide mechanism that can be activated in response to a variety of stressful stimuli. Increasing evidence suggests that apoptotic regulation relies on specialized cell death signaling pathways and also integrates diverse signals from additional regulatory circuits, including those of cellular homeostasis. We present a genome-wide RNA interference screen to sy",50,Drosophila RNAi Screening Center (DRSC),DRSC-P26,20110609,NULL,"104179793,104179794,104179795,104179796,104179797,104179798,104179799,104179800,104179801,104179802,104179803,104179804,104179805,104179806,104179807,104179808,104179809,104179810,104179811,104179812,104179813,104179814,104179815,104179816,104179817,104179818,104179819,104179820,104179821,104179822,104179823,104179824,104179825,104179826,104179827,104179828,104179829,104179830,104179831,104179832,104179833,104179834,104179835,104179836,104179837,104179838,104179839,104179840,104179841,104179842,104179843,10","30970,30971,30972,30975,30976,30977,30978,30979,30980,30981,30982,30983,30984,30985,30988,30990,30991,30996,30998,31003,31004,31005,31006,31007,31009,31012,31013,31014,31018,31019,31020,31021,31022,31023,31026,31028,31029,31031,31032,31033,31035,31036,31037,31038,31039,31042,31043,31044,31045,31046,31047,31048,31049,31050,31052,31055,31056,31057,31059,31060,31061,31062,31063,31064,31065,31066,31067,31068,31069,31070,31071,31074,31075,31080,31081,31084,31085,31089,31093,31096,31099,31100,31102,31104,31106,31",RNAi,NULL,Research and Development,17998402,1,10.1083/jcb.200708090,NULL,NULL,NULL
504793,1,Screen for novel regulators of G2/M checkpoint,"Title: A Genome-Wide RNAi Screen Identifies Core Components of the G2-M DNA Damage Checkpoint_|__|_Abstract: _|_The DNA damage checkpoint, the first pathway known to be activated in response to DNA damage, is a mechanism by which the cell cycle is temporarily arrested to allow DNA repair. The checkpoint pathway transmits signals from the sites of DNA damage to the cell cycle machinery through the evolutionarily conserved ATM (ataxia telangiectasia mutated) and ATR (ATM- and Rad3-related) kinase cascades. We",50,Drosophila RNAi Screening Center (DRSC),DRSC-P106,20110604,NULL,"104179793,104179796,104179799,104179803,104179804,104179805,104179809,104179822,104179824,104179825,104179830,104179831,104179832,104179841,104179848,104179851,104179864,104179866,104179868,104179870,104179873,104179880,104179881,104179884,104179886,104179887,104179893,104179894,104179899,104179902,104179910,104179913,104179916,104179919,104179926,104179936,104179937,104179940,104179943,104179948,104179949,104179950,104179951,104179952,104179959,104179961,104179963,104179983,104179987,104179993,104179996,10","30970,30971,30972,30973,30975,30976,30977,30978,30979,30980,30981,30982,30983,30984,30985,30986,30988,30990,30991,30994,30995,30996,30998,31000,31001,31002,31003,31004,31005,31006,31007,31009,31010,31011,31012,31013,31014,31015,31016,31017,31018,31019,31020,31021,31022,31023,31024,31025,31026,31027,31028,31029,31030,31031,31032,31033,31035,31036,31037,31038,31039,31042,31043,31044,31045,31046,31047,31048,31049,31050,31052,31054,31055,31056,31057,31059,31060,31061,31062,31063,31064,31065,31066,31067,31068,31",RNAi,NULL,Research and Development,21205937,1,10.1126/scisignal.2001350,NULL,NULL,NULL
504848,2,"Confirmation screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation","The goal of this screen is to discover new antimalarial compounds that act by inhibiting the development of the apicoplast in the malarial parasite Plasmodium falciparum. The biochemical processes that make this organelle essential for erythrocytic stage parasites are not well understood. However, antibiotics, such as azithromycin and tetracycline, which target the apicoplast translational machinery, have a potent antimalarial effect. The killing caused by these drugs is unusual in that it does not appear t",2,National Center for Advancing Translational Sciences (NCATS),DD-R1-96HR,20110624,"1400,1491,2240,2353,3947,4139,5405,5583,6197,6842,6843,7085,8480,8549,10531,14358,14710,16574,18834,21651,23205,36314,37392,37907,39794,40692,64646,64780,65558,68827,71335,72474,72571,73180,73549,74989,79437,82379,82533,90454,99625,100492,101615,109070,179336,201986,224524,224612,224644,224920,226883,235224,237061,237084,238243,238775,246783,255516,256561,257278,261413,263261,265580,277385,280859,282529,288131,319089,327045,330267,330973,331342,334739,341783,359323,367432,381816,441074,441362,442142,443604,","842222,842370,842518,842788,843025,843536,843659,844401,844514,844874,845153,845371,846391,846474,847200,847429,848333,848571,849093,849131,849442,849645,849677,850193,850269,850436,850497,850662,850988,851232,851495,853044,853313,853351,855650,855722,855836,855837,856027,856032,856075,856817,857507,857666,857745,857761,857789,857822,857967,858001,858319,859116,859459,860565,860694,861644,862581,863576,863608,863640,863643,863765,864038,864205,864233,864487,864573,864762,865057,865059,865362,865845,3711461,",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
504850,2,"Confirmation screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation","The goal of this screen is to discover new antimalarial compounds that act by inhibiting the development of the apicoplast in the malarial parasite Plasmodium falciparum. The biochemical processes that make this organelle essential for erythrocytic stage parasites are not well understood. However, antibiotics, such as azithromycin and tetracycline, which target the apicoplast translational machinery, have a potent antimalarial effect. The killing caused by these drugs is unusual in that it does not appear t",2,National Center for Advancing Translational Sciences (NCATS),DD-R1-48HR,20110625,"1400,1491,2240,2353,3947,4139,5405,5583,6197,6842,6843,7085,8480,8549,10531,14358,14710,16574,18834,21651,23205,36314,37392,37907,39794,40692,64646,64780,65558,68827,71335,72474,72571,73180,73549,74989,79437,82379,82533,90454,99625,100492,101615,109070,179336,201986,224524,224612,224644,224920,226883,235224,237061,237084,238243,238775,246783,255516,256561,257278,261413,263261,265580,277385,280859,282529,288131,319089,327045,330267,330973,331342,334739,341783,359323,367432,381816,441074,441362,442142,443604,","842222,842370,842518,842788,843025,843536,843659,844401,844514,844874,845153,845371,846391,846474,847200,847429,848333,848571,849093,849131,849442,849645,849677,850193,850269,850436,850497,850662,850988,851232,851495,853044,853313,853351,855650,855722,855836,855837,856027,856032,856075,856817,857507,857666,857745,857761,857789,857822,857967,858001,858319,859116,859459,860565,860694,861644,862581,863576,863608,863640,863643,863765,864038,864205,864233,864487,864573,864762,865057,865059,865362,865845,3711461,",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
504607,1,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Full-Length Luciferase Counterscreen assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: R03 MH089489-01_|_Assay Provider: Dr. Geoffrey M. Wahl, Salk Institute for Biological Studies, San Diego, CA_|__|_A wild type but attenuated p53 is retained in approximately 50% of human tumors, and reactivation of p53 in such tumors is an attractive chemotherapeutic",14,Burnham Center for Chemical Genomics,SBCCG-A620-Mdm2-MdmX-CP-CTR-Assay,20110328,"299,1318,1400,1401,1546,2203,2247,2406,2788,2794,2833,3037,3213,3396,3598,3611,3728,3926,4066,4122,4477,4485,4499,4641,4878,5100,5169,5267,5298,5396,5405,5614,6001,6167,6185,6197,6245,6253,6256,6320,6763,6769,6825,7085,7547,7589,8478,8975,9340,9444,10156,10206,10607,11102,11352,14169,15478,16574,20279,23205,25050,26695,31280,31316,31475,35246,36314,36462,37839,38911,53277,53329,60699,62878,64983,65329,65348,66479,66541,67238,67275,67277,68207,68546,70848,71177,71420,72402,72512,73078,73481,76357,77865,77955","842151,842186,842207,842478,842579,842629,842939,843035,843045,843472,843741,843800,844229,844306,844670,844782,845149,845167,845300,845318,845472,845529,845670,845835,845957,846128,846199,846220,846227,846402,846474,846490,846693,846756,846901,847146,847268,847300,847444,847491,847575,847638,847709,847980,848292,848397,848472,848536,848619,849093,850072,850087,850126,850269,850530,850589,850961,851062,851167,851969,852641,852689,852731,855531,855567,855601,855609,855669,855686,855722,855727,855746,855810,8",NULL,NULL,NULL,NIH Initiatives,"10722742,10827196,11403293,11528400,11917093,15284440,16204450,16540668,16905541,16905769,17616658,18219319,18677113,7477326",0,10.1021/ac0013296|10.1038/378203a0|10.1038/ng714|10.1038/sj.cdd.4402309|10.1073/pnas.0404041101|10.1074/jbc.275.12.8945|10.1074/jbc.c600147200|10.1074/jbc.m003496200|10.1074/jbc.m605405200|10.1093/nar/gni145|10.1152/physrev.00027.2001|10.1158/0008-5472.can-05-3832|10.1158/0008-5472.can-07-1313|10.4161/cc.6365,NULL,NULL,NULL
504668,1,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: R03 MH089489-01_|_Assay Provider: Dr. Geoffrey M. Wahl, Salk Institute for Biological Studies, San Diego, CA_|__|_A wild type but attenuated p53 is retained in approximately 50% of human tumors, and reactivation of p53 in such tumors is an attractive chemotherapeutic",14,Burnham Center for Chemical Genomics,SBCCG-A621-Mdm2-MdmX-CP-BRCA-CTR-Assay,20110414,"299,1318,1400,1401,1546,2203,2247,2406,2788,2794,2833,3037,3213,3396,3598,3611,3728,3926,4066,4122,4477,4485,4499,4641,4878,5100,5169,5267,5298,5396,5405,5614,6001,6167,6185,6197,6245,6253,6256,6320,6763,6769,6825,7085,7547,7589,8478,8975,9340,9444,10156,10206,10607,11102,11352,14169,15478,16574,20279,23205,25050,26695,31280,31316,31475,35246,36314,36462,37839,38911,53277,53329,60699,62878,64983,65329,65348,66479,66541,67238,67275,67277,68207,68546,70848,71177,71420,72402,72512,73078,73481,76357,77865,77955","842151,842186,842207,842478,842579,842629,842939,843035,843045,843472,843741,843800,844229,844306,844670,844782,845149,845167,845300,845318,845472,845529,845670,845835,845957,846128,846199,846220,846227,846402,846474,846490,846693,846756,846901,847146,847268,847300,847444,847491,847575,847638,847709,847980,848292,848397,848472,848536,848619,849093,850072,850087,850126,850269,850530,850589,850961,851062,851167,851969,852641,852689,852731,855531,855567,855601,855609,855669,855686,855722,855727,855746,855810,8","580,672",NULL,"P38398,Q99728",NIH Initiatives,"10722742,10827196,11403293,11528400,11917093,15284440,16204450,16540668,16905541,16905769,17616658,18219319,18677113,7477326",0,10.1021/ac0013296|10.1038/378203a0|10.1038/ng714|10.1038/sj.cdd.4402309|10.1073/pnas.0404041101|10.1074/jbc.275.12.8945|10.1074/jbc.c600147200|10.1074/jbc.m003496200|10.1074/jbc.m605405200|10.1093/nar/gni145|10.1152/physrev.00027.2001|10.1158/0008-5472.can-05-3832|10.1158/0008-5472.can-07-1313|10.4161/cc.6365,2.3.2.27,"P38398,Q99728",NULL
504316,2,qHTS for Inhibitors of Plasmodium falciparum (7G8) proliferation,"Plasmodium falciparum is a virulent malarial parasite that kills 1-2 million people worldwide each year. Malaria not only inflicts tremendous suffering and morbidity on the human population, but has dramatically influenced the course of civilization with profound sociological and economic implications (Shah, S. 2010).  Transmitted by mosquitoes, the sporozoite form of the parasite enters the blood stream to infect hepatocytes, where they become merozoites that infect red blood cells (erythrocytes). Within e",2,National Center for Advancing Translational Sciences (NCATS),bumal7g8,20110218,"2972,14611,17453,20522,82567,94862,95472,121808,198967,235616,262162,277231,297499,356976,495635,583190,606469,656412,694299,694306,728563,736185,749927,954263,1034001,1265150,2335589,2725026,2775473,2783995,2832910,3622622,4171528,4473174,5081400,5192815,5200820,6419589,6419650,6518389,6636170,6636188,6636211,6636212,6636214,6636227,6636229,6636245,6636246,6636248,6636276,6636279,6636282,6636283,6636311,6636316,6636318,6636332,6636347,6636348,6636365,6636367,6636371,6636387,6636401,6636403,6636405,6636418,","26752611,26754653,26754654,26754655,26754656,26754657,26754658,26754659,26754660,26754661,26754662,26754663,26754664,26754665,26755806,26755807,26755808,26755809,26755810,26755811,26755812,26755813,26755814,26755815,26755816,26755817,26755818,26755819,26755820,26755821,26755822,26755823,26755824,26755825,26755826,26755827,26755828,26755829,26755830,26755831,26755832,26755833,26755834,26755835,26755836,26755837,26755838,26755839,26755840,26755841,26755842,26755843,26755844,26755845,26755846,26755847,26755848",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"15105139,15871695,19734910,20101240",0,10.1038/nchembio.215|10.1038/ng.528|10.1089/adt.2005.3.213|10.1128/aac.48.5.1807-1810.2004,NULL,NULL,NULL
504318,2,qHTS for Inhibitors of Plasmodium falciparum (HB3) proliferation,"Plasmodium falciparum is a virulent malarial parasite that kills 1-2 million people worldwide each year. Malaria not only inflicts tremendous suffering and morbidity on the human population, but has dramatically influenced the course of civilization with profound sociological and economic implications (Shah, S. 2010).  Transmitted by mosquitoes, the sporozoite form of the parasite enters the blood stream to infect hepatocytes, where they become merozoites that infect red blood cells (erythrocytes). Within e",2,National Center for Advancing Translational Sciences (NCATS),bumalhb3,20110218,"2972,14611,17453,20522,82567,94862,95472,121808,198967,235616,262162,277231,297499,356976,495635,583190,606469,656412,694299,694306,728563,736185,749927,954263,1034001,1265150,2335589,2725026,2775473,2783995,2832910,3622622,4171528,4473174,5081400,5192815,5200820,6419589,6419650,6518389,6636170,6636188,6636211,6636212,6636214,6636227,6636229,6636245,6636246,6636248,6636276,6636279,6636282,6636283,6636311,6636316,6636318,6636332,6636347,6636348,6636365,6636367,6636371,6636387,6636401,6636403,6636405,6636418,","26752611,26754653,26754654,26754655,26754656,26754657,26754658,26754659,26754660,26754661,26754662,26754663,26754664,26754665,26755806,26755807,26755808,26755809,26755810,26755811,26755812,26755813,26755814,26755815,26755816,26755817,26755818,26755819,26755820,26755821,26755822,26755823,26755824,26755825,26755826,26755827,26755828,26755829,26755830,26755831,26755832,26755833,26755834,26755835,26755836,26755837,26755838,26755839,26755840,26755841,26755842,26755843,26755844,26755845,26755846,26755847,26755848",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
504315,2,qHTS for Inhibitors of Plasmodium falciparum (GB4) proliferation,"Plasmodium falciparum is a virulent malarial parasite that kills 1-2 million people worldwide each year. Malaria not only inflicts tremendous suffering and morbidity on the human population, but has dramatically influenced the course of civilization with profound sociological and economic implications (Shah, S. 2010).  Transmitted by mosquitoes, the sporozoite form of the parasite enters the blood stream to infect hepatocytes, where they become merozoites that infect red blood cells (erythrocytes). Within e",2,National Center for Advancing Translational Sciences (NCATS),bumalgb4,20110218,"2972,14611,17453,20522,82567,94862,95472,121808,198967,235616,262162,277231,297499,356976,495635,583190,606469,656412,694299,694306,728563,736185,749927,954263,1034001,1265150,2335589,2725026,2775473,2783995,2832910,3622622,4171528,4473174,5081400,5192815,5200820,6419589,6419650,6518389,6636170,6636188,6636211,6636212,6636214,6636227,6636229,6636245,6636246,6636248,6636276,6636279,6636282,6636283,6636311,6636316,6636318,6636332,6636347,6636348,6636365,6636367,6636371,6636387,6636401,6636403,6636405,6636418,","26752611,26754653,26754654,26754655,26754656,26754657,26754658,26754659,26754660,26754661,26754662,26754663,26754664,26754665,26755806,26755807,26755808,26755809,26755810,26755811,26755812,26755813,26755814,26755815,26755816,26755817,26755818,26755819,26755820,26755821,26755822,26755823,26755824,26755825,26755826,26755827,26755828,26755829,26755830,26755831,26755832,26755833,26755834,26755835,26755836,26755837,26755838,26755839,26755840,26755841,26755842,26755843,26755844,26755845,26755846,26755847,26755848",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"15105139,15871695,19734910,20101240",0,10.1038/nchembio.215|10.1038/ng.528|10.1089/adt.2005.3.213|10.1128/aac.48.5.1807-1810.2004,NULL,NULL,NULL
504320,2,qHTS for Inhibitors of Plasmodium falciparum (CP250) proliferation,"Plasmodium falciparum is a virulent malarial parasite that kills 1-2 million people worldwide each year. Malaria not only inflicts tremendous suffering and morbidity on the human population, but has dramatically influenced the course of civilization with profound sociological and economic implications (Shah, S. 2010).  Transmitted by mosquitoes, the sporozoite form of the parasite enters the blood stream to infect hepatocytes, where they become merozoites that infect red blood cells (erythrocytes). Within e",2,National Center for Advancing Translational Sciences (NCATS),bumalcp250,20110218,"2972,14611,17453,20522,82567,94862,95472,121808,198967,235616,262162,277231,297499,356976,495635,583190,606469,656412,694299,694306,728563,736185,749927,954263,1034001,1265150,2335589,2725026,2775473,2783995,2832910,3622622,4171528,4473174,5081400,5192815,5200820,6419589,6419650,6518389,6636170,6636188,6636211,6636212,6636214,6636227,6636229,6636245,6636246,6636248,6636276,6636279,6636282,6636283,6636311,6636316,6636318,6636332,6636347,6636348,6636365,6636367,6636371,6636387,6636401,6636403,6636405,6636418,","26752611,26754653,26754654,26754655,26754656,26754657,26754658,26754659,26754660,26754661,26754662,26754663,26754664,26754665,26755806,26755807,26755808,26755809,26755810,26755811,26755812,26755813,26755814,26755815,26755816,26755817,26755818,26755819,26755820,26755821,26755822,26755823,26755824,26755825,26755826,26755827,26755828,26755829,26755830,26755831,26755832,26755833,26755834,26755835,26755836,26755837,26755838,26755839,26755840,26755841,26755842,26755843,26755844,26755845,26755846,26755847,26755848",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
504314,2,qHTS for Inhibitors of Plasmodium falciparum (DD2) proliferation,"Plasmodium falciparum is a virulent malarial parasite that kills 1-2 million people worldwide each year. Malaria not only inflicts tremendous suffering and morbidity on the human population, but has dramatically influenced the course of civilization with profound sociological and economic implications (Shah, S. 2010).  Transmitted by mosquitoes, the sporozoite form of the parasite enters the blood stream to infect hepatocytes, where they become merozoites that infect red blood cells (erythrocytes). Within e",2,National Center for Advancing Translational Sciences (NCATS),bumaldd2,20110218,"2972,14611,17453,20522,82567,94862,95472,121808,198967,235616,262162,277231,297499,356976,495635,583190,606469,656412,694299,694306,728563,736185,749927,954263,1034001,1265150,2335589,2725026,2775473,2783995,2832910,3622622,4171528,4473174,5081400,5192815,5200820,6419589,6419650,6518389,6636170,6636188,6636211,6636212,6636214,6636227,6636229,6636245,6636246,6636248,6636276,6636279,6636282,6636283,6636311,6636316,6636318,6636332,6636347,6636348,6636365,6636367,6636371,6636387,6636401,6636403,6636405,6636418,","26752611,26754653,26754654,26754655,26754656,26754657,26754658,26754659,26754660,26754661,26754662,26754663,26754664,26754665,26755806,26755807,26755808,26755809,26755810,26755811,26755812,26755813,26755814,26755815,26755816,26755817,26755818,26755819,26755820,26755821,26755822,26755823,26755824,26755825,26755826,26755827,26755828,26755829,26755830,26755831,26755832,26755833,26755834,26755835,26755836,26755837,26755838,26755839,26755840,26755841,26755842,26755843,26755844,26755845,26755846,26755847,26755848",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"15105139,15871695,19734910,20101240",0,10.1038/nchembio.215|10.1038/ng.528|10.1089/adt.2005.3.213|10.1128/aac.48.5.1807-1810.2004,NULL,NULL,NULL
504465,2,"IN Cell qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon","NIH Molecular Libraries Probe Production Centers Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|_MLPCN Grant: NS059428-01_|_Assay Submitter (PI): Blenis, John; Hoffman, Greg; Harvard University_|__|__|_NCGC Assay Overview: Thee mammalian target of rapamycin (mTOR) is an intracellular serine/threonine kinase Aberrant regulation of mTOR signaling plays a causative role in a number of human diseases, including cancer, benign tumors such as lymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (",2,National Center for Advancing Translational Sciences (NCATS),MTOR200,20110316,"221091,255410,294997,612305,632275,693197,693201,698450,698807,704272,705204,709531,714239,716931,716956,719438,729756,738669,743490,743494,750666,752877,772722,806738,812504,825303,833972,833990,833991,833994,923699,935756,954456,975610,987079,992508,992514,992537,992544,992562,992565,993254,993260,993263,1003444,1003446,1003863,1003869,1003920,1003922,1004085,1004132,1009491,1017166,1017171,1025267,1025288,1025299,1025302,1025312,1025314,1050778,1077500,1077703,1078705,1078725,1080211,1086314,1086608,1091","24266769,24266786,24266788,24266796,24266798,24266825,24266828,24266829,24266832,24266840,24266842,24266844,24266846,24266867,24266869,24266880,24266917,24266920,24266928,24266944,24266961,24266968,24267008,24267016,24267033,24267039,24267058,24267063,24267087,24267088,24267090,24267135,24267145,24267148,24267151,24267161,24267165,24267167,24267169,24267187,24267189,24267191,24267193,24267195,24267199,24267201,24267216,24267242,24267244,24267248,24267264,24267270,24267278,24267284,24267292,24267308,24267328",2475,NULL,NP_004949,Governmental Organizations|NIH Initiatives,"14651849,18538731",0,10.1016/j.ccr.2008.05.005|10.1016/s0092-8674(03)00929-2,2.7.11.1,P42345,NULL
504765,2,Dose Response confirmation of uHTS small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R21AI082434-01 _|_Assay Provider: Lars Bode, Ph.D., University of California San Diego, San Diego, CA_|__|_Tropical malaria caused by the protozoan parasite Plasmodium falciparum is responsible for up to three million deaths annually. Due to increasing regional dist",14,Burnham Center for Chemical Genomics,SBCCG-A660-pfG6PDH-DR-Assay,20110518,"86,3117,3194,4477,4534,4641,4882,7090,7381,7573,10603,10842,13752,16955,17599,33528,65093,73024,85555,86926,95699,97762,98282,98608,100519,160386,161167,164981,176170,181167,186169,207054,219642,220284,222091,222761,228427,231558,232926,232928,232932,233473,237490,239577,239578,241388,241690,241783,241808,245097,247304,248614,250997,250998,252116,256129,256604,261066,264613,265527,267286,269582,270378,273249,275545,276137,279609,280615,280616,284471,286150,286363,312601,313614,314728,315063,319938,320930,32","843741,843832,845118,845565,845880,846550,847575,849645,850421,855767,856575,856589,857297,858147,859801,861067,861594,865812,3711168,3712613,3713060,3713708,3714844,3715451,3716597,3717313,3717614,3717771,4240686,4241329,4244856,4245664,4246687,4251150,4251161,4254845,4258563,4258586,4259955,4260021,4260621,4261832,4261894,4262547,4263543,7965759,7967069,7968555,7969699,7970106,7970286,7974437,7974536,7975782,7977731,11532926,11532928,11532952,14718751,14720771,14723824,14724478,14726069,14727656,14728132,",NULL,NULL,CAC24715,NIH Initiatives,"13682585,15331814,15353959,15672556,18177777,3887862,6337374,86896,9694435",0,10.1007/978-1-4615-9400-0_4|10.1007/s001090050253|10.1016/s0140-6736(08)60073-2|10.1016/s0140-6736(79)91857-9|10.1073/pnas.80.1.298|10.1097/00001432-200410000-00004|10.1136/bmj.1.5236.1346,NULL,CAC24715,NULL
504792,2,Human Glucose-6-Phosphate Dehydrogenase Dose Response Selectivity Assay for Inhibitors of Plasmodium falciparum Glucose-6-Phosphate Dehydrogenase,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R21AI082434-01 _|_Assay Provider: Lars Bode, Ph.D., University of California San Diego, San Diego, CA_|__|_Tropical malaria caused by the protozoan parasite Plasmodium falciparum is responsible for up to three million deaths annually. Due to increasing regional dist",14,Burnham Center for Chemical Genomics,SBCCG-A661-hG6PDH-DR-Assay,20111109,"86,3117,3194,4477,4534,4641,4882,7090,7381,7573,10603,10842,13752,16955,17599,33528,65093,73024,85555,86926,95699,97762,98282,98608,100519,160386,161167,164981,176170,181167,186169,207054,219642,220284,222091,222761,228427,231558,232926,232928,232932,233473,237490,239577,239578,241388,241690,241783,241808,245097,247304,248614,250997,250998,252116,256129,256604,261066,264613,265527,267286,269582,270378,273249,275545,276137,279609,280615,280616,284471,286150,286363,312601,313614,314728,315063,319938,320930,32","843741,843832,845118,845565,845880,846550,847575,849645,850421,855767,856575,856589,857297,858147,859801,861067,861594,865812,3711168,3712613,3713060,3713708,3714844,3715451,3716597,3717313,3717614,3717771,4240686,4241329,4244856,4245664,4246687,4251150,4251161,4254845,4258563,4258586,4259955,4260021,4260621,4261832,4261894,4262547,4263543,7965759,7967069,7968555,7969699,7970106,7970286,7974437,7974536,7975782,7977731,11532926,11532928,11532952,14718751,14720771,14723824,14724478,14726069,14727656,14728132,",2539,NULL,NP_001035810,NIH Initiatives,"13682585,15331814,15353959,15672556,18177777,3887862,6337374,86896,9694435",0,10.1007/978-1-4615-9400-0_4|10.1007/s001090050253|10.1016/s0140-6736(08)60073-2|10.1016/s0140-6736(79)91857-9|10.1073/pnas.80.1.298|10.1097/00001432-200410000-00004|10.1136/bmj.1.5236.1346,1.1.1.49,P11413,NULL
504536,2,qHTS Validation Assay to Find Inhibitors of Pin1,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|_MLPCN Grant: 1 R03 DA031663-01  _|_PI Name: Dr. Kun Ping Lu_|__|_NCGC Assay Overview:_|_ _|_Protein phosphorylation on certain serine or threonine residues preceding a proline (phos.Ser/Thr-Pro) is a major signaling mechanism in diverse cellular processes, and its deregulation contributes to human disease, notably cancer, Alzheimer's disease, aging, and asthma [1-2]. The unique chemical properties of Pro allow f",2,National Center for Advancing Translational Sciences (NCATS),pin1001,20110323,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",5300,NULL,NP_006212,Governmental Organizations|NIH Initiatives,"17410202,17876319,17878917",0,10.1038/nchembio.2007.35|10.1038/nrc2107|10.1038/nrm2261,5.2.1.8,Q13526,NULL
504488,2,SAR Analysis of small molecule inhibitors of Sentrin-specific proteases (SENPs) using a Caspase-3 Selectivity assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network(MLPCN)_|_Grant Proposal Number: 1R21 NS061758-01 fast track_|_Assay Provider: Dr. Guy Salvesen, Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|__|_Modification of proteins by SUMO is a dynamic and reversible process. SUMOylation/deSUMOylation cycle regulates SUMOs funct",14,Burnham Center for Chemical Genomics,SBCCG-A598-SEN-Caspase-DryPowder-Assay,20111009,"38370,66532,122909,244113,286873,326812,401582,580693,591192,669572,669589,673490,673500,675055,686534,753023,767655,770376,774901,777357,779192,784729,788810,800252,800285,822651,823967,835541,839417,843107,843289,844224,866473,871488,871656,876477,876555,936847,939330,972733,984297,1002506,1002727,1019473,1068453,1084683,1109397,1109404,1109408,1112811,1121131,1141753,1166521,1223297,1245214,1316586,1488983,1512142,1746649,1806168,1814489,1814490,1901852,1970728,2054440,2056588,2066730,2111418,2159213,215","104222573,104222574,104222575,104222576,104222577,104222578,104222579,104222580,104222581,104222582,104222583,104222584,104222585,104222586,104222587,104222588,104222589,104222590,104222591,104222592,104222593,104222594,104222595,104222596,104222597,104222598,104222599,104222600,104222601,104222602,104222603,104222604,104222606,104222607,104222608,104222609,104222610,104222611,104222612,104222613,104222614,104222615,104222616,104222617,104222618,104222619,104222620,104222621,104222622,104222623,104222624,10",836,NULL,NP_004337,NIH Initiatives,"17591783,17916063,18799455",0,10.1042/bj20070940|10.1074/jbc.m702444200|10.1074/jbc.m805655200,3.4.22.56,P42574,NULL
504497,2,SAR Analysis of small molecule inhibitors of Sentrin-specific protease 7 (SENP7) using a Luminescent assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network(MLPCN)_|_Grant Proposal Number: 1R21 NS061758-01 fast track_|_Assay Provider: Dr. Guy Salvesen, Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|__|_Modification of proteins by SUMO is a dynamic and reversible process. SUMOylation/deSUMOylation cycle regulates SUMOs function. S",14,Burnham Center for Chemical Genomics,SBCCG-A594-SENP7-DryPowder-Assay,20111009,"38370,66532,122909,244113,286873,326812,401582,580693,591192,669572,669589,673490,673500,675055,686534,753023,767655,770376,774901,777357,779192,784729,788810,800252,800285,822651,823967,835541,839417,843107,843289,844224,866473,871488,871656,876477,876555,936847,939330,972733,984297,1002506,1002727,1019473,1068453,1084683,1109397,1109404,1109408,1112811,1121131,1141753,1166521,1223297,1245214,1316586,1488983,1512142,1746649,1806168,1814489,1814490,1901852,1970728,2054440,2056588,2066730,2111418,2159213,215","104222573,104222574,104222575,104222576,104222577,104222578,104222579,104222580,104222581,104222582,104222583,104222584,104222585,104222586,104222587,104222588,104222589,104222590,104222591,104222592,104222593,104222594,104222595,104222596,104222597,104222598,104222599,104222600,104222601,104222602,104222603,104222604,104222606,104222607,104222608,104222609,104222610,104222611,104222612,104222613,104222614,104222615,104222616,104222617,104222618,104222619,104222620,104222621,104222622,104222623,104222624,10",57337,NULL,AAI29989,NIH Initiatives,"17591783,17916063,18799455",0,10.1042/bj20070940|10.1074/jbc.m702444200|10.1074/jbc.m805655200,NULL,AAI29989,NULL
504492,2,SAR Analysis of small molecule inhibitors of Sentrin-specific protease 6 (SENP6) using a Luminescent assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network(MLPCN)_|_Grant Proposal Number: 1R21 NS061758-01 fast track_|_Assay Provider: Dr. Guy Salvesen, Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|__|_Modification of proteins by SUMO is a dynamic and reversible process. SUMOylation/deSUMOylation cycle regulates SUMOs funct",14,Burnham Center for Chemical Genomics,SBCCG-A596-SENP6-DryPowder-Assay,20111009,"38370,66532,122909,244113,286873,326812,401582,580693,591192,669572,669589,673490,673500,675055,686534,753023,767655,770376,774901,777357,779192,784729,788810,800252,800285,822651,823967,835541,839417,843107,843289,844224,866473,871488,871656,876477,876555,936847,939330,972733,984297,1002506,1002727,1019473,1068453,1084683,1109397,1109404,1109408,1112811,1121131,1141753,1166521,1223297,1245214,1316586,1488983,1512142,1746649,1806168,1814489,1814490,1901852,1970728,2054440,2056588,2066730,2111418,2159213,215","104222573,104222574,104222575,104222576,104222577,104222578,104222579,104222580,104222581,104222582,104222583,104222584,104222585,104222586,104222587,104222588,104222589,104222590,104222591,104222592,104222593,104222594,104222595,104222596,104222597,104222598,104222599,104222600,104222601,104222602,104222603,104222604,104222606,104222607,104222608,104222609,104222610,104222611,104222612,104222613,104222614,104222615,104222616,104222617,104222618,104222619,104222620,104222621,104222622,104222623,104222624,10",26054,NULL,AAF04852,NIH Initiatives,"17591783,17916063,18799455",0,10.1042/bj20070940|10.1074/jbc.m702444200|10.1074/jbc.m805655200,NULL,AAF04852,NULL
504840,2,Dose responses of compounds that inhibit the Choline Transporter (CHT) - 5 point CRC,"Data Source: Johns Hopkins Ion Channel Center (JHICC_ CHT_Inh_HFCP_5pCRC)_|_BioAssay Type: Confirmatory, Concentration-Response Relationship Observed_|_Depositor Category: NIH Molecular Libraries Probe Production Network_|__|_Data Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Alicia Ruggiero, Ph.D., Vanderbilt University Medical Center_|_Network: Molecular Librarie",27,Johns Hopkins Ion Channel Center,JHICC_ CHT_Inh_HFCP_5pCRC,20110810,"191,1761,2692,5022,5807,5924,6060,8974,19646,58953,60758,60961,65324,68647,72300,72303,73157,76596,93205,97158,123504,123683,128748,137494,223280,231951,233538,264006,289745,289982,291365,323381,330590,356301,440990,448537,470952,545021,577819,598144,599120,620880,644509,644772,644999,645499,645525,645538,647624,648001,648202,648382,649592,649950,650529,650832,651002,651178,651381,651512,652131,653126,653305,653352,654026,654707,654848,655078,655095,655912,656173,656783,657301,657346,657699,657741,657969,65","842249,842412,842501,842724,843215,843243,843257,845284,845646,845843,846015,846135,846330,846887,847195,848105,848387,848553,848720,848919,849046,849633,850596,850766,850814,851450,852236,852457,852476,852712,853259,853519,855871,855932,856331,856372,856584,856613,856725,856785,856938,857342,857401,857730,857754,858085,858804,858854,858929,859209,859562,859569,860118,860698,860818,861120,861528,861575,861731,862359,862464,862597,862740,862793,862877,863177,863249,863628,863757,864105,864214,864375,864919,8",60482,NULL,NP_068587,Legacy Depositors|NIH Initiatives,"10838414,11172068,12436412,12441053,14708004,14993474,17005849,9694432",0,10.1002/neu.10153|10.1007/s001090050250|10.1016/s0896-6273(02)01020-6|10.1038/nrn1298|10.1073/pnas.98.4.2017|10.1124/mi.4.1.22|10.1177/108705719900400206|10.1523/jneurosci.1862-06.2006,NULL,Q9GZV3,NULL
504501,2,SAR Analysis of small molecule inhibitors of Sentrin-specific protease 8 (SENP8) using a Luminescent assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network(MLPCN)Grant Proposal Number: 1R21 NS061758-01 fast track_|_Assay Provider: Dr. Guy Salvesen, Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|__|_Modification of proteins by SUMO is a dynamic and reversible process. SUMOylation/deSUMOylation cycle regulates SUMOs function. Sent",14,Burnham Center for Chemical Genomics,SBCCG-A595-SENP8-DryPowder-Assay,20111009,"38370,66532,122909,244113,286873,326812,401582,580693,591192,669572,669589,673490,673500,675055,686534,753023,767655,770376,774901,777357,779192,784729,788810,800252,800285,822651,823967,835541,839417,843107,843289,844224,866473,871488,871656,876477,876555,936847,939330,972733,984297,1002506,1002727,1019473,1068453,1084683,1109397,1109404,1109408,1112811,1121131,1141753,1166521,1223297,1245214,1316586,1488983,1512142,1746649,1806168,1814489,1814490,1901852,1970728,2054440,2056588,2066730,2111418,2159213,215","104222573,104222574,104222575,104222576,104222577,104222578,104222579,104222580,104222581,104222582,104222583,104222584,104222585,104222586,104222587,104222588,104222589,104222590,104222591,104222592,104222593,104222594,104222595,104222596,104222597,104222598,104222599,104222600,104222601,104222602,104222603,104222604,104222606,104222607,104222608,104222609,104222610,104222611,104222612,104222613,104222614,104222615,104222616,104222617,104222618,104222619,104222620,104222621,104222622,104222623,104222624,10",123228,NULL,NP_660205,NIH Initiatives,"17591783,17916063,18799455",0,10.1042/bj20070940|10.1074/jbc.m702444200|10.1074/jbc.m805655200,3.4.22.-,Q96LD8,NULL
504672,2,Dose Response confirmation of uHTS small molecule inhibitors of tim23-1: a luminescent  TIM10 yeast counterscreen.,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute(SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1 R03 DA027714-01A1_|_Assay Provider: Dr. Carla Koehler, University of California, Los Angeles, CA (UCLA)_|__|_Defects in mitochondrial assembly impact a wide range of diseases from degenerative muscle and neural diseases to cancer (Wallace, 2005). The mitochondrion",14,Burnham Center for Chemical Genomics,SBCCG-A630-tim10-DR-CTR-inhibitor-Assay,20110420,"1318,1609,7087,8515,82498,139369,185478,242962,290289,332918,339735,401588,439647,517318,569594,605332,609614,624750,644550,645754,646429,650941,651512,652628,654316,657356,657882,659551,660935,663159,664956,665084,666642,675069,690502,694414,695176,698230,698960,706189,718070,724088,727521,732524,737170,739449,741732,754606,762465,774927,776045,776450,781071,783828,785022,786365,788928,791050,798166,828652,830119,831952,835330,835785,844501,849257,849282,852162,870214,873826,874744,881165,884233,885802,886","842291,843458,844120,848492,849046,850121,851723,855913,856266,856525,858199,859633,861934,863704,863831,865387,3712218,3713199,3716022,4243141,4244425,4245988,4248838,4251329,4255275,4255761,4256874,4257674,4259021,4263457,4264970,7965996,7967308,7967877,7969852,7970078,7970223,7971043,7972778,7972888,7973412,7974826,7975000,7976225,7976947,7978051,11533040,14718807,14720443,14723611,14723953,14724294,14725447,14726672,14726948,14727111,14729151,14729349,14730403,14731451,14731482,14731906,14732540,1473427",856395,NULL,DAA06693,NIH Initiatives,"15473843,16285865,9430585",0,10.1126/science.279.5349.369|10.1146/annurev.cellbio.20.010403.105057|10.1146/annurev.genet.39.110304.095751,NULL,P87108,NULL
504753,1,Single concentration confirmation of uHTS small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R21AI082434-01 _|_Assay Provider: Lars Bode, Ph.D., University of California San Diego, San Diego, CA_|__|_Tropical malaria caused by the protozoan parasite Plasmodium falciparum is responsible for up to three million deaths annually. Due to increasing regional dist",14,Burnham Center for Chemical Genomics,SBCCG-A659-pfG6PDH-CP-Assay,20110517,"86,1967,2215,3117,3194,3197,3293,3698,3728,4212,4477,4499,4534,4641,4882,6099,6763,6842,7090,7141,7381,7571,7573,9922,10145,10212,10603,10842,11102,11106,13752,13977,14358,16317,16955,17599,17818,19910,33528,65093,66714,66721,67275,67277,68081,72512,72725,72908,73024,73484,74079,74204,74495,74787,77917,85555,86926,95699,96672,96967,97762,98282,98608,100519,105671,108155,140917,144053,152086,160157,160386,161167,164981,170221,176158,176170,181167,182785,186169,207054,219296,219642,219762,219776,220284,221125","842140,842734,843035,843391,843448,843741,843832,843920,845118,845565,845685,845880,846488,846550,846686,846731,847089,847575,849538,849645,849737,849895,850043,850421,850550,850558,851084,851193,851294,851331,851723,851837,852900,853158,853369,855609,855767,856019,856108,856169,856525,856575,856589,856630,856713,856753,856775,856805,856815,857142,857297,857499,857590,858057,858147,858258,858779,858936,859229,859355,859661,859755,859801,860292,860685,860726,861067,861078,861120,861139,861347,861594,862072,8",NULL,NULL,CAC24715,NIH Initiatives,"13682585,15331814,15353959,15672556,18177777,3887862,6337374,86896,9694435",0,10.1007/978-1-4615-9400-0_4|10.1007/s001090050253|10.1016/s0140-6736(08)60073-2|10.1016/s0140-6736(79)91857-9|10.1073/pnas.80.1.298|10.1097/00001432-200410000-00004|10.1136/bmj.1.5236.1346,NULL,CAC24715,NULL
504637,2,Inhibitors of T. brucei phosphofructokinase: Hit Validation,"NCGC Assay Overview:_|__|_Various species of the protozoan family Trypanosomatidae are responsible for a range of serious human diseases in tropical and subtropical areas of the world. The subspecies Trypanosoma brucei is one of three known to cause sleeping sickness in sub-Saharan Africa, significantly contributing to the millions of people worldwide who are infected by these parasites and endangering hundreds of millions more. Many of the disorders caused by trypanosomatids are fatal if left untreated, bu",2,National Center for Advancing Translational Sciences (NCATS),PFK005,20110404,"1985,2215,4278,8323,8796,10603,14129,14358,16543,17520,28777,38853,65340,68261,69292,75846,79188,99466,151533,164981,173870,176406,197774,219325,220284,229747,241893,247304,250997,257244,261542,262093,265056,282594,287142,293807,300952,302652,302654,307505,307686,313619,319089,320930,321195,321403,331557,371593,375895,480272,566162,596635,601380,609412,612424,612806,644805,645969,646522,646826,647455,648243,650075,650443,650694,651091,651981,652026,652142,652912,653069,653233,653683,657817,658395,658682,658","842535,843005,843666,843770,844210,844499,845118,845661,845887,847665,848019,848256,848638,849487,849534,849645,849737,850132,850390,850541,850704,850719,851122,852129,852244,856458,856475,856477,856478,856748,857026,857036,857333,857599,857829,858609,858877,859047,863975,864246,864322,864389,864771,866058,3711831,3712186,3712251,3712410,3712560,3713184,3713949,3714498,3714626,3714926,3714947,3715577,3715896,3715903,3716129,3716218,3716494,3716545,3716564,3716597,3716631,3716671,3716715,3716810,3716842,3717",3656265,NULL,XP_843920,Governmental Organizations|NIH Initiatives,"11512153,15955817,19084537",0,10.1016/j.jmb.2008.11.047|10.1054/drup.2000.0177|10.1074/jbc.m502403200,NULL,XP_843920,NULL
504636,2,Tb PFK orthogonal confirmatory assay using ATP depletion (Kinase-Glo Plus) as an alternative measure of Tb PFK activity: Hit Validation,"Various species of the protozoan family Trypanosomatidae are responsible for a range of serious human diseases in tropical and subtropical areas of the world. The subspecies Trypanosoma brucei is one of three known to cause sleeping sickness in sub-Saharan Africa, significantly contributing to the millions of people worldwide who are infected by these parasites and endangering hundreds of millions more. Many of the disorders caused by trypanosomatids are fatal if left untreated, but most currently used drug",2,National Center for Advancing Translational Sciences (NCATS),PFK004,20110404,"1985,2215,4278,8323,8796,10603,14129,14358,16543,17520,28777,38853,65340,68261,69292,75846,79188,99466,151533,164981,173870,176406,197774,219325,220284,229747,241893,247304,250997,257244,261542,262093,265056,282594,287142,293807,300952,302652,302654,307505,307686,313619,319089,320930,321195,321403,331557,371593,375895,480272,566162,596635,601380,609412,612424,612806,644805,645969,646522,646826,647455,648243,650075,650443,650694,651091,651981,652026,652142,652912,653069,653233,653683,657817,658395,658682,658","842535,843005,843666,843770,844210,844499,845118,845661,845887,847665,848019,848256,848638,849487,849534,849645,849737,850132,850390,850541,850704,850719,851122,852129,852244,856458,856475,856477,856478,856748,857026,857036,857333,857599,857829,858609,858877,859047,863975,864246,864322,864389,864771,866058,3711831,3712186,3712251,3712410,3712560,3713184,3713949,3714498,3714626,3714926,3714947,3715577,3715896,3715903,3716129,3716218,3716494,3716545,3716564,3716597,3716631,3716671,3716715,3716810,3716842,3717",3656265,NULL,XP_843920,Governmental Organizations|NIH Initiatives,"11512153,15955817,19084537",0,10.1016/j.jmb.2008.11.047|10.1054/drup.2000.0177|10.1074/jbc.m502403200,NULL,XP_843920,NULL
504375,2,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia: Hit Validation with Orthogonal Assay,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|_ _|_MLPCN Grant: X01MH083259-01_|_Assay Submitter (PI): Paul Liu_|_ _|_NCGC Assay Overview:_|_ _|_Core Binding Factor (CBF) abnormalities are associated with 20-25% of all acute myeloid leukemias (AML), of which 5-10% are further sub classified as acute myelomonocytic leukemia with eosinophilia,  also known as M4Eo in the FAB classification scheme.  This subtype of leukemia is usually associated with chr",2,National Center for Advancing Translational Sciences (NCATS),CBFB004,20121204,"253,836,1057,1066,1318,1474,1607,2259,2990,3117,3442,3568,3806,3902,4624,4939,5525,5668,5731,5814,6252,6618,6917,7087,7560,7935,8395,9212,14710,15008,19318,22733,23383,30323,33028,46428,49719,55182,58144,65340,66778,67472,68089,70412,70849,73453,82316,83650,87371,87935,88499,88515,92222,93572,95692,95746,98551,98960,100053,107794,138281,138888,147560,159644,160157,199788,214464,215890,220095,220717,221767,223293,231576,231625,231705,232048,232056,232146,232204,232315,232347,232439,232570,232763,232780,23300","844096,845167,850390,851514,856021,858216,3716752,4241256,4258494,7976426,11112088,11112189,11112552,11112889,11114094,11532883,14729464,14729469,14730288,14730860,14732194,14734144,14736419,14738372,14738373,17386067,17388747,17389015,17389138,17389302,17389369,17389759,17403143,17432669,17432803,17433280,17504449,17504691,17504924,17505021,17505239,17507183,17507281,17508153,17512710,17515812,17515855,17516219,17516792,17516793,17517315,17517420,22401592,22401675,22404720,22405492,22413029,24779997,247836","861,865",NULL,"NP_001001890,NP_001746",Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,"Q01196,Q13951",NULL
504374,2,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia: Hit Validation,"NIH Chemical Genomics Center [NCGC]_|_NIH Molecular Libraries Probe Production centers Network [MLPCN]_|_ _|_MLPCN Grant: X01MH083259-01_|_Assay Submitter (PI): Paul Liu_|_ _|_NCGC Assay Overview:_|_ _|_Core Binding Factor (CBF) abnormalities are associated with 20-25% of all acute myeloid leukemias (AML), of which 5-10% are further sub classified as acute myelomonocytic leukemia with eosinophilia,  also known as M4Eo in the FAB classification scheme.  This subtype of leukemia is usually associated with chr",2,National Center for Advancing Translational Sciences (NCATS),CBFB003,20110304,"253,836,1057,1066,1318,1474,1607,2259,2990,3117,3442,3568,3806,3902,4624,4939,5525,5668,5731,5814,6618,6917,7087,7560,7935,8395,9212,14710,15008,19318,22733,23383,33028,46428,49719,55182,58144,65340,66778,67472,68089,70412,70849,73453,82316,83650,87371,87935,88499,88515,92222,93572,95692,95746,98551,98960,100053,107794,138281,138888,147560,159644,160157,199788,214464,215890,220095,220717,221767,223293,231576,231625,231705,232048,232056,232146,232204,232315,232347,232439,232570,232763,232780,233004,233009,23","845167,850390,856021,858216,3716752,4258494,7976426,11112088,11112189,11112552,11112889,11532883,14729464,14729469,14730288,14730860,14732194,14734144,14736419,14738372,14738373,17386067,17388747,17389015,17389138,17389302,17389369,17389759,17403143,17432669,17433280,17504449,17504924,17505021,17505239,17507183,17507281,17508153,17512710,17515812,17515855,17516219,17516792,17516793,17517315,17517420,22401592,22401675,22404720,22405492,22413029,24779997,24783625,24786273,24793988,24794456,24796945,24801201,2","861,865",NULL,"NP_001001890,NP_001746",Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,"Q01196,Q13951",NULL
504724,2,Dose Response confirmation of small molecule APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1 R03 MH089432-01_|_Assay Provider: Dr. Reuben S Harris, Regents of the University of Minnesota, Minneapolis, MN_|__|_The human APOBEC3G (A3G) protein is a DNA deaminase that has potent activity against HIV-1 and a variety of other retroelements.  Although HIV enco",14,Burnham Center for Chemical Genomics,SBCCG-A648-APOBEC3A-Inhibitor-DR-Assay,20110604,"5911,13659,14169,26880,38115,53025,64658,66671,78443,79419,94135,288604,590107,646236,649713,653698,656110,658077,658692,659742,659955,661469,663742,664335,665392,693993,709602,711442,741078,745831,746071,755339,781894,806571,807578,825128,828954,837410,844970,848463,892611,893042,893103,900582,900808,913826,935373,939468,950890,965856,970822,973997,975638,975943,977424,977671,978252,980164,980180,980218,980267,1017696,1051609,1075533,1117122,1118298,1136314,1138020,1243763,1262055,1265467,1279973,1292135,1","847312,847622,850151,851137,853451,855648,856030,856140,856717,857345,857912,858416,858652,860160,862513,863097,864144,3712270,3712756,3717399,4240996,4240999,4242712,4247612,4248793,4254903,4255310,4255504,4255609,4256252,4257486,4258339,4258423,4259634,4259932,4260600,4260862,4260937,4262408,4262426,4262485,4262646,4263033,4264218,4264369,4264583,4265447,4265559,7969242,7971032,7972869,7973707,7976025,7976303,11532909,14722048,14722208,14722274,14725762,14726370,14726494,14726599,14728200,14729673,1473091",200315,NULL,NP_663745,NIH Initiatives,"12097915,12453430,15019779,8618835,9560375",0,10.1016/j.jmb.2004.01.046|10.1016/s1097-2765(02)00742-6|10.1038/nature00862|10.1073/pnas.92.26.12017,3.5.4.38,P31941,NULL
504719,2,Dose Response confirmation of small molecule APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1 R03 MH089432-01_|_Assay Provider: Dr. Reuben S Harris, Regents of the University of Minnesota, Minneapolis, MN_|__|_The human APOBEC3G (A3G) protein is a DNA deaminase that has potent activity against HIV-1 and a variety of other retroelements.  Although HIV enco",14,Burnham Center for Chemical Genomics,SBCCG-A650-APOBEC3G-Inhibitor-DR-Assay,20110504,"2202,4650,10187,14358,65093,164981,250997,282594,308043,323616,375895,483894,512832,567642,588007,602897,649731,653996,658131,658169,659951,660017,660533,660619,660816,661249,664735,664797,665761,665848,665955,666848,667120,667173,670483,676284,679485,682680,684366,684731,689100,689101,692347,694414,696247,697679,698884,701684,702150,703314,704098,704306,705426,707055,708541,713089,713091,715698,715715,715719,716454,716904,720910,722909,723622,726835,726836,731724,732503,736679,737890,747315,749059,749443,7","842727,847331,849737,851427,856775,856815,858649,858709,859229,859314,859518,859947,863481,863546,864518,864606,864714,865589,865860,865915,3711817,3713350,3713989,3715290,3715451,3716039,3716512,3716597,3716842,3717771,3717898,4241965,4243374,4245711,4246311,4246779,4247483,4249463,4250642,4251161,4252330,4254845,4255757,4256202,4257285,4258837,4260621,4261828,4262481,4264578,4265405,4265528,7966079,7966309,7967069,7968555,7968902,7969475,7970779,7972158,7972470,7972575,7973456,7974016,7974102,7974285,7974",60489,NULL,NP_068594,NIH Initiatives,"12097915,12453430,15019779,8618835,9560375",0,10.1016/j.jmb.2004.01.046|10.1016/s1097-2765(02)00742-6|10.1038/nature00862|10.1073/pnas.92.26.12017,3.5.4.-,Q9HC16,NULL
504841,2,Confirmation qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1) - Round 2 Cherry Picks,"Survival of cells and the faithful propagation of the genome depend on elaborate mechanisms of detecting and repairing DNA damage. Treatment of advanced cancer relies on radiation therapy or chemotherapy, which kill cancer cells by causing extensive DNA damage. It is often found, that cancer cells develop resistance to therapy through enhanced activity of DNA repair functions; this has led to an increased interest in developing drugs that interfere with DNA repair, which could sensitize cancer cells to conv",2,National Center for Advancing Translational Sciences (NCATS),RECQ602,20110623,"1464,3564,3895,4788,5084,5591,6099,6763,7571,16850,18069,24260,44259,51040,66671,66672,72512,72725,73157,87615,125823,131673,160505,221797,229939,246666,260257,260644,312145,313619,317081,327045,381837,440226,442514,447905,559377,600239,611711,621951,625522,638310,644549,645076,645369,645969,646225,646403,646473,646493,646546,646746,648385,648595,649060,649585,650642,651078,651146,651216,651714,651810,652578,652912,653689,653949,654026,654182,654283,654659,654998,655617,655862,658003,658014,658077,659067,65","842290,842803,843089,843253,843426,843666,843917,844157,844180,844234,844420,846018,846213,846665,847187,848215,848625,848695,848761,849236,849321,850068,850149,850390,851128,851380,851450,851595,851690,852053,852375,852972,853208,856651,856662,856686,856717,857486,857708,857713,857740,857834,858057,858096,858108,858170,858503,858661,859022,859200,859770,860234,860388,860764,860916,861018,861090,861123,861138,861210,861273,861306,861400,861625,861705,861740,861938,861949,862070,862099,862206,862533,862910,8",NULL,NULL,2WWY_A,Governmental Organizations|NIH Initiatives,"16864780,18448429,19151156",0,10.1073/pnas.0604348103|10.1073/pnas.0806908106|10.1074/jbc.m709749200,NULL,2WWY_A,NULL
504687,2,SAR analysis of small molecule UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1R03 MH085677-01_|_Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_Tumor Necrosis Factor Receptor-Associated Factors (TRAFs) are a family of adapter proteins that bind an unusual ubiquitin-conjugating enzyme, Ubc13, wh",14,Burnham Center for Chemical Genomics,SBCCG-A635-UBC13-DryPowder-TR-FRET-Assay,20110419,"573349,647827,651279,742907,905708,1552177,1552178,1561554,1562474,1565837,1565842,1586630,1591183,1591184,1591192,1641544,1826320,1826382,2080746,2223459,2435396,2788298,2788684,2789047,2834392,2946917,2955709,2968521,2977380,2986780,3243667,3727149,3755468,3761611,4066233,4100896,4215797,4292343,4578336,4604062,4618002,4994408,5071301,9105716,16021605,16193610,16193613,16193615,16195168,17096209,20912274,20912317,20912338,20912355,20912356,20912360,20912361,20912362,20912364,20912445,20912482,20912511,209","104222808,104222953,104222954,104222955,104222956,104222957,104222958,104222959,104222960,104222961,104222962,104222963,104222964,104222965,104222966,104222967,104222968,104222969,104222970,104222971,104222972,104222973,104222974,104222975,104222976,104222977,104222978,104222979,104222980,104222981,104222982,104222983,104222984,104222985,104222986,104222987,104222988,104222989,104222990,104222991,104222992,104222993,104222994,104222995,104222996,104222997,104222998,104222999,104223000,104223001,104223002,10",7334,NULL,NP_003339,NIH Initiatives,"10837071,11057907,11477402,12834344,14579250,15147900,16056267,16862162,16893187,17114420,17404240",0,10.1002/bies.10352|10.1016/j.febslet.2004.04.038|10.1016/s0092-8674(00)00126-4|10.1021/bi034480t|10.1021/bi060631r|10.1038/90609|10.1038/ncb0805-758|10.1038/ni1367|10.1073/pnas.0700548104|10.1146/annurev.immunol.18.1.621|10.4049/jimmunol.177.11.7520,2.3.2.23,P61088,NULL
504364,2,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,"H Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: Fast Track K99 CA136555_|_Assay Provider: Melvin DePamphilis, NICHD, NIH_|__|_Assay Overview_|__|_Eukaryotic cells normally restrict genome duplication to once per cell division. When this process is aberrant, DNA re-replication occurs when cells reinitiate DNA replication before the first round of replication is complete. DNA re-replication induces the DNA damage response, arrests cell proliferati",2,National Center for Advancing Translational Sciences (NCATS),dnarrsw480o3,20110225,"119,178,275,289,401,408,471,546,547,564,650,785,896,903,1046,1066,1123,1216,1222,1228,1232,1233,1245,1256,1317,1318,1328,1329,1330,1340,1345,1359,1365,1367,1390,1456,1474,1564,1607,1609,1641,1645,1649,1676,1678,1683,1694,1697,1720,1727,1730,1738,1742,1756,1774,1775,1779,1794,1795,1820,1826,1845,1853,1858,1864,1868,1871,1884,1893,1908,1917,1922,1967,1986,1989,2046,2051,2052,2061,2063,2071,2083,2123,2141,2143,2145,2154,2170,2196,2207,2244,2249,2252,2259,2265,2266,2284,2303,2331,2415,2435,2436,2471,2519,2544,2","11110898,26753225,26753246,26753247,26753257,26753508,26753519,26753521,26753525,26753526,26753532,26753546,26753552,26753555,26753589,26753596,26753597,26753605,26753607,26753610,26753614,26753615,26753623,26753629,26753630,26753634,26753635,26753648,26753676,50103888,50103892,50103941,50104004,50104021,50104028,50104038,50104079,50104098,50104116,50104169,50104171,50104208,50104218,50104312,50104317,50104324,50104327,50104329,50104331,50104339,50104341,50104344,50104360,50104371,50104372,50104417,50104464",51053,NULL,NP_056979,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,O75496,NULL
504548,2,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|_MLPCN Grant: 1 R03 MH093212-01  _|_PI Name: Malcolm Walkinshaw, University of Edinburgh_|__|_NCGC Assay Overview:_|_ _|_Several species of the Trypanosomatidae family of parasitic protozoans cause a spectrum of diseases throughout the tropical and subtropical world. Sleeping sickness, caused by two subspecies of Trypanosoma brucei, is endemic to areas of sub-Saharan Africa, while Chagas disease, a manifestation ",2,National Center for Advancing Translational Sciences (NCATS),pgam001,20110404,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",5655980,NULL,XP_001687258,Governmental Organizations|NIH Initiatives,"11512153,12832797,15955817,17023066,17085493,19781556,3323902",0,10.1016/0166-6851(87)90123-x|10.1016/j.bbamcr.2006.08.019|10.1016/j.jmb.2009.09.041|10.1054/drup.2000.0177|10.1074/jbc.m502403200|10.1107/s0907444903010369|10.1529/biophysj.106.093872,NULL,XP_001687258,NULL
504547,2,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,"NIH Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|_MLPCN Grant: 1 R03 MH093212-01  _|_PI Name: Malcolm Walkinshaw, University of Edinburgh_|__|_NCGC Assay Overview:_|_ _|_Several species of the Trypanosomatidae family of parasitic protozoans cause a spectrum of diseases_|_throughout the tropical and subtropical world. Sleeping sickness, caused by two subspecies of Trypanosoma brucei, is endemic to areas of sub-Saharan Africa, while Chagas disease, a manifestatio",2,National Center for Advancing Translational Sciences (NCATS),PGK001,20110323,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",4357161,NULL,XP_001218773,Governmental Organizations|NIH Initiatives,"11063610,11512153,17023066,3323902,3830152,8341319,9642090",0,10.1006/jmbi.1998.1835|10.1016/0166-6851(87)90123-x|10.1016/0166-6851(93)90218-m|10.1016/j.bbamcr.2006.08.019|10.1021/jm000287a|10.1054/drup.2000.0177|10.1111/j.1432-1033.1987.tb10667.x,NULL,XP_001218773,NULL
504756,2,Dose response confirmation of the uHTS fluorescent assay for identification of inhibitors of ATG4B.,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH090871-01_|_Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_Autophagy is an evolutionarily conserved process whereby cells catabolize damaged proteins and organelles for purposes of generating substrates for su",14,Burnham Center for Chemical Genomics,SBCCG-A658-ATG4B-DR-Assay,20110513,"2378,6763,7329,8816,50496,66532,146332,237102,254021,262093,265935,272529,318030,383939,386355,392613,400634,434797,460747,610479,646726,648589,650282,650612,655563,686152,689208,690923,691076,697231,722908,734131,750580,764219,765457,826714,834562,843742,855903,878060,879397,881438,893102,900011,906542,935027,945654,948150,969640,972392,990301,1014967,1067700,1077699,1093796,1201904,1205867,1214139,1225466,1235169,1244750,1248344,1312855,1325115,1326684,1354036,1385343,1388730,1418314,1424255,1442467,14426","846207,848184,852919,855713,855759,3712249,3714589,3715666,3716169,4240621,4243539,4246503,4247945,4248403,4250766,4251580,4251929,4254975,4260170,4263066,7970974,7973173,7976671,7978032,14721866,14722561,14726526,14727757,14730491,14730721,14731103,14731782,14732892,14733978,14735858,14736308,14737061,14737072,14738926,14739189,14739650,14739693,14740054,14740347,14740993,14741656,14741841,14745895,14746067,16952991,16953017,17385842,17386562,17387546,17387729,17402025,17403543,17406820,17407075,17407870,1",23192,NULL,NP_037457,NIH Initiatives,"12446702,12967324,16183633,16728626,16843265,17957134,18196957,18305538",0,10.1016/j.ccr.2006.06.001|10.1038/nature06639|10.1042/bj20030826|10.1074/jbc.m208247200|10.1074/jbc.m509158200|10.1126/science.312.5777.1160|10.4161/auto.5172|10.4161/auto.5523,3.4.22.-,Q9Y4P1,NULL
504836,2,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,"Primary protein unfolding takes place for many diseases, including diabetes and hypoxia, , and triggers a reaction in the cells called ER stress response (ERSR). ). ERSR is designed as a repair mechanism, but ultimately leads to cell death via apoptosis if conditions triggering protein unfolding persist (1). The molecular clue to ERSR activation is the enhancement of the expression of key molecular chaperones, including the glucose regulated protein (GRP) 78. GRP78 is the main sensor for protein folding and",2,National Center for Advancing Translational Sciences (NCATS),ERSR000,20111119,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",NULL,NULL,CAQ08732,Governmental Organizations|NIH Initiatives,11836247,0,10.1074/jbc.m112129200,NULL,P11021,NULL
588590,2,qHTS for Inhibitors of Polymerase Iota,"DNA polymerases, such as Pol iota, are specifically involved in DNA repair. Pol iota specifically plays an important role in translesion synthesis, where the normal high-fidelity DNA polymerases cannot proceed and DNA synthesis stalls. It has been reported that human pol iota may be upregulated in a number of human cancers and specifically during the progression of breast cancer, indicating that pol iota's activities within normal living cells must be tightly regulated. Thus, while pol eta's (and most likel",2,National Center for Advancing Translational Sciences (NCATS),PolI100,20111020,"6,19,40,72,86,109,119,126,127,137,174,178,185,190,191,204,229,237,240,243,244,253,255,275,289,298,299,303,311,314,323,335,338,366,379,401,403,408,441,460,464,471,487,499,525,546,547,564,588,594,597,637,650,660,681,698,701,727,745,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1189,1201,1216,1222,1228,1232,1233,1245,1256,1292,1302,1309,1317,1318,1326,1328,1329,1330,1340,1345,1348,1359,1365,1367,1369,1390,1400,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",11201,NULL,NP_009126,Governmental Organizations|NIH Initiatives,NULL,0,NULL,2.7.7.7,Q9UNA4,NULL
588855,2,qHTS for Inhibitors of TGF-b,"TGF-b is a main component in the TGF-b signaling pathway which plays diverse roles in cellular and development pathways. TGF-b is the mediated by the transcription factors Smads. Although the Smad-dependent pathway is the primary canonical TGF-b signaling node, TGF-b1 can also activate alternative signaling pathways, including those involving MAPK (ERK, JNK and p38). This interaction may mediate or enhance Smad-dependent responses, or can exert Smad-independent effects. The complexity of this signaling casc",2,National Center for Advancing Translational Sciences (NCATS),SMAD3101,20111206,"6,19,40,72,86,109,119,126,127,137,174,185,190,191,204,229,240,243,244,253,255,289,298,299,303,311,314,323,335,338,366,379,403,441,460,464,487,499,525,546,547,564,588,594,597,637,660,681,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1189,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1348,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",4088,NULL,AAL68976,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P84022,NULL
588856,2,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,"TGF-b is a main component in the TGF-b signaling pathway which plays diverse roles in cellular and development pathways. TGF-b is mediated by transcription factors called ""Smads"". Although the Smad-dependent pathway is the primary canonical TGF-b signaling mode, TGF-b1 can also activate alternative signaling pathways, including those involving MAPK (ERK, JNK and p38). This interaction may mediate or enhance Smad-dependent responses, or can exert Smad-independent effects. The complexity of this signaling cas",2,National Center for Advancing Translational Sciences (NCATS),SMAD3201,20111207,"6,19,40,72,86,109,119,126,127,137,174,185,190,191,204,229,240,243,244,253,255,289,298,299,303,311,314,323,335,338,366,379,403,441,460,464,487,499,525,546,547,564,588,594,597,637,660,681,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1189,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1348,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
588453,2,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,"The selenoprotein thioredoxin reductase (TrxR; EC 1.8.1.9) is a FAD containing homodimeric pyridine nucleotide-disulfide oxidoreductase with many cellular roles. Together with NADPH and its prime substrate thioredoxin (Trx), the enzyme forms the core of the Trx system. The mammalian Trx system exerts a wide spectrum of functions including redox regulation, antioxidant defense, regulation of transcription factors as well as support of cell growth and replication. Many of these functions involve the reduction",2,National Center for Advancing Translational Sciences (NCATS),TRXR100,20111005,"6,19,40,72,86,109,119,126,127,137,138,174,178,185,190,191,199,204,229,237,240,243,244,248,249,253,255,275,286,289,298,299,303,305,311,314,323,335,338,366,379,401,403,408,441,444,460,462,464,471,487,499,525,535,546,547,564,588,594,597,637,650,660,681,698,701,727,745,774,785,787,802,803,838,864,892,896,899,903,904,931,932,936,938,942,951,957,978,992,995,1001,1002,1017,1018,1030,1045,1046,1047,1066,1088,1101,1102,1103,1123,1150,1174,1176,1189,1201,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,123","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",58819,NULL,AAC35244,Governmental Organizations|NIH Initiatives,"10490269,11705695,16085187,19364476",0,10.1016/j.bbagen.2009.01.014|10.1016/j.freeradbiomed.2005.04.025|10.1016/s0891-5849(01)00698-0|10.1016/s0891-5849(99)00101-x,NULL,AAC35244,NULL
588456,2,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,"The selenoprotein thioredoxin reductase (TrxR; EC 1.8.1.9) is a FAD containing homodimeric pyridine nucleotide-disulfide oxidoreductase with many cellular roles. Together with NADPH and its prime substrate thioredoxin (Trx), the enzyme forms the core of the Trx system. The mammalian Trx system exerts a wide spectrum of functions including redox regulation, antioxidant defense, regulation of transcription factors as well as support of cell growth and replication. Many of these functions involve the reduction",2,National Center for Advancing Translational Sciences (NCATS),TRXR101,20111006,"6,19,40,72,86,109,119,126,127,137,138,174,178,185,190,191,199,204,229,237,240,243,244,248,249,253,255,275,286,289,298,299,303,305,311,314,323,335,338,366,379,401,403,441,444,460,462,464,471,487,499,525,535,546,547,564,588,594,597,637,650,660,681,698,701,727,745,774,785,787,802,803,838,864,892,896,899,903,904,931,932,936,938,942,951,957,978,992,995,1001,1002,1017,1018,1030,1045,1046,1047,1066,1088,1101,1102,1103,1123,1150,1174,1176,1189,1201,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,12","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",58819,NULL,AAC35244,Governmental Organizations|NIH Initiatives,"10490269,11705695,16085187,19364476",0,10.1016/j.bbagen.2009.01.014|10.1016/j.freeradbiomed.2005.04.025|10.1016/s0891-5849(01)00698-0|10.1016/s0891-5849(99)00101-x,NULL,AAC35244,NULL
588795,2,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,"The major human flap endonuclease FEN1 is an efficient structure-specific enzyme that recognizes and cleaves a 5'-unannealed DNA flap. It belongs to the RAD2 family nucleases, which are involved in DNA metabolism and are highly conserved in prokaryotes and eukaryotes. FEN1 is a key enzyme in DNA replication, repair and maintenance of genomic stability.  5'-flap removal by FEN1 is critical for Okazaki fragment processing during lagging strand DNA synthesis, long-patch base excision repair (LP BER), and regul",2,National Center for Advancing Translational Sciences (NCATS),FEN1001,20111116,"6,19,40,72,86,109,119,126,127,137,138,174,178,185,190,191,199,204,229,237,240,243,244,248,249,253,255,275,286,289,298,299,303,305,311,314,323,335,338,366,379,401,403,441,444,460,462,464,471,487,499,525,535,546,547,564,588,594,597,637,650,660,681,698,701,727,745,774,785,787,802,803,838,864,892,896,899,903,904,931,932,936,938,942,951,957,978,992,995,1001,1002,1017,1018,1030,1045,1046,1047,1066,1088,1101,1102,1103,1123,1150,1174,1176,1189,1201,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,12","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",2237,NULL,NP_004102,Governmental Organizations|NIH Initiatives,16864780,0,10.1073/pnas.0604348103,3.1.-.-,P39748,NULL
588579,2,qHTS for Inhibitors of Polymerase Kappa,"The processing and repair of DNA interstrand crosslinks (ICL) in eukaryotic cells are extremely complex, potentially involving multiple DNA repair and damage tolerance pathways, including homologous recombination, nucleotide excision repair, translesion synthesis (TLS), and cell cycle checkpoints. In some repair models, the dually-incised strand possesses sufficient mobility that a DNA polymerase can strand displace the nucleotide patch that is 5' to the lesion, then replicate past the ICL site to complete ",2,National Center for Advancing Translational Sciences (NCATS),PolK100,20111020,"6,19,40,51,72,86,109,119,126,127,135,137,138,174,178,180,185,187,190,191,196,199,204,205,206,224,227,229,237,239,240,243,244,248,249,253,255,263,273,275,277,286,289,298,299,303,304,305,311,314,323,335,338,342,359,366,370,379,401,403,408,412,441,444,450,453,460,462,464,471,487,499,525,535,546,547,564,588,594,595,596,597,607,610,612,614,636,637,650,660,681,698,701,710,727,736,745,750,753,757,774,785,787,791,798,802,803,827,830,836,838,846,847,853,863,864,866,876,887,892,896,899,903,904,912,914,931,932,936,938","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",51426,NULL,NP_057302,Governmental Organizations|NIH Initiatives,NULL,0,NULL,2.7.7.7,Q9UBT6,NULL
588342,2,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),"MLPCN Grant: 1 R21 NS059478-01 (miR-21 grant)_|__|_Assay Provider: NCGC_|__|_NCGC Assay Overview:  _|__|_Firefly (Photinus pyralis) luciferase is one of the most commonly used transcriptional reporters for a number of reasons. It is considered one of the more dynamically responsive reporters -that is, responsive to changes in reporter transcription - as it requires no post-translational modifications and is enzymatically active directly after protein synthesis (Wood, 1998). Additionally, the half-life of th",2,National Center for Advancing Translational Sciences (NCATS),FLUC100,20110907,"6,72,119,137,191,204,229,253,289,298,299,303,323,338,366,441,460,464,487,499,525,546,547,564,588,597,637,698,701,727,774,803,864,892,899,931,932,936,938,957,1017,1018,1030,1046,1047,1066,1088,1101,1150,1174,1201,1233,1245,1292,1302,1309,1318,1329,1330,1345,1359,1367,1400,1401,1474,1483,1491,1492,1539,1546,1570,1609,1646,1676,1688,1727,1730,1738,1742,1761,1775,1780,1794,1814,1820,1832,1833,1853,1858,1868,1882,1890,1892,1893,1922,1923,1967,1981,1983,1985,1986,1988,1989,2000,2002,2007,2015,2018,2020,2048,2052,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842135,842136,842137,842138,842139,842140,842141,842142,842143,842144,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842160,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,8",NULL,NULL,AAA29795,Governmental Organizations|NIH Initiatives,"17355205,18590332,1889744,20194791,7894082",0,10.1016/0378-1119(91)90270-l|10.1016/0958-1669(95)80009-3|10.1021/cb8000793|10.1073/pnas.0909141107|10.1089/adt.2006.053,NULL,P08659,NULL
588591,2,qHTS for Inhibitors of Polymerase Eta,"The Y-family of DNA polymerases, such as Pol eta, are specifically involved in DNA repair. Pol eta copies undamaged DNA with a lower fidelity than other DNA-directed polymerases. However, it accurately replicates UV-damaged DNA; when thymine dimers are present, this polymerase inserts the complementary nucleotides in the newly synthesized DNA, thereby bypassing the lesion and suppressing the mutagenic effect of UV-induced DNA damage. Pol eta has the ability to bypass cisplatinated DNA adducts in vitro, and ",2,National Center for Advancing Translational Sciences (NCATS),PolE100,20111020,"6,19,40,72,86,109,119,127,137,174,178,185,190,191,204,229,243,253,255,275,289,298,299,303,311,314,323,335,338,366,379,401,408,441,460,464,471,487,499,525,546,547,564,588,597,637,650,660,698,701,727,745,774,785,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1216,1222,1228,1232,1233,1245,1256,1292,1302,1309,1317,1318,1326,1328,1329,1330,1340,1345,1359,1365,1367,1369,1390,1400,1401,1456,1474,1483,1486,1489,1491,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",5429,NULL,NP_006493,Governmental Organizations|NIH Initiatives,NULL,0,NULL,2.7.7.7,Q9Y253,NULL
588478,0,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37","Deubiquitinating enzymes (DUB) represent a group of cysteine proteases that cleave the isopeptide bond between ubiquitin and its conjugated proteins. This high-throughput screen aims to identify small molecule inhibitors of a human DUB, UCH37, which is tightly associated with proteasomes. Specifically, this screen seeks to identify small molecules that inhibit the fluorescence increase that results from cleavage by UCH37 of a fluorescent substrate, ubiquitin-7-amido-4-methylcoumarin (Ub-AMC)._|__|_This scre",46,"ICCB-Longwood Screening Facility, Harvard Medical School",HMS937_MLP,20161018,"6,19,72,86,109,119,127,137,174,190,191,204,229,243,255,289,298,303,311,323,335,338,366,379,412,441,444,460,464,487,499,525,546,547,564,588,597,637,660,698,727,802,803,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1491,1492,1493,1535,1539,1546,1639,1643,1646,1676,1678,1688,1727,1738,1742,1761,1775,1794,1795,1814,1820,1826,1832,1833","124772548,124772549,124772550,124772551,124772552,124772553,124772554,124772555,124772556,124772557,124772558,124772559,124772560,124772561,124772562,124772563,124772564,124772565,124772566,124772567,124772568,124772569,124772570,124772571,124772572,124772573,124772574,124772575,124772576,124772577,124772578,124772579,124772580,124772581,124772582,124772583,124772584,124772585,124772586,124772587,124772588,124772589,124772590,124772591,124772592,124772593,124772594,124772595,124772596,124772597,124772598,12",51377,NULL,AAD31528,Research and Development,"20823120,20829789",0,10.1038/nature09299|10.1074/mcp.r110.003871,NULL,Q9Y5K5,NULL
588489,1,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network(MLPCN)_|_Grant Number: R03 MH094198-01_|_Assay Provider: Kalle Gehring, Ph.D., McGill University_|_The regulation of gene expression is a mechanism that allows cells to respond to growth and proliferation stimuli, stress, and nutrient availability. It is managed at multiple levels: mRNA expressi",14,Burnham Center for Chemical Genomics,SBCCG-A704-MLLE-PAM2-Inh-Primary-Assay,20111011,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",26986,NULL,NP_002559,NIH Initiatives,"11287632,12762031,19239892,20096703,3313012,3537727",0,10.1016/j.cell.2009.01.042|10.1016/j.jmb.2010.01.032|10.1073/pnas.071024998|10.1101/sqb.2001.66.293|10.1128/mcb.6.8.2932|10.1128/mcb.7.9.3268,NULL,P11940,NULL
588493,1,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH094180-01_|_Assay Provider: Dr. Raymond Deshaies, California Institute of Technology, Pasadena, CA_|__|_Protein modification by the attachment of ubiquitin to cellular proteins is a key mechanism in regulating many cellular and physiological processes. Ubiqui",14,Burnham Center for Chemical Genomics,SBCCG-A706-Rpn11-Inh-Primary-Assay,20120225,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",10213,NULL,AAH09524,NIH Initiatives,"10619848,12183636,12183637,12353037,14744430,14990998,2538923",0,10.1016/s0092-8674(03)01074-2|10.1038/nature01071|10.1038/nrm1336|10.1093/emboj/19.1.94|10.1126/science.1075898|10.1126/science.1075901|10.1126/science.2538923,NULL,AAH09524,NULL
588621,1,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R03MH095532-01_|_Assay Provider: Dr. Lutz Tautz, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_Disturbance of the dynamic balance between protein tyrosine phosphorylation and dephosphorylation is crucial for the development of many serious condition",14,Burnham Center for Chemical Genomics,SBCCG-A754-STEP-Primary-Assay,20111024,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",84867,NULL,NP_008837,NIH Initiatives,"12895417,16025111,16237174,18923032,20427654,20956308,7869116,8331384",0,10.1016/s0896-6273(03)00434-3|10.1038/nn1503|10.1073/pnas.1013543107|10.1523/jneurosci.0157-10.2010|10.1523/jneurosci.2666-08.2008|10.1523/jneurosci.2980-05.2005,3.1.3.48,P54829,NULL
588674,1,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,"Keywords:  osteoporosis, Schnurri-3, kappa recognition component_|__|__|_Assay Overview:_|__|_This is a novel physiologically relevant cell-based_|_approach to identify inhibitors of Schnurri-3 (Shn3), a potent and essential regulator of adult bone formation._|_This screen will identify specific compounds that target the 3'UTR of Shn3 to post-transcriptionally regulate its_|_mRNA to reduce Shn3 protein levels. This assay uses a SV40 large T antigen-transformed osteoblast cell line_|_(Clone20-Shn3FFL) that m",31,Broad Institute,2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,20140317,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
588492,1,uHTS identification of small molecule modulators of myocardial damage,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 DA031671-01_|_Assay Provider: Richard Kitsis, M.D., Albert Einstein College of Medicine of Yeshiva University_|__|_Myocardial infarction (""heart attack"") is one of the most common causes of morbidity and mortality in the United States and the world1. It is pre",14,Burnham Center for Chemical Genomics,SBCCG-A705-H9c2-Inh-Primary-Assay,20111012,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,NULL,NULL,NIH Initiatives,"12517460,14744432,15800626,19218262,2014866",0,10.1016/s0092-8674(04)00046-7|10.1016/s0140-6736(03)12113-7|10.1038/nature03317|10.1136/hrt.2007.139493|10.2105/ajph.81.5.628,NULL,NULL,NULL
588692,1,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,"Keywords: N-Linked Glycosylation,  luciferase reporter, reporter gene assay, luciferin, luminescence, receptor tyrosine kinases_|__|__|_Assay Overview:_|_N-linked glycosylation is a highly regulated, site-specific protein modification important for the stability and folding  of transmembrane proteins. Formation of mature carbohydrate structures requires at least twenty different enzymes and a membrane. Although N-linked glycosylation bioprocess employs up to twenty known enzymes to date, currently there is ",31,Broad Institute,2146-01_Inhibitor_SinglePoint_HTS_Activity,20111128,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,842205,842206,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
588391,1,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: Protein Disulfide Isomerase, PDI, arterial thrombosis, inhibitors of PDI, anti-thrombotic,  insulin aggregation assay_|__|__|_Assay Overview: PDI is a key participant in an extracellular electron transport involved in the activation of the coagulation cascade.  Inhibition of extracellular PDI displayed on the surface of platelets and/or vascular cells prevents platelet accumulation and fibrin generation that leads to thrombus formation. Arterial thrombosis mediates tissue infarction in coronary ar",31,Broad Institute,2137-01_Inhibitor_SinglePoint_HTS_Activity,20110921,"6,19,86,109,119,127,137,185,191,229,255,289,298,303,314,323,338,366,460,464,487,525,546,547,564,588,597,637,698,727,745,774,864,892,896,899,903,904,932,936,938,949,992,1002,1018,1046,1047,1088,1101,1123,1174,1176,1183,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1486,1489,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,1727,1730,1738,1742,1761,1775,1794,1795,1810,1814,1820,1821,1826,1832,1853,1858,1864,1890,1892,1893,1917,1967,1972","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",5034,Biochemical,AAH10859,NIH Initiatives,NULL,0,NULL,NULL,P07237,NULL
588549,1,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: Mycobacterium tuberculosis, adenylate-forming enzymes, FadD28, inhibitor, fluorescence polarization, high throughput screening_|__|_Assay Overview:_|_Fad28 is one of fatty acyl-AMP ligases (FAALs) involved in lipid biosynthesis. Its activity can be measured through an enzyme coupling assay. Due to the requirement of two coupling enzymes, potential interference caused by the low wavelength of detection and low enzyme activity, a fluorescence polarization displacement assay has been developed as an ",31,Broad Institute,2147-01_Inhibitor_SinglePoint_HTS_Activity,20111018,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,Biochemical,CAB06100,NIH Initiatives,NULL,0,NULL,NULL,P9WQ59,NULL
588473,1,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 DA029966-01_|_Assay Providers: Selena Bartlett, Ph.D., Ernest Gallo Clinic and Research Center, University of California, San Francisco and Nick Cosford, Ph.D., Sanford-Burnham Medical Research Institute_|__|_There is accumulating scientific evidence ",14,Burnham Center for Chemical Genomics,SBCCG-A701-CRF-Agonist-Primary-Assay,20111008,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8","1393,1395",NULL,"AAR18078,CAA41086",NIH Initiatives,"10838414,12895416,15930388,16611089,17699688,18308824",0,10.1016/s0896-6273(03)00461-6|10.1113/jphysiol.2007.150078|10.1152/jn.00824.2007|10.1177/108705719900400206|10.1523/jneurosci.0955-05.2005|10.2174/187152706776359619,NULL,"CAA41086,Q13324",NULL
588850,1,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: IR21 NS061743-01_|_Assay Provider:  Rangan Maitra, Ph.D., RTI International University_|__|_The inflammatory response in Cystic Fibrosis (CF) is a complex interplay between several factors.  It has been suggested that pro-inflammatory cytokines are elevated in the ep",14,Burnham Center for Chemical Genomics,SBCCG-A764-CF-PAF-Primary-Assay,20111205,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",1080,NULL,NP_000483,NIH Initiatives,"10400842,15661927,16239509,7544594",0,10.1016/s0091-6749(99)70116-8|10.1128/iai.73.11.7151-7160.2005|10.1165/ajrcmb.13.3.7544594|10.4049/jimmunol.174.3.1638,5.6.1.6,P13569,NULL
588413,1,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network(MLPCN)_|_Grant Number: 1R03MH094195-01_|_Assay Provider: James Chen, Ph.D.,Stanford University, Stanford California_|__|_The Hh pathway plays a critical role in the patterning of certain embryonic tissues and contributes to their neoplastic transformation later in life.  Hh signaling regulates c",14,Burnham Center for Chemical Genomics,SBCCG-A686-Gli-Sufu-Antagonist-Primary-Assay,20120312,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",14632,NULL,BAA85004,NIH Initiatives,"11283316,12202832,12391318,12414725,15380514,17353198,19081070,19136624,19189974,19469545,19522463,19716296,19726763,19726788,19797115,19859563,20493695",0,10.1016/j.bmcl.2009.08.049|10.1016/j.bmcl.2010.04.110|10.1016/j.ccr.2004.08.019|10.1016/j.devcel.2008.11.010|10.1021/jm900305z|10.1021/jm900309j|10.1056/nejmoa0905360|10.1073/pnas.182542899|10.1074/jbc.m109.059964|10.1074/jbc.m611089200|10.1074/jbc.m806233200|10.1101/gad.1025302|10.1101/gad.1753809|10.1126/science.1073733|10.1126/science.1179386|10.1146/annurev.neuro.24.1.385|10.1371/journal.pone.0007608,NULL,BAA85004,NULL
588405,1,HTS Assay for Peg3 Promoter Inhibitors,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBIMR, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 2R01 GM068385-06_|_Assay Provider:  Paul B. Fisher, M.Ph., Ph.D., Virginia Commonwealth University_|__|_Cancer is a progressive disease culminating in the acquisition of metastatic potential by a subset of evolving tumor cells. Although extensively investigated, the",14,Burnham Center for Chemical Genomics,SBCCG-A685-PEG3-Inh-Primary-Assay,20110923,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",171071,NULL,NP_598230,NIH Initiatives,10918598,0,10.1038/sj.onc.1203666,NULL,Q6IN02,NULL
588458,1,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA031091-01A1_|_Assay Provider: Dr. James Stivers, Johns Hopkins University, Baltimore, MD_|__|_Hypermethylation of CpG dinucleotides in promoter regions of tumor suppressor genes by DNA 5-C-MTases is an important hallmark of human cancers [1-3]. Such",14,Burnham Center for Chemical Genomics,SBCCG-A699-DNMT1-Inh-Primary-Assay,20111006,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",1786,NULL,NP_001370,NIH Initiatives,"11751372,11960994,12154398,15491775,16234563,16341238,17485372,17998812,18076941,18246412,18314485",0,10.1007/s10555-008-9118-y|10.1016/j.juro.2007.09.038|10.1016/j.tips.2004.09.004|10.1038/ncponc0346|10.1038/sj.onc.1205597|10.1074/jbc.m203009200|10.1093/jnci/dji311|10.1158/1541-7786.mcr-07-0373|10.2741/2385|10.4161/epi.1.1.2375,2.1.1.37,P26358,NULL
588334,1,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,"Keywords: MITF, TRPM-1, melanoma, SK-MEL-5, luciferase reporter_|__|_Assay Overview:_|_The primary HTS will be performed using SK-MEL-5 cells stably expressing the TRPM1 promoter upstream of the luciferase gene. TRPM-1 is a known target of the transcription factor, MITF.  The assay in its current format utilizes plating of 2000 cells per well in 384 well plates using 30 mul total volume (cells plus media) per well. This will allow us to use a volume of 100 nl for pinning of the compounds 24 hours later. The",31,Broad Institute,2084-01_Activator_SinglePoint_HTS_Activity,20110825,"6,19,40,72,86,109,119,127,137,185,190,191,204,229,253,255,289,298,299,303,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,803,864,892,896,899,903,904,931,932,936,938,957,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1643,1646,1676,1678,1688,1689,1727,1730,1738,1761,1775,1794,1795,1814,1","842122,842123,842124,842125,842126,842128,842129,842130,842131,842134,842136,842137,842138,842140,842141,842143,842146,842148,842149,842150,842151,842152,842153,842156,842157,842159,842161,842162,842165,842166,842167,842168,842169,842170,842171,842172,842173,842178,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842201,842202,842203,842204,842205,842206,842207,842209,842211,842213,842214,842216,842217,842219,842220,842221,842222,842223,842224,8",NULL,Cell-based,NULL,NIH Initiatives,"16899407,16988713",0,10.1016/j.molmed.2006.07.008|10.1038/nature05098,NULL,NULL,NULL
588475,1,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 DA029966-01_|_Assay Providers: Selena Bartlett, Ph.D., Ernest Gallo Clinic and Research Center, University of California, San Francisco and Nick Cosford, Ph.D., Sanford-Burnham Medical Research Institute_|__|_There is accumulating scientific evidence ",14,Burnham Center for Chemical Genomics,SBCCG-A702-CRF-Antagonist-Primary-Assay,20120103,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8","1393,1395",NULL,"AAR18078,CAA41086",NIH Initiatives,"10838414,12895416,15930388,16611089,17699688,18308824",0,10.1016/s0896-6273(03)00461-6|10.1113/jphysiol.2007.150078|10.1152/jn.00824.2007|10.1177/108705719900400206|10.1523/jneurosci.0955-05.2005|10.2174/187152706776359619,NULL,"CAA41086,Q13324",NULL
588352,1,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Bert O'Malley, Baylor College of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 5U19DK062434-09_|_Grant Proposal PI: Bert O'Malley, Baylor College of Medicine_|_External Assay ID: SRC3_INH_LUMI_1536_1X%INH PRUN_|__|_Name: Luminescence-based cell-based primary high throughput screening assa",5,The Scripps Research Institute Molecular Screening Center,SRC3_INH_LUMI_1536_1X%INH PRUN,20111031,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",8202,Cell-based,NP_858045,NIH Initiatives,"15657351,16685276,18980964,19701241,19846539,20576803,2469536,3164252",0,10.1038/nrc2695|10.1038/sj.bjc.6603141|10.1158/1078-0432.ccr-08-0581|10.1210/me.2009-0276|10.1677/erc-10-0058,2.3.1.48,Q9Y6Q9,NULL
588819,1,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: MH077606-01_|_Grant Proposal PI: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_External Assay ID: CHRM1_PAM_FLUO8_1536_1X%ACT PRUN_|__|_Name: Fluorescence-based cell-based primary ",5,The Scripps Research Institute Molecular Screening Center,CHRM1_PAM_FLUO8_1536_1X%ACT PRUN,20120509,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",1128,Cell-based,NP_000729,NIH Initiatives,"18481916,19201489,2188581,2385234,3037705,3272174,3443095,7504306,7751967,9109749",0,10.1001/archneur.1997.00550160091022|10.1016/0163-7258(93)90027-b|10.1016/0896-6273(88)90190-0|10.1016/j.tips.2008.12.002|10.1126/science.3037705|10.1146/annurev.pa.30.040190.003221,NULL,P11229,NULL
588689,2,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,"Assay Provider: Brian Geiss, Colorado State University_|__|_Mosquito-borne flaviviruses (family Flaviviridae, genus flavivirus), including dengue, yellow fever and West Nile viruses can cause significant morbidity and mortality worldwide.  The Aedes aegypti mosquito, which is found on almost every continent of the world, is the primary vector for both dengue and yellow fever viruses.  Flavivirus infection can cause a wide range of disease symptoms ranging from mild febrile illness to hemorrhagic disease in ",33,Southern Research Specialized Biocontainment Screening Center,CEGtase_01,20111026,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,172","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,842205,8",NULL,NULL,3EVG_A,NIH Initiatives,"2680092,2822355",0,NULL,NULL,3EVG_A,NULL
588354,1,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Bert O'Malley, Baylor College of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 5U19DK062434-09_|_Grant Proposal PI: Bert O'Malley, Baylor College of Medicine_|_External Assay ID: SRC1_INH_LUMI_1536_1X%INH PRUN_|__|_Name: Luminescence-based cell-based primary high throughput screening assa",5,The Scripps Research Institute Molecular Screening Center,SRC1_INH_LUMI_1536_1X%INH PRUN,20110913,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",8648,Cell-based,NP_003734,NIH Initiatives,"15657351,16685276,18980964,19701241,19846539,20576803,2469536,3164252",0,10.1038/nrc2695|10.1038/sj.bjc.6603141|10.1158/1078-0432.ccr-08-0581|10.1210/me.2009-0276|10.1677/erc-10-0058,2.3.1.48,Q15788,NULL
588358,1,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,"University of New Mexico Assay Overview:  _|_Assay Support:  1 R03 DA032475-01_|_Project Title:  HTS to find inhibitors of pathogenic pemphigus antibodies_|_Assay Provider: John R. Stanley, M.D., Department of Dermatology, University of Pennsylvania_|_Screening Center/PI: UNMCMD/Larry Sklar_|_Lead Biologist: Mark K. Haynes  _|_Chemistry Center/ PI: University of Kansas Specialized Chemistry Center/Jeff Aube_|_Chemistry Lead: Jennifer Golden_|_Assay Implementation: Mark Haynes, Peiying Li , Stephanie Chavez,",6,NMMLSC,UNMCMD_DSG_PRIMARY_MLPCN,20110922,"6,19,40,72,86,109,119,127,137,174,191,229,243,255,289,298,299,311,314,323,335,338,366,379,464,487,499,525,547,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1030,1046,1047,1066,1088,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1730,1742,1761,1775,1794,1795,1810,1820,1821,1826,1832,183","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842150,842151,842152,842153,842154,842156,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842179,842180,842182,842184,842188,842189,842190,842192,842193,842194,842195,842196,842197,842198,842199,842200,842202,842203,842204,842205,842206,842207,842208,842209,842211,842213,842214,842216,842217,842218,8",NULL,NULL,NULL,NIH Initiatives,"10450720,15841178,18007588,19340014,19843946,20978359",0,10.1001/jama.282.6.572|10.1038/jid.2009.61|10.1038/sj.jid.5701132|10.1172/jci24185|10.1172/jci44425|10.4049/jimmunol.0901691,NULL,NULL,NULL
588727,2,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83","Southern Research's Specialized Biocontainment Screening Center (SRSBSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Assay Provider: Dong Hoon Chung, University of Louisville_|_Award: 1 R03 MH087448-01A1 _|__|__|_Venezuelan Equine Encephalitis Virus is a mosquito transmitted virus effecting both humans and horses.  The last major outbreak in 1995, reported an estimated 70,000 - 100,000 humans infected and a similar number of known ",33,Southern Research Specialized Biocontainment Screening Center,VEE_AV_01,20111030,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,172","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
588852,1,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: MH077606-01_|_Grant Proposal PI: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_External Assay ID: CHRM1_ANT_FLUO8_1536_1X%INH PRUN_|__|_Name: Fluorescence-based cell-based primary ",5,The Scripps Research Institute Molecular Screening Center,CHRM1_ANT_FLUO8_1536_1X%INH PRUN,20120509,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",1128,Cell-based,NP_000729,NIH Initiatives,"18481916,19201489,2188581,2385234,3037705,3272174,3443095,7504306,7751967,9109749",0,10.1001/archneur.1997.00550160091022|10.1016/0163-7258(93)90027-b|10.1016/0896-6273(88)90190-0|10.1016/j.tips.2008.12.002|10.1126/science.3037705|10.1146/annurev.pa.30.040190.003221,NULL,P11229,NULL
588436,1,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity","Keywords: V. cholerae, cqsA, luxS mutant, quorum sensing, luminescence_|_Assay Overview: A modified strain of Vibrio cholerae used in this assay uses light production to signal quorum sensing.  Vibrio cholerae is not naturally bioluminescent but the closely related species, Vibrio harveyi, produces light when the population is at a high density (i.e. a quorum is sensed). In the V. cholerae BH1578 strain, the V. harveyi luxCDABE (luciferase) operon was introduced as a cosmid and the operon is activated by en",31,Broad Institute,2132-01_Agonist_SinglePoint_HTS_Activity,20111004,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842195,842196,842197,842198,842199,842201,842202,842203,842204,842205,842206,842207,842208,842209,8",NULL,Organism-based,NULL,NIH Initiatives,21197957,0,10.1021/cb1003652,NULL,NULL,NULL
588335,1,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRISMC)_|_Center Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Mary Jackson, Colorado State_|_Network: Molecular Library Probe Production Center Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS066438-01_|_Grant Proposal PI: Mary Jackson, Colorado State_|_External Assay ID: GDH-TPI_INH_ABS_1536_1X%INH CSRUN_|__|_Name: Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tube",5,The Scripps Research Institute Molecular Screening Center,GDH-TPI_INH_ABS_1536_1X%INH CSRUN,20110825,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,Biochemical,NULL,NIH Initiatives,"18364060,18688832,19167403",0,10.1002/chem.200800857|10.1016/j.jmb.2009.01.003,NULL,NULL,NULL
588726,1,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Mary Jackson, Colorado State_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS066438-01_|_Grant Proposal PI: Mary Jackson, Colorado State_|_External Assay ID: ALD_INH_FLINT_1536_1X%INH PRUN_|__|_Name: Fluorescence-based biochemical primary high throughput screening assay to identify inhibitor",5,The Scripps Research Institute Molecular Screening Center,ALD_INH_FLINT_1536_1X%INH PRUN,20120802,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",886474,Biochemical,NP_214877,NIH Initiatives,"18364060,18688832,19167403",0,10.1002/chem.200800857|10.1016/j.jmb.2009.01.003,4.1.2.13,P9WQA3,NULL
588664,1,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: John Colicelli, UCLA_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R01 CA136699-01A1_|_Grant Proposal PI: John Colicelli, UCLA_|_External Assay ID: RIN1-ABL_INH_TRFRET_1536_1X%INH PRUN_|__|_Name: TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the inter",5,The Scripps Research Institute Molecular Screening Center,RIN1-ABL_INH_TRFRET_1536_1X%INH PRUN,20111025,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8","25,9610",Biochemical,"NP_004283,NP_005148",NIH Initiatives,"10706884,11423618,12161751,15032571,15618470,15886098,17108134,18089786,18418407,18538733,18772113,18796434,19169242,7805037",0,10.1016/j.ccr.2008.04.018|10.1016/j.ccr.2008.08.003|10.1016/j.cub.2005.03.049|10.1038/leu.2008.89|10.1038/nature07737|10.1038/ng946|10.1074/jbc.m804002200|10.1126/science.1062538|10.1146/annurev.immunol.22.012703.104753|10.1158/0008-5472.can-06-1216|10.1158/0008-5472.can-07-2756|10.1182/blood-2004-08-3097,2.7.10.2,"P00519,Q13671",NULL
588814,1,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: MH077606-01_|_Grant Proposal PI: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_External Assay ID: CHRM1_AG_FLUO8_1536_1X%ACT PRUN_|__|_Name: Fluorescence-based cell-based primary h",5,The Scripps Research Institute Molecular Screening Center,CHRM1_AG_FLUO8_1536_1X%ACT PRUN,20120509,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",1128,Cell-based,NP_000729,NIH Initiatives,"18481916,19201489,2188581,2385234,3037705,3272174,3443095,7504306,7751967,9109749",0,10.1001/archneur.1997.00550160091022|10.1016/0163-7258(93)90027-b|10.1016/0896-6273(88)90190-0|10.1016/j.tips.2008.12.002|10.1126/science.3037705|10.1146/annurev.pa.30.040190.003221,NULL,P11229,NULL
588497,1,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set","University of New Mexico Assay Overview:_|_Assay Support: 1 R03 MH093184-01A1_|_Project Title: High-throughput multiplex microsphere screening for toxin protease inhibitors_|_Assay Provider: Steven Graves Ph.D._|__|_Screening Center/PI: UNMCMD/ Larry Sklar Ph.D._|_Lead Biologist: Bruce Edwards Ph.D.,_|_Screening Operations Team: Jingshu Zhu, Mark Carter MS, Kristine Gouveia MS, Matthew Garcia_|__|_Chemistry Center PI: Craig W. Lindsley_|_Chemistry Lead: Kyle Emmitte_|_Specialized Chemistry Center: Vanderbil",6,NMMLSC,UNMCMD_Botulinum_LightChainF_Protease_HTS_MLPCN,20111013,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,NULL,ZP_02619427,NIH Initiatives,"15592454,16604538,18844202,19268493,20035615,20938917,9414082",0,10.1002/0471142956.cy1312s54|10.1002/anie.200705531|10.1002/cyto.a.20268|10.1016/j.toxicon.2008.12.027|10.1016/s0014-5793(97)01328-8|10.1038/nature03123|10.1089/adt.2009.0219,NULL,EDT84149,NULL
588501,1,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set","University of New Mexico Assay Overview:_|_Assay Support: 1 R03 MH093184-01A1_|_Project Title: High-throughput multiplex microsphere screening for toxin protease inhibitors_|_Assay Provider: Steven Graves Ph.D._|__|_Screening Center/PI: UNMCMD/ Larry Sklar Ph.D._|_Lead Biologist: Bruce Edwards Ph.D.,_|_Screening Operations Team: Jingshu Zhu, Mark Carter MS, Kristine Gouveia MS, Matthew Garcia_|__|_Chemistry Center PI: Craig W. Lindsley_|_Chemistry Lead: Kyle Emmitte_|_Specialized Chemistry Center: Vanderbil",6,NMMLSC,UNMCMD_Anthrax_LethalFactor_Protease_HTS_MLPCN,20111013,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,NULL,NP_652928,NIH Initiatives,"15592454,16604538,18844202,19268493,20035615,20938917,9414082",0,10.1002/0471142956.cy1312s54|10.1002/anie.200705531|10.1002/cyto.a.20268|10.1016/j.toxicon.2008.12.027|10.1016/s0014-5793(97)01328-8|10.1038/nature03123|10.1089/adt.2009.0219,NULL,NP_652928,NULL
588499,1,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set","University of New Mexico Assay Overview:_|_Assay Support: 1 R03 MH093184-01A1_|_Project Title: High-throughput multiplex microsphere screening for toxin protease inhibitors_|_Assay Provider: Steven Graves Ph.D._|__|_Screening Center/PI: UNMCMD/ Larry Sklar Ph.D._|_Lead Biologist: Bruce Edwards Ph.D.,_|_Screening Operations Team: Jingshu Zhu, Mark Carter MS, Kristine Gouveia MS, Matthew Garcia_|__|_Chemistry Center PI: Craig W. Lindsley_|_Chemistry Lead: Kyle Emmitte_|_Specialized Chemistry Center: Vanderbil",6,NMMLSC,UNMCMD_Botulinum_LightChainA_Protease_HTS_MLPCN,20111114,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",5185061,NULL,YP_001253342,NIH Initiatives,"15592454,16604538,18844202,19268493,20035615,20938917,9414082",0,10.1002/0471142956.cy1312s54|10.1002/anie.200705531|10.1002/cyto.a.20268|10.1016/j.toxicon.2008.12.027|10.1016/s0014-5793(97)01328-8|10.1038/nature03123|10.1089/adt.2009.0219,3.4.24.69,P0DPI1,NULL
588519,0,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,"Viral RNA-dependent RNA polymerase (RdRP) enzymes are essential for the replication of positive-strand RNA viruses and established targets for the development of selective antiviral therapeutics. We performed a high-throughput screen using a fluorescence-based RNA elongation assay to identify poliovirus polymerase inhibitors. Screening and subsequent validation experiments resulted in the identification of seven inhibitors that affect the RNA binding, initiation, or elongation activity of the polymerase. X-",46,"ICCB-Longwood Screening Facility, Harvard Medical School",HMS750,20161018,"89,108,119,127,190,204,253,303,311,323,325,340,346,370,397,437,464,564,727,774,782,785,830,863,864,873,896,904,914,932,938,994,1002,1046,1066,1072,1134,1148,1150,1176,1203,1204,1234,1236,1309,1321,1348,1359,1366,1377,1379,1380,1400,1420,1433,1449,1464,1493,1539,1560,1563,1570,1599,1609,1645,1646,1649,1720,1727,1732,1754,1756,1775,1780,1781,1814,1825,1830,1833,1853,1863,1880,1890,1892,1960,1967,1981,1983,1984,1985,1986,1989,1990,1995,2004,2005,2046,2049,2051,2063,2075,2081,2082,2083,2092,2116,2117,2120,2122,","92117389,92117390,92117391,92117392,92117393,92117394,92117395,92117396,92117397,92117398,92117399,92117400,92117401,92117402,92117403,92117404,92117405,92117406,92117407,92117408,92117409,92117410,92117411,92117412,92117413,92117414,92117415,92117416,92117417,92117418,92117419,92117420,92117421,92117422,92117423,92117424,92117425,92117426,92117427,92117428,92117429,92117430,92117431,92117432,92117433,92117434,92117435,92117436,92117437,92117438,92117439,92117440,92117441,92117442,92117443,92117444,92117445",NULL,NULL,1RA7_A,Research and Development,"15306852,17475199,21722674",0,10.1016/j.ab.2007.03.039|10.1016/j.antiviral.2011.06.006|10.1038/sj.emboj.7600357,NULL,1RA7_A,NULL
588676,1,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,"Data Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Xinzhong Dong, Ph.D._|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA033176-01_|_Grant Proposal PI: Xinzhong Dong, Ph.D., Johns Hopkins University School of Medicine_|_Assay Implementation: Zhihong Lin Ph.D., Xiaofang Huang M.S., Kaiping Xu M.S., Shunyou Long",27,Johns Hopkins Ion Channel Center,JHICC_MrgX1_Antagonist_Primary,20111025,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,727,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1018,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1486,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1761,1775,1780,1794,1795,1820,1826,1832,1833,1853,1858,1864,1868,1882,1889,1890","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",259249,Cell-based,ACG60652,Legacy Depositors|NIH Initiatives,"10838414,11850634,12397184,16465162,16670758,16791143,1714354,17626210,17855615,18650342,19146417,19230660,20724664",0,10.1007/bf00319042|10.1016/j.bmcl.2009.01.085|10.1021/jm800962k|10.1038/nbt1186|10.1038/nn815|10.1038/nrn1950|10.1073/pnas.1011221107|10.1073/pnas.192565799|10.1172/jci28553|10.1177/108705719900400206|10.1523/jneurosci.1249-07.2007|10.1523/jneurosci.1760-08.2008|10.1523/jneurosci.2862-07.2007,NULL,ACG60652,NULL
588675,1,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,"Data Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Xinzhong Dong, Ph.D._|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA033176-01_|_Grant Proposal PI: Xinzhong Dong, Ph.D., Johns Hopkins University School of Medicine_|_Assay Implementation: Zhihong Lin Ph.D., Xiaofang Huang M.S., Kaiping Xu M.S., Shunyou Long",27,Johns Hopkins Ion Channel Center,JHICC_MrgX1_AlloAgonist_Primary,20111025,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,727,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1018,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1486,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1761,1775,1780,1794,1795,1820,1826,1832,1833,1853,1858,1864,1868,1882,1889,1890","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",259249,Cell-based,ACG60652,Legacy Depositors|NIH Initiatives,"10838414,11850634,12397184,16465162,19146417,19230660,20724664",0,10.1016/j.bmcl.2009.01.085|10.1021/jm800962k|10.1038/nbt1186|10.1038/nn815|10.1073/pnas.1011221107|10.1073/pnas.192565799|10.1177/108705719900400206,NULL,ACG60652,NULL
588627,1,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,"Data Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Xinzhong Dong, Ph.D._|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA033176-01_|_Grant Proposal PI: Xinzhong Dong, Ph.D., Johns Hopkins University School of Medicine_|_Assay Implementation: Zhihong Lin Ph.D., Xiaofang Huang M.S., Kaiping Xu M.S., Shunyou Long",27,Johns Hopkins Ion Channel Center,JHICC_MrgX1_Agonist_Primary,20111024,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,727,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1018,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1486,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1761,1775,1780,1794,1795,1820,1826,1832,1833,1853,1858,1864,1868,1882,1889,1890","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",259249,Cell-based,ACG60652,Legacy Depositors|NIH Initiatives,"10838414,11850634,12397184,16465162,19146417,19230660,20724664",0,10.1016/j.bmcl.2009.01.085|10.1021/jm800962k|10.1038/nbt1186|10.1038/nn815|10.1073/pnas.1011221107|10.1073/pnas.192565799|10.1177/108705719900400206,NULL,ACG60652,NULL
588511,1,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),"Data Source: Johns Hopkins Ion Channel Center (JHICC_CaCC_Inh_Primary)_|_BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed, single_|__|_Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Meng Wu, Ph.D._|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA031670-01_|_Grant Proposal PI: Me",27,Johns Hopkins Ion Channel Center,JHICC_CaCC_Inh_Primary,20130327,"6,19,72,86,109,119,127,137,190,191,204,229,253,289,298,303,311,323,338,366,403,412,441,444,460,464,487,499,525,546,547,564,588,597,637,698,727,774,785,802,803,864,892,896,899,903,932,936,938,942,978,992,1001,1018,1046,1047,1057,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1486,1492,1493,1539,1546,1570,1609,1639,1646,1662,1676,1678,1688,1727,1730,1738,1761,1775,1780,1794,1795,1820,1826,1832,1833,1853,1858,1864,1868,1882,1889,1890","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842132,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,8",101772,Cell-based,NP_848757,Legacy Depositors|NIH Initiatives,"10838414,16465162,18279971,18724360,18772398,18805094,18959787,19015192,20006941,20581223,20686072,21041307,21056985,21084298,21115851,21615117",0,10.1016/j.bpj.2009.09.024|10.1016/j.cell.2008.09.003|10.1016/j.jneumeth.2007.12.016|10.1021/cb200146a|10.1038/nature07313|10.1038/nbt1186|10.1074/jbc.m110.164970|10.1074/jbc.m110.174847|10.1074/jbc.m110.175109|10.1096/fj.10-160648|10.1096/fj.10-166884|10.1113/jphysiol.2008.163709|10.1126/science.1163518|10.1152/ajpcell.00018.2010|10.1177/108705719900400206|10.1186/1756-6606-1-14,NULL,Q8BHY3,NULL
588812,0,Cell Viability Profiling of Human Lymphoblast Cell Lines,"NIH Chemical Genomics Center [NCGC]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_The University of North Carolina at Chapel Hill_|__|_NCGC Assay Overview:_|__|_We have developed a 1536-well cell-based assay for quantitative high throughput screening (qHTS) against a panel of 81 immortalized human lymphoblast cell lines (CEU pedigree) that represent 27 trios (two parents and one child) obtained from Corriell Institute for Medical Research (Camden, NJ) t",2,National Center for Advancing Translational Sciences (NCATS),HAPV101,20111118,"289,299,311,403,785,896,1057,1318,1752,1923,1988,2078,2087,2265,2272,2286,2406,2708,2767,2788,2950,3037,3039,3048,3220,3224,3278,3293,3385,3397,3485,3589,3598,4485,4650,4993,5340,5455,5546,5590,5743,5757,5770,5801,5930,5935,5993,5994,6001,6167,6197,6264,6279,6319,6333,6478,6629,6732,6782,6901,7015,7120,7216,7243,7263,7264,7265,7308,7329,7331,7381,7472,7490,7494,7501,7573,7586,7589,7607,7737,7835,8341,8371,8478,8606,8640,8722,8749,8805,8813,8816,9074,9444,9809,10168,10236,10332,10757,10788,10866,10868,11057,","17388662,17388663,17388665,17388668,17388675,17388678,17388687,17388695,17388699,17388700,17388706,17388715,17388718,17388732,17388733,17388741,17388744,17388745,17388747,17388754,17388760,17388763,17388767,17388781,17388789,17388790,17388802,17388809,17388810,17388816,17388818,17388822,17388842,17388848,17388852,17388853,17388854,17388857,17388858,17388859,17388868,17388878,17388880,17388881,17388883,17388885,17388887,17388898,17388909,17388910,17388919,17388927,17388931,17388943,17388945,17388955,17388983",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
588813,0,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,"NIH Chemical Genomics Center [NCGC]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_The University of North Carolina at Chapel Hill_|__|_NCGC Assay Overview:_|__|_We have developed a 1536-well cell-based assay for quantitative high throughput screening (qHTS) against a panel of 81 immortalized human lymphoblast cell lines (CEU pedigree) that represent 27 trios (two parents and one child) obtained from Corriell Institute for Medical Research (Camden, NJ) t",2,National Center for Advancing Translational Sciences (NCATS),HAPC101,20111118,"289,299,311,403,785,896,1057,1318,1752,1923,1988,2078,2087,2265,2272,2286,2406,2708,2767,2788,2950,3037,3039,3048,3220,3224,3278,3293,3385,3397,3485,3589,3598,4485,4650,4993,5340,5455,5546,5590,5743,5757,5770,5801,5930,5935,5993,5994,6001,6167,6197,6264,6279,6319,6333,6478,6629,6732,6782,6901,7015,7120,7216,7243,7263,7264,7265,7308,7329,7331,7381,7472,7490,7494,7501,7573,7586,7589,7607,7737,7835,8341,8371,8478,8606,8640,8722,8749,8805,8813,8816,9074,9444,9809,10168,10236,10332,10757,10788,10866,10868,11057,","17388662,17388663,17388665,17388668,17388675,17388678,17388687,17388695,17388699,17388700,17388706,17388715,17388718,17388732,17388733,17388741,17388744,17388745,17388747,17388754,17388760,17388763,17388767,17388781,17388789,17388790,17388802,17388809,17388810,17388816,17388818,17388822,17388842,17388848,17388852,17388853,17388854,17388857,17388858,17388859,17388868,17388878,17388880,17388881,17388883,17388885,17388887,17388898,17388909,17388910,17388919,17388927,17388931,17388943,17388945,17388955,17388983",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
588516,2,qHTS assay for small molecule antagonists of androgen receptor signaling,"NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_Androgen receptor (AR), located at chromosome Xq11-12, is an important member of nuclear hormone receptors. AR signaling plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Considerable attention has been given in the past decades to the possibility of some of en",2,National Center for Advancing Translational Sciences (NCATS),ARN101,20111014,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",367,NULL,AAI32976,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,AAI32976,NULL
588535,2,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,"NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_The Peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely PPAR alpha, PPAR delta (also called PPAR beta) and PPAR gamma. All these subtypes heterodimerizes with Retinoid X receptor (RXR) and",2,National Center for Advancing Translational Sciences (NCATS),PPARDN,20111017,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",5467,NULL,BAH02282,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,BAH02282,NULL
588547,2,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_Thyroid hormone receptor (TR) belongs to nuclear hormone receptor superfamily. There are two subtypes for TR: TR-alpha and TR-beta. TR-beta plays a major role in regulating plasma cholesterol levels and it mediates the biological activities of thyroid hormone. Screening environmental chemicals on TR-b,2,National Center for Advancing Translational Sciences (NCATS),TRBN10,20111017,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",7068,NULL,NP_001121649,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,P10828,NULL
588537,2,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,"NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_The Peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely PPAR alpha, PPAR delta (also called PPAR beta) and PPAR gamma. All these subtypes heterodimerizes with Retinoid X receptor (RXR) and",2,National Center for Advancing Translational Sciences (NCATS),PPARGN,20111017,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",5468,NULL,BAH02283,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,BAH02283,NULL
588544,2,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,"NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_The Retinoid X receptor (RXR), a nuclear hormone receptor is expressed in liver, spleen, placenta, epidermis, central nervous system. These receptors are able to form homo and heterodimers with other nuclear receptors and due to this heterodimerizing ability, RXR functions as master regulators produci",2,National Center for Advancing Translational Sciences (NCATS),RXRA10,20111017,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",6256,NULL,ADZ17354,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,P19793,NULL
588533,2,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,"NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_The Glucocorticoid receptor (GR), a nuclear receptor subfamily member and its natural ligands includes mineralcorticoids, estrogen and thyroid hormones etc. The GR is a validated drug target for inflammation. GR ligands such as dexamethasone are clinically available as anti-inflammatory drugs. Glucoco",2,National Center for Advancing Translational Sciences (NCATS),GRN101,20111017,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",2908,NULL,ADP91253,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,NP_001019265,NULL
588526,2,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,"NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_The farnesoid-X-receptor (FXR), a nuclear hormone receptor is highly expressed in liver, intestine, kidney and adrenal cortex. Natural ligands of FXR are the bile acids (Cholic acid, Chenodeoxy cholic acid etc). It is an important regulator of diverse metabolic pathways, including the bile acid homeos",2,National Center for Advancing Translational Sciences (NCATS),FXRN10,20111015,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",9971,NULL,ADZ17382,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,ADZ17382,NULL
588546,2,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,"NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_The Retinoid X receptor (RXR), a nuclear hormone receptor is expressed in liver, spleen, placenta, epidermis, central nervous system. These receptors are able to form homo and heterodimers with other nuclear receptors and due to this heterodimerizing ability, RXR functions as master regulators produci",2,National Center for Advancing Translational Sciences (NCATS),RXRN10,20111017,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",6256,NULL,ADZ17354,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,P19793,NULL
588541,2,qHTS assay for small molecule antagonists of vitamin D receptor signaling,"NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_The Vitamin D receptor (VDR) is a member of nuclear hormone receptor superfamily and it plays a critical role in calcium homeostasis and bone metabolism. It plays a role in inducing cell differentiation, inhibiting cell growth and in thrombogenicity. So, VDR that mediates these effects represents a ph",2,National Center for Advancing Translational Sciences (NCATS),VDRN10,20111017,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",7421,NULL,BAH02291,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,BAH02291,NULL
588515,2,qHTS assay for small molecule agonists of androgen receptor signaling,"NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_Androgen receptor (AR), located at chromosome Xq11-12, is an important member of nuclear hormone receptors. AR signaling plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Considerable attention has been given in the past decades to the possibility of some of en",2,National Center for Advancing Translational Sciences (NCATS),ARA101,20111014,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",367,NULL,AAI32976,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,AAI32976,NULL
588532,2,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,"NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_The Glucocorticoid receptor (GR), a nuclear receptor subfamily member and its natural ligands includes mineralcorticoids, estrogen and thyroid hormones etc. The GR is a validated drug target for inflammation. GR ligands such as dexamethasone are clinically available as anti-inflammatory drugs. Glucoco",2,National Center for Advancing Translational Sciences (NCATS),GRA101,20111017,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",2908,NULL,ADP91253,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,NP_001019265,NULL
588545,2,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_Thyroid hormone receptor (TR) belongs to nuclear hormone receptor superfamily. There are two subtypes for TR: TR-alpha and TR-beta. TR-beta plays a major role in regulating plasma cholesterol levels and it mediates the biological activities of thyroid hormone. Screening environmental chemicals on TR-b,2,National Center for Advancing Translational Sciences (NCATS),TRBA10,20111017,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",7068,NULL,NP_001121649,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,P10828,NULL
588536,2,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,"NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_The Peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely PPAR alpha, PPAR delta (also called PPAR beta) and PPAR gamma. All these subtypes heterodimerizes with Retinoid X receptor (RXR) and",2,National Center for Advancing Translational Sciences (NCATS),PPARGA,20111017,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",5468,NULL,BAH02283,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,BAH02283,NULL
588534,2,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,"NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_The Peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely PPAR alpha, PPAR delta (also called PPAR beta) and PPAR gamma. All these subtypes heterodimerizes with Retinoid X receptor (RXR) and",2,National Center for Advancing Translational Sciences (NCATS),PPARDA,20111017,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",5467,NULL,BAH02282,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,BAH02282,NULL
588527,2,qHTS assay for small molecule agonists of farnesoid X receptor signaling,"NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_The farnesoid-X-receptor (FXR), a nuclear hormone receptor is highly expressed in liver, intestine, kidney and adrenal cortex. Natural ligands of FXR are the bile acids (Cholic acid, Chenodeoxy cholic acid etc). It is an important regulator of diverse metabolic pathways, including the bile acid homeos",2,National Center for Advancing Translational Sciences (NCATS),FXRA10,20111015,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",9971,NULL,ADZ17382,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,ADZ17382,NULL
588514,2,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_Estrogen receptor alpha (ER-alpha) is an important member of nuclear hormone receptors. ER-alpha plays important role in breast cancer as well as in other women's health issues. The majority of breast cancers is estrogen receptor (ER) positive and depends on estrogen for growth. There is also growing ,2,National Center for Advancing Translational Sciences (NCATS),ERA101,20111014,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",2099,NULL,AEP43755,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,P03372,NULL
588543,2,qHTS assay for small molecule agonists of vitamin D receptor signaling,"NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_The Vitamin D receptor (VDR) is a member of nuclear hormone receptor superfamily and it plays a critical role in calcium homeostasis and bone metabolism. It plays a role in inducing cell differentiation, inhibiting cell growth and in thrombogenicity. So, VDR that mediates these effects represents a ph",2,National Center for Advancing Translational Sciences (NCATS),VDRA10,20111017,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",7421,NULL,BAH02291,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,BAH02291,NULL
588834,2,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,NIH Chemical Genomics Center [NCGC]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview:_|__|_We have developed a 1536-well cell-based assay for quantitative high throughput screening (qHTS) to determine in vitro hERG channel blockage as a measure of cardio toxicity with small molecules. This particular assay uses the U2OS cell line which is derived from human osteosarcoma.,2,National Center for Advancing Translational Sciences (NCATS),HERG01,20171017,"11,13,51,66,119,174,177,178,180,190,196,204,227,240,241,243,244,261,263,275,289,299,300,308,311,323,335,370,379,398,401,403,408,447,460,464,471,527,546,547,564,588,594,612,614,650,660,681,700,701,702,712,713,727,753,774,785,791,795,798,830,863,864,876,887,892,896,903,904,931,936,938,949,957,967,978,985,991,992,994,995,996,1004,1017,1018,1030,1046,1049,1050,1053,1057,1066,1072,1080,1110,1123,1140,1174,1176,1183,1203,1216,1222,1228,1232,1233,1234,1245,1256,1257,1309,1317,1318,1328,1329,1330,1340,1345,1355,135","855626,855750,855904,11110898,11112213,11112219,11112307,11112680,11112745,11112806,11112878,11112956,11113364,11113949,11114076,11114136,11114278,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388",3757,Cell-based,NP_001191727,Governmental Organizations|NIH Initiatives,"19583963,21362439",0,10.1016/j.ab.2009.07.003|10.1016/j.taap.2011.02.016,NULL,Q12809,NULL
588513,2,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_NCGC Assay Overview_|__|_Estrogen receptor alpha (ER-alpha) is an important member of nuclear hormone receptors. ER-alpha plays important role in breast cancer as well as in other women's health issues. The majority of breast cancers is estrogen receptor (ER) positive and depends on estrogen for growth. There is also growing ,2,National Center for Advancing Translational Sciences (NCATS),ERN101,20111014,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","11112138,17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717",2099,NULL,AEP43755,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,P03372,NULL
588778,0,A High Throughput Screening Assay for Inhibitors of Bacterial Motility in Vibrio cholerae,"Cholera is an acute water-borne diarrheal disease caused by Vibrio cholerae of serogroups O1 and O139.  Vibrio cholerae is a pathogen that has historically caused human disease and epidemics and continues to cause outbreaks in endemic areas. It still has the potential to cause outbreaks where ever sanitation is poor and clean drinking water is unavailable.   The advent of modern waste water treatment and drinking water purification has virtually eliminated cholera from developed countries, but any disruptio",26,Southern Research Institute,CHOL_MOT,20111108,"253,1675,2017,2063,2123,4114,7597,8765,11840,12140,12870,14343,14623,15629,15819,22752,22769,27211,30479,30620,31559,34623,38072,41972,55683,66561,67353,68210,69758,70137,70849,70974,71025,73249,74433,74434,74553,76106,76797,77410,79416,79676,79785,79869,80946,80991,83278,83284,88389,89847,90261,92039,94473,95047,95066,95709,97023,97160,97582,97908,98736,99383,100135,100492,108511,112786,119836,120432,120570,134973,138746,142278,152190,174572,177728,200283,202411,204387,205208,209044,209291,219137,219301,22","49761636,49761639,49761640,49761645,49761650,49761657,49761659,49761665,49761666,49761667,49761675,49761686,49761687,49761691,49761695,49761698,49761699,49761702,49761704,49761709,49761720,49761734,49761739,49761749,49761763,49761765,49761771,49761776,49761780,49761781,49761792,49761797,49761798,49761799,49761810,49761827,49761851,49761855,49761858,49761859,49761863,49761864,49761866,49761867,49761871,49761874,49761875,49761884,49761888,49761907,49761924,49761926,49761927,49761930,49761931,49761936,49761941",NULL,"Cell-based,Organism-based",NULL,Research and Development,17644774,0,10.1177/1087057107304478,NULL,NULL,NULL
588827,2,HSF-1 induced GFP reporter and Doxycycline induced RFP reporter Measured in Cell-Based System Using Plate Reader - 2038-03_Inhibitor_Dose_CherryPick_Activity_Set4,"Keywords: Heat Shock Factor-1 (HSF-1), Stress Response, NIH3T3, GFP, RFP_|__|_Assay Overview: Modified NIH3T3, transformed to express GFP under the control of a HSF-1 response element, and RFP under the control of a Doxycycline inducible (Tet-On) promoter will be exposed to small molecules.  Upon addition of small molecules, Doxycycline is added to wells to induce RFP expression, and cells are exposed to a 2hr thermal heat-shock at 42 degrees C to elicit a stress response and resulting GFP expression. After",31,Broad Institute,2038-03_Inhibitor_Dose_CherryPick_Activity_Set4,20111128,"119,1546,1820,2466,3639,3640,4843,5546,5743,5755,5775,5795,6245,6825,8566,8660,8975,10607,12855,16179,22650,32030,32798,37839,41781,60825,65182,70989,71827,72813,72972,75599,78545,84224,86670,91401,100520,130606,135191,138928,166785,183411,185484,199161,200953,224561,224810,230606,230939,232432,233815,233874,245648,250855,253602,254339,259161,265711,265940,268967,271030,285779,288290,288336,296157,307166,309281,313441,316235,320267,320919,326579,330973,334373,342633,346767,367783,375895,406042,443955,444036","842128,842137,842329,842547,842641,842750,842812,842874,842939,842944,843032,843091,843843,843947,844028,844056,844306,844445,844960,845029,845094,845188,845320,845634,845662,846089,846157,846503,846723,847214,847299,847476,847843,848385,848468,848657,848733,848812,848966,849071,849081,849291,849360,849417,849676,849725,849762,849861,850079,850276,850534,850556,850877,851006,851186,851853,851921,851963,852087,852107,852199,852281,852504,852779,852863,853035,853162,853163,853216,853409,853443,853602,853698,8",15499,Cell-based,AAH94064,NIH Initiatives,19335068,0,10.1517/14728220902832697,NULL,AAH94064,NULL
588397,2,qHTS of small molecules that selectively kill Giardia lamblia: Hit Validation.,"Giardia lamblia is a human pathogen afflicting impoverished nations, and the most common cause of outbreaks of diarrhea in the United States. Giardia has been classified by the CDC as a category B bioterrorism organism. The favored anti giardiasis drugs in the US are metronidazole or tinidazole, compounds that have undesirable side effects. Moreover, increasing resistance to drug regimes and recurrence are a concern. It is thus clear that alternative drug treatments are needed. _|__|_In a collaboration betw",2,National Center for Advancing Translational Sciences (NCATS),GIAR101,20110922,"237,1493,1546,2082,2199,2569,3117,3197,3334,3676,4122,4173,4815,4878,5094,5104,5479,6093,6197,6731,6828,7589,7629,8115,10303,18834,19646,20279,23009,24944,28061,31593,31772,42650,53277,56909,70633,71407,72790,77793,78545,83213,87889,89105,91467,96068,97662,97976,102198,107950,120116,122737,148471,155315,156816,160386,162162,182791,198148,220706,221597,225436,225676,227663,228590,233324,233768,234637,237337,237673,241907,241911,242567,243450,244989,250654,253602,254285,256660,259819,260168,260309,262649,2661","842973,843606,847444,849882,850845,855618,855645,855672,855702,855748,855809,856587,857602,858053,858439,858441,858552,858554,858870,862265,864623,864709,864911,3712684,3713454,4241879,4242633,4257228,4257985,4259396,4261505,4263778,4263833,4264333,7965001,7965110,7965860,7966585,7967308,7967645,7968623,7968793,7969422,7969977,7970555,7971181,7972193,7972229,7973370,7974713,7976579,7976637,7977710,7978039,14719201,14719244,14720547,14720979,14721100,14723550,14723649,14724399,14724499,14726526,14727695,1472",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
588398,2,TES1 - eGFP vs TES2 -dsRED Pathway Differentiation Measured in Cell-Based System Using Imaging - 2122-04_Inhibitor_Dose_CherryPick_Activity,"Keywords:_|_NF-kappaB, Epstein-Barr Virus, inhibitor, LMP1, Latent Membrane Protein 1, luciferase reporter, TES1, TES2, cytotoxicity, EBV-transformed TES 1 - eGFP and TES2 - dsRED_|__|_Assay Overview:_|_Epstein-Barr Virus is a ubiquitous Herpesvirus that is an important cause of Hodgkin's Disease, other Lymphoproliferative Diseases, and Nasopharyngeal Carcinoma. EBV infection mimics NF-kB hyperactivation states present in many malignancies. The EBV oncoprotein LMP1 constitutively activates both canonical an",31,Broad Institute,2122-04_Inhibitor_Dose_CherryPick_Activity,20110922,"1489,1858,2215,2361,2754,3326,3793,4499,4878,4883,5744,5790,5995,6252,6253,6256,6769,6825,9782,10237,10251,28803,36302,36462,37542,39912,44383,54384,56801,62882,66266,68546,70848,77995,80311,91668,94959,97673,99760,102426,107750,128355,165528,176157,214258,220696,223708,224618,231422,236357,238643,238958,240098,244989,248473,256179,256465,258079,260054,263866,265450,265734,266266,266926,266962,267294,270510,271956,272191,272411,272609,274045,274061,274086,274593,278929,280492,280522,282598,286326,286354,288","842498,843619,843712,844240,844306,844843,845090,845192,845835,846246,846473,848229,848239,849081,849288,849505,850011,850961,851085,851517,851562,852914,855532,855804,855946,855975,856076,856148,856251,856690,857125,857509,857562,857655,857885,858389,859054,859422,859885,860769,861237,861516,861589,863423,863924,864177,864406,864609,864709,864874,865107,865680,866025,866157,3711595,3711681,3711742,3711842,3711912,3712004,3713285,3713434,3713637,3714081,3714100,3714268,3714300,3715135,3715357,3715947,371645",3783750,Cell-based,CAD53472,NIH Initiatives,NULL,0,NULL,NULL,CAD53472,NULL
588832,1,Hedgehog Measured in Biochemical System Using Plate Reader - 2070-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: Hedgehog, sonic hedgehog, autosplicing, autoprocessing_|__|_Assay Overview:_|_Hedgehog (Hh) signaling plays an important role in embryonic patterning and adult stem cell renewal, but has recently been found also to be involved in certain stem-cell cancers, including pancreatic, small cell lung, intestinal, and prostate, all of which are notoriously difficult to treat. One of the first steps in Hh signaling is the autoprocessing of Hh protein, in which the C-terminal domain (Hh-C) catalyzes a chole",31,Broad Institute,2070-01_Inhibitor_SinglePoint_HTS_Activity,20111129,"40,72,174,190,204,243,253,299,311,335,379,441,499,596,660,701,802,803,931,942,957,978,995,1001,1017,1030,1066,1150,1201,1483,1491,1833,1868,1882,1889,1923,1983,2000,2002,2015,2073,2108,2181,2199,2202,2203,2236,2345,2347,2355,2537,2554,2692,2730,2757,2758,2775,2866,2969,2973,3102,3118,3218,3264,3282,3293,3431,3449,3458,3589,3593,3611,3845,3893,3945,3951,4049,4114,4115,4246,4276,4544,4605,4728,4749,4757,4971,5204,5408,5564,5668,5743,5758,5780,5801,5865,5921,5959,6009,6024,6035,6043,6113,6124,6197,6199,6245,62","845916,3711129,3711373,3715869,4255217,7964552,7964553,7964555,7964556,7964557,7964558,7964561,7964562,7964564,7964568,7964569,7964571,7964572,7964575,7964576,7964578,7964580,7964581,7964585,7964588,7964591,7964592,7964593,7964595,7964597,7964602,7964603,7964604,7964606,7964609,7964611,7964615,7964619,7964621,7964623,7964625,7964629,7964633,7964634,7964637,7964640,7964642,7964643,7964644,7964649,7964650,7964652,7964656,7964657,7964658,7964663,7964664,7964665,7964667,7964669,7964670,7964675,7964688,7964690,7",NULL,Biochemical,AAF56102,NIH Initiatives,20930213,0,10.1177/1087057110377498,NULL,Q02936,NULL
588382,2,qHTS of small molecules that selectively kill Giardia lamblia: Hit Validation in HepG2 cytotox,"Giardia lamblia is a human pathogen afflicting impoverished nations, and the most common cause of outbreaks of diarrhea in the United States. Giardia has been classified by the CDC as a category B bioterrorism organism. The favored anti giardiasis drugs in the US are metronidazole or tinidazole, compounds that have undesirable side effects. Moreover, increasing resistance to drug regimes and recurrence are a concern. It is thus clear that alternative drug treatments are needed. _|__|_In a collaboration betw",2,National Center for Advancing Translational Sciences (NCATS),GIAR201,20111004,"237,1493,1546,2082,2199,2569,3117,3197,3334,3676,4122,4173,4815,4878,5094,5104,5479,6093,6197,6731,6828,7589,7629,8115,10303,18834,19646,20279,23009,24944,28061,31593,31772,42650,53277,56909,70633,71407,72790,77793,78545,83213,87889,89105,91467,96068,97662,97976,102198,107950,120116,122737,148471,155315,156816,160386,162162,182791,198148,220706,221597,225436,225676,227663,228590,233324,233768,234637,237337,237673,241907,241911,242567,243450,244989,250654,253602,254285,256660,259819,260168,260309,262649,2661","842973,843606,847444,849882,850845,855618,855645,855672,855702,855748,855809,856587,857602,858053,858439,858441,858552,858554,858870,862265,864623,864709,864911,3712684,3713454,4241879,4242633,4257228,4257985,4259396,4261505,4263778,4263833,4264333,7965001,7965110,7965860,7966585,7967308,7967645,7968623,7968793,7969422,7969977,7970555,7971181,7972193,7972229,7973370,7974713,7976579,7976637,7977710,7978039,14719201,14719244,14720547,14720979,14721100,14723550,14723649,14724399,14724499,14726526,14727695,1472",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
588820,1,Luminescence-based cell-based high throughput confirmation assay for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Bert O'Malley, Baylor College of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number 5U19DK062434-09_|_Grant Proposal PI: Bert O'Malley, Baylor College of Medicine_|_External Assay ID: SRC1_INH_LUMI_1536_3X%INH CRUN_|__|_Name: Luminescence-based cell-based high throughput confirmation assay for ",5,The Scripps Research Institute Molecular Screening Center,SRC1_INH_LUMI_1536_3X%INH CRUN,20111123,"596,1821,2199,3197,3213,3385,3458,3832,3879,4112,4212,4491,4605,4749,5043,5100,5153,5303,5396,5614,5790,6185,6245,6253,6763,6796,8975,9283,9444,11293,14710,15478,16955,17201,20345,23205,24466,26964,32875,36431,36462,38777,41946,42640,47508,47522,52167,54368,63118,64983,65237,68094,70848,72402,72438,72512,72699,72810,73427,76357,77917,82498,83851,87372,91378,91467,91754,93572,96015,97976,98614,99927,101486,107346,108155,122815,124496,125322,126941,131182,137226,138252,140230,145758,148673,148870,149800,15681","842526,843073,843813,844117,844306,844482,844722,845090,845300,845318,845357,845366,845835,846033,846220,846381,848460,848536,848966,849081,850126,852313,852615,852692,852945,853098,855836,855946,856076,857195,857342,857534,857562,857755,857793,857902,858005,858068,858150,858898,859461,859698,859930,860230,860512,860541,860920,861070,861262,861516,861637,861945,861959,862471,862581,862623,862811,863423,863765,864478,864609,864660,865680,866055,3711421,3711742,3712338,3712992,3713111,3713285,3713434,3713771,",8648,Cell-based,NP_003734,NIH Initiatives,"15657351,16685276,18980964,19701241,19846539,20576803,2469536,3164252",0,10.1038/nrc2695|10.1038/sj.bjc.6603141|10.1158/1078-0432.ccr-08-0581|10.1210/me.2009-0276|10.1677/erc-10-0058,2.3.1.48,Q15788,NULL
588824,1,Counterscreen for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Bert O'Malley, Baylor College of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 5U19DK062434-09_|_Grant Proposal PI: Bert O'Malley, Baylor College of Medicine_|_External Assay ID: VP16_INH_LUMI_1536_3X%INH CSRUN for SRC1_|__|_Name: Counterscreen for inhibitors of the Steroid Receptor Coact",5,The Scripps Research Institute Molecular Screening Center,VP16_INH_LUMI_1536_3X%INH CSRUN for SRC1,20111128,"596,1821,2199,3197,3213,3385,3458,3832,3879,4112,4212,4491,4605,4749,5043,5100,5153,5303,5396,5614,5790,6185,6245,6253,6763,6796,8975,9283,9444,11293,14710,15478,16955,17201,20345,23205,24466,26964,32875,36431,36462,38777,41946,42640,47508,47522,52167,54368,63118,64983,65237,68094,70848,72402,72438,72512,72699,72810,73427,76357,77917,82498,83851,87372,91378,91467,91754,93572,96015,97976,98614,99927,101486,107346,108155,122815,124496,125322,126941,131182,137226,138252,140230,145758,148673,148870,149800,15681","842526,843073,843813,844117,844306,844482,844722,845090,845300,845318,845357,845366,845835,846033,846220,846381,848460,848536,848966,849081,850126,852313,852615,852692,852945,853098,855836,855946,856076,857195,857342,857534,857562,857755,857793,857902,858005,858068,858150,858898,859461,859698,859930,860230,860512,860541,860920,861070,861262,861516,861637,861945,861959,862471,862581,862623,862811,863423,863765,864478,864609,864660,865680,866055,3711421,3711742,3712338,3712992,3713111,3713285,3713434,3713771,",NULL,Cell-based,NP_044650,NIH Initiatives,"15657351,16685276,18980964,19701241,19846539,20576803,2469536,3164252",0,10.1038/nrc2695|10.1038/sj.bjc.6603141|10.1158/1078-0432.ccr-08-0581|10.1210/me.2009-0276|10.1677/erc-10-0058,NULL,NP_044650,NULL
588794,1,Counterscreen for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Bert O'Malley, Baylor College of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 5U19DK062434-09_|_Grant Proposal PI: Bert O'Malley, Baylor College of Medicine_|_External Assay ID: VP16_INH_LUMI_1536_3X%INH CSRUN for SRC3_|__|_Name: Counterscreen for inhibitors of the Steroid Receptor Coact",5,The Scripps Research Institute Molecular Screening Center,VP16_INH_LUMI_1536_3X%INH CSRUN for SRC3,20111116,"1492,1821,2199,3197,3213,3385,3458,3687,3832,3879,4112,4491,4605,4749,4912,5043,5100,5153,5303,5396,5614,5790,6035,6185,6245,6253,6763,8975,9283,9444,11293,14710,15478,16955,17201,20345,22658,23205,24466,36462,42640,52167,54360,54368,60699,64983,65237,68094,70848,72402,72438,72512,72699,72810,76357,77917,78379,81675,82498,87372,91378,91467,93572,96015,97976,99625,99927,101486,107346,108155,122815,126941,131182,137226,138252,140230,145758,148673,148870,149800,150365,156816,159917,160386,164754,175533,182791,","842440,842526,844028,844196,844306,844482,844492,845300,845318,845366,845835,846033,846220,846304,847431,847444,847877,848966,849081,849396,850065,850114,850126,851567,852001,852182,852615,852945,853098,853171,855810,855836,855946,856076,856284,856337,856947,857018,857081,857195,857517,857534,857562,857671,857755,857837,857902,857953,858005,858016,858150,858151,858177,858389,858505,858898,858962,859461,859698,859930,860230,860288,860293,860512,860541,860710,860920,861070,861262,861516,861637,861945,861949,8",NULL,Cell-based,NP_044650,NIH Initiatives,"15657351,16685276,18980964,19701241,19846539,20576803,2469536,3164252",0,10.1038/nrc2695|10.1038/sj.bjc.6603141|10.1158/1078-0432.ccr-08-0581|10.1210/me.2009-0276|10.1677/erc-10-0058,NULL,NP_044650,NULL
588792,1,Luminescence-based cell-based high throughput confirmation assay for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Bert O'Malley, Baylor College of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 5U19DK062434-09_|_Grant Proposal PI: Bert O'Malley, Baylor College of Medicine_|_External Assay ID: SRC3_INH_LUMI_1536_3X%INH CRUN_|__|_Name: Luminescence-based cell-based high throughput confirmation assay for",5,The Scripps Research Institute Molecular Screening Center,SRC3_INH_LUMI_1536_3X%INH CRUN,20111115,"1492,1821,2199,3197,3213,3385,3458,3687,3832,3879,4112,4491,4605,4749,4912,5043,5100,5153,5303,5396,5614,5790,6035,6185,6245,6253,6763,8975,9283,9444,11293,14710,15478,16955,17201,20345,22658,23205,24466,36462,42640,52167,54360,54368,60699,64983,65237,68094,70848,72402,72438,72512,72699,72810,76357,77917,78379,81675,82498,87372,91378,91467,93572,96015,97976,99625,99927,101486,107346,108155,122815,126941,131182,137226,138252,140230,145758,148673,148870,149800,150365,156816,159917,160386,164754,175533,182791,","842440,842526,844028,844196,844306,844482,844492,845300,845318,845366,845835,846033,846220,846304,847431,847444,847877,848966,849081,849396,850065,850114,850126,851567,852001,852182,852615,852945,853098,853171,855810,855836,855946,856076,856284,856337,856947,857018,857081,857195,857517,857534,857562,857671,857755,857837,857902,857953,858005,858016,858150,858151,858177,858389,858505,858898,858962,859461,859698,859930,860230,860288,860293,860512,860541,860710,860920,861070,861262,861516,861637,861945,861949,8",8202,Cell-based,NP_858045,NIH Initiatives,"15657351,16685276,18980964,19701241,19846539,20576803,2469536,3164252",0,10.1038/nrc2695|10.1038/sj.bjc.6603141|10.1158/1078-0432.ccr-08-0581|10.1210/me.2009-0276|10.1677/erc-10-0058,2.3.1.48,Q9Y6Q9,NULL
588379,2,qHTS for inhibitors of Vif-A3G interactions: Validation,"The recent discovery and characterization of host restriction factors, which provide a potent defense to invading retroviruses, has provided new targets for antiviral drug development. APOBEC3G (A3G) and APOBEC3F (A3F) are potent cytidine deaminases that block HIV-1 replication; HIV-1 expresses the Vif protein, which counteracts A3G and A3F by binding to them and inducing their proteasomal degradation._|__|_The Vif-A3G and Vif-A3F interactions provide two potential targets for development of small molecules",2,National Center for Advancing Translational Sciences (NCATS),VIFG001,20111004,"119,199,239,304,408,471,610,636,698,750,846,847,864,896,912,932,1050,1066,1072,1102,1103,1123,1183,1214,1309,1329,1348,1354,1355,1359,1370,1433,1449,1456,1533,1574,1598,1645,1649,1727,1734,1779,1797,1809,1858,1884,1893,1935,1960,1983,2039,2051,2052,2117,2120,2125,2126,2131,2146,2196,2199,2200,2201,2227,2236,2240,2355,2374,2376,2377,2396,2415,2419,2435,2438,2457,2477,2519,2520,2532,2545,2562,2689,2690,2753,2754,2756,2762,2765,2790,2797,2801,2803,2913,2993,3012,3019,3074,3077,3101,3108,3139,3177,3185,3218,322","11113333,11113349,11113352,11113357,11113360,11113366,11113369,11113370,11113374,11113378,11113379,11113380,11113381,11113382,11113383,11113384,11113386,11113387,11113388,11113393,11113394,11113395,11113396,11113397,11113398,11113399,11113401,11113402,11113403,11113404,11113405,11113408,11113409,11113410,11113411,11113412,11113413,11113414,11113417,11113418,11113423,11113425,11113426,11113427,11113428,11113429,11113430,11113431,11113432,11113433,11113434,11113438,11113439,11113440,11113441,11113442,11113443",60489,NULL,NP_068594,Governmental Organizations|NIH Initiatives,"18806783,20363737",0,10.1038/nbt.1496|10.1074/jbc.m109.085308,3.5.4.-,Q9HC16,NULL
588463,2,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor: Hit Validation,"The concept of biased agonism [1] is an emerging concept of molecular pharmacology which proposes that seven transmembrane receptors (7TMRs) or G protein-coupled receptors (GPCRs), exist in multiple signaling conformations and complexes and that ligands (either agonists or antagonists) can induce signaling biased responses for distinct signal transduction cascades. _|__|_Recently, this concept has been highlighted by beta-arrestin-biased signaling through 7TMRs [1]. beta-arrestins have been known to interac",2,National Center for Advancing Translational Sciences (NCATS),TANGO200,20111006,"1570,5807,5924,12120,13770,19910,23702,31316,38911,56801,71486,73481,75253,92163,97035,100489,100787,119442,152746,219987,226329,226508,237591,247486,248998,254722,256661,272568,275363,286421,332185,341783,351531,360474,360560,371271,376106,389129,408736,444034,455444,503737,558625,561049,561900,573775,630757,640180,645727,647931,648038,648473,648977,649562,649722,649754,650702,651623,653216,654330,655127,655687,656601,656783,657301,657722,658255,658612,658753,659101,660761,662721,663107,663249,663842,66459","843430,845278,845575,845675,846101,846588,847164,847322,847355,848264,849153,850687,851737,852502,853046,853363,855560,855637,855651,855787,855845,855847,856010,856022,856355,856404,856901,857270,857409,857745,859387,859459,860575,861480,861878,862019,862608,863344,863426,863506,863513,863796,864271,864392,864565,864910,865572,865593,865786,3711096,3711703,3712259,3712852,3712903,3713385,3713548,3714219,3714707,3715915,3715973,3716166,3716256,3717534,3717710,3717801,4241774,4241809,4241883,4242153,4242758,4",154,NULL,NP_000015,Governmental Organizations|NIH Initiatives,"17305471,17644195,17925438,18165312",0,10.1016/j.tips.2007.06.006|10.1073/pnas.0707936104|10.1073/pnas.0710487105|10.1146/annurev.physiol.69.022405.154749,NULL,P07550,NULL
588378,2,qHTS for Inhibitors of ATXN expression: Validation,"Spinocerebellar ataxia type 2 (SCA2) is a multisystem neurodegenerative disease caused by a dominantly-acting mutation leading to expansion of a polyQ domain in the ataxin-2 protein (ATXN2).  SCA2 patients develop progressive ataxia and later lose function in other neuronal systems. Prominent parkinsonian signs develop in some patients. Similar to many neurodegenerative disorders, no symptomatic or disease-modifying treatments are known._|__|_The primary objective of project is to identify compounds inhibit",2,National Center for Advancing Translational Sciences (NCATS),SCA2001,20110921,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",6311,NULL,NP_002964,Governmental Organizations|NIH Initiatives,8896555,0,10.1038/ng1196-269,NULL,Q99700,NULL
588345,2,MLPCN Dyrk1A Kinase Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_Dose_CherryPick_Activity,"Keywords: Dyrk-1 kinase, ADP-Glo Kinase Assay, Nuclear Factor Activated T-cells, NFAT_|__|_Assay Overview: The goal of this project is to develop small molecule modulators of the Nuclear Factor Activated T-cells (NFAT) signaling by identifying inhibitors of Dyrk1A kinase.  Using the Promega ADP-Glo Kinase Assay kit, a low volume, 1536-well assay will be used to screen the MLPCN.  Small-molecule inhibitors of Dyrk1A kinase activity will be identified and tested in the assay critical path.  Dyrk1 A kinase inh",31,Broad Institute,2124-01_Inhibitor_Dose_CherryPick_Activity,20110907,"2355,3213,3220,3564,4212,4564,4578,5153,5894,6293,6701,10154,11102,13356,20612,30935,34920,37560,40118,56251,56801,64961,65188,68094,68230,72512,74468,84728,87372,93271,96506,97209,97600,98119,98360,98760,108104,138888,159809,178054,185848,206388,216328,219583,219962,220929,221125,223824,224585,224672,225436,229821,232806,233068,233994,235224,237102,238065,241893,242417,242586,244087,247486,247635,248131,248507,254021,255084,255771,264201,265037,266106,267863,267865,268501,270853,270861,272529,273034,273483","842897,842913,843158,843211,843279,843393,843406,843407,843675,843925,844027,844131,844372,844401,845237,845318,845366,845636,845817,845835,846878,847389,847669,847793,847820,848421,848690,849655,850293,850366,850491,850887,850961,852023,852179,852423,852900,852914,852980,853412,853589,853726,856044,856076,856515,856589,856610,856618,856959,857125,857157,857189,857255,857460,857570,858046,858246,858701,858912,859145,859183,859211,859250,859394,859479,859687,860022,860060,860339,860564,860860,861064,861453,8",25255,Biochemical,NP_036923,NIH Initiatives,NULL,0,NULL,2.7.12.1,Q63470,NULL
588349,2,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,"Spinocerebellar ataxia type 2 (SCA2) is a multisystem neurodegenerative disease caused by a dominantly-acting mutation leading to expansion of a polyQ domain in the ataxin-2 protein (ATXN2).  SCA2 patients develop progressive ataxia and later lose function in other neuronal systems. Prominent parkinsonian signs develop in some patients. Similar to many neurodegenerative disorders, no symptomatic or disease-modifying treatments are known._|_The primary objective of project is to identify compounds inhibiting",2,National Center for Advancing Translational Sciences (NCATS),SCA2002,20110909,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,8896555,0,10.1038/ng1196-269,NULL,NULL,NULL
588742,2,Vero Cytoxicity Assay: A Cell Based Secondary Assay to Explore Cytotoxicity of Compounds that Inhibit Flavivirus Genomic Capping Enzyme,"Vero Cytoxicity Assay: A Cell Based Secondary Assay to Explore Cytotoxicity of Compounds that Inhibit Flavivirus Genomic Capping Enzyme _|__|_Southern Research Specialized Biocontainment Screening Center (SRSBSC)_|_Assay Provider: Brian Geiss, Colorado State University_|_Award: 1 R03 MH093191-01_|__|_This functional assay was developed for detection of compounds inhibiting Vero E6 cells viability as a secondary screen to the effort to identify inhibitors of the Flavivirus genomic capping enzyme._|_In this a",33,Southern Research Specialized Biocontainment Screening Center,CEGtase_Tox_01,20111030,"1369,4882,4971,6284,9922,10143,10603,18834,18990,20043,21672,31280,40586,62413,66528,66671,66672,66721,67062,68106,70837,71060,71172,72571,73157,73677,80417,86926,90474,94986,96506,97167,105671,111488,112939,160254,162386,164676,198015,209253,216328,219799,219926,220284,221125,222091,222167,222169,222761,223149,224275,224560,224618,224810,228250,231106,231532,231904,232780,232926,232928,232932,233473,235224,235574,235598,235837,235857,236275,237102,237490,238781,239577,241217,241388,245533,246783,246853,247","842979,843005,843097,843998,844329,844461,844852,847157,847351,847632,847760,848021,848195,848370,850355,850760,851128,851782,851903,852322,852635,852707,853098,856108,856169,856201,856503,856589,856828,857260,857297,857387,857425,857484,857633,858000,858060,858147,858150,858170,858195,858298,858629,858685,858699,858892,859055,859275,859316,859355,859770,860234,860639,860819,860828,860888,861126,861135,861328,861740,861865,862138,862769,862947,863306,864603,865067,865635,865806,865982,3712636,3713011,371369",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
588343,2,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_Dose_CherryPick_Activity,"Keywords: NF-kappaB, Epstein-Barr Virus, inhibitor, LMP1, Latent Membrane Protein 1, luciferase reporter, TES1, TES2_|__|_Assay Overview: Epstein-Barr Virus is a ubiquitous Herpesvirus that is an important cause of Hodgkin's Disease, other Lymphoproliferative Diseases, and Nasopharyngeal Carcinoma. EBV infection mimics NF-kB hyperactivation states present in many malignancies. The EBV oncoprotein LMP1 constitutively activates both canonical and noncanonical NF-kB pathways in a ligand-independent fashion.  L",31,Broad Institute,2122-01_Inhibitor_Dose_CherryPick_Activity,20110907,"1489,1858,2215,2361,2754,3326,3793,4499,4878,4883,5744,5790,5995,6252,6253,6256,6769,6825,9782,10237,10251,28803,36302,36462,37542,39912,44383,54384,56801,62882,66266,68546,70848,77995,80311,91668,94959,97673,99760,102426,107750,128355,165528,176157,214258,220696,223708,224618,231422,236357,238643,238958,240098,244989,248473,256179,256465,258079,260054,263866,265450,265734,266266,266926,266962,267294,270510,271956,272191,272411,272609,274045,274061,274086,274593,278929,280492,280522,282598,286326,286354,288","842498,843619,843712,844240,844306,844843,845090,845192,845835,846246,846473,848229,848239,849081,849288,849505,850011,850961,851085,851517,851562,852914,855532,855804,855946,855975,856076,856148,856251,856690,857125,857509,857562,857655,857885,858389,859054,859422,859885,860769,861237,861516,861589,863423,863924,864177,864406,864609,864709,864874,865107,865680,866025,866157,3711595,3711681,3711742,3711842,3711912,3712004,3713285,3713434,3713637,3714081,3714100,3714268,3714300,3715135,3715357,3715947,371645",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
588400,2,Dose response counterscreen of uHTS hits for ATG4B inhibitors in a Phospholipase A2 assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH090871-01_|_Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_This assay is a counterscreen for the primary screen (AID504462) which looked for inhibitors of Autophagin 1 (ATG4B). In screening for compounds that ",14,Burnham Center for Chemical Genomics,SBCCG-A693-ATG4B-PLA2-DR-CTR-Assay,20110922,"2378,6763,7329,8816,50496,66532,146332,237102,254021,262093,265935,272529,318030,383939,386355,392613,400634,434797,460747,610479,646726,648589,650282,650612,655563,686152,689208,690923,691076,697231,722908,734131,750580,764219,765457,826714,834562,843742,855903,878060,879397,881438,893102,900011,906542,935027,945654,948150,969640,972392,990301,1014967,1067700,1077699,1093796,1201904,1205867,1214139,1225466,1235169,1244750,1248344,1312855,1325115,1326684,1354036,1385343,1388730,1418314,1424255,1442467,14426","846207,848184,852919,855713,855759,3712249,3714589,3715666,3716169,4240621,4243539,4246503,4247945,4248403,4250766,4251580,4251929,4254975,4260170,4263066,7970974,7973173,7976671,7978032,14721866,14722561,14726526,14727757,14730491,14730721,14731103,14731782,14732892,14733978,14735858,14736308,14737061,14737072,14738926,14739189,14739650,14739693,14740054,14740347,14740993,14741656,14741841,14745895,14746067,16952991,16953017,17385842,17386562,17387546,17387729,17402025,17403543,17406820,17407075,17407870,1",5319,NULL,NP_000919,NIH Initiatives,"12446702,12967324,16183633,16728626,16843265,17957134,18196957,18305538",0,10.1016/j.ccr.2006.06.001|10.1038/nature06639|10.1042/bj20030826|10.1074/jbc.m208247200|10.1074/jbc.m509158200|10.1126/science.312.5777.1160|10.4161/auto.5172|10.4161/auto.5523,3.1.1.4,P04054,NULL
588719,2,Vero 76 Cytoxicity Assay for VEEV Compounds,"Southern Research's Specialized Biocontainment Screening Center (SRSBSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Assay Provider: Dong Hoon Chung, University of Louisville_|_Award: 1 R03 MH087448-01A1_|__|_This functional assay was developed for detection of compounds inhibiting Vero 76 cells viability as a secondary screen to the VEEV Inhibition screen. _|__|_In this assay, we treated Vero 76 cells with compounds selected as hi",33,Southern Research Specialized Biocontainment Screening Center,VEE_VERO_01,20111030,"2453,2569,2788,3117,3126,3879,4011,4605,4749,5303,5614,6185,6301,6769,15478,19103,19891,27692,28693,32875,38531,54368,57163,60496,64143,67238,67277,68546,71060,73684,83107,94986,95326,95587,97267,97676,97893,97976,99602,99803,123596,201986,219207,219563,219940,220466,222612,224384,224687,225371,227345,227453,227517,229949,238775,239486,240484,242651,244317,246230,246231,246322,248020,252247,253793,261066,261339,262425,263065,263922,264663,264884,265337,266203,266410,268511,272568,272755,274159,274213,274569","843025,843472,843841,844825,845118,846474,847849,850067,850436,855516,855880,855901,856075,856564,857507,857918,860068,860114,860153,860418,861006,861210,862614,862910,864038,864830,3712491,3713127,3713285,3713316,3714716,3716246,3716946,3717254,3717395,4240690,4242089,4242440,4244291,4244475,4244637,4244956,4245381,4245484,4245677,4245970,4246645,4247100,4248026,4248427,4248620,4248885,4249399,4251258,4252388,4256111,4256670,4256677,4256727,4257946,4258362,4259556,4259929,4261498,4261894,4262547,4263066,42",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
588647,2,SAR analysis of small molecule inhibitors of mouse intestinal alkaline phosphatase via a luminescent assay - Set 2,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Proposal Number: X01-MH077602-01_|_Assay Provider Dr. Jose Luis Millan, Sanford-Burnham Medical Research Institute(SBMRI, San Diego, CA)_|__|_Alkaline phosphatase (EC 3.1.3.1) (APs) catalyze the hydrolysis of phosphomonoesters, releasing inorganic phosphate and alcohol. APs are d",14,Burnham Center for Chemical Genomics,SBCCG-A756-Mouse_IAP_Inhibitor-DryPowder-Assay-2,20111211,"702139,974154,1872117,1940547,3240362,3244678,3245865,4040785,5121501,5332714,5332715,5333838,5333882,5339616,5348178,5995876,6870508,6873969,6883555,6883690,6898838,6901225,6902035,6902233,6902791,6903630,9551714,9563610,9608055,9612064,9629999,9649751,9652466,9655941,9783532,16009407,16010037,16010043,16010074,17126512,17461319,20868954,20868958,20868970,20868973,20949345,20949346,20949350,20949367,20949380,20949385,20949386,20949387,20949388,20949391,24790971,24790972,24790973,24790974,24790980,24790992,","104169819,104169825,110067435,110067436,110067437,110067439,110067441,110067444,110067455,110067460,110067462,110067463,110067464,110067465,110067466,110067467,110067468,110067469,110067470,110067471,110067472,110067473,110067474,110067475,110067476,110067477,110067479,110067480,110067481,110067482,110067483,110067484,110067485,110067486,110067487,110067488,110067489,110067490,110067491,110067492,110067493,110067494,110067495,110067496,110067497,110067498,110067499,110067500,110067501,110067502,110067503,11",76768,NULL,NP_001074551,NIH Initiatives,"5023163,5139211,5911626,6950431",0,10.1073/pnas.79.3.879|10.1177/20.5.336,NULL,NP_001074551,NULL
588780,2,Dose response confirmation of uHTS hits for small molecule modulators of myocardial damage using 2-dexoy-glucose,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 DA031671-01_|_Assay Provider: Richard Kitsis, M.D., Albert Einstein College of Medicine of Yeshiva University_|__|_Myocardial infarction (""heart attack"") is one of the most common causes of morbidity and mortality in the United States and the world1. It is pre",14,Burnham Center for Chemical Genomics,SBCCG-A763-H9c2-Inh-2DG-DR-Assay,20120123,"366,1340,1853,3151,19708,31840,52070,72699,90490,95413,101459,136417,203420,233835,235496,238797,242234,242586,247352,248116,248118,248119,248223,265049,269039,270669,271215,274929,274930,276233,278729,278829,287724,288819,308157,323007,323364,323484,334335,348622,387075,456869,494031,565741,582530,616651,644419,644744,645236,645256,645369,645493,645736,646133,646473,646547,646676,646757,646780,646961,646987,647168,647243,647606,647662,647674,647945,648499,648742,649249,649546,649754,649901,650437,650811,65","842163,842480,842958,842978,843209,843439,844157,844235,844356,844431,844455,844629,844837,845266,845318,845330,845550,845589,846128,846134,846357,846853,847146,847355,847496,847770,848365,848666,849029,850708,850983,851270,851944,852154,852158,852625,853174,853217,853480,853501,853640,855562,855880,856517,856753,856755,857170,857755,857783,857955,858275,858667,859213,859411,860191,860266,860353,860369,860533,860544,860804,860900,861048,861071,861097,861156,861280,861381,861437,861479,861530,861566,861584,8",NULL,NULL,NULL,NIH Initiatives,"12517460,14744432,15800626,19218262,2014866",0,10.1016/s0092-8674(04)00046-7|10.1016/s0140-6736(03)12113-7|10.1038/nature03317|10.1136/hrt.2007.139493|10.2105/ajph.81.5.628,NULL,NULL,NULL
588402,0,Single concentration counterscreen of uHTS hits for ATG4B inhibitors in a Phospholipase A2 assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH090871-01_|_Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_This assay is a counterscreen for the primary screen (AID504462) which looked for inhibitors of Autophagin 1 (ATG4B). In screening for compounds that ",14,Burnham Center for Chemical Genomics,SBCCG-A692-ATG4B-PLA2-CP-CTR-Assay,20110922,"2333,2378,3598,6763,7329,8816,11102,11852,16955,47484,50248,50496,63983,66532,91440,100105,146332,155889,221756,222490,224644,225126,228624,237102,238709,238854,254021,256872,262093,265935,267330,272529,300573,318030,376354,383939,386355,392613,400634,434695,434797,460747,598175,607001,610479,614848,644274,644774,645939,646081,646682,646726,647595,647972,648060,648589,649930,650067,650241,650282,650426,650612,651190,651272,651662,652850,653031,654082,654426,654999,655046,655563,655818,655864,656002,656097,6","842503,843642,843776,845255,845617,845698,846207,847827,847840,848002,848184,848819,850293,850336,850500,851507,852376,852423,852919,853167,853210,853438,853481,853670,855713,855759,856654,857755,858283,858468,860538,860615,860916,861354,861709,861894,862021,862139,862291,862440,862442,862844,863868,863987,864381,3711385,3711644,3711863,3712249,3712589,3712897,3713253,3713486,3714214,3714589,3714660,3714779,3715456,3715666,3716169,3716645,3716731,3716877,3716931,3717484,3717942,4240621,4240666,4240874,42418",5319,NULL,NP_000919,NIH Initiatives,"12446702,12967324,16183633,16728626,16843265,17957134,18196957,18305538",0,10.1016/j.ccr.2006.06.001|10.1038/nature06639|10.1042/bj20030826|10.1074/jbc.m208247200|10.1074/jbc.m509158200|10.1126/science.312.5777.1160|10.4161/auto.5172|10.4161/auto.5523,3.1.1.4,P04054,NULL
588779,2,Dose response confirmation of uHTS hits for small molecule modulators of myocardial damage,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 DA031671-01_|_Assay Provider: Richard Kitsis, M.D., Albert Einstein College of Medicine of Yeshiva University_|__|_Myocardial infarction (""heart attack"") is one of the most common causes of morbidity and mortality in the United States and the world1. It is pre",14,Burnham Center for Chemical Genomics,SBCCG-A762-H9c2-Inh-DMSO-DR-Assay,20120123,"366,1340,1853,3151,19708,31840,52070,72699,90490,95413,101459,136417,203420,233835,235496,238797,242234,242586,247352,248116,248118,248119,248223,265049,269039,270669,271215,274929,274930,276233,278729,278829,287724,288819,308157,323007,323364,323484,334335,348622,387075,456869,494031,565741,582530,616651,644419,644744,645236,645256,645369,645493,645736,646133,646473,646547,646676,646757,646780,646961,646987,647168,647243,647606,647662,647674,647945,648499,648742,649249,649546,649754,649901,650437,650811,65","842163,842480,842958,842978,843209,843439,844157,844235,844356,844431,844455,844629,844837,845266,845318,845330,845550,845589,846128,846134,846357,846853,847146,847355,847496,847770,848365,848666,849029,850708,850983,851270,851944,852154,852158,852625,853174,853217,853480,853501,853640,855562,855880,856517,856753,856755,857170,857755,857783,857955,858275,858667,859213,859411,860191,860266,860353,860369,860533,860544,860804,860900,861048,861071,861097,861156,861280,861381,861437,861479,861530,861566,861584,8",NULL,NULL,NULL,NIH Initiatives,"12517460,14744432,15800626,19218262,2014866",0,10.1016/s0092-8674(04)00046-7|10.1016/s0140-6736(03)12113-7|10.1038/nature03317|10.1136/hrt.2007.139493|10.2105/ajph.81.5.628,NULL,NULL,NULL
588348,2,MLPCN Dyrk1A Artifact Assay Measured in Biochemical System Using Plate Reader - 2124-02_Inhibitor_Dose_CherryPick_Activity,"Keywords: Dyrk1a kinase artifact, ADP-Glo luciferase inhibition test_|__|__|_Assay Overview: The goal of this project is to develop small molecule modulators of the Nuclear Factor Activated T-cells (NFAT) signaling by identifying inhibitors of Dyrk1A kinase.  Using the Promega ADP-Glo Kinase Assay kit, a low volume, 1536-well assay will be used to screen the MLSMR.  Small-molecule inhibitors of Dyrk1A kinase activity will be identified and tested in the assay critical path.  Dyrk1 A kinase inhibitors that d",31,Broad Institute,2124-02_Inhibitor_Dose_CherryPick_Activity,20110909,"2355,3213,3220,3564,4212,4564,4578,5153,5894,6293,6701,10154,11102,13356,20612,30935,34920,37560,40118,56251,56801,64961,65188,68094,68230,72512,74468,84728,87372,93271,96506,97209,97600,98119,98360,98760,108104,138888,159809,178054,185848,206388,216328,219583,219962,220929,221125,223824,224585,224672,225436,229821,232806,233068,233994,235224,237102,238065,241893,242417,242586,244087,247486,247635,248131,248507,254021,255084,255771,264201,265037,266106,267863,267865,268501,270853,270861,272529,273034,273483","842897,842913,843158,843211,843279,843393,843406,843407,843675,843925,844027,844131,844372,844401,845237,845318,845366,845636,845817,845835,846878,847389,847669,847793,847820,848421,848690,849655,850293,850366,850491,850887,850961,852023,852179,852423,852900,852914,852980,853412,853589,853726,856044,856076,856515,856589,856610,856618,856959,857125,857157,857189,857255,857460,857570,858046,858246,858701,858912,859145,859183,859211,859250,859394,859479,859687,860022,860060,860339,860564,860860,861064,861453,8",NULL,Biochemical,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
588524,2,Dose response confirmation of uHTS hits for Apaf-1 in a Fluorescent assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBIMR, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: R01 CA136513_|_Assay Provider: Dr. Xuejun Jiang, Sloan-Kettering Institute for Cancer Research, New York, NY_|__|_Apoptosis is a major form of programmed cell death that multicellular organisms utilize to maintain tissue homeostasis and to eliminate unwanted or dama",14,Burnham Center for Chemical Genomics,SBCCG-A712-APAF-1-Inhibitor-DR-Assay,20111025,"1201,6099,6763,7085,8478,11102,11106,18834,68207,72571,74787,96932,164676,185478,235224,254021,262093,263463,263534,272514,272529,282594,312589,312590,344131,367783,369539,378581,410099,439654,443939,460747,478574,548573,582632,591407,614841,616267,616832,625142,644274,652210,657484,658797,658849,658921,658939,659124,659226,659456,662264,662288,662388,662864,663108,663945,664029,664599,666440,667143,667215,671256,672470,691731,693329,698849,703093,713096,721129,726977,727030,738951,741095,750480,752162,7531","847157,849703,856108,857352,857446,857500,857588,857769,860990,861018,861123,861465,861625,861879,862713,862796,863344,865594,865885,865959,3712249,3713302,4241909,4242461,4245955,4252106,4255374,4256677,4258938,4259468,4259929,4261754,4262072,4263637,4264192,7964733,7970869,7971540,7972100,7972268,7972581,7973721,7974300,7974352,7977434,7977700,7978031,7978441,14718751,14719117,14720531,14720688,14723856,14724478,14724653,14726375,14726526,14726722,14727098,14727734,14727791,14727821,14729290,14729539,1473",317,NULL,AAI36532,NIH Initiatives,"10940292,11864614,12522243,16630893,17724022",0,10.1016/j.molcel.2006.03.030|10.1016/s1097-2765(02)00442-2|10.1074/jbc.c000405200|10.1074/jbc.m705258200|10.1126/science.1076807,NULL,O14727,NULL
588690,0,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_CherryPick_Activity,"Keywords: transcription factor, delta FosB homodimer, AP-1 DNA binding, activator screening, biochemical, fluorescence polarization assay_|__|_Assay Overview:_|_The assay uses fluorescence polarization to measure the binding of purified recombinant delta FosB to a TAMRA labeled oligonucleotide or a probe. The oligonucleotide sequence is derived from the AP-1 consensus site of the Cdk5 gene, a confirmed target of delta FosB. The assay relies on the tumbling of the probe (TAMRA-CDK5) in solution that slows do",31,Broad Institute,2072-01_Activator_SinglePoint_CherryPick_Activity,20111026,"1794,5546,12456,42650,73078,73442,154436,160876,172306,223752,223753,223985,234245,240490,241697,245077,247061,253501,258078,276563,285470,295591,300949,306548,328773,328774,330267,330740,334409,366109,374056,380164,394580,478528,579397,587596,616284,623037,644535,644597,644684,644742,644942,645029,645244,645520,646088,646901,646995,646997,647145,647324,647541,647631,648011,648851,649202,649431,649589,649670,649958,650068,650104,650207,650575,651643,651753,651987,652126,652440,652695,652916,653071,653178,65","842276,842339,842478,842671,842754,842966,843237,843266,843783,844984,845199,845292,845656,845908,846463,846809,847191,847271,847552,847657,847695,847792,848146,848898,849276,849628,849929,850184,850394,850544,850648,850786,851044,851103,851443,851926,851966,851984,852237,852747,853336,853517,853591,855896,856685,856728,857319,857373,858764,858898,859053,859440,860114,860148,860407,860584,860714,861066,861149,863609,863614,863802,863837,864100,864826,865038,865498,865762,3711270,3711309,3711608,3712239,3712",14282,Biochemical,NP_032062,NIH Initiatives,"15840499,17580968",0,10.1016/j.ab.2005.02.012|10.1021/bi700494v,NULL,P13346,NULL
588691,0,Counterscreen using fluorescein-CDK5 in fluorescence polarization assay Measured in Biochemical System Using Plate Reader - 2072-02_Activator_SinglePoint_CherryPick_Activity,"Keywords: delta FosB homodimer, AP-1 DNA binding, activator, counterscreen, biochemical fluorescence polarization assay_|__|_Assay Overview:_|_Fluorescence polarization assay has been widely used for high-throughput screening due to its operational simplicity and robust performance. The major source of false positives for this assay is fluorescence interference of the compounds with the assay. In the primary screen, a red shifted fluorescent dye, TAMRA, has been used to minimize this impact. In this counter",31,Broad Institute,2072-02_Activator_SinglePoint_CherryPick_Activity,20111026,"1794,5546,12456,42650,73078,73442,154436,160876,172306,223752,223753,223985,234245,240490,241697,245077,247061,253501,258078,276563,285470,295591,300949,306548,328773,328774,330267,330740,334409,366109,374056,380164,394580,478528,579397,587596,616284,623037,644535,644597,644684,644742,644942,645029,645244,645520,646088,646901,646995,646997,647145,647324,647541,647631,648011,648851,649202,649431,649589,649670,649958,650068,650104,650207,650575,651643,651753,651987,652126,652440,652695,652916,653071,653178,65","842276,842339,842478,842671,842754,842966,843237,843266,843783,844984,845199,845292,845656,845908,846463,846809,847191,847271,847552,847657,847695,847792,848146,848898,849276,849628,849929,850184,850394,850544,850648,850786,851044,851103,851443,851926,851966,851984,852237,852747,853336,853517,853591,855896,856685,856728,857319,857373,858764,858898,859053,859440,860114,860148,860407,860584,860714,861066,861149,863609,863614,863802,863837,864100,864826,865038,865498,865762,3711270,3711309,3711608,3712239,3712",14282,Biochemical,NP_032062,NIH Initiatives,"15840499,17580968",0,10.1016/j.ab.2005.02.012|10.1021/bi700494v,NULL,P13346,NULL
588599,2,SAR Analysis of small molecule inhibitors of Sentrin-specific proteases (SENPs) using a Caspase-3 Selectivity assay - Set 2,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network(MLPCN)_|_Grant Proposal Number: 1R21 NS061758-01 fast track_|_Assay Provider: Dr. Guy Salvesen, Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|__|_Modification of proteins by SUMO is a dynamic and reversible process. SUMOylation/deSUMOylation cycle regulates SUMOs funct",14,Burnham Center for Chemical Genomics,SBCCG-A749-SEN-Caspase-DryPowder-Assay-2,20111021,"673490,843289,844224,1548480,1588017,1814489,1814490,2066730,2159213,2312943,2343603,2701444,2814504,2990985,3143005,5296010,5296023,5336336,5348455,5348651,5729026,7034421,7087112,7087114,7117332,7117425,7117487,7117504,7117550,8379104,16232676,16258092,16811400,16815047,16866696,17422800,17456764,17483224,18291044,18554036,18573326,18587990,19324407,20879510,24980728,27667674,30371220,30608281,32148706,39952307,45898490,46502851,49852494,49852501,49852503,49852504,49852505,49852518,49852521,49852524,49852","104222653,104222654,104222671,104222675,104222676,104222699,104222701,104222707,104222806,104222810,104222811,104222812,104222813,104222814,104222815,104222817,104222868,104222869,104222874,104222876,104222889,104222890,104222891,104222893,104222894,104222896,104222897,104222898,104222899,104222900,110067362,110067366,110067376,110067378,110067379,110067380,110067383,110067384,110067385,110067386,110067423,110067424,110067426,124756864,124756865,124756866,124756867,124756868,124756869,124756870,124756871,12",836,NULL,NP_004337,NIH Initiatives,"17591783,17916063,18799455",0,10.1042/bj20070940|10.1074/jbc.m702444200|10.1074/jbc.m805655200,3.4.22.56,P42574,NULL
588601,2,SAR Analysis of small molecule inhibitors of Sentrin-specific protease 8 (SENP8) using a Luminescent assay - Set 2,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network(MLPCN)Grant Proposal Number: 1R21 NS061758-01 fast track_|_Assay Provider: Dr. Guy Salvesen, Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|__|_Modification of proteins by SUMO is a dynamic and reversible process. SUMOylation/deSUMOylation cycle regulates SUMOs function. Sent",14,Burnham Center for Chemical Genomics,SBCCG-A747-SENP8-DryPowder-Assay-2,20111021,"673490,843289,844224,1548480,1588017,1814489,1814490,2066730,2159213,2312943,2343603,2701444,2814504,2990985,3143005,5296010,5296023,5336336,5348455,5348651,5729026,7034421,7087112,7087114,7117332,7117425,7117487,7117504,7117550,8379104,16232676,16258092,16811400,16815047,16866696,17422800,17456764,17483224,18291044,18554036,18573326,18587990,19324407,20879510,24980728,27667674,30371220,30608281,32148706,39952307,45898490,46502851,49852494,49852501,49852503,49852504,49852505,49852518,49852521,49852524,49852","104222653,104222654,104222671,104222675,104222676,104222699,104222701,104222707,104222806,104222810,104222811,104222812,104222813,104222814,104222815,104222817,104222868,104222869,104222874,104222876,104222889,104222890,104222891,104222893,104222894,104222896,104222897,104222898,104222899,104222900,110067362,110067366,110067376,110067378,110067379,110067380,110067383,110067384,110067385,110067386,110067423,110067424,110067426,124756864,124756865,124756866,124756867,124756868,124756869,124756870,124756871,12",123228,NULL,NP_660205,NIH Initiatives,"17591783,17916063,18799455",0,10.1042/bj20070940|10.1074/jbc.m702444200|10.1074/jbc.m805655200,3.4.22.-,Q96LD8,NULL
588764,2,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_Dose_CherryPick_Activity,"Keywords:  Rtt109, Vps75, Histone H3, Lys56, K56, acetyl transferase, anti-fungal_|__|_Assay Overview:  Rtt109, a histone acetyl transferase enzyme unique to fungii such as C. albicans, is associated with both resistance to genotoxic stress (such as H2O2 or Camptothecin) and pathogenesis.  It is thought that small molecule inhibition of Rtt109 activity in vivo could be a viable route to a novel antifungal which may work alone or in combination with existing anti-fungal treatments.  Rtt109 acetyl transferase",31,Broad Institute,2106-01_Inhibitor_Dose_CherryPick_Activity,20111102,"3117,3194,3598,5455,10603,11102,16088,22783,31280,37200,68553,206388,224037,224935,231576,245530,247304,313619,320930,330500,340721,406670,594152,607883,646785,646829,647624,647940,648299,650622,651191,653237,654443,654537,659438,661865,662967,664366,681184,682204,684642,685138,691373,703841,718725,720536,723732,724615,728026,729908,734035,742486,752969,753169,757091,763902,774099,781927,784748,787384,788110,796318,802513,829993,836402,851028,851372,864284,881214,892537,894364,895000,895165,896933,897117,90","844460,844853,845284,845584,845931,846495,848195,848733,851931,855882,855892,857788,858083,859440,860581,861733,862735,3711517,3711695,3714298,3716129,3716687,3717683,4242260,4243929,4244128,4244345,4246221,4248102,4249087,4251553,4260655,4263090,4264151,7965364,7968555,7971788,7973536,7974219,7974437,7975274,7977658,7977913,7978195,11532926,11532928,11532952,11532980,11533000,14718865,14718880,14721103,14721520,14721667,14722247,14722915,14723575,14724089,14724347,14724456,14725731,14726960,14727203,147293","3639678,3646682",Biochemical,"XP_711691,XP_718648",NIH Initiatives,NULL,0,NULL,2.3.1.48,"Q5AAJ8,XP_711691",NULL
588600,2,SAR Analysis of small molecule inhibitors of Sentrin-specific protease 7 (SENP7) using a Luminescent assay - Set 2,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network(MLPCN)_|_Grant Proposal Number: 1R21 NS061758-01 fast track_|_Assay Provider: Dr. Guy Salvesen, Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|__|_Modification of proteins by SUMO is a dynamic and reversible process. SUMOylation/deSUMOylation cycle regulates SUMOs function. S",14,Burnham Center for Chemical Genomics,SBCCG-A746-SENP7-DryPowder-Assay-2,20111021,"673490,843289,844224,1548480,1588017,1814489,1814490,2066730,2159213,2312943,2343603,2701444,2814504,2990985,3143005,5296010,5296023,5336336,5348455,5348651,5729026,7034421,7087112,7087114,7117332,7117425,7117487,7117504,7117550,8379104,16232676,16258092,16811400,16815047,16866696,17422800,17456764,17483224,18291044,18554036,18573326,18587990,19324407,20879510,24980728,27667674,30371220,30608281,32148706,39952307,45898490,46502851,49852494,49852501,49852503,49852504,49852505,49852518,49852521,49852524,49852","104222653,104222654,104222671,104222675,104222676,104222699,104222701,104222707,104222806,104222810,104222811,104222812,104222813,104222814,104222815,104222817,104222868,104222869,104222874,104222876,104222889,104222890,104222891,104222893,104222894,104222896,104222897,104222898,104222899,104222900,110067362,110067366,110067376,110067378,110067379,110067380,110067383,110067384,110067385,110067386,110067423,110067424,110067426,124756864,124756865,124756866,124756867,124756868,124756869,124756870,124756871,12",57337,NULL,AAI29989,NIH Initiatives,"17591783,17916063,18799455",0,10.1042/bj20070940|10.1074/jbc.m702444200|10.1074/jbc.m805655200,NULL,AAI29989,NULL
588574,2,Dose response confirmation of uHTS hits for Apaf-1 using a LZ-Caspase-9/Caspase-3 Fluorescent Selectivity assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBIMR, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: R01 CA136513_|_Assay Provider: Dr. Xuejun Jiang, Sloan-Kettering Institute for Cancer Research, New York, NY_|__|_Apoptosis is a major form of programmed cell death that multicellular organisms utilize to maintain tissue homeostasis and to eliminate unwanted or dama",14,Burnham Center for Chemical Genomics,SBCCG-A720-APAF-1-Inhibitor-Casp9-3-DR-Assay,20111020,"1201,6099,6763,7085,8478,11102,11106,18834,68207,72571,74787,96932,164676,185478,235224,254021,262093,263463,263534,272514,272529,282594,312589,312590,344131,367783,369539,439654,443939,460747,478574,548573,591407,614841,616267,616832,625142,644274,652210,657484,658797,658849,658921,658939,659124,659226,662288,662388,662864,663108,664100,664599,666440,667143,667215,671256,691731,693329,698849,703093,713096,721129,726977,727030,738951,750480,752162,753169,766079,771515,774975,784380,791069,798725,833970,8683","847157,849703,856108,857446,857500,857588,857769,861018,861123,861465,861625,861879,862867,863344,865594,865885,865959,3712249,3713302,4241909,4242461,4245955,4252106,4255374,4256677,4258938,4259468,4259929,4261754,4262072,4263637,4264192,7964733,7970869,7971540,7972100,7972268,7972581,7973721,7974352,7977434,7977700,7978031,7978441,14718751,14719117,14720531,14720688,14723856,14724478,14724653,14726375,14726526,14726722,14727734,14727791,14727821,14729290,14729539,14730031,14730721,14730815,14730875,147312","836,842",NULL,"NP_001220,NP_004337",NIH Initiatives,"10940292,11864614,12522243,16630893,17724022",0,10.1016/j.molcel.2006.03.030|10.1016/s1097-2765(02)00442-2|10.1074/jbc.c000405200|10.1074/jbc.m705258200|10.1126/science.1076807,"3.4.22.56,3.4.22.62","P42574,P55211",NULL
588538,2,Dose Response validation of Inhibitors of Apaf-1 using a Fluorescent Interference Counterscreen assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBIMR, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: R01 CA136513_|_Assay Provider: Dr. Xuejun Jiang, Sloan-Kettering Institute for Cancer Research, New York, NY_|__|_Apoptosis is a major form of programmed cell death that multicellular organisms utilize to maintain tissue homeostasis and to eliminate unwanted or dama",14,Burnham Center for Chemical Genomics,SBCCG-A715-APAF-1-Inhibitor-CTR-DR-Assay,20111017,"1201,6099,6763,7085,8478,11102,11106,18834,68207,72571,74787,96932,164676,185478,235224,254021,262093,263463,263534,272514,272529,282594,312589,312590,344131,367783,369539,378581,410099,439654,443939,460747,478574,548573,582632,591407,614841,616267,616832,625142,644274,652210,657484,658797,658849,658921,658939,659124,659226,659456,662264,662288,662388,662864,663108,663945,664029,664599,666440,667215,671256,691731,693329,698849,703093,713096,721129,727030,738951,741095,750480,752162,753169,766079,771515,7749","847157,849703,856108,857446,857500,857588,857769,860990,861018,861123,861465,861625,861879,862713,862796,863344,865594,865959,3712249,3713302,4241909,4242461,4245955,4252106,4255374,4256677,4258938,4259468,4259929,4261754,4262072,4263637,4264192,7964733,7970869,7971540,7972100,7972268,7972581,7973721,7974352,7977434,7977700,7978031,7978441,14718751,14719117,14720531,14720688,14723856,14724478,14724653,14726375,14726526,14726722,14727098,14727734,14727791,14727821,14729290,14729539,14730031,14730721,14730815",317,NULL,AAI36532,NIH Initiatives,"10940292,11864614,12522243,16630893,17724022",0,10.1016/j.molcel.2006.03.030|10.1016/s1097-2765(02)00442-2|10.1074/jbc.c000405200|10.1074/jbc.m705258200|10.1126/science.1076807,NULL,O14727,NULL
588598,2,SAR Analysis of small molecule inhibitors of Sentrin-specific protease 6 (SENP6) using a Luminescent assay - Set 2,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network(MLPCN)_|_Grant Proposal Number: 1R21 NS061758-01 fast track_|_Assay Provider: Dr. Guy Salvesen, Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|__|_Modification of proteins by SUMO is a dynamic and reversible process. SUMOylation/deSUMOylation cycle regulates SUMOs funct",14,Burnham Center for Chemical Genomics,SBCCG-A748-SENP6-DryPowder-Assay-2,20111021,"673490,843289,1548480,1588017,1814489,1814490,2066730,2159213,2312943,2343603,2701444,2814504,2990985,3143005,5296010,5296023,5336336,5348455,7034421,7087112,7087114,7117332,7117425,7117487,7117504,7117550,8379104,16232676,16258092,16811400,16815047,16866696,17422800,17456764,17483224,18291044,18554036,18573326,18587990,19324407,20879510,24980728,27667674,30371220,30608281,32148706,39952307,45898490,46502851,49852494,49852501,49852503,49852504,49852505,49852518,49852521,49852524,49852528,49852530,49852532,4","104222653,104222654,104222671,104222701,104222707,104222806,104222810,104222811,104222812,104222813,104222814,104222815,104222817,104222868,104222869,104222874,104222876,104222889,104222890,104222891,104222893,104222894,104222896,104222897,104222898,104222899,104222900,110067362,110067366,110067376,110067378,110067379,110067380,110067383,110067384,110067385,110067386,110067423,110067424,110067426,124756864,124756865,124756866,124756867,124756868,124756869,124756870,124756871,124756872,124756873,124756874,12",26054,NULL,AAF04852,NIH Initiatives,"17591783,17916063,18799455",0,10.1042/bj20070940|10.1074/jbc.m702444200|10.1074/jbc.m805655200,NULL,AAF04852,NULL
602332,2,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,"Primary protein unfolding takes place for many diseases, including diabetes and hypoxia, , and triggers a reaction in the cells called ER stress response (ERSR). ). ERSR is designed as a repair mechanism, but ultimately leads to cell death via apoptosis if conditions triggering protein unfolding persist (1). The molecular clue to ERSR activation is the enhancement of the expression of key molecular chaperones, including the glucose regulated protein (GRP) 78. GRP78 is the main sensor for protein folding and",2,National Center for Advancing Translational Sciences (NCATS),ERSR100,20120308,"6,19,40,51,72,86,109,119,126,127,135,137,138,174,178,180,185,187,190,191,196,199,204,205,206,224,227,229,232,237,239,240,243,244,248,249,253,255,263,273,275,277,286,289,298,299,303,304,305,311,314,323,335,338,342,359,366,370,379,389,401,403,408,412,441,444,450,453,460,462,464,471,487,499,525,535,546,547,564,588,594,595,596,597,607,610,612,614,636,637,650,660,681,698,700,701,710,727,736,745,750,753,757,774,785,787,791,798,802,803,827,830,836,838,846,847,853,863,864,866,871,876,887,892,896,899,903,904,912,914","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",NULL,NULL,CAQ08732,Governmental Organizations|NIH Initiatives,11836247,0,10.1074/jbc.m112129200,NULL,P11021,NULL
602179,2,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,"Unbiased genomic sequencing for 22 glioma genomes found recurrent mutation of isocitrate dehydrogenase 1 (IDH1) on chromosome 2q33-a gene encoding the cytosolic isoform of IIDH1associated with the tricarboxylic acid cycle (TCA) that catalyzes the oxidative decarboxylation of isocitrate, yielding alpha-ketoglutarate and CO2 via NADP+ to NADPH conversion. Subsequent studies confirmed the recurrent IDH mutations in up to 70% of secondary gliomas and in 10% of AML cases. We have found that the somatic mutation ",2,National Center for Advancing Translational Sciences (NCATS),IDH001,20120405,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",3417,NULL,ABD77215,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,ABD77215,NULL
602310,2,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,"The recent discovery and characterization of host restriction factors, which provide a potent defense to invading retroviruses, has provided new targets for antiviral drug development. APOBEC3G (A3G) and APOBEC3F (A3F) are potent cytidine deaminases that block HIV-1 replication; HIV-1 expresses the Vif protein, which counteracts A3G and A3F by binding to them and inducing their proteasomal degradation._|__|_The Vif-A3G and Vif-A3F interactions provide two potential targets for development of small molecules",2,National Center for Advancing Translational Sciences (NCATS),VIFG100,20121127,"6,19,40,72,86,109,119,126,127,137,174,185,190,191,204,229,240,243,244,253,255,289,298,299,303,311,314,323,335,338,366,379,403,441,460,464,487,499,525,546,547,564,588,594,597,637,660,681,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1189,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1348,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",60489,NULL,NP_068594,Governmental Organizations|NIH Initiatives,"18806783,20363737",0,10.1038/nbt.1496|10.1074/jbc.m109.085308,3.5.4.-,Q9HC16,NULL
602313,2,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,"The recent discovery and characterization of host restriction factors, which provide a potent defense to invading retroviruses, has provided new targets for antiviral drug development. APOBEC3G (A3G) and APOBEC3F (A3F) are potent cytidine deaminases that block HIV-1 replication; HIV-1 expresses the Vif protein, which counteracts A3G and A3F by binding to them and inducing their proteasomal degradation._|__|_The Vif-A3G and Vif-A3F interactions provide two potential targets for development of small molecules",2,National Center for Advancing Translational Sciences (NCATS),VIFF100,20120308,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842205,842206,8",200316,NULL,NP_660341,Governmental Organizations|NIH Initiatives,"18806783,20363737",0,10.1038/nbt.1496|10.1074/jbc.m109.085308,3.5.4.38,Q8IUX4,NULL
602233,2,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,"Several species of the Trypanosomatidae family of parasitic protozoans cause a spectrum of diseases throughout the tropical and subtropical world. Sleeping sickness, caused by two subspecies of Trypanosoma brucei, is endemic to areas of sub-Saharan Africa, while Chagas disease, a manifestation of Trypanosoma cruzi infection, is prevalent throughout Central and South America. In addition, many species of Leishmania are responsible for a range of cutaneous and visceral diseases, causing ulcers, destructive le",2,National Center for Advancing Translational Sciences (NCATS),PGK100,20120127,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842123,842125,842126,842127,842128,842129,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842205,842206,8",4357161,NULL,XP_001218773,Governmental Organizations|NIH Initiatives,"11063610,11512153,17023066,3323902,3830152,8341319,9642090",0,10.1006/jmbi.1998.1835|10.1016/0166-6851(87)90123-x|10.1016/0166-6851(93)90218-m|10.1016/j.bbamcr.2006.08.019|10.1021/jm000287a|10.1054/drup.2000.0177|10.1111/j.1432-1033.1987.tb10667.x,NULL,XP_001218773,NULL
602440,1,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH094200-01_|_Assay Provider: Dr. Guy Salvesen, Sanford-Burnham Medical Research Institute, La Jolla, CA._|__|_The human peptidase clan CE is defined by seven proteases with a common fold and catalytic mechanism, commonly known as SENPs [1-3]. SENPs 1,",14,Burnham Center for Chemical Genomics,SBCCG-A815-SENP8-Primary-Assay,20120321,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",123228,NULL,NP_660205,NIH Initiatives,"12730221,12759362,12759363,15688063,17591783,17916063,18799455,20142034",0,10.1016/j.chembiol.2010.01.002|10.1038/nrm1547|10.1042/bj20070940|10.1074/jbc.m212948200|10.1074/jbc.m302888200|10.1074/jbc.m302890200|10.1074/jbc.m702444200|10.1074/jbc.m805655200,3.4.22.-,Q96LD8,NULL
602244,1,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1R03MH095589-01 (Cycle 18)_|_Assay Provider:  Gregory Roth Ph.D., Sanford Burnham Medical Research Institute._|__|_Prostate cancer (PCa) is the second leading cause of cancer death in American men and its morbidity has increased globally in recent years. The high m",14,Burnham Center for Chemical Genomics,SBCCG-A778-CXCR6-Primary-DR-Assay,20120313,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",10663,NULL,NP_006555,NIH Initiatives,"11017100,14625285,18452560",0,10.1038/79738|10.1074/jbc.m311660200|10.1111/j.1349-7006.2008.00833.x,NULL,O00574,NULL
602438,1,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford Burnham Medical Research Institute, La Jolla, CA_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH096589-01_|_Assay Provider: Dr. Erkki Ruoslahti, Sanford Burnham Medical Research Institute, La Jolla, CA _|__|_Neuropilin-1 (NRP-1) is a a pleiotrophic cell surface receptor with multiple ligands that plays an essential role in angiogenesis, cardiovascular developme",14,Burnham Center for Chemical Genomics,SBCCG-A823-CendR-Primary-Assay,20120320,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,NULL,2QQI_A,NIH Initiatives,"11687497,11891274,12032302,15197262,15920019,16513643,16959272,17503412,18180379,18829396,19805273,19962669",0,10.1002/path.2182|10.1016/j.ccr.2009.10.013|10.1016/j.lfs.2006.08.005|10.1016/j.nano.2008.07.007|10.1073/pnas.022017899|10.1073/pnas.0403317101|10.1073/pnas.062189599|10.1073/pnas.0908201106|10.1074/jbc.m512121200|10.1146/annurev.cellbio.17.1.463|10.1161/01.res.0000171756.13554.49|10.1182/blood-2007-08-110205,NULL,2QQI_A,NULL
602274,1,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1R21NS064855-01 _|_Assay Provider: Dr. April Pyle, University of California Los Angeles, Los Angeles, CA. _|__|_The recent derivation of human induced pluripotent stem cells (hiPSCs) has allowed for an abundant supply of undifferentiated cells that avoid immune rej",14,Burnham Center for Chemical Genomics,SBCCG-A784-hiPSC-Primary-Assay,20120313,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,NULL,NULL,NIH Initiatives,"17529971,18029452,18157115,18181945,18287077,19074420",0,10.1038/nature06534|10.1038/nbt1310|10.1073/pnas.0711983105|10.1111/j.1365-2184.2008.00493.x|10.1126/science.1151526|10.1634/stemcells.2008-0596,NULL,NULL,NULL
602429,1,uHTS identification of SUMO1-mediated protein-protein interactions,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford Burnham Medical Research Institute, La Jolla, CA_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R21NS066498-01_|_Assay Provider:  Yuan Chen, Ph.D., City of Hope, Duarte, CA_|__|_There are no published patents or studies specifically describing small molecule inhibitors of proteinprotein interactions mediated by the Small Ubiquitin-like Modifications (SUMO). Given this",14,Burnham Center for Chemical Genomics,SBCCG-A824-SUMO1-Primary-Assay,20120320,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",7341,NULL,AAC50996,NIH Initiatives,"10692421,11343927,20129245",0,10.1016/j.ccr.2009.12.030|10.1016/s0968-0004(01)01849-7|10.1074/jbc.275.9.6252,NULL,P63165,NULL
602329,1,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords:_|_RAD54, Branch migration, Holliday Junction, homologous recombination, DNA repair, cancer_|__|_Assay Overview:_|_The goal of this proposal is to develop specific small-molecule inhibitors of human RAD54, one of the key homologous recombination (HR) proteins.  Basically, RAD54 and DNA that forms Holiday Junctions are added according to plate design with BioRAPTR (Beckman) to respective wells of 1536-well assay ready plates (Aurora 19180) that contain 2.5 nL/well of 10 mM compound.   The reaction i",31,Broad Institute,2159-01_Inhibitor_SinglePoint_HTS_Activity,20120308,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,323,335,338,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1643,1646,1676,1678,1688,1727,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,8",8438,Biochemical,NP_001136020,NIH Initiatives,"16862129,21428443",0,10.1021/cb100428c|10.1038/nature04889,3.6.4.-,Q92698,NULL
602393,1,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords:_|_Mouse embryonic stem cells, ATP-dependent chromatin-remodeling complex, esBAF, Bmi1, cell-based reporter assay, inhibitor screen_|__|_Assay Overview:_|_Recent data indicate that the SWI/SNF-like, ATP-dependent chromatin-remodeling complex (Brg/Brahma Associated Factors complex, referred to as BAF) is both necessary and, in certain contexts, sufficient for the induction of pluripotency. The ATPase, Brg1 or Brm, is a central component of the complex.  Mutations in these genes have been linked to h",31,Broad Institute,2141-01_Inhibitor_SinglePoint_HTS_Activity,20120314,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,323,335,338,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1400,1401,1474,1480,1483,1489,1491,1493,1535,1539,1546,1570,1609,1643,1646,1676,1678,1688,1727,1730,1738,1742,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842136,842137,842138,842139,842141,842142,842143,842145,842146,842148,842150,842151,842152,842153,842154,842155,842156,842159,842161,842162,842163,842164,842165,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842195,842196,842197,842198,842199,842201,842202,842203,842204,842205,842206,842207,842208,842209,842210,842211,8",20586,Cell-based,NP_001167549,NIH Initiatives,"19279218,19279220",0,10.1073/pnas.0812888106|10.1073/pnas.0812889106,3.6.4.-,Q3TKT4,NULL
602340,1,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,"Keywords: 3-hydroxy-3methylglutaryl-coenzyme A (HMG-CoA) inhibitors, low-density lipoprotein (LDL), statin, muscle toxicity, ATP, cholesterol biogenesis, C2C12 myotubes, simvastatin,_|__|_Assay Overview: Mouse C2C12 myoblasts can be differentiated to myotubes when grown to confluency in the presence of 2% horse serum.  This differentiation causes the cells to fuse to form syncytial myotubes characteristic of muscle tissue.  It was previously shown that C2C12 myotubes treated with 10uM simvastatin show a phe",31,Broad Institute,2112-01_Suppressor_SinglePoint_HTS_Activity,20120328,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,323,335,338,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1400,1401,1474,1480,1483,1489,1491,1493,1535,1539,1546,1570,1609,1643,1646,1676,1678,1688,1727,1730,1738,1742,17","842122,842123,842124,842125,842128,842129,842130,842131,842133,842136,842137,842138,842139,842141,842142,842143,842145,842146,842148,842151,842152,842153,842154,842155,842156,842159,842161,842162,842163,842164,842165,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842195,842196,842197,842199,842201,842202,842203,842204,842205,842206,842207,842208,842209,842210,842211,842214,842216,842217,842219,842220,842224,8",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
602346,1,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: VIF, multimerization, HIV, high content, imaging_|__|__|_Assay Overview: The goal of this project is to develop small molecules that antagonize Vif self-association and hence, viral infectivity. Basically, EGFP-V5-VIF and VIF-HA-REACh2 are coexpressed in HEK293T cells by transient transfection.  Transfected cells are incubated with approximately 7.5 uM compounds for 24 hrs.  Compounds that disrupt VIF self-association will lead to an increase in signal that will be detected by imaging on ImagExpre",31,Broad Institute,2108-01_Inhibitor_SinglePoint_HTS_Activity,20120309,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842136,842138,842139,842140,842141,842142,842143,842145,842146,842149,842150,842151,842152,842153,842154,842155,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,842205,842206,842207,842208,842209,8",155459,Cell-based,NP_057851,NIH Initiatives,"11071884,18036235",0,10.1074/jbc.m004895200|10.1186/1742-4690-4-81,NULL,P69723,NULL
602342,1,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords:  microRNA, miR-122, HCV, hepatoma Huh7_|__|__|_Assay Overview:   The primary screen searches for small molecule inhibitors of miR-122 using Huh7 cells that have been stably transfected with a plasmid based on the psiCHECK-2 vector that acts as a sensor for endogenous miR-122 by the control of Renilla luciferase expression. Huh7-psiCHECK-miR122 cells are grown in 384 assay plates with compound for 48 hours. Renilla luciferase reagent is added and output is read via plate reader. An increase in sign",31,Broad Institute,2144-01_Inhibitor_SinglePoint_HTS_Activity,20120316,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1646,1676,1678,1688,1727,173","842121,842122,842123,842124,842125,842126,842127,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842167,842168,842169,842170,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842194,842195,842196,842197,842198,842199,842200,842201,842203,842204,842205,842206,842207,842208,842209,842210,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
602399,1,uHTS identification of inhibitors of NadD in a Colorimetric assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH095597-01A1_|_Assay Provider: Dr. Andrei Osterman, Sanford Burnham Medical Research Institute, La Jolla, CA_|__|_The increasing occurrence of multidrug resistant strains of bacterial pathogens poses a significant threat to public health calling for urgent act",14,Burnham Center for Chemical Genomics,SBCCG-A804-NadD-Primary-Assay,20120620,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,NULL,NP_374707,NIH Initiatives,"12142426,17195474,18490451,19249205,19408950,19716475,20199601,20578699",0,10.1007/978-3-7643-7567-6_6|10.1016/j.bmcl.2009.02.034|10.1016/j.chembiol.2009.07.006|10.1021/cc9000357|10.1021/jm100377f|10.1074/jbc.m800694200|10.1111/j.1365-2958.2010.07099.x|10.1128/jb.184.16.4555-4572.2002,NULL,P65502,NULL
602449,1,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH096534-01 _|_Assay Provider: Michael Forte, Ph.D., Oregon Health & Science University, Portland, OR_|__|_Given its multifactorial roles, regulation of cellular Ca2+ metabolism and bioenergetics functions as an integrated system. In terms of normal physiology",14,Burnham Center for Chemical Genomics,SBCCG-A822-mtPTP-Primary-Assay,20120328,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,NULL,NULL,NIH Initiatives,"10508231,16087232,16649987,17294078,18400691,19161975",0,10.1007/s10495-007-0723-y|10.1016/j.bbabio.2008.12.011|10.1016/j.ceca.2005.06.011|10.1111/j.1742-4658.2006.05213.x|10.1152/physiol.00046.2007|10.1152/physrev.1999.79.4.1127,NULL,NULL,NULL
602261,1,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R03MH095532-01_|_Assay Provider: Dr. Jeffrey Smith, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_This study will focus on developing drug-like inhibitors/probes against fatty acid synthase, an enzyme that is essential for growth of solid tumors.   ",14,Burnham Center for Chemical Genomics,SBCCG-A782-FAS-TE-Primary-Assay,20120216,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",2194,NULL,NP_004095,NIH Initiatives,"10716717,1374214,17620441,18796435,8022791,9191002",0,10.1016/s0046-8177(97)90177-5|10.1073/pnas.050582897|10.1073/pnas.91.14.6379|10.1074/jbc.m803384200|10.1093/ajcp/97.5.686|10.1158/1535-7163.mct-07-0187,"1.1.1.100,1.3.1.39,2.3.1.38,2.3.1.39,2.3.1.41,2.3.1.85,3.1.2.14,4.2.1.59",P49327,NULL
602481,1,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords:_|_Mycobacterium tuberculosis (Mtb), Tuberculosis (TB), bioA, BioA enzyme, biotin biosynthesis, KAPA (7-keto-8-aminopelargonic acid), DAPA (7,8-diaminopelargonic acid)_|__|_Assay Overview:_|_BioA catalyzes the reversible transamination between KAPA and DAPA in the biotin biosynthetic pathway.  BioD catalyzes the irreversible ATP-dependent carbonylation of DAPA to provide dethiobiotin (DTB), and this step drives the BioA reaction forward.  Dethiobiotin is detected by diplacement of a fluorescent det",31,Broad Institute,2163-01_Inhibitor_SinglePoint_HTS_Activity,20120324,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,323,335,338,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1643,1646,1676,1678,1688,1727,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842165,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",NULL,Biochemical,CCE37082,NIH Initiatives,NULL,0,NULL,NULL,CCE37082,NULL
602141,1,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: IR21 NS061743-01_|_Assay Provider:  Rangan Maitra, Ph.D., RTI International University_|__|_The inflammatory response in Cystic Fibrosis (CF) is a complex interplay between several factors.  It has been suggested that pro-inflammatory cytokines are elevated in the ep",14,Burnham Center for Chemical Genomics,SBCCG-A769-CF-PAF-Cytotox-Assay,20111212,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,Toxicity,NULL,NIH Initiatives,"10400842,15661927,16239509,7544594",0,10.1016/s0091-6749(99)70116-8|10.1128/iai.73.11.7151-7160.2005|10.1165/ajrcmb.13.3.7544594|10.4049/jimmunol.174.3.1638,NULL,NULL,NULL
602363,1,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,"Keywords: start codon, AUG, UUG, firefly luciferase and redox activity_|__|_Assay Overview: The recognition of the start codon in the mRNA by the translational machinery is a crucial step in gene expression as it sets the reading frame for decoding of the message and defines the N-terminus of the protein product. Compounds that modulate the fidelity of start codon recognition will certainly be useful research tools for probing the molecular mechanics of the start codon recognition in vitro and in vivo and f",31,Broad Institute,2155-01_Modulator_SinglePoint_HTS_Activity,20120312,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,323,335,338,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1643,1646,1676,1678,1688,1727,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,8",NULL,Organism-based,NULL,NIH Initiatives,21220547,0,10.1261/rna.2475211,NULL,NULL,NULL
602405,1,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords:PglD, N-linked glycosylation, bacterial cell wall, C. jejuni_|__|_Assay Overview:  This is an endpoint absorbance based enzymatic assay.  Purified recombinant C. jejuni PglD is mixed with the substrates Ac-CoA, UDP-2-acetyl-4-amino-2,4,6-trideoxyhexose as well as compound of interest.  The reaction is allowed to proceed and is then stopped by the addition of Ellman's reagent dissolved in 1-propanol.  Ellman's reagent reacts with CoA reaction product and forms a chromophore with an absorption maximu",31,Broad Institute,2164-01_Inhibitor_SinglePoint_HTS_Activity,20120315,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,323,335,338,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1643,1646,1676,1678,1688,1727,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842164,842165,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,8",NULL,Biochemical,O86157,NIH Initiatives,NULL,0,NULL,NULL,O86157,NULL
602396,1,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Patrick Griffin, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: CA134873_|_Grant Proposal PI: Patrick Griffin, TSRI_|_External Assay ID: LRH1_INH_LUMI_1536_1X%INH PRUN_|__|_Name: Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver rec",5,The Scripps Research Institute Molecular Screening Center,LRH1_INH_LUMI_1536_1X%INH PRUN,20120921,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",2494,Cell-based,NP_003813,NIH Initiatives,"10078197,11108279,15130581,15707893,15721253,16289203,1709303,8139576,8187173,8668203,9332374",0,10.1016/0092-8674(94)90211-9|10.1016/j.cell.2005.01.024|10.1016/j.jmb.2005.10.009|10.1016/j.molcel.2005.02.002|10.1016/j.tcb.2004.03.008|10.1016/s0378-1119(97)00270-9|10.1016/s1097-2765(00)80305-6|10.1126/science.1709303|10.1128/mcb.14.4.2786|10.1128/mcb.16.7.3853|10.1210/endo.141.12.7808,NULL,O00482,NULL
602247,1,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 c,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: MH077606-01_|_Grant Proposal PI: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_External Assay ID: CHOK1_PAM_FLUO8_1536_1X%ACT CSRUN M1_|__|_Name: Full deck counterscreen for positi",5,The Scripps Research Institute Molecular Screening Center,CHOK1_PAM_FLUO8_1536_1X%ACT CSRUN M1,20120509,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,Cell-based,NULL,NIH Initiatives,"18481916,19201489,2188581,2385234,3037705,3272174,3443095,7504306,7751967,9109749",0,10.1001/archneur.1997.00550160091022|10.1016/0163-7258(93)90027-b|10.1016/0896-6273(88)90190-0|10.1016/j.tips.2008.12.002|10.1126/science.3037705|10.1146/annurev.pa.30.040190.003221,NULL,NULL,NULL
602229,1,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Konstantin Petrukhin, Columbia University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS061718-01 Fast Track_|_Grant Proposal PI: Konstantin Petrukhin, Columbia University_|_External Assay ID: NR2E3-CELL_AG_LUMI_1536_1X%INH_|__|_Name: Luminescence-based cell-based high throughput primary screening ",5,The Scripps Research Institute Molecular Screening Center,NR2E3-CELL_AG_LUMI_1536_1X%INH,20120126,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",10002,Cell-based,BAH02301,NIH Initiatives,"10221899,10805811,11071390,11487564,12842037,12963616,15190009,15634773,15914712,16834531,17255935,17564971,17982421,18294254,18592265",0,10.1001/archopht.121.9.1316|10.1007/s00427-008-0232-1|10.1007/s004390000350|10.1016/s0969-2126(03)00133-3|10.1038/sj.emboj.7601548|10.1073/pnas.97.10.5551|10.1086/518426|10.1089/adt.2006.4.253|10.1093/hmg/10.16.1619|10.1093/hmg/ddh173|10.1111/j.1399-0004.2008.00963.x|10.1126/science.284.5415.757|10.1210/me.2005-0046|10.1523/jneurosci.3571-04.2005,NULL,Q9Y5X4,NULL
602250,1,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: MH077606-01_|_Grant Proposal PI: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_External Assay ID: CHOK1_ANT_FLUO8_1536_1X%INH CSRUN M1_|__|_Name: Full deck counterscreen for antago",5,The Scripps Research Institute Molecular Screening Center,CHOK1_ANT_FLUO8_1536_1X%INH CSRUN M1,20120509,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,Cell-based,NULL,NIH Initiatives,"18481916,19201489,2188581,2385234,3037705,3272174,3443095,7504306,7751967,9109749",0,10.1001/archneur.1997.00550160091022|10.1016/0163-7258(93)90027-b|10.1016/0896-6273(88)90190-0|10.1016/j.tips.2008.12.002|10.1126/science.3037705|10.1146/annurev.pa.30.040190.003221,NULL,NULL,NULL
602281,1,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: James Granneman, Wayne State University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS061634-01_|_Grant Proposal PI: James Granneman, Wayne State University_|_External Assay ID: ABHD5-MLDP_INH_LUMI_1536_1X%INH PRUN_|__|_Name: Luminescence-based biochemical primary high throughput screening",5,The Scripps Research Institute Molecular Screening Center,ABHD5-MLDP_INH_LUMI_1536_1X%INH PRUN,20120229,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8","51099,440503",Biochemical,"NP_001013728,NP_057090",NIH Initiatives,"10948207,11590543,11943743,16731815,17052606,18996284,19064991,19299455",0,10.1016/j.arcmed.2008.09.005|10.1016/j.chembiol.2006.09.010|10.1074/jbc.m007322200|10.1074/jbc.m808251200|10.1086/324121|10.1210/edrv.23.2.0461|10.1210/en.2008-0913|10.2337/db06-0263,2.3.1.51,"Q00G26,Q8WTS1",NULL
602123,1,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: There are 2 Assay Providers: Irene Lee, Case Western Reserve and Carolyn Suzuki, University of Medicine and Dentistry of New Jersey_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R01 GM084039-01A1_|_Grant Proposal PI: Irene Lee, Case Western Reserve and Carolyn Suzuki, University of Medicine and ",5,The Scripps Research Institute Molecular Screening Center,ELON_INH_FP_1536_1X%INH PRUN,20111210,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",945085,Biochemical,NP_414973,NIH Initiatives,"10672180,11262158,11473577,12135363,12540547,14124942,1480111,16072036,16494849,1652461,2931432,2950089,3886165,6325386,6453650,6458037,7845219,7862644,8982462,9927482",0,10.1006/abio.2001.4988|10.1016/0014-5793(91)80053-6|10.1016/0076-6879(94)44027-1|10.1016/0092-8674(81)90518-3|10.1016/j.bcp.2005.11.023|10.1016/s0092-8674(85)80031-3|10.1021/bi0255470|10.1038/nrm1684|10.1046/j.1365-2443.2001.00447.x|10.1046/j.1365-2958.2000.01726.x|10.1073/pnas.78.8.4931|10.1073/pnas.92.4.1113|10.1128/iai.71.2.690-696.2003|10.1146/annurev.genet.30.1.465,3.4.21.53,P0A9M0,NULL
602163,1,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Herbert Weissbach, Florida Atlantic University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R03DA032473-01_|_Grant Proposal PI: Herbert Weissbach, Florida Atlantic University_|_External Assay ID: MSRA_ACT_ABS_1536_1X%ACT_|__|_Name: Absorbance-based biochemical primary high throughput screening a",5,The Scripps Research Institute Molecular Screening Center,MSRA_ACT_ABS_1536_1X%ACT,20120103,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",281312,Biochemical,AAI02981,NIH Initiatives,"10841552,10964927,11063566,11795868,11867705,12693988,12837786,14745014,15680228,15914630,16735467,17180746,18719109,19085252,19461988,19844733,20515413,8622914,8700890,9275166,9826655",0,10.1006/abbi.2001.2664|10.1007/s00239-005-0281-2|10.1007/s00403-009-0996-9|10.1016/j.bbapap.2004.10.004|10.1021/bi0020269|10.1042/bj20030443|10.1073/pnas.0308215100|10.1073/pnas.032671199|10.1073/pnas.0602826103|10.1073/pnas.0802025105|10.1073/pnas.93.5.2095|10.1073/pnas.93.8.3205|10.1073/pnas.94.18.9585|10.1073/pnas.95.24.14071|10.1073/pnas.97.12.6463|10.1074/jbc.m006137200|10.1080/10715760802566541|10.1089/adt.2009.0263|10.1128/jb.185.14.4119-4126.2003|10.1167/iovs.05-0018,NULL,P54149,NULL
602248,1,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: MH077606-01_|_Grant Proposal PI: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_External Assay ID: CHOK1_AG_FLUO8_1536_1X%ACT CSRUN M1_|__|_Name: Full deck counterscreen for agonist",5,The Scripps Research Institute Molecular Screening Center,CHOK1_AG_FLUO8_1536_1X%ACT CSRUN M1,20120509,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,Cell-based,NULL,NIH Initiatives,"18481916,19201489,2188581,2385234,3037705,3272174,3443095,7504306,7751967,9109749",0,10.1001/archneur.1997.00550160091022|10.1016/0163-7258(93)90027-b|10.1016/0896-6273(88)90190-0|10.1016/j.tips.2008.12.002|10.1126/science.3037705|10.1146/annurev.pa.30.040190.003221,NULL,NULL,NULL
602252,1,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,"Keywords: CFTR, CAL, PDZ domain, fluorescence polarization, Cystic fibrosis_|__|_Assay Overview: A purified CAL PDZ domain construct is allowed to interact with a tetramethylrhodamine (TMR) labeled fluorescent reporter peptide that binds in the canonical peptide-binding groove. The disruption of the interaction is monitored using fluorescence polarization (FP). Fluorescence is measured at 535 nM in the S and P planes with the Perkin-Elmer Viewlux plate reader after 1 hour incubation at room temperature and ",31,Broad Institute,2109-02_Inhibitor_SinglePoint_HTS_Activity,20120210,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,1738,1742,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842142,842143,842145,842146,842148,842149,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,842205,842206,8","1080,57120",Biochemical,"NP_000483,NP_001017408",NIH Initiatives,"17158866,21105033",0,10.1002/anie.201005585|10.1074/jbc.m611049200,5.6.1.6,"P13569,Q9HD26",NULL
602162,1,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,"University of New Mexico Assay Overview:_|_Assay Support: NIH 1 R03 MH093193-01A1_|_High Throughput Screening for inhibitors of the ABC transporter ABCB6_|_PI: Partha Krishnamurthy, Ph.D._|__|_Screening Center PI: Larry Sklar, Ph.D. / UNMCMD_|_Screening Lead: Mohiuddin Khan, Ph.D. _|_Assay Implementation: Dominique Perez, Stephanie Chavez, Matthew Garcia, J. Jacob Strouse, Ph.D., Mark Carter, M.S.,  Anna Waller, Ph.D., George Tegos, Ph.D._|_UNM Cheminformatics: Cristian Bologa, Ph.D., Oleg Ursu, Ph.D._|__|_",6,NMMLSC,UNMCMD_ABCB6_1o_MLPCN,20111228,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",10058,NULL,NP_005680,NIH Initiatives,"15324696,15342794,17006453,17661442,19656490,20075923,21118089",0,10.1016/j.ccr.2004.06.026|10.1016/j.cmet.2009.06.012|10.1021/bi700015m|10.1038/nature05125|10.1038/nrc2789|10.1124/mol.104.005009|10.2174/138920111795163995,NULL,Q9NP58,NULL
602410,1,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,"Data Source: Johns Hopkins Ion Channel Center (JHICC)_|_BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed_|__|_Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Meng Wu, Ph.D., Johns Hopkins University, School of Medicine_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R03 MH090849-01_|_Gr",27,Johns Hopkins Ion Channel Center,JHICC_KCNK3_Inh_Primary,20120316,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,1730,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",3777,Cell-based,AAG29340,Legacy Depositors|NIH Initiatives,NULL,0,NULL,NULL,O14649,NULL
602314,0,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,"A global transcriptional regulator, MgrA, was identified previously as a key virulence determinant in Staphylococcus aureus. A fluorescence anisotropy (FA)-based high-throughput screen was performed that identified 5, 5-methylenedisalicylic acid (MDSA) as capable of blocking the DNA-binding activity of MgrA. MDSA represses the expression of alpha-toxin that is normally stimulated by MgrA and activates transcription of the protein A gene, which is normally suppressed by MgrA. MDSA alters bacterial antibiotic",46,"ICCB-Longwood Screening Facility, Harvard Medical School",HMS836,20161018,"89,119,127,185,190,204,253,298,303,323,370,437,464,564,727,774,782,785,802,830,863,864,896,904,914,932,938,1002,1046,1066,1072,1134,1148,1150,1176,1204,1234,1236,1309,1321,1348,1359,1377,1379,1380,1400,1420,1433,1449,1464,1474,1493,1560,1563,1599,1609,1645,1646,1649,1670,1720,1727,1732,1754,1756,1775,1780,1781,1802,1814,1825,1830,1832,1853,1863,1880,1892,1960,1967,1981,1983,1984,1985,1986,1989,1990,2000,2004,2005,2041,2046,2049,2051,2063,2075,2081,2082,2083,2092,2116,2117,2120,2122,2123,2125,2126,2129,2130,","92123927,92123928,92123929,92123930,92123931,92123932,92123933,92123934,92123935,92123936,92123937,92123938,92123939,92123940,92123941,92123942,92123943,92123944,92123945,92123946,92123947,92123948,92123949,92123950,92123951,92123952,92123953,92123954,92123955,92123956,92123957,92123958,92123959,92123960,92123961,92123962,92123963,92123964,92123965,92123966,92123967,92123968,92123969,92123970,92123971,92123972,92123973,92123974,92123975,92123976,92123977,92123978,92123979,92123980,92123981,92123982,92123983",NULL,NULL,YP_001331689,Research and Development,"16980961,21867918",0,10.1016/j.chembiol.2011.05.014|10.1038/nchembio820,NULL,YP_001331689,NULL
602196,0,siRNA Chemosensitization in A549 Lung Cancer Cells,"A genome-wide library of siRNAs (2 x gene) from Qiagen was transfected into A549 lung cancer cells for 48h. Cisplatin was then administered at a concentration that killed 50% of control cells (transfected with a control siRNA). Each of the two siRNAs per gene were assessed for being cytotoxic (LDH release) and for being antiproliferative (WST-1 assay).  If neither of these was found to be the case, the siRNAs were assessed for inhibiting or exacerbating CDDP-induced cell death from the fixed control respons",55,"INSERM, Institut National de la Sante et de la Recherche Medicale",siRNA_A549_lung_cancer_cells1,20120118,NULL,"131500289,131500290,131500291,131500292,131500293,131500294,131500295,131500296,131500297,131500298,131500299,131500300,131500301,131500302,131500303,131500304,131500305,131500306,131500307,131500308,131500309,131500310,131500311,131500312,131500313,131500314,131500315,131500316,131500317,131500318,131500319,131500320,131500321,131500322,131500323,131500324,131500325,131500326,131500327,131500328,131500329,131500330,131500331,131500332,131500333,131500334,131500335,131500336,131500337,131500338,131500339,13",NULL,RNAi,NULL,Governmental Organizations|Legacy Depositors,20145152,1,10.1158/0008-5472.can-09-3112,NULL,NULL,NULL
602276,1,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-SeV Stimulus,"Assay Provider - Saumendra N. Sarkar, University of Pittsburgh Cancer Institute._|_Grant # 1U24AI082673-01_|__|_Receptors of the innate immune system, such as Toll-like Receptors (TLR) are key components that sense microbial infection and trigger antimicrobial host defense responses [Akira et al. Cell. 2006;124(4):783-801.] TLR3, is one of the primary sensors of double stranded (ds) RNA. TLR3 is activated either by natural dsRNA from virus infection, or synthetic dsRNA applied externally. This leads to NF-k",9,University of Pittsburgh Molecular Library Screening Center,Inhibition of Sendai Virus Induced TLR3 Reporter Activation,20120225,"1329,1676,1688,1780,1820,1832,1892,1893,1967,1981,1986,2082,2123,2153,2170,2196,2247,2249,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2794,2890,2955,3012,3019,3025,3059,3108,3126,3151,3168,3169,3182,3194,3213,3229,3278,3295,3308,3331,3332,3333,3334,3339,3371,3374,3394,3446,3463,3478,3488,3512,3542,3559,3616,3639,3647,3672,3676,3702,3715,3728,3747,3767,3786,3793,3828,3878,3883,3899,3957,3969,4021,4030,4038,4044,4100,4107,4173,4201,4342,4421,4472,4485,44","842122,842150,842164,842175,842176,842177,842182,842183,842196,842197,842215,842219,842220,842228,842252,842259,842260,842266,842280,842282,842291,842292,842299,842322,842332,842341,842349,842351,842360,842363,842378,842380,842382,842383,842386,842401,842402,842414,842423,842425,842426,842437,842442,842455,842457,842463,842471,842473,842484,842486,842488,842496,842502,842509,842511,842521,842524,842535,842549,842556,842560,842564,842568,842573,842574,842576,842580,842598,842605,842608,842668,842670,842674,8",7098,NULL,O15455,NIH Initiatives,"16497588,20382888",0,10.1016/j.cell.2006.02.015|10.4049/jimmunol.0903559,NULL,O15455,NULL
602277,1,Novel Modifiers of Toll-like and RIG-like Receptor Signaling-Poly IC Stimulus,"Assay Provider - Saumendra N. Sarkar, University of Pittsburgh Cancer Institute._|_Grant # 1U24AI082673-01_|__|_Receptors of the innate immune system, such as Toll-like Receptors (TLR) are key components that sense microbial infection and trigger antimicrobial host defense responses [Akira et al. Cell. 2006;124(4):783-801.] TLR3, is one of the primary sensors of double stranded (ds) RNA. TLR3 is activated either by natural dsRNA from virus infection, or synthetic dsRNA applied externally. This leads to NF-k",9,University of Pittsburgh Molecular Library Screening Center,Inhibition of Poly IC Induced TLR3 Reporter Activation,20120225,"1329,1676,1688,1780,1820,1832,1892,1893,1967,1981,1986,2082,2123,2153,2170,2196,2247,2249,2284,2315,2333,2343,2378,2391,2406,2435,2466,2471,2480,2554,2576,2708,2720,2727,2754,2762,2771,2788,2794,2890,2955,3012,3019,3025,3059,3108,3126,3151,3168,3169,3182,3194,3213,3229,3278,3295,3308,3331,3332,3333,3334,3339,3371,3374,3394,3446,3463,3478,3488,3512,3542,3559,3616,3639,3647,3672,3676,3702,3715,3728,3747,3767,3786,3793,3828,3878,3883,3899,3957,3969,4021,4030,4038,4044,4100,4107,4173,4201,4342,4421,4472,4485,44","842122,842150,842164,842175,842176,842177,842182,842183,842196,842197,842215,842219,842220,842228,842252,842259,842260,842266,842280,842282,842291,842292,842299,842322,842332,842341,842349,842351,842360,842363,842378,842380,842382,842383,842386,842401,842402,842414,842423,842425,842426,842437,842442,842455,842457,842463,842471,842473,842484,842486,842488,842496,842502,842509,842511,842521,842524,842535,842549,842556,842560,842564,842568,842573,842574,842576,842580,842598,842605,842608,842668,842670,842674,8",7098,NULL,O15455,NIH Initiatives,"16497588,20382888",0,10.1016/j.cell.2006.02.015|10.4049/jimmunol.0903559,NULL,O15455,NULL
602473,2,Dose Response confirmation of uHTS hits for small molecule agonists of the CRF-binding protein and CRF-R2 receptor complex,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 DA029966-01_|_Assay Providers: Selena Bartlett, Ph.D., Ernest Gallo Clinic and Research Center, University of California, San Francisco and Nick Cosford, Ph.D., Sanford-Burnham Medical Research Institute_|__|_There is accumulating scientific evidence ",14,Burnham Center for Chemical Genomics,SBCCG-A832-CRF-Agonist-DMSO-DR-Assay,20120329,"3384,4100,5382,6634,6944,9953,11859,13752,17599,20043,21436,27775,44827,47726,68628,70011,71407,91332,97211,97676,109070,114429,120526,137753,141295,147354,162461,181107,186169,187970,219448,223131,223149,223673,226883,230798,231836,236644,238158,240163,242563,242765,243556,246654,247157,247352,247426,254813,255020,255923,256114,256179,256551,257105,258032,258079,261336,261391,262998,264670,264732,265820,265885,265887,266415,268108,268934,269431,269578,273367,274061,276647,276653,279275,281331,282420,282671","842462,842955,843198,843241,843450,843608,843889,843920,844676,845198,845259,845443,845802,846050,846442,846584,847110,847327,847966,848021,848116,848118,848267,848324,848365,848457,848690,848850,849039,849059,849668,849830,849981,850100,850142,850199,850280,850601,850671,850709,850817,851143,851206,851248,851303,851694,851967,852008,852634,852691,852801,852840,852980,853273,853313,853484,853616,853684,855645,855821,856088,856180,856425,856491,856505,856522,856658,856926,857240,857350,857576,857600,857924,8","1393,1395",NULL,"AAR18078,CAA41086",NIH Initiatives,"10838414,12895416,15930388,16611089,17699688,18308824",0,10.1016/s0896-6273(03)00461-6|10.1113/jphysiol.2007.150078|10.1152/jn.00824.2007|10.1177/108705719900400206|10.1523/jneurosci.0955-05.2005|10.2174/187152706776359619,NULL,"CAA41086,Q13324",NULL
602180,2,Dose Response confirmation of uHTS hits for small molecule antagonists of the CRF-binding protein and CRF-R2 receptor complex,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 DA029966-01_|_Assay Providers: Selena Bartlett, Ph.D., Ernest Gallo Clinic and Research Center, University of California, San Francisco and Nick Cosford, Ph.D., Sanford-Burnham Medical Research Institute_|__|_There is accumulating scientific evidence ",14,Burnham Center for Chemical Genomics,SBCCG-A770-CRF-Antagonist-DMSO-DR-Assay,20120329,"3384,4100,5382,6634,6944,9953,11859,13752,20043,68628,70011,71407,91332,97211,109070,120526,141295,147354,162461,181107,186169,187970,219448,223131,223149,223673,226883,230798,231836,236644,238158,240163,242765,243556,246654,247157,247426,255020,255923,256114,256179,256551,257105,258032,261336,261391,262998,264670,264732,265820,265885,265887,266415,268108,268934,269431,269578,273367,281331,282420,282671,283211,283218,285498,291920,295326,296470,298141,304514,304849,307717,313624,316274,321832,325823,327890,","842955,843198,843241,843450,843608,843889,843920,845198,845259,845443,846442,846584,847110,847966,848118,848267,848324,848365,848690,848850,849039,849668,849830,849981,850142,850199,850280,850601,850671,850709,850817,851143,851206,851248,851694,851967,852634,852691,852801,852840,852980,853273,853313,853484,853684,855645,855821,856088,856180,856491,856505,856522,857350,857956,858084,858088,858494,858558,858592,858708,859039,859351,859442,859532,859879,860338,860539,860961,861176,861521,862213,862336,862542,8","1393,1395",NULL,"AAR18078,CAA41086",NIH Initiatives,"10838414,12895416,15930388,16611089,17699688,18308824",0,10.1016/s0896-6273(03)00461-6|10.1113/jphysiol.2007.150078|10.1152/jn.00824.2007|10.1177/108705719900400206|10.1523/jneurosci.0955-05.2005|10.2174/187152706776359619,NULL,"CAA41086,Q13324",NULL
602156,100,Novartis GNF Liver Stage Dataset: Malariabox Annotation,"Most malaria drug development focuses on parasite stages detected in red-blood cells even though to achieve eradication next-generation drugs active against both erythrocytic and exo-erythrocytic forms would be preferable. We applied a multifactorial approach to a set of >4,000 commercially available compounds with previously demonstrated blood stage activity (IC50 < 1 uM), and identified chemical scaffolds with potent activity against both forms. From this screen, we identified an imidazolopiperazine scaff",54,GNF / Scripps  Winzeler lab,Plasmodium_liver_antimalarial_discovery,20111213,"237,1065,1221,1329,1691,2019,2071,2165,2199,2240,2247,2353,2719,2757,2798,2812,2957,2993,3197,3468,3602,3649,3979,4046,4235,4335,4626,4735,4930,4932,4993,5186,5417,5649,5953,6197,6311,6764,7572,7680,8245,8548,8549,8934,9049,9284,9426,10170,10219,10304,10841,13076,13487,14169,18867,19009,19931,21396,21651,24650,29636,31549,31783,36332,37369,42258,42876,44259,48128,51196,51703,63708,64949,65237,66541,67947,68841,68928,70848,71386,71826,72323,72378,72519,72812,73293,73549,74396,74450,75463,77227,79513,83979,84","131331949,131331950,131331951,131331952,131331953,131331954,131331955,131331956,131331957,131331958,131331959,131331960,131331961,131331962,131331963,131331964,131331965,131331966,131331967,131331968,131331969,131331970,131331971,131331972,131331973,131331974,131331975,131331976,131331977,131331978,131331979,131331980,131331981,131331982,131331983,131331984,131331985,131331986,131331987,131331988,131331989,131331990,131331991,131331992,131331993,131331994,131331995,131331996,131331997,131331998,131331999,13",NULL,NULL,NULL,Legacy Depositors|Research and Development,22096101,0,10.1126/science.1211936,NULL,NULL,NULL
602472,1,Single concentration confirmation of uHTS hits for cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: IR21 NS061743-01_|_Assay Provider:  Rangan Maitra, Ph.D., RTI International University_|__|_The inflammatory response in Cystic Fibrosis (CF) is a complex interplay between several factors.  It has been suggested that pro-inflammatory cytokines are elevated in the ep",14,Burnham Center for Chemical Genomics,SBCCG-A833-CF-PAF-Inh-CP-Assay,20120322,"1689,2363,2471,3037,3126,3381,3820,4499,4865,5092,5426,5743,6197,6215,6436,6769,10631,15209,16490,16543,16547,20502,21718,27648,29893,32798,34920,41946,64971,71386,73427,77917,80481,82153,85555,87372,95587,97637,97865,98059,100037,140230,161167,163751,216328,219325,221032,223708,227494,228252,228947,230798,231435,231744,231773,233068,233768,234165,235262,236584,237065,238735,240936,244087,245736,246322,250948,252247,253602,254824,255330,257278,257455,259213,267221,267860,268761,269217,270221,270811,270853,2","844482,844574,844670,844782,845318,846220,849081,850126,851697,851703,855516,855535,855541,855624,855663,855669,855675,855857,855862,855869,855884,855991,856044,856076,856542,856750,857125,857211,857562,857755,858244,858674,859315,859461,860058,860288,860575,860594,860906,861070,861154,861167,861415,861516,861637,861945,861949,862514,863162,863937,864478,864609,864658,865636,3711912,3712347,3712888,3713822,3713893,3714362,3714418,3714463,3715175,3716103,3716687,3716773,3716833,3716906,3717942,4240489,424064",1080,NULL,NP_000483,NIH Initiatives,"10400842,15661927,16239509,7544594",0,10.1016/s0091-6749(99)70116-8|10.1128/iai.73.11.7151-7160.2005|10.1165/ajrcmb.13.3.7544594|10.4049/jimmunol.174.3.1638,5.6.1.6,P13569,NULL
602292,2,qHTS for antagonists of the Thyroid Stimulation Hormone Receptor: Hit Validation in Primary Screen,The thyroid-stimulating hormone receptor (TSHR) is a member of the 7 trans-membrane-spanning receptor (7TMR) family of cell surface receptors. TSHR-mediated hyperthyroidism is important in thyroid pathology. The development of small molecule antagonists of TSHR may lead to therapeutic approaches for TSHR-mediated hyperthyroidism caused by constitutively activating mutations or stimulating auto-antibodies associated with Graves' disease. Graves' disease is the leading cause of hyperthyroidism and is caused b,2,National Center for Advancing Translational Sciences (NCATS),TSH720,20120305,"1329,3037,3598,4477,6099,6185,15284,16547,19495,20992,26695,31475,42574,63382,63711,67133,67238,67275,69448,73157,75253,77955,95237,234934,254577,255085,256444,260556,262093,282274,282594,313619,323616,351549,373692,375895,447980,470952,470958,565049,567207,569453,570353,578247,587037,617614,628678,631552,644937,645992,646364,646653,647253,647343,647427,649180,650589,652568,652605,652727,652855,653741,653912,654707,654892,655875,657796,658475,658573,658797,659191,659390,659453,659551,659623,659988,660054,66","842666,843689,844054,844333,844923,845005,845090,845870,846729,846787,848160,848955,850057,850097,850217,850341,851181,851341,852277,853221,855876,856436,857119,857223,857446,857840,858033,858098,858199,858283,858680,858748,859343,860938,861727,862116,862137,862844,863379,863585,863619,863668,864316,864952,3711344,3711546,3711570,3712328,3712339,3712558,3712813,3713100,3713618,3713904,3714391,3714399,3714415,3714715,3715045,3715198,3715595,3715942,3715971,3716090,3716102,3716690,3716867,3716868,3716944,3717",7253,NULL,AAI27629,Governmental Organizations|NIH Initiatives,"18216391,19592511,20427476",0,10.1073/pnas.0904506106|10.1177/1087057107313786|10.1210/en.2010-0199,NULL,AAI27629,NULL
602296,2,Sustained Induction of HSF-1 Measured in Cell-Based System Using Plate Reader - 2038-07_Activator_Dose_CherryPick_Activity,"Keywords: Heat Shock Factor-1 (HSF-1), Induction, Stress Response, NIH3T3, Luminescence_|__|_Assay Overview:_|__|_Confirmation testing of small molecules originally identified in PubChem Bioassay AID 2098 as increasing expression of a firefly luciferase under the control of a HSF-1 response element in modified NIH3T3 cells. This assay sought to address 3 specific aims._|__|_i.Are these compounds capable of long-term (48hr) induction of a HSF-1 reporter, compared to the shorter interval (8hr) originally assa",31,Broad Institute,2038-07_Activator_Dose_CherryPick_Activity,20120308,"4534,8321,16543,22780,34617,69314,72402,72512,81124,92249,163121,179485,220846,224524,234249,238775,247304,250997,266203,267330,272364,272567,285054,285164,295350,304906,321213,329163,348698,365016,371687,373692,478805,536451,543159,543990,548573,561606,572406,572680,587596,590107,596095,598633,612628,613215,618001,619222,620060,621551,621898,621973,628678,638439,643392,644592,645773,645800,646079,646564,646746,646860,647259,647949,648129,648162,648208,648283,648349,648491,648878,649076,649300,649371,649381","842333,843246,843478,843506,843774,844245,844420,844533,844929,845593,845767,845800,845849,845874,845913,845981,846119,846364,846490,846535,846682,846907,846974,846986,847254,847366,847506,847745,848307,848384,848635,848666,848914,849046,849756,849805,850047,850562,850662,850999,851090,851166,851590,851792,851979,852203,852503,852688,853043,853424,853558,853591,853676,855767,856143,856159,856443,856474,856600,856973,857212,857259,857271,857304,857346,857472,857745,857860,857953,858026,858301,858581,858603,8",15499,Cell-based,AAH94064,NIH Initiatives,NULL,0,NULL,NULL,AAH94064,NULL
602428,1,Single concentration confirmation of uHTS antagonist hits from Gli-SUFU in a luminescent reporter assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network(MLPCN)_|_Grant Number: 1R03MH094195-01_|_Assay Provider: James Chen, Ph.D.,Stanford University, Stanford California_|__|_The Hh pathway plays a critical role in the patterning of certain embryonic tissues and contributes to their neoplastic transformation later in life.  Hh signaling regulates c",14,Burnham Center for Chemical Genomics,SBCCG-A805-Gli-Sufu-Antagonist-CP-Assay,20120320,"2363,3197,4544,5043,5311,5396,9283,10156,12446,12498,20279,25050,29893,31276,43640,54368,55498,57162,57163,65237,67275,69765,72438,72699,72705,72827,82498,91754,97811,97866,100037,110119,131182,156816,174326,175533,198909,209253,215090,230508,232146,233874,237621,238745,240980,243725,245151,247955,253602,255762,260168,260261,261361,262649,264884,268760,275781,284708,290486,293603,294920,299645,300573,310860,322539,332697,334334,339411,341880,347381,354677,358793,360558,368337,371346,380164,381392,382054,382","842321,842332,842392,842444,842446,842563,842952,842959,843298,843335,843683,843813,844118,844269,844450,844586,844634,844867,844876,845126,845160,845525,846246,846265,846304,847393,847548,848231,848536,848734,849061,849320,849876,850139,850334,850589,851317,851517,851844,851924,852008,852275,852388,852563,852761,853152,853296,853358,853376,853477,855966,856098,856330,856388,856521,856522,856526,856536,856690,856815,857056,857195,857423,857425,857461,857655,857789,857931,858026,858079,858147,858154,858189,8",14632,NULL,BAA85004,NIH Initiatives,"11283316,12202832,12391318,12414725,15380514,17353198,19081070,19136624,19189974,19469545,19522463,19716296,19726763,19726788,19797115,19859563,20493695",0,10.1016/j.bmcl.2009.08.049|10.1016/j.bmcl.2010.04.110|10.1016/j.ccr.2004.08.019|10.1016/j.devcel.2008.11.010|10.1021/jm900305z|10.1021/jm900309j|10.1056/nejmoa0905360|10.1073/pnas.182542899|10.1074/jbc.m109.059964|10.1074/jbc.m611089200|10.1074/jbc.m806233200|10.1101/gad.1025302|10.1101/gad.1753809|10.1126/science.1073733|10.1126/science.1179386|10.1146/annurev.neuro.24.1.385|10.1371/journal.pone.0007608,NULL,BAA85004,NULL
602441,2,qHTS for antagonists of the Thyroid Stimulation Hormone Receptor: Hit Validation in Parental Cell Line,The thyroid-stimulating hormone receptor (TSHR) is a member of the 7 trans-membrane-spanning receptor (7TMR) family of cell surface receptors. TSHR-mediated hyperthyroidism is important in thyroid pathology. The development of small molecule antagonists of TSHR may lead to therapeutic approaches for TSHR-mediated hyperthyroidism caused by constitutively activating mutations or stimulating auto-antibodies associated with Graves' disease. Graves' disease is the leading cause of hyperthyroidism and is caused b,2,National Center for Advancing Translational Sciences (NCATS),TSHR722,20120321,"1329,3037,3598,4477,6099,6185,15284,16547,19495,20992,26695,31475,42574,63382,63711,67133,67238,67275,69448,73157,75253,77955,95237,234934,254577,255085,256444,260556,262093,282274,282594,313619,323616,351549,373692,375895,447980,470952,470958,565049,567207,569453,570353,578247,587037,617614,628678,631552,644937,645992,646364,646653,647253,647343,647427,649180,650589,652568,652605,652727,652855,653741,653912,654707,654892,655875,657796,658475,658573,658797,659191,659390,659453,659551,659623,659988,660054,66","842666,843689,844054,844333,844923,845005,845090,845870,846729,846787,848160,848955,850057,850097,850217,850341,851181,851341,852277,853221,855876,856436,857119,857223,857446,857840,858033,858098,858199,858283,858680,858748,859343,860938,861727,862116,862137,862844,863379,863585,863619,863668,864316,864952,3711344,3711546,3711570,3712328,3712339,3712558,3712813,3713100,3713618,3713904,3714391,3714399,3714415,3714715,3715045,3715198,3715595,3715942,3715971,3716090,3716102,3716690,3716867,3716868,3716944,3717",7253,NULL,AAI27629,Governmental Organizations|NIH Initiatives,"18216391,19592511,20427476",0,10.1073/pnas.0904506106|10.1177/1087057107313786|10.1210/en.2010-0199,NULL,AAI27629,NULL
602192,1,Luminescence-based cell-based high throughput confirmation assay for biased ligands (agonists) of the melanocortin 4 receptor (MC4R),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRISMC)_|_Center Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Scott DeWire, Trevena Inc_|_Network: Molecular Library Probe Production Center Network (MLPCN)_|_Grant Proposal Number: 1 RC2 MH090877-01_|_Grant Proposal PI: Scott DeWire, Trevena Inc_|_External Assay ID: MC4R_AG_LUMI_1536_3X%ACT CRUN_|__|_Name: Luminescence-based cell-based high throughput confirmation assay for biased ligands (agonists",5,The Scripps Research Institute Molecular Screening Center,MC4R_AG_LUMI_1536_3X%ACT CRUN,20120117,"2361,4552,4671,8478,22324,31316,66856,72300,72512,73157,83612,208719,224082,228252,228383,232146,237092,239788,240167,247550,255771,258078,259580,259769,260000,271953,272871,274146,283001,291365,291927,291929,292795,293085,300949,306836,315626,317113,320518,329184,330740,330807,340708,380164,387042,392616,393608,397075,434797,448949,563688,571251,586918,591338,602473,603842,620060,628149,631552,644500,644700,644789,644944,644952,645044,645526,645553,646088,646386,646995,647007,648119,648555,648583,648707,64","842435,842673,842681,842770,843244,843272,843783,844076,844676,845757,846173,846201,846321,846463,847244,847441,847825,847980,848055,848530,849480,849538,849907,849922,850215,850393,850436,850473,850748,851196,851559,851647,851703,852295,852322,852528,852546,852860,853158,855892,856232,856428,857180,858338,858468,858569,859511,860065,860182,860243,860380,860587,860944,861167,861335,861336,861604,861609,861767,861784,861793,862116,862175,862645,862697,862833,863026,863115,863163,863173,863211,863220,863236,8",4160,Cell-based,NP_005903,NIH Initiatives,"17041250,17629964,17959251,18370232,18382464,19648111",0,10.1007/978-1-59745-205-2_6|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2007.06.001|10.1038/nrd2518|10.1074/jbc.m109.039339|10.1074/jbc.m605982200,NULL,P32245,NULL
602293,2,qHTS for antagonists of the Thyroid Stimulation Hormone Receptor: Hit Validation in HTRF Activity in a Luteinizing Hormone Receptor Cell Line,The thyroid-stimulating hormone receptor (TSHR) is a member of the 7 trans-membrane-spanning receptor (7TMR) family of cell surface receptors. TSHR-mediated hyperthyroidism is important in thyroid pathology. The development of small molecule antagonists of TSHR may lead to therapeutic approaches for TSHR-mediated hyperthyroidism caused by constitutively activating mutations or stimulating auto-antibodies associated with Graves' disease. Graves' disease is the leading cause of hyperthyroidism and is caused b,2,National Center for Advancing Translational Sciences (NCATS),TSH721,20120305,"1329,3037,3598,4477,6099,6185,15284,16547,19495,20992,26695,31475,42574,63382,63711,67133,67238,67275,69448,73157,75253,77955,95237,234934,254577,255085,256444,260556,262093,282274,282594,313619,323616,351549,373692,375895,447980,470952,470958,565049,567207,569453,570353,578247,587037,617614,628678,631552,644937,645992,646364,646653,647253,647343,647427,649180,650589,652568,652605,652727,652855,653741,653912,654707,654892,655875,657796,658475,658573,658797,659191,659390,659453,659551,659623,659988,660054,66","842666,843689,844054,844333,844923,845005,845090,845870,846729,846787,848160,848955,850057,850097,850217,850341,851181,851341,852277,853221,855876,856436,857119,857223,857446,857840,858033,858098,858199,858283,858680,858748,859343,860938,861727,862116,862137,862844,863379,863585,863619,863668,864316,864952,3711344,3711546,3711570,3712328,3712339,3712558,3712813,3713100,3713618,3713904,3714391,3714399,3714415,3714715,3715045,3715198,3715595,3715942,3715971,3716090,3716102,3716690,3716867,3716868,3716944,3717",3973,NULL,AAB19917,Governmental Organizations|NIH Initiatives,"18216391,19592511,20427476",0,10.1073/pnas.0904506106|10.1177/1087057107313786|10.1210/en.2010-0199,NULL,P22888,NULL
602259,2,Dose-response confirmation of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network(MLPCN)_|_Grant Number: R03 MH094198-01_|_Assay Provider: Kalle Gehring, Ph.D., McGill University_|__|_The regulation of gene expression is a mechanism that allows cells to respond to growth and proliferation stimuli, stress, and nutrient availability. It is managed at multiple levels: mRNA expre",14,Burnham Center for Chemical Genomics,SBCCG-A779-MLLE-PAM2-DMSO-DR-Assay,20120214,"3082,4112,5392,5394,6697,6706,6868,7333,8323,8515,11061,14710,18311,26964,34312,67062,68433,72146,72781,93572,94986,95699,99985,117746,139030,160157,164981,185146,219926,220284,223293,224037,224641,225181,225407,232704,237490,238013,241217,244091,245206,246783,256430,256561,257242,258743,259084,260098,261131,261413,262134,265905,266923,268524,269862,272582,274911,276581,276685,278092,282598,286497,288481,288875,292250,318160,322539,323999,327044,327045,327583,327585,329023,333953,369539,371593,377971,378196","842199,842517,842936,843005,843097,843448,843770,844174,844258,844976,845770,846399,846445,846450,846465,846488,846800,847428,847547,848529,848616,848842,848871,849018,849130,849276,849509,850264,850272,850355,850633,851022,851304,851707,852008,853071,853369,856487,856608,856658,856661,856678,856758,856828,857066,857091,857633,857675,858078,858661,858713,858882,858899,859287,859355,859357,859490,861563,861765,863588,863905,864032,864471,864508,865568,3711137,3711189,3711437,3711444,3711500,3711794,3711891,3",26986,NULL,NP_002559,NIH Initiatives,"11287632,12762031,19239892,20096703,3313012,3537727",0,10.1016/j.cell.2009.01.042|10.1016/j.jmb.2010.01.032|10.1073/pnas.071024998|10.1101/sqb.2001.66.293|10.1128/mcb.6.8.2932|10.1128/mcb.7.9.3268,NULL,P11940,NULL
602194,1,Counterscreen for biased ligands (agonists) of the melanocortin 4 receptor (MC4R): Luminescence-based cell-based high throughput assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRISMC)_|_Center Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Scott DeWire, Trevena Inc_|_Network: Molecular Library Probe Production Center Network (MLPCN)_|_Grant Proposal Number: 1 RC2 MH090877-01_|_Grant Proposal PI: Scott DeWire, Trevena Inc_|_External Assay ID: OPRM1-OPRD1_AG_LUMI_1536_3X%ACT CSRUN for MC4R AG_|__|_Name: Counterscreen for biased ligands (agonists) of the melanocortin 4 recepto",5,The Scripps Research Institute Molecular Screening Center,OPRM1-OPRD1_AG_LUMI_1536_3X%ACT CSRUN for MC4R AG,20120117,"2361,4552,4671,8478,22324,31316,66856,72300,72512,73157,83612,208719,224082,228252,228383,232146,237092,239788,240167,247550,255771,258078,259580,259769,260000,271953,272871,274146,283001,291365,291927,291929,292795,293085,300949,306836,315626,317113,320518,329184,330740,330807,340708,380164,387042,392616,393608,397075,434797,448949,563688,571251,586918,591338,602473,603842,620060,628149,631552,644500,644700,644789,644944,644952,645044,645526,645553,646088,646386,646995,647007,648119,648555,648583,648707,64","842435,842673,842681,842770,843244,843272,843783,844076,844676,845757,846173,846201,846321,846463,847244,847441,847825,847980,848055,848530,849480,849538,849907,849922,850215,850393,850436,850473,850748,851196,851559,851647,851703,852295,852322,852528,852546,852860,853158,855892,856232,856428,857180,858338,858468,858569,859511,860065,860182,860243,860380,860587,860944,861167,861335,861336,861604,861609,861767,861784,861793,862116,862175,862645,862697,862833,863026,863115,863163,863173,863211,863220,863236,8","4985,4988",Cell-based,"NP_000902,NP_000905",NIH Initiatives,"17041250,17629964,17959251,18370232,18382464,19648111",0,10.1007/978-1-59745-205-2_6|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2007.06.001|10.1038/nrd2518|10.1074/jbc.m109.039339|10.1074/jbc.m605982200,NULL,"P35372,P41143",NULL
602211,2,Dose response confirmation of uHTS hits for small molecule modulators of myocardial damage - Set 2,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 DA031671-01_|_Assay Provider: Richard Kitsis, M.D., Albert Einstein College of Medicine of Yeshiva University_|__|_Myocardial infarction (""heart attack"") is one of the most common causes of morbidity and mortality in the United States and the world1. It is pre",14,Burnham Center for Chemical Genomics,SBCCG-A771-H9c2-Inh-DMSO-DR-Assay-2,20120123,"52070,136417,235496,248116,248118,248119,276233,308157,323484,387075,456869,494031,645256,645493,645736,646676,646757,646987,647168,647606,647662,647945,648499,650811,651495,653833,654771,655898,658526,659111,660704,661498,662340,662418,662626,662681,662839,662870,662985,663015,663031,665114,665215,665438,665522,665687,665693,666440,675349,687924,740861,790478,836595,849564,849577,856280,906418,989262,990758,992707,1025945,1068314,1076561,1088395,1096252,1096807,1105606,1105743,1132520,1136282,1147549,11648","842978,843209,843439,844356,844431,844837,845266,845318,845550,845589,846128,848365,849029,851270,852158,857170,857755,857783,859411,860191,861071,861156,861381,861437,861599,861632,861756,861788,861805,862293,863162,863861,863960,864190,864275,864440,864446,3711493,3712202,3712633,3714080,3714715,3714933,3715423,3716365,3717212,3717876,4241659,4242734,4243263,4244445,4244650,4245738,4245784,4246057,4246203,4247541,4248161,4249345,4249660,4250640,4250701,4251419,4254525,4255791,4257319,4258413,4258517,42586",NULL,NULL,NULL,NIH Initiatives,"12517460,14744432,15800626,19218262,2014866",0,10.1016/s0092-8674(04)00046-7|10.1016/s0140-6736(03)12113-7|10.1038/nature03317|10.1136/hrt.2007.139493|10.2105/ajph.81.5.628,NULL,NULL,NULL
602210,2,Dose response confirmation of uHTS hits for small molecule modulators of myocardial damage using 2-dexoy-glucose - Set 2,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 DA031671-01_|_Assay Provider: Richard Kitsis, M.D., Albert Einstein College of Medicine of Yeshiva University_|__|_Myocardial infarction (""heart attack"") is one of the most common causes of morbidity and mortality in the United States and the world1. It is pre",14,Burnham Center for Chemical Genomics,SBCCG-A772-H9c2-Inh-2DG-DR-Assay-2,20120123,"52070,136417,235496,248116,248118,248119,276233,308157,323484,387075,456869,494031,645256,645493,645736,646676,646757,646987,647168,647606,647662,647945,648499,650811,651495,653833,654771,655898,658526,659111,660704,661498,662340,662418,662626,662681,662839,662870,662985,663015,663031,665114,665215,665438,665522,665687,665693,666440,675349,687924,740861,790478,836595,849564,849577,856280,906418,989262,990758,992707,1025945,1068314,1076561,1088395,1096252,1096807,1105606,1105743,1132520,1136282,1147549,11648","842978,843209,843439,844356,844431,844837,845266,845318,845550,845589,846128,848365,849029,851270,852158,857170,857755,857783,859411,860191,861071,861156,861381,861437,861599,861632,861756,861788,861805,862293,863162,863861,863960,864190,864275,864440,864446,3711493,3712202,3712633,3714080,3714715,3714933,3715423,3716365,3717212,3717876,4241659,4242734,4243263,4244445,4244650,4245738,4245784,4246057,4246203,4247541,4248161,4249345,4249660,4250640,4250701,4251419,4254525,4255791,4257319,4258413,4258517,42586",NULL,NULL,NULL,NIH Initiatives,"12517460,14744432,15800626,19218262,2014866",0,10.1016/s0092-8674(04)00046-7|10.1016/s0140-6736(03)12113-7|10.1038/nature03317|10.1136/hrt.2007.139493|10.2105/ajph.81.5.628,NULL,NULL,NULL
602199,2,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation in Primary Screen,"The vitamin D receptor (VDR) is a ligand-activated transcription factor and is partially responsible for the regulation of the endocrine system. This includes the transcriptional regulation of genes involved in the production of the parathyroid hormone (PTH) and the regulation of the blood calcium level. High levels of PHT can cause hypercalcemia in the case of primary and tertiary hyperparathyroidism. The VDR-mediated gene regulation, activated by its ligand 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3), is gove",2,National Center for Advancing Translational Sciences (NCATS),VDR201,20120118,"1609,1880,3885,4485,4499,4594,4641,6763,7573,11106,16347,34772,115936,160254,176406,205491,219296,254021,254824,261253,282594,307157,313619,323616,342561,367783,369538,369539,371271,375895,385252,388579,395402,406009,439647,496348,573747,610143,614841,630991,637760,638276,638439,651191,651962,653192,655335,658778,659095,660829,663900,665480,667215,667381,671836,672376,674819,680344,680345,682361,684123,685684,686852,691106,695112,695637,707439,711175,712700,718402,726569,731724,731728,739872,743706,745143,7","843534,847157,847255,848733,849468,850662,853078,855901,856251,856726,857269,857427,857738,857788,858298,858560,859533,863619,864233,865959,866122,3712084,3712150,3713060,3713350,3715069,3716039,3717614,4239178,4240624,4241330,4241357,4241889,4242461,4243283,4244717,4245498,4246228,4247680,4247922,4247943,4248359,4248807,4249294,4250773,4251920,4252330,4254739,4255874,4257991,4258563,4258902,4259886,4260021,4260621,4261270,4262481,4263674,4263828,4265405,7964739,7966982,7967797,7968521,7970106,7972100,79747",7421,NULL,NP_001017535,Governmental Organizations|NIH Initiatives,10678179,0,10.1016/s1097-2765(00)80413-x,NULL,P11473,NULL
602330,1,Single concentration validation of uHTS RPN11 inhibitor hits using a MMP-2 Fluorescence assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH094180-01_|_Assay Provider: Dr. Raymond Deshaies, California Institute of Technology, Pasadena, CA_|__|_Protein modification by the attachment of ubiquitin to cellular proteins is a key mechanism in regulating many cellular and physiological processes. Ubiqui",14,Burnham Center for Chemical Genomics,SBCCG-A792-Rpn11-MMP-2-CTR-CP-Assay,20120308,"2722,3564,7120,42574,52210,65558,72571,73677,81704,88733,96212,152086,159809,160510,165308,190396,227311,230550,231112,232780,238285,238958,240812,242313,248413,252617,258436,261397,265337,268605,270995,274579,275253,276651,292550,306924,315531,322448,327645,328867,335352,340715,371271,380164,386296,386355,392616,392758,395175,395179,398175,456869,461310,586333,587597,606590,607388,632654,638296,644466,644478,644688,644818,644935,645482,645641,645903,646378,646391,646524,646742,646857,647102,647535,647594,6","842211,842223,842423,842548,842595,843198,843351,843808,844068,844212,844530,844770,845193,845760,846551,846663,847794,848175,849279,849485,849853,851037,851647,851766,853388,853413,856459,856464,856629,857030,857247,857367,857374,857465,857466,857585,857599,857681,857694,857711,857713,857732,857733,858027,858473,858517,858569,858615,858948,859359,859497,859527,859578,859640,860452,860477,860630,860662,860916,861336,862062,862415,862500,862504,863758,863819,864016,864225,864274,864303,864736,864838,864859,8",4313,NULL,NP_004521,NIH Initiatives,"10619848,12183636,12183637,12353037,14744430,14990998,2538923",0,10.1016/s0092-8674(03)01074-2|10.1038/nature01071|10.1038/nrm1336|10.1093/emboj/19.1.94|10.1126/science.1075898|10.1126/science.1075901|10.1126/science.2538923,3.4.24.24,P08253,NULL
602385,1,Single concentration confirmation of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA031091-01A1_|_Assay Provider: Dr. James Stivers, Johns Hopkins University, Baltimore, MD_|__|_Hypermethylation of CpG dinucleotides in promoter regions of tumor suppressor genes by DNA 5-C-MTases is an important hallmark of human cancers [1-3]. Such",14,Burnham Center for Chemical Genomics,SBCCG-A800-DNMT1-Inh-CP-Assay,20120313,"253,4728,5074,6024,6029,6697,7550,7571,9878,9922,10168,10187,16317,17534,20502,21307,22641,64971,66671,70837,80417,80771,97509,97688,100058,122734,139991,143191,182791,185819,186169,188677,199391,202512,207753,217907,219402,224275,224560,224922,229999,230550,236275,240812,242262,243462,244240,245150,245744,245769,247228,248874,251979,253353,255595,258692,263534,265171,265522,266200,269039,273110,273590,275409,276150,277067,279596,280615,280616,280618,281416,282261,285026,286873,287282,288481,292921,296527,2","842389,842471,842502,842604,842894,842970,843005,843306,843664,843770,844690,844705,845872,845890,846098,847187,847191,847444,847763,848379,848397,848612,849279,849379,849761,850043,850249,850646,850681,851427,851495,851848,855713,855879,856062,856125,856485,856687,856717,856755,857345,857465,857486,857585,857661,857713,857868,857910,857981,858060,858533,858548,858840,859030,859124,859291,859341,859770,860182,860452,860594,860916,860990,861648,861705,862017,862070,862523,862581,862797,862800,862867,862944,8",1786,NULL,NP_001370,NIH Initiatives,"11751372,11960994,12154398,15491775,16234563,16341238,17485372,17998812,18076941,18246412,18314485",0,10.1007/s10555-008-9118-y|10.1016/j.juro.2007.09.038|10.1016/j.tips.2004.09.004|10.1038/ncponc0346|10.1038/sj.onc.1205597|10.1074/jbc.m203009200|10.1093/jnci/dji311|10.1158/1541-7786.mcr-07-0373|10.2741/2385|10.4161/epi.1.1.2375,2.1.1.37,P26358,NULL
602333,1,Single concentration validation of uHTS RPN11 inhibitor hits using a Thrombin Fluorescence Polarization assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH094180-01_|_Assay Provider: Dr. Raymond Deshaies, California Institute of Technology, Pasadena, CA_|__|_Protein modification by the attachment of ubiquitin to cellular proteins is a key mechanism in regulating many cellular and physiological processes. Ubiqui",14,Burnham Center for Chemical Genomics,SBCCG-A793-Rpn11-Thrombin-CTR-CP-Assay,20120308,"2722,3564,7120,42574,52210,65558,72571,73677,81704,88733,96212,152086,159809,160510,165308,190396,227311,230550,231112,232780,238285,238958,240812,242313,248413,252617,258436,261397,265337,268605,270995,274579,275253,276651,292550,306924,315531,322448,327645,328867,335352,340715,371271,380164,386296,386355,392616,392758,395175,395179,398175,456869,461310,586333,587597,606590,607388,632654,638296,644466,644478,644688,644818,644935,645482,645641,645903,646378,646391,646524,646742,646857,647102,647535,647594,6","842211,842223,842423,842548,842595,843198,843351,843808,844068,844212,844530,844770,845193,845760,846551,846663,847794,848175,849279,849485,849853,851037,851647,851766,853388,853413,856459,856464,856629,857030,857247,857367,857374,857465,857466,857585,857599,857681,857694,857711,857713,857732,857733,858027,858473,858517,858569,858615,858948,859359,859497,859527,859578,859640,860452,860477,860630,860662,860916,861336,862062,862415,862500,862504,863758,863819,864016,864225,864274,864303,864736,864838,864859,8",280685,NULL,DAA21754,NIH Initiatives,"10619848,12183636,12183637,12353037,14744430,14990998,2538923",0,10.1016/s0092-8674(03)01074-2|10.1038/nature01071|10.1038/nrm1336|10.1093/emboj/19.1.94|10.1126/science.1075898|10.1126/science.1075901|10.1126/science.2538923,NULL,P00735,NULL
602387,1,Single concentration validation of uHTS inhibitor hits from DNMT1 for spectral interference using a Fluorescent Molecular Beacon assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA031091-01A1_|_Assay Provider: Dr. James Stivers, Johns Hopkins University, Baltimore, MD_|__|_Hypermethylation of CpG dinucleotides in promoter regions of tumor suppressor genes by DNA 5-C-MTases is an important hallmark of human cancers [1-3]. Such",14,Burnham Center for Chemical Genomics,SBCCG-A801-DNMT1-Inh-CP-Interference-Assay,20120313,"253,4728,5074,6024,6029,6697,7550,7571,9878,9922,10168,10187,16317,17534,20502,21307,22641,64971,66671,70837,80417,80771,97509,97688,100058,122734,139991,143191,182791,185819,186169,188677,199391,202512,207753,217907,219402,224275,224560,224922,229999,230550,236275,240812,242262,243462,244240,245150,245744,245769,247228,248874,251979,253353,255595,258692,263534,265171,265522,266200,269039,273110,273590,275409,276150,277067,279596,280615,280616,280618,281416,282261,285026,286873,287282,288481,292921,296527,2","842389,842471,842502,842604,842894,842970,843005,843306,843664,843770,844690,844705,845872,845890,846098,847187,847191,847444,847763,848379,848397,848612,849279,849379,849761,850043,850249,850646,850681,851427,851495,851848,855713,855879,856062,856125,856485,856687,856717,856755,857345,857465,857486,857585,857661,857713,857868,857910,857981,858060,858533,858548,858840,859030,859124,859291,859341,859770,860182,860452,860594,860916,860990,861648,861705,862017,862070,862523,862581,862797,862800,862867,862944,8",NULL,NULL,NULL,NIH Initiatives,"11751372,11960994,12154398,15491775,16234563,16341238,17485372,17998812,18076941,18246412,18314485",0,10.1007/s10555-008-9118-y|10.1016/j.juro.2007.09.038|10.1016/j.tips.2004.09.004|10.1038/ncponc0346|10.1038/sj.onc.1205597|10.1074/jbc.m203009200|10.1093/jnci/dji311|10.1158/1541-7786.mcr-07-0373|10.2741/2385|10.4161/epi.1.1.2375,NULL,NULL,NULL
602200,2,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Fluorescein Assay,"The vitamin D receptor (VDR) is a ligand-activated transcription factor and is partially responsible for the regulation of the endocrine system. This includes the transcriptional regulation of genes involved in the production of the parathyroid hormone (PTH) and the regulation of the blood calcium level. High levels of PHT can cause hypercalcemia in the case of primary and tertiary hyperparathyroidism. The VDR-mediated gene regulation, activated by its ligand 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3), is gove",2,National Center for Advancing Translational Sciences (NCATS),VDR202,20120118,"1609,1880,3885,4485,4499,4594,4641,6763,7573,11106,16347,34772,115936,160254,176406,205491,219296,254021,254824,261253,282594,307157,313619,323616,342561,367783,369538,369539,371271,375895,385252,388579,395402,406009,439647,496348,573747,610143,614841,630991,637760,638276,638439,651191,651962,653192,655335,658778,659095,660829,663900,665480,667215,667381,671836,672376,674819,680344,680345,682361,684123,685684,686852,691106,695112,695637,707439,711175,712700,718402,726569,731724,731728,739872,743706,745143,7","843534,847157,847255,848733,849468,850662,853078,855901,856251,856726,857269,857427,857738,857788,858298,858560,859533,863619,864233,865959,866122,3712084,3712150,3713060,3713350,3715069,3716039,3717614,4239178,4240624,4241330,4241357,4241889,4242461,4243283,4244717,4245498,4246228,4247680,4247922,4247943,4248359,4248807,4249294,4250773,4251920,4252330,4254739,4255874,4257991,4258563,4258902,4259886,4260021,4260621,4261270,4262481,4263674,4263828,4265405,7964739,7966982,7967797,7968521,7970106,7972100,79747",7421,NULL,NP_001017535,Governmental Organizations|NIH Initiatives,10678179,0,10.1016/s1097-2765(00)80413-x,NULL,P11473,NULL
602368,2,Dose response confirmation of uHTS RPN11 inhibitor hits in a Fluorescence Polarization assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH094180-01_|_Assay Provider: Dr. Raymond Deshaies, California Institute of Technology, Pasadena, CA_|__|_Protein modification by the attachment of ubiquitin to cellular proteins is a key mechanism in regulating many cellular and physiological processes. Ubiqui",14,Burnham Center for Chemical Genomics,SBCCG A794-Rpn11-Inh-DMSO-DR-Assay,20120312,"7120,52210,159809,248413,258436,265337,275253,380164,386355,392616,395175,638296,644466,644818,650604,658948,660805,672465,676300,690946,697577,698490,726408,745301,780975,790785,860123,868611,920321,942378,948551,1005290,1025943,1028188,1108983,1115796,1134800,1151133,1154835,1202408,1206896,1209375,1214087,1214175,1240113,1244329,1247094,1255215,1261721,1266032,1284790,1285929,1295575,1309362,1328767,1360413,1370241,1371564,1381590,1566198,1571543,1571545,1580366,1584574,1625680,1632449,1745927,1746420,17","842211,842548,848175,857367,857599,858615,860477,3711140,3715215,3716055,3716608,3717960,4244331,4246822,4249441,4252418,4254914,4256097,4260569,4261830,7966121,7970184,7970829,7970974,7974684,7977237,14718894,14719210,14720891,14730606,14731409,14732157,14738173,14738461,14740573,14741605,14742128,14742942,14742951,14744425,14744522,14747145,16952709,16953035,16953453,16953658,16953881,17385880,17385926,17386050,17386181,17387017,17401143,17401604,17401691,17401726,17403580,17406614,17406951,17408110,17408",10213,NULL,AAH09524,NIH Initiatives,"10619848,12183636,12183637,12353037,14744430,14990998,2538923",0,10.1016/s0092-8674(03)01074-2|10.1038/nature01071|10.1038/nrm1336|10.1093/emboj/19.1.94|10.1126/science.1075898|10.1126/science.1075901|10.1126/science.2538923,NULL,AAH09524,NULL
602201,2,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Texas Red Assay,"The vitamin D receptor (VDR) is a ligand-activated transcription factor and is partially responsible for the regulation of the endocrine system. This includes the transcriptional regulation of genes involved in the production of the parathyroid hormone (PTH) and the regulation of the blood calcium level. High levels of PHT can cause hypercalcemia in the case of primary and tertiary hyperparathyroidism. The VDR-mediated gene regulation, activated by its ligand 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3), is gove",2,National Center for Advancing Translational Sciences (NCATS),VDR203,20120118,"1609,1880,3885,4485,4499,4594,4641,6763,7573,11106,16347,34772,115936,160254,176406,205491,219296,254021,254824,261253,282594,307157,313619,323616,342561,367783,369538,369539,371271,375895,385252,388579,395402,406009,439647,496348,573747,610143,614841,630991,637760,638276,638439,651191,651962,653192,655335,658778,659095,660829,663900,665480,667215,667381,671836,672376,674819,680344,680345,682361,684123,685684,686852,691106,695112,695637,707439,711175,712700,718402,726569,731724,731728,739872,743706,745143,7","843534,847157,847255,848733,849468,850662,853078,855901,856251,856726,857269,857427,857738,857788,858298,858560,859533,863619,864233,865959,866122,3712084,3712150,3713060,3713350,3715069,3716039,3717614,4239178,4240624,4241330,4241357,4241889,4242461,4243283,4244717,4245498,4246228,4247680,4247922,4247943,4248359,4248807,4249294,4250773,4251920,4252330,4254739,4255874,4257991,4258563,4258902,4259886,4260021,4260621,4261270,4262481,4263674,4263828,4265405,7964739,7966982,7967797,7968521,7970106,7972100,79747",7421,NULL,NP_001017535,Governmental Organizations|NIH Initiatives,10678179,0,10.1016/s1097-2765(00)80413-x,NULL,P11473,NULL
602202,2,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Beta-Lactamase Assay,"The vitamin D receptor (VDR) is a ligand-activated transcription factor and is partially responsible for the regulation of the endocrine system. This includes the transcriptional regulation of genes involved in the production of the parathyroid hormone (PTH) and the regulation of the blood calcium level. High levels of PHT can cause hypercalcemia in the case of primary and tertiary hyperparathyroidism. The VDR-mediated gene regulation, activated by its ligand 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3), is gove",2,National Center for Advancing Translational Sciences (NCATS),VDR204,20120118,"1609,1880,3885,4485,4499,4594,4641,6763,7573,11106,16347,34772,115936,160254,176406,205491,219296,254021,254824,261253,282594,307157,313619,323616,342561,367783,369538,369539,371271,375895,385252,388579,395402,406009,439647,496348,573747,610143,614841,630991,637760,638276,638439,651191,651962,653192,655335,658778,659095,660829,663900,665480,667215,667381,671836,672376,674819,680344,680345,682361,684123,685684,686852,691106,695112,695637,707439,711175,712700,718402,726569,731724,731728,739872,743706,745143,7","843534,847157,847255,848733,849468,850662,853078,855901,856251,856726,857269,857427,857738,857788,858298,858560,859533,863619,864233,865959,866122,3712084,3712150,3713060,3713350,3715069,3716039,3717614,4239178,4240624,4241330,4241357,4241889,4242461,4243283,4244717,4245498,4246228,4247680,4247922,4247943,4248359,4248807,4249294,4250773,4251920,4252330,4254739,4255874,4257991,4258563,4258902,4259886,4260021,4260621,4261270,4262481,4263674,4263828,4265405,7964739,7966982,7967797,7968521,7970106,7972100,79747",7421,NULL,NP_001017535,Governmental Organizations|NIH Initiatives,10678179,0,10.1016/s1097-2765(00)80413-x,NULL,P11473,NULL
602369,2,Dose Response validation of uHTS RPN11 inhibitor hits using a Thrombin Fluorescence Polarization assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH094180-01_|_Assay Provider: Dr. Raymond Deshaies, California Institute of Technology, Pasadena, CA_|__|_Protein modification by the attachment of ubiquitin to cellular proteins is a key mechanism in regulating many cellular and physiological processes. Ubiqui",14,Burnham Center for Chemical Genomics,SBCCG-A799-Rpn11-Thrombin-CTR-DMSO-DR-Assay,20120312,"7120,52210,159809,248413,258436,265337,275253,380164,386355,392616,395175,638296,644466,644818,650604,658948,660805,672465,676300,690946,697577,698490,726408,745301,780975,790785,860123,868611,920321,942378,948551,1005290,1025943,1028188,1108983,1115796,1134800,1151133,1154835,1202408,1206896,1209375,1214087,1214175,1240113,1244329,1247094,1255215,1261721,1266032,1284790,1285929,1295575,1309362,1328767,1360413,1370241,1371564,1381590,1566198,1571543,1571545,1580366,1584574,1625680,1632449,1745927,1746420,17","842211,842548,848175,857367,857599,858615,860477,3711140,3715215,3716055,3716608,3717960,4244331,4246822,4249441,4252418,4254914,4256097,4260569,4261830,7966121,7970184,7970829,7970974,7974684,7977237,14718894,14719210,14720891,14730606,14731409,14732157,14738173,14738461,14740573,14741605,14742128,14742942,14742951,14744425,14744522,14747145,16952709,16953035,16953453,16953658,16953881,17385880,17385926,17386050,17386181,17387017,17401143,17401604,17401691,17401726,17403580,17406614,17406951,17408110,17408",280685,NULL,DAA21754,NIH Initiatives,"10619848,12183636,12183637,12353037,14744430,14990998,2538923",0,10.1016/s0092-8674(03)01074-2|10.1038/nature01071|10.1038/nrm1336|10.1093/emboj/19.1.94|10.1126/science.1075898|10.1126/science.1075901|10.1126/science.2538923,NULL,P00735,NULL
602204,2,qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation using a Cytotoxicity Assay,"The vitamin D receptor (VDR) is a ligand-activated transcription factor and is partially responsible for the regulation of the endocrine system. This includes the transcriptional regulation of genes involved in the production of the parathyroid hormone (PTH) and the regulation of the blood calcium level. High levels of PHT can cause hypercalcemia in the case of primary and tertiary hyperparathyroidism. The VDR-mediated gene regulation, activated by its ligand 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3), is gove",2,National Center for Advancing Translational Sciences (NCATS),VDR205,20120118,"1609,1880,3885,4485,4499,4594,4641,6763,7573,11106,16347,34772,115936,160254,176406,205491,219296,254021,254824,261253,282594,307157,313619,323616,342561,367783,369538,369539,371271,375895,385252,388579,395402,406009,439647,496348,573747,610143,614841,630991,637760,638276,638439,651191,651962,653192,655335,658778,659095,660829,663900,665480,667215,667381,671836,672376,674819,680344,680345,682361,684123,685684,686852,691106,695112,695637,707439,711175,712700,718402,726569,731724,731728,739872,743706,745143,7","843534,847157,847255,848733,849468,850662,853078,855901,856251,856726,857269,857427,857738,857788,858298,858560,859533,863619,864233,865959,866122,3712084,3712150,3713060,3713350,3715069,3716039,3717614,4239178,4240624,4241330,4241357,4241889,4242461,4243283,4244717,4245498,4246228,4247680,4247922,4247943,4248359,4248807,4249294,4250773,4251920,4252330,4254739,4255874,4257991,4258563,4258902,4259886,4260021,4260621,4261270,4262481,4263674,4263828,4265405,7964739,7966982,7967797,7968521,7970106,7972100,79747",NULL,Toxicity,NULL,Governmental Organizations|NIH Initiatives,10678179,0,10.1016/s1097-2765(00)80413-x,NULL,NULL,NULL
602361,2,Dose Response validation of uHTS RPN11 inhibitor hits using a MMP-2 Fluorescence assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH094180-01_|_Assay Provider: Dr. Raymond Deshaies, California Institute of Technology, Pasadena, CA_|__|_Protein modification by the attachment of ubiquitin to cellular proteins is a key mechanism in regulating many cellular and physiological processes. Ubiqui",14,Burnham Center for Chemical Genomics,SBCCG-A798-Rpn11-MMP-2-CTR-DMSO-DR-Assay,20120312,"7120,52210,159809,248413,258436,265337,275253,380164,386355,392616,395175,638296,644466,644818,650604,658948,660805,672465,676300,690946,697577,698490,726408,745301,780975,790785,860123,868611,920321,942378,948551,1005290,1025943,1028188,1108983,1115796,1134800,1151133,1154835,1202408,1206896,1209375,1214087,1214175,1240113,1244329,1247094,1255215,1261721,1266032,1284790,1285929,1295575,1309362,1328767,1360413,1370241,1371564,1381590,1566198,1571543,1571545,1580366,1584574,1625680,1632449,1745927,1746420,17","842211,842548,848175,857367,857599,858615,860477,3711140,3715215,3716055,3716608,3717960,4244331,4246822,4249441,4252418,4254914,4256097,4260569,4261830,7966121,7970184,7970829,7970974,7974684,7977237,14718894,14719210,14720891,14730606,14731409,14732157,14738173,14738461,14740573,14741605,14742128,14742942,14742951,14744425,14744522,14747145,16952709,16953035,16953453,16953658,16953881,17385880,17385926,17386050,17386181,17387017,17401143,17401604,17401691,17401726,17403580,17406614,17406951,17408110,17408",4313,NULL,NP_004521,NIH Initiatives,"10619848,12183636,12183637,12353037,14744430,14990998,2538923",0,10.1016/s0092-8674(03)01074-2|10.1038/nature01071|10.1038/nrm1336|10.1093/emboj/19.1.94|10.1126/science.1075898|10.1126/science.1075901|10.1126/science.2538923,3.4.24.24,P08253,NULL
602356,2,SAR analysis of small molecule Agonists NTR1 in a image based assay set 3,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH089653-01_|_Assay Provider: Dr. Lawrence Barak, Duke University Medical Center_|__|_Addiction leading to abuse should  be treatable by pharmacological approaches, and programs that identify new drugs to treat methamphetamine abuse address an immedia",14,Burnham Center for Chemical Genomics,SBCCG-A790-NTR1-Agonist-DryPowder-Assay-3,20120503,"119192,1230851,1230852,1848580,1866078,1920221,1928753,1941471,1951822,2135349,2135478,2135485,2135541,2135542,2135551,2135553,2135821,2135823,2135839,2135843,2136142,2136147,2136152,2136303,2136476,2136477,2136872,2136873,2136874,2136877,2136878,2136890,2136900,2136901,2136904,2136906,2136907,2136908,2136917,2136935,2137199,2137214,2137215,2137217,4679731,5213858,5311451,6622607,9550477,10339735,20868706,20868713,20868734,20868737,20868739,20868742,20868743,20868745,20868748,20868749,44157038,44157040,4983","104164380,104164381,104164382,104164383,104164384,104164385,104164386,104164387,104164388,104164389,104164395,104164396,104164397,104164399,104164401,104164403,110067513,113635342,113635343,113635344,113635345,113635346,113635347,113635348,113635349,117695568,117695569,117695570,123050379,123050380,123050381,123050382,123050383,123050384,123050385,123050386,124360461,124360466,124360467,124360468,124360477,124360478,124360479,124360481,124360491,124360492,124360493,124360494,124360495,124360496,124360497,12",4923,NULL,NP_002522,NIH Initiatives,"18547468,7754478,8380498,8808171,9160965",0,10.1073/pnas.90.1.65|10.1111/j.1472-8206.1995.tb00528.x|10.1111/j.1749-6632.1997.tb46151.x|10.1177/039463200802100201,NULL,P30989,NULL
602318,1,Single concentration confirmation of uHTS inhibitor hits from RPN11 in a Fluorescence Polarization assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH094180-01_|_Assay Provider: Dr. Raymond Deshaies, California Institute of Technology, Pasadena, CA_|__|_Protein modification by the attachment of ubiquitin to cellular proteins is a key mechanism in regulating many cellular and physiological processes. Ubiqui",14,Burnham Center for Chemical Genomics,SBCCG-A789-Rpn11-Inh-CP-Assay,20120308,"2722,3564,7120,42574,52210,65558,72571,73677,81704,88733,96212,152086,159809,160510,165308,190396,227311,230550,231112,232780,238285,238958,240812,242313,248413,252617,258436,261397,265337,268605,270995,274579,275253,276651,292550,306924,315531,322448,327645,328867,335352,340715,371271,380164,386296,386355,392616,392758,395175,395179,398175,456869,461310,586333,587597,606590,607388,632654,638296,644466,644478,644688,644818,644935,645482,645641,645903,646378,646391,646524,646742,646857,647102,647535,647594,6","842211,842223,842423,842548,842595,843198,843351,843808,844068,844212,844530,844770,845193,845760,846551,846663,847794,848175,849279,849485,849853,851037,851647,851766,853388,853413,856459,856464,856629,857030,857247,857367,857374,857465,857466,857585,857599,857681,857694,857711,857713,857732,857733,858027,858473,858517,858569,858615,858948,859359,859497,859527,859578,859640,860452,860477,860630,860662,860916,861336,862062,862415,862500,862504,863758,863819,864016,864225,864274,864303,864736,864838,864859,8",10213,NULL,AAH09524,NIH Initiatives,"10619848,12183636,12183637,12353037,14744430,14990998,2538923",0,10.1016/s0092-8674(03)01074-2|10.1038/nature01071|10.1038/nrm1336|10.1093/emboj/19.1.94|10.1126/science.1075898|10.1126/science.1075901|10.1126/science.2538923,NULL,AAH09524,NULL
602195,1,TRFRET-based cell-based high throughput confirmation assay for biased ligands (antagonists) of the melanocortin 4 receptor (MC4R),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRISMC)_|_Center Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Scott DeWire, Trevena Inc_|_Network: Molecular Library Probe Production Center Network (MLPCN)_|_Grant Proposal Number: 1 RC2 MH090877-01_|_Grant Proposal PI: Scott DeWire, Trevena Inc_|_External Assay ID: MC4R_ANT_TRFRET_1536_3X%INH CRUN_|__|_Name: TRFRET-based cell-based high throughput confirmation assay for biased ligands (antagonists",5,The Scripps Research Institute Molecular Screening Center,MC4R_ANT_TRFRET_1536_3X%INH CRUN,20120619,"1201,2799,4882,6245,8737,28777,31316,73121,75244,78545,81873,97637,179617,182638,222612,225310,232079,237490,237811,239578,245550,245966,248118,248413,259469,262093,266121,270378,272783,276685,282598,282735,284471,292969,303610,307124,309417,311251,313619,317824,324320,334858,362663,370033,371346,371687,375895,392616,404472,405724,406563,407401,448949,457901,496641,539183,540178,566653,567207,570999,582041,588806,592408,609295,612628,616498,620237,625773,628678,644274,645767,648182,648859,649382,649848,6511","843472,844181,845820,846471,846495,846987,848673,848919,850453,851695,852106,853096,853190,856251,856671,857059,857254,857668,858108,860132,860230,860588,861648,861784,862514,863619,3712003,3712857,3713261,3713723,3714474,3714824,3714947,3715673,3716576,3717231,3717262,3717829,4241883,4242300,4244287,4245080,4245977,4245983,4246927,4247203,4247734,4247897,4248527,4248800,4251083,4255786,4256104,4256255,4260103,4261279,4262587,4262882,4262897,4262942,4263207,4263373,4263512,4264567,4264603,4265380,4265399,42",4160,Cell-based,NP_005903,NIH Initiatives,"17041250,17629964,17959251,18370232,18382464,19648111",0,10.1007/978-1-59745-205-2_6|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2007.06.001|10.1038/nrd2518|10.1074/jbc.m109.039339|10.1074/jbc.m605982200,NULL,P32245,NULL
602193,1,Counterscreen for biased ligands (antagonists) of the melanocortin 4 receptor (MC4R): TRFRET-based cell-based high throughput assay to identify nonselective inhibitors of cAMP signaling,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRISMC)_|_Center Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Scott DeWire, Trevena Inc_|_Network: Molecular Library Probe Production Center Network (MLPCN)_|_Grant Proposal Number: 1 RC2 MH090877-01_|_Grant Proposal PI: Scott DeWire, Trevena Inc_|_External Assay ID: U2OS_ANT_TRFRET_1536_3X%INH CSRUN_|__|_Name: Counterscreen for biased ligands (antagonists) of the melanocortin 4 receptor (MC4R): TRF",5,The Scripps Research Institute Molecular Screening Center,U2OS_ANT_TRFRET_1536_3X%INH CSRUN,20120117,"1201,2799,4882,6245,8737,28777,31316,73121,75244,78545,81873,97637,179617,182638,222612,225310,232079,237490,237811,239578,245550,245966,248118,248413,259469,262093,266121,270378,272783,276685,282598,282735,284471,292969,303610,307124,309417,311251,313619,317824,324320,334858,362663,370033,371346,371687,375895,392616,404472,405724,406563,407401,448949,457901,496641,539183,540178,566653,567207,570999,582041,588806,592408,609295,612628,616498,620237,625773,628678,644274,645767,648182,648859,649382,649848,6511","843472,844181,845820,846471,846495,846987,848673,848919,850453,851695,852106,853096,853190,856251,856671,857059,857254,857668,858108,860132,860230,860588,861648,861784,862514,863619,3712003,3712857,3713261,3713723,3714474,3714824,3714947,3715673,3716576,3717231,3717262,3717829,4241883,4242300,4244287,4245080,4245977,4245983,4246927,4247203,4247734,4247897,4248527,4248800,4251083,4255786,4256104,4256255,4260103,4261279,4262587,4262882,4262897,4262942,4263207,4263373,4263512,4264567,4264603,4265380,4265399,42",NULL,Cell-based,NULL,NIH Initiatives,"17041250,17629964,17959251,18370232,18382464,19648111",0,10.1007/978-1-59745-205-2_6|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2007.06.001|10.1038/nrd2518|10.1074/jbc.m109.039339|10.1074/jbc.m605982200,NULL,NULL,NULL
602254,2,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_Dose_CherryPick_Activity_Set2,"Keywords: CFTR, CAL, PDZ domain, fluorescence polarization, Cystic fibrosis_|__|_Assay Overview: A purified CAL PDZ domain construct is allowed to interact with a tetramethylrhodamine (TMR) labeled fluorescent reporter peptide that binds in the canonical peptide-binding groove. The disruption of the interaction is monitored using fluorescence polarization (FP). Fluorescence is measured at 535 nM in the S and P planes with the Perkin-Elmer Viewlux plate reader after 1 hour incubation at room temperature and ",31,Broad Institute,2109-02_Inhibitor_Dose_CherryPick_Activity_Set2,20120210,"95202,96781,120587,227936,230939,234263,236822,238471,240428,242918,251270,252422,256305,258240,266124,292612,295052,303580,304798,315017,318911,331795,419547,429442,593452,609956,612869,645394,646706,647324,648218,649060,649394,649459,650409,651899,652353,653230,653329,653925,655523,655863,655888,655913,660327,665861,666079,668306,669546,670110,673069,685911,688003,698876,700253,700899,701718,702091,707046,711403,712286,717898,718360,719141,719260,728524,733622,739803,743793,748770,750093,750100,750255,750","844380,844984,845859,846665,846999,847064,847991,849413,849843,850701,850790,852878,853189,853209,853234,853260,859026,860629,860721,862429,864619,864831,865076,3711812,3712891,3713249,3714462,3716409,3717220,3717554,3717570,3717690,4240741,4241114,4242458,4243647,4244418,4245190,4245523,4246507,4247631,4248152,4249503,4249557,4250016,4250323,4250348,4250411,4254552,4254785,4255721,4256947,4258270,4258387,4258529,4259917,4260244,4260417,4261049,4261205,4262021,4262818,4263016,4263215,4263737,4263987,4264354","1080,57120",Biochemical,"NP_000483,NP_001017408",NIH Initiatives,"17158866,21105033",0,10.1002/anie.201005585|10.1074/jbc.m611049200,5.6.1.6,"P13569,Q9HD26",NULL
602374,2,Dose Response selectivity of inhibitors of STriatal-Enriched Phosphatase (STEP) in the dual-specificity protein-tyrosine phosphatase VHR Inhibition Assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R03MH095532-01_|_Assay Provider: Dr. Lutz Tautz, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_Disturbance of the dynamic balance between protein tyrosine phosphorylation and dephosphorylation is crucial for the development of many serious condition",14,Burnham Center for Chemical Genomics,SBCCG-A797-STEP-VHR1-DMSO-DR-Assay,20120324,"6868,9354,67062,96015,246750,265117,277512,652142,662579,665287,666560,696894,704124,799876,805196,848272,848275,874190,887096,888529,888623,888688,891883,892521,892618,895032,947438,963027,972870,1213438,1221629,1258959,1261822,1295810,1304048,1324805,1329095,1338419,1339774,1362375,1381903,1602394,1758037,1800867,1801772,1921067,2063317,2102825,2111233,2137364,2151521,2162931,2176498,2185493,2186383,2193503,2193708,2207747,2237510,2237734,2286547,2319222,2320014,2455027,2509623,2545467,2716725,2826665,288","849645,861329,864036,865306,3712358,4242487,4244331,4261832,7971998,7973019,7974892,14723136,14730316,14733734,14737647,14737892,14745670,14746285,16952779,16953345,17386181,17401737,17402005,17412403,17413992,17414144,17414373,17415379,17415497,17415498,17432536,17432592,17432776,17433048,17433931,17434151,17506099,17509666,17509667,17511294,17511367,22400528,22403014,22404440,22405357,22405745,22407579,22409046,22409556,22411909,22412882,22414546,24779806,24779881,24780151,24780792,24782761,24783221,24783",1845,NULL,NP_004081,NIH Initiatives,"12895417,16025111,16237174,18923032,20427654,20956308,7869116,8331384",0,10.1016/s0896-6273(03)00434-3|10.1038/nn1503|10.1073/pnas.1013543107|10.1523/jneurosci.0157-10.2010|10.1523/jneurosci.2666-08.2008|10.1523/jneurosci.2980-05.2005,"3.1.3.16,3.1.3.48",P51452,NULL
602118,0,"NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.","Title: Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery._|__|_Abstract: Most malaria drug development focuses on parasite stages detected in red blood cells, even though, to achieve eradication, next-generation drugs active against both erythrocytic and exo-erythrocytic forms would be preferable. We applied a multifactorial approach to a set of >4000 commercially available compounds with previously demonstrated blood-stage activity (median inhibitory concentration < 1 ",43,ChEMBL,752282,20180919,"237,2240,2757,2812,4235,4993,5186,6197,6764,8547,9048,10219,10649,11069,12456,14169,21651,36332,51196,51703,63708,66541,73549,77227,79513,84191,91851,93114,94920,94975,95996,99599,101711,101965,102185,107464,136402,138402,153378,156473,157284,161091,180548,181831,181834,182785,182786,182788,182791,182792,182807,182816,186645,198062,199862,212242,224178,224185,225911,228284,230632,241056,241241,244183,266124,268956,276817,285506,288412,291270,297912,299693,304558,306442,340280,345657,346529,348623,374829,379","103163899,103164645,103164913,103165594,103165858,103172426,103175998,103176241,103177814,103177821,103178850,103179001,103189472,103203359,103234593,103238097,103274177,103280797,103287987,103292864,103306601,103311545,103313627,103327047,103330076,103340382,103346353,103348651,103351070,103355196,103356848,103357048,103372248,103376868,103382559,103382595,103401109,103440455,103454266,103465619,103465902,103466140,103466177,103466178,103466248,103466424,103468333,103469361,103469388,103469389,103476369,10",NULL,NULL,NULL,Curation Efforts|Research and Development,22096101,0,10.1126/science.1211936,NULL,NULL,NULL
602260,2,Dose-response secondary confirmation of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay using Cy5 labeled peptide,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network(MLPCN)_|_Grant Number: R03 MH094198-01_|_Assay Provider: Kalle Gehring, Ph.D., McGill University_|__|_The poly(A) tail of mRNA is bound by several molecules of the poly(A)-binding protein (PABP), an abundant cytoplasmic protein in eukaryotes that promotes translation (2). PABPC1 is a multi-domai",14,Burnham Center for Chemical Genomics,SBCCG-A780-MLLE-PAM2-DMSO-DR-CY5-Assay,20120214,"3082,4112,5392,5394,6697,6706,6868,7333,8323,8515,11061,14710,18311,26964,34312,67062,68433,72146,72781,93572,94986,95699,99985,117746,139030,160157,164981,185146,219926,220284,223293,224037,224641,225181,225407,232704,237490,238013,241217,244091,245206,246783,256430,256561,257242,258743,259084,260098,261131,261413,262134,265905,266923,268524,269862,272582,274911,276581,276685,278092,282598,286497,288481,288875,292250,318160,322539,323999,327044,327045,327583,327585,329023,333953,369539,371593,377971,378196","842199,842517,842936,843005,843097,843448,843770,844174,844258,844976,845770,846399,846445,846450,846465,846488,846800,847428,847547,848529,848616,848842,848871,849018,849130,849276,849509,850264,850272,850355,850633,851022,851304,851707,852008,853071,853369,856487,856608,856658,856661,856678,856758,856828,857066,857091,857633,857675,858078,858661,858713,858882,858899,859287,859355,859357,859490,861563,861765,863588,863905,864032,864471,864508,865568,3711137,3711189,3711437,3711444,3711500,3711794,3711891,3",26986,NULL,NP_002559,NIH Initiatives,"11287632,12762031,19239892,20096703,3313012,3537727",0,10.1016/j.cell.2009.01.042|10.1016/j.jmb.2010.01.032|10.1073/pnas.071024998|10.1101/sqb.2001.66.293|10.1128/mcb.6.8.2932|10.1128/mcb.7.9.3268,NULL,P11940,NULL
602230,1,Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: There are 2 Assay Providers: Irene Lee, Case Western Reserve and Carolyn Suzuki, University of Medicine and Dentistry of New Jersey_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R01 GM084039-01A1_|_Grant Proposal PI: Irene Lee, Case Western Reserve and Carolyn Suzuki, University of Medicine and ",5,The Scripps Research Institute Molecular Screening Center,ELON_INH_FP_1536_3X%INH CRUN,20120127,"3108,6683,6687,6706,6868,7085,8428,8515,14987,17599,21013,22641,28693,28777,32875,42640,43795,53313,60699,62770,68106,68207,72414,72652,72721,72781,73024,73252,73484,73677,83851,87935,93572,94022,94986,95699,101196,125322,131349,137479,137753,140457,151582,160876,185146,202512,216328,220389,222515,224641,224922,225421,232704,234816,235224,237065,241217,241388,247054,247104,247173,247894,250572,254813,258743,258923,261413,265527,268659,277039,277045,279291,282544,288481,288814,288819,295538,296473,301273,305","842157,842683,842936,843496,843649,843753,843918,844150,844258,844732,844950,845662,845892,846075,846371,846382,846436,846985,847863,848292,848443,848830,848928,849268,849357,849481,849500,850355,850858,851980,852008,852341,852707,855660,856072,856074,856291,856416,856658,856880,856957,857091,857162,857242,857323,857356,857484,857512,858000,858057,858394,858661,858727,858841,858905,859022,859141,859178,859411,859579,860231,860302,860631,860925,861135,861375,861687,861737,862138,862228,862432,862594,862786,8",945085,Biochemical,NP_414973,NIH Initiatives,"10672180,11262158,11473577,12135363,12540547,14124942,1480111,16072036,16494849,1652461,2931432,2950089,3886165,6325386,6453650,6458037,7845219,7862644,8982462,9927482",0,10.1006/abio.2001.4988|10.1016/0014-5793(91)80053-6|10.1016/0076-6879(94)44027-1|10.1016/0092-8674(81)90518-3|10.1016/j.bcp.2005.11.023|10.1016/s0092-8674(85)80031-3|10.1021/bi0255470|10.1038/nrm1684|10.1046/j.1365-2443.2001.00447.x|10.1046/j.1365-2958.2000.01726.x|10.1073/pnas.78.8.4931|10.1073/pnas.92.4.1113|10.1128/iai.71.2.690-696.2003|10.1146/annurev.genet.30.1.465,3.4.21.53,P0A9M0,NULL
602417,1,Single concentration confirmation of uHTS hits for Peg3 Promoter Inhibitors via a luciferase reporter assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBIMR, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 2R01 GM068385-06_|_Assay Provider:  Paul B. Fisher, M.Ph., Ph.D., Virginia Commonwealth University_|__|_Cancer is a progressive disease culminating in the acquisition of metastatic potential by a subset of evolving tumor cells. Although extensively investigated, the",14,Burnham Center for Chemical Genomics,SBCCG-A819-PEG3-Inh-CP-Assay,20120320,"1401,1821,2453,2569,2722,2788,4641,6197,9444,11352,14161,14710,18990,22650,33144,54368,60496,60834,62878,65557,72735,76357,82498,83851,85555,93572,97762,101486,105671,108155,122723,122815,124496,145758,148673,159917,161167,174343,179617,206388,219207,225484,227345,231422,232570,233768,233874,235224,237305,248597,253632,260168,260556,261066,263463,265935,266923,275781,279782,280615,282938,288101,295538,306691,313614,317081,319735,327045,328774,331140,333096,334858,337396,341816,354677,361816,361838,365002,36","842502,847444,848084,848269,851008,852571,852919,855601,855880,856443,856525,857381,857886,857898,858166,858235,858954,858986,859211,859266,859633,859950,860052,860114,860541,861287,861604,861945,862340,863308,863620,864475,866064,3711421,3712282,3712992,3713133,3714130,3714284,3714425,3714493,3715644,3715852,3716305,3716485,3716724,3716906,3717070,3717076,4240627,4241720,4242680,4243251,4243651,4243980,4245031,4246650,4246752,4247100,4248192,4249772,4250001,4250640,4250683,4250780,4251127,4254571,4254756,4",171071,NULL,NP_598230,NIH Initiatives,10918598,0,10.1038/sj.onc.1203666,NULL,Q6IN02,NULL
602464,2,Dose response confirmation of uHTS antagonist hits from Gli-SUFU in a luminescent reporter assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network(MLPCN)_|_Grant Number: 1R03MH094195-01_|_Assay Provider: James Chen, Ph.D.,Stanford University, Stanford California_|__|_The Hh pathway plays a critical role in the patterning of certain embryonic tissues and contributes to their neoplastic transformation later in life.  Hh signaling regulates c",14,Burnham Center for Chemical Genomics,SBCCG-A827-Gli-Sufu-Antagonist-DMSO-DR-Assay,20120905,"5311,54368,72438,72827,110119,175533,360558,371346,386511,644660,645986,646427,647462,651526,654035,657754,657771,657878,657891,663916,664853,667127,667213,669165,674277,743662,754594,765802,782243,785514,800766,808194,838339,846378,869896,921775,951675,951679,977208,1017652,1091514,1095103,1096045,1111832,1132552,1147047,1214679,1227109,1231799,1245647,1251584,1261460,1276160,1387702,1427983,1435354,1436935,1448435,1460629,1475855,1476615,1504737,1504739,1540596,1603523,1796527,1882806,1998339,1999904,2025","842392,843683,844118,845126,849061,856388,856521,856536,857789,862684,862725,863604,865868,865957,3711343,3714263,3714291,3714469,3717335,4248020,4251746,4251984,4261169,4263205,4264986,4265908,7965183,7965426,7966417,7969174,7970564,7972021,7975125,7976775,14720779,14721602,14721863,14722946,14723130,14723818,14726872,14727179,14729079,14731109,14731301,14731863,14732183,14732488,14733455,14733533,14734091,14734108,14739835,14743195,14744781,14746015,17386304,17402345,17406704,17406848,17407392,17408208,17",14632,NULL,BAA85004,NIH Initiatives,"11283316,12202832,12391318,12414725,15380514,17353198,19081070,19136624,19189974,19469545,19522463,19716296,19726763,19726788,19797115,19859563,20493695",0,10.1016/j.bmcl.2009.08.049|10.1016/j.bmcl.2010.04.110|10.1016/j.ccr.2004.08.019|10.1016/j.devcel.2008.11.010|10.1021/jm900305z|10.1021/jm900309j|10.1056/nejmoa0905360|10.1073/pnas.182542899|10.1074/jbc.m109.059964|10.1074/jbc.m611089200|10.1074/jbc.m806233200|10.1101/gad.1025302|10.1101/gad.1753809|10.1126/science.1073733|10.1126/science.1179386|10.1146/annurev.neuro.24.1.385|10.1371/journal.pone.0007608,NULL,BAA85004,NULL
602124,1,"TRFRET-based biochemical high throughput confirmation assay for inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: John Colicelli, UCLA_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R01 CA136699-01A1_|_Grant Proposal PI: John Colicelli, UCLA_|_External Assay ID: RIN1-ABL_INH_TRFRET_1536_3X%INH CRUN_|__|_Name: TRFRET-based biochemical high throughput confirmation assay for inhibitors of the interaction of the",5,The Scripps Research Institute Molecular Screening Center,RIN1-ABL_INH_TRFRET_1536_3X%INH CRUN,20111210,"253,7428,9128,10603,11106,13122,16955,26964,28181,36159,39371,47522,49659,66541,72146,72721,72810,74480,83055,88309,94986,95699,96506,99927,114776,120053,122815,126054,160157,171548,176170,227197,237637,239462,243175,244159,245533,245742,246648,246944,254021,268748,270995,274108,279596,281376,287209,288819,293619,298136,306456,317587,321306,323637,340034,342111,356768,357106,360404,374010,377971,378196,384400,392762,395171,395745,404404,434797,440990,445027,460747,495940,534281,564425,574830,581511,592744,5","843399,843690,843731,844392,844471,845054,846353,847500,847652,848337,848666,850357,850446,852059,852488,852658,852712,853402,853532,853575,856055,856289,856548,857139,857725,857850,857941,858261,858584,859154,859597,859616,859768,860073,860105,860335,860378,861018,861068,861123,862249,862267,862480,862587,863754,863861,864391,864663,864811,864812,865040,865086,865243,865321,865644,3711758,3712026,3712869,3714044,3714339,3714357,3715354,3715360,3715396,3715678,3716123,3716197,3716864,4240495,4241256,4242026","25,9610",Biochemical,"NP_004283,NP_005148",NIH Initiatives,"15657351,16685276,18980964,19701241,19846539,20576803,2469536,3164252",0,10.1038/nrc2695|10.1038/sj.bjc.6603141|10.1158/1078-0432.ccr-08-0581|10.1210/me.2009-0276|10.1677/erc-10-0058,2.7.10.2,"P00519,Q13671",NULL
602125,1,"Counterscreen for inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl): Fluorescence-based biochemical high throughput assay to identify GFP inhibitors and fluorescence q","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: John Colicelli, UCLA_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R01 CA136699-01A1_|_Grant Proposal PI: John Colicelli, UCLA_|_External Assay ID: GFP_INH_QFRET_1536_3X%INH CSRUN_|__|_Name: Counterscreen for inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-",5,The Scripps Research Institute Molecular Screening Center,GFP_INH_QFRET_1536_3X%INH CSRUN,20111212,"253,7428,9128,10603,11106,13122,16955,26964,28181,36159,39371,47522,49659,66541,72146,72721,72810,74480,83055,88309,94986,95699,96506,99927,114776,120053,122815,126054,160157,171548,176170,227197,237637,239462,243175,244159,245533,245742,246648,246944,254021,268748,270995,274108,279596,281376,287209,288819,293619,298136,306456,317587,321306,323637,340034,342111,356768,357106,360404,374010,377971,378196,384400,392762,395171,395745,404404,434797,440990,445027,460747,495940,534281,564425,574830,581511,592744,5","843399,843690,843731,844392,844471,845054,846353,847500,847652,848337,848666,850357,850446,852059,852488,852658,852712,853402,853532,853575,856055,856289,856548,857139,857725,857850,857941,858261,858584,859154,859597,859616,859768,860073,860105,860335,860378,861018,861068,861123,862249,862267,862480,862587,863754,863861,864391,864663,864811,864812,865040,865086,865243,865321,865644,3711758,3712026,3712869,3714044,3714339,3714357,3715354,3715360,3715396,3715678,3716123,3716197,3716864,4240495,4241256,4242026",NULL,Biochemical,CAA58789,NIH Initiatives,"15657351,16685276,18980964,19701241,19846539,20576803,2469536,3164252",0,10.1038/nrc2695|10.1038/sj.bjc.6603141|10.1158/1078-0432.ccr-08-0581|10.1210/me.2009-0276|10.1677/erc-10-0058,NULL,CAA58789,NULL
602372,2,Dose response confirmation of uHTS small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R03MH095532-01_|_Assay Provider: Dr. Lutz Tautz, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_Disturbance of the dynamic balance between protein tyrosine phosphorylation and dephosphorylation is crucial for the development of many serious condition",14,Burnham Center for Chemical Genomics,SBCCG-A795-STEP-DMSO-DR-Assay,20120324,"6868,9354,67062,96015,246750,265117,277512,652142,662579,665287,666560,696894,704124,799876,805196,848272,848275,874190,887096,888529,888623,888688,891883,892521,892618,895032,947438,963027,972870,1213438,1221629,1258959,1261822,1295810,1304048,1324805,1329095,1338419,1339774,1362375,1381903,1602394,1758037,1800867,1801772,1921067,2063317,2102825,2111233,2137364,2151521,2162931,2176498,2185493,2186383,2193503,2193708,2207747,2237510,2237734,2286547,2319222,2320014,2455027,2509623,2545467,2716725,2826665,288","849645,861329,864036,865306,3712358,4242487,4244331,4261832,7971998,7973019,7974892,14723136,14730316,14733734,14737647,14737892,14745670,14746285,16952779,16953345,17386181,17401737,17402005,17412403,17413992,17414144,17414373,17415379,17415497,17415498,17432536,17432592,17432776,17433048,17433931,17434151,17506099,17509666,17509667,17511294,17511367,22400528,22403014,22404440,22405357,22405745,22407579,22409046,22409556,22411909,22412882,22414546,24779806,24779881,24780151,24780792,24782761,24783221,24783",84867,NULL,NP_008837,NIH Initiatives,"12895417,16025111,16237174,18923032,20427654,20956308,7869116,8331384",0,10.1016/s0896-6273(03)00434-3|10.1038/nn1503|10.1073/pnas.1013543107|10.1523/jneurosci.0157-10.2010|10.1523/jneurosci.2666-08.2008|10.1523/jneurosci.2980-05.2005,3.1.3.48,P54829,NULL
602367,2,Dose Response selectivity of inhibitors of Striatal-Enriched Phosphatase (STEP) in a SHP2 (PTPN11) Inhibition Assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R03MH095532-01_|_Assay Provider: Dr. Lutz Tautz, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_Disturbance of the dynamic balance between protein tyrosine phosphorylation and dephosphorylation is crucial for the development of many serious condition",14,Burnham Center for Chemical Genomics,SBCCG-A796-STEP-SHP2-DMSO-DR-Assay,20120324,"6868,9354,67062,96015,246750,265117,277512,652142,662579,665287,666560,696894,704124,799876,805196,848272,848275,874190,887096,888529,888623,888688,891883,892521,892618,895032,947438,963027,972870,1213438,1221629,1258959,1261822,1295810,1304048,1324805,1329095,1338419,1339774,1362375,1381903,1602394,1758037,1800867,1801772,1921067,2063317,2102825,2111233,2137364,2151521,2162931,2176498,2185493,2186383,2193503,2193708,2207747,2237510,2237734,2286547,2319222,2320014,2455027,2509623,2545467,2716725,2826665,288","849645,861329,864036,865306,3712358,4242487,4244331,4261832,7971998,7973019,7974892,14723136,14730316,14733734,14737647,14737892,14745670,14746285,16952779,16953345,17386181,17401737,17402005,17412403,17413992,17414144,17414373,17415379,17415497,17415498,17432536,17432592,17432776,17433048,17433931,17434151,17506099,17509666,17509667,17511294,17511367,22400528,22403014,22404440,22405357,22405745,22407579,22409046,22409556,22411909,22412882,22414546,24779806,24779881,24780151,24780792,24782761,24783221,24783",5781,NULL,NP_002825,NIH Initiatives,"12895417,16025111,16237174,18923032,20427654,20956308,7869116,8331384",0,10.1016/s0896-6273(03)00434-3|10.1038/nn1503|10.1073/pnas.1013543107|10.1523/jneurosci.0157-10.2010|10.1523/jneurosci.2666-08.2008|10.1523/jneurosci.2980-05.2005,3.1.3.48,Q06124,NULL
602235,2,Luminescence-based cell-based high throughput dose response assay for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Bert O'Malley, Baylor College of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 5U19DK062434-09_|_Grant Proposal PI: Bert O'Malley, Baylor College of Medicine_|_External Assay ID: SRC1_INH_LUMI_1536_4XIC50 DRUN_|__|_Name: Luminescence-based cell-based high throughput dose response assay fo",5,The Scripps Research Institute Molecular Screening Center,SRC1_INH_LUMI_1536_4XIC50 DRUN,20120130,"596,4112,5396,6253,36462,38777,72699,77917,97976,108155,126941,148870,230508,230794,235292,244087,263866,265037,284638,288047,310860,313582,327404,425430,608806,616433,647662,651572,652633,660762,661798,663857,665723,669136,696849,699126,699688,702724,703074,706653,709430,721008,738018,738092,746405,759147,765926,766646,808844,848267,848793,878541,881056,892451,900806,901690,902705,915026,935927,975378,1014820,1143231,1150831,1167228,1201125,1208078,1208332,1216754,1240200,1309471,1344474,1346846,1350142,13","845318,845835,850126,859461,860512,861959,862623,864478,3714531,3717025,4244884,4247839,4251053,4255577,4263640,4265458,7964597,7976785,14722323,14724132,14725753,14727509,14729100,14729469,14732184,14732850,14739757,14742081,17385627,17386369,17387759,17388122,17402009,17409322,17409814,17414224,17415292,17431760,17503929,17504675,17506042,17506126,17506847,17507742,17508619,17508734,17509483,17509718,17509737,17510019,17510125,17510479,17511215,17511467,17512173,17512298,17513018,17513040,17513176,1751343",8648,Cell-based,NP_003734,NIH Initiatives,"15657351,16685276,18980964,19701241,19846539,20576803,2469536,3164252",0,10.1038/nrc2695|10.1038/sj.bjc.6603141|10.1158/1078-0432.ccr-08-0581|10.1210/me.2009-0276|10.1677/erc-10-0058,2.3.1.48,Q15788,NULL
602234,2,Counterscreen for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1): Luminescence-based cell-based high throughput dose response assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Bert O'Malley, Baylor College of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 5U19DK062434-09_|_Grant Proposal PI: Bert O'Malley, Baylor College of Medicine_|_External Assay ID: SRC3_INH_LUMI_1536_4XIC50 DCSRUN for SRC1_|__|_Name: Counterscreen for inhibitors of the Steroid Receptor Coac",5,The Scripps Research Institute Molecular Screening Center,SRC3_INH_LUMI_1536_4XIC50 DCSRUN for SRC1,20120130,"596,4112,5396,6253,36462,38777,72699,77917,97976,108155,126941,148870,230508,230794,235292,244087,263866,265037,284638,288047,310860,313582,327404,425430,608806,616433,647662,651572,652633,660762,661798,663857,665723,669136,696849,699126,699688,702724,703074,706653,709430,721008,738018,738092,746405,759147,765926,766646,808844,848267,848793,878541,881056,892451,900806,901690,902705,915026,935927,975378,1014820,1143231,1150831,1167228,1201125,1208078,1208332,1216754,1240200,1309471,1344474,1346846,1350142,13","845318,845835,850126,859461,860512,861959,862623,864478,3714531,3717025,4244884,4247839,4251053,4255577,4263640,4265458,7964597,7976785,14722323,14724132,14725753,14727509,14729100,14729469,14732184,14732850,14739757,14742081,17385627,17386369,17387759,17388122,17402009,17409322,17409814,17414224,17415292,17431760,17503929,17504675,17506042,17506126,17506847,17507742,17508619,17508734,17509483,17509718,17509737,17510019,17510125,17510479,17511215,17511467,17512173,17512298,17513018,17513040,17513176,1751343",8202,Cell-based,NP_858045,NIH Initiatives,"15657351,16685276,18980964,19701241,19846539,20576803,2469536,3164252",0,10.1038/nrc2695|10.1038/sj.bjc.6603141|10.1158/1078-0432.ccr-08-0581|10.1210/me.2009-0276|10.1677/erc-10-0058,2.3.1.48,Q9Y6Q9,NULL
602236,2,Counterscreen for inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1): Luminescence-based cell-based high throughput dose response assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Bert O'Malley, Baylor College of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 5U19DK062434-09_|_Grant Proposal PI: Bert O'Malley, Baylor College of Medicine_|_External Assay ID: VP16_INH_LUMI_1536_4XIC50 DCSRUN for SRC1_|__|_Name: Counterscreen for inhibitors of the Steroid Receptor Coac",5,The Scripps Research Institute Molecular Screening Center,VP16_INH_LUMI_1536_4XIC50 DCSRUN for SRC1,20120130,"596,4112,5396,6253,36462,38777,72699,77917,97976,108155,126941,148870,230508,230794,235292,244087,263866,265037,284638,288047,310860,313582,327404,425430,608806,616433,647662,651572,652633,660762,661798,663857,665723,669136,696849,699126,699688,702724,703074,706653,709430,721008,738018,738092,746405,759147,765926,766646,808844,848267,848793,878541,881056,892451,900806,901690,902705,915026,935927,975378,1014820,1143231,1150831,1167228,1201125,1208078,1208332,1216754,1240200,1309471,1344474,1346846,1350142,13","845318,845835,850126,859461,860512,861959,862623,864478,3714531,3717025,4244884,4247839,4251053,4255577,4263640,4265458,7964597,7976785,14722323,14724132,14725753,14727509,14729100,14729469,14732184,14732850,14739757,14742081,17385627,17386369,17387759,17388122,17402009,17409322,17409814,17414224,17415292,17431760,17503929,17504675,17506042,17506126,17506847,17507742,17508619,17508734,17509483,17509718,17509737,17510019,17510125,17510479,17511215,17511467,17512173,17512298,17513018,17513040,17513176,1751343",NULL,Cell-based,NP_044650,NIH Initiatives,"15657351,16685276,18980964,19701241,19846539,20576803,2469536,3164252",0,10.1038/nrc2695|10.1038/sj.bjc.6603141|10.1158/1078-0432.ccr-08-0581|10.1210/me.2009-0276|10.1677/erc-10-0058,NULL,NP_044650,NULL
602217,2,Dose response confirmation of uHTS hits for small molecule modulators of myocardial damage in HL-1 cells using  2-dexoy-glucose,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 DA031671-01_|_Assay Provider: Richard Kitsis, M.D., Albert Einstein College of Medicine of Yeshiva University_|__|_Myocardial infarction (""heart attack"") is one of the most common causes of morbidity and mortality in the United States and the world(1). It is p",14,Burnham Center for Chemical Genomics,SBCCG-A777-HL-1-Inh-2DG-DR-Assay,20120124,"248116,248118,248119,387075,647168,647606,648499,658526,659111,663015,675349,687924,790478,849577,906418,990758,1068314,1096252,1096807,1105743,1164937,1257799,1293762,1307958,1312044,1511416,1522478,1522537,1522597,1547871,1566703,1632909,1923395,2080084,2103345,2105343,2113786,2128248,2200860,2242679,2326988,2329875,2331793,2342996,2361004,2366328,2411191,2417657,2420449,2441248,2465038,2564298,2594608,2885105,2943967,3177341,3177377,3177697,3177717,3177722,3180258,3180269,3185701,3188766,3188776,3189222,","844837,845266,846128,857170,857755,861788,863162,3714080,3714715,4245784,4246057,4250640,4250701,4254525,7970847,14720936,14725605,14727071,14728578,14732628,14733345,14735221,14740993,14744406,14745825,14746141,17386378,17386632,17386991,17387912,17403224,17403535,17406854,17410183,17412075,17413268,17504172,17505705,17509541,17509840,17512894,17513750,17516095,17517371,22402083,22403068,22406943,22407044,22407642,22408476,22408493,22408771,22408791,22411279,22411881,22413696,22414089,24785052,24789323,248",NULL,NULL,NULL,NIH Initiatives,"12517460,14744432,15800626,19218262,2014866",0,10.1016/s0092-8674(04)00046-7|10.1016/s0140-6736(03)12113-7|10.1038/nature03317|10.1136/hrt.2007.139493|10.2105/ajph.81.5.628,NULL,NULL,NULL
602215,2,Dose response confirmation of uHTS hits for small molecule modulators of myocardial damage in HL-1 cells using Peroxide,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 DA031671-01_|_Assay Provider: Richard Kitsis, M.D., Albert Einstein College of Medicine of Yeshiva University_|__|_Myocardial infarction (""heart attack"") is one of the most common causes of morbidity and mortality in the United States and the world(1). It is p",14,Burnham Center for Chemical Genomics,SBCCG-A776-HL-1-Inh-DMSO-DR-Assay,20120124,"248116,248118,248119,387075,647168,647606,648499,658526,659111,663015,675349,687924,790478,849577,906418,990758,1068314,1096252,1096807,1105743,1164937,1257799,1293762,1307958,1312044,1511416,1522478,1522537,1522597,1547871,1566703,1632909,1923395,2080084,2103345,2105343,2113786,2128248,2200860,2242679,2326988,2329875,2331793,2342996,2361004,2366328,2411191,2417657,2420449,2441248,2465038,2564298,2594608,2885105,2943967,3177341,3177377,3177697,3177717,3177722,3180258,3180269,3185701,3188766,3188776,3189222,","844837,845266,846128,857170,857755,861788,863162,3714080,3714715,4245784,4246057,4250640,4250701,4254525,7970847,14720936,14725605,14727071,14728578,14732628,14733345,14735221,14740993,14744406,14745825,14746141,17386378,17386632,17386991,17387912,17403224,17403535,17406854,17410183,17412075,17413268,17504172,17505705,17509541,17509840,17512894,17513750,17516095,17517371,22402083,22403068,22406943,22407044,22407642,22408476,22408493,22408771,22408791,22411279,22411881,22413696,22414089,24785052,24789323,248",NULL,NULL,NULL,NIH Initiatives,"12517460,14744432,15800626,19218262,2014866",0,10.1016/s0092-8674(04)00046-7|10.1016/s0140-6736(03)12113-7|10.1038/nature03317|10.1136/hrt.2007.139493|10.2105/ajph.81.5.628,NULL,NULL,NULL
602167,2,Counterscreen for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3): Luminescence-based cell-based high throughput dose response assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Bert O'Malley, Baylor College of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 5U19DK062434-09_|_Grant Proposal PI: Bert O'Malley, Baylor College of Medicine_|_External Assay ID: VP16_INH_LUMI_1536_3XIC50 DCSRUN for SRC3_|__|_Name: Counterscreen for inhibitors of the Steroid Receptor Coac",5,The Scripps Research Institute Molecular Screening Center,VP16_INH_LUMI_1536_3XIC50 DCSRUN for SRC3,20120103,"4112,5396,24466,36462,54368,72699,101486,108155,126941,148673,148870,220401,230794,231224,237305,263866,270481,291128,295538,297252,310860,313582,327404,341279,356768,386490,389166,394839,403758,417287,425430,594152,608806,621645,628678,647662,648405,651572,652727,658308,660762,662755,663172,663373,663857,669136,726942,738092,756728,759147,805690,848267,849396,861664,874291,893110,900806,902152,902705,926663,935927,945537,974969,975378,990978,1078331,1117870,1143231,1150809,1160939,1201125,1208078,1208332,1","845318,845835,846033,856947,859461,861516,861949,861959,862623,4242259,4245728,4249345,4255577,4256168,4261439,4262527,7971240,14723802,14725254,14726820,14727509,14729469,14731906,14732273,14735928,14738755,14742081,14743646,17386002,17387038,17387259,17387757,17402009,17402357,17407867,17408597,17409322,17431755,17431760,17433846,17503966,17504675,17505786,17507574,17507742,17508699,17509713,17509714,17509718,17509737,17510019,17510125,17510280,17510429,17510448,17512164,17512913,17513018,17513791,1751582",NULL,Cell-based,NP_044650,NIH Initiatives,"15657351,16685276,18980964,19701241,19846539,20576803,2469536,3164252",0,10.1038/nrc2695|10.1038/sj.bjc.6603141|10.1158/1078-0432.ccr-08-0581|10.1210/me.2009-0276|10.1677/erc-10-0058,NULL,NP_044650,NULL
602166,2,Luminescence-based cell-based high throughput dose response assay for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Bert O'Malley, Baylor College of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 5U19DK062434-09_|_Grant Proposal PI: Bert O'Malley, Baylor College of Medicine_|_External Assay ID: SRC3_INH_LUMI_1536_3XIC50 DRUN_|__|_Name: Luminescence-based cell-based high throughput dose response assay fo",5,The Scripps Research Institute Molecular Screening Center,SRC3_INH_LUMI_1536_3XIC50 DRUN,20120103,"4112,5396,24466,36462,54368,72699,101486,108155,126941,148673,148870,220401,230794,231224,237305,263866,270481,291128,295538,297252,310860,313582,327404,341279,356768,386490,389166,394839,403758,417287,425430,594152,608806,621645,628678,647662,648405,651572,652727,658308,660762,662755,663172,663373,663857,669136,726942,738092,756728,759147,805690,848267,849396,861664,874291,893110,900806,902152,902705,926663,935927,945537,974969,975378,990978,1078331,1117870,1143231,1150809,1160939,1201125,1208078,1208332,1","845318,845835,846033,856947,859461,861516,861949,861959,862623,4242259,4245728,4249345,4255577,4256168,4261439,4262527,7971240,14723802,14725254,14726820,14727509,14729469,14731906,14732273,14735928,14738755,14742081,14743646,17386002,17387038,17387259,17387757,17402009,17402357,17407867,17408597,17409322,17431755,17431760,17433846,17503966,17504675,17505786,17507574,17507742,17508699,17509713,17509714,17509718,17509737,17510019,17510125,17510280,17510429,17510448,17512164,17512913,17513018,17513791,1751582",8202,Cell-based,NP_858045,NIH Initiatives,"15657351,16685276,18980964,19701241,19846539,20576803,2469536,3164252",0,10.1038/nrc2695|10.1038/sj.bjc.6603141|10.1158/1078-0432.ccr-08-0581|10.1210/me.2009-0276|10.1677/erc-10-0058,2.3.1.48,Q9Y6Q9,NULL
602224,2,qHTS Assay for the Inhibitors of L3MBTL1: Hit Validationin AlphaScreen Counterscreen,The histone code is comprised of many post-translational modifications that occur mainly in histone tail peptides. The identity and location of these marks are read by a variety of histone binding proteins that are emerging as important regulators of cellular differentiation and development and are increasingly being implicated in numerous disease states.  Small molecule probes that disrupt the interaction between histone binding proteins and chromatin would enable a systematic chemical biology study of pro,2,National Center for Advancing Translational Sciences (NCATS),L3MB202,20120125,"38370,66671,68261,69161,75253,85895,131349,182785,208719,236275,260644,301798,319089,336937,368866,542828,602665,602926,613010,622290,646403,648470,649614,650763,656134,658014,658547,658692,659101,661612,661849,662679,663113,663742,664224,664552,665043,665152,665287,666333,666410,666560,670145,684250,686152,686860,697640,707445,717599,732372,742170,751001,752950,753116,755947,756954,757322,763463,771613,781894,786704,790305,812103,812108,822499,825128,835173,844091,850411,860102,877361,879444,881472,896090,","844690,846098,847214,848328,853477,856662,857146,857194,857345,857745,858661,860311,860565,861435,861887,862513,862986,863306,863787,863900,864036,865081,865160,865306,3711592,3711831,3711852,3712099,3712109,3712171,3712399,3712410,3712644,3713011,3713051,3714239,3714282,3714369,3714388,3714926,3715555,3716059,3716812,3717399,3717497,3717535,3717615,3717823,4240908,4241305,4241430,4241881,4242061,4242147,4242272,4242283,4243236,4244684,4245926,4246057,4248885,4248909,4249591,4250565,4251580,4254599,4254903,",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"18026117,20008125",0,10.1038/nsmb1340|10.1177/1087057109352902,NULL,NULL,NULL
602168,2,Counterscreen for inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3): Luminescence-based cell-based high throughput dose response assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Bert O'Malley, Baylor College of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 5U19DK062434-09_|_Grant Proposal PI: Bert O'Malley, Baylor College of Medicine_|_External Assay ID: SRC1_INH_LUMI_1536_3XIC50 DCSRUN for SRC3_|__|_Name: Counterscreen for inhibitors of the Steroid Receptor Coac",5,The Scripps Research Institute Molecular Screening Center,SRC1_INH_LUMI_1536_3XIC50 DCSRUN for SRC3,20120103,"4112,5396,24466,36462,54368,72699,101486,108155,126941,148673,148870,220401,230794,231224,237305,263866,270481,291128,295538,297252,310860,313582,327404,341279,356768,386490,389166,394839,403758,417287,425430,594152,608806,621645,628678,647662,648405,651572,652727,658308,660762,662755,663172,663373,663857,669136,726942,738092,756728,759147,805690,848267,849396,861664,874291,893110,900806,902152,902705,926663,935927,945537,974969,975378,990978,1078331,1117870,1143231,1150809,1160939,1201125,1208078,1208332,1","845318,845835,846033,856947,859461,861516,861949,861959,862623,4242259,4245728,4249345,4255577,4256168,4261439,4262527,7971240,14723802,14725254,14726820,14727509,14729469,14731906,14732273,14735928,14738755,14742081,14743646,17386002,17387038,17387259,17387757,17402009,17402357,17407867,17408597,17409322,17431755,17431760,17433846,17503966,17504675,17505786,17507574,17507742,17508699,17509713,17509714,17509718,17509737,17510019,17510125,17510280,17510429,17510448,17512164,17512913,17513018,17513791,1751582",8648,Cell-based,NP_003734,NIH Initiatives,"15657351,16685276,18980964,19701241,19846539,20576803,2469536,3164252",0,10.1038/nrc2695|10.1038/sj.bjc.6603141|10.1158/1078-0432.ccr-08-0581|10.1210/me.2009-0276|10.1677/erc-10-0058,2.3.1.48,Q15788,NULL
602409,1,Single concentration confirmation of uHTS hits from a small molecule antagonists of the CXCR6 receptor via a luminescent beta-arrestin assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1R03MH095589-01 (Cycle 18)_|_Assay Provider:  Gregory Roth Ph.D., Sanford Burnham Medical Research Institute._|__|_Prostate cancer (PCa) is the second leading cause of cancer death in American men and its morbidity has increased globally in recent years. The high m",14,Burnham Center for Chemical Genomics,SBCCG-A811-CXCR6-CP-Assay,20120316,"2817,6301,33528,65549,81400,92993,97637,99844,138252,164981,200953,220284,227494,234636,239578,241787,241808,242563,245097,252247,270378,272837,273465,288760,291920,291921,291923,303610,305244,313603,324571,325517,328009,330973,334410,336482,341502,360560,367978,373493,381514,381571,388993,389753,394239,400634,404470,404472,457901,495575,512832,630233,631571,645266,647549,647878,649567,650200,650319,651034,652068,653186,654359,660230,660447,660829,661967,663318,663743,664030,664291,665621,666884,667046,6683","842988,845207,847169,847784,848585,849215,851766,858019,858026,858923,859147,859533,859739,860690,862096,862514,862797,863051,864373,865625,865786,3712283,3712980,3714726,3715548,4241842,4242002,4242820,4244475,4244637,4246149,4248004,4254448,4255246,4256659,4256816,4258900,4259843,4259886,4260674,4261466,4261777,4262272,4263386,4263559,4265593,7965379,7966015,7970265,7970766,7970980,7971249,7971643,7974324,7974691,7976509,7976903,7977964,7978332,14718966,14721057,14722583,14724191,14724991,14725477,1472633",10663,NULL,NP_006555,NIH Initiatives,"11017100,14625285,18452560",0,10.1038/79738|10.1074/jbc.m311660200|10.1111/j.1349-7006.2008.00833.x,NULL,O00574,NULL
602382,2,Dose response validation of uHTS inhibitor hits from DNMT1 for spectral interference using a Fluorescent Molecular Beacon assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA031091-01A1_|_Assay Provider: Dr. James Stivers, Johns Hopkins University, Baltimore, MD_|__|_Hypermethylation of CpG dinucleotides in promoter regions of tumor suppressor genes by DNA 5-C-MTases is an important hallmark of human cancers [1-3]. Such",14,Burnham Center for Chemical Genomics,SBCCG-A803-DNMT1-Inh-DMSO-DR-Interference-Assay,20120313,"6024,6697,9922,10187,16317,80771,122734,185819,188677,219402,224560,265522,276150,280615,280616,280618,281416,285026,288481,335392,648470,659329,661489,664033,665287,698490,698849,750541,806905,812129,821004,865238,877917,946898,946987,1070294,1075698,1147557,1208412,1231130,1231306,1257875,1285929,1326684,1327876,1418314,1494229,1559791,1595371,1596435,1597719,1632447,1632449,1650543,1724273,1728957,1782309,1797469,1829455,1871839,1909603,1909760,1935947,1973720,1986560,1990677,2030972,2031402,2052803,2088","846098,857981,860182,862800,4251608,4254748,4260569,7973270,7975075,7975176,11532888,14724448,14727861,14731941,14733092,14733887,14734093,14738725,14739275,14740573,14740840,14742005,14742355,14742465,14743503,17386285,17388061,17401726,17403369,17406808,17408801,17408998,17409043,17412566,17415430,17416093,17431609,17432518,17505008,17505022,17505486,17505596,17506010,17506409,17508839,17509498,17510753,17511877,17512313,17512316,17512463,17514101,22400449,22401406,22405684,22409769,22411460,22412359,2478",NULL,NULL,NULL,NIH Initiatives,"11751372,11960994,12154398,15491775,16234563,16341238,17485372,17998812,18076941,18246412,18314485,4503351",0,10.1007/s10555-008-9118-y|10.1016/j.juro.2007.09.038|10.1016/j.tips.2004.09.004|10.1038/ncponc0346|10.1038/sj.onc.1205597|10.1074/jbc.m203009200|10.1093/jnci/dji311|10.1158/1541-7786.mcr-07-0373|10.2741/2385|10.4161/epi.1.1.2375,NULL,NULL,NULL
602380,2,SAR analysis of small molecule inhibitors of tim23-1: a luminescent  TIM10 yeast counterscreen.,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute(SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1 R03 DA027714-01A1_|_Assay Provider: Dr. Carla Koehler, University of California, Los Angeles, CA (UCLA)_|__|_Defects in mitochondrial assembly impact a wide range of diseases from degenerative muscle and neural diseases to cancer (Wallace, 2005). The mitochondrion",14,Burnham Center for Chemical Genomics,SBCCG-A786-tim10-CTR-inhibitor-DryPowder-Assay,20120313,"664956,695176,708520,743195,786365,791050,828644,828654,872357,874744,896091,921932,948969,1247280,1286516,1312356,1462216,1580706,1584401,2085985,2104090,2328475,2342380,2557756,2673431,2812638,2849147,2871317,2936947,2973487,3642892,3738927,3832733,4417817,4564672,4783990,4799699,4848686,4881267,5096427,5337954,5343255,5344872,5410709,5482549,5548040,5865054,5899355,5919570,6861718,7488336,7754748,8003341,8083593,8083597,8087994,8891617,9567277,9567347,9567404,9567416,9580457,9580892,9581104,9581171,95833","124360389,124360390,124360391,124360392,124360393,124360394,124360395,124360396,124360397,124360398,124360399,124360400,124360401,124360402,124360403,124360404,124360405,124360406,124360407,124360408,124360409,124360410,124360411,124360412,124360413,124360414,124360415,124360416,124360417,124360418,124360419,124360420,124360550,124360551,124360552,124360553,124360554,124360555,124360556,124360557,124360558,124360559,124360560,124360561,124360562,124360563,124360564,124360565,124360566,124360567,124360568,12",856395,NULL,DAA06693,NIH Initiatives,"15473843,16285865,9430585",0,10.1126/science.279.5349.369|10.1146/annurev.cellbio.20.010403.105057|10.1146/annurev.genet.39.110304.095751,NULL,P87108,NULL
602420,1,Re-confirmation screening for identification of compounds that antagonize MrgX1 receptor signaling,"Data Source: Johns Hopkins Ion Channel Center (JHICC_MrgX1_Antagonist_Primary)_|_BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed, Duplicate_|__|_Data Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Xinzhong Dong, Ph.D._|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA033176-01_|",27,Johns Hopkins Ion Channel Center,JHICC_MrgX1_Antagonist_Re-confirmation,20120320,"727,903,1400,1546,3132,7389,7573,9340,15165,22883,62547,67238,68497,74495,76175,79480,82414,85270,90260,94273,95311,148673,165542,170530,185848,213331,219761,235224,238013,255202,261413,262698,265996,266468,281790,285479,286220,298316,317578,333140,341783,341980,348698,351033,351549,442897,443953,455264,470952,531819,545836,566938,573572,576941,576955,582245,587596,589102,592588,593655,594870,599987,600165,601670,604548,606565,613467,623348,629074,638296,640062,641184,644215,644397,644487,644520,644567,6446","842141,842232,842261,842308,842350,842355,842409,842565,842579,842647,842746,842752,842913,842923,842932,843004,843010,843044,843160,843224,843334,843403,843495,844019,844070,844363,844418,844523,844564,844637,844705,844856,844870,844956,845065,845218,845397,845516,845561,845700,845849,845980,846016,846129,846270,846352,846432,846490,846492,846515,846567,846665,846682,846910,847007,847035,847138,847167,847255,847332,847413,847464,847567,847722,847745,847839,847855,847863,848063,848305,848502,848569,848589,8",259249,NULL,ACG60652,Legacy Depositors|NIH Initiatives,"10838414,11850634,12397184,16465162,16670758,16791143,1714354,17626210,17855615,18650342,19146417,19230660,20724664",0,10.1007/bf00319042|10.1016/j.bmcl.2009.01.085|10.1021/jm800962k|10.1038/nbt1186|10.1038/nn815|10.1038/nrn1950|10.1073/pnas.1011221107|10.1073/pnas.192565799|10.1172/jci28553|10.1177/108705719900400206|10.1523/jneurosci.1249-07.2007|10.1523/jneurosci.1760-08.2008|10.1523/jneurosci.2862-07.2007,NULL,ACG60652,NULL
602270,1,Absorbance-based biochemical high throughput confirmation assay for activators of Methionine sulfoxide reductase A (MsrA),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Herbert Weissbach, Florida Atlantic University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R03DA032473-01_|_Grant Proposal PI: Herbert Weissbach, Florida Atlantic University_|_External Assay ID: MSRA_ACT_ABS_1536_3X%ACT CRUN_|__|_Name: Absorbance-based biochemical high throughput confirmation a",5,The Scripps Research Institute Molecular Screening Center,MSRA_ACT_ABS_1536_3X%ACT CRUN,20120222,"2002,4882,6099,14358,14710,16317,17748,22641,31772,65093,66245,66541,72810,75846,77623,80771,82533,95223,128599,164981,220717,223920,225436,231106,231719,233453,234106,239677,239740,240739,247404,254021,260540,260556,262808,265898,265940,270920,276685,279291,279596,283138,285522,294256,294983,297934,308243,309593,314707,321405,321721,324140,324518,341543,344341,353644,379337,386517,392754,392758,392760,392762,395171,406009,460747,480272,520108,531845,532088,551245,561453,573142,589107,597032,603150,612806,6","843193,843401,844304,844693,844911,845118,845730,846017,846817,847446,848811,849030,849216,849352,849501,849848,850097,850262,850427,851096,852307,852435,852547,852781,853230,853454,853466,853666,856372,856396,857107,857741,858090,858135,858767,858798,858811,858990,859308,859354,860063,860190,860701,860710,860890,860951,861062,861301,861619,863135,863386,863496,864132,864169,864593,864896,864913,865028,865289,865924,3711118,3711246,3712834,3713122,3713466,3713698,3714352,3714828,3714919,3715751,3716475,3716",281312,Biochemical,AAI02981,NIH Initiatives,"10841552,10964927,11063566,11795868,11867705,12693988,12837786,14745014,15680228,15914630,16735467,17180746,18719109,19085252,19461988,19844733,20515413,8622914,8700890,9275166,9826655",0,10.1006/abbi.2001.2664|10.1007/s00239-005-0281-2|10.1007/s00403-009-0996-9|10.1016/j.bbapap.2004.10.004|10.1021/bi0020269|10.1042/bj20030443|10.1073/pnas.0308215100|10.1073/pnas.032671199|10.1073/pnas.0602826103|10.1073/pnas.0802025105|10.1073/pnas.93.5.2095|10.1073/pnas.93.8.3205|10.1073/pnas.94.18.9585|10.1073/pnas.95.24.14071|10.1073/pnas.97.12.6463|10.1074/jbc.m006137200|10.1080/10715760802566541|10.1089/adt.2009.0263|10.1128/jb.185.14.4119-4126.2003|10.1167/iovs.05-0018,NULL,P54149,NULL
602386,2,Dose response confirmation of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA031091-01A1_|_Assay Provider: Dr. James Stivers, Johns Hopkins University, Baltimore, MD_|__|_Hypermethylation of CpG dinucleotides in promoter regions of tumor suppressor genes by DNA 5-C-MTases is an important hallmark of human cancers [1-3]. Such",14,Burnham Center for Chemical Genomics,SBCCG-A802-DNMT1-Inh-DMSO-DR-Assay,20120313,"6024,6697,9922,10187,16317,80771,122734,185819,188677,219402,224560,265522,276150,280615,280616,280618,281416,285026,288481,335392,648470,659329,661489,664033,665287,698490,698849,750541,806905,812129,821004,865238,877917,946898,946987,1070294,1075698,1147557,1208412,1231130,1231306,1257875,1285929,1326684,1327876,1418314,1494229,1559791,1595371,1596435,1597719,1632447,1632449,1650543,1724273,1728957,1782309,1797469,1829455,1871839,1909603,1909760,1935947,1973720,1986560,1990677,2030972,2031402,2052803,2088","846098,857981,860182,862800,4251608,4254748,4260569,7973270,7975075,7975176,11532888,14724448,14727861,14731941,14733092,14733887,14734093,14738725,14739275,14740573,14740840,14742005,14742355,14742465,14743503,17386285,17388061,17401726,17403369,17406808,17408801,17408998,17409043,17412566,17415430,17416093,17431609,17432518,17505008,17505022,17505486,17505596,17506010,17506409,17508839,17509498,17510753,17511877,17512313,17512316,17512463,17514101,22400449,22401406,22405684,22409769,22411460,22412359,2478",1786,NULL,NP_001370,NIH Initiatives,"11751372,11960994,12154398,15491775,16234563,16341238,17485372,17998812,18076941,18246412,18314485",0,10.1007/s10555-008-9118-y|10.1016/j.juro.2007.09.038|10.1016/j.tips.2004.09.004|10.1038/ncponc0346|10.1038/sj.onc.1205597|10.1074/jbc.m203009200|10.1093/jnci/dji311|10.1158/1541-7786.mcr-07-0373|10.2741/2385|10.4161/epi.1.1.2375,2.1.1.37,P26358,NULL
602289,0,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion: Hit Validation in Malachite Green Assay,"The budding yeast S. cerevisiae is a powerful system to study mitochondrial fusion. Unlike other organisms, yeast cells without functional mitochondrial DNA (mtDNA) can be propagated and studied as long as they maintain a mitochondrial compartment and are provided with a fermentable carbon source. When mitochondrial fusion is blocked in yeast, mitochondrial tubules rapidly fragment and division continues unopposed. Under conditions where fusion is compromised in mammalian cells, nearly identical changes in ",2,National Center for Advancing Translational Sciences (NCATS),MIT547,20120305,"2378,2482,2722,2788,3463,3559,3606,3747,6048,6291,6436,9880,11276,14623,14709,17231,19529,21700,37175,41368,43234,47471,71478,73057,77388,82054,82516,85659,101991,114250,140002,169870,185478,223899,228478,228580,248943,258747,265192,289037,289464,298316,298930,315734,315810,325875,332972,334608,340129,344075,354677,407897,455107,456201,489420,538214,540331,564213,575819,581000,582695,592527,596134,598906,609394,609748,614144,621369,623089,630888,630962,631552,644606,644711,644846,645425,645767,645883,646150","842348,842446,842578,842596,842791,843147,843472,843581,843845,844229,844358,844488,844498,844657,844757,844852,844876,845102,845104,845285,845443,845634,845669,845723,845782,846260,846364,846498,846519,846565,846694,846996,847042,847494,847565,847761,847942,847974,848049,848415,848519,848694,848895,849084,849233,849235,849552,850003,850032,850132,851059,851233,851448,851580,851873,851901,852001,852037,852120,852176,852261,852341,852408,852872,853003,853109,853207,853302,853332,853558,855528,855597,855601,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,4932,0,10.1007/bf01785724,NULL,NULL,NULL
602181,2,"TRFRET-based biochemical high throughput dose response assay for inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: John Colicelli, UCLA_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R01 CA136699-01A1_|_Grant Proposal PI: John Colicelli, UCLA_|_External Assay ID: RIN1-ABL_INH_TRFRET_1536_3XIC50 DRUN_|__|_Name: TRFRET-based biochemical high throughput dose response assay for inhibitors of the interaction of th",5,The Scripps Research Institute Molecular Screening Center,RIN1-ABL_INH_TRFRET_1536_3XIC50 DRUN,20120112,"253,47522,66541,72721,72810,88309,171548,237637,239462,243175,321306,323637,356768,384400,395745,440990,445027,460747,638759,646795,650772,651118,654665,655113,657440,657664,657902,660900,663821,666338,666440,666497,666575,678696,721596,766079,871656,882256,1081265,1081556,1103613,1242321,1295868,1327046,1442486,1818178,1825756,1890403,2044030,2200375,2217398,2217915,2217917,2481264,2537884,2549560,2570777,2623236,2766134,2810445,2828330,2828331,2871530,2897807,2920563,2930719,2931982,2940983,2959810,296244","844471,848337,848666,852059,852488,856055,856289,856548,859597,862587,865086,865243,865321,3712869,3715360,3715678,3716864,4242461,4244029,4244101,4245111,4246017,4249119,4249725,4251194,4251283,4254598,4257231,4257838,4259329,4259666,4260091,4260247,4262628,4265581,7967670,7968624,7969997,7971690,7972316,7975317,7976549,7976982,7977022,14721420,14726526,14726847,14735054,14735982,14736166,14737964,14738591,14746360,17386726,17411401,17414888,17433666,17504906,17505256,17511337,17511669,17512591,17512592,22","25,9610",Biochemical,"NP_004283,NP_005148",NIH Initiatives,"10706884,11423618,12161751,15032571,15618470,15886098,17108134,18089786,18418407,18538733,18772113,18796434,19169242,7805037",0,10.1016/j.ccr.2008.04.018|10.1016/j.ccr.2008.08.003|10.1016/j.cub.2005.03.049|10.1038/leu.2008.89|10.1038/nature07737|10.1038/ng946|10.1074/jbc.m804002200|10.1126/science.1062538|10.1146/annurev.immunol.22.012703.104753|10.1158/0008-5472.can-06-1216|10.1158/0008-5472.can-07-2756|10.1182/blood-2004-08-3097,2.7.10.2,"P00519,Q13671",NULL
602427,2,SAR analysis of small molecule agonists of the NTR1 receptor via a luminescent beta-arrestin assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH089653-01_|_Assay Provider: Dr. Lawrence Barak, Duke University Medical Center_|__|_Addiction leading to abuse should  be treatable by pharmacological approaches, and programs that identify new drugs to treat methamphetamine abuse address an immedia",14,Burnham Center for Chemical Genomics,SBCCG-A817-NTR1-Agonist-bArrestin-DryPowder-Assay,20120425,"119192,661231,1230852,1241151,1301905,1314697,1315297,1316595,1384918,1482681,1489260,1489267,1489268,1848580,1866078,1881562,1920221,1928753,1941471,1951822,1978884,1981284,1985544,1987348,2135349,2135478,2135485,2135541,2135542,2135551,2135553,2135821,2135823,2135839,2135843,2136142,2136147,2136152,2136281,2136303,2136476,2136477,2136829,2136862,2136872,2136873,2136874,2136877,2136878,2136900,2136901,2136904,2136906,2136907,2136908,2136917,2136935,2137192,2137199,2137214,2137215,2137217,2766111,2768147,27","104164380,104164381,104164382,104164383,104164384,104164385,104164386,104164387,104164388,104164389,104164390,104164391,104164392,104164393,104164394,104164395,104164396,104164397,104164398,104164399,104164400,104164401,104164402,104164403,110067513,113635342,113635343,113635344,113635345,113635346,113635347,113635348,113635349,117695568,117695569,117695570,123050379,123050380,123050381,123050382,123050383,123050384,123050385,123050386,124360461,124360462,124360463,124360464,124360465,124360466,124360467,12",4923,NULL,NP_002522,NIH Initiatives,"18547468,7754478,8380498,8808171,9160965",0,10.1073/pnas.90.1.65|10.1111/j.1472-8206.1995.tb00528.x|10.1111/j.1749-6632.1997.tb46151.x|10.1177/039463200802100201,NULL,P30989,NULL
602243,2,"Cholera Quorum: HTS for inducers of light production in the absence of autoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_Dose_CherryPick_Activity","Keywords: V. cholerae, cqsA, luxS mutant, quorum sensing, luminescence_|_Assay Overview: A modified strain of Vibrio cholerae used in this assay uses light production to signal quorum sensing.  Vibrio cholerae is not naturally bioluminescent but the closely related species, Vibrio harveyi, produces light when the population is at a high density (i.e. a quorum is sensed). In the V. cholerae BH1578 strain, the V. harveyi luxCDABE (luciferase) operon was introduced as a cosmid and the operon is activated by en",31,Broad Institute,2132-01_Agonist_Dose_CherryPick_Activity,20120203,"182638,222105,266802,313562,313582,558420,566573,611836,644380,644931,644999,645699,645726,645797,645971,646271,646346,647259,647715,648235,648869,649238,649246,649625,649793,649834,650320,650509,650584,651174,651339,651414,651937,652190,652455,652479,652505,652506,652740,653049,653053,653300,653544,654039,654369,654373,654653,655115,655279,655776,656343,657801,657946,658285,658405,658671,658800,658962,659628,659736,661249,662182,662678,662860,663249,663294,663336,664209,664273,664467,664629,665390,665465,6","842129,842660,842724,843411,843429,843503,843668,843905,843965,844036,844929,845878,846481,846850,847225,847398,847428,847902,848085,848716,848953,849683,849945,849970,849999,850000,850231,850519,850523,850609,850761,851463,851776,851780,852490,852642,853124,853683,856441,856589,856932,857048,857323,857449,857614,858289,858410,859559,859754,859947,860909,861434,861621,861763,861939,862019,862069,862115,862971,863032,863220,863374,864142,864218,864273,864279,864822,864939,864999,865545,865671,865968,3711719,",NULL,Organism-based,NULL,NIH Initiatives,21197957,0,10.1021/cb1003652,NULL,NULL,NULL
602350,2,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_Dose_CherryPick_Activity,"Keywords: Protein Disulfide Isomerase, PDI, arterial thrombosis, inhibitors of PDI, anti-thrombotic,  insulin aggregation assay_|__|__|_Assay Overview: PDI is a key participant in an extracellular electron transport involved in the activation of the coagulation cascade.  Inhibition of extracellular PDI displayed on the surface of platelets and/or vascular cells prevents platelet accumulation and fibrin generation that leads to thrombus formation. Arterial thrombosis mediates tissue infarction in coronary ar",31,Broad Institute,2137-01_Inhibitor_Dose_CherryPick_Activity,20120309,"698,3267,6769,54900,57381,66419,83851,97604,108003,223368,252247,273280,276150,285507,306804,317587,321194,386018,404472,405724,442437,503737,567572,615593,624732,633303,645552,646970,647198,648008,648609,648950,651078,651310,652474,652915,654778,655134,656054,656131,658929,660933,661858,662153,662616,663256,663896,665049,665253,666290,698700,741353,771148,773500,786799,788580,799959,802044,851480,854947,858824,883359,884216,900803,935288,950131,979431,1035550,1038543,1039919,1042164,1043221,1048988,1069130","843271,844638,844866,845653,846229,846558,847849,849964,850393,851994,852165,852509,853399,853473,855745,857577,859074,859440,859631,860574,860878,861366,863793,864001,865044,3711306,3711678,3711920,3712288,3714729,3715516,3716225,4241352,4247818,4249550,4251960,4255230,4255880,4255925,4257483,4258313,4259963,4261002,4262297,4265154,4265584,4265772,7967378,7972571,7975242,7975746,7978284,8139975,14721689,14726198,14726742,14728383,14729304,14729607,14730705,14730732,14731673,14731786,14733876,14734404,14735",5034,Biochemical,AAH10859,NIH Initiatives,NULL,0,NULL,NULL,P07237,NULL
602378,2,SAR analysis of small molecule inhibitors of tim23-1: a luminescent  tim10-1 yeast counterscreen.,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute(SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1 R03 DA027714-01A1_|_Assay Provider: Dr. Carla Koehler, University of California, Los Angeles, CA (UCLA)_|__|_Defects in mitochondrial assembly impact a wide range of diseases from degenerative muscle and neural diseases to cancer (Wallace, 2005). The mitochondrion",14,Burnham Center for Chemical Genomics,SBCCG-A787-tim10-1-CTR-inhibitor-DryPowder-Assay,20120313,"664956,695176,708520,743195,786365,791050,828644,828654,872357,874744,896091,921932,948969,1247280,1286516,1312356,1462216,1580706,1584401,2085985,2104090,2328475,2342380,2557756,2673431,2812638,2849147,2871317,2936947,2973487,3642892,3738927,3832733,4417817,4564672,4783990,4799699,4848686,4881267,5096427,5337954,5343255,5344872,5410709,5482549,5548040,5865054,5899355,5919570,6861718,7488336,7754748,8003341,8083593,8083597,8087994,8891617,9567277,9567347,9567404,9567416,9580457,9580892,9581104,9581171,95833","124360389,124360390,124360391,124360392,124360393,124360394,124360395,124360396,124360397,124360398,124360399,124360400,124360401,124360402,124360403,124360404,124360405,124360406,124360407,124360408,124360409,124360410,124360411,124360412,124360413,124360414,124360415,124360416,124360417,124360418,124360419,124360420,124360550,124360551,124360552,124360553,124360554,124360555,124360556,124360557,124360558,124360559,124360560,124360561,124360562,124360563,124360564,124360565,124360566,124360567,124360568,12",856395,NULL,DAA06693,NIH Initiatives,"15473843,16285865,9430585",0,10.1126/science.279.5349.369|10.1146/annurev.cellbio.20.010403.105057|10.1146/annurev.genet.39.110304.095751,NULL,P87108,NULL
602404,2,SAR analysis of small molecule UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay - Set 4,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1R03 MH085677-01_|_Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_Tumor Necrosis Factor Receptor-Associated Factors (TRAFs) are a family of adapter proteins that bind an unusual ubiquitin-conjugating enzyme, Ubc13, wh",14,Burnham Center for Chemical Genomics,SBCCG-A810-UBC13-DryPowder-TR-FRET-Assay-4,20120503,"16021599,16021605,16021607,16021755,16021815,20912274,20912293,20912317,20912332,20912334,20912338,20912340,20912342,20912355,20912356,20912360,20912361,20912362,20912364,20912440,20912444,20912445,20912446,20912454,20912477,20912482,20912496,20912511,20912514,20912528,20912544,20912547,20912558,20912561,20912563,20912564,20912570,20912574,20912576,20912577,20912578,20912579,20912582,20912586,20912600,56593276,56593285,56593287,56639532,56639540,56639543,56639549,56639551,56639552,56639554,56639556,56639559","104223044,104223047,104223048,104223049,104223050,104223051,104223052,104223053,104223054,104223055,104223056,104223057,104223058,104223059,104223062,104223063,104223067,124384842,124384843,124384844,124384845,124384846,124384848,124384849,124384850,124384851,124384852,125317312,125317314,125317315,125317316,125317317,125317318,125317319,125317320,125317321,125317322,125317323,134225056,134225057,134225058,134415614,134415615,134415616,134415617,134415618,134415619,134415620,134415621,134415622,134415623,13",7334,NULL,NP_003339,NIH Initiatives,"10837071,11057907,11477402,12834344,14579250,15147900,16056267,16862162,16893187,17114420,17404240",0,10.1002/bies.10352|10.1016/j.febslet.2004.04.038|10.1016/s0092-8674(00)00126-4|10.1021/bi034480t|10.1021/bi060631r|10.1038/90609|10.1038/ncb0805-758|10.1038/ni1367|10.1073/pnas.0700548104|10.1146/annurev.immunol.18.1.621|10.4049/jimmunol.177.11.7520,2.3.2.23,P61088,NULL
624246,2,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,"The Ets family of proteins is a family of ~30 conserved transcription factors defined by the presence of an ~85 amino acid domain referred to as the Ets domain, which mediates sequence-specific DNA binding to a core DNA element GGAA/T.The Ets family member ERG has been linked to several neoplasms. ERG has been shown to be frequently over-expressed in prostate cancer. Perhaps more strikingly, ERG and the Ets protein ETV1 have recently been shown to be the targets of chromosomal translocations with TMPRSS2 wh",2,National Center for Advancing Translational Sciences (NCATS),ERG100,20120601,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1727,1730,17","842121,842125,842126,842127,842131,842133,842134,842137,842138,842139,842140,842141,842142,842143,842145,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842167,842169,842170,842171,842173,842174,842178,842179,842181,842182,842183,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842198,842200,842201,842203,842205,842206,842207,842208,842209,842210,842211,842213,842214,842217,842218,842219,842220,842221,842222,842223,8",2078,NULL,NP_001230357,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P11308,NULL
624297,2,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,"H Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: Fast Track K99 CA136555_|_Assay Provider: Melvin DePamphilis, NICHD, NIH_|__|_Assay Overview_|__|_Eukaryotic cells normally restrict genome duplication to once per cell division. When this process is aberrant, DNA re-replication occurs when cells reinitiate DNA replication before the first round of replication is complete. DNA re-replication induces the DNA damage response, arrests cell proliferati",2,National Center for Advancing Translational Sciences (NCATS),DNARRSW480PRI,20120615,"6,19,40,51,72,86,109,119,127,137,174,180,185,190,191,196,204,205,206,227,229,243,244,253,255,263,289,298,299,303,311,314,323,335,338,359,366,370,379,408,441,453,460,464,487,499,525,546,547,564,588,594,595,597,612,637,660,681,698,701,710,727,736,745,753,774,785,791,798,802,803,827,830,863,864,866,876,887,892,896,899,903,904,931,932,936,938,942,957,967,978,985,992,995,1001,1002,1004,1017,1018,1023,1030,1046,1047,1050,1051,1052,1053,1057,1066,1072,1080,1088,1101,1110,1123,1131,1132,1140,1150,1174,1176,1201,120","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",51053,NULL,NP_056979,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,O75496,NULL
624170,2,qHTS for Inhibitors of Glutaminase (GLS),"Glutaminase (GLS) catalyzes the hydrolysis of glutamine into glutamate and ammonia. It plays a critical role in glutaminolysis, which is an important energy source for proliferating cells. It was shown that c-Myc, an oncogenic transcription factor known to regulate microRNAs and to stimulate cell proliferation, increases glutamine metabolism by stimulating the expression of GLS via direct suppression of miR23a and miR23b. Glutamine deprivation, or GLS siRNA treatment in PC3 cancer cells or P-493 B lymphoma ",2,National Center for Advancing Translational Sciences (NCATS),GLS100,20120522,"6,19,40,51,72,86,109,119,127,137,174,180,185,187,190,191,196,204,205,206,227,229,232,240,243,244,248,253,255,263,289,298,299,303,305,311,314,323,335,338,359,366,370,379,389,403,408,441,453,460,464,487,499,525,546,547,564,588,594,595,597,607,612,637,660,681,698,700,701,710,727,736,745,750,753,774,785,791,798,802,803,827,830,863,864,866,871,876,887,892,896,899,903,904,931,932,936,938,942,949,957,967,975,978,985,992,995,996,999,1001,1002,1004,1017,1018,1023,1030,1046,1047,1050,1051,1052,1053,1054,1057,1066,107","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,8",2744,NULL,AAH38507,Governmental Organizations|NIH Initiatives,"14675161,17581113,17596215,19212100,19219026,19222703",0,10.1038/nature07823|10.1042/bj20070039|10.1046/j.1471-4159.2003.02146.x|10.1111/j.1471-4159.2007.04594.x|10.1111/j.1471-4159.2009.05989.x|10.1620/tjem.217.87,NULL,O94925,NULL
624296,2,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,"H Molecular Libraries Probe Production Network [MLPCN]_|_NIH Chemical Genomics Center [NCGC]_|__|_MLPCN Grant: Fast Track K99 CA136555_|_Assay Provider: Melvin DePamphilis, NICHD, NIH_|__|_Assay Overview_|__|_Eukaryotic cells normally restrict genome duplication to once per cell division. When this process is aberrant, DNA re-replication occurs when cells reinitiate DNA replication before the first round of replication is complete. DNA re-replication induces the DNA damage response, arrests cell proliferati",2,National Center for Advancing Translational Sciences (NCATS),DNARRMCF10aPRI,20120615,"6,19,40,51,72,86,109,119,127,137,174,180,185,190,191,196,204,205,206,227,229,243,244,253,255,263,289,298,299,303,311,314,323,335,338,359,366,370,379,408,441,453,460,464,487,499,525,546,547,564,588,594,595,597,612,637,660,681,698,701,710,727,736,745,753,774,785,791,798,802,803,827,830,863,864,866,876,887,892,896,899,903,904,931,932,936,938,942,957,967,978,985,992,995,1001,1002,1004,1017,1018,1023,1030,1046,1047,1050,1051,1052,1053,1057,1066,1072,1080,1088,1101,1110,1123,1131,1132,1140,1150,1174,1176,1201,120","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",51053,NULL,NP_056979,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,O75496,NULL
624417,2,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),"The overall goal of this project was to develop a novel assay for discovering small molecule ligands for class B1 G protein-coupled receptors (GPCRs). Very few agonists (or inverse agonists in inhibition mode) with generally weak activity for this entire group of physiologically important receptors are known to date. To establish proof-of-principle that this critical bottleneck can be overcome with a suitable screening approach, our studies focused on the class B1 receptor for glucagon-like peptide-1 (GLP-1",2,National Center for Advancing Translational Sciences (NCATS),GLPIA100,20120726,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",2740,NULL,AAB64013,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAB64013,NULL
624418,2,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,"The overall goal of this project was to develop a novel assay for discovering small molecule ligands for class B1 G protein-coupled receptors (GPCRs). Very few agonists (or inverse agonists) with generally weak activity for this entire group of physiologically important receptors are known to date. To establish proof-of-principle that this critical bottleneck can be overcome with a suitable screening approach, our studies focused on the class B1 receptor for glucagon-like peptide-1 (GLP-1R), a potential the",2,National Center for Advancing Translational Sciences (NCATS),GLPIA10,20120726,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
624202,2,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,"Functionally, BRCA1 has been implicated in a wide array of cellular activities, including DNA damage repair, cell-cycle checkpoint control, growth inhibition, apoptosis, transcriptional regulation, chromatin remodeling, protein ubiquitylation, and mammary stem cell self-renewal and differentiation. Reduction in BRCA1 levels is associated with an increase in tumor growth and resistance to anti-estrogenic agents, such as tamoxifen, while an increase in BRCA1 expression leads to cell growth arrest and apoptosi",2,National Center for Advancing Translational Sciences (NCATS),BRCA1100,20120524,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,237,243,244,253,255,289,298,299,303,311,314,323,335,338,366,379,403,441,460,464,487,499,525,546,547,564,588,594,597,637,660,681,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1189,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1348,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,164","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",672,NULL,AAC37594,Governmental Organizations|NIH Initiatives,15546503,0,10.1111/j.1349-7006.2004.tb02195.x,NULL,P38398,NULL
624173,2,qHTS of Trypanosoma Brucei Inhibitors,"Members of the Trypanosomatidae family of parasitic protozoans cause a spectrum of diseases throughout the tropical and subtropical world.  Sleeping sickness, caused by two subspecies of Trypanosoma brucei, is endemic to areas of sub-Saharan Africa, while Chagas' disease, a manifestation of Trypanosoma cruzi infection, is prevalent throughout Central and South America.  In addition, many species of Leishmania are responsible for a range of cutaneous and visceral diseases, causing ulcers, destructive lesions",2,National Center for Advancing Translational Sciences (NCATS),TbPyK101,20120530,"6,19,40,51,72,86,109,119,127,137,174,180,185,187,190,191,196,204,205,206,227,229,232,240,243,244,248,253,255,263,289,298,299,303,305,311,314,323,335,338,359,366,370,379,389,403,408,441,453,460,464,487,499,525,546,547,564,588,594,595,597,607,612,637,660,681,698,700,701,710,727,736,745,750,753,774,785,791,798,802,803,827,830,863,864,866,871,876,887,892,896,899,903,904,931,932,936,938,942,949,957,967,975,978,985,992,995,996,999,1001,1002,1004,1017,1018,1023,1030,1046,1047,1050,1051,1052,1053,1054,1057,1066,107","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,8",NULL,NULL,AAX80043,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAX80043,NULL
624263,2,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,The overall goal of this project is to develop new tools for understanding and treating the mitochondrial basis for neurodegenerative disease such as Parkinson's disease (PD).   The PINK1 campaign was developed from recent data pointing towards mitochondrial dysfunction as a major contributor to dopaminergic neuron loss.  The discovery of PINK1/Parkin mediated mitophagy has highlighted the potential for mitochondrial quality control as a novel target for therapeutic intervention.  Mitophagy has been shown t,2,National Center for Advancing Translational Sciences (NCATS),PINK1PRI-Acumen,20120605,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,237,243,244,253,255,289,298,299,303,311,314,323,335,338,366,379,403,441,460,464,487,499,525,535,546,547,564,588,594,596,597,636,637,660,681,698,701,727,745,774,802,803,827,846,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1064,1066,1088,1101,1123,1150,1174,1176,1189,1201,1233,1245,1287,1292,1302,1309,1318,1326,1329,1330,1340,1345,1348,1359,1365,1367,1369,1400,1401,1474,1480,1482,1483,1486,1487,1488,148","842121,842122,842124,842125,842126,842127,842130,842131,842133,842134,842137,842138,842139,842140,842141,842142,842143,842145,842147,842148,842149,842150,842151,842152,842153,842155,842156,842157,842159,842161,842162,842163,842164,842165,842167,842169,842170,842171,842173,842174,842178,842179,842180,842181,842182,842183,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842198,842200,842201,842202,842203,842205,842206,842207,842208,842209,842210,842211,842213,842214,842215,842217,842218,8",5071,NULL,"AAQ89316,BAA25751",Governmental Organizations|NIH Initiatives,"19029340,19966284,20098416,20404107",0,10.1038/ncb2012|10.1073/pnas.0911187107|10.1083/jcb.200809125|10.1083/jcb.200910140,NULL,"AAQ89316,BAA25751",NULL
624172,2,qHTS of GLP-1 Receptor Agonists,"The overall goal of this project was to develop a novel assay for discovering small molecule ligands for class B1 G protein-coupled receptors (GPCRs).  Very few agonists (or inverse agonists) with generally weak activity for this entire group of physiologically important receptors are known to date.  To establish proof-of-principle that this critical bottleneck can be overcome with a suitable screening approach, our studies focused on the class B1 receptor for glucagon-like peptide-1 (GLP-1R), a potential t",2,National Center for Advancing Translational Sciences (NCATS),GLPA1101,20120522,"6,19,40,51,72,86,109,119,127,137,174,180,185,187,190,191,196,204,205,206,227,229,232,240,243,244,248,253,255,263,289,298,299,303,305,311,314,323,335,338,359,366,370,379,389,403,408,441,453,460,464,487,499,525,546,547,564,588,594,595,597,607,612,637,660,681,698,700,701,710,727,736,745,750,753,774,785,791,798,802,803,827,830,863,864,866,871,876,887,892,896,899,903,904,931,932,936,938,942,949,957,967,975,978,985,992,995,996,999,1001,1002,1004,1017,1018,1023,1030,1046,1047,1050,1051,1052,1053,1054,1057,1066,107","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",2740,NULL,AAB64013,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAB64013,NULL
624291,2,qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy,"Integrins are a diverse family of transmembrane cell surface receptors that mediate interactions between cells and the extracellular matrix. These heterodimeric proteins are composed of alpha and beta subunits and the a7b1 interacts with laminin in the extracellular matrix and actin of the cell cytoskeleton. Both chains contribute to ligand binding, but the alpha chain mediates the specificity of the interaction. The alpha7beta1 integrin is a major laminin receptor in skeletal, cardiac and vascular smooth m",2,National Center for Advancing Translational Sciences (NCATS),Alpha7100,20120613,"40,72,127,174,190,191,204,243,253,255,311,314,335,366,379,441,499,525,660,802,803,942,949,978,995,1001,1002,1066,1150,1201,1309,1326,1369,1400,1486,1492,1535,1539,1639,1643,1651,1689,1742,1810,1814,1821,1833,1853,1868,1882,1889,1890,1972,1983,1988,2000,2002,2015,2048,2064,2078,2108,2181,2199,2202,2203,2236,2240,2256,2265,2268,2314,2336,2345,2348,2355,2361,2363,2537,2569,2692,2722,2741,2748,2757,2758,2775,2795,2817,2833,2854,2866,2871,2890,2904,2921,2969,2973,2999,3003,3026,3092,3102,3197,3218,3264,3286,3346","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",1081,NULL,P01215,Governmental Organizations|NIH Initiatives,10199978,0,10.1007/s004410051279,NULL,P01215,NULL
624287,2,"qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS","McCune-Albright syndrome (MAS) is a rare disease caused by somatic mutations in Gsgsp), a widely expressed protein central in signal transduction from G-coupled protein receptors (GPCRs). The disease symptoms are diverse, owing to the fact that the patients are mosaics with varying degrees of tissue involvement. Greater than 90% of the mutations in Gs in MAS occur at the R201 position and are equally divided between R201H and R201C. The R201 residue is central in the intrinsic GTPase activity of Gs and the ",2,National Center for Advancing Translational Sciences (NCATS),GSPA200,20120612,"127,191,255,314,335,366,525,660,949,995,1002,1201,1309,1326,1369,1400,1486,1492,1535,1539,1639,1643,1651,1689,1742,1810,1814,1821,1853,1882,1889,1890,1972,1988,2048,2064,2078,2181,2199,2202,2240,2256,2265,2268,2314,2336,2348,2355,2361,2363,2537,2569,2722,2741,2748,2775,2795,2817,2833,2854,2866,2871,2890,2904,2921,2973,2999,3003,3026,3092,3102,3197,3286,3346,3351,3370,3381,3384,3449,3475,3593,3611,3687,3786,3787,3800,3820,3832,3893,3951,4011,4045,4112,4114,4121,4159,4212,4487,4491,4537,4605,4619,4632,4731,47","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",2778,NULL,P63092,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P63092,NULL
624288,2,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS","McCune-Albright syndrome (MAS) is a rare disease caused by somatic mutations in Gsgsp), a widely expressed protein central in signal transduction from G-coupled protein receptors (GPCRs). The disease symptoms are diverse, owing to the fact that the patients are mosaics with varying degrees of tissue involvement. Greater than 90% of the mutations in Gs in MAS occur at the R201 position and are equally divided between R201H and R201C. The R201 residue is central in the intrinsic GTPase activity of Gs and the ",2,National Center for Advancing Translational Sciences (NCATS),GSPI200,20120612,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",2778,NULL,P63092,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P63092,NULL
624171,2,qHTS of Nrf2 Activators,"Many diseases have some form of oxidative stress injury and ties to inflammation, causing a host of problems for the patient. The antioxidant response element (ARE) plays an important role in alleviating the harmful effects of oxidative stress. The antioxidant response element (ARE) is a transcriptional regulatory element involved in the activation of genes coding for a number of antioxidant proteins and detoxifying enzymes. These enzymes work in concert to protect tissues from oxidative insults and chemica",2,National Center for Advancing Translational Sciences (NCATS),Nrf2101,20120522,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",4780,NULL,AAB32188,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAB32188,NULL
624415,1,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),"Mutations of human Mucolipin transient receptor potential 1 (TRPML1) cause type IV mucolipidosis (ML4), a devastating neurodegenerative disease in young children.  ML4 patients exhibit motor defects, mental retardation, and retinal degeneration.  Currently, there is no treatment for ML4.  By developing a Patch Clamp method to directly measure the functions of TRPML proteins in the late endosome and lysosome (LEL), we found that TRPML1 mediates Ca2+ and Fe2+ efflux from endosomes and lysosomes, and that PI(3",2,National Center for Advancing Translational Sciences (NCATS),TRMPLI1100,20130104,"6,19,86,109,119,127,137,185,191,204,229,255,289,298,299,303,314,323,335,338,366,460,464,487,525,546,547,564,588,597,637,660,698,701,727,745,774,864,892,896,899,903,904,931,932,936,938,949,957,992,995,1002,1017,1018,1030,1046,1047,1088,1101,1123,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,1727,1730,1738,1742,1761,1775,1794,1795,1810,1814,1820,1821,1826,1832,18","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",57192,NULL,NP_065394,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,Q9GZU1,NULL
624178,2,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,"Atherosclerosis is the underlying process for cardiovascular disease and thus is a major contributor to disease burden in the population. The infiltration of LDL into the subendothelial space of the vessel wall, and more importantly its retention, has been shown to be the key factors in the initiation of atherosclerosis. Recently, it has been found that secretory acid sphingomyelinase (S-ASM) action on LDL promotes the retention of LDL by causing its aggregation and enhancing its uptake by macrophages. Thus",2,National Center for Advancing Translational Sciences (NCATS),ASM200,20120523,"6,19,40,72,86,109,119,126,127,137,174,185,190,191,204,229,237,240,243,244,253,255,289,298,299,303,311,314,323,335,338,366,379,403,441,460,464,487,499,525,546,547,564,588,594,597,637,660,681,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1189,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1348,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",6609,NULL,AAA58377,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAA58377,NULL
624354,1,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH095562-01A1_|_Assay Provider: Kristiina Vuori, M.D., Ph.D. Sanford Burnham Medical Research Institute_|__|_Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) is of great potential use as an anticancer therapeutic; however its use as a potential t",14,Burnham Center for Chemical Genomics,SBCCG-A869-Caspase8-Trail-Primary-Assay,20120703,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",8795,NULL,NP_003833,NIH Initiatives,"18989337,19383910,19470771,19838056,19923319,9285725,9311998,9373179,9430227",0,10.1016/s0014-5793(97)01231-3|10.1016/s0960-9822(06)00297-1|10.1016/s1074-7613(00)80400-8|10.1038/nrd2637|10.1091/mbc.e09-09-0769|10.1093/emboj/16.17.5386|10.1158/0008-5472.can-08-3731|10.1158/0008-5472.can-08-3937|10.4161/cc.8.21.9649,NULL,O14763,NULL
624414,1,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),"Mutations of human Mucolipin transient receptor potential 1 (TRPML1) cause type IV mucolipidosis (ML4), a devastating neurodegenerative disease in young children.  ML4 patients exhibit motor defects, mental retardation, and retinal degeneration.  Currently, there is no treatment for ML4.  By developing a patchclamp method to directly measure the functions of TRPML proteins in the late endosome and lysosome (LEL), we found that TRPML1 mediates Ca2+ and Fe2+ efflux from endosomes and lysosomes, and that PI(3,",2,National Center for Advancing Translational Sciences (NCATS),TRMPL1A100,20120726,"6,19,86,109,119,126,127,137,185,191,204,229,237,240,244,255,289,298,299,303,314,323,335,338,366,403,460,464,487,525,546,547,564,588,594,597,637,660,681,698,701,727,745,774,864,892,896,899,903,904,931,932,936,938,942,949,957,992,995,1002,1017,1018,1030,1046,1047,1088,1101,1123,1174,1176,1189,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1348,1359,1365,1367,1369,1400,1401,1474,1483,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1677,1678,1688,1689,1697,1727,1730,1738,1742,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",57192,NULL,NP_065394,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,Q9GZU1,NULL
624304,1,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number: 1R21NS067678-01_|_Assay Provider: Keith Choe, Ph.D., University of Florida, Fl_|__|_Assay Provider:  Keith Choe, Ph.D.,  University of Florida_|_Nematodes parasitize ~1/3 of humans world-wide. Helminth targeting drugs, or anthelmintics, have been used to control parasitic",14,Burnham Center for Chemical Genomics,SBCCG-A855-SKN1-Inh-Primary-Assay,20130315,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",177343,NULL,NP_741406,NIH Initiatives,"19575768,19627265,20585349,7939715",0,10.1111/j.1474-9726.2009.00473.x|10.1111/j.1474-9726.2009.00501.x|10.1126/science.7939715|10.1371/journal.pone.0011194,NULL,P34707,NULL
624463,0,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,"There is great interest in identifying small molecule ligands for G-protein coupled receptors (GPCRs) as nearly 50% of all FDA-approved drugs target these important receptor proteins. Unfortunately, many of the ligands that are used as drugs, or as pharmacological tools, are not selective and exhibit problematic or limiting side effects due to inappropriate signaling activities. Amongst the dopamine receptors (DARs), the D2 is arguably one of the most validated drug targets in neurology and psychiatry. For ",2,National Center for Advancing Translational Sciences (NCATS),D2BAAn100,20120807,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",1813,NULL,NP_000786,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P14416,NULL
624464,0,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,"There is great interest in identifying small molecule ligands for G-protein coupled receptors (GPCRs) as nearly 50% of all FDA-approved drugs target these important receptor proteins. Unfortunately, many of the ligands that are used as drugs, or as pharmacological tools, are not selective and exhibit problematic or limiting side effects due to inappropriate signaling activities. Amongst the dopamine receptors (DARs), the D2 is arguably one of the most validated drug targets in neurology and psychiatry. For ",2,National Center for Advancing Translational Sciences (NCATS),D2BAPo100,20120807,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",1813,NULL,NP_000786,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P14416,NULL
624204,1,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay","Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number: 1R03MH095586-01_|_Assay Provider: Jorge A. Iniguez-Lluhi, Ph.D., University of Michigan Medical School, Ann Arbor, MI_|__|_A growing body of evidence indicates that, SUMOylation plays key homeostatic roles in the androgen mediated development and function of the prostate ",14,Burnham Center for Chemical Genomics,SBCCG-A850-SENP1-Inh-Primary-Assay,20121011,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,NULL,NP_055369,NIH Initiatives,"10913186,12511558,14663148,17932034,18616636,19116244,19763609",0,10.1007/s00424-009-0723-6|10.1073/pnas.2136933100|10.1074/jbc.m210440200|10.1074/jbc.m706978200|10.1111/j.1474-9726.2008.00411.x|10.1128/mcb.20.16.6040-6050.2000|10.1210/me.2008-0219,NULL,NP_055369,NULL
624465,0,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,"There is great interest in identifying small molecule ligands for G-protein coupled receptors (GPCRs) as nearly 50% of all FDA-approved drugs target these important receptor proteins. Unfortunately, many of the ligands that are used as drugs, or as pharmacological tools, are not selective and exhibit problematic or limiting side effects due to inappropriate signaling activities. Amongst the dopamine receptors (DARs), the D2 is arguably one of the most validated drug targets in neurology and psychiatry. For ",2,National Center for Advancing Translational Sciences (NCATS),D2BAAg100,20120807,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",1813,NULL,NP_000786,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P14416,NULL
624352,1,uHTS identification of HIF-2a Inhibitors in a luminesence assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 DA033980-01A1_|_Assay Provider: Mei Yee Koh, Ph.D.,  University of Texas M.D. Anderson Cancer Center_|__|_Most solid tumors and their metastases experience regions of hypoxia, which promotes both tumor progression and resistance to therapy. Critical mediators o",14,Burnham Center for Chemical Genomics,SBCCG-A870-HIF-2a-Primary-Assay,20120703,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",2034,NULL,NP_001421,NIH Initiatives,"22068265,22093255,22277691,22367913",0,10.1002/ajh.23123|10.1007/s00439-011-1109-3|10.1016/j.jdermsci.2011.10.003|10.1016/j.jvs.2011.10.111,NULL,Q99814,NULL
624168,1,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH085693-01A1_|_Assay Provider: Xiaohua Wu, M.D., Ph.D., Carolinas Medical Center, Charlotte, NC_|__|_A number of muscular dystrophies (MD) are associated with abnormal O-mannosylation of alpha dystroglycan (alpha-DG) that plays a central role in linking the ex",14,Burnham Center for Chemical Genomics,SBCCG-A848-a-DG-Primary-Assay,20120522,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",9215,NULL,CAG30396,NIH Initiatives,"15184894,15788414,17591965,19086062,19109526",0,10.1002/mus.21198|10.1038/nm1059|10.1074/jbc.m500069200|10.1152/ajpcell.00456.2008|10.2353/ajpath.2007.060927,NULL,O95461,NULL
624256,1,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,"UNMCMD Assay Overview:_|_Assay Support:  1 R03 DA032471-01   _|_Project Title:  Discovering small molecules that overcome differentiation arrest in acute myeloid leukemia  _|_PI:  David Sykes, PhD_|__|_Screening Center PI:  Larry Sklar, PhD / UNMCMD _|_Screening Center Manager: Kristine Gouveia_|_Screening Lead: Mark Haynes, PhD_|_Assay Implementation:  Mark Haynes, Stephanie Chavez_|__|_Chemistry Center PI:  Stuart Schreiber, PhD / BIPDeC_|_Chemistry Center Manager: Patti Aha_|_Chemistry Lead: Tim Lewis_|_",6,NMMLSC,UNMCMD_HOXA9_MYELOIDDIFFERENTIATION_PRIMARY_MLPCN,20120618,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,842205,8",3205,NULL,NULL,NIH Initiatives,"11840284,14770183,16630659,18668134,19056693,8241496,8563754,8724694",0,10.1002/stem.140281|10.1016/j.leukres.2006.02.022|10.1038/leu.2008.198|10.1038/ng0296-159|10.1038/ng1305|10.1038/sj.leu.2402354|10.1182/blood-2007-09-113597,NULL,NULL,NULL
624330,2,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,"Southern Research's Specialized Biocontainment Screening Center (SRSBSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Assay Provider: Krister Wennerberg, FIMM & Southern Research Institute_|__|_Introduction:_|_The Ras superfamily of small G-protein comprises more than 150 proteins (Wennerberg et al., 2005) and in their function as molecular switches they regulate steps in almost all aspects of cellular signaling, including both phys",33,Southern Research Specialized Biocontainment Screening Center,MgcRacGap_PrimConf,20120703,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,172","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",29127,Biochemical,NP_037409,NIH Initiatives,15731001,0,10.1242/jcs.01660,NULL,Q9H0H5,NULL
624466,1,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: RTI International_|_Assay Provider: Brian P. Gilmour, RTI International_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R21NS064780-01A1_|_Grant Proposal PI: Brian P. Gilmour, RTI Internationall_|_External Assay ID: TAAR1_ANT_FLUO8_1536_1X%INH PRUN_|__|_Name: Fluorescence-based cell-based primary high throughput screening assay to identify antagonists ",5,The Scripps Research Institute Molecular Screening Center,TAAR1_ANT_FLUO8_1536_1X%INH PRUN,20120816,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",134864,Cell-based,NP_612200,NIH Initiatives,"11109299,11459929,11504935,11723224,12550748,15329799,15644497,15718104,15764732,15936832,16263097,16831861,17629964,17959251,18370232,18382464,19892733,6141619,6518200,7218373,8115671,8363648",0,10.1002/jnr.490060106|10.1007/978-1-59745-205-2_6|10.1016/0006-2952(93)90564-d|10.1016/0278-5846(83)90067-2|10.1016/0278-5846(94)90022-1|10.1016/j.brainres.2005.09.009|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2005.05.002|10.1016/j.tips.2007.06.001|10.1016/j.ygeno.2004.11.010|10.1016/s1471-4892(02)00028-0|10.1038/nrd2518|10.1073/pnas.0906522106|10.1073/pnas.151105198|10.1073/pnas.181356198|10.1086/424887|10.1124/jpet.105.084459|10.1124/mol.104.007427|10.1124/mol.60.6.1181|10.1177/1087057106289891,NULL,Q96RJ0,NULL
624126,1,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Colleen Niswender, Vanderbilt University School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: MH077606-01_|_Grant Proposal PI: Colleen Niswender, Vanderbilt University School of Medicine_|_External Assay ID: CHRM4_PAM_FLUO8_1536_1X%ACT PRUN_|__|_Name: Fluorescence-based cell-based prim",5,The Scripps Research Institute Molecular Screening Center,CHRM4_PAM_FLUO8_1536_1X%ACT PRUN,20120509,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",1132,Cell-based,NP_000732,NIH Initiatives,"18481916,19201489,2188581,2385234,3037705,3272174,3443095,7504306,7751967,9109749",0,10.1001/archneur.1997.00550160091022|10.1016/0163-7258(93)90027-b|10.1016/0896-6273(88)90190-0|10.1016/j.tips.2008.12.002|10.1126/science.3037705|10.1146/annurev.pa.30.040190.003221,NULL,P08173,NULL
624040,1,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: MH077606-01_|_Grant Proposal PI: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_External Assay ID: CHRM5_ANT_FLUO8_1536_1X%INH PRUN_|__|_Name: Fluorescence-based cell-based primary ",5,The Scripps Research Institute Molecular Screening Center,CHRM5_ANT_FLUO8_1536_1X%INH PRUN,20120509,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",1133,Cell-based,NP_036257,NIH Initiatives,"18481916,19201489,2188581,2385234,3037705,3272174,3443095,7504306,7751967,9109749",0,10.1001/archneur.1997.00550160091022|10.1016/0163-7258(93)90027-b|10.1016/0896-6273(88)90190-0|10.1016/j.tips.2008.12.002|10.1126/science.3037705|10.1146/annurev.pa.30.040190.003221,NULL,P08912,NULL
624125,1,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Colleen Niswender, Vanderbilt University School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: MH077606-01_|_Grant Proposal PI: Colleen Niswender, Vanderbilt University School of Medicine_|_External Assay ID: CHRM4_ANT_FLUO8_1536_1X%INH PRUN_|__|_Name: Fluorescence-based cell-based prim",5,The Scripps Research Institute Molecular Screening Center,CHRM4_ANT_FLUO8_1536_1X%INH PRUN,20130911,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",1132,Cell-based,NP_000732,NIH Initiatives,"18481916,19201489,2188581,2385234,3037705,3272174,3443095,7504306,7751967,9109749",0,10.1001/archneur.1997.00550160091022|10.1016/0163-7258(93)90027-b|10.1016/0896-6273(88)90190-0|10.1016/j.tips.2008.12.002|10.1126/science.3037705|10.1146/annurev.pa.30.040190.003221,NULL,P08173,NULL
624038,1,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: MH077606-01_|_Grant Proposal PI: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_External Assay ID: CHRM5_PAM_FLUO8_1536_1X%ACT PRUN_|__|_Name: Fluorescence-based cell-based primary ",5,The Scripps Research Institute Molecular Screening Center,CHRM5_PAM_FLUO8_1536_1X%ACT PRUN,20120509,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",1133,Cell-based,NP_036257,NIH Initiatives,"18481916,19201489,2188581,2385234,3037705,3272174,3443095,7504306,7751967,9109749",0,10.1001/archneur.1997.00550160091022|10.1016/0163-7258(93)90027-b|10.1016/0896-6273(88)90190-0|10.1016/j.tips.2008.12.002|10.1126/science.3037705|10.1146/annurev.pa.30.040190.003221,NULL,P08912,NULL
624377,1,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: University of North Carolina at Chapel Hill_|_Assay Provider: Qisheng Zhang, University of North Carolina at Chapel Hill_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R21NS073041 (Fast Track)_|_Grant Proposal PI: Qisheng Zhang, University of North Carolina at Chapel Hill_|_External Assay ID: ASAP1_INH_FP_1536_1X%INH PRUN_|__|_Name: Fluorescence polar",5,The Scripps Research Institute Molecular Screening Center,ASAP1_INH_FP_1536_1X%INH PRUN,20120710,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",50807,Biochemical,NP_001234925,NIH Initiatives,"16413272,16904307,20510928,21587297,21593484",0,10.1016/j.ceb.2006.08.002|10.1016/j.cell.2010.03.051|10.1016/s0076-6879(05)04021-8|10.1038/nrm3117|10.1177/1087057111408420,NULL,Q9ULH1,NULL
624267,1,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Peter S. Tobias, The Scripps Research Institute (TSRI)_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R21 AI090446_|_Grant Proposal PI: Peter S. Tobias, The Scripps Research Institute (TSRI)_|_External Assay ID: NOD2-RIPK2_INH_BLA_1536_1X%INH PRUN_|__|_Name: Fluorescence-based cell-based primary hi",5,The Scripps Research Institute Molecular Screening Center,NOD2-RIPK2_INH_BLA_1536_1X%INH PRUN,20120614,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8","8767,64127",Cell-based,"EAW82767,NP_003812",NIH Initiatives,"11385576,11385577,11528384,12514169,12527755,12791997,12796777,14699116,16498449,17615244,19464198,19483708,19667203,21190821",0,10.1016/j.coi.2010.12.003|10.1016/j.immuni.2009.04.011|10.1038/35079107|10.1038/35079114|10.1038/ng720|10.1038/ni945|10.1038/nrd2783|10.1038/nri1788|10.1073/pnas.0907131106|10.1074/jbc.c200651200|10.1074/jbc.c200673200|10.1074/jbc.m311564200|10.1124/mol.107.038349|10.1126/science.1084677,"2.7.10.2,2.7.11.1","O43353,Q9HC29",NULL
624169,1,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Laura Bohn_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: DA025158-01A1_|_Grant Proposal PI: Laura Bohn_|_External Assay ID: HTR2A_ACT_LUMI_1536_1X%ACT PRUN_|__|_Name: Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (seroto",5,The Scripps Research Institute Molecular Screening Center,HTR2A_ACT_LUMI_1536_1X%ACT PRUN,20120522,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",15558,Cell-based,NP_766400,NIH Initiatives,"18195357,18640136,19630576,1980030,20713067,20925600,21218149",0,10.1007/bf01233097|10.1016/j.ddtec.2010.06.005|10.1016/j.neuropharm.2008.06.048|10.1016/j.neuropharm.2010.08.003|10.1073/pnas.0708862105|10.1146/annurev.med.60.042307.110802|10.3109/10409238.2010.516741,NULL,P35363,NULL
624467,1,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: RTI International_|_Assay Provider: Brian P. Gilmour, RTI International_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R21NS064780-01A1_|_Grant Proposal PI: Brian P. Gilmour, RTI Internationall_|_External Assay ID: TAAR1_AG_FLUO8_1536_1X%ACT PRUN_|__|_Name: Fluorescence-based cell-based primary high throughput screening assay to identify agonists of t",5,The Scripps Research Institute Molecular Screening Center,TAAR1_AG_FLUO8_1536_1X%ACT PRUN,20120808,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",134864,Cell-based,NP_612200,NIH Initiatives,"11109299,11459929,11504935,11723224,12550748,15329799,15644497,15718104,15764732,15936832,16263097,16831861,17629964,17959251,18370232,18382464,6141619,6518200,7218373,8115671,8363648",0,10.1002/jnr.490060106|10.1007/978-1-59745-205-2_6|10.1016/0006-2952(93)90564-d|10.1016/0278-5846(83)90067-2|10.1016/0278-5846(94)90022-1|10.1016/j.brainres.2005.09.009|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2005.05.002|10.1016/j.tips.2007.06.001|10.1016/j.ygeno.2004.11.010|10.1016/s1471-4892(02)00028-0|10.1038/nrd2518|10.1073/pnas.151105198|10.1073/pnas.181356198|10.1086/424887|10.1124/jpet.105.084459|10.1124/mol.104.007427|10.1124/mol.60.6.1181|10.1177/1087057106289891,NULL,Q96RJ0,NULL
624483,1,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,"University of New Mexico Assay Overview:  _|_Assay Support: 1 R03 MH093184-01A1_|_Project Title:  High-throughput multiplex microsphere screening for toxin protease inhibitors_|_Assay Provider:  Steven Graves Ph.D._|__|_Screening Center/PI: UNMCMD/ Larry Sklar Ph.D._|_Lead Biologist:  Bruce Edwards Ph.D., _|_Screening Operations Team: Jingshu Zhu, Mark Carter MS, Kristine Gouveia MS, Matthew Garcia_|__|_Chemistry Center PI:  Craig W. Lindsley_|_Chemistry Lead: Kyle Emmitte_|_Specialized Chemistry Center: Va",6,NMMLSC,UNMCMD_FluorescenceCounterscreen_Protease_HTS,20120814,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,NULL,NULL,NIH Initiatives,"15592454,16604538,18844202,19268493,20035615,20938917,9414082",0,10.1002/0471142956.cy1312s54|10.1002/anie.200705531|10.1002/cyto.a.20268|10.1016/j.toxicon.2008.12.027|10.1016/s0014-5793(97)01328-8|10.1038/nature03123|10.1089/adt.2009.0219,NULL,NULL,NULL
624037,1,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: MH077606-01_|_Grant Proposal PI: P. Jeffrey Conn, Vanderbilt University School of Medicine_|_External Assay ID: CHRM5_AG_FLUO8_1536_1X%ACT PRUN_|__|_Name: Fluorescence-based cell-based primary h",5,The Scripps Research Institute Molecular Screening Center,CHRM5_AG_FLUO8_1536_1X%ACT PRUN,20120509,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",1133,Cell-based,NP_036257,NIH Initiatives,"18481916,19201489,2188581,2385234,3037705,3272174,3443095,7504306,7751967,9109749",0,10.1001/archneur.1997.00550160091022|10.1016/0163-7258(93)90027-b|10.1016/0896-6273(88)90190-0|10.1016/j.tips.2008.12.002|10.1126/science.3037705|10.1146/annurev.pa.30.040190.003221,NULL,P08912,NULL
624416,1,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Michael J. Caulfield , International Aids Vaccine Initiative_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: DA033177-01_|_Grant Proposal PI: Michael J. Caulfield , International Aids Vaccine Initiative_|_External Assay ID: HIV-PG9-GP120_INH_TRFRET_1536_1X%INH PRUN_|__|_Name: TRFRET-based biochemica",5,The Scripps Research Institute Molecular Screening Center,HIV-PG9-GP120_INH_TRFRET_1536_1X%INH PRUN,20120726,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",155971,Biochemical,NP_057856,NIH Initiatives,"14985706,1698859,16989638,17038830,17721546,18197170,18815292,18987148,19525964,20686044,20943652,21561918,8692823,9764777",0,10.1038/ni0304-233|10.1038/nm.1949|10.1038/nm1624|10.1038/nrmicro1819|10.1073/pnas.93.13.6377|10.1074/jbc.m110.172197|10.1097/00002030-199813000-00005|10.1128/jvi.00196-11|10.1128/jvi.00552-10|10.1128/jvi.01762-08|10.1128/jvi.02036-08|10.1586/14760584.5.4.579|10.4161/hv.1.2.1764,NULL,P04578,NULL
624127,1,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Colleen Niswender, Vanderbilt University School of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: MH077606-01_|_Grant Proposal PI: Colleen Niswender, Vanderbilt University School of Medicine_|_External Assay ID: CHRM4_AG_FLUO8_1536_1X%ACT PRUN_|__|_Name: Fluorescence-based cell-based prima",5,The Scripps Research Institute Molecular Screening Center,CHRM4_AG_FLUO8_1536_1X%ACT PRUN,20120509,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",1132,Cell-based,NP_000732,NIH Initiatives,"18481916,19201489,2188581,2385234,3037705,3272174,3443095,7504306,7751967,9109749",0,10.1001/archneur.1997.00550160091022|10.1016/0163-7258(93)90027-b|10.1016/0896-6273(88)90190-0|10.1016/j.tips.2008.12.002|10.1126/science.3037705|10.1146/annurev.pa.30.040190.003221,NULL,P08173,NULL
624268,1,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: University of Washington_|_Assay Provider: Wilhelmus Hol, University of Washington_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R01 AI084004-01A1_|_Grant Proposal PI: Wilhelmus Hol, University of Washington_|_External Assay ID: METRS_INH_LUMI_1536_1X%INH PRUN_|__|_Name: Luminescence-based biochemical primary high throughput screening assay to ident",5,The Scripps Research Institute Molecular Screening Center,METRS_INH_LUMI_1536_1X%INH PRUN,20120723,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",3662741,Biochemical,XP_822407,NIH Initiatives,"18590962,21282428,21322634,21428846",0,10.1016/j.bmcl.2008.06.032|10.1021/jm101225g|10.1128/aac.01796-10|10.1517/13543776.2011.565334,NULL,XP_822407,NULL
624158,3,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression: Summary,"Functionally, BRCA1 has been implicated in a wide array of cellular activities, including DNA damage repair, cell-cycle checkpoint control, growth inhibition, apoptosis, transcriptional regulation, chromatin remodeling, protein ubiquitylation, and mammary stem cell self-renewal and differentiation. Reduction in BRCA1 levels is associated with an increase in tumor growth and resistance to anti-estrogenic agents, such as tamoxifen, while an increase in BRCA1 expression leads to cell growth arrest and apoptosi",2,National Center for Advancing Translational Sciences (NCATS),BRCA1000,20120525,NULL,NULL,NULL,NULL,AAC37594,Governmental Organizations|NIH Initiatives,15546503,0,10.1111/j.1349-7006.2004.tb02195.x,NULL,P38398,NULL
624255,1,Inhibition of T.cruzi proliferation in culture Measured in Cell-Based System Using Plate Reader - 2138-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: Trypanosoma cruzi, Chagas disease_|__|_Assay Overview: The assay detects intracellular trypanosomes that are replicating inside host cells.  NIH3T3 cells are trypsinized, counted, and plated in 384-well tissue culture plates.  After plating the NIH3T3 cells, compounds are added to the wells.  T. cruzi that are genetically modified to express b-galactosidase are then harvested and active Trypomastigotes form  are counted and co-cultured with the NIH3T3 cells.  After 90 hours of co-culture, all cell",31,Broad Institute,2138-01_Inhibitor_SinglePoint_HTS_Activity,20120604,"44201991,44201992,44201993,44201994,44201996,44201997,44201998,44201999,44202000,44202001,44202002,44202004,44202005,44202006,44202007,44202008,44202009,44202010,44202011,44202012,44202013,44202015,44202016,44202017,44202019,44202020,44202021,44202023,44202024,44202026,44202028,44202030,44202032,44202034,44202035,44202036,44202038,44202039,44202040,44202041,44202042,44202043,44202044,44202045,44202046,44202048,44202049,44202050,44202053,44202055,44202056,44202057,44202058,44202060,44202061,44202062,44202118","85789756,85789757,85789758,85789759,85789760,85789761,85789763,85789764,85789765,85789766,85789767,85789768,85789769,85789770,85789771,85789772,85789773,85789774,85789776,85789777,85789778,85789779,85789780,85789782,85789784,85789785,85789786,85789787,85789788,85789789,85789790,85789791,85789793,85789794,85789796,85789797,85789798,85789799,85789800,85789801,85789802,85789803,85789804,85789805,85789806,85789807,85789808,85789809,85789810,85789811,85789812,85789813,85789814,85789815,85789816,85789818,85789819",NULL,Cell-based,NULL,NIH Initiatives,"19238193,8913471",0,10.1371/journal.pntd.0000384,NULL,NULL,NULL
624101,1,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords:_|__|_Isocitrate dehydrogenase IDH1,  IDH1(R132H), dehydrogenase, a-ketoglutarate, tumorigenesis, human glioma, HTS_|__|_Assay Overview:_|_The R132H mutation in IDH1 encoding cytosolic NADP+-dependent isocitrate dehydrogenase 1 is very frequent in human glioma diffuse astrocytoma and oligodendroglioma, common in AML.  So far, all IDH1 mutations in gliomas affect codon 132 and more than 90% of the mutations are of the R132H type.  IDH1 mutated protein hydrolyzes alpha-ketoglutarate and produces 2-hy",31,Broad Institute,2107-01_Inhibitor_SinglePoint_HTS_Activity,20120420,"86,237,323,444,861,903,932,1203,1204,1219,1220,1225,1234,1236,1240,1241,1242,1243,1257,1302,1329,1340,1342,1345,1346,1348,1354,1355,1359,1370,1400,1456,1464,1480,1486,1493,1533,1534,1564,1573,1585,1609,1649,1663,1674,1683,1691,1694,1713,1720,1733,1775,1794,1797,1830,1833,1845,1853,1858,1863,1882,1893,1917,1935,1960,1973,1978,1979,1989,2002,2004,2019,2031,2044,2048,2049,2051,2052,2061,2063,2064,2072,2078,2082,2083,2092,2119,2120,2122,2123,2129,2132,2145,2153,2159,2162,2170,2200,2203,2206,2229,2230,2249,2253,","85281118,85281121,85281123,85281134,85281138,85281143,85281145,85281150,85281152,85281153,85281161,85281174,85281175,85787110,85787111,85787112,85787113,85787114,85787115,85787116,85787117,85787119,85787120,85787121,85787122,85787124,85787126,85787127,85787128,85787129,85787130,85787131,85787132,85787133,85787134,85787135,85787136,85787137,85787138,85787139,85787140,85787143,85787144,85787145,85787146,85787147,85787149,85787150,85787151,85787152,85787154,85787155,85787156,85787157,85787158,85787159,85787160",3417,Biochemical,AAH93020,NIH Initiatives,20559394,0,10.1038/nature09132,NULL,AAH93020,NULL
624156,1,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,"Keywords: Reactive oxygen species, cancer cells, transformed cells._|__|_Assay Overview: Detection of reactive oxygen species using fluorescent dye_|_Cancer cells are known to have higher concentrations of reactive oxygen species (ROS) compared to nontumorigenic cells.  Although the increase in ROS levels has been linked to cancer initiation, progression and drug resistance, excessively high levels can lead to cell toxicity. One strategy in cancer therapy aims to exploit the biochemical differences between ",31,Broad Institute,2044-01_Activator_SinglePoint_HTS_Activity,20120516,"86,237,323,444,861,863,896,903,932,992,1002,1203,1204,1219,1220,1225,1234,1236,1240,1242,1302,1329,1342,1345,1346,1348,1354,1355,1359,1370,1400,1464,1480,1486,1493,1533,1599,1609,1649,1663,1674,1683,1694,1713,1720,1733,1775,1779,1820,1830,1833,1845,1853,1863,1880,1882,1884,1892,1893,1917,1923,1935,1960,1978,1979,1981,1988,1989,2002,2004,2031,2044,2048,2049,2051,2052,2061,2063,2064,2078,2082,2083,2092,2119,2120,2122,2123,2125,2126,2129,2132,2145,2153,2160,2162,2170,2196,2200,2203,2206,2230,2247,2249,2256,226","85787078,85787079,85787080,85787081,85787082,85787083,85787084,85787085,85787086,85787087,85787088,85787089,85787090,85787091,85787092,85787093,85787094,85787095,85787096,85787097,85787098,85787099,85787100,85787101,85787102,85787103,85787104,85787105,85787106,85787107,85787108,85787109,85787110,85787111,85787112,85787113,85787114,85787115,85787116,85787117,85787118,85787119,85787120,85787121,85787122,85787123,85787124,85787125,85787126,85787127,85787128,85787129,85787130,85787131,85787132,85787133,85787134",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
624260,1,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords:_|_H3K36, methyltransferase, cancer, NSD1, histone-modifying, small molecule inhibitors_|__|__|_Assay Overview:_|_Dysregulation of histone-modifying enzymes has been observed in a variety of_|_disease states, most notably cancer. In various tumor types, histone methyltransferases_|_and other epigenetic regulators have been shown to undergo somatic mutation, copy_|_number alteration, and altered expression levels. After surveying the available cancer_|_genomics reports, the Chemical Biology Program ",31,Broad Institute,2115-01_Inhibitor_SinglePoint_HTS_Activity,20120605,"86,323,903,932,1203,1204,1219,1220,1225,1234,1240,1241,1243,1257,1302,1329,1340,1342,1345,1346,1348,1354,1355,1359,1370,1400,1464,1480,1486,1493,1533,1534,1564,1573,1585,1609,1649,1663,1674,1683,1694,1713,1720,1733,1775,1794,1797,1830,1833,1845,1853,1858,1863,1882,1893,1917,1960,1973,1979,1989,2002,2004,2048,2049,2052,2063,2072,2078,2083,2092,2120,2122,2123,2129,2132,2153,2159,2162,2203,2206,2229,2249,2253,2256,2264,2267,2268,2303,2310,2328,2333,2336,2337,2347,2351,2355,2356,2366,2374,2377,2378,2396,2399,24","85281118,85281121,85281123,85281134,85281138,85281143,85281145,85281150,85281152,85281153,85281161,85281174,85281175,85787112,85787113,85787114,85787121,85787122,85787126,85787128,85787131,85787135,85787136,85787137,85787138,85787140,85787149,85787150,85787152,85787153,85787154,85787156,85787157,85787159,85787160,85787161,85787162,85787163,85787164,85787165,85787166,85787167,85787170,85787171,85787173,85787174,85787176,85787177,85787178,85787183,85787184,85787185,85787186,85787187,85787188,85787189,85787190",7468,Biochemical,NP_001035889,NIH Initiatives,NULL,0,NULL,2.1.1.356,O96028,NULL
624151,1,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,"Keywords: P53, transcription and tumor._|__|_Assay Overview: Luciferase reporter assay using PUMA P53 promoter in SW480 cells._|_Tumor suppressor p53 is a potent transcription factor that effectively blocks cell cycle progression or induces apoptosis in response to diverse forms of stress, thus protecting normal cells from malignant transformation. p53 is the most frequently altered gene in cancer and approximately 50% of all human tumors harbor dysfunctional protein, which plays a critical role in tumor ev",31,Broad Institute,2071-01_Activator_SinglePoint_HTS_Activity,20120516,"86,237,323,861,903,932,1203,1204,1219,1225,1236,1240,1241,1242,1243,1257,1302,1340,1342,1345,1456,1493,1534,1564,1573,1585,1649,1683,1691,1713,1720,1733,1794,1797,1830,1833,1853,1858,1863,1893,1935,1960,1973,1989,2002,2019,2031,2044,2048,2049,2051,2052,2064,2072,2082,2083,2092,2120,2122,2123,2132,2159,2162,2170,2200,2203,2229,2230,2253,2264,2265,2267,2284,2293,2310,2311,2333,2336,2351,2355,2356,2366,2377,2378,2391,2399,2400,2419,2422,2426,2428,2448,2457,2460,2462,2467,2474,2480,2482,2512,2519,2545,2583,2585","85281118,85281121,85281123,85281134,85281138,85281143,85281145,85281150,85281152,85281153,85281161,85281174,85281175,85787110,85787111,85787112,85787113,85787115,85787116,85787117,85787119,85787120,85787122,85787124,85787126,85787127,85787128,85787129,85787130,85787132,85787133,85787134,85787135,85787136,85787137,85787138,85787139,85787140,85787143,85787144,85787145,85787146,85787147,85787149,85787151,85787152,85787154,85787155,85787156,85787157,85787158,85787161,85787162,85787163,85787164,85787165,85787166",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
624099,0,An siRNA screen for human genes that are involved in human papilloma virus (HPV) E2 transcriptional repression of the E6 and E7 oncogenes,"An essential step in the pathogenesis of human papillomavirus (HPV)-associated cancers is the dysregulated expression of the viral oncogenes. The papillomavirus E2 protein can silence the long control region (LCR) promoter that controls viral E6 and E7 oncogene expression. The mechanisms by which E2 represses oncogene expression and the cellular factors through which E2 mediates this silencing are largely unknown. We conducted an unbiased, genome-wide siRNA screen and series of secondary screens that identi",46,"ICCB-Longwood Screening Facility, Harvard Medical School",HMS729,20161014,NULL,"56478464,56478466,56478467,56478468,56478469,56478470,56478471,56478472,56478473,56478474,56478476,56478477,56478478,56478479,56478480,56478481,56478483,56478484,56478485,56478486,56478487,56478488,56478489,56478490,56478491,56478492,56478493,56478494,56478495,56478496,56478497,56478498,56478499,56478500,56478501,56478502,56478503,56478504,56478505,56478506,56478507,56478508,56478509,56478510,56478511,56478512,56478513,56478515,56478516,56478517,56478518,56478519,56478520,56478521,56478522,56478523,56478524","1,2,9,10,12,13,14,15,16,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,43,47,48,49,50,51,52,53,54,55,56,58,59,60,70,71,72,81,86,87,88,89,90,91,92,93,94,95,97,98,100,101,102,103,104,105,107,108,109,111,112,113,114,115,116,117,118,119,120,123,124,125,126,127,128,130,131,132,133,134,135,136,140,141,142,143,146,147,148,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,172,173,174,175,176,177,178,181,182,183,185,186,187,189,190,191,196,197,199,202,203,204,205,207,20",RNAi,NULL,Research and Development,"20133580,20181716",1,10.1073/pnas.0914818107|10.1128/jvi.02390-09,NULL,NULL,NULL
624044,2,S16 Schwann cell PMP22 intronic element beta-lactamase assay,"Description:_|_Charcot-Marie-Tooth-Association [CMTA]_|_National Center for Advancing Translational Sciences  [NCATS]_|__|_Charcot-Marie-Tooth (CMT) disease was first characterized by Jean-Martin Charcot and Pierre Marie in France and, independently, by Howard Henry Tooth in England in 1886. CMT is one of the most common inherited neurological diseases, affecting approximately 1 in 2,500 Americans. CMT patients typically exhibit muscle atrophy in the extremities and sensory loss. The most prevalent type of ",2,National Center for Advancing Translational Sciences (NCATS),cmt-p4-fda-blac,20120430,"51,119,180,190,196,205,206,227,244,263,298,323,359,370,379,408,453,460,464,546,564,588,594,595,612,681,710,727,736,753,774,785,791,798,827,830,863,864,866,876,887,892,896,904,931,936,938,967,978,985,1004,1018,1023,1030,1046,1050,1051,1052,1053,1057,1072,1080,1110,1123,1131,1132,1140,1174,1176,1203,1234,1236,1254,1292,1355,1359,1483,1546,1676,1683,1687,1727,1732,1775,1892,1935,1967,1979,1983,1984,1985,1986,1989,1990,2000,2005,2017,2018,2052,2061,2075,2081,2082,2083,2088,2099,2116,2118,2119,2120,2122,2123,213","3714055,4252459,4252462,4252481,4252484,4252489,4252498,4252505,4252514,4252542,4252550,4252556,4252663,4252664,4252672,4252673,4252682,4252707,4252720,4252736,4252762,4252766,4252873,4252936,4252942,4253003,4253075,4253130,4253134,4253165,4253169,4253170,4253171,4253172,4253243,4253288,4253342,4253464,4253491,4253760,4253884,4253929,4253930,4253932,4253933,4253943,4253976,4254064,4254080,4254095,4254117,4254158,4254257,4254365,7972459,7975373,11110658,11110743,11110779,11110790,11110844,11110946,11110953,1",24660,NULL,NP_058733,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P25094,NULL
624137,1,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,"Keywords: _|_ID4, F/B, SMMAssay Overview:_|_Small Molecule Microarrays (SMM) are generated by covalently immobilizing small molecules on an isocyanate surface glass slide. SMMs are incubated with the Flag-tagged ID4 (Id-related helix-loop-helix protein ) target protein solution at 4 degrees for 2 hours. The slides are then breifly washed and incubated with an anti-His Flag antibody. Slides are breifly washed, and fluroescent anti-rabbit antibody was incubated with slides. Slides arewashed dried ans scanned.",31,Broad Institute,2128-01_Other_SinglePoint_HTS_Activity,20120509,"86,323,903,932,1203,1204,1219,1220,1225,1234,1240,1241,1243,1257,1302,1329,1340,1342,1345,1346,1348,1354,1355,1359,1370,1400,1464,1480,1486,1493,1533,1534,1564,1573,1585,1609,1649,1663,1674,1683,1694,1713,1720,1733,1775,1794,1797,1830,1833,1845,1853,1858,1863,1882,1893,1917,1960,1973,1979,1989,2002,2004,2048,2049,2052,2063,2072,2078,2083,2092,2120,2122,2123,2129,2132,2153,2159,2162,2203,2206,2229,2249,2253,2256,2264,2267,2268,2303,2310,2328,2333,2336,2337,2347,2351,2355,2356,2366,2374,2377,2378,2396,2399,24","85281118,85281121,85281123,85281134,85281138,85281143,85281145,85281150,85281152,85281153,85281161,85281174,85281175,85787112,85787113,85787114,85787121,85787122,85787126,85787128,85787131,85787135,85787136,85787137,85787138,85787140,85787149,85787150,85787152,85787153,85787154,85787156,85787157,85787159,85787160,85787161,85787162,85787163,85787164,85787165,85787166,85787167,85787170,85787171,85787173,85787174,85787176,85787177,85787178,85787183,85787184,85787185,85787186,85787187,85787188,85787189,85787190",3400,Biochemical,AAA73923,NIH Initiatives,NULL,0,NULL,NULL,P47928,NULL
624030,2,Biochemical firefly luciferase enzyme assay for NPC,"Charcot-Marie-Tooth-Association [CMTA]_|_National Center for Advancing Translational Sciences  [NCATS]_|__|_Charcot-Marie-Tooth (CMT) disease was first characterized by Jean-Martin Charcot and Pierre Marie in France and, independently, by Howard Henry Tooth in England in 1886. CMT is one of the most common inherited neurological diseases, affecting approximately 1 in 2,500 Americans. CMT patients typically exhibit muscle atrophy in the extremities and sensory loss. The most prevalent type of CMT is known as",2,National Center for Advancing Translational Sciences (NCATS),adst-fluc-km-fda-o1_regid,20120430,"51,119,180,187,190,196,205,206,227,232,240,244,248,253,263,298,305,311,323,338,359,370,379,389,403,408,453,460,464,546,564,588,594,595,607,612,681,698,700,710,727,736,750,753,774,785,791,798,827,830,863,864,866,871,876,887,892,896,904,931,936,938,967,975,978,985,996,999,1004,1018,1023,1030,1046,1050,1051,1052,1053,1054,1057,1072,1080,1101,1110,1123,1131,1132,1140,1156,1174,1175,1176,1183,1203,1206,1234,1236,1254,1292,1355,1359,1483,1489,1546,1614,1615,1676,1683,1687,1727,1732,1775,1892,1923,1935,1967,1979,1","3714055,4252459,4252462,4252481,4252484,4252489,4252498,4252505,4252514,4252542,4252550,4252556,4252663,4252664,4252672,4252673,4252682,4252707,4252719,4252720,4252736,4252762,4252766,4252873,4252936,4252942,4253003,4253075,4253130,4253134,4253165,4253169,4253170,4253171,4253172,4253243,4253288,4253342,4253464,4253491,4253760,4253884,4253929,4253930,4253932,4253933,4253943,4253976,4254064,4254080,4254095,4254117,4254126,4254158,4254257,4254365,7972459,7975373,11110658,11110743,11110779,11110790,11110844,111",NULL,Biochemical,AAA29795,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P08659,NULL
624349,0,A screen for compounds that inhibit liver stage malaria,"In humans, a malaria infection begins with a one-time, asymptomatic liver stage followed by a cyclic symptomatic blood stage.  All high-throughput malaria drug discovery efforts have focused on the cyclic blood stage, and this focus has limited potential for the prophylaxis, transmission-blocking, and eradication efforts needed for the next stages of malaria treatment.  A high-throughput phenotypic liver-stage screen was developed to systematically identify molecules with liver stage efficacy that could add",46,"ICCB-Longwood Screening Facility, Harvard Medical School",HMS980,20161018,"89,119,137,187,190,204,237,243,253,298,323,370,412,444,460,564,727,785,830,838,861,864,892,896,904,914,932,936,938,1046,1054,1066,1072,1123,1148,1150,1176,1236,1302,1646,1694,1727,1732,1733,1775,1833,1892,1893,1935,1967,1981,1983,1984,1985,1986,1989,1990,2004,2005,2018,2044,2048,2049,2051,2063,2075,2081,2082,2083,2092,2116,2117,2118,2119,2120,2122,2123,2125,2132,2133,2140,2141,2145,2148,2149,2151,2153,2154,2155,2157,2159,2161,2162,2170,2176,2187,2194,2196,2197,2202,2206,2244,2247,2249,2265,2266,2272,2283,22","92123927,92123928,92123929,92123930,92123931,92123932,92123933,92123934,92123935,92123936,92123937,92123938,92123939,92123940,92123941,92123942,92123943,92123944,92123945,92123946,92123947,92123948,92123949,92123950,92123951,92123952,92123953,92123954,92123955,92123956,92123957,92123958,92123959,92123960,92123961,92123962,92123963,92123964,92123965,92123966,92123967,92123968,92123969,92123970,92123971,92123972,92123973,92123974,92123975,92123976,92123977,92123978,92123979,92123980,92123981,92123982,92123983",NULL,NULL,NULL,Research and Development,"19924309,22586124,6267054",0,10.1073/pnas.1118370109|10.1371/journal.pone.0007881,NULL,NULL,NULL
624032,2,S16 Schwann cell PMP22 intronic element firefly luciferase assay,"Description:_|_Charcot-Marie-Tooth-Association [CMTA]_|_National Center for Advancing Translational Sciences  [NCATS]_|__|_Charcot-Marie-Tooth (CMT) disease was first characterized by Jean-Martin Charcot and Pierre Marie in France and, independently, by Howard Henry Tooth in England in 1886. CMT is one of the most common inherited neurological diseases, affecting approximately 1 in 2,500 Americans. CMT patients typically exhibit muscle atrophy in the extremities and sensory loss. The most prevalent type of ",2,National Center for Advancing Translational Sciences (NCATS),cmt-p4-fluc-fda_regid,20120430,"51,119,180,190,196,205,206,227,244,263,298,323,359,370,379,408,453,460,464,546,564,588,594,595,612,681,710,727,736,753,774,785,791,798,827,830,863,864,866,876,887,892,896,904,931,936,938,967,978,985,1004,1018,1023,1030,1046,1050,1051,1052,1053,1057,1072,1080,1110,1123,1131,1132,1140,1174,1176,1203,1234,1236,1254,1292,1355,1359,1483,1546,1676,1683,1687,1727,1732,1775,1892,1935,1967,1979,1983,1984,1985,1986,1989,1990,2000,2005,2017,2018,2052,2061,2075,2081,2082,2083,2088,2099,2116,2118,2119,2120,2122,2123,213","3714055,4252459,4252462,4252481,4252484,4252489,4252498,4252505,4252514,4252542,4252550,4252556,4252663,4252664,4252672,4252673,4252682,4252707,4252720,4252736,4252762,4252766,4252873,4252936,4252942,4253003,4253075,4253130,4253134,4253165,4253169,4253170,4253171,4253172,4253243,4253288,4253342,4253464,4253491,4253760,4253884,4253929,4253930,4253932,4253933,4253943,4253976,4254064,4254080,4254095,4254117,4254158,4254257,4254365,7972459,7975373,11110658,11110743,11110779,11110790,11110844,11110946,11110953,1",24660,NULL,NP_058733,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P25094,NULL
624129,2,Dose Response confirmation of uHTS hits from a small molecule antagonists of the CXCR6 receptor in a screening assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number:  1R03MH095589-01 (Cycle 18)_|_Assay Provider:  Gregory Roth Ph.D., Sanford Burnham Medical Research Institute._|__|_Prostate cancer (PCa) is the second leading cause of cancer death in American men and its morbidity has increased globally in recent years. The high m",14,Burnham Center for Chemical Genomics,SBCCG-A845-CXCR6-DMSO-Panel-Assay,20120508,"1570,2722,2788,2817,6301,18990,33528,74204,81400,82533,83156,85555,97637,99844,101486,161167,179617,200953,220284,227494,234636,239578,241787,241808,242563,243574,248597,252247,265711,270378,272837,273465,275684,282938,288760,291921,291923,303610,305244,313603,313619,324571,325517,328009,330973,334410,334858,336424,336482,341502,342201,360474,360560,367978,371711,373493,376034,378512,381504,381511,381514,388993,389753,392787,394239,394449,395402,396733,397604,404470,404472,436058,457901,495575,512832,630233","845207,847169,847784,850450,855601,858019,858026,860445,862514,864052,865625,3712283,3712980,3715548,4242820,4244475,4244637,4246149,4248004,4249557,4250780,4254448,4254770,4258900,4259843,4259886,4260674,4263559,7965379,7966015,7966115,7968539,7970265,7970946,7970980,7971643,7977964,14721057,14724991,14725477,14726330,14726352,14727254,14727639,14727718,14728984,14729238,14730541,14731075,14731317,14731515,14731800,14732895,14734290,14734519,14734630,14736320,14736710,14736780,14738788,14738847,14739172,14","187,1235,10663",NULL,"NP_004358,NP_004358,NP_005152,NP_005152,NP_005152,NP_006555,NP_006555,NP_006555,NP_006555,NP_006555,Q8VNN2",NIH Initiatives,"11017100,14625285,18452560",0,10.1038/79738|10.1074/jbc.m311660200|10.1111/j.1349-7006.2008.00833.x,3.2.1.23,"O00574,P35414,P51684,Q8VNN2",NULL
624031,2,S16 Schwann cell viability assay (CellTiter-Glo assay),"Charcot-Marie-Tooth-Association [CMTA]_|_National Center for Advancing Translational Sciences  [NCATS]_|__|_Charcot-Marie-Tooth (CMT) disease was first characterized by Jean-Martin Charcot and Pierre Marie in France and, independently, by Howard Henry Tooth in England in 1886. CMT is one of the most common inherited neurological diseases, affecting approximately 1 in 2,500 Americans. CMT patients typically exhibit muscle atrophy in the extremities and sensory loss. The most prevalent type of CMT is known as",2,National Center for Advancing Translational Sciences (NCATS),cmt-p4-fda-celltiter_regid,20120430,"51,119,180,190,196,205,206,227,244,263,298,323,359,370,379,408,453,460,464,546,564,588,594,595,612,681,710,727,736,753,774,785,791,798,827,830,863,864,866,876,887,892,896,904,931,936,938,967,978,985,1004,1018,1023,1030,1046,1050,1051,1052,1053,1057,1072,1080,1110,1123,1131,1132,1140,1174,1176,1203,1234,1236,1254,1292,1355,1359,1483,1546,1676,1683,1687,1727,1732,1775,1892,1935,1967,1979,1983,1984,1985,1986,1989,1990,2000,2005,2017,2018,2052,2061,2075,2081,2082,2083,2088,2099,2116,2118,2119,2120,2122,2123,213","3714055,4252459,4252462,4252481,4252484,4252489,4252498,4252505,4252514,4252542,4252550,4252556,4252663,4252664,4252672,4252673,4252682,4252707,4252720,4252736,4252762,4252766,4252873,4252936,4252942,4253003,4253075,4253130,4253134,4253165,4253169,4253170,4253171,4253172,4253243,4253288,4253342,4253464,4253491,4253760,4253884,4253929,4253930,4253932,4253933,4253943,4253976,4254064,4254080,4254095,4254117,4254158,4254257,4254365,7972459,7975373,11110658,11110743,11110779,11110790,11110844,11110946,11110953,1",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
624167,2,Dose Response confirmation of uHTS small molecule Peg3 Promoter Inhibitor hits in a screening assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBIMR, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 2R01 GM068385-06_|_Assay Provider:  Paul B. Fisher, M.Ph., Ph.D., Virginia Commonwealth University_|__|_Cancer is a progressive disease culminating in the acquisition of metastatic potential by a subset of evolving tumor cells. Although extensively investigated, the",14,Burnham Center for Chemical Genomics,SBCCG-A846-PEG3-DMSO-Panel-Assay,20120522,"1401,1821,2453,2569,2722,2788,4641,6197,9444,11352,14161,14710,18990,33144,54368,60496,60834,62878,65557,72735,82498,83851,85555,93572,97762,101486,105671,108155,122815,124496,145758,148673,159917,161167,174343,179617,206388,219207,225484,227345,231422,232570,233768,233874,237305,248597,260168,260556,261066,263463,265935,266923,275781,279782,280615,282938,288101,295538,306691,313614,317081,319735,327045,328774,333096,334858,337396,341816,354677,361816,361838,365002,368778,371509,371711,376034,377877,381504,","847444,848084,848269,855601,856443,856525,857381,857886,857898,858166,858235,858954,858986,859211,859633,860114,860541,861945,863620,864475,3711421,3712282,3712992,3713133,3714130,3714284,3714425,3714493,3715644,3715852,3716305,3716485,3716724,4240627,4241720,4242680,4243251,4243651,4243980,4245031,4247100,4249772,4250640,4250780,4251127,4254571,4255902,4256991,4257840,4259021,4261133,4261716,4261863,4262159,4262950,4262957,4263122,7964734,7966286,7967684,7970545,7970627,7970738,7971349,7972883,7973536,7973","2597,171071",NULL,"NP_598230,NP_598230,NP_598230,NP_598230,P04406,P04406,P04406",NIH Initiatives,10918598,0,10.1038/sj.onc.1203666,"1.2.1.12,2.6.99.-","P04406,Q6IN02",NULL
624344,2,Dose Response confirmation of uHTS small molecule hits for cystic fibrosis induced NFkb Inhibitors in a panel assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: IR21 NS061743-01_|_Assay Provider:  Rangan Maitra, Ph.D., RTI International University_|__|_The inflammatory response in Cystic Fibrosis (CF) is a complex interplay between several factors.  It has been suggested that pro-inflammatory cytokines are elevated in the ep",14,Burnham Center for Chemical Genomics,SBCCG-A856-CF-PAF-Panel-Assay,20120627,"1689,2363,3037,3820,4865,5092,6197,6769,16543,16547,20502,29893,34920,41946,64971,80481,87372,95587,97865,100037,161167,163751,216328,219325,221032,223708,228252,230798,231435,231773,233768,238735,240936,244087,253602,255330,257278,259213,267221,267860,269217,270811,270853,270861,278502,282082,283489,286354,288865,291128,297252,299926,300573,303610,308437,310867,314312,315392,321017,323007,323649,327536,343070,345759,353380,383253,383285,386355,421494,494161,496134,496244,509245,546854,568592,589102,622172,","844670,844782,845318,846220,849081,850126,855669,855869,856044,856076,856542,857125,857211,857562,857755,859461,860058,860288,860575,861070,861154,861167,861415,861516,861637,861945,861949,863162,863937,864478,864609,864658,865636,3711912,3712888,3714463,3716103,3716833,3717942,4240489,4242113,4243143,4247898,4248317,4250167,4250972,4252159,4255093,4255098,4256168,4256714,4258190,4261757,4262901,4263153,4264577,4264941,4265193,4265292,4265459,4265481,7964790,7965251,7965355,7965424,7965705,7966235,7967048,7",1080,NULL,"NP_000483,NP_000483,NP_000483,NP_000483",NIH Initiatives,"10400842,15661927,16239509,7544594",0,10.1016/s0091-6749(99)70116-8|10.1128/iai.73.11.7151-7160.2005|10.1165/ajrcmb.13.3.7544594|10.4049/jimmunol.174.3.1638,5.6.1.6,P13569,NULL
624504,1,Single concentration confirmation of uHTS inhibitor hits of the mitochondrial permeability transition pore via a fluorescent based assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH096534-01 _|_Assay Provider: Michael Forte, Ph.D., Oregon Health & Science University, Portland, OR_|__|_Given its multifactorial roles, regulation of cellular Ca2+ metabolism and bioenergetics functions as an integrated system. In terms of normal physiology",14,Burnham Center for Chemical Genomics,SBCCG-A888-mtPTP-CP-Assay,20120821,"992,2162,2247,2799,3035,3037,3126,3220,3396,3598,3634,4011,4211,4477,4748,5059,5376,5405,5564,5614,6240,6320,7085,7329,9340,9365,10662,11061,11852,11859,13619,13752,16362,16547,16955,19495,20043,20784,21013,22324,24351,26695,29893,31475,37392,40813,42574,43795,47484,50088,51028,55694,55704,60496,60795,60834,62034,62857,62878,62969,63009,65327,65329,65341,65464,65557,66062,66069,66714,67275,67277,68539,68617,71060,71177,71420,71478,71821,73078,73157,74495,74989,76915,77215,79174,79309,80481,91499,91754,92783","842387,842476,843298,843487,843549,843813,843814,843883,844118,844425,844482,844530,844547,844670,845189,845357,845619,845870,846141,846304,846396,846557,846656,846706,846731,846852,846969,847110,847243,847327,847426,847825,847836,848224,848362,848424,848529,848536,848547,848570,848884,849061,849360,849504,849761,849876,850065,850196,850340,850687,851085,851115,851321,851377,852023,852091,852388,852712,852878,852924,853028,853296,853484,853529,855516,855591,855640,855668,855693,855785,855832,855892,856256,8",NULL,NULL,NULL,NIH Initiatives,"10508231,16087232,16649987,17294078,18400691,19161975",0,10.1007/s10495-007-0723-y|10.1016/j.bbabio.2008.12.011|10.1016/j.ceca.2005.06.011|10.1111/j.1742-4658.2006.05213.x|10.1152/physiol.00046.2007|10.1152/physrev.1999.79.4.1127,NULL,NULL,NULL
624141,1,SMM c-myc Measured in Biochemical System Using Small Molecule MicroArray - 2081-01_Other_SinglePoint_HTS_Activity,"Keywords:_|_c-myc, SMM, F/B_|__|_Assay Overview:_|_Small Molecule Microarrays (SMM) are generated by covalently immobilizing small molecules on an isocyanate surface glass slide. SMMs are incubated with the his-tagged transcription factor c-Myc target protein solution at 4 degrees for 2 hours. The slides are then breifly washed and incubated with a conjugated anti-His tag antibody. Slides are breifly washed, dried, and scanned . Fluorescence on each spot is monitored and a spot that exhibits a Fluorecence o",31,Broad Institute,2081-01_Other_SinglePoint_HTS_Activity,20120510,"86,323,861,903,1203,1204,1225,1236,1240,1241,1243,1257,1302,1342,1456,1493,1534,1564,1573,1585,1691,1713,1720,1733,1794,1833,1853,1858,1863,1973,1989,2002,2031,2044,2064,2072,2083,2122,2132,2159,2203,2229,2253,2264,2267,2293,2310,2311,2333,2336,2356,2377,2378,2399,2400,2419,2422,2426,2428,2448,2457,2460,2462,2467,2512,2545,2583,2603,2608,2674,2687,2689,2690,2691,2703,2710,2724,2725,2743,2754,2756,2763,2776,2777,2782,2790,2804,2832,2833,2856,2876,2904,2948,2956,2984,3003,3016,3038,3055,3065,3066,3077,3105,31","85787110,85787111,85787112,85787113,85787115,85787116,85787117,85787119,85787120,85787122,85787124,85787126,85787127,85787128,85787129,85787130,85787132,85787133,85787134,85787135,85787136,85787137,85787138,85787139,85787140,85787143,85787144,85787145,85787146,85787147,85787149,85787151,85787152,85787154,85787155,85787156,85787157,85787158,85787161,85787162,85787163,85787164,85787165,85787166,85787167,85787168,85787169,85787172,85787173,85787176,85787177,85787178,85787179,85787182,85787183,85787187,85787189",4609,Biochemical,NP_002458,NIH Initiatives,NULL,0,NULL,NULL,P01106,NULL
624139,1,NF-KappaB Measured in Biochemical System Using Small Molecule MicroArray - 2080-01_Other_SinglePoint_HTS_Activity,"Keywords: SMM , NF-KappaB, P50, F/B_|__|_Assay Overview:_|_Small Molecule Microarrays (SMM) are generated by covalently immobilizing small molecules on an isocyanate surface glass slide. SMMs are incubated with the his-tagged NF-KappaB P50 subunit (Nuclear factor of kappa light polypeptide gene enhancer in B-cell1 P50 subunit) target protein solution at 4 degrees for 2 hours. The slides are then breifly washed and incubated with a conjugated anti-His tag antibody. Slides are breifly washed, dried, and scann",31,Broad Institute,2080-01_Other_SinglePoint_HTS_Activity,20120509,"86,323,861,903,1203,1204,1225,1236,1240,1241,1243,1257,1302,1342,1456,1493,1534,1564,1573,1585,1691,1713,1720,1733,1794,1833,1853,1858,1863,1973,1989,2002,2031,2044,2064,2072,2083,2122,2132,2159,2203,2229,2253,2264,2267,2293,2310,2311,2333,2336,2356,2377,2378,2399,2400,2419,2422,2426,2428,2448,2457,2460,2462,2467,2512,2545,2583,2603,2608,2674,2687,2689,2690,2691,2703,2710,2724,2725,2743,2754,2756,2763,2776,2777,2782,2790,2804,2832,2833,2856,2876,2904,2948,2956,2984,3003,3016,3038,3055,3065,3066,3077,3105,31","85787110,85787111,85787112,85787113,85787115,85787116,85787117,85787119,85787120,85787122,85787124,85787126,85787127,85787128,85787129,85787130,85787132,85787133,85787134,85787135,85787136,85787137,85787138,85787139,85787140,85787143,85787144,85787145,85787146,85787147,85787149,85787151,85787152,85787154,85787155,85787156,85787157,85787158,85787161,85787162,85787163,85787164,85787165,85787166,85787167,85787168,85787169,85787172,85787173,85787176,85787177,85787178,85787179,85787182,85787183,85787187,85787189",4790,Biochemical,NP_003989,NIH Initiatives,NULL,0,NULL,NULL,P19838,NULL
624136,1,mutant P53 Measured in Biochemical System Using Small Molecule MicroArray - 2077-01_Other_SinglePoint_HTS_Activity,"Keywords: P53 , F/B, SMM_|__|_Assay Overview:_|_Small Molecule Microarrays (SMM) are generated by covalently immobilizing small molecules on an isocyanate surface glass slide. SMMs are incubated with a GST tagged mutant tumor supressor P53 (a transcription factor that effectively blocks cell cycle progression or induce apoptosis in response to diverse forms of stress) target protein solution at 4 degrees for 2 hours. The slides are then breifly washed and incubated with a conjugated anti-His tag antibody. S",31,Broad Institute,2077-01_Other_SinglePoint_HTS_Activity,20120509,"86,323,861,903,1203,1204,1225,1236,1240,1241,1243,1257,1302,1342,1456,1493,1534,1564,1573,1585,1691,1713,1720,1733,1794,1833,1853,1858,1863,1973,1989,2002,2031,2044,2064,2072,2083,2122,2132,2159,2203,2229,2253,2264,2267,2293,2310,2311,2333,2336,2356,2377,2378,2399,2400,2419,2422,2426,2428,2448,2457,2460,2462,2467,2512,2545,2583,2603,2608,2674,2687,2689,2690,2691,2703,2710,2724,2725,2743,2754,2756,2763,2776,2777,2782,2790,2804,2832,2833,2856,2876,2904,2948,2956,2984,3003,3016,3038,3055,3065,3066,3077,3105,31","85787110,85787111,85787112,85787113,85787115,85787116,85787117,85787119,85787120,85787122,85787124,85787126,85787127,85787128,85787129,85787130,85787132,85787133,85787134,85787135,85787136,85787137,85787138,85787139,85787140,85787143,85787144,85787145,85787146,85787147,85787149,85787151,85787152,85787154,85787155,85787156,85787157,85787158,85787161,85787162,85787163,85787164,85787165,85787166,85787167,85787168,85787169,85787172,85787173,85787176,85787177,85787178,85787179,85787182,85787183,85787187,85787189",7157,Biochemical,ACI25593,NIH Initiatives,NULL,0,NULL,NULL,ACI25593,NULL
624138,1,SMM STAT-3 Measured in Biochemical System Using Small Molecule MicroArray - 2076-01_Other_SinglePoint_HTS_Activity_Set2,"Keywords: STAT-3 , F/B, SMM_|__|_Assay Overview:_|_Small Molecule Microarrays (SMM) are generated by covalently immobilizing small molecules on an isocyanate surface glass slide. SMMs are incubated with the his-tagged STAT3 (a transcription factor that emerged as synergistic initiators and master regulators of mesenchymal transformation) target protein solution at 4 degrees for 2 hours. The slides are then breifly washed and incubated with a conjugated anti-His tag antibody. Slides are breifly washed, dried",31,Broad Institute,2076-01_Other_SinglePoint_HTS_Activity_Set2,20120509,"86,323,861,903,1203,1204,1225,1236,1240,1241,1243,1257,1302,1342,1456,1493,1534,1564,1573,1585,1691,1713,1720,1733,1794,1833,1853,1858,1863,1973,1989,2002,2031,2044,2064,2072,2083,2122,2132,2159,2203,2229,2253,2264,2267,2293,2310,2311,2333,2336,2356,2377,2378,2399,2400,2419,2422,2426,2428,2448,2457,2460,2462,2467,2512,2545,2583,2603,2608,2674,2687,2689,2690,2691,2703,2710,2724,2725,2743,2754,2756,2763,2776,2777,2782,2790,2804,2832,2833,2856,2876,2904,2948,2956,2984,3003,3016,3038,3055,3065,3066,3077,3105,31","85787110,85787111,85787112,85787113,85787115,85787116,85787117,85787119,85787120,85787122,85787124,85787126,85787127,85787128,85787129,85787130,85787132,85787133,85787134,85787135,85787136,85787137,85787138,85787139,85787140,85787143,85787144,85787145,85787146,85787147,85787149,85787151,85787152,85787154,85787155,85787156,85787157,85787158,85787161,85787162,85787163,85787164,85787165,85787166,85787167,85787168,85787169,85787172,85787173,85787176,85787177,85787178,85787179,85787182,85787183,85787187,85787189",6774,Biochemical,NP_644805,NIH Initiatives,NULL,0,NULL,NULL,P40763,NULL
624326,2,"Dose response confirmation of small molecule inhibitors of the thioesterase domain of fatty acid synthase via a kinetic, fluorescence intensity assay","Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R03MH095532-01_|_Assay Provider: Dr. Jeffrey Smith, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_This study will focus on developing drug-like inhibitors/probes against fatty acid synthase, an enzyme that is essential for growth of solid tumors.   ",14,Burnham Center for Chemical Genomics,SBCCG-A867-FAS-TE-Kinetic-DMSO-DR-Assay,20120622,"3598,7329,11852,72571,220366,221330,228946,228947,229183,229197,229216,235292,268751,270779,276685,282415,282594,293085,293227,298755,308963,315805,330815,334858,339730,360404,360443,381511,395179,496641,568849,610612,624519,649031,652579,652747,654842,656211,657154,658006,658830,658973,662584,663743,663900,664366,665449,666267,666479,667043,667341,672446,675719,675893,695642,699557,705245,709746,716982,756543,767837,782283,784670,786671,806205,807827,814715,823709,828211,832985,862152,873835,877371,878649,","850070,857479,857625,861334,862514,865021,865225,866081,3714540,4241813,4245475,4248907,4252228,4252268,4255460,4256399,4256447,4258016,4258523,4258801,4261503,4261854,4263631,4263671,4265196,4265767,7965466,7969549,7971224,7973446,7973467,7974416,7974980,7977943,14718944,14720488,14720805,14722177,14723513,14726721,14726730,14727639,14728180,14728475,14729147,14729913,14730128,14730454,14731333,14733549,14734157,14734280,14734497,14735158,14736780,14737398,14737494,14737610,14739832,14739896,14740484,14740",2194,NULL,NP_004095,NIH Initiatives,"10716717,1374214,17620441,18796435,8022791,9191002",0,10.1016/s0046-8177(97)90177-5|10.1073/pnas.050582897|10.1073/pnas.91.14.6379|10.1074/jbc.m803384200|10.1093/ajcp/97.5.686|10.1158/1535-7163.mct-07-0187,"1.1.1.100,1.3.1.39,2.3.1.38,2.3.1.39,2.3.1.41,2.3.1.85,3.1.2.14,4.2.1.59",P49327,NULL
624327,2,Dose response confirmation of uHTS inhibitor hits of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R03MH095532-01_|_Assay Provider: Dr. Jeffrey Smith, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_This study will focus on developing drug-like inhibitors/probes against fatty acid synthase, an enzyme that is essential for growth of solid tumors.   ",14,Burnham Center for Chemical Genomics,SBCCG-A866-FAS-TE-DMSO-DR-Assay,20120622,"3598,7329,11852,72571,220366,221330,228946,228947,229183,229197,229216,235292,268751,270779,276685,282415,282594,293085,293227,298755,308963,315805,330815,334858,339730,360404,360443,381511,395179,496641,568849,610612,624519,649031,652579,652747,654842,656211,657154,658006,658830,658973,662584,663743,663900,664366,665449,666267,666479,667043,667341,672446,675719,675893,695642,699557,705245,709746,716982,756543,767837,782283,784670,786671,806205,807827,814715,823709,828211,832985,862152,873835,877371,878649,","850070,857479,857625,861334,862514,865021,865225,866081,3714540,4241813,4245475,4248907,4252228,4252268,4255460,4256399,4256447,4258016,4258523,4258801,4261503,4261854,4263631,4263671,4265196,4265767,7965466,7969549,7971224,7973446,7973467,7974416,7974980,7977943,14718944,14720488,14720805,14722177,14723513,14726721,14726730,14727639,14728180,14728475,14729147,14729913,14730128,14730454,14731333,14733549,14734157,14734280,14734497,14735158,14736780,14737398,14737494,14737610,14739832,14739896,14740484,14740",2194,NULL,NP_004095,NIH Initiatives,"10716717,1374214,17620441,18796435,8022791,9191002",0,10.1016/s0046-8177(97)90177-5|10.1073/pnas.050582897|10.1073/pnas.91.14.6379|10.1074/jbc.m803384200|10.1093/ajcp/97.5.686|10.1158/1535-7163.mct-07-0187,"1.1.1.100,1.3.1.39,2.3.1.38,2.3.1.39,2.3.1.41,2.3.1.85,3.1.2.14,4.2.1.59",P49327,NULL
624405,2,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Other_Dose_CherryPick_Activity,"Keywords: 3-hydroxy-3methylglutaryl-coenzyme A (HMG-CoA) inhibitors, low-density lipoprotein (LDL), statin, muscle toxicity, ATP, cholesterol biogenesis, C2C12 myotubes, simvastatin,_|__|_Assay Overview: Mouse C2C12 myoblasts can be differentiated to myotubes when grown to confluency in the presence of 2% horse serum.  This differentiation causes the cells to fuse to form syncytial myotubes characteristic of muscle tissue.  It was previously shown that C2C12 myotubes treated with 10uM simvastatin show a phe",31,Broad Institute,2112-01_Other_Dose_CherryPick_Activity,20120723,"2199,6197,6821,8338,8570,8588,17599,78268,81493,95108,220437,223211,223561,233991,239197,239713,240900,241012,241689,242586,258011,262698,281093,294566,306464,308661,319496,349626,350697,373719,379402,534121,535305,540424,572777,588745,593654,604408,608033,608338,612869,619417,623348,644514,644605,644658,644716,644788,644962,645193,645574,645649,645918,646049,646079,646379,646480,646547,646745,646771,646885,647228,647321,647368,647621,647686,647777,647835,647866,647944,648156,648174,648603,648923,649013,649","842254,842347,842390,842518,842691,842921,843294,843359,843620,843785,844069,844164,844235,844445,844558,844897,844981,845030,845281,845342,845426,845516,845588,845793,845812,846222,846531,846617,846619,846627,846651,846835,846868,846898,846918,846979,847013,847253,847331,847337,847450,847468,847602,847779,847956,848119,848124,848211,848339,848555,848947,848983,849006,849054,849175,849735,849852,850227,850255,850453,850501,850748,850971,851259,851397,851483,851546,851564,851612,851676,851840,851940,851988,8",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
624157,2,Inhibitors of galactofuranose residues in Mycobacterium Tuberculosis,"Tuberculosis (TB) is globally the most widespread infectious disease. Two billion people, one third of the world's population, are infected with Mycobacterium tuberculosis and 5-10% of these suffer active disease, leading to nearly 3 million deaths annually. The alarming world-wide increase in multidrug-resistant and extensively drug-resistant TB calls for new anti-mycobacterial drugs against new types of targets that are less likely to undergo mutations that lead to drug resistance._|__|_We are interested ",33,Southern Research Specialized Biocontainment Screening Center,TB_UGM_BACTGROWTH01,20120628,NULL,"125082045,125082046,125082047,125082048,125082049,125082050,125082051,125082052,125082053,125082054,125082055",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
624491,2,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_Dose_CherryPick_Activity,"Keywords: N-Linked Glycosylation,  luciferase reporter, reporter gene assay, luciferin, luminescence, receptor tyrosine kinases_|__|__|_Assay Overview:_|_N-linked glycosylation is a highly regulated, site-specific protein modification important for the stability and folding  of transmembrane proteins. Formation of mature carbohydrate structures requires at least twenty different enzymes and a membrane. Although N-linked glycosylation bioprocess employs up to twenty known enzymes to date, currently there is ",31,Broad Institute,2146-01_Inhibitor_Dose_CherryPick_Activity,20120816,"2854,3687,3820,5265,5311,5905,6035,7085,42725,43640,53232,54454,64715,72735,72827,81400,85070,95263,98059,100710,100761,114429,121848,124496,125001,132163,145758,150655,161091,182791,185146,188677,219206,221307,226752,227453,228624,232570,232850,232950,232951,236184,237765,240061,241787,242178,242436,244701,247550,248466,251355,252074,255605,256604,258692,260504,263521,265292,265522,265580,267286,269217,269919,272110,272112,274950,276225,279426,282594,282697,285026,285758,286183,296314,296316,305322,307192,","842151,843035,843404,843426,844185,844279,844649,845121,845755,846033,846509,847478,847871,849318,849343,849396,850289,850589,851173,852615,853686,855901,856050,856075,856443,857056,858184,858634,858704,858908,859168,859633,860176,860182,860229,861034,861137,861321,861716,862119,862271,862346,862521,862845,863171,863570,863572,864460,865038,865063,865502,865658,3711591,3712570,3713362,3713578,3714774,3715848,3715895,3716060,3716957,3717539,4240477,4240489,4240859,4240946,4241106,4241224,4241422,4242001,4242",NULL,Cell-based,NULL,NIH Initiatives,20413434,0,10.1158/1078-0432.ccr-09-3331,NULL,NULL,NULL
624474,2,Dose Response Confirmation of SKN-1 Inhibitor hits in a fluorescence ratio assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number: 1R21NS067678-01_|_Assay Provider: Keith Choe, Ph.D., University of Florida, Fl_|__|_Nematodes parasitize ~1/3 of humans world-wide. Helminth targeting drugs, or anthelmintics, have been used to control parasitic nematodes for decades and many species are evolving multidru",14,Burnham Center for Chemical Genomics,SBCCG-A886-SKN1-Inh-DMSO-DR-Assay,20130315,"441,2361,3197,6706,7087,7421,8408,9922,10295,11293,13271,16679,21749,24056,26160,30897,36851,65758,66486,76075,76930,79322,79529,82516,96695,96845,96854,98136,98148,181390,219326,219776,220147,220594,227530,230606,230761,233874,234165,234468,236319,236342,244206,245964,248346,250620,251365,252398,254069,254070,255025,256438,256445,256447,259756,259840,261391,264329,266705,270482,272027,278529,278716,288768,289769,290289,298285,299645,300574,300580,307139,308065,312385,320930,326670,329187,329201,335306,3397","842256,842286,842305,842687,842819,843029,843174,843292,843417,843626,843663,843899,843901,844246,844434,844524,844555,844608,844858,845563,845697,845900,845992,846040,846208,846222,846450,846500,846525,846654,846707,846752,846898,846910,846945,846979,847089,847349,847704,848143,848360,848365,848385,848492,848867,849827,850060,850063,850118,850185,850222,850460,850494,850576,850812,850815,850821,851661,851709,852031,852353,852640,852647,852688,852939,856106,856274,856460,856525,856839,856931,857840,857843,8",177343,NULL,NP_741406,NIH Initiatives,"19575768,19627265,20585349,7939715",0,10.1111/j.1474-9726.2009.00473.x|10.1111/j.1474-9726.2009.00501.x|10.1126/science.7939715|10.1371/journal.pone.0011194,NULL,P34707,NULL
624351,2,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP - Counter Screen Coupled Enzyme,"Southern Research's Specialized Biocontainment Screening Center (SRSBSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Assay Provider: Krister Wennerberg, FIMM & Southern Research Institute_|_Award: 1 R03 MH096578-01 _|__|_The Ras superfamily of small G-protein comprises more than 150 proteins (Wennerberg et al., 2005) and in their function as molecular switches they regulate steps in almost all aspects of cellular signaling, includi",33,Southern Research Specialized Biocontainment Screening Center,MgcRacGap_CE_CS01,20120703,"1864,2268,4212,6842,7090,7108,7111,7546,7567,8411,8413,8588,8765,8816,9212,10842,10855,11293,11316,14358,15529,16414,16955,17599,20499,21373,21504,23119,32875,40304,40586,41206,65558,66672,66732,66807,67062,67065,68094,68106,68297,72276,72512,72571,72628,72705,74491,79394,80417,81131,83156,84572,85517,91499,95477,96927,97167,97289,98192,100519,108155,108661,114776,118982,124496,136624,152086,160157,160818,162461,165308,176170,182785,185848,198995,199391,219926,223368,223470,223471,223840,224178,224641,22715","842488,842838,843172,843192,843313,843317,843652,843787,844306,844401,844433,844645,845069,845123,845457,845543,845549,845960,846098,846128,846475,846945,846996,847415,848613,849311,849433,849468,849899,850121,850373,850379,850466,850490,850576,850802,850965,851294,852758,852900,852949,853193,853249,855650,855899,856092,856252,856524,856532,856534,857044,857297,857837,857880,858185,858274,858873,858893,859668,860462,860629,861361,861384,861532,861740,861899,861977,862796,862844,862846,863245,863323,863447,8",NULL,Biochemical,NULL,NIH Initiatives,15731001,0,10.1242/jcs.01660,NULL,NULL,NULL
624252,2,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair: Hit Confirmation with Unstimulated Viability Assay,"Cancer cells divide rapidly compared to normal cells in the body. During cell division, cancer cells need to duplicate their genome by DNA replication. The failure of genome duplication leads to cancer cells' death. Therefore, inhibitors of DNA replication could specifically kill cancer cells. Based on this concept, many chemotherapeutic agents were developed and have been used to treat cancer patients. However, there are a limited number of agents available in the clinical setting, and some of those that d",2,National Center for Advancing Translational Sciences (NCATS),ELG437,20120604,"1830,1983,2048,2051,2082,3201,4119,4122,4261,4817,5298,5339,5649,9427,9444,10156,11377,23205,37783,53708,66834,94525,99938,237358,243723,252925,253602,349934,351332,444732,466276,478574,490036,533557,537520,541723,544174,573993,617341,630400,642384,645210,645509,646398,648009,648044,648438,648826,649032,649171,649788,649949,652133,652192,652316,652384,652610,652633,652753,653445,653549,654714,655328,655811,656062,656286,656378,657692,657896,658106,658751,658814,658842,658865,658914,659111,659352,659552,6595","842939,843225,844088,845654,845681,846066,846437,846636,846778,847393,847542,849635,849685,849805,849876,850103,850126,850244,850899,850996,852110,852694,853160,853407,853628,853719,856322,856542,856747,857407,857463,857493,857516,857562,857755,858005,858200,858221,858244,858549,859045,860296,861520,861616,862203,862342,862638,862939,862974,863002,863465,864150,864609,865126,865590,3712137,3713326,3713944,3714418,3715378,3715395,3716103,3716187,3716427,3716608,3717257,4237841,4239256,4240749,4240846,4241878",79915,NULL,AAH15051,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAH15051,NULL
624132,2,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_Dose_CherryPick_Activity,"Keywords:  osteoporosis, Schnurri-3, kappa recognition component_|__|__|_Assay Overview:_|__|_This is a novel physiologically relevant cell-based approach to identify inhibitors of Schnurri-3 (Shn3), a potent and essential regulator of adult bone formation._|__|_This screen will identify specific compounds that target the 3'UTR of Shn3 to post-transcriptionally regulate its mRNA to reduce Shn3 protein levels. This assay uses a SV40 large T antigen-transformed osteoblast cell line (Clone20-Shn3FFL) that main",31,Broad Institute,2134-01_Inhibitor_Dose_CherryPick_Activity,20120508,"1400,2199,2247,3197,4477,5396,5404,5405,5745,6084,6197,6769,12498,14169,23205,31316,33144,52167,53232,62882,67059,71821,72438,77865,81400,89341,91378,91467,91754,98652,100475,107346,130606,148673,148870,156816,176406,179617,203396,225126,226441,226752,233768,234636,235262,236584,240061,240350,243093,245742,246952,253602,254984,255329,255762,260976,263434,268239,268760,268762,268975,270378,270787,271216,272334,272378,272529,272568,275903,288760,298116,299645,310900,310951,315406,327044,328132,328138,328144,3","842204,842762,843298,844482,844525,844737,845300,847146,847393,847836,848536,851085,851321,852129,852303,852388,852701,852911,855514,855836,856091,856196,856251,856521,856525,856536,857195,857372,857621,857655,857671,857885,858068,858151,858220,858389,858611,858889,859630,859637,860183,861001,861006,861817,862514,862638,863149,863423,863619,863659,864658,864787,865957,3711304,3711988,3712502,3712888,3713133,3713760,3714089,3714469,3714582,3714634,3715971,3716076,3716675,3716687,3716773,3717335,3717519,42404",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
624404,2,Counterscreen for inhibitors of NLG  for Luciferase Activators Measured in Cell-Based System Using Plate Reader - 2146-03_Inhibitor_Dose_CherryPick_Activity,"Keywords: N-Linked Glycosylation,  luciferase reporter, reporter gene assay, luciferin, luminescence, counterscreen, non specific luciferase activators_|__|__|_Assay Overview:_|_The counterscreen is designed to eliminate false positives._|_The counterscreen uses  D54 LucT reporter cell line.  This is the same parental cell line as the primary and retest stably transfected with a similar reporter construct as the reporter cell line used in the primary screen.  The reporter construct for the counterscreen con",31,Broad Institute,2146-03_Inhibitor_Dose_CherryPick_Activity,20120723,"2854,3687,3820,5265,5311,5905,6035,7085,42725,43640,53232,54454,64715,72735,72827,81400,85070,95263,98059,100710,100761,114429,121848,124496,125001,132163,145758,150655,161091,182791,185146,188677,219206,221307,226752,227453,228624,232570,232850,232950,232951,236184,237765,240061,241787,242178,242436,244701,247550,248466,251355,252074,255605,256604,258692,260504,263521,265292,265522,265580,267286,269217,269919,272110,272112,274950,276225,279426,282594,282697,285026,285758,286183,296314,296316,305322,307192,","842151,843035,843404,843426,844185,844279,844649,845121,845755,846033,846509,847478,847871,849318,849343,849396,850289,850589,851173,852615,853686,855901,856050,856075,856443,857056,858184,858634,858704,858908,859168,859633,860176,860182,860229,861034,861137,861321,861716,862119,862271,862346,862521,862845,863171,863570,863572,864460,865063,865502,865658,3711591,3712570,3713362,3713578,3714774,3715895,3716060,3716957,3717539,4240477,4240489,4240859,4240946,4241106,4241224,4241422,4242001,4242160,4242163,424",NULL,Cell-based,NULL,NIH Initiatives,20413434,0,10.1158/1078-0432.ccr-09-3331,NULL,NULL,NULL
624300,2,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  HeLa Cytotoxicity,"Southern Research's Specialized Biocontainment Screening Center (SRSBSC)_|_Southern Research Institute (Birmingham, Alabama)_|_NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Assay Provider: Krister Wennerberg, FIMM & Southern Research Institute_|_Award: 1 R03 MH096578-01 _|__|_The Ras superfamily of small G-protein comprises more than 150 proteins (Wennerberg et al., 2005) and in their function as molecular switches they regulate steps in almost all aspects of cellular signaling, includi",33,Southern Research Specialized Biocontainment Screening Center,MgcRacGap_HeLaTox01,20120615,"1864,2268,4212,6842,7090,7108,7111,7546,7567,8411,8413,8588,8765,8816,9212,10842,10855,11293,11316,14358,15529,16414,16955,17599,20499,21373,21504,23119,32875,40304,40586,41206,65558,66672,66732,66807,67062,67065,68094,68106,68297,72276,72512,72571,72628,72705,74491,79394,80417,81131,83156,84572,85517,91499,95477,96927,97167,97289,98192,100519,108155,108661,114776,118982,124496,136624,152086,160157,160818,162461,165308,176170,182785,185848,198995,199391,219926,223368,223470,223471,223840,224178,224641,22715","842488,842838,843172,843192,843313,843317,843652,843787,844306,844401,844433,844645,845069,845123,845457,845543,845549,845960,846098,846128,846475,846945,846996,847415,848613,849311,849433,849468,849899,850121,850373,850379,850466,850490,850576,850802,850965,851294,852758,852900,852949,853193,853249,855650,855899,856092,856252,856524,856532,856534,857044,857297,857837,857880,858185,858274,858873,858893,859668,860462,860629,861361,861384,861532,861740,861899,861977,862796,862844,862846,863245,863323,863447,8",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
624134,2,Shn3: Cytotox assay Measured in Cell-Based System Using Plate Reader - 2134-03_Inhibitor_Dose_CherryPick_Activity,"Keywords:  osteoporosis, Schnurri-3, kappa recognition component_|__|__|_Assay Overview:  The basic assay strategy will consist of HepG2 mammalian cells cultured in 384-well format. Test compounds that do not inhibit subsequent growth will merit further evaluation for their lack of mammalian cell toxicity. Compound activity will be measured by Cell Titer Glo, an ATP reagent._|__|__|_Expected Outcome:  no change in signal from non-toxic compounds, reduction in signal from toxic compounds.",31,Broad Institute,2134-03_Inhibitor_Dose_CherryPick_Activity,20120508,"1400,2199,2247,3197,4477,5396,5404,5405,5745,6084,6197,6769,12498,14169,23205,31316,33144,52167,53232,62882,67059,71821,72438,77865,81400,89341,91378,91467,91754,98652,100475,107346,130606,148673,148870,156816,176406,179617,203396,225126,226441,226752,233768,234636,235262,236584,240061,240350,243093,245742,246952,253602,254984,255329,255762,260976,263434,268239,268760,268762,268975,270378,270787,271216,272334,272378,272529,272568,275903,288760,298116,299645,310900,310951,315406,327044,328132,328138,328144,3","842204,842762,843298,844482,844525,844737,845300,847146,847393,847836,848536,851085,851321,852129,852303,852388,852701,852911,855514,855836,856091,856196,856251,856521,856525,856536,857195,857372,857621,857655,857671,857885,858068,858151,858220,858389,858611,858889,859630,859637,860183,861001,861006,861817,862514,862638,863149,863423,863619,863659,864658,864787,865957,3711304,3711988,3712502,3712888,3713133,3713760,3714089,3714469,3714582,3714634,3715971,3716076,3716675,3716687,3716773,3717335,3717519,42404",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
624146,2,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,"Glutaminase (GLS) catalyzes the hydrolysis of glutamine into glutamate and ammonia. It plays a critical role in glutaminolysis, which is an important energy source for proliferating cells. It was shown that c-Myc, an oncogenic transcription factor known to regulate microRNAs and to stimulate cell proliferation, increases glutamine metabolism by stimulating the expression of GLS via direct suppression of miR23a and miR23b. Glutamine deprivation, or GLS siRNA treatment in PC3 cancer cells or P-493 B lymphoma ",2,National Center for Advancing Translational Sciences (NCATS),GLS001,20120515,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",2744,NULL,AAH38507,Governmental Organizations|NIH Initiatives,"14675161,17581113,17596215,19212100,19219026,19222703",0,10.1038/nature07823|10.1042/bj20070039|10.1046/j.1471-4159.2003.02146.x|10.1111/j.1471-4159.2007.04594.x|10.1111/j.1471-4159.2009.05989.x|10.1620/tjem.217.87,NULL,O94925,NULL
624325,1,Single concentration confirmation of uHTS inhibitor hits of the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R03MH095532-01_|_Assay Provider: Dr. Jeffrey Smith, Sanford-Burnham Medical Research Institute, San Diego CA_|__|_This study will focus on developing drug-like inhibitors/probes against fatty acid synthase, an enzyme that is essential for growth of solid tumors.   ",14,Burnham Center for Chemical Genomics,SBCCG-A865-FAS-TE-CP-Assay,20120622,"3598,7329,11852,72571,164676,220366,221330,223752,223753,228946,228947,229183,229197,229216,235292,268605,268751,270779,276685,279304,282415,282594,293085,293227,298755,308963,312601,315805,321193,330815,334858,339730,351332,360404,360443,378581,380438,381511,382447,383253,383280,392613,394280,395179,420759,496641,568849,610612,624519,645250,646857,647674,648114,648532,649031,649837,649915,650554,652579,652747,653519,654842,656211,657154,657699,658006,658830,658973,659944,660062,660321,661875,662340,662563,","844530,845330,847431,847510,848125,850070,850966,855721,856331,857479,857625,858641,858757,859020,860594,861071,861311,861334,861715,862017,862514,862523,863353,865021,865225,866081,3714107,3714540,3715738,4240522,4240874,4241813,4245104,4245363,4245475,4248270,4248907,4249653,4250922,4251980,4252228,4252268,4255460,4256399,4256447,4257003,4258016,4258065,4258170,4258262,4258523,4258801,4261503,4261854,4263631,4263671,4264812,4265196,4265656,4265767,7965466,7968195,7968960,7969549,7971224,7973446,7973467,79",2194,NULL,NP_004095,NIH Initiatives,"10716717,1374214,17620441,18796435,8022791,9191002",0,10.1016/s0046-8177(97)90177-5|10.1073/pnas.050582897|10.1073/pnas.91.14.6379|10.1074/jbc.m803384200|10.1093/ajcp/97.5.686|10.1158/1535-7163.mct-07-0187,"1.1.1.100,1.3.1.39,2.3.1.38,2.3.1.39,2.3.1.41,2.3.1.85,3.1.2.14,4.2.1.59",P49327,NULL
624378,1,"Luminescence-based cell-based high throughput confirmation assay for agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Konstantin Petrukhin, Columbia University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS061718-01 Fast Track_|_Grant Proposal PI: Konstantin Petrukhin, Columbia University_|_External Assay ID: NR2E3-CELL_AG_LUMI_1536_3X%INH CRUN_|__|_Name: Luminescence-based cell-based high throughput confirmation ",5,The Scripps Research Institute Molecular Screening Center,NR2E3-CELL_AG_LUMI_1536_3X%INH CRUN,20120711,"992,1570,1821,2199,2333,2812,3117,3197,3598,3686,3800,4112,4882,5153,5455,5614,6197,6245,7329,8975,9444,10221,10662,11852,12498,16547,16955,17520,19103,19910,20043,21013,23205,26695,40586,52167,53232,54454,65237,66541,67238,67277,68939,71821,72402,72810,76357,77865,80481,82498,82533,91467,91754,93149,97976,99045,99927,99929,100472,100492,101246,104830,108144,130606,131182,156525,156816,161167,174343,181390,198909,209651,221032,221850,224561,224594,228297,228424,230132,230508,230798,231773,231836,233068,2337","842146,843298,843577,843675,843813,844007,844482,844579,845357,846209,846304,846503,847836,848199,848317,848373,848536,848570,848619,848734,848739,849093,849360,849903,850120,850457,851321,851721,852129,852388,853296,855836,856199,856337,856947,856955,857027,857044,857180,857356,857389,857470,857655,857885,858150,858509,858521,858542,858611,858742,859094,859211,859461,859698,860029,860541,860690,860940,861006,861129,861193,861567,861720,861727,861838,861934,861945,862099,862678,862684,862844,863149,863379,8",10002,Cell-based,BAH02301,NIH Initiatives,"10221899,10805811,11071390,11487564,12842037,12963616,15190009,15634773,15914712,16834531,17255935,17564971,17982421,18294254,18592265",0,10.1001/archopht.121.9.1316|10.1007/s00427-008-0232-1|10.1007/s004390000350|10.1016/s0969-2126(03)00133-3|10.1038/sj.emboj.7601548|10.1073/pnas.97.10.5551|10.1086/518426|10.1089/adt.2006.4.253|10.1093/hmg/10.16.1619|10.1093/hmg/ddh173|10.1111/j.1399-0004.2008.00963.x|10.1126/science.284.5415.757|10.1210/me.2005-0046|10.1523/jneurosci.3571-04.2005,NULL,Q9Y5X4,NULL
624147,2,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,"Members of the Trypanosomatidae family of parasitic protozoans cause a spectrum of diseases throughout the tropical and subtropical world.  Sleeping sickness, caused by two subspecies of Trypanosoma brucei, is endemic to areas of sub-Saharan Africa, while Chagas' disease, a manifestation of Trypanosoma cruzi infection, is prevalent throughout Central and South America.  In addition, many species of Leishmania are responsible for a range of cutaneous and visceral diseases, causing ulcers, destructive lesions",2,National Center for Advancing Translational Sciences (NCATS),TbPyK001,20190821,"119,138,178,199,237,247,249,275,286,289,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,1820","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616,90340617",NULL,NULL,AAX80043,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAX80043,NULL
624455,2,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,"Dopamine receptors (DARs) are involved in the etiology and/or therapy of a number of neuropsychiatric and endocrine disorders. For instance, all receptor-based antiparkinsonian drugs work via stimulating the D2 DAR subtype whereas all FDA-approved antipsychotic agents are antagonists of this receptor. Most drugs targeting the D2 DAR are problematic, however, either being less efficacious as desired or possessing limiting side effects, most of which are due to reactivity at other receptors. One approach towa",2,National Center for Advancing Translational Sciences (NCATS),DOP2402,20120803,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",1812,NULL,AAB26273,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P21728,NULL
624248,2,HTS assay for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1: Hit Confirmation,"Cancer cells divide rapidly compared to normal cells in the body. During cell division, cancer cells need to duplicate their genome by DNA replication. The failure of genome duplication leads to cancer cells' death. Therefore, inhibitors of DNA replication could specifically kill cancer cells. Based on this concept, many chemotherapeutic agents were developed and have been used to treat cancer patients. However, there are a limited number of agents available in the clinical setting, and some of those that d",2,National Center for Advancing Translational Sciences (NCATS),ELG433,20120604,"1830,1983,2051,3201,5298,5339,5649,9444,23205,99938,237358,243723,253602,351332,478574,490036,533557,537520,541723,544174,573993,617341,630400,645210,645509,646398,648009,648044,648438,649032,649788,652133,652192,652316,652384,652610,652633,652753,653445,654714,655328,655811,656062,656286,657692,657896,658106,658751,658814,658842,658865,658914,659111,659352,659552,659587,659861,660344,662758,662855,663426,663570,664178,664212,664239,664720,665398,665851,666376,666849,699222,711025,728950,731991,740791,74215","842939,843225,844088,845654,845681,846066,846636,847393,849635,849685,849805,849876,850103,850126,850244,850899,852110,852694,853160,853407,853628,856322,856542,856747,857407,857463,857493,857516,857562,857755,858005,858200,858221,858244,858549,859045,860296,861520,861616,862203,862342,862638,862939,862974,863002,863465,864150,864609,865126,865590,3713326,3714418,3715378,3715395,3716103,3716427,3717257,4237841,4240749,4240846,4241878,4242089,4242209,4244735,4245796,4245948,4246240,4247604,4249058,4249296,42",79915,NULL,AAH15051,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAH15051,NULL
624379,1,"Counterscreen for agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3): Luminescence-based cell-based high throughput screening assay to identify agonists of the Herpes Virus Virion Protein 16 (VP16)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Konstantin Petrukhin, Columbia University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS061718-01 Fast Track_|_Grant Proposal PI: Konstantin Petrukhin, Columbia University_|_External Assay ID: VP16_AG_LUMI_1536_3X%INH CSRUN_|__|_Name: Counterscreen for agonists of nuclear receptor subfamily 2, grou",5,The Scripps Research Institute Molecular Screening Center,VP16_AG_LUMI_1536_3X%INH CSRUN,20120711,"992,1570,1821,2199,2333,2812,3117,3197,3598,3686,3800,4112,4882,5153,5455,5614,6197,6245,7329,8975,9444,10221,10662,11852,12498,16547,16955,17520,19103,19910,20043,21013,23205,26695,40586,52167,53232,54454,65237,66541,67238,67277,68939,71821,72402,72810,76357,77865,80481,82498,82533,91467,91754,93149,97976,99045,99927,99929,100472,100492,101246,104830,108144,130606,131182,156525,156816,161167,174343,181390,198909,209651,221032,221850,224561,224594,228297,228424,230132,230508,230798,231773,231836,233068,2337","842146,843298,843577,843675,843813,844007,844482,844579,845357,846209,846304,846503,847836,848199,848317,848373,848536,848570,848619,848734,848739,849093,849360,849903,850120,850457,851321,851721,852129,852388,853296,855836,856199,856337,856947,856955,857027,857044,857180,857356,857389,857470,857655,857885,858150,858509,858521,858542,858611,858742,859094,859211,859461,859698,860029,860541,860690,860940,861006,861129,861193,861567,861720,861727,861838,861934,861945,862099,862678,862684,862844,863149,863379,8",NULL,Cell-based,NP_044650,NIH Initiatives,"10221899,10805811,11071390,11487564,12842037,12963616,15190009,15634773,15914712,16834531,17255935,17564971,17982421,18294254,18592265",0,10.1001/archopht.121.9.1316|10.1007/s00427-008-0232-1|10.1007/s004390000350|10.1016/s0969-2126(03)00133-3|10.1038/sj.emboj.7601548|10.1073/pnas.97.10.5551|10.1086/518426|10.1089/adt.2006.4.253|10.1093/hmg/10.16.1619|10.1093/hmg/ddh173|10.1111/j.1399-0004.2008.00963.x|10.1126/science.284.5415.757|10.1210/me.2005-0046|10.1523/jneurosci.3571-04.2005,NULL,NP_044650,NULL
624305,2,qHTS assay for re-activators of p53 using a Luc reporter: Hit Validation,"The p53 tumor suppressor plays a key role in suppression of tumorigenesis and in human carcinogenesis. It is frequently found inactivated in human cancers, mainly by point mutation. These point mutations are found in a wide variety of human cancers and a majority of them affect the DNA binding domain of the protein. The point mutations either alter native p53 conformation or abolish DNA contact. Additionally, cancer cells with p53 mutations are more resistant to chemo-radiation therapies._|__|_In order to f",2,National Center for Advancing Translational Sciences (NCATS),p53200,20120619,"79889,100335,139031,162928,182791,219760,240967,244716,252925,265867,269970,292795,303144,308647,314146,327045,432820,442813,535812,576549,583365,589610,599999,600721,606787,623089,623378,624478,644396,644440,644527,644559,644647,644704,644846,644915,645564,645679,646541,648164,648418,648601,650457,650525,650550,650589,650830,651231,651585,651655,651998,652390,652594,652702,652841,652928,652973,653069,653674,653744,653933,653989,653996,654316,655214,655365,655426,655460,656128,656248,656376,656385,657531,65","842140,842184,842268,842300,842379,842439,842578,842643,843284,843390,844229,845802,846046,846220,848033,848101,848121,848160,848385,848776,849114,849186,849505,849882,850085,850191,850327,850406,850452,850541,851113,851184,851364,851420,851427,851723,852591,852715,852724,852786,852820,853470,853589,853717,853726,856044,856152,856302,856813,856981,857487,857840,857861,857863,857999,858153,858213,858216,858370,858485,858627,858701,858722,859143,859211,859314,859461,859529,859550,859880,860045,860073,860632,8",7157,NULL,BAC16799,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,BAC16799,NULL
624249,2,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1: Hit Confirmation using MMS Stimulated ELG1,"Cancer cells divide rapidly compared to normal cells in the body. During cell division, cancer cells need to duplicate their genome by DNA replication. The failure of genome duplication leads to cancer cells' death. Therefore, inhibitors of DNA replication could specifically kill cancer cells. Based on this concept, many chemotherapeutic agents were developed and have been used to treat cancer patients. However, there are a limited number of agents available in the clinical setting, and some of those that d",2,National Center for Advancing Translational Sciences (NCATS),ELG434,20120604,"1830,1983,2051,3201,5298,5339,5649,9444,23205,99938,237358,243723,253602,351332,478574,490036,533557,537520,541723,544174,573993,617341,630400,645210,645509,646398,648009,648044,648438,649032,649788,652133,652192,652316,652384,652610,652633,652753,653445,654714,655328,655811,656062,656286,657692,657896,658106,658751,658814,658842,658865,658914,659111,659352,659552,659587,659861,660344,662758,662855,663426,663570,664178,664212,664239,664720,665398,665851,666376,666849,699222,711025,728950,731991,740791,74215","842939,843225,844088,845654,845681,846066,846636,847393,849635,849685,849805,849876,850103,850126,850244,850899,852110,852694,853160,853407,853628,856322,856542,856747,857407,857463,857493,857516,857562,857755,858005,858200,858221,858244,858549,859045,860296,861520,861616,862203,862342,862638,862939,862974,863002,863465,864150,864609,865126,865590,3713326,3714418,3715378,3715395,3716103,3716427,3717257,4237841,4240749,4240846,4241878,4242089,4242209,4244735,4245796,4245948,4246240,4247604,4249058,4249296,42",79915,NULL,AAH15051,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAH15051,NULL
624381,1,Luminescence-based cell-based high throughput confirmation assay for agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Laura Bohn_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: DA025158-01A1_|_Grant Proposal PI: Laura Bohn_|_External Assay ID: HTR2A_ACT_LUMI_1536_3X%ACT CRUN_|__|_Name: Luminescence-based cell-based high throughput confirmation assay for agonists of the mouse 5-hydroxytryptamine (serotonin) receptor",5,The Scripps Research Institute Molecular Screening Center,HTR2A_ACT_LUMI_1536_3X%ACT CRUN,20120713,"1340,1832,1833,2215,2662,4140,4552,4650,4678,4692,4994,5070,5335,5359,5909,5924,5983,6088,6421,7436,8468,8975,9367,14987,15284,17748,24109,25681,31840,38258,45592,47812,49659,52096,55397,59286,60795,60961,65324,65327,65329,65340,65944,66259,68938,69085,71401,73484,77409,78438,78559,83932,86470,94318,95221,96453,98289,100493,100984,104895,155107,160436,162386,170617,173870,198284,199200,202477,222169,223541,224468,225319,227518,232269,234415,238485,238674,247260,251939,256646,260315,260390,261673,265171,2708","842198,842229,842364,842481,842596,842963,843285,843638,843850,843902,844541,844959,845292,845468,845844,845880,846143,846154,846415,847245,848390,849871,850988,851498,851682,851751,851878,851936,852974,853155,853253,853296,853556,855513,855560,855721,855832,855844,855873,856146,856720,857244,857318,857464,857539,857629,857673,857734,857885,858018,858028,858109,858297,858551,858578,858862,858963,859002,859194,859229,860867,861113,861215,861257,861529,862182,862386,862823,863014,863553,864004,864234,864681,8",15558,Cell-based,NP_766400,NIH Initiatives,"18195357,18640136,19630576,1980030,20713067,20925600,21218149",0,10.1007/bf01233097|10.1016/j.ddtec.2010.06.005|10.1016/j.neuropharm.2008.06.048|10.1016/j.neuropharm.2010.08.003|10.1073/pnas.0708862105|10.1146/annurev.med.60.042307.110802|10.3109/10409238.2010.516741,NULL,P35363,NULL
624331,2,qHTS assay for re-activators of p53 using a Luc reporter: Hit Validation with no p53 Expressed,"The p53 tumor suppressor plays a key role in suppression of tumorigenesis and in human carcinogenesis. It is frequently found inactivated in human cancers, mainly by point mutation. These point mutations are found in a wide variety of human cancers and a majority of them affect the DNA binding domain of the protein. The point mutations either alter native p53 conformation or abolish DNA contact. Additionally, cancer cells with p53 mutations are more resistant to chemo-radiation therapies._|__|_This counter ",2,National Center for Advancing Translational Sciences (NCATS),p53201,20120625,"79889,100335,139031,162928,182791,219760,240967,244716,252925,265867,269970,292795,303144,308647,314146,327045,432820,442813,535812,576549,583365,589610,599999,600721,606787,623089,623378,624478,644396,644440,644527,644559,644647,644704,644846,644915,645564,645679,646541,648164,648418,648601,650457,650525,650550,650589,650830,651231,651585,651655,651998,652390,652594,652702,652841,652928,652973,653069,653674,653744,653933,653989,653996,654316,655214,655365,655426,655460,656128,656248,656376,656385,657531,65","842140,842184,842268,842300,842379,842439,842578,842643,843284,843390,844229,845802,846046,846220,848033,848101,848121,848160,848385,848776,849114,849186,849505,849882,850085,850191,850327,850406,850452,850541,851113,851184,851364,851420,851427,851723,852591,852715,852724,852786,852820,853470,853589,853717,853726,856044,856152,856302,856813,856981,857487,857840,857861,857863,857999,858153,858213,858216,858370,858485,858627,858701,858722,859143,859211,859314,859461,859529,859550,859880,860045,860073,860632,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
624002,2,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): Confirmation of Cherrypicks,"Malignant glioblastomas (WHO grade IV), including primary and secondary glioblastomas, are among the most lethal with a median survival of one year, and unfortunately they are also the most prevalent type of brain tumors [1]. By and large the standard of care of gliomas remains the use of the oral alkylating agent temozolomide and radiotherapy following surgical tumor resection [2]. There is an urgent unmet medical need for novel therapeutics for gliomas._|__|_IDH mutations occur in up to 70% of grade II-IV",2,National Center for Advancing Translational Sciences (NCATS),IDH002,20120405,"4871,31316,44008,68261,73121,100492,219597,220466,223752,223753,233390,235856,253078,261066,262085,285820,330973,341783,369539,371271,378581,381571,387546,387851,395402,441336,443958,496641,542526,570353,583515,605837,624107,628864,631429,644274,644932,645968,646405,646814,647316,647878,648194,649429,650119,650168,650713,651152,651824,652037,652444,652452,653474,653999,654620,654901,655435,655504,659046,659186,659274,660157,660282,661523,665426,665618,666075,666535,666763,666946,666973,675492,717270,723174,","844095,844486,844976,845834,847034,847759,848275,848701,849335,852013,852795,857687,857834,857920,858850,858979,860218,861174,864178,864370,864827,865685,865712,3711314,3713050,3717767,4241682,4242337,4244318,4245141,4245468,4245892,4246614,4246733,4247666,4247883,4248909,4249243,4250773,4251634,4251800,4254549,4255133,4257863,4258122,4258473,4258919,4259995,4262308,4264240,7973996,7975263,7975670,7977441,7978083,7978364,14720897,14721156,14721719,14721871,14721965,14722003,14724182,14724946,14725132,147254",3417,NULL,ABD77215,Governmental Organizations|NIH Initiatives,"19107440,19228619,19657110,19933982,19935646",0,10.1007/978-1-60327-492-0_14|10.1038/nature08617|10.1056/nejmoa0808710|10.1056/nejmoa0903840|10.1212/wnl.0b013e3181c34ace,NULL,ABD77215,NULL
624251,2,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair: Hit Confirmation with MMS Viability,"Cancer cells divide rapidly compared to normal cells in the body. During cell division, cancer cells need to duplicate their genome by DNA replication. The failure of genome duplication leads to cancer cells' death. Therefore, inhibitors of DNA replication could specifically kill cancer cells. Based on this concept, many chemotherapeutic agents were developed and have been used to treat cancer patients. However, there are a limited number of agents available in the clinical setting, and some of those that d",2,National Center for Advancing Translational Sciences (NCATS),ELG436,20120604,"1830,1983,2051,3201,5298,5339,5649,9444,23205,99938,237358,243723,253602,351332,478574,490036,533557,537520,541723,544174,573993,617341,630400,645210,645509,646398,648009,648044,648438,649032,649788,652133,652192,652316,652384,652610,652633,652753,653445,654714,655328,655811,656062,656286,657692,657896,658106,658751,658814,658842,658865,658914,659111,659352,659552,659587,659861,660344,662758,662855,663426,663570,664178,664212,664239,664720,665398,665851,666376,666849,699222,711025,728950,731991,740791,74215","842939,843225,844088,845654,845681,846066,846636,847393,849635,849685,849805,849876,850103,850126,850244,850899,852110,852694,853160,853407,853628,856322,856542,856747,857407,857463,857493,857516,857562,857755,858005,858200,858221,858244,858549,859045,860296,861520,861616,862203,862342,862638,862939,862974,863002,863465,864150,864609,865126,865590,3713326,3714418,3715378,3715395,3716103,3716427,3717257,4237841,4240749,4240846,4241878,4242089,4242209,4244735,4245796,4245948,4246240,4247604,4249058,4249296,42",79915,NULL,AAH15051,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAH15051,NULL
624380,1,Counterscreen for agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A): Luminescence-based cell-based high throughput screening assay to identify agonists of the mu 1 opioid receptor (OPRM1),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Laura Bohn_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: DA025158-01A1_|_Grant Proposal PI: Laura Bohn_|_External Assay ID: OPRM1_ACT_LUMI_1536_3X%ACT CSRUN (HTR2A)_|__|_Name: Counterscreen for agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A): Luminescence-based cell-based",5,The Scripps Research Institute Molecular Screening Center,OPRM1_ACT_LUMI_1536_3X%ACT CSRUN (HTR2A),20120713,"1340,1832,1833,2215,2662,4140,4552,4650,4678,4692,4994,5070,5335,5359,5909,5924,5983,6088,6421,7436,8468,8975,9367,14987,15284,17748,24109,25681,31840,38258,45592,47812,49659,52096,55397,59286,60795,60961,65324,65327,65329,65340,65944,66259,68938,69085,71401,73484,77409,78438,78559,83932,86470,94318,95221,96453,98289,100493,100984,104895,155107,160436,162386,170617,173870,198284,199200,202477,222169,223541,224468,225319,227518,232269,234415,238485,238674,247260,251939,256646,260315,260390,261673,265171,2708","842198,842229,842364,842481,842596,842963,843285,843638,843850,843902,844541,844959,845292,845468,845844,845880,846143,846154,846415,847245,848390,849871,850988,851498,851682,851751,851878,851936,852974,853155,853253,853296,853556,855513,855560,855721,855832,855844,855873,856146,856720,857244,857318,857464,857539,857629,857673,857734,857885,858018,858028,858109,858297,858551,858578,858862,858963,859002,859194,859229,860867,861113,861215,861257,861529,862182,862386,862823,863014,863553,864004,864234,864681,8",4988,Cell-based,NP_000905,NIH Initiatives,"18195357,18640136,19630576,1980030,20713067,20925600,21218149",0,10.1007/bf01233097|10.1016/j.ddtec.2010.06.005|10.1016/j.neuropharm.2008.06.048|10.1016/j.neuropharm.2010.08.003|10.1073/pnas.0708862105|10.1146/annurev.med.60.042307.110802|10.3109/10409238.2010.516741,NULL,P35372,NULL
624148,2,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,"The overall goal of this project was to develop a novel assay for discovering small molecule ligands for class B1 G protein-coupled receptors (GPCRs).  Very few agonists (or inverse agonists) with generally weak activity for this entire group of physiologically important receptors are known to date.  To establish proof-of-principle that this critical bottleneck can be overcome with a suitable screening approach, our studies focused on the class B1 receptor for glucagon-like peptide-1 (GLP-1R), a potential t",2,National Center for Advancing Translational Sciences (NCATS),GLPA1001,20120516,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",2740,NULL,AAB64013,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAB64013,NULL
624250,2,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair: Hit Confirmation with 5FU Viability,"Cancer cells divide rapidly compared to normal cells in the body. During cell division, cancer cells need to duplicate their genome by DNA replication. The failure of genome duplication leads to cancer cells' death. Therefore, inhibitors of DNA replication could specifically kill cancer cells. Based on this concept, many chemotherapeutic agents were developed and have been used to treat cancer patients. However, there are a limited number of agents available in the clinical setting, and some of those that d",2,National Center for Advancing Translational Sciences (NCATS),ELG435,20120604,"1830,1983,2051,3201,5298,5339,5649,9444,23205,99938,237358,243723,253602,351332,478574,490036,533557,537520,541723,544174,573993,617341,630400,645210,645509,646398,648009,648044,648438,649032,649788,652133,652192,652316,652384,652610,652633,652753,653445,654714,655328,655811,656062,656286,657692,657896,658106,658751,658814,658842,658865,658914,659111,659352,659552,659587,659861,660344,662758,662855,663426,663570,664178,664212,664239,664720,665398,665851,666376,666849,699222,711025,728950,731991,740791,74215","842939,843225,844088,845654,845681,846066,846636,847393,849635,849685,849805,849876,850103,850126,850244,850899,852110,852694,853160,853407,853628,856322,856542,856747,857407,857463,857493,857516,857562,857755,858005,858200,858221,858244,858549,859045,860296,861520,861616,862203,862342,862638,862939,862974,863002,863465,864150,864609,865126,865590,3713326,3714418,3715378,3715395,3716103,3716427,3717257,4237841,4240749,4240846,4241878,4242089,4242209,4244735,4245796,4245948,4246240,4247604,4249058,4249296,42",79915,NULL,AAH15051,Governmental Organizations|NIH Initiatives,79915,0,10.1016/s0140-6736(78)92881-7,NULL,AAH15051,NULL
624133,2,Shn3: Dual-Go Shn3RL cells Measured in Cell-Based System Using Plate Reader - 2134-02_Inhibitor_Dose_CherryPick_Activity,"Keywords:  osteoporosis, Schnurri-3, kappa recognition component_|__|__|_Assay Overview:_|__|_This screen will identify specific compounds that target the 3'UTR non-specifically . This cell line (Clone20-Shn3RL) contains a ""control"" reporter construct that is also under the control of an EF1alpha promoter generating a transcript that encodes for the renilla luciferase gene fused to a control 3'UTR. Compounds of interest identified in this screen would reduce the levels of firefly luciferase without altering",31,Broad Institute,2134-02_Inhibitor_Dose_CherryPick_Activity,20120508,"1400,2199,2247,3197,4477,5396,5404,5405,5745,6084,6197,6769,12498,14169,23205,31316,33144,52167,53232,62882,67059,71821,72438,77865,81400,89341,91378,91467,91754,98652,100475,107346,130606,148673,148870,156816,176406,179617,203396,225126,226441,226752,233768,234636,235262,236584,240061,240350,243093,245742,246952,253602,254984,255329,255762,260976,263434,268239,268760,268762,268975,270378,270787,271216,272334,272378,272529,272568,275903,288760,298116,299645,310900,310951,315406,327044,328132,328138,328144,3","842204,842762,843298,844482,844525,844737,845300,847146,847393,847836,848536,851085,851321,852129,852303,852388,852701,852911,855514,855836,856091,856196,856251,856521,856525,856536,857195,857372,857621,857655,857671,857885,858068,858151,858220,858389,858611,858889,859630,859637,860183,861001,861006,861817,862514,862638,863149,863423,863619,863659,864658,864787,865957,3711304,3711988,3712502,3712888,3713133,3713760,3714089,3714469,3714582,3714634,3715971,3716076,3716675,3716687,3716773,3717335,3717519,42404",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
624392,0,A screen for known kinase inhibitors that affect liver stage malaria,"In humans, a malaria infection begins with a one-time, asymptomatic liver stage followed by a cyclic symptomatic blood stage.  All high-throughput malaria drug discovery efforts have focused on the cyclic blood stage, and this focus has limited potential for the prophylaxis, transmission-blocking, and eradication efforts needed for the next stages of malaria treatment.  A high-throughput phenotypic liver-stage screen was developed to systematically identify molecules with liver stage efficacy that could add",46,"ICCB-Longwood Screening Facility, Harvard Medical School",HMS980-2,20161017,"1401,1694,2399,2400,2403,2608,3796,4273,5034,5040,5083,5084,5097,5166,5169,5291,5307,123596,123631,156414,176155,176158,176167,176870,206042,208908,216239,354929,447966,448008,448949,449054,453216,484948,579429,599038,644215,644241,695484,702319,766948,766949,2043868,2047501,2207831,2754564,2864586,2888715,3004085,3008319,3038522,3062316,3081361,3086685,3146377,3251696,3323623,3444454,3610835,3925868,3935292,4367562,4993744,5005498,5278396,5281813,5311510,5311511,5327651,5327652,5327653,5327654,5327655,5327","134352552,134352553,134352554,134352555,134352556,134352557,134352558,134352559,134352560,134352561,134352562,134352563,134352564,134352565,134352566,134352567,134352568,134352569,134352570,134352571,134352572,134352573,134352574,134352575,134352576,134352577,134352578,134352579,134352580,134352581,134352582,134352583,134352584,134352585,134352586,134352587,134352588,134352589,134352590,134352591,134352592,134352593,134352594,134352595,134352596,134352597,134352598,134352599,134352600,134352601,134352602,13",NULL,NULL,NULL,Research and Development,"19924309,22586124,6267054",0,10.1073/pnas.1118370109|10.1371/journal.pone.0007881,NULL,NULL,NULL
624149,2,qHTS of Nrf2 Activators: LOPAC Validation,"Many diseases have some form of oxidative stress injury and ties to inflammation, causing a host of problems for the patient. The antioxidant response element (ARE) plays an important role in alleviating the harmful effects of oxidative stress. The antioxidant response element (ARE) is a transcriptional regulatory element involved in the activation of genes coding for a number of antioxidant proteins and detoxifying enzymes. These enzymes work in concert to protect tissues from oxidative insults and chemica",2,National Center for Advancing Translational Sciences (NCATS),Nrf2001,20120515,"119,138,178,199,237,248,249,275,286,289,305,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340588,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616",4780,NULL,AAB32188,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAB32188,NULL
624309,1,Single concentration confirmation of uHTS inhibitor hits from NadD in a Colorimetric assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH095597-01A1_|_Assay Provider: Dr. Andrei Osterman, Sanford Burnham Medical Research Institute, La Jolla, CA_|__|_The increasing occurrence of multidrug resistant strains of bacterial pathogens poses a significant threat to public health calling for urgent act",14,Burnham Center for Chemical Genomics,SBCCG-A859-NadD-CP-Assay,20120626,"3728,3760,10494,10842,24260,40116,54900,64971,65558,67065,72571,72704,90490,92993,140917,152086,165308,222091,222761,224618,244635,247228,248597,250303,250323,255329,255330,255871,258035,265171,265380,266203,276215,276216,276218,276219,280499,280618,281457,296527,330740,341783,367535,389012,436059,457913,566975,611216,615913,616267,629074,644466,644735,645132,645140,645247,645967,646394,646746,647102,647185,647691,648114,648675,648696,649080,650679,650825,650995,651714,653519,653861,653996,654092,654955,655","842211,842471,842855,842863,843664,844084,844770,844852,845348,846289,846310,846686,848241,848379,848546,849236,849658,850966,851298,851427,851517,852341,852406,855609,855880,856575,856728,856861,857094,857113,857294,857528,857590,857961,858015,858569,858753,858812,859200,859755,859785,860271,860584,860713,860768,860916,861068,861311,861351,861421,861631,861784,862395,862721,862871,863066,863774,864100,864347,864493,864669,864910,865418,865498,865589,865855,865860,865911,3711107,3711166,3711182,3711852,3712",NULL,NULL,NP_374707,NIH Initiatives,"12142426,17195474,18490451,19249205,19408950,19716475,20199601,20578699",0,10.1007/978-3-7643-7567-6_6|10.1016/j.bmcl.2009.02.034|10.1016/j.chembiol.2009.07.006|10.1021/cc9000357|10.1021/jm100377f|10.1074/jbc.m800694200|10.1111/j.1365-2958.2010.07099.x|10.1128/jb.184.16.4555-4572.2002,NULL,P65502,NULL
624273,2,Fluorescence polarization aasay to screen for inhibitors that compete for the binding of FadD28 to a bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_Dose_CherryPick_Activity,"Keywords: Mycobacterium tuberculosis, adenylate-forming enzymes, FadD28, inhibitor, fluorescence polarization, high throughput screening_|__|_Assay Overview:_|_Fad28 is one of several fatty acyl-AMP ligases (FAALs) involved in lipid biosynthesis. Its activity can be measured through an enzyme coupling assay. Due to the requirement of two coupling enzymes, potential interference caused by the low wavelength of detection and low enzyme activity, a fluorescence polarization displacement assay has been develope",31,Broad Institute,2147-01_Inhibitor_Dose_CherryPick_Activity,20120606,"3126,6683,11106,14710,16347,66541,68207,72721,72810,80444,80816,85511,91499,95535,96103,137292,138888,164676,185819,224232,224275,224922,229852,237102,239705,246853,246902,251570,258032,259797,260054,263067,269582,278712,278714,281376,283716,293227,299965,306162,307686,312589,315063,317641,324518,361939,387725,392613,442813,572152,580199,581177,602523,639427,645312,645817,646103,646126,646200,647436,649682,649877,650475,651871,652080,652921,653582,653978,656290,657255,657860,658589,658692,659447,659511,6596","843037,843798,843821,846747,847284,849580,850399,851030,853632,855516,855693,856072,856500,857243,857345,857412,858092,858588,858633,858964,859785,859820,860543,862991,863308,864819,864997,865490,865796,865991,3711417,3712003,3714631,3715493,3715541,3715906,3716539,3716567,3716574,3717539,4241253,4241437,4242321,4242838,4244022,4244194,4245067,4245453,4245528,4246390,4247191,4247259,4248030,4248149,4248392,4249419,4249567,4249660,4249867,4250248,4250913,4251194,4252002,4255096,4255572,4256157,4256607,425661",NULL,Biochemical,CAB06100,NIH Initiatives,20450872,0,10.1016/j.ab.2010.04.033,NULL,P9WQ59,NULL
624319,1,Single concentration confirmation of uHTS inhibitor hits of Sentrin-Specific Protease 8 using Nedd8 Protein Substrate,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH094200-01_|_Assay Provider: Dr. Guy Salvesen, Sanford-Burnham Medical Research Institute, La Jolla, CA._|__|_The human peptidase clan CE is defined by seven proteases with a common fold and catalytic mechanism, commonly known as SENPs [1-3]. SENPs 1,",14,Burnham Center for Chemical Genomics,SBCCG-A861-SENP8-inh-CP-Assay,20120626,"499,1889,2181,2236,2973,3102,3264,3449,3593,4749,5204,5801,6549,6782,6890,7054,7121,7127,7571,8496,8815,9015,9903,10680,10709,10718,10917,12456,13625,14566,16547,17076,19266,23386,25711,31236,43795,60758,61205,62362,64127,65614,66536,66656,67038,68215,69845,70349,70765,73878,76622,81675,86053,88738,91286,94870,95168,100058,122850,128356,140917,151922,155874,162350,165073,185484,220995,221597,224618,224935,229543,229813,229852,232780,232928,232932,239930,243447,246047,248209,252617,254341,255872,257871,25892","842340,842378,842508,842920,843005,843172,843204,843712,843944,844867,845001,845034,845540,845809,846626,846653,847568,848687,849012,849538,849700,850150,850653,850871,851240,851247,851285,851303,851355,852470,852925,853491,853532,856045,856240,856331,856507,856535,856713,856956,857100,858053,858060,858148,858170,858271,858353,858417,859055,859289,860897,861151,861287,861411,861465,862855,863120,863135,864020,864229,864791,865006,865730,865835,3711224,3711333,3711469,3711600,3711928,3712641,3712721,3712727,",123228,NULL,NP_660205,NIH Initiatives,"12730221,12759362,12759363,15688063,17591783,17916063,18799455,20142034",0,10.1016/j.chembiol.2010.01.002|10.1038/nrm1547|10.1042/bj20070940|10.1074/jbc.m212948200|10.1074/jbc.m302888200|10.1074/jbc.m302890200|10.1074/jbc.m702444200|10.1074/jbc.m805655200,3.4.22.-,Q96LD8,NULL
624115,1,Counter-screen against parental HEK293 cells for identification of compounds that activate MrgX1 receptor signaling,"Data Source: Johns Hopkins Ion Channel Center (JHICC_MrgX1_Agonist_Parental)_|_BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed, Duplicate_|__|_Data Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Xinzhong Dong, Ph.D._|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA033176-01_|_G",27,Johns Hopkins Ion Channel Center,JHICC_MrgX1_Agonist_Parental,20120427,"191,727,903,1400,1546,1761,1795,1917,2723,3132,4630,4993,5022,5265,5831,6060,6114,7389,7573,7578,9340,11106,11886,15165,22883,34312,36302,40230,44008,49659,62547,65551,66738,67238,67974,68304,68497,71060,74495,76175,79480,79580,82414,82516,85270,86470,89372,90260,92827,93565,94273,95311,95692,97024,101430,118982,123683,126157,128748,148673,164981,165348,165542,170530,185848,189406,200953,201096,206650,213331,219756,219761,222275,227775,231168,235224,235621,235981,237065,238013,239526,242571,242789,255202,26","842141,842232,842261,842308,842350,842355,842409,842565,842579,842647,842746,842752,842913,842923,842932,843004,843010,843044,843160,843224,843334,843403,843495,843559,843565,843947,844019,844070,844094,844283,844363,844405,844418,844458,844523,844564,844637,844705,844856,844866,844870,844956,845065,845218,845232,845272,845397,845402,845486,845516,845543,845561,845570,845700,845787,845849,845980,846016,846129,846142,846265,846270,846352,846373,846432,846490,846492,846515,846567,846665,846682,846798,846910,8",259249,NULL,ACG60652,Legacy Depositors|NIH Initiatives,"10838414,11850634,12397184,16465162,19146417,19230660,20724664",0,10.1016/j.bmcl.2009.01.085|10.1021/jm800962k|10.1038/nbt1186|10.1038/nn815|10.1073/pnas.1011221107|10.1073/pnas.192565799|10.1177/108705719900400206,NULL,ACG60652,NULL
624322,2,Dose response confirmation of uHTS inhibitor hits of Sentrin-Specific Protease 8 using Nedd8 Protein Substrate,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH094200-01_|_Assay Provider: Dr. Guy Salvesen, Sanford-Burnham Medical Research Institute, La Jolla, CA._|__|_The human peptidase clan CE is defined by seven proteases with a common fold and catalytic mechanism, commonly known as SENPs [1-3]. SENPs 1,",14,Burnham Center for Chemical Genomics,SBCCG-A863-SENP8-inh-DMSO-DR-Assay,20120626,"12456,13625,23386,43795,60758,66656,67038,140917,151922,185484,221597,224618,239930,246047,248209,257871,260644,272514,276114,279589,280099,286873,304626,323999,349435,359247,362861,372186,379416,385674,400634,453131,459731,478574,541760,574330,591407,606590,623812,628390,646014,647339,647372,651138,656148,656186,657611,664088,664517,665269,666040,693381,693468,713096,719449,738951,749032,753169,762757,767399,769125,773154,776146,781700,783852,798725,804043,833493,849362,879314,889704,892976,895662,935465,9","843712,845001,845034,848687,849538,853491,853532,856240,858417,861465,862855,864791,3711224,3711333,3711469,3711928,3713934,3716337,3716650,4241909,4242378,4244396,4244904,4245007,4245344,4245766,4245955,4246197,4246341,4247404,4248364,4249638,4255664,4256194,4256666,4257205,4257386,4259880,4259887,4261832,7964650,7964733,7964976,7967325,7972100,7972128,7973036,7973714,7975410,7975754,14719050,14720518,14723000,14723055,14723599,14723856,14724613,14724802,14729290,14735066,14742244,14742772,14744329,1474446",123228,NULL,NP_660205,NIH Initiatives,"12730221,12759362,12759363,15688063,17591783,17916063,18799455,20142034",0,10.1016/j.chembiol.2010.01.002|10.1038/nrm1547|10.1042/bj20070940|10.1074/jbc.m212948200|10.1074/jbc.m302888200|10.1074/jbc.m302890200|10.1074/jbc.m702444200|10.1074/jbc.m805655200,3.4.22.-,Q96LD8,NULL
624479,2,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway.,"The TNF alpha/NFkB signaling pathway was assayed in NFkB-bla cells (Invitrogen), a ME-180 cervical carcinoma line containing a stably integrated beta-lactamase reporter gene controlled by a NFkB response element. This reporter is induced by TNF alpha at 10 pM EC50 and inhibited by the proteosome inhibitor MG-132 at approximately 100 nM IC50. The assay was screened at the EC50 of TNF alpha activation to identify inhibitors of TNF alpha/NFkB signaling.",2,National Center for Advancing Translational Sciences (NCATS),MIPE3-NFKB-an,20120813,"1345,1401,1973,2375,2520,2662,2703,2900,2907,2956,3203,3408,3503,3652,3793,3899,3902,3922,4091,4261,4593,4594,4829,5070,5163,5291,5311,5339,5376,5591,5754,9444,10607,17513,20279,31703,39562,56463,60490,60602,60700,60703,60750,65628,65709,65909,65999,66414,71992,72172,72686,73461,88353,105066,107935,107985,119192,119373,123631,123723,126758,133021,135411,148124,148177,151183,154256,156414,156422,159324,160355,176155,176167,176870,177336,178024,188914,208908,216239,216326,216467,219077,300471,379077,387447,38","11112768,11112856,11113545,11113817,11113845,11113932,11113953,11114010,11114025,11114100,11114141,11114146,11114151,11114202,11114209,11114246,11114298,26747277,26753179,26753243,26753282,26755034,26755036,26755749,26756784,29215247,29215400,29215442,29215463,50103983,50107499,50111708,50111715,50112875,50112887,50112903,50112924,50112942,50112950,50113171,50125886,50125937,50126334,85736407,90340623,90340633,90340771,90340808,90340847,90340882,90340900,90341009,90341155,90341307,90341326,90341340,90341390",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
624111,1,Counter-screen against parental HEK293 cells for identification of compounds that antagonize MrgX1 receptor signaling,"Data Source (MLPCN Center Name): Johns Hopkins Ion Channel Center (JHICC)_|_Center Affiliation: Johns Hopkins University, School of Medicine_|_Screening Center PI: Min Li, Ph.D._|_Assay Provider: Xinzhong Dong, Ph.D._|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA033176-01_|_Grant Proposal PI: Xinzhong Dong, Ph.D., Johns Hopkins University School of Medicine_|_Assay Implementation: Zhihong Lin Ph.D., Kaiping Xu M.S., Shunyou Long M.S., Alison Neal, B",27,Johns Hopkins Ion Channel Center,JHICC_MrgX1_Antagonist_Parental,20120424,"191,727,903,1400,1546,1761,1795,1917,2723,3132,4630,4993,5022,5265,5831,6060,6114,7389,7573,7578,9340,11106,11886,15165,22883,34312,36302,40230,44008,49659,62547,65551,66738,67238,67974,68304,68497,71060,74495,76175,79480,79580,82414,82516,85270,86470,89372,90260,92827,93565,94273,95311,95692,97024,101430,118982,123683,126157,128748,148673,164981,165348,165542,170530,185848,189406,200953,201096,206650,213331,219756,219761,222275,227775,231168,235224,235621,235981,237065,238013,239526,242571,242789,255202,26","842141,842232,842261,842308,842350,842355,842409,842565,842579,842647,842746,842752,842913,842923,842932,843004,843010,843044,843160,843224,843334,843403,843495,843559,843565,843947,844019,844070,844094,844283,844363,844405,844418,844458,844523,844564,844637,844705,844856,844866,844870,844956,845065,845218,845232,845272,845397,845402,845486,845516,845543,845561,845570,845700,845787,845849,845980,846016,846129,846142,846265,846270,846352,846373,846432,846490,846492,846515,846567,846665,846682,846798,846910,8",259249,NULL,ACG60652,Legacy Depositors|NIH Initiatives,"10838414,11850634,12397184,16465162,16670758,16791143,1714354,17626210,17855615,18650342,19146417,19230660,20724664",0,10.1007/bf00319042|10.1016/j.bmcl.2009.01.085|10.1021/jm800962k|10.1038/nbt1186|10.1038/nn815|10.1038/nrn1950|10.1073/pnas.1011221107|10.1073/pnas.192565799|10.1172/jci28553|10.1177/108705719900400206|10.1523/jneurosci.1249-07.2007|10.1523/jneurosci.1760-08.2008|10.1523/jneurosci.2862-07.2007,NULL,ACG60652,NULL
651635,2,qHTS for Inhibitors of ATXN expression,"Spinocerebellar ataxia type 2 (SCA2) is a multisystem neurodegenerative disease caused by a dominantly-acting mutation leading to expansion of a polyQ domain in the ataxin-2 protein (ATXN2).  SCA2 patients develop progressive ataxia and later lose function in other neuronal systems. Prominent parkinsonian signs develop in some patients.  Similar to many neurodegenerative disorders, no symptomatic or disease-modifying treatments are known._|__|_The primary objective of the proposed research is to identify co",2,National Center for Advancing Translational Sciences (NCATS),SCA2100,20121018,"6,19,40,72,86,109,119,127,137,138,174,178,185,190,191,199,204,229,237,243,249,253,255,275,286,289,298,299,303,311,314,323,335,338,366,379,401,441,444,460,462,464,471,487,499,525,535,546,547,564,588,597,637,650,660,681,698,701,727,745,774,785,787,802,803,838,864,892,896,899,903,904,931,932,936,938,942,949,951,957,978,992,995,1001,1002,1017,1018,1030,1045,1046,1047,1054,1066,1088,1101,1102,1103,1123,1150,1174,1176,1201,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,8",6311,NULL,NP_002964,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,Q99700,NULL
651820,2,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),"Hepatitis C virus (HCV) infects about 200 million people in the world.  Many infected people progress to chronic liver disease including cirrhosis with a risk of developing liver cancer.  To date, there is no effective vaccine for hepatitis C.  Current therapy based on interferon is only effective in about half of the patients and is associated with significant adverse effects.  The fraction of people with HCV who can complete a successful treatment is estimated to be no more than 10 percent.  Recent develo",2,National Center for Advancing Translational Sciences (NCATS),HCV100,20121128,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1676,1678,1688,1689,1727,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842176,842178,842179,842180,842181,842182,842183,842184,842185,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
651644,2,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,"Human immunodeficiency virus type 1 (HIV-1), the causative agent of AIDS, contains a protein called viral protein R (Vpr) that plays an important role in the viral life cycle and the pathogenesis of HIV-1._|__|_Vpr plays multiple roles during the viral life cycle and displays several distinct activities in host cells. These Vpr specific activities include cytoplasmic-nuclear shuttling, induction of cell cycle G2 arrest and cell killing. The cytoplasmic-nuclear shuttling is believed to participate in nuclear",2,National Center for Advancing Translational Sciences (NCATS),VPR001,20121016,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",155807,NULL,NP_057852,Governmental Organizations|NIH Initiatives,11531413,0,10.1006/viro.2001.1007,NULL,NP_057852,NULL
651768,2,qHTS for Inhibitors of WRN Helicase,"Inhibition of DNA repair is proposed as a strategy for combating cancer.  Synthetic lethality is an approach that exploits preexisting DNA repair deficiencies in certain tumors to develop inhibitors of DNA repair pathways that compensate for the tumor-associated DNA repair deficiency.  Because helicases play critical roles in the DNA damage response and in DNA repair, particularly in actively dividing and replicating cells, characterization of synthetic lethal relationships of DNA helicases may be of value ",2,National Center for Advancing Translational Sciences (NCATS),WRN100,20121116,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",7486,NULL,AAC63361,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAC63361,NULL
651647,1,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute(SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1R03DA033979-01 (Cycle 19)_|_Assay Provider: Vladislav Golubkov, Ph.D. Sanford Burnham Medical Research Institute  _|__|_Twenty four individual MMPs are encoded by the human genome (1). MT1-MMP (aka MMP-14) is distinguished from soluble MMPs by a transmembrane domain",14,Burnham Center for Chemical Genomics,SBCCG-A917-MT1-MMP-Primary-Assay,20121018,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",4323,NULL,NP_004986,NIH Initiatives,"15489334,17081065,8804434",0,10.1016/0014-5793(96)00861-7|10.1021/pr060363j|10.1101/gr.2596504,3.4.24.80,P50281,NULL
651965,2,qHTS Assay for Activators of ClpP,"The Clp protease proteolytic subunit (ClpP) is the core unit of the Clp complex belonging to the peptidase family S14 that hydrolyzes protein into small peptides in the presence of ATP and magnesium.  It is ubiquitously expressed and is the major protease in bacteria.  Studies showed that ClpP is a target for a novel class of acyldepsipeptides (ADEP) in bacteria that are resistant to current antibiotic treatment.  Unlike common antibiotics that simply interfere with the essential enzyme activity, ADEP bindi",2,National Center for Advancing Translational Sciences (NCATS),CLPP001,20130103,"6,19,40,72,86,109,119,126,137,174,185,190,191,204,229,237,240,243,244,253,289,298,299,303,311,314,323,335,338,366,379,403,441,460,464,487,499,525,546,547,564,588,594,597,637,660,681,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1189,1201,1233,1245,1292,1302,1309,1318,1329,1330,1340,1345,1348,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1539,1546,1570,1609,1639,1646,1651,167","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",NULL,NULL,AAC46381,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAC46381,NULL
651725,1,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,"The Six1 homeobox gene encodes a transcription factor that is crucial for the development of many organs but is down-regulated after organ development is complete.  Its expression is low or undetectable in normal adult breast tissue but the gene is over-expressed in 50% of primary breast tumors and 90% of metastatic lesions.  Our analysis of public microarray databases containing 535 breast cancer samples demonstrates that Six1 levels correlate significantly with shortened time to relapse, shortened time to",2,National Center for Advancing Translational Sciences (NCATS),Six1100,20121029,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",6495,NULL,CAA62974,Governmental Organizations|NIH Initiatives,6495,0,10.3168/jds.s0022-0302(76)84328-7,NULL,Q15475,NULL
651631,2,qHTS assay for small molecule agonists of the p53 signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_p53, a tumor suppressor protein, is activated following cellular insult, including DNA damage and other cellular stresses.  The activation of p53 regulates cell fate by in",58,Tox21,P53581,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",7157,NULL,P04637,Governmental Organizations,NULL,0,NULL,NULL,P04637,NULL
651819,1,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,"The eukaryotic chaperonin named TRiC (for TCP-1 ring complex), also called CCT (for chaperonin containing TCP1), is an essential and conserved chaperone required for the folding and activation of 10-15% of the proteins encoded by the human genome. TRiC is indispensable for cell survival, as folding of an essential subset of cytosolic proteins, including cytoskeletal components, cell cycle regulators and tumor suppressor proteins, exhibits a strict requirement for TRiC which cannot be substituted by other cy",2,National Center for Advancing Translational Sciences (NCATS),CHAP100,20121128,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",153562,NULL,BAE54513,Governmental Organizations|NIH Initiatives,17460696,0,10.1038/nsmb1236,NULL,BAE54513,NULL
651699,1,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute(SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: R03 DA034599-01_|_Assay Provider: Matthew D. Petroski, Ph.D., Sanford-Burnham Medical Research Institute_|__|_Cullin-RING ubiquitin ligases (CRLs) are responsible for ~20% of all intracellular protein degradation by the proteasome. This critical role in maintaining p",14,Burnham Center for Chemical Genomics,SBCCG-A931-UBC12-Primary-Assay,20121025,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8","8883,9040",NULL,"NP_003896,NP_003960",NIH Initiatives,"11027288,15021886,15688063,18805092,19352404,21316600,8883",0,10.1016/j.ccr.2011.01.002|10.1016/j.cell.2008.07.022|10.1038/nrm1547|10.1038/nrm2673|10.1038/sj.onc.1207414|10.1128/mcb.20.21.8185-8197.2000,2.3.2.-,"P61081,Q13564",NULL
651724,1,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,"Carboxyl-terminal binding protein (CtBP) is a co-repressor for many transcription factors.  CtBP was initially recognized as an adenoviral E1A-binding protein and its over-activation, in combination with mutated Ras, leads to tumorigenesis and metastasis, suggesting CtBP plays a critical role in oncogenesis.  Our studies have shown that CtBP is overexpressed in multiple human cancers, including lung, breast, and head and neck cancers.  In particular, it is over-expressed in 50% of primary lung cancer and 90",2,National Center for Advancing Translational Sciences (NCATS),CTBP100,20121029,"6,19,40,72,86,109,119,127,137,174,185,190,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",5932,NULL,AAC14371,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAC14371,NULL
651636,1,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute(SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH097522-01_|_Assay Provider: Robert Rickert, Ph.D., Sanford-Burnham Medical Research Institute_|__|_Epstein-Barr virus-induced gene 2 (EBI2) (1-4), also known as GPR183, is expressed on B cells and is highly induced upon activation (5). Recent gene targeting e",14,Burnham Center for Chemical Genomics,SBCCG-A912-EBI2-Primary-Assay,20121012,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",1880,NULL,NP_004942,NIH Initiatives,"19597478,19615922,20727031,21796211,21796212",0,10.1016/j.immuni.2009.06.016|10.1038/nature08226|10.1038/nature10226|10.1038/nature10280|10.1111/j.1600-065x.2010.00942.x,NULL,P32249,NULL
651610,1,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: cell fusion, Env protein, HIV, luciferase_|__|_Assay Overview:_|__|_Although some inhibitors of HIV-1 entry exist, these are not suitable for use in a prophylactic setting because of limitations in potency, breadth and/or adaptability to a microbicide formulation. HIV-1 Envs expressed on the surface of cells can mediate the fusion of cells with target cells expressing the CD4 and CCR5/CXCR4 receptors, such as CEM lymphoblasts. We have established an assay that monitors the cell-cell fusion activit",31,Broad Institute,7013-01_Inhibitor_SinglePoint_HTS_Activity,20121024,"6,19,109,119,127,137,185,191,229,289,298,303,314,323,338,464,487,525,546,547,564,588,597,637,698,727,745,864,892,896,899,903,904,932,936,949,992,1002,1018,1047,1088,1101,1174,1233,1245,1292,1309,1318,1326,1329,1330,1340,1345,1359,1367,1369,1480,1486,1489,1535,1539,1546,1570,1639,1643,1646,1651,1676,1689,1727,1732,1738,1742,1761,1775,1794,1795,1810,1814,1826,1832,1853,1858,1864,1890,1892,1917,1981,1982,1985,1986,1988,1989,1995,2005,2020,2048,2052,2078,2082,2117,2122,2123,2132,2143,2145,2148,2151,2153,2162,21","842121,842122,842127,842134,842138,842139,842141,842145,842147,842151,842152,842153,842154,842155,842157,842159,842162,842163,842164,842165,842170,842173,842174,842178,842179,842189,842190,842192,842194,842199,842200,842201,842203,842205,842208,842209,842210,842213,842214,842216,842218,842219,842223,842224,842226,842228,842229,842230,842233,842237,842238,842240,842241,842242,842244,842246,842248,842251,842254,842255,842257,842261,842262,842263,842266,842267,842272,842274,842275,842276,842277,842287,842288,8",NULL,Cell-based,NULL,NIH Initiatives,22069466,0,10.1371/journal.pone.0026731,NULL,NULL,NULL
651560,1,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay","Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number: 1 R03 DA033986-01_|_Assay Provider: Nunzio Bottini, M.D., Ph.D., La Jolla Institute for Allergy & Immunology, La Jolla, CA_|__|_Obesity is frequently complicated by a constellation of metabolic and cardiovascular anomalies, called the metabolic syndrome, which significant",14,Burnham Center for Chemical Genomics,SBCCG-A890-LMPTP-Inh-Primary-Assay,20120904,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",52,NULL,P24666,NIH Initiatives,"12050202,12409270,12800095,1304913,15660501,17353188",0,10.1002/pro.5560010603|10.1016/s0026-0495(03)00065-9|10.1016/s1096-7192(02)00120-8|10.1074/jbc.m609626200|10.1146/annurev.med.56.082103.104751|10.1210/jcem.87.6.8641,"3.1.3.2,3.1.3.48",P24666,NULL
651687,1,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: GCN5,flag PGC1a adenovirus, acetyl transferase, SIRT1 deacetylase, Alphascreen, acetylation, inflammation, diabetes_|__|_Assay Overview: The fact that the discovery and identification of chemical compounds that through deacetylation of PGC-_|_1a might mimic the ""healthy"" conditions of exercise and calorie restriction makes the outcomes of this_|_work of high biological and therapeutic significance. The close relationship between PGC-1a acetylation_|_and metabolic diseases suggests the possibility ",31,Broad Institute,2139-01_Inhibitor_SinglePoint_HTS_Activity,20121023,"6,19,40,72,86,109,119,127,137,174,185,190,204,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1302,1309,1318,1326,1329,1330,1340,1345,1359,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1643,1646,1676,1678,1727,1730,1738,1742,1761,1775,17","842121,842122,842123,842124,842125,842126,842128,842129,842130,842131,842133,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842150,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842167,842168,842169,842170,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842207,842209,842210,842211,842213,842214,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
651723,1,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,"Keywords: GCN5,flag PGC1a adenovirus, acetyl transferase, SIRT1 deacetylase, Alphascreen, acetylation, inflammation, diabetes_|__|_Assay Overview: The fact that the discovery and identification of chemical compounds that through deacetylation of PGC-_|_1a might mimic the ""healthy"" conditions of exercise and calorie restriction makes the outcomes of this_|_work of high biological and therapeutic significance. The close relationship between PGC-1a acetylation_|_and metabolic diseases suggests the possibility ",31,Broad Institute,2139-01_Activator_SinglePoint_HTS_Activity,20121028,"6,19,40,72,86,109,119,127,137,174,185,190,204,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1302,1309,1318,1326,1329,1330,1340,1345,1359,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1643,1646,1676,1678,1727,1730,1738,1742,1761,1775,17","842121,842122,842123,842124,842125,842126,842128,842129,842130,842131,842133,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842150,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842167,842168,842169,842170,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842207,842209,842210,842211,842213,842214,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
651661,1,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: Ewing sarcoma, transcription factor, chromosomal translocation_|__|_Assay Overview: Luciferase reporter assay using  NR0B1 promoter in human A673 rhabdosarcoma cells._|_Ewing sarcoma is a pediatric and young adult cancer that results from a translocation that fuses the DNA binding domain of the Friend leukemia virus integration 1 (FLI1) transcription factor to the transactivation domain of the EWS protein, forming the EWS/FLI oncoprotein. This chromosomal translocation produce a mutant transcripti",31,Broad Institute,7014-01_Inhibitor_SinglePoint_HTS_Activity,20121026,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,379,441,460,464,487,499,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1546,1570,1609,1639,1643,1646,1651,1676,1678,1687,1688,","842123,842124,842146,842150,842166,842168,842180,842184,842202,842204,842220,842225,842256,842306,842317,842344,842376,842392,842419,842426,842433,842435,842439,842458,842459,842482,842491,842506,842536,842539,842542,842543,842548,842601,842611,842612,842615,842616,842621,842637,842640,842647,842656,842665,842681,842682,842699,842711,842749,842762,842774,842779,842797,842822,842851,842867,842872,842874,842903,842928,842934,842947,842960,842964,842972,842977,843011,843012,843020,843028,843037,843041,843047,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
651550,1,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,"The serine/threonine protein kinase Akt (protein kinase B) regulates various cellular processes, including cell survival, growth, proliferation, migration and differentiation. It has been well established that Akt is activated through two essential steps involving membrane translocation and phosphorylation. Cytosolic Akt is recruited to the plasma membrane via the interaction between the PH domain and membrane PIP3 produced by phosphoinositide-3 kinase (PI3K) upon growth factor receptor stimulation. The mem",2,National Center for Advancing Translational Sciences (NCATS),AKT100,20120824,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1340,1345,1359,1365,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,1727,1730,1738,17","842121,842122,842123,842124,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842150,842151,842153,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842196,842197,842198,842199,842200,842201,842202,842203,842205,842206,842207,842208,8",207,NULL,P31749,Governmental Organizations|NIH Initiatives,NULL,0,NULL,2.7.11.1,P31749,NULL
651640,1,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,"Keywords: Dengue Virus 2, Flaviviridae, Cytopathic Effect, BHK-21 Cells, Antivirals_|__|_Assay Overview:  The cytopathic effect (CPE) assay has been successfully adapted for studying different virus with aims of identifying novel antiviral compounds.  The goal of this assay is to identify inhibitors of Dengue virus, by using a CPE assay.  BHK-21 cells were treated with compounds and infected with Dengue virus 2 in 1536-well plates.  After a 5-day incubation, CellTiter-Glo reagent (Promega) was added to quan",31,Broad Institute,2149-01_Other_SinglePoint_HTS_Activity,20121012,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,379,441,460,464,487,499,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1546,1570,1609,1639,1643,1646,1651,1676,1678,1687,1688,","842123,842124,842146,842150,842168,842184,842202,842204,842220,842225,842256,842306,842317,842344,842349,842376,842392,842419,842426,842435,842439,842458,842459,842482,842489,842491,842506,842536,842539,842542,842543,842548,842565,842601,842611,842612,842616,842621,842635,842637,842640,842647,842656,842665,842681,842682,842699,842711,842749,842762,842774,842779,842797,842822,842851,842867,842871,842872,842874,842903,842928,842947,842960,842964,842972,842977,843011,843012,843028,843034,843037,843041,843047,8",NULL,"Cell-based,Organism-based",NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
651582,1,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number: 1 R24 DK084969 (FT1012)_|_Assay Provider: Daniel Kelly, Ph.D. Sanford Burnham Medical Research Institute_|_                    _|_In the obese state, complex lipids, chiefly triacylglycerides (TAG), accumulate within cells of tissues that do not typically store fat, inclu",14,Burnham Center for Chemical Genomics,SBCCG-A901-TAG-Primary-Assay,20120912,"6,19,86,109,119,127,137,185,191,229,255,289,298,303,314,323,338,366,460,464,487,525,546,547,564,588,597,637,698,727,745,774,864,892,896,899,903,904,932,936,938,949,992,1002,1018,1046,1047,1088,1101,1123,1174,1176,1183,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1486,1489,1493,1535,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,1727,1730,1738,1742,1761,1775,1794,1795,1810,1814,1820,1821,1826,1832,1853,1858,1864,1892,1893,1917,1967,1972,1981,1982,1985","842121,842125,842126,842127,842131,842133,842134,842137,842138,842139,842140,842143,842145,842153,842155,842156,842157,842161,842163,842165,842167,842169,842170,842173,842174,842178,842179,842181,842182,842183,842187,842188,842191,842194,842195,842196,842198,842201,842203,842205,842207,842208,842209,842210,842211,842213,842218,842219,842221,842222,842223,842230,842232,842235,842238,842242,842243,842244,842247,842248,842249,842251,842252,842253,842254,842259,842261,842262,842264,842265,842266,842270,842271,8",NULL,NULL,NULL,NIH Initiatives,"12055349,17130651",0,10.1146/annurev.nutr.22.010402.102912|10.2337/db06-s002,NULL,NULL,NULL
651704,1,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords:AF4, AF9, Alpha screen, inhibitor,peptide_|__|__|_Assay Overview:_|_This assay  screens for inhibitors of the interaction of AF4 and AF9 . This is a homogeneous AlphaScreen assay that measures binding of a biotinylated AF4 peptide to FLAG-tagged AF9. The assay configuration comprises a 27-amino acid peptide biotinylated on the N-terminus. The selected peptide encompasses the portion of AF4 shown to be essential for AF9 binding, and an additional N-terminal sequence to provide a spacer between the b",31,Broad Institute,2160-01_Inhibitor_SinglePoint_HTS_Activity,20130221,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,303,311,314,323,335,338,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,932,936,938,942,949,978,992,995,1001,1002,1018,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1401,1474,1480,1486,1489,1492,1493,1535,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,1727,1732,1738,1742,1761,1775,1794,1795","842123,842124,842146,842150,842166,842168,842180,842184,842202,842204,842220,842225,842256,842306,842317,842344,842349,842376,842392,842419,842426,842433,842435,842439,842458,842459,842482,842489,842491,842506,842536,842539,842542,842543,842548,842560,842565,842588,842601,842611,842612,842615,842616,842621,842635,842637,842640,842647,842656,842665,842681,842682,842688,842699,842711,842729,842749,842762,842774,842779,842797,842822,842851,842867,842871,842872,842874,842903,842928,842934,842946,842947,842960,8",4300,Biochemical,NP_004520,NIH Initiatives,"19535349,19956800",0,10.1371/journal.pbio.1000249|10.3324/haematol.2008.002436,NULL,P42568,NULL
651654,1,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: Cryptococcus neoformans, adenylate kinase, cell wall integrity, antifungal_|__|__|_Assay Overview:  This is a novel HTS assay that specifically detects molecules that directly kill Cryptococcus yeast cells through the detection of AK released into the growth medium by cells that have undergone lysis. The assay is a simple ""add and read"" assay that uses a commercially available adenylate kinase detection cocktail (ToxiLight, Lonza, Cambridge, MA). The compounds are charged into yeast medium (12.5 u",31,Broad Institute,2162-01_Inhibitor_SinglePoint_HTS_Activity,20121019,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,323,335,338,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1643,1646,1676,1678,1688,1727,17","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,8",NULL,Organism-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
651711,1,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: PDIA6 protein disulfide isomerase family A, member 6 , ERp5,  arterial thrombosis, inhibitors of ERp5, anti-thrombotic,  insulin aggregation assay_|__|__|_Assay Overview:_|__|_An assay was set up to monitor and identify inhibitors of the ERp5 mediated aggregation of insulin. The assay measures aggregation of insulin chains by monitoring absorbance at 650 nm.  ERp5 is a member of the thiol isomerase family and cleaves disulfide bonds in  the beta chain of  insulin  causing them to aggregate.   When",31,Broad Institute,7002-01_Inhibitor_SinglePoint_HTS_Activity,20121028,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,379,441,460,464,487,499,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1546,1570,1609,1639,1643,1646,1651,1676,1678,1687,1688,","842123,842124,842146,842150,842166,842168,842180,842184,842189,842202,842204,842220,842223,842225,842237,842256,842267,842291,842306,842317,842344,842349,842376,842388,842392,842395,842419,842426,842433,842435,842439,842452,842458,842459,842474,842482,842489,842491,842506,842536,842539,842542,842543,842548,842565,842569,842571,842582,842594,842601,842606,842611,842612,842615,842616,842621,842635,842637,842638,842640,842647,842654,842656,842659,842665,842681,842682,842688,842699,842711,842749,842762,842766,8",10130,Biochemical,Q15084,NIH Initiatives,NULL,0,NULL,5.3.4.1,Q15084,NULL
651702,1,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,"University of New Mexico Assay Overview:_|_Assay Support: NIH R21 NS066462_|_A high-throughput screen of lytic granule exocytosis_|_PI: Adam Zweifach, Ph.D. _|_PI Affiliation: Department of Molecular and Cell Biology, University of Connecticut_|__|_Screening Center PI: Larry Sklar, Ph.D. / UNMCMD_|_Screening Lead: Mark Haynes, Ph.D. _|_Assay Implementation:  Bruce Edwards, Ph.D., Matthew Garcia, Mark Carter, M.S._|_UNM Cheminformatics: Oleg Ursu, Ph.D._|__|_Chemistry: Vanderbilt Specialized Chemistry Center",6,NMMLSC,UNMCMD_CTL_LyticGranule_MLPCN,20130304,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",NULL,NULL,NULL,NIH Initiatives,16020463,0,10.1113/jphysiol.2005.089565,NULL,NULL,NULL
651999,1,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay","Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford Burnham Medical Research Institute, La Jolla, CA_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R21 NS071527-01A1_|_Assay Provider: Dr. Raymond Deshaies, California Institute of Technology_|__|_Protein modification by the attachment of ubiquitin to cellular proteins is a key mechanism in regulating many cellular and organismal processes. Ubiquitin is covalently attac",14,Burnham Center for Chemical Genomics,SBCCG-A954-CSN5-Inh-Primary-Assay,20130130,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,842203,842204,8",10987,NULL,NP_006828,NIH Initiatives,"12183637,18805092,19214193",0,10.1016/j.cell.2008.07.022|10.1038/emboj.2009.27|10.1126/science.1075901,3.4.-.-,Q92905,NULL
651811,1,Genome-wide high-content siRNA screens for regulators of Parkin translocation in selective mitophagy (Ambion Library),High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy_|__|_An increasing body of evidence points to mitochondrial dysfunction as a contributor to the molecular pathogenesis of neurodegenerative diseases such as Parkinson's (1).  Recent studies of the PD-associated genes PINK12 and PARK2 (Parkin) (3) suggest that they may act in a quality control pathway preventing the accumulation of dysfunctional mitochondria (4-7).  Following the loss of mitochondrial membrane potential,2,National Center for Advancing Translational Sciences (NCATS),Parkin-RNAi-Ambion,20131210,NULL,"160713784,160713785,160713786,160713787,160713788,160713789,160713790,160713791,160713792,160713793,160713794,160713795,160713796,160713797,160713798,160713799,160713800,160713801,160713802,160713803,160713804,160713805,160713806,160713807,160713808,160713809,160713810,160713811,160713812,160713813,160713814,160713815,160713816,160713817,160713818,160713819,160713820,160713821,160713822,160713823,160713824,160713825,160713826,160713827,160713828,160713829,160713830,160713831,160713832,160713833,160713834,16","1,2,9,10,12,13,14,15,16,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,43,47,48,49,50,51,52,53,54,55,56,58,59,70,71,72,81,86,87,88,89,90,91,92,93,94,95,97,98,100,101,102,103,104,105,107,108,109,111,112,113,114,115,116,117,118,119,120,123,124,125,127,130,131,132,133,134,135,136,140,141,142,143,146,147,148,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,173,174,175,176,177,178,181,182,183,185,186,187,189,190,191,196,197,199,202,203,204,205,207,208,210,211,212,2",RNAi,NULL,Governmental Organizations|NIH Initiatives,24270810,1,10.1038/nature12748,NULL,NULL,NULL
651710,1,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,"Keywords: Homologous Recombination, DNA repair, RAD52_|__|_Assay Overview:  The primary assay is a prompt fluorescent gain of signal biochemical assay based on a quenched substrate.  Two DNA substrates are provided to recombinant purified His tagged RAD52; a quenched dual labeled double stranded DNA with a single strand tail and a homologous unlabeled single strand.   The labels are Black Hole Quencher (BHQ) and Fluorescein (FL) which are close together on the double stranded DNA.  The enzyme catalyzes anne",31,Broad Institute,7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,20121026,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,379,441,460,464,487,499,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1546,1570,1609,1639,1643,1646,1651,1676,1678,1687,1688,","842123,842124,842146,842150,842166,842168,842180,842184,842189,842202,842204,842220,842223,842225,842237,842256,842267,842291,842306,842317,842344,842349,842376,842388,842392,842395,842419,842426,842433,842435,842439,842452,842458,842459,842474,842482,842489,842491,842506,842536,842539,842542,842543,842548,842565,842569,842571,842582,842594,842601,842606,842611,842612,842615,842616,842621,842635,842637,842638,842640,842647,842654,842656,842659,842665,842681,842682,842688,842699,842711,842749,842762,842766,8",5893,Biochemical,NP_602296,NIH Initiatives,NULL,0,NULL,NULL,P43351,NULL
651957,1,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Bert O'Malley, Baylor College of Medicine_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 5U19DK062434-09_|_Grant Proposal PI: Bert O'Malley, Baylor College of Medicine_|_External Assay ID: SRC2_INH_LUMI_1536_1X%INH PRUN_|__|_Name: Luminescence-based cell-based primary high throughput screening assa",5,The Scripps Research Institute Molecular Screening Center,SRC2_INH_LUMI_1536_1X%INH PRUN,20121226,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1050,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",10499,Cell-based,NP_006531,NIH Initiatives,"17803935,19039140,21195347,7481822,8643509,8670870,9192892,9252329",0,10.1016/j.cmet.2010.12.001|10.1016/j.molcel.2007.08.012|10.1038/42652|10.1073/pnas.93.10.4948|10.1126/science.1164847|10.1126/science.270.5240.1354|10.1126/science.277.5328.965,NULL,Q15596,NULL
651958,1,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Scott Pegan, University of Illinois at Chicago (UIC)_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 MH097507-01A1_|_Grant Proposal PI: Scott Pegan_|__|_External Assay ID: CCHFVOTU-PEP-AMC_INH_FLINT_1536_1X%INH PRUN_|__|_Name: Fluorescence-based biochemical high throughput screening ",5,The Scripps Research Institute Molecular Screening Center,CCHFVOTU-PEP-AMC_INH_FLINT_1536_1X%INH PRUN,20121226,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1050,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",2943075,Biochemical,YP_325663,NIH Initiatives,"16009940,17585367,18078692,18593526,18976568,19027345,19626045,21228232,21245344,21266548",0,10.1007/s00705-007-1013-2|10.1016/j.chom.2007.09.014|10.1016/j.cytogfr.2008.11.001|10.1038/nrm2731|10.1073/pnas.0504754102|10.1073/pnas.1013388108|10.1073/pnas.1015287108|10.1128/jvi.02496-10|10.3201/eid1411.071676|10.5483/bmbrep.2008.41.6.435,NULL,YP_325663,NULL
651821,1,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Matthew Disney, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA033977-010_|_Grant Proposal PI: Matthew Disney_|_External Assay ID: R(CAG)_INH_FLINT_1536_1X%INH PRUN_|__|_Name: Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) ",5,The Scripps Research Institute Molecular Screening Center,R(CAG)_INH_FLINT_1536_1X%INH PRUN,20130425,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1050,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",NULL,Biochemical,NULL,NIH Initiatives,"10976074,12747895,14671308,15223312,1589758,17417937,19608921,8937828",0,10.1016/j.jmb.2004.05.021|10.1016/s0140-6736(03)13304-1|10.1016/s0959-4388(96)80097-3|10.1126/science.1088583|10.1126/science.1173110|10.1126/science.1589758|10.1126/science.289.5485.1769|10.1146/annurev.neuro.29.051605.113042,NULL,NULL,NULL
651572,1,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: University of North Carolina at Chapel Hill_|_Assay Provider: Qisheng Zhang, University of North Carolina at Chapel Hill_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R21NS073041 (Fast Track)_|_Grant Proposal PI: Qisheng Zhang, University of North Carolina at Chapel Hill_|_External Assay ID: ARFGAP1_INH_FP_1536_1X%INH PRUN_|__|_Name: Fluorescence pol",5,The Scripps Research Institute Molecular Screening Center,ARFGAP1_INH_FP_1536_1X%INH PRUN,20120918,"6,13,19,40,72,86,109,119,127,137,174,185,190,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1687,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",246310,Biochemical,NP_659558,NIH Initiatives,"16413272,16904307,20510928,21587297,21593484",0,10.1016/j.ceb.2006.08.002|10.1016/j.cell.2010.03.051|10.1016/s0076-6879(05)04021-8|10.1038/nrm3117|10.1177/1087057111408420,NULL,Q62848,NULL
651800,1,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Luc Teyton, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R01 AI095511-01_|_Grant Proposal PI: Luc Teyton, TSRI_|_External Assay ID: TCR_INH_FP_1536_1X%INH PRUN_|__|_Name: Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction usi",5,The Scripps Research Institute Molecular Screening Center,TCR_INH_FP_1536_1X%INH PRUN,20121119,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",6955,Biochemical,AAB69001,NIH Initiatives,"17761671,19750565,20685342,20882273,20948291,21073873,21126660,21301478,21711350,21751954,21839291,21856944",0,10.1007/s00228-010-0902-6|10.1016/j.drudis.2010.05.013|10.1016/j.transproceed.2011.06.021|10.1016/j.trre.2010.10.002|10.1038/icb.2010.150|10.1053/j.gastro.2010.10.059|10.1074/jbc.m705348200|10.1111/j.1365-2567.2011.03470.x|10.2217/imt.11.61|10.3748/wjg.15.4225|10.4049/jimmunol.1003224|10.4161/mabs.2.6.13586,NULL,A0A0B4J268,NULL
651719,1,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Patricia McDonald, The Scripps Research Institute_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS067631-01_|_Grant Proposal PI: Patricia McDonald, The Scripps Research Institute_|_External Assay ID: GALR3_ANT_CNGC_1536_1X%INH PRUN_|__|_Name: Fluorescence-based cell-based primary high throug",5,The Scripps Research Institute Molecular Screening Center,GALR3_ANT_CNGC_1536_1X%INH PRUN,20121029,"13,19,40,72,127,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,464,487,499,525,547,564,588,596,637,660,698,802,803,864,892,896,899,904,931,932,942,949,957,978,992,995,996,1001,1002,1017,1030,1066,1101,1150,1174,1183,1201,1245,1292,1309,1318,1326,1329,1330,1340,1359,1369,1400,1483,1486,1489,1491,1492,1535,1539,1546,1570,1639,1643,1651,1676,1687,1689,1732,1742,1794,1795,1810,1814,1826,1833,1853,1858,1868,1882,1889,1890,1923,1981,1982,1983,1985,1986,1988,2000,2002,2005,","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",8484,Cell-based,NP_003605,NIH Initiatives,"16287967,17002216,17160146",0,10.1073/pnas.0508970102|10.1358/dnp.2006.19.8.1043963,NULL,O60755,NULL
651602,1,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Gerald R. Smith, Fred Hutchinson Cancer Research Center_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 AI083736_|_Grant Proposal PI: Gerald R. Smith_|_External Assay ID: RECBCD_INH_ABS_1536_1X%INH PRUN_|__|_Name: Absorbance-based primary bacterial cell-based high throughput screening assay to",5,The Scripps Research Institute Molecular Screening Center,RECBCD_INH_ABS_1536_1X%INH PRUN,20120927,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8","947286,947287,947294",Cell-based,"NP_417296,NP_417297,NP_417299",NIH Initiatives,"19542287,22443934,4884815,4898990,5335129",0,10.1021/cb300018x|10.1128/jb.00254-09,3.1.11.5,"P04993,P07648,P08394",NULL
651718,1,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Herbert Weissbach, Florida Atlantic University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R03DA032473-01_|_Grant Proposal PI: Herbert Weissbach, Florida Atlantic University_|_External Assay ID: MSRA_INH_ABS_1536_1X%INH_|__|_Name: Absorbance-based biochemical primary high throughput screening a",5,The Scripps Research Institute Molecular Screening Center,MSRA_INH_ABS_1536_1X%INH,20121029,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",281312,Biochemical,AAI02981,NIH Initiatives,"10841552,10964927,11063566,11795868,11867705,12693988,12837786,14745014,15680228,15914630,16735467,17180746,18719109,19085252,19461988,19844733,20515413,8622914,8700890,9275166,9826655",0,10.1006/abbi.2001.2664|10.1007/s00239-005-0281-2|10.1007/s00403-009-0996-9|10.1016/j.bbapap.2004.10.004|10.1021/bi0020269|10.1042/bj20030443|10.1073/pnas.0308215100|10.1073/pnas.032671199|10.1073/pnas.0602826103|10.1073/pnas.0802025105|10.1073/pnas.93.5.2095|10.1073/pnas.93.8.3205|10.1073/pnas.94.18.9585|10.1073/pnas.95.24.14071|10.1073/pnas.97.12.6463|10.1074/jbc.m006137200|10.1080/10715760802566541|10.1089/adt.2009.0263|10.1128/jb.185.14.4119-4126.2003|10.1167/iovs.05-0018,NULL,P54149,NULL
651658,1,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords:_|_fibroblast growth factor (FGF), FGF22, FGF7, label-free Thermal Shift_|__|__|_Assay Overview:_|_A fluorescence-based thermal shift assay will be used to identify small molecule binders to FGF22.  This label-free approach is based on the principal of ligand-induced thermodynamic stabilization of proteins.  Changes in protein thermal stability can be induced by ligand binding, and these changes can be measured using an environmentally-sensitive fluorescent dye._|_Recombinant FGF22 is reconstituted",31,Broad Institute,7012-01_Inhibitor_SinglePoint_HTS_Activity,20121019,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,379,441,460,464,487,499,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1546,1570,1609,1639,1643,1646,1676,1678,1687,1688,1689,","842123,842124,842146,842150,842166,842168,842180,842184,842202,842204,842220,842225,842256,842306,842317,842344,842349,842376,842419,842426,842433,842435,842458,842459,842482,842489,842491,842506,842536,842542,842543,842548,842565,842601,842611,842612,842615,842616,842621,842635,842637,842640,842647,842656,842665,842681,842682,842699,842711,842749,842762,842774,842779,842797,842851,842867,842871,842872,842874,842903,842928,842934,842946,842947,842960,842964,842972,842977,843011,843012,843020,843028,843034,8",27006,Biochemical,NP_065688,NIH Initiatives,NULL,0,NULL,NULL,Q9HCT0,NULL
651633,2,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_p53, a tumor suppressor protein, is activated following cellular insult, including DNA damage and other cellular stresses.  The activation of p53 regulates cell fate by in",58,Tox21,P53429,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,NULL,0,NULL,NULL,NULL,NULL
651634,2,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|__|_Tox21 Assay Overview:_|__|_Enhanced Level of Genome Instability Gene 1 (ELG1; human ATAD5) protein levels increase in response to various types of DNA damage. Using a luciferase reporter-gene tag,58,Tox21,ELG617,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,Toxicity,NULL,Governmental Organizations,22431602,0,10.1073/pnas.1114278109,NULL,NULL,NULL
651632,2,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_As cancer cells divide rapidly and during every cell division they need to duplicate their genome by DNA replication. The failure to do so results in the cancer cell death,58,Tox21,ELG372,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",79915,Toxicity,Q96QE3,Governmental Organizations,22431602,0,10.1073/pnas.1114278109,NULL,Q96QE3,NULL
651838,0,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|__|_Assay overview:_|__|_DNA repair pathways play a critical role in cellular homeostasis by repairing DNA damage induced by endogenous processes and xenobiotics. Isogenic chicken DT40 cell lines deficient in different DNA repair pathways can be used to identify ge,2,National Center for Advancing Translational Sciences (NCATS),DT4026,20121203,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",NULL,Toxicity,NULL,Governmental Organizations|NIH Initiatives,21538559,0,10.1002/em.20656,NULL,NULL,NULL
651810,1,Genome-wide high-content siRNA screens for regulators of Parkin translocation in selective mitophagy (Dharmacon Library),High-content genome-wide RNAi screens identify regulators of parkin upstream of mitophagy_|__|_An increasing body of evidence points to mitochondrial dysfunction as a contributor to the molecular pathogenesis of neurodegenerative diseases such as Parkinson's (1).  Recent studies of the PD-associated genes PINK12 and PARK2 (Parkin) (3) suggest that they may act in a quality control pathway preventing the accumulation of dysfunctional mitochondria (4-7).  Following the loss of mitochondrial membrane potential,2,National Center for Advancing Translational Sciences (NCATS),Parkin-RNAi-Dharmacon,20131202,NULL,"56478465,56478467,56478468,56478471,56478474,56478482,56478483,56478485,56478487,56478490,56478493,56478503,56478510,56478513,56478514,56478519,56478524,56478525,56478526,56478534,56478536,56478542,56478543,56478546,56478547,56478550,56478551,56478553,56478554,56478561,56478566,56478568,56478572,56478573,56478574,56478577,56478578,56478580,56478581,56478582,56478584,56478587,56478590,56478591,56478592,56478594,56478596,56478597,56478598,56478599,56478600,56478602,56478604,56478606,56478608,56478615,56478616","1,2,9,10,12,13,14,15,16,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,43,47,48,49,50,51,52,53,54,55,56,58,59,60,70,71,72,81,86,87,88,89,90,91,92,93,94,95,97,98,100,101,102,103,104,105,107,108,109,111,112,113,114,115,116,117,118,119,120,123,124,125,126,127,128,130,131,132,133,134,135,136,140,141,142,143,146,147,148,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,173,174,175,176,177,178,181,182,183,185,186,187,189,190,191,196,197,199,202,203,204,205,207,208,21",RNAi,NULL,Governmental Organizations|NIH Initiatives,24270810,1,10.1038/nature12748,NULL,NULL,NULL
651548,1,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords:  Cancer, target-based, Polycomb Repressive complex 2, histone-modifying enzymes, histone methyltransferases_|__|_Assay Overview: The central goal of this project is to develop small-molecule probes that can be used to better understand the regulation of H3K27Me3 by EZH2 and associated proteins in PRC2, their connections in cancer development, and their roles in cancer treatment.",31,Broad Institute,2125-01_Inhibitor_SinglePoint_HTS_Activity,20120823,"86,323,903,1329,1340,1342,1346,1348,1354,1355,1359,1370,1400,1464,1480,1486,1493,1533,1609,1649,1663,1674,1694,1713,1720,1733,1775,1794,1797,1833,1845,1853,1858,1863,1882,1893,1917,1960,1973,1989,2002,2048,2049,2052,2063,2072,2078,2120,2123,2132,2153,2206,2229,2256,2268,2310,2328,2333,2336,2337,2347,2355,2366,2374,2377,2396,2399,2419,2442,2448,2457,2467,2471,2477,2482,2519,2603,2608,2662,2674,2689,2690,2703,2723,2733,2741,2746,2753,2754,2764,2765,2775,2777,2782,2790,2801,2871,2876,2913,2948,2950,2973,2984,3","85281118,85281121,85281123,85281134,85281138,85281143,85281145,85281150,85281152,85281153,85281161,85281174,85281175,85787112,85787113,85787121,85787122,85787126,85787131,85787135,85787136,85787137,85787138,85787140,85787150,85787153,85787154,85787157,85787159,85787160,85787161,85787162,85787163,85787165,85787167,85787170,85787171,85787174,85787176,85787177,85787178,85787183,85787184,85787185,85787186,85787187,85787188,85787189,85787192,85787193,85787195,85787197,85787199,85787200,85787201,85787205,85787206",2146,Biochemical,NP_004447,NIH Initiatives,NULL,0,NULL,2.1.1.356,Q15910,NULL
651828,0,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,"Rift Valley fever virus (RVFV) is an emerging infectious pathogen that causes severe disease in humans and livestock and has the potential for global spread. Currently, there is no proven effective treatment for RVFV infection, and there is no licensed vaccine. Inhibition of RNA binding to the essential viral nucleocapsid (N) protein represents a potential antiviral therapeutic strategy because all of the functions performed by N during infection involve RNA binding. To target this interaction, we developed",46,"ICCB-Longwood Screening Facility, Harvard Medical School",HMS1061,20161017,"119,137,178,187,237,244,275,289,298,389,401,412,444,460,471,546,547,564,650,675,785,838,861,863,896,903,936,938,967,994,1046,1066,1123,1174,1188,1203,1209,1216,1222,1228,1232,1233,1236,1245,1256,1317,1318,1329,1330,1340,1345,1359,1365,1367,1390,1456,1474,1564,1607,1609,1641,1645,1649,1662,1676,1678,1683,1694,1697,1727,1733,1738,1742,1774,1775,1779,1794,1795,1820,1826,1833,1853,1858,1864,1868,1871,1880,1890,1893,1908,1917,1922,1935,1967,1979,1981,1986,1989,2018,2044,2048,2049,2051,2052,2063,2071,2082,2083,20","92117401,92117402,92117403,92117404,92117405,92117406,92117407,92117408,92117409,92117410,92117411,92117412,92117413,92117414,92117415,92117416,92117417,92117418,92117419,92117420,92117421,92117422,92117423,92117424,92117425,92117426,92117427,92117428,92117429,92117430,92117431,92117432,92117436,92117438,92117439,92117440,92117441,92117442,92117443,92117444,92117445,92117446,92117447,92117448,92117449,92117450,92117451,92117452,92117453,92117454,92117455,92117456,92117457,92117458,92117459,92117460,92117461",NULL,NULL,P21700,Research and Development,"1846496,22252167,22644268",0,10.1016/0042-6822(91)90087-r|10.1016/j.antiviral.2012.01.002|10.1177/1087057112448100,NULL,P21700,NULL
651741,2,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_Assay Overview:_|__|_Oxidative stress has been implicated in the pathogenesis of a variety of diseases ranging from cancer to neurodegeneration. The antioxidant response element (ARE) signaling pathway plays an important role in the amelioration of oxidative stres,2,National Center for Advancing Translational Sciences (NCATS),ARE408,20121101,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1054,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2160,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",4780,NULL,NP_006155,Governmental Organizations|NIH Initiatives,22551509,0,10.1289/ehp.1104709,NULL,Q16236,NULL
651743,2,qHTS assay for small molecule activators of the p53 signaling pathway,"National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_Assay Overview:_|__|_p53, a tumor suppressor protein, is activated following cellular insult, including DNA damage and other cellular stresses.  The activation of p53 regulates cell fate by inducing DNA repair, cell cycle arrest, apoptosis, or cellular senescence.",2,National Center for Advancing Translational Sciences (NCATS),P53298,20121101,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",7157,NULL,P04637,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P04637,NULL
651749,2,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_Assay Overview:_|__|_Transcription factors and their stimulated target gene expression play pivotal roles across many cellular processes including responses to environmental stimuli.  Proper regulation of associated pathways is critical to maintain cell health and,2,National Center for Advancing Translational Sciences (NCATS),NFkB916,20121105,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",4790,NULL,NP_003989,Governmental Organizations|NIH Initiatives,20067776,0,10.1016/j.bcp.2009.12.021,NULL,P19838,NULL
651903,1,Intracellular Trypanosomes Measured in Cell-Based/Microorganism System Using Plate Reader - 2017-01_Inhibitor_SinglePoint_HTS_Activity_Set2,"Keywords: Trypanosoma cruzi, Chagas disease_|__|_Assay Overview: The assay detects intracellular trypanosomes that are replicating inside host cells.  NIH3T3 cells are trypsinized, counted, and plated in 384-well tissue culture plates.  After plating the NIH3T3 cells, compounds are added to the wells.  T. cruzi that are genetically modified to express b-galactosidase are then harvested and active Trypomastigotes form  are counted and co-cultured with the NIH3T3 cells.  After 90 hours of co-culture, all cell",31,Broad Institute,2017-01_Inhibitor_SinglePoint_HTS_Activity_Set2,20121211,"716999,790092,795082,2743067,4158809,4455627,5331525,5332009,5332016,5332204,5332576,5333026,5333884,5333947,5334374,5334616,5334689,5334948,5335261,5340131,5340562,5341081,5348511,5409798,6566094,6858067,6861716,6864562,6865079,6867133,6868776,6868778,6868793,6868961,6868963,6870001,6870009,6870526,6870805,6870937,6877815,6878451,6878477,6878742,6878781,6878832,6878849,6879061,6879152,6879251,6879309,6879356,6879453,6879568,6879723,6879934,6880370,6880465,6880530,6882879,6884055,6885369,6885697,6887460,688","85789756,85789757,85789758,85789759,85789760,85789761,85789762,85789763,85789764,85789765,85789766,85789767,85789768,85789769,85789770,85789771,85789772,85789773,85789774,85789775,85789776,85789777,85789778,85789779,85789780,85789781,85789782,85789783,85789784,85789785,85789786,85789787,85789788,85789789,85789790,85789791,85789792,85789793,85789794,85789795,85789796,85789797,85789798,85789799,85789800,85789801,85789802,85789803,85789804,85789805,85789806,85789807,85789808,85789809,85789810,85789811,85789812",NULL,"Cell-based,Organism-based",NULL,NIH Initiatives,"19238193,8913471",0,10.1371/journal.pntd.0000384,NULL,NULL,NULL
651758,2,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_Assay Overview:_|__|_Interleukin-8 is a 8 kDa chemokine produced by macrophages and other cells like epithelial cells that is often associated with inflammation. Interleukin-8 secretion is a key parameter in localized inflammation. There is a growing concern for some of environmental chemicals which may cont,2,National Center for Advancing Translational Sciences (NCATS),IL8424,20121107,"11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,370,379,398,403,447,460,527,612,650,660,700,701,702,713,753,785,795,864,887,896,904,931,949,957,967,978,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1309,1318,1483,1486,1491,1493,1732,1752,1775,1923,1983,1988,1989,2078,2087,2153,2155,2202,2244,2256,2265,2268,2272,2286,2331,2347,2355,2365,2391,2406,2478,2482,2519,2537,2554,2576,2662,2708,2720,2727,2730,2756,2758,2767,2788,2879,2950,2955,2969,3017,3026,3035,30","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",3576,NULL,AAA59158,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P10145,NULL
651755,2,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,"National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|__|_Assay overview:_|__|_Mitochondrial membrane potential (MMP), one of the parameters for mitochondrial function, is generated by mitochondrial electron transport chain that creates an electrochemical gradient by a series of redox reactions. This gradient drives the synthesis of ATP, a crucial molecule for v",2,National Center for Advancing Translational Sciences (NCATS),MMP618,20121106,"11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,370,379,398,403,447,460,527,612,650,660,700,701,702,713,753,785,795,864,887,896,904,931,949,957,967,978,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1309,1318,1483,1486,1491,1493,1732,1752,1775,1923,1983,1988,1989,2078,2087,2153,2155,2202,2244,2256,2265,2268,2272,2286,2331,2347,2355,2365,2391,2406,2478,2482,2519,2537,2554,2576,2662,2708,2720,2727,2730,2756,2758,2767,2788,2879,2950,2955,2969,3017,3026,3035,30","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,22433785,0,10.1152/physiolgenomics.00161.2011,NULL,NULL,NULL
651754,2,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,"National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|__|_Assay overview:_|__|_Mitochondrial membrane potential (MMP), one of the parameters for mitochondrial function, is generated by mitochondrial electron transport chain that creates an electrochemical gradient by a series of redox reactions. This gradient drives the synthesis of ATP, a crucial molecule for v",2,National Center for Advancing Translational Sciences (NCATS),MMP193,20121106,"11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,370,379,398,403,447,460,527,612,650,660,700,701,702,713,753,785,795,864,887,896,904,931,949,957,967,978,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1309,1318,1483,1486,1491,1493,1732,1752,1775,1923,1983,1988,1989,2078,2087,2153,2155,2202,2244,2256,2265,2268,2272,2286,2331,2347,2355,2365,2391,2406,2478,2482,2519,2537,2554,2576,2662,2708,2720,2727,2730,2756,2758,2767,2788,2879,2950,2955,2969,3017,3026,3035,30","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,22433785,0,10.1152/physiolgenomics.00161.2011,NULL,NULL,NULL
651757,2,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,"National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_Assay Overview:_|__|_Tumor Necrosis Factor-alpha (TNF-alpha), a secreted cytokine, plays an important role in inflammatory diseases and immune disorders. TNF-alpha, a 17 kDa cytokine, is mainly secreted by activated macrophages and monocytes in response to several inflammatory and immunological stimuli. To s",2,National Center for Advancing Translational Sciences (NCATS),TNF757,20121107,"11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,370,379,398,403,447,460,527,612,650,660,700,701,702,713,753,785,795,864,887,896,904,931,949,957,967,978,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1309,1318,1483,1486,1491,1493,1732,1752,1775,1923,1983,1988,1989,2078,2087,2153,2155,2202,2244,2256,2265,2268,2272,2286,2331,2347,2355,2365,2391,2406,2478,2482,2519,2537,2554,2576,2662,2708,2720,2727,2730,2756,2758,2767,2788,2879,2950,2955,2969,3017,3026,3035,30","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",7124,NULL,NP_000585,Governmental Organizations|NIH Initiatives,21643507,0,10.2174/1875397301105010021,NULL,P01375,NULL
651751,2,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,"National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_Assay overview:_|__|_The Pregnane X receptor (PXR), a ligand activated nuclear receptor plays a critical role in the regulation of genes involved in drug metabolism and transporters. PXR binds xenobiotics and when compounds interact with PXR produces enhanced expr",2,National Center for Advancing Translational Sciences (NCATS),PXR613,20121105,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",84385,NULL,AAD47214,Governmental Organizations|NIH Initiatives,20966043,0,10.1124/dmd.110.035105,NULL,Q9R1A7,NULL
651778,2,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,"National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_Assay overview:_|__|_The Peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes (alpha, garmma and beta/delta). All these subtypes heterodimerize with retinoid ",2,National Center for Advancing Translational Sciences (NCATS),PPARA536,20121115,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",5465,NULL,Q07869,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,Q07869,NULL
651777,2,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_Assay overview:_|__|_The Aryl hydrocarbon Receptor (AhR) plays a critical role in the development of cancer or neoplasm and its formation is most likely due to genetic mutations and the influence of environment. Exposure to environmental pollutants such as polycyc,2,National Center for Advancing Translational Sciences (NCATS),AHR421,20121115,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",196,NULL,EAL24281,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P35869,NULL
651596,1,Single concentration confirmation of Caspase-8 TRAIL sensitizer hits in a luminesence panel assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH095562-01A1_|_Assay Provider: Kristiina Vuori, M.D., Ph.D. Sanford Burnham Medical Research Institute_|__|_Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) is of great potential use as an anticancer therapeutic; however its use as a potential t",14,Burnham Center for Chemical Genomics,SBCCG-A907-Caspase8-Trail-CP_Panel-Assay,20120924,"6,2199,2361,3786,3832,4749,4931,5153,5303,5546,6245,7087,11106,15478,37560,43795,74477,74566,76075,91486,95263,95745,96854,97637,98360,98652,101486,102185,104830,122737,134450,147157,156816,175533,179617,181390,211017,219325,224146,224481,225126,226774,227494,230761,234504,236584,237305,241113,241318,242962,249097,250303,252247,252608,253289,253632,253834,254234,255770,259797,260001,260168,264006,266266,266379,267850,269792,270249,270507,271585,271920,274159,275781,275900,280518,280522,280859,280861,283277,","842578,842803,842811,843458,844138,844348,844372,844759,845017,845692,846149,846465,846550,846636,846656,846658,846707,846887,846985,847098,847307,847444,847491,848139,848269,848719,849081,849093,849276,849882,850336,850413,850845,851420,851517,851714,851759,852263,852448,852523,852790,852820,853183,853470,853726,855896,856149,856587,856604,856732,856813,857239,857510,857908,858020,858153,858166,858305,858782,859422,859633,859885,860618,861959,862019,862076,862148,862423,862623,862647,863230,863777,864125,8",8795,NULL,"NP_003833,NP_003833,NP_003833,NP_003833,NP_003833,NP_003833,NP_003833,NP_003833,NP_003833,NP_003833,NP_003833",NIH Initiatives,"18989337,19383910,19470771,19838056,19923319,9285725,9311998,9373179,9430227",0,10.1016/s0014-5793(97)01231-3|10.1016/s0960-9822(06)00297-1|10.1016/s1074-7613(00)80400-8|10.1038/nrd2637|10.1091/mbc.e09-09-0769|10.1093/emboj/16.17.5386|10.1158/0008-5472.can-08-3731|10.1158/0008-5472.can-08-3937|10.4161/cc.8.21.9649,NULL,O14763,NULL
651650,2,Dose Response confirmation of small molecule modulators of the interaction between CendR and NRP-1 in a panel assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford Burnham Medical Research Institute, La Jolla, CA_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH096589-01_|_Assay Provider: Dr. Erkki Ruoslahti, Sanford Burnham Medical Research Institute, La Jolla, CA _|__|_Neuropilin-1 (NRP-1) is a a pleiotrophic cell surface receptor with multiple ligands that plays an essential role in angiogenesis, cardiovascular developme",14,Burnham Center for Chemical Genomics,SBCCG-A919-CendR-DMSO-DR-Panel-Assay,20121018,"14129,14987,71055,79529,225181,227378,228947,246949,261767,263125,264984,266438,306235,307406,325875,350703,367064,383280,389115,612460,616284,616971,647455,647709,648052,648308,649751,651993,654174,657788,658259,659349,659555,659991,660583,665300,665545,679778,684283,686900,711834,714205,721347,726368,730662,735018,738125,738616,745625,746614,752969,753177,764355,765394,766594,786403,801085,810149,819511,822394,828706,833088,833806,848609,848620,851519,858944,868151,894807,901902,916048,929991,930489,93546","844602,845118,845366,845690,845940,847352,849500,850372,851587,851720,851790,852359,856415,856427,856906,858002,858205,858683,859286,859436,863030,863037,864049,864299,3711137,3713708,3715710,3715790,3715847,3717572,4241815,4241930,4243556,4244343,4244552,4246557,4246822,4247082,4247502,4247625,4248338,4248919,4249487,4251149,4251899,4251991,4254857,4256500,4256664,4256732,4257386,4260548,4260990,4261140,4263284,4263641,4265907,7966431,7967038,7968744,7969653,7972056,7972079,7972904,7973474,7974866,7975738,",NULL,NULL,"2QQI_A,2QQI_A,2QQI_A,2QQI_A,2QQI_A,2QQI_A",NIH Initiatives,"11687497,11891274,12032302,15197262,15920019,16513643,16959272,17503412,18180379,18829396,19805273,19962669",0,10.1002/path.2182|10.1016/j.ccr.2009.10.013|10.1016/j.lfs.2006.08.005|10.1016/j.nano.2008.07.007|10.1073/pnas.022017899|10.1073/pnas.0403317101|10.1073/pnas.062189599|10.1073/pnas.0908201106|10.1074/jbc.m512121200|10.1146/annurev.cellbio.17.1.463|10.1161/01.res.0000171756.13554.49|10.1182/blood-2007-08-110205,NULL,2QQI_A,NULL
651616,1,Fluorescence-based biochemical high throughput confirmation assay for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Mary Jackson, Colorado State_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS066438-01_|_Grant Proposal PI: Mary Jackson, Colorado State_|_External Assay ID: ALD_INH_FLINT_1536_3X%INH CRUN_|__|_Name: Fluorescence-based biochemical high throughput confirmation assay for inhibitors of the fruc",5,The Scripps Research Institute Molecular Screening Center,ALD_INH_FLINT_1536_3X%INH CRUN,20121003,"86,338,1369,2108,3333,3469,3821,4140,5353,5712,6738,6760,6942,7050,7057,8338,8408,8679,9128,10154,10748,11352,11913,13698,17534,19405,20926,25160,35922,47484,62978,64961,65188,66642,66671,66807,67062,67065,67238,67456,68478,68546,68872,69161,70052,70385,71034,71446,72300,72774,72826,73484,75505,76075,76977,79416,81146,84193,85555,87372,88598,89973,92134,94022,94473,94719,94999,95307,95311,95477,95745,95746,96695,100335,100475,107936,108104,115141,117636,121216,121269,135005,137494,138666,139143,142164,14405","842209,842237,842315,842332,842337,842339,842394,842410,842480,842570,842667,842689,842698,842759,842775,842925,842998,843094,843097,843144,843279,843284,843386,843407,843411,843493,843526,843600,843679,843711,843782,843876,843970,843992,844004,844091,844095,844138,844175,844453,844491,844533,844539,844622,844666,844783,844794,844843,845017,845037,845086,845124,845157,845173,845175,845347,845506,845604,845759,845760,845830,845846,845853,845863,845873,845926,845946,846062,846105,846128,846289,846363,846404,8",886474,Biochemical,NP_214877,NIH Initiatives,"18364060,18688832,19167403",0,10.1002/chem.200800857|10.1016/j.jmb.2009.01.003,4.1.2.13,P9WQA3,NULL
651815,2,qHTS for inhibitors of Vif-A3F interactions: Cherry picks counterscreen,"The recent discovery and characterization of host restriction factors, which provide a potent defense to invading retroviruses, has provided new targets for antiviral drug development. APOBEC3G (A3G) and APOBEC3F (A3F) are potent cytidine deaminases that block HIV-1 replication; HIV-1 expresses the Vif protein, which counteracts A3G and A3F by binding to them and inducing their proteasomal degradation._|__|_The Vif-A3G and Vif-A3F interactions provide two potential targets for development of small molecules",2,National Center for Advancing Translational Sciences (NCATS),VIFF201,20121127,"3213,5396,7031,7085,17599,19103,43795,54888,67485,70848,79174,89341,92993,95022,95917,99053,100335,100761,145792,146609,161091,165441,176158,226518,230706,234845,237061,237490,238710,238958,240478,242314,242563,245882,247104,251934,253632,254069,254070,254080,254340,254365,255326,255770,256073,256430,256431,256654,257275,260645,261066,263454,265935,268760,268761,268762,272247,272989,274941,275187,276685,286183,288865,291072,291710,292556,292560,300375,300571,300576,300842,312601,313562,313614,314728,315391,","842521,844855,845086,845735,845849,846756,849323,849701,850589,851635,852689,852942,853383,853589,856081,857272,857352,857898,858468,858495,858569,859170,859409,859413,859717,859735,859832,860294,860525,861161,861717,862075,862271,862584,862845,862908,862978,863259,863985,864292,864593,864679,864778,865581,3711742,3711897,3712233,3712264,3712782,3713133,3713362,3713643,3714713,3714774,3715767,3715952,3716156,3716608,3716751,3716957,4240556,4240957,4241224,4241593,4241819,4242663,4242696,4242856,4242927,4243",200316,NULL,NP_660341,Governmental Organizations|NIH Initiatives,"18806783,20363737",0,10.1038/nbt.1496|10.1074/jbc.m109.085308,3.5.4.38,Q8IUX4,NULL
651813,2,qHTS for inhibitors of Vif-A3G interactions: Cherry picks counterscreen,"The recent discovery and characterization of host restriction factors, which provide a potent defense to invading retroviruses, has provided new targets for antiviral drug development. APOBEC3G (A3G) and APOBEC3F (A3F) are potent cytidine deaminases that block HIV-1 replication; HIV-1 expresses the Vif protein, which counteracts A3G and A3F by binding to them and inducing their proteasomal degradation._|__|_The Vif-A3G and Vif-A3F interactions provide two potential targets for development of small molecules",2,National Center for Advancing Translational Sciences (NCATS),VIFG201,20121127,"3213,5396,7031,7085,17599,19103,43795,54888,67485,70848,79174,89341,92993,95022,95917,99053,100335,100761,145792,146609,161091,165441,176158,226518,230706,234845,237061,237490,238710,238958,240478,242314,242563,245882,247104,251934,253632,254069,254070,254080,254340,254365,255326,255770,256073,256430,256431,256654,257275,260645,261066,263454,265935,268760,268761,268762,272247,272989,274941,275187,276685,286183,288865,291072,291710,292556,292560,300375,300571,300576,300842,312601,313562,313614,314728,315391,","842521,844855,845086,845735,845849,846756,849323,849701,850589,851635,852689,852942,853383,853589,856081,857272,857352,857898,858468,858495,858569,859170,859409,859413,859717,859735,859832,860294,860525,861161,861717,862075,862271,862584,862845,862908,862978,863259,863985,864292,864593,864679,864778,865581,3711742,3711897,3712233,3712264,3712782,3713133,3713362,3713643,3714713,3714774,3715767,3715952,3716156,3716608,3716751,3716957,4240556,4240957,4241224,4241593,4241819,4242663,4242696,4242856,4242927,4243",60489,NULL,NP_068594,Governmental Organizations|NIH Initiatives,"18806783,20363737",0,10.1038/nbt.1496|10.1074/jbc.m109.085308,3.5.4.-,Q9HC16,NULL
651814,2,qHTS for inhibitors of Vif-A3F interactions: Cherry picks,"The recent discovery and characterization of host restriction factors, which provide a potent defense to invading retroviruses, has provided new targets for antiviral drug development. APOBEC3G (A3G) and APOBEC3F (A3F) are potent cytidine deaminases that block HIV-1 replication; HIV-1 expresses the Vif protein, which counteracts A3G and A3F by binding to them and inducing their proteasomal degradation._|__|_The Vif-A3G and Vif-A3F interactions provide two potential targets for development of small molecules",2,National Center for Advancing Translational Sciences (NCATS),VIFF200,20121127,"3213,5396,7031,7085,17599,19103,43795,54888,67485,70848,79174,89341,92993,95022,95917,99053,100335,100761,145792,146609,161091,165441,176158,226518,230706,234845,237061,237490,238710,238958,240478,242314,242563,245882,247104,251934,253632,254069,254070,254080,254340,254365,255326,255770,256073,256430,256431,256654,257275,260645,261066,263454,265935,268760,268761,268762,272247,272989,274941,275187,276685,286183,288865,291072,291710,292556,292560,300375,300571,300576,300842,312601,313562,313614,314728,315391,","842521,844855,845086,845735,845849,846756,849323,849701,850589,851635,852689,852942,853383,853589,856081,857272,857352,857898,858468,858495,858569,859170,859409,859413,859717,859735,859832,860294,860525,861161,861717,862075,862271,862584,862845,862908,862978,863259,863985,864292,864593,864679,864778,865581,3711742,3711897,3712233,3712264,3712782,3713133,3713362,3713643,3714713,3714774,3715767,3715952,3716156,3716608,3716751,3716957,4240556,4240957,4241224,4241593,4241819,4242663,4242696,4242856,4242927,4243",200316,NULL,NP_660341,Governmental Organizations|NIH Initiatives,"18806783,20363737",0,10.1038/nbt.1496|10.1074/jbc.m109.085308,3.5.4.38,Q8IUX4,NULL
651812,2,qHTS for inhibitors of Vif-A3G interactions: Cherry picks,"The recent discovery and characterization of host restriction factors, which provide a potent defense to invading retroviruses, has provided new targets for antiviral drug development. APOBEC3G (A3G) and APOBEC3F (A3F) are potent cytidine deaminases that block HIV-1 replication; HIV-1 expresses the Vif protein, which counteracts A3G and A3F by binding to them and inducing their proteasomal degradation._|__|_The Vif-A3G and Vif-A3F interactions provide two potential targets for development of small molecules",2,National Center for Advancing Translational Sciences (NCATS),VIFG200,20121127,"3213,5396,7031,7085,17599,19103,43795,54888,67485,70848,79174,89341,92993,95022,95917,99053,100335,100761,145792,146609,161091,165441,176158,226518,230706,234845,237061,237490,238710,238958,240478,242314,242563,245882,247104,251934,253632,254069,254070,254080,254340,254365,255326,255770,256073,256430,256431,256654,257275,260645,261066,263454,265935,268760,268761,268762,272247,272989,274941,275187,276685,286183,288865,291072,291710,292556,292560,300375,300571,300576,300842,312601,313562,313614,314728,315391,","842521,844855,845086,845735,845849,846756,849323,849701,850589,851635,852689,852942,853383,853589,856081,857272,857352,857898,858468,858495,858569,859170,859409,859413,859717,859735,859832,860294,860525,861161,861717,862075,862271,862584,862845,862908,862978,863259,863985,864292,864593,864679,864778,865581,3711742,3711897,3712233,3712264,3712782,3713133,3713362,3713643,3714713,3714774,3715767,3715952,3716156,3716608,3716751,3716957,4240556,4240957,4241224,4241593,4241819,4242663,4242696,4242856,4242927,4243",60489,NULL,NP_068594,Governmental Organizations|NIH Initiatives,"18806783,20363737",0,10.1038/nbt.1496|10.1074/jbc.m109.085308,3.5.4.-,Q9HC16,NULL
651561,2,Dose response confirmation of uHTS inhibitor hits of the mitochondrial permeability transition pore via an absorbance assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH096534-01 _|_Assay Provider: Michael Forte, Ph.D., Oregon Health & Science University, Portland, OR_|__|_Given its multifactorial roles, regulation of cellular Ca2+ metabolism and bioenergetics functions as an integrated system. In terms of normal physiology",14,Burnham Center for Chemical Genomics,SBCCG-A891-mtPTP-DMSO-DR-Assay,20120905,"2799,3035,3396,4011,4211,6240,9340,9365,11061,20784,29893,50088,55694,55704,60496,60834,62034,62857,62969,63062,65327,65341,65557,66062,71177,92783,98360,124887,133633,200370,222275,225126,230761,246378,275179,310139,324091,324415,391190,441358,587874,628785,644955,645259,645852,646751,646857,647528,648949,649447,652707,653946,655523,657811,658199,658668,659418,659436,659520,660013,660299,660911,661250,661339,663466,663569,663896,664716,665044,665062,665288,665289,667127,693389,695082,712225,717029,726838,7","843549,843883,844425,844530,845189,846141,846396,846557,846731,846969,847052,848529,850196,851377,852091,852878,856256,856296,856452,856839,857319,857411,858062,858081,858168,858705,858920,858996,859047,859608,859613,859825,859948,860032,862243,862341,862664,863463,863788,863809,863911,864037,864038,865868,3711344,3711606,3712651,3712781,3713915,3713957,3714129,3714177,3714742,3715081,3715193,3716952,3717526,4241720,4242374,4243526,4244429,4244717,4244774,4245298,4245900,4246539,4246633,4246705,4247091,4247",NULL,NULL,NULL,NIH Initiatives,"10508231,16087232,16649987,17294078,18400691,19161975",0,10.1007/s10495-007-0723-y|10.1016/j.bbabio.2008.12.011|10.1016/j.ceca.2005.06.011|10.1111/j.1742-4658.2006.05213.x|10.1152/physiol.00046.2007|10.1152/physrev.1999.79.4.1127,NULL,NULL,NULL
651802,2,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,"National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_Assay Overview:_|__|_Nuclear steroid hormone receptors are involved in many biological processes including inflammatory responses, cell proliferation, and apoptosis.  Environmental factors or compounds disrupting these nuclear receptor pathways and gene expression may promote susceptibility to immunotoxicant",2,National Center for Advancing Translational Sciences (NCATS),ROR993,20121120,"11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,370,379,398,403,447,460,527,612,650,660,700,701,702,713,753,785,795,864,887,896,904,931,949,957,967,978,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1309,1318,1483,1486,1491,1493,1732,1752,1775,1923,1983,1988,1989,2078,2087,2153,2155,2202,2244,2256,2265,2268,2272,2286,2331,2347,2355,2365,2391,2406,2478,2482,2519,2537,2554,2576,2662,2708,2720,2727,2730,2756,2758,2767,2788,2879,2950,2955,2969,3017,3026,3035,30","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",6097,NULL,P51449,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P51449,NULL
651742,0,NIH/3T3 (mouse embryonic fibroblast) toxicity Measured in Cell-Based System Using Plate Reader - 2138-02_Inhibitor_SinglePoint_CherryPick_Activity,"Keywords: NIH3T3, cytotoxic_|__|_Assay Overview: The assay detects compounds that are cytotoxic to NIH3T3 cells afer ~90hrs in culture.  After plating the NIH3T3 cells, compounds are added to the wells.    After 90 hours culturing, all cells in the well are lysed and ATP is detected using Cell Titer Glo_|__|_Expected Outcome: Compounds significantly suppressing luminescence, and therefore cytotoxic to NIH3T3s will be resolved as hits.  This is a counter screen to primary  screen to determine compounds that ",31,Broad Institute,2138-02_Inhibitor_SinglePoint_CherryPick_Activity,20121101,"44259,3238551,44202039,44202372,44202561,44202697,44202767,44483522,44483639,44483670,44483723,44483782,44483855,44484090,44484112,44484137,44484153,44484189,44484202,44484222,44484398,44484515,44484555,44484583,44484588,44484730,44484747,44484944,44484967,44485051,44485076,44485085,44485096,44485103,44485109,44485120,44485174,44485177,44485182,44485236,44485309,44485355,44485386,44485402,44485403,44485414,44485420,44485456,44485501,44485593,44485594,44485743,44485746,44485795,44485811,44485856,44485890,444","85789804,85789924,85790042,85790075,85790129,85790189,85790264,85790503,85790525,85790550,85790566,85790603,85790616,85790636,85790826,85790945,85790985,85791013,85791018,85791169,85791187,85791387,85791410,85791495,85791520,85791529,85791540,85791547,85791553,85791564,85791618,85791621,85791626,85791680,85791755,85791802,85791833,85791849,85791850,85791861,85791868,85791904,85791949,85792044,85792045,85792247,85792263,85792310,85792345,85792504,85792586,85792633,85792643,85792705,85792781,85792831,85792843",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,"19238193,8913471",0,10.1371/journal.pntd.0000384,NULL,NULL,NULL
651740,0,Inhibition of T.cruzi proliferation in culture Measured in Cell-Based System Using Plate Reader - 2138-01_Inhibitor_SinglePoint_CherryPick_Activity_Set2,"Keywords: Trypanosoma cruzi, Chagas disease_|__|_Assay Overview: The assay detects intracellular trypanosomes that are replicating inside host cells.  NIH3T3 cells are trypsinized, counted, and plated in 384-well tissue culture plates.  After plating the NIH3T3 cells, compounds are added to the wells.  T. cruzi that are genetically modified to express b-galactosidase are then harvested and active Trypomastigotes form  are counted and co-cultured with the NIH3T3 cells.  After 90 hours of co-culture, all cell",31,Broad Institute,2138-01_Inhibitor_SinglePoint_CherryPick_Activity_Set2,20121101,"44259,3238551,44202039,44202372,44202561,44202697,44202767,44483522,44483639,44483670,44483723,44483782,44483855,44484090,44484112,44484137,44484153,44484189,44484202,44484222,44484398,44484515,44484555,44484583,44484588,44484730,44484747,44484944,44484967,44485051,44485076,44485085,44485096,44485103,44485109,44485120,44485174,44485177,44485182,44485236,44485309,44485355,44485386,44485402,44485403,44485414,44485420,44485456,44485501,44485593,44485594,44485743,44485746,44485795,44485811,44485856,44485890,444","85789804,85789924,85790042,85790075,85790129,85790189,85790264,85790503,85790525,85790550,85790566,85790603,85790616,85790636,85790826,85790945,85790985,85791013,85791018,85791169,85791187,85791387,85791410,85791495,85791520,85791529,85791540,85791547,85791553,85791564,85791618,85791621,85791626,85791680,85791755,85791802,85791833,85791849,85791850,85791861,85791868,85791904,85791949,85792044,85792045,85792247,85792263,85792310,85792345,85792504,85792586,85792633,85792643,85792705,85792781,85792831,85792843",NULL,Cell-based,NULL,NIH Initiatives,"19238193,8913471",0,10.1371/journal.pntd.0000384,NULL,NULL,NULL
651739,0,Inhibition of T.cruzi proliferation in culture Measured in Cell-Based System Using Plate Reader - 2138-01_Inhibitor_SinglePoint_CherryPick_Activity,"Keywords: Trypanosoma cruzi, Chagas disease_|__|_Assay Overview: The assay detects intracellular trypanosomes that are replicating inside host cells.  NIH3T3 cells are trypsinized, counted, and plated in 384-well tissue culture plates.  After plating the NIH3T3 cells, compounds are added to the wells.  T. cruzi that are genetically modified to express b-galactosidase are then harvested and active Trypomastigotes form  are counted and co-cultured with the NIH3T3 cells.  After 90 hours of co-culture, all cell",31,Broad Institute,2138-01_Inhibitor_SinglePoint_CherryPick_Activity,20121031,"44259,3238551,44202039,44202372,44202561,44202697,44202767,44483522,44483639,44483670,44483723,44483782,44483855,44484090,44484112,44484137,44484153,44484189,44484202,44484222,44484398,44484515,44484555,44484583,44484588,44484730,44484747,44484944,44484967,44485051,44485076,44485085,44485096,44485103,44485109,44485120,44485174,44485177,44485182,44485236,44485309,44485355,44485386,44485402,44485403,44485414,44485420,44485456,44485501,44485593,44485594,44485743,44485746,44485795,44485811,44485856,44485890,444","85789804,85789924,85790042,85790075,85790129,85790189,85790264,85790503,85790525,85790550,85790566,85790603,85790616,85790636,85790826,85790945,85790985,85791013,85791018,85791169,85791187,85791387,85791410,85791495,85791520,85791529,85791540,85791547,85791553,85791564,85791618,85791621,85791626,85791680,85791755,85791802,85791833,85791849,85791850,85791861,85791868,85791904,85791949,85792044,85792045,85792247,85792263,85792310,85792345,85792504,85792586,85792633,85792643,85792705,85792781,85792831,85792843",NULL,Cell-based,NULL,NIH Initiatives,"19238193,8913471",0,10.1371/journal.pntd.0000384,NULL,NULL,NULL
651558,2,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling: Hit Validation in Primary Screen,"Diffuse large B-cell lymphoma (DLBCL) is the most common category of non-Hodgkin lymphoma, with ~20,000 new cases per year in the United States. DLBCL should be regarded as a collection of different neoplasms. Microarray gene expression analysis has defined two principal types of DLBCL, named for their similarity to normal B cell stages or activation states: a germinal center B-cell (GCB) type, and an activated B-cell (ABC) type. In ABC-DLBCL, a constitutive high-level activity of the NF-kappaB family of tr",2,National Center for Advancing Translational Sciences (NCATS),TMD8200,20120831,"1688,1761,2203,2692,2833,3194,3334,3512,5455,5754,5834,5991,5994,6084,6167,6724,6741,8974,10156,10607,16490,18469,19910,26133,42725,66414,74902,75526,82533,93205,100335,101430,120879,123683,126054,137226,161091,161167,211186,222275,223368,224214,226756,242436,242587,247839,250997,253793,260644,260645,264006,265594,272568,275363,280492,282697,322919,325108,327861,355876,360474,360560,389128,398148,446849,448222,551870,568416,570206,604128,605332,613657,617341,626288,631721,638278,638439,644407,646414,646455,","842151,844105,844139,845575,846887,847164,850589,850617,852641,853705,855580,855615,855624,855641,855649,855652,855653,855658,855688,855748,855789,855897,855908,855961,855973,855995,855996,856002,856308,856344,856362,856525,856947,857056,857270,857272,857677,857775,858187,858683,859077,859832,859869,861109,861129,861321,861400,861415,861435,861634,861716,861731,861918,861970,862386,862793,862999,863953,864370,864460,864533,865818,866078,3711925,3712782,3712888,3713133,3713171,3714362,3714713,3715341,3715474",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"11748286,16572121,17355202,20054396",0,10.1038/nature04687|10.1038/nature08638|10.1084/jem.194.12.1861|10.1089/adt.2006.048,NULL,NULL,NULL
651564,2,Dose response confirmation of uHTS inhibitor hits of the mitochondrial permeability transition pore via a fluorescent based counterscreen assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH096534-01 _|_Assay Provider: Michael Forte, Ph.D., Oregon Health & Science University, Portland, OR_|__|_Given its multifactorial roles, regulation of cellular Ca2+ metabolism and bioenergetics functions as an integrated system. In terms of normal physiology",14,Burnham Center for Chemical Genomics,SBCCG-A892-mtPTP-CTR-DMSO-DR-Assay,20120905,"2799,3035,3396,4011,4211,6240,9340,9365,11061,20784,29893,50088,55694,55704,60496,60834,62034,62857,62969,63062,65327,65341,65557,66062,71177,92783,98360,124887,133633,200370,222275,225126,230761,246378,275179,310139,324091,324415,391190,441358,587874,628785,644955,645259,645852,646751,646857,647528,648949,649447,652707,653946,655523,657811,658199,658668,659418,659436,659520,660013,660299,660911,661250,661339,663466,663569,663896,664716,665044,665062,665288,665289,667127,693389,695082,712225,717029,726838,7","843549,843883,844425,844530,845189,846141,846396,846557,846731,846969,847052,848529,850196,851377,852091,852878,856256,856296,856452,856839,857319,857411,858062,858081,858168,858705,858920,858996,859047,859608,859613,859825,859948,860032,862243,862341,862664,863463,863788,863809,863911,864037,864038,865868,3711344,3711606,3712651,3712781,3713915,3713957,3714129,3714177,3714742,3715081,3715193,3716952,3717526,4241720,4242374,4243526,4244429,4244717,4244774,4245298,4245900,4246539,4246633,4246705,4247091,4247",NULL,NULL,NULL,NIH Initiatives,"10508231,16087232,16649987,17294078,18400691,19161975",0,10.1007/s10495-007-0723-y|10.1016/j.bbabio.2008.12.011|10.1016/j.ceca.2005.06.011|10.1111/j.1742-4658.2006.05213.x|10.1152/physiol.00046.2007|10.1152/physrev.1999.79.4.1127,NULL,NULL,NULL
651700,2,"Dose response confirmation of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay","Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number: 1 R03 DA033986-01_|_Assay Provider: Nunzio Bottini, M.D., Ph.D., La Jolla Institute for Allergy & Immunology, La Jolla, CA_|__|_Obesity is frequently complicated by a constellation of metabolic and cardiovascular anomalies, called the metabolic syndrome, which significant",14,Burnham Center for Chemical Genomics,SBCCG-A930-LMPTP-Inh-DMSO-DR-Assay,20121031,"4993,7436,8266,12560,66672,140917,172306,223696,248874,258829,271585,277512,285249,307156,343097,343098,353909,368866,389733,402652,651756,660058,660761,661087,661646,662595,663340,665279,665400,665595,666333,666486,667384,675226,690108,694792,715715,750959,767427,784622,800337,804795,806823,821004,832184,869895,883304,929654,931186,978001,986648,1003680,1034155,1043824,1045642,1046489,1080599,1132506,1167954,1187249,1187250,1208412,1230862,1258959,1261644,1266395,1280531,1281724,1284704,1289171,1304048,131","843005,849279,858753,859785,860348,861345,862119,864028,864152,864347,864665,865081,865232,866125,3717697,4243033,4246343,4248673,4248968,4249524,4255985,4260153,4260844,4260883,4262120,4262408,7966414,7968015,7972587,7974447,7975187,14723136,14736765,14738690,14743950,14745409,14746933,16953197,17387017,17387657,17388075,17388139,17401779,17403669,17407053,17408088,17408934,17410150,17410781,17410933,17411051,17411971,17412559,17414130,17415497,17415870,17431604,17431818,17432592,17432658,17433367,17433547",52,NULL,P24666,NIH Initiatives,"12050202,12409270,12800095,1304913,15660501,17353188",0,10.1002/pro.5560010603|10.1016/s0026-0495(03)00065-9|10.1016/s1096-7192(02)00120-8|10.1074/jbc.m609626200|10.1146/annurev.med.56.082103.104751|10.1210/jcem.87.6.8641,"3.1.3.2,3.1.3.48",P24666,NULL
651804,2,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction: HTRF assay against cherry picks,"The Ets family of proteins is a family of ~30 conserved transcription factors defined by the presence of an ~85 amino acid domain referred to as the Ets domain, which mediates sequence-specific DNA binding to a core DNA element GGAA/T.The Ets family member ERG has been linked to several neoplasms. ERG has been shown to be frequently over-expressed in prostate cancer. Perhaps more strikingly, ERG and the Ets protein ETV1 have recently been shown to be the targets of chromosomal translocations with TMPRSS2 wh",2,National Center for Advancing Translational Sciences (NCATS),ERG201,20121121,"119,303,978,1365,2153,2482,2794,3672,3969,4115,4748,5147,5215,5353,5918,6010,7141,7641,10635,11352,11548,13109,13436,13698,14169,15753,16097,19646,21796,22641,24370,47812,60758,64150,66259,68094,68106,70464,72571,72894,74989,80123,88012,100135,108155,114811,128355,129791,160157,176170,198284,202512,229278,229301,235004,239492,239740,239930,240425,246431,254758,256518,257819,260266,261673,262093,264201,266054,267862,269062,274929,276233,285779,302873,320362,327044,331342,346741,357403,386481,387806,459531,53","842819,842877,843711,845272,846036,848752,852312,855757,855829,855872,856146,856443,856773,857006,857162,858000,858850,860058,860441,860901,861022,861998,862192,862375,863323,866157,3712166,3713643,3714921,3716615,4240712,4243232,4243345,4244683,4245474,4246411,4247261,4247361,4248469,4248853,4249185,4249193,4250886,4251120,4251760,4254533,4254966,4256341,4257919,4259279,4260444,4262063,4264372,4265469,7965355,7965567,7965726,7967687,7967795,7968050,7968466,7968637,7968942,7969296,7969511,7969671,7970760,79",2078,NULL,NP_001230357,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P11308,NULL
651630,2,Dose Response confirmation of small molecule Triacylglycerol inhbitors in a panel assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network (MLPCN)_|_Grant Number: 1 R24 DK084969 (FT1012)_|_Assay Provider: Daniel Kelly, Ph.D. Sanford Burnham Medical Research Institute_|_                    _|_In the obese state, complex lipids, chiefly triacylglycerides (TAG), accumulate within cells of tissues that do not typically store fat, inclu",14,Burnham Center for Chemical Genomics,SBCCG-A911-TAG-DMSO-DR-Panel-Assay,20121009,"2082,3334,5887,6824,10607,10788,22694,54360,65327,66062,97865,98360,104895,125001,146609,161091,222612,227345,230761,235856,239677,246378,262649,271216,289018,292560,295583,309279,310867,322539,327010,328154,328772,330164,341279,348206,358091,360562,369623,378957,379302,380570,381393,384851,387350,390232,443958,575337,645997,647168,648620,651460,653546,653589,655208,655603,657680,658276,658462,659479,659554,660660,661234,661342,661767,662336,665375,665411,665525,665678,666079,666262,666600,666759,702131,705","843694,848994,850993,851037,852585,852958,855721,855748,855809,855832,857104,858124,858204,859932,860035,862160,864126,864163,864831,865016,865346,865505,3711925,3712782,3713340,3714713,3714774,3715857,3716415,3716489,3717767,4241653,4242001,4242079,4243699,4244629,4245327,4246178,4246203,4247318,4247661,4247666,4248039,4250129,4250583,4256880,4258659,4259385,4259642,4259843,4260246,4261804,4264220,4265121,4265157,7965051,7965285,7965546,7966057,7966535,7967657,7968819,7970578,7973934,7974355,7976210,797735",NULL,NULL,NULL,NIH Initiatives,"12055349,17130651",0,10.1146/annurev.nutr.22.010402.102912|10.2337/db06-s002,NULL,NULL,NULL
651744,0,NIH/3T3 (mouse embryonic fibroblast) toxicity Measured in Cell-Based System Using Plate Reader - 2138-02_Inhibitor_SinglePoint_CherryPick_Activity_Set2,"Keywords: NIH3T3, cytotoxic_|__|_Assay Overview: The assay detects compounds that are cytotoxic to NIH3T3 cells afer ~90hrs in culture.  After plating the NIH3T3 cells, compounds are added to the wells.    After 90 hours culturing, all cells in the well are lysed and ATP is detected using Cell Titer Glo_|__|_Expected Outcome: Compounds significantly suppressing luminescence, and therefore cytotoxic to NIH3T3s will be resolved as hits.  This is a counter screen to primary  screen to determine compounds that ",31,Broad Institute,2138-02_Inhibitor_SinglePoint_CherryPick_Activity_Set2,20121101,"44259,3238551,44202039,44202372,44202561,44202697,44202767,44483522,44483639,44483670,44483723,44483782,44483855,44484090,44484112,44484137,44484153,44484189,44484202,44484222,44484398,44484515,44484555,44484583,44484588,44484730,44484747,44484944,44484967,44485051,44485076,44485085,44485096,44485103,44485109,44485120,44485174,44485177,44485182,44485236,44485309,44485355,44485386,44485402,44485403,44485414,44485420,44485456,44485501,44485593,44485594,44485743,44485746,44485795,44485811,44485856,44485890,444","85789804,85789924,85790042,85790075,85790129,85790189,85790264,85790503,85790525,85790550,85790566,85790603,85790616,85790636,85790826,85790945,85790985,85791013,85791018,85791169,85791187,85791387,85791410,85791495,85791520,85791529,85791540,85791547,85791553,85791564,85791618,85791621,85791626,85791680,85791755,85791802,85791833,85791849,85791850,85791861,85791868,85791904,85791949,85792044,85792045,85792247,85792263,85792310,85792345,85792504,85792586,85792633,85792643,85792705,85792781,85792831,85792843",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,"19238193,8913471",0,10.1371/journal.pntd.0000384,NULL,NULL,NULL
651593,2,qHTS of Nrf2 Activators: Hit Validation in Primary Assay,"Many diseases have some form of oxidative stress injury and ties to inflammation, causing a host of problems for the patient. The antioxidant response element (ARE) plays an important role in alleviating the harmful effects of oxidative stress. The antioxidant response element (ARE) is a transcriptional regulatory element involved in the activation of genes coding for a number of antioxidant proteins and detoxifying enzymes. These enzymes work in concert to protect tissues from oxidative insults and chemica",2,National Center for Advancing Translational Sciences (NCATS),Nrf2200,20121204,"4641,5311,6825,9181,10709,12888,13801,14161,18311,22694,22797,36302,43795,71034,72837,73427,97900,100434,120053,146694,219326,220147,220850,225916,226774,231608,231723,238448,240703,244240,248021,248148,248690,252766,252780,255021,255770,256762,259241,259769,259799,261413,263261,263855,263869,269062,270482,271955,272282,272385,274053,274055,274061,274564,275900,277056,277060,279091,279303,280101,282544,283529,284471,288319,288865,289037,289769,291365,297344,297345,300580,305283,305309,306831,307190,308065,3","842211,842443,843119,843706,844771,845451,845660,845794,846135,847068,847636,848745,849158,850239,850466,851005,851793,857486,857634,857707,858230,858736,859170,859770,860120,860495,860525,863191,863211,863401,863650,864142,864210,864212,864446,864778,865526,865573,865837,3711817,3712613,3712685,3715264,3715276,3715547,3716827,3716877,3717116,3717305,3717974,3717985,4240684,4240918,4241619,4242708,4243367,4243501,4244117,4244445,4244701,4244888,4244974,4245131,4245852,4245958,4246052,4246153,4246317,4246374",4780,NULL,AAB32188,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAB32188,NULL
651568,2,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling: Hit Validation in Renilla Reporter Assay,"Diffuse large B-cell lymphoma (DLBCL) is the most common category of non-Hodgkin lymphoma, with ~20,000 new cases per year in the United States. DLBCL should be regarded as a collection of different neoplasms. Microarray gene expression analysis has defined two principal types of DLBCL, named for their similarity to normal B cell stages or activation states: a germinal center B-cell (GCB) type, and an activated B-cell (ABC) type. In ABC-DLBCL, a constitutive high-level activity of the NF-kappaB family of tr",2,National Center for Advancing Translational Sciences (NCATS),TMD8202,20120906,"1688,1761,2203,2692,2833,3194,3334,3512,5455,5754,5834,5991,5994,6084,6167,6724,6741,8974,10156,10607,16490,18469,19910,26133,42725,66414,74902,75526,82533,93205,100335,101430,120879,123683,126054,137226,161091,161167,211186,222275,223368,224214,226756,242436,242587,247839,250997,253793,260644,260645,264006,265594,272568,275363,280492,282697,322919,325108,327861,355876,360474,360560,389128,398148,446849,448222,551870,568416,570206,604128,605332,613657,617341,626288,631721,638278,638439,644407,646414,646455,","842151,844105,844139,845575,846887,847164,850589,850617,852641,853705,855580,855615,855624,855641,855649,855652,855653,855658,855688,855748,855789,855897,855908,855961,855973,855995,855996,856002,856308,856344,856362,856525,856947,857056,857270,857272,857677,857775,858187,858683,859077,859832,859869,861109,861129,861321,861400,861415,861435,861634,861716,861731,861918,861970,862386,862793,862999,863953,864370,864460,864533,865818,866078,3711925,3712782,3712888,3713133,3713171,3714362,3714713,3715341,3715474",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"11748286,16572121,17355202,20054396",0,10.1038/nature04687|10.1038/nature08638|10.1084/jem.194.12.1861|10.1089/adt.2006.048,NULL,NULL,NULL
651597,2,qHTS of Nrf2 Activators: Hit Validation in Secondary FLuc Assay,"Many diseases have some form of oxidative stress injury and ties to inflammation, causing a host of problems for the patient. The antioxidant response element (ARE) plays an important role in alleviating the harmful effects of oxidative stress. The antioxidant response element (ARE) is a transcriptional regulatory element involved in the activation of genes coding for a number of antioxidant proteins and detoxifying enzymes. These enzymes work in concert to protect tissues from oxidative insults and chemica",2,National Center for Advancing Translational Sciences (NCATS),Nrf2201,20120924,"4641,5311,6825,9181,10709,12888,13801,14161,18311,22694,22797,36302,43795,71034,72837,73427,97900,100434,120053,146694,219326,220147,220850,225916,226774,231608,231723,238448,240703,244240,248021,248148,248690,252766,252780,255021,255770,256762,259241,259769,259799,261413,263261,263855,263869,269062,270482,271955,272282,272385,274053,274055,274061,274564,275900,277056,277060,279091,279303,280101,282544,283529,284471,288319,288865,289037,289769,291365,297344,297345,300580,305283,305309,306831,307190,308065,3","842211,842443,843119,843706,844771,845451,845660,845794,846135,847068,847636,848745,849158,850239,850466,851005,851793,857486,857634,857707,858230,858736,859170,859770,860120,860495,860525,863191,863211,863401,863650,864142,864210,864212,864446,864778,865526,865573,865837,3711817,3712613,3712685,3715264,3715276,3715547,3716827,3716877,3717116,3717305,3717974,3717985,4240684,4240918,4241619,4242708,4243367,4243501,4244117,4244445,4244701,4244888,4244974,4245131,4245852,4245958,4246052,4246153,4246317,4246374",4780,NULL,AAB32188,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAB32188,NULL
651803,2,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction: TR assay against cherry picks,"The Ets family of proteins is a family of ~30 conserved transcription factors defined by the presence of an ~85 amino acid domain referred to as the Ets domain, which mediates sequence-specific DNA binding to a core DNA element GGAA/T.The Ets family member ERG has been linked to several neoplasms. ERG has been shown to be frequently over-expressed in prostate cancer. Perhaps more strikingly, ERG and the Ets protein ETV1 have recently been shown to be the targets of chromosomal translocations with TMPRSS2 wh",2,National Center for Advancing Translational Sciences (NCATS),ERG200,20121121,"119,303,978,1365,2153,2482,2794,3672,3969,4115,4748,5147,5215,5353,5918,6010,7141,7641,10635,11352,11548,13109,13436,13698,14169,15753,16097,19646,21796,22641,24370,47812,60758,64150,66259,68094,68106,70464,72571,72894,74989,80123,88012,100135,108155,114811,128355,129791,160157,176170,198284,202512,229278,229301,235004,239492,239740,239930,240425,246431,254758,256518,257819,260266,261673,262093,264201,266054,267862,269062,274929,276233,285779,302873,320362,327044,331342,346741,357403,386481,387806,459531,53","842819,842877,843711,845272,846036,848752,852312,855757,855829,855872,856146,856443,856773,857006,857162,858000,858850,860058,860441,860901,861022,861998,862192,862375,863323,866157,3712166,3713643,3714921,3716615,4240712,4243232,4243345,4244683,4245474,4246411,4247261,4247361,4248469,4248853,4249185,4249193,4250886,4251120,4251760,4254533,4254966,4256341,4257919,4259279,4260444,4262063,4264372,4265469,7965355,7965567,7965726,7967687,7967795,7968050,7968466,7968637,7968942,7969296,7969511,7969671,7970760,79",2078,NULL,NP_001230357,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P11308,NULL
651997,1,Single concentration confirmation of uHTS hits from a small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute(SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 MH097522-01_|_Assay Provider: Robert Rickert, Ph.D., Sanford-Burnham Medical Research Institute_|__|_Epstein-Barr virus-induced gene 2 (EBI2) (1-4), also known as GPR183, is expressed on B cells and is highly induced upon activation (5). Recent gene targeting e",14,Burnham Center for Chemical Genomics,SBCCG-A951-EBI2-Antagonist-CP-Assay,20130129,"2799,3351,36339,66733,78416,161803,162076,185371,224146,258829,259580,261330,269357,282662,296157,304881,307156,308950,320412,328910,355941,455444,489420,525811,584971,595570,596877,613159,624046,624107,638860,643007,644405,644628,644930,645092,645211,645522,645641,646172,646306,646876,647421,647586,647711,648031,648243,649081,649589,649642,650148,650196,650383,650386,650430,650501,651244,652073,652079,652408,654196,654330,654443,654590,654722,655112,655651,655953,656125,656221,656249,657568,657804,657957,6","842149,842364,842659,842940,843351,843868,844549,845083,845246,845668,845887,846687,847191,847243,847739,847780,847965,847968,848005,848077,848791,849495,849573,849579,849899,851610,851737,851986,853301,853562,853590,856192,856444,856600,857466,857475,858019,858185,858753,858810,859042,859195,859277,859865,860001,860016,860327,860906,861119,861166,861337,861351,861356,861410,861547,861784,861835,862055,862471,862721,863191,863355,863998,864032,864167,864279,864478,864565,864941,3711120,3711425,3712974,37133",1880,NULL,NP_004942,NIH Initiatives,"19597478,19615922,20727031,21796211,21796212",0,10.1016/j.immuni.2009.06.016|10.1038/nature08226|10.1038/nature10226|10.1038/nature10280|10.1111/j.1600-065x.2010.00942.x,NULL,P32249,NULL
651611,1,Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based cell-based high throughput assay to identify nonselective inhibitors of the Steroidogenic acute regulatory protein (StAR) promoter or luminescence assay ,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Patrick Griffin, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: CA134873_|_Grant Proposal PI: Patrick Griffin, TSRI_|_External Assay ID: STAR_INH_LUMI_1536_3X%INH CSRUN for LRH1 IAG_|__|_Name: Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based",5,The Scripps Research Institute Molecular Screening Center,STAR_INH_LUMI_1536_3X%INH CSRUN for LRH1 IAG,20121003,"1318,1570,2199,2754,3197,3832,3879,4112,4491,4605,4749,4931,5153,5303,5396,5614,6099,6185,6197,6245,6842,7578,8467,8975,9283,9444,11293,11352,14710,15478,16955,17201,20345,22324,32875,36462,38777,40586,42640,43795,47508,52167,54368,60699,62770,65237,66541,70848,71821,72402,72438,72512,72810,72908,73549,76357,82498,83851,91467,91754,93149,96015,97662,97976,99927,100158,101486,104830,122723,124496,125322,126941,131182,137226,138252,146600,148471,148673,150655,152086,159917,167666,170158,174343,175533,181390,1","842161,842331,842526,843813,844380,845357,845979,846230,846385,846634,847372,848021,848536,848621,848734,849396,850120,851450,851613,853296,853530,855836,856337,856947,857389,857647,857729,857793,857902,858016,858142,858150,858279,858303,858574,858611,858666,858683,858889,859312,859698,859699,859735,860176,860388,860541,860818,860886,860891,861262,861283,861440,861529,861595,861629,861731,861945,861959,861996,862117,862386,862797,863762,863764,863765,863788,863876,863908,863998,864174,864323,864349,864460,8",NULL,Cell-based,NULL,NIH Initiatives,"10078197,11108279,15130581,15707893,15721253,16289203,1709303,8139576,8187173,8668203,9332374",0,10.1016/0092-8674(94)90211-9|10.1016/j.cell.2005.01.024|10.1016/j.jmb.2005.10.009|10.1016/j.molcel.2005.02.002|10.1016/j.tcb.2004.03.008|10.1016/s0378-1119(97)00270-9|10.1016/s1097-2765(00)80305-6|10.1126/science.1709303|10.1128/mcb.14.4.2786|10.1128/mcb.16.7.3853|10.1210/endo.141.12.7808,NULL,NULL,NULL
651951,1,Counterscreen for agonists of the human trace amine associated receptor 1 (hTAAR1): Fluorescence-based cell-based high throughput screening assay to identify hTAAR1 agonists that also desensitize TAAR1 receptor response.,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: RTI International_|_Assay Provider: Brian P. Gilmour, RTI International_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R21NS064780-01A1_|_Grant Proposal PI: Brian P. Gilmour, RTI International_|_External Assay ID: TAAR1_ANT_FLUO8_1536_3X%INH CSRUN for TAAR1 AG_|__|_Name: Counterscreen for agonists of the human trace amine associated receptor 1 (hTAAR1",5,The Scripps Research Institute Molecular Screening Center,TAAR1_ANT_FLUO8_1536_3X%INH CSRUN for TAAR1 AG,20130214,"1868,2247,2949,4398,4621,5265,5610,6048,7085,7594,8606,9301,9306,9377,10648,11079,12892,14358,14987,16955,17275,20118,22275,29893,36302,48154,49659,61100,65329,65614,72652,72816,87615,87935,97605,98724,100304,102484,112939,153617,158798,164981,170617,199161,202512,203875,207650,208719,230117,231170,235976,237490,238328,240902,241049,241146,241200,241808,241822,243154,243515,243849,243962,244409,245287,260645,262093,266203,266528,267391,267923,272806,275505,276191,279885,283138,283977,297256,309182,324932,32","842462,842617,842695,842842,842875,842954,843783,843861,843976,844213,844372,844446,844506,844654,844749,844770,844822,845444,845561,845637,845870,846192,848100,848136,848350,848470,848636,849046,849090,849171,849312,849585,849609,849752,850312,850321,850491,850624,851480,852087,852174,852476,852615,852715,852843,852944,852947,852980,853175,853325,853427,853437,853491,853535,853543,855698,855701,857394,857436,857642,857668,857788,857898,858070,858227,858460,859538,859881,860230,860525,860747,860760,860882,8",134864,Cell-based,NP_612200,NIH Initiatives,"11109299,11459929,11504935,11723224,12550748,15329799,15644497,15718104,15764732,15936832,16263097,16831861,17629964,17959251,18370232,18382464,6141619,6518200,7218373,8115671,8363648",0,10.1002/jnr.490060106|10.1007/978-1-59745-205-2_6|10.1016/0006-2952(93)90564-d|10.1016/0278-5846(83)90067-2|10.1016/0278-5846(94)90022-1|10.1016/j.brainres.2005.09.009|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2005.05.002|10.1016/j.tips.2007.06.001|10.1016/j.ygeno.2004.11.010|10.1016/s1471-4892(02)00028-0|10.1038/nrd2518|10.1073/pnas.151105198|10.1073/pnas.181356198|10.1086/424887|10.1124/jpet.105.084459|10.1124/mol.104.007427|10.1124/mol.60.6.1181|10.1177/1087057106289891,NULL,Q96RJ0,NULL
651703,2,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_Dose_CherryPick_Activity,"Keywords: Aryl hydrocarbon receptor nuclear translocator (ARNT), coil coil coactivators (CCC), basic helix-loop-helix/per-ARNT-Sim (bHLH/PAS), hypoxia, xenobiotic exposure_|__|__|_Assay Overview: The Alphascreen protein/protein interaction (Perkin Elmer) is used for the primary assay.  This in vitro assay relies on luminescence proximity between ""donor"" and ""acceptor"" beads to report on complex formation, requiring that two beads localize within 200 nm for the singlet O2-mediated process to occur in high ef",31,Broad Institute,2158-01_Inhibitor_Dose_CherryPick_Activity,20121026,"774,3728,4112,4491,9679,16955,17335,19103,26964,40586,60758,67074,70821,72908,81406,96506,96673,98514,151506,166785,170616,173262,186762,224618,225906,234105,234311,234845,237126,242579,243459,246744,246745,248894,254477,254813,260943,271293,272245,272568,274337,278037,281376,314836,314992,315109,317843,320267,345777,364824,371509,379559,382447,386227,386231,386517,404519,430455,440226,453131,457825,470918,542828,586912,591407,594190,600113,601464,605535,606080,607082,607627,614315,630398,644442,644608,6457","842350,843440,843503,843711,844954,845261,845471,846810,846852,847355,847563,847835,848087,848687,848741,848949,849149,849226,849377,849956,849974,850894,850915,852900,853104,853131,853169,853640,855609,856522,856833,857300,857322,858026,858313,858474,859141,859740,860493,860763,860976,860993,861138,861193,861314,861365,861396,861465,861480,861756,861778,861961,861997,862019,862060,862547,863571,864829,865063,865561,865572,3711096,3711297,3712718,3712742,3713051,3713454,3713662,3713759,3713861,3714178,37155","405,10460",Biochemical,"AAC03365,NP_006333",NIH Initiatives,"15585582,16129688,16181639,19129502,19324882,19950993,20112293,21512126",0,10.1002/jcp.22067|10.1016/j.jmb.2005.08.043|10.1021/ja9073062|10.1073/pnas.0406374101|10.1073/pnas.0808092106|10.1073/pnas.1101357108|10.1074/jbc.m501755200|10.1074/jbc.m808479200,NULL,"AAC03365,Q9Y6A5",NULL
651952,1,Counterscreen for agonists of the human trace amine associated receptor 1 (hTAAR1): Fluorescence-based cell-based high throughput screening assay to identify nonselective Ga16 antagonists,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: RTI International_|_Assay Provider: Brian P. Gilmour, RTI International_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R21NS064780-01A1_|_Grant Proposal PI: Brian P. Gilmour, RTI International_|_External Assay ID: CHO-GA16_ANT_FLUO8_1536_3X%INH CSRUN for TAAR1 AG_|__|_Name: Counterscreen for agonists of the human trace amine associated receptor 1 (hTA",5,The Scripps Research Institute Molecular Screening Center,CHO-GA16_ANT_FLUO8_1536_3X%INH CSRUN for TAAR1 AG,20130220,"1868,2247,2949,4398,4621,5265,5610,6048,7085,7594,8606,9301,9306,9377,10648,11079,12892,14358,14987,16955,17275,20118,22275,29893,36302,48154,49659,61100,65329,65614,72652,72816,87615,87935,97605,98724,100304,102484,112939,153617,158798,164981,170617,199161,202512,203875,207650,208719,230117,231170,235976,237490,238328,240902,241049,241146,241200,241808,241822,243154,243515,243849,243962,244409,245287,260645,262093,266203,266528,267391,267923,272806,275505,276191,279885,283138,283977,297256,309182,324932,32","842462,842617,842695,842842,842875,842954,843783,843861,843976,844213,844372,844446,844506,844654,844749,844770,844822,845444,845561,845637,845870,846192,848100,848136,848350,848470,848636,849046,849090,849171,849312,849585,849609,849752,850312,850321,850491,850624,851480,852087,852174,852476,852615,852715,852843,852944,852947,852980,853175,853325,853427,853437,853491,853535,853543,855698,855701,857394,857436,857642,857668,857788,857898,858070,858227,858460,859538,859881,860230,860525,860747,860760,860882,8",2769,Cell-based,NP_002059,NIH Initiatives,"11109299,11459929,11504935,11723224,12550748,15329799,15644497,15718104,15764732,15936832,16263097,16831861,17629964,17959251,18370232,18382464,6141619,6518200,7218373,8115671,8363648",0,10.1002/jnr.490060106|10.1007/978-1-59745-205-2_6|10.1016/0006-2952(93)90564-d|10.1016/0278-5846(83)90067-2|10.1016/0278-5846(94)90022-1|10.1016/j.brainres.2005.09.009|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2005.05.002|10.1016/j.tips.2007.06.001|10.1016/j.ygeno.2004.11.010|10.1016/s1471-4892(02)00028-0|10.1038/nrd2518|10.1073/pnas.151105198|10.1073/pnas.181356198|10.1086/424887|10.1124/jpet.105.084459|10.1124/mol.104.007427|10.1124/mol.60.6.1181|10.1177/1087057106289891,NULL,P30679,NULL
651615,1,Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based cell-based high throughput assay to identify inhibitors of the Herpes Virus Virion Protein 16 (VP16),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Patrick Griffin, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: CA134873_|_Grant Proposal PI: Patrick Griffin, TSRI_|_External Assay ID: VP16_INH_LUMI_1536_3X%INH CSRUN for LRH1 IAG_|__|_Name: Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based",5,The Scripps Research Institute Molecular Screening Center,VP16_INH_LUMI_1536_3X%INH CSRUN for LRH1 IAG,20121003,"1318,1570,2199,2754,3197,3832,3879,4112,4491,4605,4749,4931,5153,5303,5396,5614,6099,6185,6197,6245,6842,7578,8467,8975,9283,9444,11293,11352,14710,15478,16955,17201,20345,22324,32875,36462,38777,40586,42640,43795,47508,52167,54368,60699,62770,65237,66541,70848,71821,72402,72438,72512,72810,72908,73549,76357,82498,83851,91467,91754,93149,96015,97662,97976,99927,100158,101486,104830,122723,124496,125322,126941,131182,137226,138252,146600,148471,148673,150655,152086,159917,167666,170158,174343,175533,181390,1","842161,842331,842526,843813,844380,845357,845979,846230,846385,846634,847372,848021,848536,848621,848734,849396,850120,851450,851613,853296,853530,855836,856337,856947,857389,857647,857729,857793,857902,858016,858142,858150,858279,858303,858574,858611,858666,858683,858889,859312,859698,859699,859735,860176,860388,860541,860818,860886,860891,861262,861283,861440,861529,861595,861629,861731,861945,861959,861996,862117,862386,862797,863762,863764,863765,863788,863876,863908,863998,864174,864323,864349,864460,8",NULL,Cell-based,NP_044650,NIH Initiatives,"10078197,11108279,15130581,15707893,15721253,16289203,1709303,8139576,8187173,8668203,9332374",0,10.1016/0092-8674(94)90211-9|10.1016/j.cell.2005.01.024|10.1016/j.jmb.2005.10.009|10.1016/j.molcel.2005.02.002|10.1016/j.tcb.2004.03.008|10.1016/s0378-1119(97)00270-9|10.1016/s1097-2765(00)80305-6|10.1126/science.1709303|10.1128/mcb.14.4.2786|10.1128/mcb.16.7.3853|10.1210/endo.141.12.7808,NULL,NP_044650,NULL
651787,1,Counterscreen for agonists of the human trace amine associated receptor 1 (hTAAR1): Fluorescence-based cell-based high throughput screening assay to identify nonselective agonists,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: RTI International_|_Assay Provider: Brian P. Gilmour, RTI International_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R21NS064780-01A1_|_Grant Proposal PI: Brian P. Gilmour, RTI International_|_External Assay ID: CHO-Ga16_AG_FLUO8_1536_3X%ACT CSRUN1_|__|_Name: Counterscreen for agonists of the human trace amine associated receptor 1 (hTAAR1): Fluores",5,The Scripps Research Institute Molecular Screening Center,CHO-Ga16_AG_FLUO8_1536_3X%ACT CSRUN1,20130219,"1868,2247,2949,4398,4621,5265,5610,6048,7085,7594,8606,9301,9306,9377,10648,11079,12892,14358,14987,16955,17275,20118,22275,29893,36302,48154,49659,61100,65329,65614,72652,72816,87615,87935,97605,98724,100304,102484,112939,153617,158798,164981,170617,199161,202512,203875,207650,208719,230117,231170,235976,237490,238328,240902,241049,241146,241200,241808,241822,243154,243515,243849,243962,244409,245287,260645,262093,266203,266528,267391,267923,272806,275505,276191,279885,283138,283977,297256,309182,324932,32","842462,842617,842695,842842,842875,842954,843783,843861,843976,844213,844372,844446,844506,844654,844749,844770,844822,845444,845561,845637,845870,846192,848100,848136,848350,848470,848636,849046,849090,849171,849312,849585,849609,849752,850312,850321,850491,850624,851480,852087,852174,852476,852615,852715,852843,852944,852947,852980,853175,853325,853427,853437,853491,853535,853543,855698,855701,857394,857436,857642,857668,857788,857898,858070,858227,858460,859538,859881,860230,860525,860747,860760,860882,8",2769,Cell-based,NP_002059,NIH Initiatives,"11109299,11459929,11504935,11723224,12550748,15329799,15644497,15718104,15764732,15936832,16263097,16831861,17629964,17959251,18370232,18382464,6141619,6518200,7218373,8115671,8363648",0,10.1002/jnr.490060106|10.1007/978-1-59745-205-2_6|10.1016/0006-2952(93)90564-d|10.1016/0278-5846(83)90067-2|10.1016/0278-5846(94)90022-1|10.1016/j.brainres.2005.09.009|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2005.05.002|10.1016/j.tips.2007.06.001|10.1016/j.ygeno.2004.11.010|10.1016/s1471-4892(02)00028-0|10.1038/nrd2518|10.1073/pnas.151105198|10.1073/pnas.181356198|10.1086/424887|10.1124/jpet.105.084459|10.1124/mol.104.007427|10.1124/mol.60.6.1181|10.1177/1087057106289891,NULL,P30679,NULL
651783,1,Fluorescence-based cell-based primary high throughput confirmation assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: RTI International_|_Assay Provider: Brian P. Gilmour, RTI International_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R21NS064780-01A1_|_Grant Proposal PI: Brian P. Gilmour, RTI International_|_External Assay ID: TAAR1_AG_FLUO8_1536_3X%ACT CRUN1_|__|_Name: Fluorescence-based cell-based primary high throughput confirmation assay to identify agonists o",5,The Scripps Research Institute Molecular Screening Center,TAAR1_AG_FLUO8_1536_3X%ACT CRUN1,20130219,"1868,2247,2949,4398,4621,5265,5610,6048,7085,7594,8606,9301,9306,9377,10648,11079,12892,14358,14987,16955,17275,20118,22275,29893,36302,48154,49659,61100,65329,65614,72652,72816,87615,87935,97605,98724,100304,102484,112939,153617,158798,164981,170617,199161,202512,203875,207650,208719,230117,231170,235976,237490,238328,240902,241049,241146,241200,241808,241822,243154,243515,243849,243962,244409,245287,260645,262093,266203,266528,267391,267923,272806,275505,276191,279885,283138,283977,297256,309182,324932,32","842462,842617,842695,842842,842875,842954,843783,843861,843976,844213,844372,844446,844506,844654,844749,844770,844822,845444,845561,845637,845870,846192,848100,848136,848350,848470,848636,849046,849090,849171,849312,849585,849609,849752,850312,850321,850491,850624,851480,852087,852174,852476,852615,852715,852843,852944,852947,852980,853175,853325,853427,853437,853491,853535,853543,855698,855701,857394,857436,857642,857668,857788,857898,858070,858227,858460,859538,859881,860230,860525,860747,860760,860882,8",134864,Cell-based,NP_612200,NIH Initiatives,"11109299,11459929,11504935,11723224,12550748,15329799,15644497,15718104,15764732,15936832,16263097,16831861,17629964,17959251,18370232,18382464,6141619,6518200,7218373,8115671,8363648",0,10.1002/jnr.490060106|10.1007/978-1-59745-205-2_6|10.1016/0006-2952(93)90564-d|10.1016/0278-5846(83)90067-2|10.1016/0278-5846(94)90022-1|10.1016/j.brainres.2005.09.009|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2005.05.002|10.1016/j.tips.2007.06.001|10.1016/j.ygeno.2004.11.010|10.1016/s1471-4892(02)00028-0|10.1038/nrd2518|10.1073/pnas.151105198|10.1073/pnas.181356198|10.1086/424887|10.1124/jpet.105.084459|10.1124/mol.104.007427|10.1124/mol.60.6.1181|10.1177/1087057106289891,NULL,Q96RJ0,NULL
651995,1,Single concentration confirmation of uHTS Gli-SUFU antagonist hits in a Wnt3a luminescent reporter assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network(MLPCN)_|_Grant Number: 1R03MH094195-01_|_Assay Provider: James Chen, Ph.D.,Stanford University, Stanford California_|__|_The Hh pathway plays a critical role in the patterning of certain embryonic tissues and contributes to their neoplastic transformation later in life.  Hh signaling regulates c",14,Burnham Center for Chemical Genomics,SBCCG-A949-Gli-Sufu-Antagonist-CP-Wnt3-Assay,20130124,"2363,3197,4544,5043,5311,5396,9283,10156,12446,12498,20279,25050,29893,31276,43640,54368,55498,57162,57163,65237,67275,69765,72438,72699,72705,72827,82498,91754,97811,97866,100037,110119,131182,156816,174326,175533,198909,209253,215090,230508,232146,233874,237621,238745,240980,243725,245151,247955,253602,255762,260168,260261,261361,262649,264884,268760,275781,284708,290486,293603,294920,299645,300573,310860,322539,332697,334334,339411,341880,347381,354677,358793,360558,368337,371346,380164,381392,382054,382","842321,842332,842392,842444,842446,842563,842952,842959,843298,843335,843683,843813,844118,844269,844450,844586,844634,844867,844876,845126,845160,845525,846246,846265,846304,847393,847548,848231,848536,848734,849061,849320,849876,850139,850334,850589,851317,851517,851844,851924,852008,852275,852388,852563,852761,853152,853296,853358,853376,853477,855966,856098,856330,856388,856521,856522,856526,856536,856690,856815,857056,857195,857423,857425,857461,857655,857789,857931,858026,858079,858147,858154,858189,8",14632,NULL,BAA85004,NIH Initiatives,"11283316,12202832,12391318,12414725,15380514,17353198,19081070,19136624,19189974,19469545,19522463,19716296,19726763,19726788,19797115,19859563,20493695",0,10.1016/j.bmcl.2009.08.049|10.1016/j.bmcl.2010.04.110|10.1016/j.ccr.2004.08.019|10.1016/j.devcel.2008.11.010|10.1021/jm900305z|10.1021/jm900309j|10.1056/nejmoa0905360|10.1073/pnas.182542899|10.1074/jbc.m109.059964|10.1074/jbc.m611089200|10.1074/jbc.m806233200|10.1101/gad.1025302|10.1101/gad.1753809|10.1126/science.1073733|10.1126/science.1179386|10.1146/annurev.neuro.24.1.385|10.1371/journal.pone.0007608,NULL,BAA85004,NULL
651955,1,Counterscreen for antagonists of the human trace amine associated receptor 1 (hTAAR1): Fluorescence-based cell-based high throughput screening assay to identify TAAR1 Agonists,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: RTI International_|_Assay Provider: Brian P. Gilmour, RTI International_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R21NS064780-01A1_|_Grant Proposal PI: Brian P. Gilmour, RTI International_|_External Assay ID: TAAR1_AG_FLUO8_1536_3X%ACT CSRUN for TAAR1 ANT_|__|_Name: Counterscreen for antagonists of the human trace amine associated receptor 1 (hTA",5,The Scripps Research Institute Molecular Screening Center,TAAR1_AG_FLUO8_1536_3X%ACT CSRUN for TAAR1 ANT,20130214,"299,3396,15284,19708,60795,68589,72669,95413,146332,167666,223368,223855,225912,228252,229767,232680,232681,235496,246902,264339,267020,268733,268748,275446,279055,285952,302448,330743,340898,420750,441383,448537,448949,494031,559927,609869,630988,634713,645206,645256,646253,646403,646727,647079,647168,647479,647625,647659,647748,647945,648074,648232,649027,649115,649279,649640,650135,650218,651023,651201,651552,651871,652558,652814,653366,654636,654712,654743,655744,655902,656033,656062,658662,659111,65935","842801,843465,843947,844093,844401,844747,844837,845145,845285,845315,846631,846725,847726,847803,848574,849081,850047,850250,850299,852108,853073,853092,853249,853378,856454,857313,857678,858499,858909,859697,859865,860186,860510,860895,860968,861315,861995,862258,863333,863453,863633,864680,864976,865755,866059,3711493,3713087,3713194,3713665,3713777,3713917,3714298,3714834,3714985,3715037,3715735,3716294,3716305,3716883,3717034,3717035,3717368,3717412,4241547,4241674,4241723,4242621,4242680,4243241,42433",134864,Cell-based,NP_612200,NIH Initiatives,"11109299,11459929,11504935,11723224,12550748,15329799,15644497,15718104,15764732,15936832,16263097,16831861,17629964,17959251,18370232,18382464,6141619,6518200,7218373,8115671,8363648",0,10.1002/jnr.490060106|10.1007/978-1-59745-205-2_6|10.1016/0006-2952(93)90564-d|10.1016/0278-5846(83)90067-2|10.1016/0278-5846(94)90022-1|10.1016/j.brainres.2005.09.009|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2005.05.002|10.1016/j.tips.2007.06.001|10.1016/j.ygeno.2004.11.010|10.1016/s1471-4892(02)00028-0|10.1038/nrd2518|10.1073/pnas.151105198|10.1073/pnas.181356198|10.1086/424887|10.1124/jpet.105.084459|10.1124/mol.104.007427|10.1124/mol.60.6.1181|10.1177/1087057106289891,NULL,Q96RJ0,NULL
651785,1,Fluorescence-based cell-based primary high throughput confirmation assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: RTI International_|_Assay Provider: Brian P. Gilmour, RTI International_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R21NS064780-01A1_|_Grant Proposal PI: Brian P. Gilmour, RTI International_|_External Assay ID: TAAR1_ANT_FLUO8_1536_3X%INH CRUN1_|__|_Name: Fluorescence-based cell-based primary high throughput confirmation assay to identify antagonis",5,The Scripps Research Institute Molecular Screening Center,TAAR1_ANT_FLUO8_1536_3X%INH CRUN1,20130219,"299,3396,15284,19708,60795,68589,72669,95413,146332,167666,223368,223855,225912,228252,229767,232680,232681,235496,246902,264339,267020,268733,268748,275446,279055,285952,302448,330743,340898,420750,441383,448537,448949,494031,559927,609869,630988,634713,645206,645256,646253,646403,646727,647079,647168,647479,647625,647659,647748,647945,648074,648232,649027,649115,649279,649640,650135,650218,651023,651201,651552,651871,652558,652814,653366,654636,654712,654743,655744,655902,656033,656062,658662,659111,65935","842801,843465,843947,844093,844401,844747,844837,845145,845285,845315,846631,846725,847726,847803,848574,849081,850047,850250,850299,852108,853073,853092,853249,853378,856454,857313,857678,858499,858909,859697,859865,860186,860510,860895,860968,861315,861995,862258,863333,863453,863633,864680,864976,865755,866059,3711493,3713087,3713194,3713665,3713777,3713917,3714298,3714834,3714985,3715037,3715735,3716294,3716305,3716883,3717034,3717035,3717368,3717412,4241547,4241674,4241723,4242621,4242680,4243241,42433",134864,Cell-based,NP_612200,NIH Initiatives,"11109299,11459929,11504935,11723224,12550748,15329799,15644497,15718104,15764732,15936832,16263097,16831861,17629964,17959251,18370232,18382464,19892733,6141619,6518200,7218373,8115671,8363648",0,10.1002/jnr.490060106|10.1007/978-1-59745-205-2_6|10.1016/0006-2952(93)90564-d|10.1016/0278-5846(83)90067-2|10.1016/0278-5846(94)90022-1|10.1016/j.brainres.2005.09.009|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2005.05.002|10.1016/j.tips.2007.06.001|10.1016/j.ygeno.2004.11.010|10.1016/s1471-4892(02)00028-0|10.1038/nrd2518|10.1073/pnas.0906522106|10.1073/pnas.151105198|10.1073/pnas.181356198|10.1086/424887|10.1124/jpet.105.084459|10.1124/mol.104.007427|10.1124/mol.60.6.1181|10.1177/1087057106289891,NULL,Q96RJ0,NULL
651614,1,Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based cell-based high throughput assay to identify inverse agonists of the Steroidogenic Factor 1 Nuclear Receptor (SF1; NR5A1),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Patrick Griffin, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: CA134873_|_Grant Proposal PI: Patrick Griffin, TSRI_|_External Assay ID: SF1_INH_LUMI_1536_3X%INH CSRUN for LRH1 IAG_|__|_Name: Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based ",5,The Scripps Research Institute Molecular Screening Center,SF1_INH_LUMI_1536_3X%INH CSRUN for LRH1 IAG,20121003,"1318,1570,2199,2754,3197,3832,3879,4112,4491,4605,4749,4931,5153,5303,5396,5614,6099,6185,6197,6245,6842,7578,8467,8975,9283,9444,11293,11352,14710,15478,16955,17201,20345,22324,32875,36462,38777,40586,42640,43795,47508,52167,54368,60699,62770,65237,66541,70848,71821,72402,72438,72512,72810,72908,73549,76357,82498,83851,91467,91754,93149,96015,97662,97976,99927,100158,101486,104830,122723,124496,125322,126941,131182,137226,138252,146600,148471,148673,150655,152086,159917,167666,170158,174343,175533,181390,1","842161,842331,842526,843813,844380,845357,845979,846230,846385,846634,847372,848021,848536,848621,848734,849396,850120,851450,851613,853296,853530,855836,856337,856947,857389,857647,857729,857793,857902,858016,858142,858150,858279,858303,858574,858611,858666,858683,858889,859312,859698,859699,859735,860176,860388,860541,860818,860886,860891,861262,861283,861440,861529,861595,861629,861731,861945,861959,861996,862117,862386,862797,863762,863764,863765,863788,863876,863908,863998,864174,864323,864349,864460,8",2516,Cell-based,NP_004950,NIH Initiatives,"10078197,11108279,15130581,15707893,15721253,16289203,1709303,8139576,8187173,8668203,9332374",0,10.1016/0092-8674(94)90211-9|10.1016/j.cell.2005.01.024|10.1016/j.jmb.2005.10.009|10.1016/j.molcel.2005.02.002|10.1016/j.tcb.2004.03.008|10.1016/s0378-1119(97)00270-9|10.1016/s1097-2765(00)80305-6|10.1126/science.1709303|10.1128/mcb.14.4.2786|10.1128/mcb.16.7.3853|10.1210/endo.141.12.7808,NULL,Q13285,NULL
651613,1,Luminescence-based cell-based high throughput confirmation assay for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Patrick Griffin, TSRI_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: CA134873_|_Grant Proposal PI: Patrick Griffin, TSRI_|_External Assay ID: LRH1_INH_LUMI_1536_3X%INH CRUN_|__|_Name: Luminescence-based cell-based high throughput confirmation assay for inverse agonists of the liver receptor homolog",5,The Scripps Research Institute Molecular Screening Center,LRH1_INH_LUMI_1536_3X%INH CRUN,20121003,"1318,1570,2199,2754,3197,3832,3879,4112,4491,4605,4749,4931,5153,5303,5396,5614,6099,6185,6197,6245,6842,7578,8467,8975,9283,9444,11293,11352,14710,15478,16955,17201,20345,22324,32875,36462,38777,40586,42640,43795,47508,52167,54368,60699,62770,65237,66541,70848,71821,72402,72438,72512,72810,72908,73549,76357,82498,83851,91467,91754,93149,96015,97662,97976,99927,100158,101486,104830,122723,124496,125322,126941,131182,137226,138252,146600,148471,148673,150655,152086,159917,167666,170158,174343,175533,181390,1","842161,842331,842526,843813,844380,845357,845979,846230,846385,846634,847372,848021,848536,848621,848734,849396,850120,851450,851613,853296,853530,855836,856337,856947,857389,857647,857729,857793,857902,858016,858142,858150,858279,858303,858574,858611,858666,858683,858889,859312,859698,859699,859735,860176,860388,860541,860818,860886,860891,861262,861283,861440,861529,861595,861629,861731,861945,861959,861996,862117,862386,862797,863762,863764,863765,863788,863876,863908,863998,864174,864323,864349,864460,8",2494,Cell-based,NP_003813,NIH Initiatives,"10078197,11108279,15130581,15707893,15721253,16289203,1709303,8139576,8187173,8668203,9332374",0,10.1016/0092-8674(94)90211-9|10.1016/j.cell.2005.01.024|10.1016/j.jmb.2005.10.009|10.1016/j.molcel.2005.02.002|10.1016/j.tcb.2004.03.008|10.1016/s0378-1119(97)00270-9|10.1016/s1097-2765(00)80305-6|10.1126/science.1709303|10.1128/mcb.14.4.2786|10.1128/mcb.16.7.3853|10.1210/endo.141.12.7808,NULL,O00482,NULL
651595,2,qHTS of Nrf2 Activators: Hit Validation in Cytotox Assay,"Many diseases have some form of oxidative stress injury and ties to inflammation, causing a host of problems for the patient. The antioxidant response element (ARE) plays an important role in alleviating the harmful effects of oxidative stress. The antioxidant response element (ARE) is a transcriptional regulatory element involved in the activation of genes coding for a number of antioxidant proteins and detoxifying enzymes. These enzymes work in concert to protect tissues from oxidative insults and chemica",2,National Center for Advancing Translational Sciences (NCATS),Nrf2202,20121204,"4641,5311,6825,9181,10709,12888,13801,14161,18311,22694,22797,36302,43795,71034,72837,73427,97900,100434,120053,146694,219326,220147,220850,225916,226774,231608,231723,238448,240703,244240,248021,248148,248690,252766,252780,255021,255770,256762,259241,259769,259799,261413,263261,263855,263869,269062,270482,271955,272282,272385,274053,274055,274061,274564,275900,277056,277060,279091,279303,280101,282544,283529,284471,288319,288865,289037,289769,291365,297344,297345,300580,305283,305309,306831,307190,308065,3","842211,842443,843119,843706,844771,845451,845660,845794,846135,847068,847636,848745,849158,850239,850466,851005,851793,857486,857634,857707,858230,858736,859170,859770,860120,860495,860525,863191,863211,863401,863650,864142,864210,864212,864446,864778,865526,865573,865837,3711817,3712613,3712685,3715264,3715276,3715547,3716827,3716877,3717116,3717305,3717974,3717985,4240684,4240918,4241619,4242708,4243367,4243501,4244117,4244445,4244701,4244888,4244974,4245131,4245852,4245958,4246052,4246153,4246317,4246374",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
651953,1,Counterscreen for antagonists of the human trace amine associated receptor 1 (hTAAR1): Fluorescence-based cell-based high throughput screening assay to identify nonselective Ga16 agonists,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: RTI International_|_Assay Provider: Brian P. Gilmour, RTI International_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R21NS064780-01A1_|_Grant Proposal PI: Brian P. Gilmour, RTI International_|_External Assay ID: CHO-GA16_AG_FLUO8_1536_3X%ACT CSRUN for TAAR1 ANT_|__|_Name: Counterscreen for antagonists of the human trace amine associated receptor 1 (",5,The Scripps Research Institute Molecular Screening Center,CHO-GA16_AG_FLUO8_1536_3X%ACT CSRUN for TAAR1 ANT,20130215,"299,3396,15284,19708,60795,68589,72669,95413,146332,167666,223368,223855,225912,228252,229767,232680,232681,235496,246902,264339,267020,268733,268748,275446,279055,285952,302448,330743,340898,420750,441383,448537,448949,494031,559927,609869,630988,634713,645206,645256,646253,646403,646727,647079,647168,647479,647625,647659,647748,647945,648074,648232,649027,649115,649279,649640,650135,650218,651023,651201,651552,651871,652558,652814,653366,654636,654712,654743,655744,655902,656033,656062,658662,659111,65935","842801,843465,843947,844093,844401,844747,844837,845145,845285,845315,846631,846725,847726,847803,848574,849081,850047,850250,850299,852108,853073,853092,853249,853378,856454,857313,857678,858499,858909,859697,859865,860186,860510,860895,860968,861315,861995,862258,863333,863453,863633,864680,864976,865755,866059,3711493,3713087,3713194,3713665,3713777,3713917,3714298,3714834,3714985,3715037,3715735,3716294,3716305,3716883,3717034,3717035,3717368,3717412,4241547,4241674,4241723,4242621,4242680,4243241,42433",2769,Cell-based,NP_002059,NIH Initiatives,"11109299,11459929,11504935,11723224,12550748,15329799,15644497,15718104,15764732,15936832,16263097,16831861,17629964,17959251,18370232,18382464,6141619,6518200,7218373,8115671,8363648",0,10.1002/jnr.490060106|10.1007/978-1-59745-205-2_6|10.1016/0006-2952(93)90564-d|10.1016/0278-5846(83)90067-2|10.1016/0278-5846(94)90022-1|10.1016/j.brainres.2005.09.009|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2005.05.002|10.1016/j.tips.2007.06.001|10.1016/j.ygeno.2004.11.010|10.1016/s1471-4892(02)00028-0|10.1038/nrd2518|10.1073/pnas.151105198|10.1073/pnas.181356198|10.1086/424887|10.1124/jpet.105.084459|10.1124/mol.104.007427|10.1124/mol.60.6.1181|10.1177/1087057106289891,NULL,P30679,NULL
651567,2,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling: Hit Validation in OCI-Ly3 Assay,"Diffuse large B-cell lymphoma (DLBCL) is the most common category of non-Hodgkin lymphoma, with ~20,000 new cases per year in the United States. DLBCL should be regarded as a collection of different neoplasms. Microarray gene expression analysis has defined two principal types of DLBCL, named for their similarity to normal B cell stages or activation states: a germinal center B-cell (GCB) type, and an activated B-cell (ABC) type. In ABC-DLBCL, a constitutive high-level activity of the NF-kappaB family of tr",2,National Center for Advancing Translational Sciences (NCATS),TMD8201,20120906,"1688,1761,2203,2692,2833,3194,3334,3512,5455,5754,5834,5991,5994,6084,6167,6724,6741,8974,10156,10607,16490,18469,19910,26133,42725,66414,74902,75526,82533,93205,100335,101430,120879,123683,126054,137226,161091,161167,211186,222275,223368,224214,226756,242436,242587,247839,250997,253793,260644,260645,264006,265594,272568,275363,280492,282697,322919,325108,327861,355876,360474,360560,389128,398148,446849,448222,551870,568416,570206,604128,605332,613657,617341,626288,631721,638278,638439,644407,646414,646455,","842151,844105,844139,845575,846887,847164,850589,850617,852641,853705,855580,855615,855624,855641,855649,855652,855653,855658,855688,855748,855789,855897,855908,855961,855973,855995,855996,856002,856308,856344,856362,856525,856947,857056,857270,857272,857677,857775,858187,858683,859077,859832,859869,861109,861129,861321,861400,861415,861435,861634,861716,861731,861918,861970,862386,862793,862999,863953,864370,864460,864533,865818,866078,3711925,3712782,3712888,3713133,3713171,3714362,3714713,3715341,3715474",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"11748286,16572121,17355202,20054396",0,10.1038/nature04687|10.1038/nature08638|10.1084/jem.194.12.1861|10.1089/adt.2006.048,NULL,NULL,NULL
651705,2,ARNT-TACC3: counter AlphaScreen Measured in Biochemical System Using Plate Reader - 2158-02_Inhibitor_Dose_CherryPick_Activity,"Keywords: Aryl hydrocarbon receptor nuclear translocator (ARNT), coil coil coactivators (CCC), basic helix-loop-helix/per-ARNT-Sim (bHLH/PAS), hypoxia, xenobiotic exposure_|__|__|_Assay Overview: A dual tagged protein Alphascreen detection (Perkin Elmer) is used for this secondary assay.  This in vitro assay relies on luminescence proximity between ""donor"" and ""acceptor"" beads, requiring that two beads localize within 200 nm for the singlet O2-mediated process to occur in high efficiency. This assay is look",31,Broad Institute,2158-02_Inhibitor_Dose_CherryPick_Activity,20121026,"774,3728,4112,4491,9679,16955,17335,19103,26964,40586,60758,67074,70821,72908,81406,96506,96673,98514,151506,166785,170616,173262,186762,224618,225906,234105,234311,234845,237126,242579,243459,246744,246745,248894,254477,254813,260943,271293,272245,272568,274337,278037,281376,314836,314992,315109,317843,320267,345777,364824,371509,379559,382447,386227,386231,386517,404519,430455,440226,453131,457825,470918,542828,586912,591407,594190,600113,601464,605535,606080,607082,607627,614315,630398,644442,644608,6457","842350,843440,843503,843711,844954,845261,845471,846810,846852,847355,847563,847835,848087,848687,848741,848949,849149,849226,849377,849956,849974,850894,850915,852900,853104,853131,853169,853640,855609,856522,856833,857300,857322,858026,858313,858474,859141,859740,860493,860763,860976,860993,861138,861193,861314,861365,861396,861465,861480,861756,861778,861961,861997,862019,862060,862547,863571,864829,865063,865561,865572,3711096,3711297,3712718,3712742,3713051,3713454,3713662,3713759,3713861,3714178,37155",NULL,Biochemical,NULL,NIH Initiatives,"15585582,16129688,16181639,19129502,19324882,19950993,20112293,21512126",0,10.1002/jcp.22067|10.1016/j.jmb.2005.08.043|10.1021/ja9073062|10.1073/pnas.0406374101|10.1073/pnas.0808092106|10.1073/pnas.1101357108|10.1074/jbc.m501755200|10.1074/jbc.m808479200,NULL,NULL,NULL
651994,1,Single concentration validation of uHTS antagonist hits from Gli-SUFU in a luminescent cytotoxicity assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)_|_Network: NIH Molecular Libraries Production Centers Network(MLPCN)_|_Grant Number: 1R03MH094195-01_|_Assay Provider: James Chen, Ph.D.,Stanford University, Stanford California_|__|_The Hh pathway plays a critical role in the patterning of certain embryonic tissues and contributes to their neoplastic transformation later in life.  Hh signaling regulates c",14,Burnham Center for Chemical Genomics,SBCCG-A948-Gli-Sufu-Antagonist-CP-Assay-2,20130126,"2363,3197,4544,5043,5311,5396,9283,10156,12446,12498,20279,25050,29893,31276,43640,54368,55498,57162,57163,65237,67275,69765,72438,72699,72705,72827,82498,91754,97811,97866,100037,110119,131182,156816,174326,175533,198909,209253,215090,230508,232146,233874,237621,238745,240980,243725,245151,247955,253602,255762,260168,260261,261361,262649,264884,268760,275781,284708,290486,293603,294920,299645,300573,310860,322539,332697,334334,339411,341880,347381,354677,358793,360558,368337,371346,380164,381392,382054,382","842321,842332,842392,842444,842446,842563,842952,842959,843298,843335,843683,843813,844118,844269,844450,844586,844634,844867,844876,845126,845160,845525,846246,846265,846304,847393,847548,848231,848536,848734,849061,849320,849876,850139,850334,850589,851317,851517,851844,851924,852008,852275,852388,852563,852761,853152,853296,853358,853376,853477,855966,856098,856330,856388,856521,856522,856526,856536,856690,856815,857056,857195,857423,857425,857461,857655,857789,857931,858026,858079,858147,858154,858189,8",14632,Toxicity,BAA85004,NIH Initiatives,"11283316,12202832,12391318,12414725,15380514,17353198,19081070,19136624,19189974,19469545,19522463,19716296,19726763,19726788,19797115,19859563,20493695",0,10.1016/j.bmcl.2009.08.049|10.1016/j.bmcl.2010.04.110|10.1016/j.ccr.2004.08.019|10.1016/j.devcel.2008.11.010|10.1021/jm900305z|10.1021/jm900309j|10.1056/nejmoa0905360|10.1073/pnas.182542899|10.1074/jbc.m109.059964|10.1074/jbc.m611089200|10.1074/jbc.m806233200|10.1101/gad.1025302|10.1101/gad.1753809|10.1126/science.1073733|10.1126/science.1179386|10.1146/annurev.neuro.24.1.385|10.1371/journal.pone.0007608,NULL,BAA85004,NULL
651780,1,Counterscreen for antagonists of the human trace amine associated receptor 1 (hTAAR1): Fluorescence-based cell-based high throughput screening assay to identify nonselective antagonists,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: RTI International_|_Assay Provider: Brian P. Gilmour, RTI International_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R21NS064780-01A1_|_Grant Proposal PI: Brian P. Gilmour, RTI International_|_External Assay ID: CHO-Ga16_ANT_FLUO8_1536_3X%INH CSRUN_|__|_Name: Counterscreen for antagonists of the human trace amine associated receptor 1 (hTAAR1): Fluo",5,The Scripps Research Institute Molecular Screening Center,CHO-Ga16_ANT_FLUO8_1536_3X%INH CSRUN,20130219,"299,3396,15284,19708,60795,68589,72669,95413,146332,167666,223368,223855,225912,228252,229767,232680,232681,235496,246902,264339,267020,268733,268748,275446,279055,285952,302448,330743,340898,420750,441383,448537,448949,494031,559927,609869,630988,634713,645206,645256,646253,646403,646727,647079,647168,647479,647625,647659,647748,647945,648074,648232,649027,649115,649279,649640,650135,650218,651023,651201,651552,651871,652558,652814,653366,654636,654712,654743,655744,655902,656033,656062,658662,659111,65935","842801,843465,843947,844093,844401,844747,844837,845145,845285,845315,846631,846725,847726,847803,848574,849081,850047,850250,850299,852108,853073,853092,853249,853378,856454,857313,857678,858499,858909,859697,859865,860186,860510,860895,860968,861315,861995,862258,863333,863453,863633,864680,864976,865755,866059,3711493,3713087,3713194,3713665,3713777,3713917,3714298,3714834,3714985,3715037,3715735,3716294,3716305,3716883,3717034,3717035,3717368,3717412,4241547,4241674,4241723,4242621,4242680,4243241,42433",2769,Cell-based,NP_002059,NIH Initiatives,"11109299,11459929,11504935,11723224,12550748,15329799,15644497,15718104,15764732,15936832,16263097,16831861,17629964,17959251,18370232,18382464,19892733,6141619,6518200,7218373,8115671,8363648",0,10.1002/jnr.490060106|10.1007/978-1-59745-205-2_6|10.1016/0006-2952(93)90564-d|10.1016/0278-5846(83)90067-2|10.1016/0278-5846(94)90022-1|10.1016/j.brainres.2005.09.009|10.1016/j.pharmthera.2007.09.003|10.1016/j.tips.2005.05.002|10.1016/j.tips.2007.06.001|10.1016/j.ygeno.2004.11.010|10.1016/s1471-4892(02)00028-0|10.1038/nrd2518|10.1073/pnas.0906522106|10.1073/pnas.151105198|10.1073/pnas.181356198|10.1086/424887|10.1124/jpet.105.084459|10.1124/mol.104.007427|10.1124/mol.60.6.1181|10.1177/1087057106289891,NULL,P30679,NULL
651674,1,"Counterscreen for inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5): Luminescence-based biochemical high throughput assay to identify inhibitors of Hepatocyte nuclear f","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: James Granneman, Wayne State University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS061634-01_|_Grant Proposal PI: James Granneman, Wayne State University_|_External Assay ID: HNF4_INH_LUMI_1536_3X%INH CSRUN_|__|_Name: Counterscreen for inhibitors of the interaction of the lipase co-acti",5,The Scripps Research Institute Molecular Screening Center,HNF4_INH_LUMI_1536_3X%INH CSRUN,20121022,"311,1826,3194,3278,3458,4499,4641,8589,11293,14358,15432,16955,17520,18834,19891,21718,23205,26160,33528,37839,40586,52167,55694,55704,65494,66721,68262,73252,74204,80417,81400,83107,83156,86926,89341,89966,90010,91378,95326,95353,95587,96506,97637,97784,97900,98059,99600,99625,99844,117176,119583,122188,138252,140230,185478,200953,219206,219207,219296,219799,220284,224037,225407,227197,230132,231106,231714,233577,234165,235262,236063,236065,236275,236584,236589,237490,238775,238781,238795,239577,239578,241","842300,842352,842958,843431,844210,845300,845471,845863,846246,846465,848529,848733,849093,849761,850662,850763,851026,851195,851792,851952,852128,852508,852701,853134,853234,855901,856072,856251,856280,856443,856476,857090,857412,857668,857671,857710,857837,857953,858032,858753,858920,859449,859936,860039,861157,861619,861727,861741,861893,862243,862433,862514,862583,862594,862923,863051,863193,863208,863499,864711,865081,865232,865622,865845,3711364,3711619,3711624,3712100,3712834,3712884,3713011,3713060,",3172,Biochemical,NP_000448,NIH Initiatives,"10948207,11590543,11943743,16731815,17052606,18996284,19064991,19299455",0,10.1016/j.arcmed.2008.09.005|10.1016/j.chembiol.2006.09.010|10.1074/jbc.m007322200|10.1074/jbc.m808251200|10.1086/324121|10.1210/edrv.23.2.0461|10.1210/en.2008-0913|10.2337/db06-0263,NULL,P41235,NULL
651612,1,"Luminescence-based biochemical high throughput confirmation assay for inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)","Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: James Granneman, Wayne State University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R21 NS061634-01_|_Grant Proposal PI: James Granneman, Wayne State University_|_External Assay ID: ABHD5-MLDP_INH_LUMI_1536_3X%INH CRUN_|__|_Name: Luminescence-based biochemical high throughput confirmation assa",5,The Scripps Research Institute Molecular Screening Center,ABHD5-MLDP_INH_LUMI_1536_3X%INH CRUN,20121003,"311,1826,3194,3278,3458,4499,4641,8589,11293,14358,15432,16955,17520,18834,19891,21718,23205,26160,33528,37839,40586,52167,55694,55704,65494,66721,68262,73252,74204,80417,81400,83107,83156,86926,89341,89966,90010,91378,95326,95353,95587,96506,97637,97784,97900,98059,99600,99625,99844,117176,119583,122188,138252,140230,185478,200953,219206,219207,219296,219799,220284,224037,225407,227197,230132,231106,231714,233577,234165,235262,236063,236065,236275,236584,236589,237490,238775,238781,238795,239577,239578,241","842300,842352,842958,843431,844210,845300,845471,845863,846246,846465,848529,848733,849093,849761,850662,850763,851026,851195,851792,851952,852128,852508,852701,853134,853234,855901,856072,856251,856280,856443,856476,857090,857412,857668,857671,857710,857837,857953,858032,858753,858920,859449,859936,860039,861157,861619,861727,861741,861893,862243,862433,862514,862583,862594,862923,863051,863193,863208,863499,864711,865081,865232,865622,865845,3711364,3711619,3711624,3712100,3712834,3712884,3713011,3713060,","51099,440503",Biochemical,"NP_001013728,NP_057090",NIH Initiatives,"10948207,11590543,11943743,16731815,17052606,18996284,19064991,19299455",0,10.1016/j.arcmed.2008.09.005|10.1016/j.chembiol.2006.09.010|10.1074/jbc.m007322200|10.1074/jbc.m808251200|10.1086/324121|10.1210/edrv.23.2.0461|10.1210/en.2008-0913|10.2337/db06-0263,2.3.1.51,"Q00G26,Q8WTS1",NULL
651580,1,Single concentration confirmation of uHTS identification of HIF-2a Inhibitors in a luminesence assay,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 DA033980-01A1_|_Assay Provider: Mei Yee Koh, Ph.D.,  University of Texas M.D. Anderson Cancer Center_|__|_Most solid tumors and their metastases experience regions of hypoxia, which promotes both tumor progression and resistance to therapy. Critical mediators o",14,Burnham Center for Chemical Genomics,SBCCG-A900-HIF-2a-CP-Assay,20120912,"1400,2199,2361,3458,4749,4878,4993,5100,5303,5405,6185,6245,8975,15478,18990,22694,29893,31280,31316,52167,67133,68094,72699,72813,73427,82533,83156,91378,97976,99844,101486,104830,105671,107346,118982,120053,122723,122737,123191,140230,156816,161167,162076,179617,181390,185848,200953,203396,224561,231625,234165,234636,235262,236063,236065,236331,236584,238775,239578,242048,243756,244677,245097,247352,252247,252608,257243,257275,260168,262537,262540,263261,263454,264884,268760,268761,268762,268993,274159,27","842440,842526,843004,844306,844398,844782,845090,845300,845543,845820,846503,847139,847214,847434,847444,848269,848384,849093,850880,851517,851876,852615,852945,853531,856129,856149,856175,856443,856677,857019,858142,858166,858172,858305,858328,858753,859633,859637,859780,859843,860230,860618,861167,861727,861731,861846,862514,862581,863102,864038,864096,864498,865090,865107,865680,865786,865944,866055,3711421,3712260,3713781,3713944,3714284,3714425,3714573,3715644,3715824,3716773,3716906,4241430,4241663,42",2034,NULL,NP_001421,NIH Initiatives,"22068265,22093255,22277691,22367913",0,10.1002/ajh.23123|10.1007/s00439-011-1109-3|10.1016/j.jdermsci.2011.10.003|10.1016/j.jvs.2011.10.111,NULL,Q99814,NULL
651784,2,"Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Hit Validation","The mammalian target of rapamycin (mTOR) is an intracellular serine/threonine kinase Aberrant regulation of mTOR signaling plays a causative role in a number of human diseases, including cancer, benign tumors such as lymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC), and metabolic diseases such as diabetes and obesity. This project aims to identify inhibitors of ribosomal protein S6 (rpS6) phosphorylation. The phosphorylation of rpS6 is a key event downstream of mTOR activation. The assay ",2,National Center for Advancing Translational Sciences (NCATS),mTOR200,20121119,"3440,16230,35370,51082,62969,123596,123631,126565,156414,160355,163751,176155,176870,208908,399616,406563,448949,632275,660215,660725,663204,709531,716931,749850,750826,754406,833972,833976,833991,833993,833994,923699,954456,992544,992562,992565,993254,1003446,1007061,1017166,1017171,1025302,1025314,1086314,1088998,1091508,1091656,1107221,1115170,1119877,1129686,1129710,1152505,1152516,1152622,1157630,1186897,1189494,1190566,1190610,1192173,1192174,1216011,1268397,1284207,1288922,1292084,1296670,1300573,130","11113952,11114151,17390027,24266769,24266786,24266829,24266842,24266869,24266880,24266934,24266944,24267039,24267145,24267244,24267248,24267292,24267298,24267366,24267372,24267374,24267405,24267409,24267460,24267465,24267496,24267502,24267651,24267653,24267655,24267657,24267659,24267682,24267697,24267751,24267773,24267782,24267793,24267816,24267818,24267829,24267853,24267875,24267939,24267968,24268049,24268069,24268080,24268233,24268416,24268475,24268481,24268499,24268622,24268633,24268650,24268832,24268945",2475,NULL,NP_004949,Governmental Organizations|NIH Initiatives,"14651849,18538731,613254",0,10.1016/j.ccr.2008.05.005|10.1016/s0092-8674(03)00929-2,2.7.11.1,P42345,NULL
651581,2,Dose response confirmation of uHTS identification of HIF-2a Inhibitors in screening - selectivity counterscreen assays,"Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)_|_Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, La Jolla, CA)_|_Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Number: 1 R03 DA033980-01A1_|_Assay Provider: Mei Yee Koh, Ph.D.,  University of Texas M.D. Anderson Cancer Center_|__|_Most solid tumors and their metastases experience regions of hypoxia, which promotes both tumor progression and resistance to therapy. Critical mediators o",14,Burnham Center for Chemical Genomics,SBCCG-A902-HIF-2a-DMSO-DR-Assay,20120920,"18990,67133,82533,83156,101486,105671,161167,282082,288561,304835,312145,364428,584778,620459,638439,646724,649840,654478,656185,659499,666941,684128,692729,707664,721101,724880,725903,749289,753352,774798,776110,781047,784698,802111,802651,805875,832320,839470,843208,843415,854968,883348,885297,888424,892370,894181,900837,907197,919235,930984,931189,967677,971004,971765,972733,972742,973504,975543,1011983,1072709,1080132,1089417,1090735,1123597,1132849,1157635,1249317,1286643,1335691,1341811,1433876,147512","844398,847434,851876,853531,858142,858166,865680,3712260,3714573,4243980,4247304,4248060,4248821,4249581,4252437,4254515,4254560,4254571,4259726,4261133,4261260,4262956,4263122,7967684,7970813,7970974,14721402,14722386,14727378,14727617,14727905,14730424,14730425,14731793,14734290,14735515,14735522,14735523,14735524,14737190,14741707,14742551,14742592,14745301,14747080,17386603,17402478,17402880,17408140,17410787,17412045,17412065,17412124,17416103,17416347,17432782,17432878,17433254,17433268,17433481,17504","2034,3091",NULL,"NP_001421,NP_001421,NP_001421,NP_001421,NP_001421,NP_001421,NP_001421,NP_001521,NP_001521,NP_001521",NIH Initiatives,"22068265,22093255,22277691,22367913",0,10.1002/ajh.23123|10.1007/s00439-011-1109-3|10.1016/j.jdermsci.2011.10.003|10.1016/j.jvs.2011.10.111,NULL,"Q16665,Q99814",NULL
720706,1,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: rRNA, antibiotics, protein synthesis inhibitor, 23S ribosome, resistance_|__|_Biological Relevance: _|_Successful treatment of bacterial infections has become increasingly difficult due to the rapid emergence of drug resistant strains. The human and economic cost of antibiotic resistance is enormous. Despite the urgent need to develop new antibiotics, only four classes have been launched since 1970. Among hundreds of essential enzymes in the bacterial cell, the ribosome is an evolutionary preferre",31,Broad Institute,7056-01_Inhibitor_SinglePoint_HTS_Activity,20140305,"6,13,40,72,86,109,119,127,137,174,191,243,253,255,299,300,314,379,441,460,499,546,597,660,727,745,774,803,892,903,931,936,938,942,949,957,978,995,996,1001,1002,1017,1018,1030,1046,1047,1088,1123,1183,1233,1302,1309,1326,1345,1365,1367,1369,1401,1474,1480,1483,1486,1491,1492,1493,1535,1609,1639,1643,1646,1651,1678,1687,1688,1689,1727,1738,1742,1761,1775,1810,1814,1820,1832,1864,1868,1890,1892,1917,1988,1989,1995,2000,2015,2018,2048,2064,2073,2078,2108,2153,2162,2203,2206,2214,2215,2236,2240,2247,2249,2253,22","842123,842124,842146,842150,842166,842168,842180,842184,842189,842202,842204,842220,842223,842225,842237,842256,842267,842306,842317,842344,842349,842376,842388,842392,842395,842419,842426,842433,842435,842439,842452,842458,842459,842474,842482,842489,842491,842506,842536,842539,842542,842543,842548,842565,842569,842571,842582,842594,842601,842606,842611,842612,842615,842616,842621,842635,842637,842640,842647,842654,842656,842665,842681,842682,842688,842711,842749,842762,842766,842774,842779,842797,842821,8",NULL,Organism-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
720709,2,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,"In multi-cellular eukaryotic organisms, the effects of cAMP are transduced by two ubiquitously-expressed intracellular cAMP receptors, the classic protein kinase A/cAMP-dependent protein kinase (PKA/cAPK) and the more recently discovered exchange protein directly activated by cAMP/cAMP-regulated guanine nucleotide exchange factor (EPAC/cAMP-GEF) [1, 2].  Both PKA and EPAC are ubiquitously expressed in all tissues, and an increase in intracellular cAMP levels will lead to the activation of both PKA and EPAC.",2,National Center for Advancing Translational Sciences (NCATS),EPAC1-antagonist-p1,20131031,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",10411,NULL,O95398,Governmental Organizations|NIH Initiatives,"10777494,9853756,9856955",0,10.1038/24884|10.1074/jbc.m001113200|10.1126/science.282.5397.2275,NULL,O95398,NULL
720542,2,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,"Plasmodium, the causative agent of malaria, is one of the world's deadliest parasitic diseases. Currently there is no vaccine available and there is widespread resistance to common anti-malarial drugs. This warrants novel, alternative approaches for developing improved therapy. During infection, one such essential interaction is between two parasite proteins, the apical membrane antigen1 (AMA1) that is translocated onto the merozoite surface and the rhoptry neck protein 2 (RON2), which is transferred to the",2,National Center for Advancing Translational Sciences (NCATS),AMA1100,20130727,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",NULL,NULL,AAN35928,Governmental Organizations|NIH Initiatives,"19247437,21778402,21788485",0,10.1073/pnas.1110303108|10.1126/science.1204988|10.1371/journal.ppat.1000309,NULL,AAN35928,NULL
720504,2,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,"The polo-like kinase 1 (Plk1) is a member of a conserved subfamily of serine / threonine protein kinases that plays a pivotal roles in cell proliferation.  It has a C-terminal non-catalytic region called the polo-box domain (PBD) that plays a crucial role in the subcellular localization of the Plk1.  Recent publications also revealed that Plk1 is the major kinase required for the viability of activated Ras or inactivated p53 mutation-bearing cancer cells, but not the respective normal cells.  Furthermore, d",2,National Center for Advancing Translational Sciences (NCATS),PLK1100,20130709,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",5347,NULL,NP_005021,Governmental Organizations|NIH Initiatives,NULL,0,NULL,2.7.11.21,P53350,NULL
720708,2,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,"In multi-cellular eukaryotic organisms, the effects of cAMP are transduced by two ubiquitously-expressed intracellular cAMP receptors, the classic protein kinase A/cAMP-dependent protein kinase (PKA/cAPK) and the more recently discovered exchange protein directly activated by cAMP/cAMP-regulated guanine nucleotide exchange factor (EPAC/cAMP-GEF) [1, 2].  Both PKA and EPAC are ubiquitously expressed in all tissues, and an increase in intracellular cAMP levels will lead to the activation of both PKA and EPAC.",2,National Center for Advancing Translational Sciences (NCATS),EPAC2-antagonist-p1,20131031,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",11069,NULL,Q8WZA2,Governmental Organizations|NIH Initiatives,"10777494,9853756,9856955",0,10.1038/24884|10.1074/jbc.m001113200|10.1126/science.282.5397.2275,NULL,Q8WZA2,NULL
720707,2,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,"In multi-cellular eukaryotic organisms, the effects of cAMP are transduced by two ubiquitously-expressed intracellular cAMP receptors, the classic protein kinase A/cAMP-dependent protein kinase (PKA/cAPK) and the more recently discovered exchange protein directly activated by cAMP/cAMP-regulated guanine nucleotide exchange factor (EPAC/cAMP-GEF) [1, 2].  Both PKA and EPAC are ubiquitously expressed in all tissues, and an increase in intracellular cAMP levels will lead to the activation of both PKA and EPAC.",2,National Center for Advancing Translational Sciences (NCATS),EPAC1-agonist-p1,20131031,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",10411,NULL,O95398,Governmental Organizations|NIH Initiatives,"10777494,9853756,9856955",0,10.1038/24884|10.1074/jbc.m001113200|10.1126/science.282.5397.2275,NULL,O95398,NULL
720711,2,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,"In multi-cellular eukaryotic organisms, the effects of cAMP are transduced by two ubiquitously-expressed intracellular cAMP receptors, the classic protein kinase A/cAMP-dependent protein kinase (PKA/cAPK) and the more recently discovered exchange protein directly activated by cAMP/cAMP-regulated guanine nucleotide exchange factor (EPAC/cAMP-GEF) [1, 2].  Both PKA and EPAC are ubiquitously expressed in all tissues, and an increase in intracellular cAMP levels will lead to the activation of both PKA and EPAC.",2,National Center for Advancing Translational Sciences (NCATS),EPAC2-agonist-p1,20131031,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",11069,NULL,Q8WZA2,Governmental Organizations|NIH Initiatives,"10777494,9853756,9856955",0,10.1038/24884|10.1074/jbc.m001113200|10.1126/science.282.5397.2275,NULL,Q8WZA2,NULL
720580,2,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,"Orthopoxviruses are a genus of viruses that include monkeypox, variola (the causative agent of smallpox) and vaccinia, the prototypical orthopoxvirus which was used in the world-wide vaccination program that eradicated smallpox [1]. Smallpox was once the most deadly human pathogen, and is estimated to have killed more than 300 million people. Following the eradication of smallpox, routine vaccination was discontinued in the 1970s, and there has consequently been a precipitous decline in population immunity ",2,National Center for Advancing Translational Sciences (NCATS),Vaccinia-p2Venus,20130819,"6,19,40,72,86,109,119,126,127,137,174,185,187,190,191,199,204,224,229,237,239,240,243,244,253,255,275,289,298,299,303,311,314,323,335,338,366,370,379,401,403,408,412,441,460,462,464,487,499,525,535,546,547,564,588,594,596,597,636,637,660,681,698,701,727,745,774,785,802,803,827,836,846,853,864,892,896,899,903,904,912,914,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1064,1066,1072,1088,1101,1123,1148,1150,1174,1176,1182,1189,1201,1204,1212,1214,1217,1218,1219,1220,1222,1225,1233,","842121,842122,842123,842124,842125,842126,842128,842129,842130,842131,842136,842137,842138,842139,842140,842143,842146,842148,842156,842161,842163,842166,842167,842168,842169,842170,842171,842172,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842191,842192,842193,842194,842195,842196,842197,842199,842201,842202,842205,842207,842211,842213,842214,842215,842216,842217,842218,842219,842220,842221,842222,842223,842224,842225,842231,842232,842233,842235,842238,842242,842243,842244,842247,8",3707576,NULL,BAA01847,Governmental Organizations|NIH Initiatives,17553242,0,10.3201/eid1306.061540,NULL,BAA01847,NULL
720579,2,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,"Orthopoxviruses are a genus of viruses that include monkeypox, variola (the causative agent of smallpox) and vaccinia, the prototypical orthopoxvirus which was used in the world-wide vaccination program that eradicated smallpox [1].  Smallpox was once the most deadly human pathogen, and is estimated to have killed more than 300 million people.  Following the eradication of smallpox, routine vaccination was discontinued in the 1970s, and there has consequently been a precipitous decline in population immunit",2,National Center for Advancing Translational Sciences (NCATS),Vaccinia-p2mCherry,20130821,"6,19,40,72,86,109,119,126,127,137,174,185,187,190,191,199,204,224,229,237,239,240,243,244,253,255,275,289,298,299,303,311,314,323,335,338,370,379,401,403,408,412,441,460,462,464,487,499,525,535,546,547,564,588,594,596,597,636,637,660,681,698,701,727,745,774,785,802,803,827,836,846,853,864,892,896,899,903,904,912,914,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1064,1066,1072,1088,1101,1123,1148,1150,1174,1176,1182,1189,1201,1204,1212,1214,1217,1218,1219,1220,1222,1225,1233,1234","842121,842122,842123,842124,842126,842128,842129,842130,842131,842136,842137,842138,842139,842140,842143,842146,842156,842161,842163,842166,842167,842168,842170,842172,842178,842179,842180,842183,842184,842186,842188,842191,842192,842193,842194,842196,842197,842199,842201,842202,842205,842207,842213,842214,842215,842216,842218,842219,842220,842221,842222,842223,842224,842225,842231,842232,842233,842238,842242,842243,842244,842253,842254,842255,842256,842258,842268,842269,842270,842272,842274,842276,842278,8",3707576,NULL,BAA01847,Governmental Organizations|NIH Initiatives,17553242,0,10.3201/eid1306.061540,NULL,BAA01847,NULL
720553,2,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,"_|_The recently identified KCNH2 3.1 potassium channel, a brain selective isoform of the KCNH2 (hERG1) potassium channel, has been shown to be increased in the brains of patients with schizophrenia, a genetic risk factor for the emergence of schizophrenia, and to affect neuronal cell activity and brain physiology.  Many antipsychotic drugs that inhibit the neurotransmitter dopamine also bind to hERG1 channel which might help explain their antipsychotic activity but also produces cardiac side effects.  The d",2,National Center for Advancing Translational Sciences (NCATS),herg-kcnh2-3.1-p2-mutant,20130731,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",3757,NULL,AEL63844,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AEL63844,NULL
720551,2,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,"_|_The recently identified KCNH2 3.1 potassium channel, a brain selective isoform of the KCNH2 (hERG1) potassium channel, has been shown to be increased in the brains of patients with schizophrenia, a genetic risk factor for the emergence of schizophrenia, and to affect neuronal cell activity and brain physiology.  Many antipsychotic drugs that inhibit the neurotransmitter dopamine also bind to hERG1 channel which might help explain their antipsychotic activity but also produces cardiac side effects.  The d",2,National Center for Advancing Translational Sciences (NCATS),herg-kcnh2-3.1-p2-wildtype,20130731,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",3757,NULL,AEL63844,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AEL63844,NULL
720635,2,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Mitochondrial membrane potential (MMP), one of the parameters for mitochondrial function, is generated by mitochondrial electron transport chain that creates an electroche",58,Tox21,MMP205,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,22433785,0,10.1152/physiolgenomics.00161.2011,NULL,NULL,NULL
720692,2,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The Glucocorticoid receptor (GR) is one of the members of the nuclear receptor family of ligand-dependent transcription factors. GR plays a critical role in carbohydrate, ",58,Tox21,GRN257,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",2908,NULL,ADP91253,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,NP_001019265,NULL
720691,2,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The Glucocorticoid receptor (GR) is one of the members of the nuclear receptor family of ligand-dependent transcription factors. GR plays a critical role in carbohydrate, ",58,Tox21,GRA481,20150805,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",2908,NULL,ADP91253,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,NP_001019265,NULL
720647,1,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,"Keywords: HEK293, LGR2, Bursicon_|__|_Assay Overview:  HEK293 cells are utilized to screen for LGR2 GPCR antagonists. First, cells are transfected with a construct to express the Bursicon agonist. Conditioned media is generated in bulk.  Separately, HEK293 cells are co-transfected with plasmid encoding the cDNA for the wild type Bursicon receptor and a CRE-luciferase reporter gene. After 24 hours, cells are treated with compound for 30 minutes and then stimulated with Bursicon conditioned media at half maxi",31,Broad Institute,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition - 7011-01_Antagonist_SinglePoint_HTS_Activity,20150115,"6,13,40,72,86,109,119,127,174,185,191,229,243,253,255,298,299,300,303,311,314,323,335,338,379,460,487,499,546,547,564,588,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1123,1174,1183,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1369,1401,1474,1480,1483,1486,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1687,1688,1689,1727,1732,1738,1742,1761,1794,1795,1810,1814,1820,","842123,842124,842128,842136,842146,842150,842161,842166,842168,842180,842181,842182,842184,842189,842192,842202,842204,842217,842220,842223,842225,842229,842237,842240,842252,842256,842259,842267,842268,842279,842280,842285,842287,842294,842296,842306,842313,842317,842336,842337,842338,842342,842344,842349,842371,842375,842376,842388,842389,842392,842396,842400,842411,842419,842421,842426,842433,842435,842439,842440,842445,842452,842456,842457,842458,842459,842467,842469,842474,842482,842488,842489,842491,8",NULL,NULL,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
720641,0,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,"The current epidemic of infections caused by antibiotic-resistant Gram-positive bacteria requires the discovery of new drug targets and the development of new therapeutics. Lipoteichoic acid (LTA), a cell wall polymer of Gram-positive bacteria, consists of 1,3-polyglycerol-phosphate linked to glycolipid. LTA synthase (LtaS) polymerizes polyglycerol-phosphate from phosphatidylglycerol, a reaction that is essential for the growth of Gram-positive bacteria. We screened small molecule libraries for compounds in",46,"ICCB-Longwood Screening Facility, Harvard Medical School",HMS979,20161102,"108,127,187,190,204,237,243,253,303,311,323,325,340,346,370,397,412,437,444,460,464,564,675,727,782,785,830,863,873,892,896,904,936,938,994,1002,1046,1054,1123,1134,1148,1176,1188,1203,1236,1309,1366,1474,1539,1570,1599,1727,1732,1775,1802,1814,1832,1833,1890,1892,1893,1935,1967,1981,1983,1985,1986,1989,1990,1995,2018,2048,2075,2082,2083,2092,2116,2117,2118,2119,2120,2122,2123,2125,2132,2140,2141,2145,2148,2153,2157,2159,2161,2162,2170,2176,2187,2193,2194,2196,2197,2202,2206,2240,2244,2247,2249,2265,2266,22","92117389,92117390,92117391,92117392,92117393,92117394,92117395,92117396,92117397,92117398,92117399,92117400,92117401,92117402,92117403,92117404,92117405,92117406,92117407,92117408,92117409,92117410,92117411,92117412,92117413,92117414,92117415,92117416,92117417,92117418,92117419,92117420,92117421,92117422,92117423,92117424,92117425,92117426,92117427,92117428,92117429,92117430,92117431,92117432,92117433,92117434,92117435,92117436,92117437,92117438,92117439,92117440,92117441,92117442,92117443,92117444,92117445",NULL,NULL,NP_371243,Research and Development,21378186,0,10.1128/jb.00027-11,NULL,Q99VQ4,NULL
720511,1,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_,"Keywords: Cystic Fibrosis, CFTR and corrector_|__|_Assay Overview: Halide-sensitive YFP quenching assay in CFBE cells expressing a mutated form of CFTR._|_Cystic fibrosis (CF) is an autosomal recessive disease, caused by mutations in the gene coding for the Cystic Fibrosis Transmembrane conductance Regulator (CFTR). About 90% of people with CF have at least one copy of the ""F508del"" mutation (deletion of phenylalanine at position 508, or CFTR-F508del), and over 70% of CF patients are homozygous for this mut",31,Broad Institute,7017-01_Other_SinglePoint_HTS_Activity,20130716,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,379,441,460,464,487,499,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1330,1340,1345,1359,1365,1367,1369,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1546,1570,1609,1639,1643,1646,1651,1676,1678,1687,1688,1689,1727","842123,842124,842146,842150,842166,842168,842180,842184,842202,842204,842220,842225,842256,842306,842317,842344,842376,842392,842419,842426,842433,842435,842439,842458,842459,842482,842491,842506,842536,842539,842542,842543,842548,842601,842611,842612,842615,842616,842621,842637,842640,842647,842656,842665,842681,842682,842699,842711,842749,842762,842774,842779,842797,842822,842851,842867,842872,842874,842903,842928,842934,842947,842960,842964,842972,842977,843011,843012,843020,843028,843037,843041,843047,8",1080,Cell-based,ABD72211,NIH Initiatives,21050066,0,10.1089/adt.2010.0312,NULL,P13569,NULL
720582,1,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: Torrey Pines Institute for Molecular Sciences (TPIMS)_|_Assay Provider: Dmitriy Minond, Torrey Pines Institute for Molecular Sciences (TPIMS)_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA033985-01_|_Grant Proposal PI: Dmitriy Minond, Torrey Pines Institute for Molecular Sciences (TPIMS)_|_External Assay ID: ADAM10_INH_QFRET_1536_1X%I",5,The Scripps Research Institute Molecular Screening Center,ADAM10_INH_QFRET_1536_1X%INH PRUN,20130821,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1050,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",102,Biochemical,AAC51766,NIH Initiatives,"15688065,16627988,20136654,20184396,20197081,20459566,20549373,20849079,21175594,21203579,21236490,21752713,21906355",0,10.1007/s00508-010-1373-6|10.1016/j.bbcan.2010.02.002|10.1016/j.it.2011.05.005|10.1016/j.molimm.2010.12.005|10.1021/pr100556z|10.1038/nrm1548|10.1111/j.1365-2249.2010.04298.x|10.1111/j.1365-2559.2010.03494.x|10.1111/j.1742-4658.2010.07566.x|10.1186/1559-0275-8-9|10.1371/journal.pbio.1000563|10.3109/10409231003628015|10.4161/cbt.5.6.2707,NULL,O14672,NULL
720702,1,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute (TSRI)_|_Assay Provider: Sanjay Adhikari, Georgetown University_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA035193-01A1_|_Grant Proposal PI: Sanjay Adhikari_|__|_External Assay ID: TPD2_INH_EPIABS_1536_1X%INH PRUN_|__|_Name: Epi Absorbance-based biochemical primary high throughput screening assay to id",5,The Scripps Research Institute Molecular Screening Center,TPD2_INH_EPIABS_1536_1X%INH PRUN,20131029,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1050,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",51567,Biochemical,NP_057698,NIH Initiatives,"16009940,17585367,18078692,18593526,18976568,19027345,19626045,21228232,21245344,21266548",0,10.1007/s00705-007-1013-2|10.1016/j.chom.2007.09.014|10.1016/j.cytogfr.2008.11.001|10.1038/nrm2731|10.1073/pnas.0504754102|10.1073/pnas.1013388108|10.1073/pnas.1015287108|10.1128/jvi.02496-10|10.3201/eid1411.071676|10.5483/bmbrep.2008.41.6.435,3.1.4.-,O95551,NULL
720596,1,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Corinne Lasmezas, The Scripps Research Institute Molecular Screening Center_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA035192-01_|_Grant Proposal PI: Corinne Lasmezas, The Scripps Research Institute Molecular Screening Center_|_External Assay ID: PRPC_INH_TRFRET_1536_1X%INH PRUN_|__|_Na",5,The Scripps Research Institute Molecular Screening Center,PRPC_INH_TRFRET_1536_1X%INH PRUN,20130903,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1050,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",5621,Cell-based,NP_000302,NIH Initiatives,"12970413,14522849,15229281,15269390,15286333,15286374,16816391,17896936,1876183,19264641,2895800,6801762,7902575,8419912,8598754,8657276,8962161,9045652",0,10.1016/s0140-6736(96)91412-9|10.1038/352679a0|10.1038/381743a0|10.1073/pnas.90.1.1|10.1073/pnas.90.23.10962|10.1073/pnas.93.25.14945|10.1074/jbc.272.10.6324|10.1091/mbc.e03-05-0271|10.1093/bmb/66.1.61|10.1093/brain/awl150|10.1099/0022-1317-69-4-955|10.1099/vir.0.009084-0|10.1099/vir.0.80082-0|10.1126/science.1100195|10.1126/science.305.5684.589a|10.1126/science.6801762|10.1128/jvi.77.19.10288-10294.2003|10.2174/138620707781996475,NULL,P04156,NULL
720704,1,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute_|_Assay Provider: Qisheng Zhang, University of North Carolina at Chapel Hill_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R01GM098894_|_Grant Proposal PI: Qisheng Zhang, University of North Carolina at Chapel Hill_|_External Assay ID: PLCB3_INH_QFRET_1536_1X%INH PRUN_|__|_Name: Fluorescence-based biochemical hi",5,The Scripps Research Institute Molecular Screening Center,PLCB3_INH_QFRET_1536_1X%INH PRUN,20131114,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1050,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",5331,Biochemical,AAI42682,NIH Initiatives,"15684042,16402909,17086182,17130835,17403917,17429106,18493969,19074886,1963096,20179606,20426766,20590620,20833646,21266572,2147038,21550986,7763279,8396627,8738291",0,10.1002/hipo.20443|10.1007/bf00167177|10.1016/0006-2952(95)00050-a|10.1038/ng1918|10.1038/sj.onc.1210115|10.1074/jbc.m110.191783|10.1074/jbc.m111.231993|10.1093/brain/awq238|10.1093/carcin/bgm078|10.1095/biolreprod43.4.704|10.1097/fjc.0b013e3181d8bec5|10.1111/j.1476-5381.2010.00795.x|10.1124/dmd.106.014498|10.1124/mol.105.011007|10.1146/annurev.pharmtox.46.120604.141223|10.1158/0008-5472.can-08-1181|10.2174/138945010791591331,NULL,Q01970,NULL
720700,1,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute_|_Assay Provider: Qisheng Zhang, University of North Carolina at Chapel Hill_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R01GM098894_|_Grant Proposal PI: Qisheng Zhang, University of North Carolina at Chapel Hill_|_External Assay ID: PLCG1_INH_QFRET_1536_1X%INH PRUN_|__|_Name: Fluorescence-based biochemical hi",5,The Scripps Research Institute Molecular Screening Center,PLCG1_INH_QFRET_1536_1X%INH PRUN,20140128,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1050,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",5335,Biochemical,AAI36467,NIH Initiatives,"15684042,16402909,17086182,17130835,17403917,17429106,18493969,19074886,1963096,20179606,20426766,20590620,20833646,21266572,2147038,21550986,7763279,8396627,8738291",0,10.1002/hipo.20443|10.1007/bf00167177|10.1016/0006-2952(95)00050-a|10.1038/ng1918|10.1038/sj.onc.1210115|10.1074/jbc.m110.191783|10.1074/jbc.m111.231993|10.1093/brain/awq238|10.1093/carcin/bgm078|10.1095/biolreprod43.4.704|10.1097/fjc.0b013e3181d8bec5|10.1111/j.1476-5381.2010.00795.x|10.1124/dmd.106.014498|10.1124/mol.105.011007|10.1146/annurev.pharmtox.46.120604.141223|10.1158/0008-5472.can-08-1181|10.2174/138945010791591331,NULL,AAI36467,NULL
720543,1,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute_|_Assay Provider: Ben Cravatt, The Scripps Research Institute_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R01 DA033760_|_Grant Proposal PI: Ben Cravatt, The Scripps Research Institute_|_External Assay ID: ABHD4_INH_FP_1536_1X%INH PRUN_|__|_Name: Fluorescence polarization-based biochemical high throughput prima",5,The Scripps Research Institute Molecular Screening Center,ABHD4_INH_FP_1536_1X%INH PRUN,20130724,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1050,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",105501,Biochemical,NP_598837,NIH Initiatives,"14634025,16605240,16818490,18429637,18446159,6726229,7126608",0,10.1016/0005-2760(82)90352-6|10.1021/bi060163l|10.1021/cr0782067|10.1038/nrd2553|10.1074/jbc.m306642200|10.1074/jbc.m604660200|10.1111/j.1471-4159.1984.tb12750.x,3.1.1.-,Q8VD66,NULL
720508,1,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: Harvard Medical School/Massachusetts General Hospital_|_Assay Provider: Peter Caravan, Harvard Medical School/Massachusetts General Hospital_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R21 NS075627_|_Grant Proposal PI: Peter Caravan, Harvard Medical School/Massachusetts General Hospital_|_External Assay ID: FIBRIN-TN7_INH_FP_1536_1X%INH PRU",5,The Scripps Research Institute Molecular Screening Center,FIBRIN-TN7_INH_FP_1536_1X%INH PRUN,20130710,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1050,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",NULL,Biochemical,1N8E_E,NIH Initiatives,"15367435,18425519,18645920,19809344,20175866,20632262,21162604,21836064,2465781,2478057,3537791,3546076",0,10.1002/bjs.7156|10.1007/s00330-008-0965-2|10.1016/0304-419x(89)90004-8|10.1016/s0046-8177(87)80010-2|10.1055/s-2008-1079255|10.1056/nejm198612253152606|10.1097/rli.0b013e3181b092a7|10.1111/j.1365-2796.2009.02205.x|10.1161/atvbaha.111.230631|10.1164/ajrccm/140.4.1104|10.1182/blood-2004-06-2272|10.2165/1158583-s0-000000000-00000,NULL,1N8E_E,NULL
720648,1,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: Torrey Pines Institute for Molecular Sciences (TPIMS)_|_Assay Provider: Dmitriy Minond, Torrey Pines Institute for Molecular Sciences (TPIMS)_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA033985-01_|_Grant Proposal PI: Dmitriy Minond, Torrey Pines Institute for Molecular Sciences (TPIMS)_|_External Assay ID: ADAM17_INH_QFRET_1536_1X%I",5,The Scripps Research Institute Molecular Screening Center,ADAM17_INH_QFRET_1536_1X%INH PRUN,20131017,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1050,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",6868,Biochemical,NP_003174,NIH Initiatives,"15688065,16627988,20136654,20184396,20197081,20459566,20549373,20849079,21175594,21203579,21236490,21752713,21906355",0,10.1007/s00508-010-1373-6|10.1016/j.bbcan.2010.02.002|10.1016/j.it.2011.05.005|10.1016/j.molimm.2010.12.005|10.1021/pr100556z|10.1038/nrm1548|10.1111/j.1365-2249.2010.04298.x|10.1111/j.1365-2559.2010.03494.x|10.1111/j.1742-4658.2010.07566.x|10.1186/1559-0275-8-9|10.1371/journal.pbio.1000563|10.3109/10409231003628015|10.4161/cbt.5.6.2707,3.4.24.86,P78536,NULL
720509,1,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: Harvard Medical School/Massachusetts General Hospital_|_Assay Provider: Peter Caravan, Harvard Medical School/Massachusetts General Hospital_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R21 NS075627_|_Grant Proposal PI: Peter Caravan, Harvard Medical School/Massachusetts General Hospital_|_External Assay ID: FIBRIN-TN6_INH_FP_1536_1X%INH PRU",5,The Scripps Research Institute Molecular Screening Center,FIBRIN-TN6_INH_FP_1536_1X%INH PRUN,20130710,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1050,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",NULL,Biochemical,1N8E_E,NIH Initiatives,"15367435,18425519,18645920,19809344,20175866,20632262,21162604,21836064,2465781,2478057,3537791,3546076",0,10.1002/bjs.7156|10.1007/s00330-008-0965-2|10.1016/0304-419x(89)90004-8|10.1016/s0046-8177(87)80010-2|10.1055/s-2008-1079255|10.1056/nejm198612253152606|10.1097/rli.0b013e3181b092a7|10.1111/j.1365-2796.2009.02205.x|10.1161/atvbaha.111.230631|10.1164/ajrccm/140.4.1104|10.1182/blood-2004-06-2272|10.2165/1158583-s0-000000000-00000,NULL,1N8E_E,NULL
720693,2,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The Glucocorticoid receptor (GR) is one of the members of the nuclear receptor family of ligand-dependent transcription factors.  GR plays a critical role in carbohydrate,",58,Tox21,GRV193,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,NULL,NULL
720634,2,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Mitochondrial membrane potential (MMP), one of the parameters for mitochondrial function, is generated by mitochondrial electron transport chain that creates an electroche",58,Tox21,MMP852,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,NULL,0,NULL,NULL,NULL,NULL
720717,0,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,"Kaposi's sarcoma associated herpesvirus (KSHV) is associated with cancer in immunosuppressed hosts. KSHV latently infects cells and the viral genome persists as a circular episome (plasmid).  KSHV LANA tethers the viral genome to mitotic chromosomes to segregate episomes to daughter nuclei. N-terminal LANA binds histones H2A/H2B to attach to chromosomes. Here, we report a screen for inhibitors of N-terminal LANA peptide binding to nucleosomes. A fluorescence polarization assay was used to detect N-LANA bind",46,"ICCB-Longwood Screening Facility, Harvard Medical School",HMS791,20161017,"89,108,119,187,190,204,237,243,253,303,323,346,370,412,437,444,460,564,675,727,774,782,785,830,864,892,896,904,914,932,936,938,994,1046,1054,1066,1072,1123,1134,1148,1150,1176,1188,1203,1204,1234,1236,1253,1309,1321,1348,1359,1377,1379,1380,1400,1420,1433,1449,1464,1493,1539,1560,1563,1609,1645,1646,1649,1720,1727,1732,1754,1756,1775,1780,1781,1825,1830,1833,1853,1863,1880,1890,1892,1893,1935,1960,1967,1981,1983,1984,1985,1986,1989,1990,1995,2004,2005,2018,2046,2049,2051,2063,2075,2081,2082,2083,2092,2116,2","92117389,92117390,92117391,92117392,92117393,92117394,92117395,92117396,92117397,92117398,92117399,92117400,92117401,92117402,92117403,92117404,92117405,92117406,92117407,92117408,92117409,92117410,92117411,92117412,92117413,92117414,92117415,92117416,92117417,92117418,92117419,92117420,92117421,92117422,92117423,92117424,92117425,92117426,92117427,92117428,92117429,92117430,92117431,92117432,92117433,92117434,92117435,92117436,92117437,92117438,92117439,92117440,92117441,92117442,92117443,92117444,92117445",NULL,NULL,AAC57158,Research and Development,"14671111,16469929",0,10.1126/science.1120541|10.1128/jvi.78.1.294-301.2004,NULL,AAC57158,NULL
720574,1,HTS to Identify Inhibitors of Demethylase GASC-1 Measured in Biochemical System Using Plate Reader - 2043-05_Inhibitor_SinglePoint_HTS_Activity,"Keywords: GASC-1 (gene amplified in squamous cell carcinoma-1), JMJD2C, KDM4C, histone demethylase, LANCE, HTS_|__|__|_Assay Overview:_|_The goal of this project is to identify inhibitors of the histone demethylase GASC-1 (gene amplified in squamous cell carcinoma-1; also known as JMJD2C and KDM4C).  GASC-1 has roles in cancer, androgen receptor signaling and the maintenance of pluripotency. GASC-1 directly and specifically removes repressive histone H3 lysine 9 tri-methylation in an iron and 2-oxoglutarate",31,Broad Institute,2043-05_Inhibitor_SinglePoint_HTS_Activity,20130814,"44201991,44201992,44201993,44201994,44201995,44201996,44201997,44201998,44201999,44202000,44202001,44202002,44202004,44202005,44202006,44202007,44202008,44202009,44202010,44202011,44202012,44202015,44202016,44202017,44202018,44202019,44202020,44202021,44202022,44202023,44202024,44202025,44202026,44202028,44202029,44202030,44202031,44202032,44202034,44202035,44202036,44202037,44202038,44202039,44202041,44202042,44202043,44202044,44202045,44202046,44202048,44202049,44202050,44202052,44202053,44202055,44202056","85789756,85789757,85789758,85789759,85789760,85789762,85789763,85789764,85789765,85789766,85789767,85789768,85789769,85789770,85789772,85789773,85789774,85789775,85789776,85789777,85789778,85789780,85789781,85789782,85789783,85789785,85789787,85789788,85789789,85789790,85789791,85789793,85789794,85789795,85789796,85789797,85789798,85789799,85789800,85789801,85789802,85789803,85789804,85789805,85789806,85789807,85789808,85789809,85789810,85789811,85789812,85789813,85789814,85789815,85789816,85789817,85789818",23081,Biochemical,AAI43572,NIH Initiatives,16732293,0,10.1038/nature04837,NULL,AAI43572,NULL
720532,2,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,"Marburg virus is a filovirus that is originated in Central and East Africa and can cause Marburg hemorrhagic fever in humans. Marburg virus is in the same taxonomic family as Ebola virus. Marburg virus is enveloped, nonsegmented, and contains a negative-sense RNA strand. To identify inhibitors of Marburg virus entry into cells, a pseudotype virus system was used where the nonpathogenic vesicular stomatitis virus (VSV) contains the Marburg virus envelop glycoproteins. This pseudotype virus, termed VSV-MARV, ",2,National Center for Advancing Translational Sciences (NCATS),VSVM-OFFLINE,20130720,"51,119,135,180,185,187,190,191,196,199,204,224,227,239,240,244,247,253,263,273,275,277,304,308,311,323,338,342,370,379,401,403,408,412,450,453,460,462,464,471,535,546,547,564,588,594,595,596,610,612,614,636,681,698,700,712,727,750,753,757,774,785,791,798,827,836,846,847,853,863,864,866,876,887,892,896,903,904,912,914,931,932,936,938,967,978,985,992,994,996,999,1001,1004,1018,1030,1046,1050,1053,1054,1057,1060,1064,1066,1072,1080,1101,1102,1103,1110,1123,1132,1134,1140,1148,1150,1174,1175,1176,1182,1183,1204","855652,4237474,4237475,4237489,4237492,4237495,4237508,4237519,4237526,4237541,4237563,4237605,4237624,4237658,4237662,4237704,4237706,4237710,4237711,4237719,4237735,4237745,4237760,4237772,4237774,4237791,4237802,4237836,4237841,4237849,4237853,4237893,4237899,4237916,4237919,4237920,4237935,4237940,4237944,4237964,4237968,4237981,4237996,4238022,4238031,4238033,4238034,4238039,4238043,4238055,4238061,4238074,4238079,4238091,4238095,4238115,4238123,4238134,4238157,4238191,4238195,4238201,4238204,4238209,4",NULL,NULL,B45705,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,B45705,NULL
720533,2,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,"Lassa virus is an arenavirus that is endemic in West Africa and can cause severe hemorrhagic fever in humans. Lassa virus is composed of a nucleocapsid core surrounded by a lipid bilayer containing glycoproteins that mediate host cell binding. To identify inhibitors of Lassa virus entry into cells, a pseudotype virus system was used where the nonpathogenic vesicular stomatitis virus (VSV) contains the Lassa virus envelop glycoproteins. This pseudotype virus, termed VSV-LV, has a Photinus luciferase reporter",2,National Center for Advancing Translational Sciences (NCATS),VSVL-OFFLINE,20130720,"51,119,135,180,185,187,190,191,196,199,204,224,227,239,240,244,247,253,263,273,275,277,304,308,311,323,338,342,370,379,401,403,408,412,450,453,460,462,464,471,535,546,547,564,588,594,595,596,610,612,614,636,681,698,700,712,727,750,753,757,774,785,791,798,827,836,846,847,853,863,864,866,876,887,892,896,903,904,912,914,931,932,936,938,967,978,985,992,994,996,999,1001,1004,1018,1030,1046,1050,1053,1054,1057,1060,1064,1066,1072,1080,1101,1102,1103,1110,1123,1132,1134,1140,1148,1150,1174,1175,1176,1182,1183,1204","855652,4237474,4237475,4237489,4237492,4237495,4237508,4237519,4237526,4237541,4237563,4237605,4237624,4237658,4237662,4237704,4237706,4237710,4237711,4237719,4237735,4237745,4237760,4237772,4237774,4237791,4237802,4237836,4237841,4237849,4237853,4237893,4237899,4237916,4237919,4237920,4237935,4237940,4237944,4237964,4237968,4237981,4237996,4238022,4238031,4238033,4238034,4238039,4238043,4238055,4238061,4238074,4238079,4238091,4238095,4238115,4238123,4238134,4238157,4238191,4238195,4238201,4238204,4238209,4",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
720554,0,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,"Quorum sensing is a signalling and regulatory phenomenon in bacteria that controls many behaviors including virulence. In many species of Proteobacteria quorum sensing is mediated by a diffusible acyl-homoserine lactone (acyl-HSL) signal. We have developed a screen to target the octanoyl-HSL synthase of Burkholderia mallei, BmaI1. Our new screen is a cell-free assay that couples a prduct of the reaction to generation of a fluorescence signal.  There were technical hurdles in the development of the screen. F",46,"ICCB-Longwood Screening Facility, Harvard Medical School",HMS1126,20161017,"137,298,397,412,444,838,861,936,938,1046,1833,1893,1986,2018,2082,2092,2118,2123,2125,2133,2145,2153,2159,2161,2162,2170,2176,2187,2249,2265,2315,2333,2375,2378,2435,2471,2478,2554,2576,2577,2585,2662,2678,2690,2708,2712,2720,2722,2727,2732,2733,2756,2771,2790,2794,2812,2955,2972,3003,3016,3019,3059,3108,3117,3121,3157,3168,3177,3194,3242,3256,3278,3279,3308,3324,3333,3339,3363,3365,3366,3373,3384,3385,3394,3397,3440,3463,3476,3478,3488,3598,3616,3639,3647,3672,3675,3676,3686,3702,3746,3747,3749,3767,3784,3","92126174,92126175,92126176,92126177,92126178,92126179,92126180,92126181,92126182,92126183,92126184,92126185,92126186,92126187,92126188,92126189,92126190,92126191,92126192,92126195,92126196,92126197,92126198,92126199,92126200,92126201,92126202,92126203,92126204,92126205,92126206,92126207,92126208,92126209,92126210,92126211,92126212,92126213,92126214,92126218,92126219,92126220,92126221,92126222,92126223,92126224,92126225,92126226,92126227,92126228,92126229,92126230,92126231,92126232,92126233,92126234,92126235",3087402,NULL,AAU46702,Research and Development,"19362649,7031424",0,10.1016/s0076-6879(09)04617-5|10.1016/s0076-6879(81)72029-9,NULL,AAU46702,NULL
720679,2,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Compound auto fluorescence often interferes with screening of the compound library against various biological targets and signaling pathways. Some of these compounds may h,58,Tox21,SPEC167CR,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,18363325,0,10.1021/jm701301m,NULL,NULL,NULL
720678,2,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Compound auto fluorescence often interferes with screening of the compound library against various biological targets and signaling pathways. Some of these compounds may h,58,Tox21,SPEC167CB,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,18363325,0,10.1021/jm701301m,NULL,NULL,NULL
720681,2,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Compound auto fluorescence often interferes with screening of the compound library against various biological targets and signaling pathways. Some of these compounds may h,58,Tox21,SPEC167MB,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,18363325,0,10.1021/jm701301m,NULL,NULL,NULL
720674,2,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Compound auto fluorescence often interferes with screening of the compound library against various biological targets and signaling pathways. Some of these compounds may h,58,Tox21,SPEC478CR,20161028,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,18363325,0,10.1021/jm701301m,NULL,NULL,NULL
720687,2,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Compound auto fluorescence often interferes with screening of the compound library against various biological targets and signaling pathways. Some of these compounds may h,58,Tox21,SPEC478CB,20161028,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,18363325,0,10.1021/jm701301m,NULL,NULL,NULL
720683,2,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Compound auto fluorescence often interferes with screening of the compound library against various biological targets and signaling pathways. Some of these compounds may h,58,Tox21,SPEC167MR,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,18363325,0,10.1021/jm701301m,NULL,NULL,NULL
720685,2,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Compound auto fluorescence often interferes with screening of the compound library against various biological targets and signaling pathways. Some of these compounds may h,58,Tox21,SPEC478MB,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,18363325,0,10.1021/jm701301m,NULL,NULL,NULL
720684,2,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Compound auto fluorescence often interferes with screening of the compound library against various biological targets and signaling pathways. Some of these compounds may h,58,Tox21,SPEC478MR,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,18363325,0,10.1021/jm701301m,NULL,NULL,NULL
720675,2,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Compound auto fluorescence often interferes with screening of the compound library against various biological targets and signaling pathways. Some of these compounds may h,58,Tox21,SPEC478CG,20161028,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,18363325,0,10.1021/jm701301m,NULL,NULL,NULL
720686,2,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Compound auto fluorescence often interferes with screening of the compound library against various biological targets and signaling pathways. Some of these compounds may h,58,Tox21,SPEC478MG,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,18363325,0,10.1021/jm701301m,NULL,NULL,NULL
720680,2,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Compound auto fluorescence often interferes with screening of the compound library against various biological targets and signaling pathways. Some of these compounds may h,58,Tox21,SPEC167CG,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,18363325,0,10.1021/jm701301m,NULL,NULL,NULL
720682,2,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Compound auto fluorescence often interferes with screening of the compound library against various biological targets and signaling pathways. Some of these compounds may h,58,Tox21,SPEC167MG,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,18363325,0,10.1021/jm701301m,NULL,NULL,NULL
720505,1,CRACM1 Is a Plasma Membrane Protein Essential for Store-Operated Ca2+ Entry,Title: CRACM1 Is a Plasma Membrane Protein Essential for Store-Operated Ca2+ Entry_|__|_Abstract: _|_Store-operated Ca2+ entry is mediated by Ca2+ release-activated Ca2+ (CRAC) channels following Ca2+ release from intracellular stores. We performed a genomewide RNA interference (RNAi) screen in Drosophila cells to identify proteins that inhibit store-operated Ca2+ influx. A secondary patch-clamp screen identified CRACM1 and CRACM2 (CRAC modulators 1 and 2) as modulators of Drosophila CRAC currents. We chara,50,Drosophila RNAi Screening Center (DRSC),DRSC-P64,20130709,NULL,"104179793,104179794,104179795,104179796,104179797,104179798,104179799,104179800,104179801,104179802,104179803,104179804,104179805,104179806,104179807,104179808,104179809,104179810,104179811,104179812,104179813,104179814,104179815,104179816,104179817,104179818,104179819,104179820,104179821,104179822,104179823,104179824,104179825,104179826,104179827,104179828,104179829,104179830,104179831,104179832,104179833,104179834,104179835,104179836,104179837,104179838,104179839,104179840,104179841,104179842,104179843,10","30970,30971,30972,30973,30975,30976,30977,30978,30979,30980,30981,30982,30983,30984,30985,30986,30988,30990,30991,30994,30995,30996,30998,31000,31001,31002,31003,31004,31005,31006,31007,31009,31010,31011,31012,31013,31014,31015,31016,31017,31018,31019,31020,31021,31022,31023,31024,31025,31026,31027,31028,31029,31030,31031,31032,31033,31036,31037,31038,31039,31042,31043,31044,31045,31046,31047,31048,31049,31050,31052,31054,31055,31056,31057,31059,31060,31061,31062,31063,31064,31065,31066,31067,31068,31069,31",RNAi,NULL,Research and Development,16645049,1,10.1126/science.1127883,NULL,NULL,NULL
720659,2,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,"Assay overview:_|__|_The Pregnane X receptor (PXR) plays a critical role in the regulation of genes involved in drug metabolism and transporters. Activation of PXR may be involved in the unwanted adverse drug-drug interactions. The interaction of drugs and xenobiotics with PXR will induce a group of enzymes including cytochrome P450 enzymes and glutathione transferases. Therefore, identification of compounds with the potential for PXR activation can be of importance in improving the efficacy of drugs with l",2,National Center for Advancing Translational Sciences (NCATS),PXR192,20131018,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",8856,NULL,ADZ17384,Governmental Organizations|NIH Initiatives,20966043,0,10.1124/dmd.110.035105,NULL,ADZ17384,NULL
720653,2,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_Assay Overview:_|__|_Oxidative stress has been implicated in the pathogenesis of a variety of diseases ranging from cancer to neurodegeneration. The antioxidant response element (ARE) signaling pathway plays an important role in the amelioration of oxidative stres,2,National Center for Advancing Translational Sciences (NCATS),ARE853,20131017,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,"21643505,22551509",0,10.1289/ehp.1104709|10.2174/1875397301105010001,NULL,NULL,NULL
720636,2,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,"National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_Assay Overview:_|__|_The antioxidant response element (ARE) signaling pathway plays an important role in the cellular anti-oxidant defense. Exposure to stressors which are exogenous like ionizing radiations, chemicals, U-V light, and endogenous like cell signaling",2,National Center for Advancing Translational Sciences (NCATS),NRF205,20130910,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1054,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2160,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",4780,NULL,NP_006155,Governmental Organizations|NIH Initiatives,"21643505,22551509",0,10.1289/ehp.1104709|10.2174/1875397301105010001,NULL,Q16236,NULL
720488,1,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of a ChemBridge library: biochemical high-throughput screening assay to identify compounds that enhance or quench Cy5 fluorescence,"The hepatitis C virus (HCV) is a major cause of liver failure and hepatocellular cancer, with about 170 million people infected worldwide (1).  HCV has a small RNA genome that is directly translated by the infected host cell into a single precursor polyprotein that is processed by enzymatic cleavage into 10 proteins of diverse function. The non-structural proteins include p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B, and are responsible for the replication and packaging of the HCV genome into capsids formed by ",60,Milwaukee Institute for Drug Discovery,20130627FPNS3INTERFERECB,20130710,"1492,1833,4793,4933,7032,7543,7571,8341,9047,12847,12901,13728,13768,14137,15631,16357,16947,17471,17709,18090,18334,18705,20627,22763,31385,32044,32774,33839,36303,37320,37405,38116,41866,41912,47522,47523,52216,52817,53471,54713,57383,60582,63708,66686,66717,66720,68378,69145,70362,70826,72817,73249,73865,74117,74433,75181,75887,77379,78203,78707,79195,80434,80579,80671,81896,82027,82513,83070,83156,84327,84347,85430,86523,87007,88309,93558,94929,95050,95276,95707,95709,96468,97511,97781,98791,99749,10124","163598229,163598230,163598231,163598232,163598233,163598234,163598235,163598236,163598237,163598238,163598239,163598240,163598241,163598242,163598243,163598244,163598245,163598246,163598247,163598248,163598249,163598250,163598251,163598252,163598253,163598254,163598255,163598256,163598257,163598258,163598259,163598260,163598261,163598262,163598263,163598264,163598265,163598266,163598267,163598268,163598269,163598270,163598271,163598272,163598273,163598274,163598275,163598276,163598277,163598278,163598279,16",NULL,Biochemical,NULL,Research and Development,NULL,0,NULL,NULL,NULL,NULL
720637,3,qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Mitochondrial membrane potential (MMP), one of the parameters for mitochondrial function, is generated by mitochondrial electron transport chain that creates an electroche",58,Tox21,MMP146,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,22433785,0,10.1152/physiolgenomics.00161.2011,NULL,NULL,NULL
720502,2,qHTS for Inhibitors of Polymerase Eta: Confirmatory Assay for Cherry-picked Compounds,"The Y-family of DNA polymerases, such as the Polymerase Eta (Pol eta), are specifically involved in DNA repair. Pol eta copies undamaged DNA with a lower fidelity than other DNA-directed polymerases. However, it accurately replicates UV-damaged DNA.  When thymine dimers are present, this polymerase inserts the complementary nucleotides in the newly synthesized DNA, thereby bypassing the lesion and suppressing the mutagenic effect of UV-induced DNA damage. Pol eta has the ability to bypass cisplatinated DNA ",2,National Center for Advancing Translational Sciences (NCATS),pol-eta-ases-set-p1-selec,20130709,"3197,3431,4212,4971,5923,6024,6047,6293,6683,6842,7085,8266,8323,8408,9305,9922,10168,10603,11095,14313,14710,18834,22650,30923,31475,32875,33613,53025,62770,66541,66671,67062,67065,67074,68106,68207,68995,69161,72571,72768,73024,73677,75583,80175,80417,80458,80629,80771,83156,83851,85485,85517,86926,92993,94104,94986,96506,96927,97167,97509,97688,100058,105671,122734,122815,125322,131349,139991,161385,174343,176170,213329,216328,219926,224275,224560,224922,227197,230132,230133,232680,235240,235574,235598,2","842159,842213,842352,843666,843770,844210,844458,844879,845072,845890,846098,846213,847064,847187,847741,847763,848328,848566,848612,849243,849520,850196,850481,850949,851427,851848,855879,855939,856108,856472,856662,856717,857194,857345,857486,857522,857550,857588,857868,858489,858569,858661,859124,859598,859770,860922,861705,862070,863066,863170,863193,863306,863408,864493,864581,864603,865306,865343,865489,865879,3711664,3711831,3711852,3712105,3712109,3712171,3712200,3712249,3712251,3712270,3712386,3712",5429,NULL,NP_006493,Governmental Organizations|NIH Initiatives,23056190,0,10.1371/journal.pone.0045032,2.7.7.7,Q9Y253,NULL
720725,3,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The Glucocorticoid receptor (GR) is one of the members of the nuclear receptor family of ligand-dependent transcription factors.  GR plays a critical role in carbohydrate,",58,Tox21,GRN811,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",2908,NULL,ADP91253,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,NP_001019265,NULL
720552,3,qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_p53, a tumor suppressor protein, is activated following cellular insult, including DNA damage and other cellular stresses.  The activation of p53 regulates cell fate by in",58,Tox21,P53823,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",7157,NULL,P04637,Governmental Organizations,NULL,0,NULL,NULL,P04637,NULL
720719,3,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The Glucocorticoid receptor (GR) is one of the members of the nuclear receptor family of ligand-dependent transcription factors.  GR plays a critical role in carbohydrate,",58,Tox21,GRA646,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",2908,NULL,ADP91253,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,NP_001019265,NULL
720506,2,qHTS of D3 Dopamine Receptor Agonist: D3 Dopamine Receptor B-arrestin Agonist Confirmatory Assay,"D3 DARs represent a very important target for the treatment of several neuropsychiatric disorders. Indeed, one of the most promising therapeutic applications for the D3 DAR is in the area of addiction and related disorders. Several lines of evidence suggest that partial agonists or antagonists of the D3 DAR may be therapeutic for drug abuse and relapse. Accumulating evidence suggests that reducing D3 DAR activity may regulate the motivation to self-administer drugs and disrupt drug-associated cue-induced cr",2,National Center for Advancing Translational Sciences (NCATS),D3-arrstn-ag-confirm,20130710,"1761,2215,2972,3169,3306,4140,4612,5610,5614,5924,6018,6114,6202,7475,7589,7671,7908,8366,8559,11137,11236,11368,11568,11803,15443,22162,23702,28207,34920,47812,62935,65340,66259,71412,73484,84298,88012,88708,133721,134551,173870,198284,198798,199200,202477,219770,228580,234540,234859,234937,247228,247570,260286,260291,260310,261297,269295,309182,328144,360218,395945,401019,404637,443951,444034,506605,541836,561041,562638,575440,600165,600181,601380,609668,612957,620153,630233,630980,631854,632654,637930,64","842134,842258,842366,842699,843334,843578,844078,844802,844959,845074,845577,845812,845844,845902,846143,846908,847038,847205,847362,847958,847998,848061,848183,848458,848576,848916,848945,849186,849300,849556,849667,850486,850490,850553,850718,851071,851518,851642,851830,852616,852697,852829,853013,853284,853292,853333,853354,853543,853556,853649,853675,855542,855558,855560,855622,855636,855721,855729,855743,855842,855845,855847,855917,856009,856022,856032,856036,856146,856312,857431,857536,857539,857664,8",1814,NULL,NP_387512,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P35462,NULL
720507,2,qHTS of D3 Dopamine Receptor Agonist: D2 Dopamine Receptor B-arrestin Agonist Counterscreen,"D3 DARs represent a very important target for the treatment of several neuropsychiatric disorders. Indeed, one of the most promising therapeutic applications for the D3 DAR is in the area of addiction and related disorders. Several lines of evidence suggest that partial agonists or antagonists of the D3 DAR may be therapeutic for drug abuse and relapse. Accumulating evidence suggests that reducing D3 DAR activity may regulate the motivation to self-administer drugs and disrupt drug-associated cue-induced cr",2,National Center for Advancing Translational Sciences (NCATS),D2-arrstn-ag-counter,20130710,"1761,2215,2972,3169,3306,4140,4612,5610,5614,5924,6018,6114,6202,7475,7589,7671,7908,8366,8559,11137,11236,11368,11568,11803,15443,22162,23702,28207,34920,47812,62935,65340,66259,71412,73484,84298,88012,88708,133721,134551,173870,198284,198798,199200,202477,219770,228580,234540,234859,234937,247228,247570,260286,260291,260310,261297,269295,309182,328144,360218,395945,401019,404637,443951,444034,506605,541836,561041,562638,575440,600165,600181,601380,609668,612957,620153,630233,630980,631854,632654,637930,64","842134,842258,842366,842699,843334,843578,844078,844802,844959,845074,845577,845812,845844,845902,846143,846908,847038,847205,847362,847958,847998,848061,848183,848458,848576,848916,848945,849186,849300,849556,849667,850486,850490,850553,850718,851071,851518,851642,851830,852616,852697,852829,853013,853284,853292,853333,853354,853543,853556,853649,853675,855542,855558,855560,855622,855636,855721,855729,855743,855842,855845,855847,855917,856009,856022,856032,856036,856146,856312,857431,857536,857539,857664,8",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
720516,3,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_As cancer cells divide rapidly and during every cell division they need to duplicate their genome by DNA replication. The failure to do so results in the cancer cell death,58,Tox21,ELG271,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",79915,Toxicity,Q96QE3,Governmental Organizations,22431602,0,10.1073/pnas.1114278109,NULL,Q96QE3,NULL
720534,2,qHTS for Inhibitors of TGF-b: Confirmation of Cherry Picks,"TGF-b is a main component in the TGF-b signaling pathway which plays diverse roles in cellular and development pathways. TGF-b is mediated through transcription factors called ""Smads"". Although the Smad-dependent pathway is the primary canonical TGF-b signaling mode, TGF-b1 can also activate alternative signaling pathways, including those involving MAPK (ERK, JNK and p38). This interaction may mediate or enhance Smad-dependent responses, or can exert Smad-independent effects. The complexity of this signalin",2,National Center for Advancing Translational Sciences (NCATS),tgfb-smad3-f1-cherrypick-hepg2-caga-gfp,20130725,"2199,3800,3820,3832,4605,4882,5153,5712,6245,7547,7594,8616,8975,10662,14161,26695,27647,32875,42640,43795,56909,58953,67238,67275,67277,71060,72402,72438,72512,77955,81124,82533,91378,91467,95307,99927,100520,122737,122815,148870,150655,156816,160386,161167,182791,203396,209651,221121,233768,237305,240350,242436,242571,247955,252247,253602,255329,260557,261769,262540,264006,264884,265036,265940,266923,268953,269050,270669,270853,274159,275098,275781,276233,277056,280101,280899,282274,282594,282697,286701,2","842825,843472,845245,845300,846190,846209,846246,846887,847082,848647,849093,850269,852129,855645,855836,856525,857211,857671,858172,858770,858798,860222,860470,860681,861415,861918,862581,862958,863133,865658,3712293,3712781,3712953,3713133,3714949,3715390,3716166,3716457,4241241,4241466,4242143,4242820,4243116,4243255,4245327,4248346,4248488,4248779,4251800,4251843,4254529,4254847,4255465,4255516,4256056,4257571,4257617,4257655,4258273,4259769,4260224,4260492,4261036,4261086,4262188,4262411,4262547,426333",4088,NULL,AAL68976,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P84022,NULL
720536,2,qHTS for Inhibitors of TGF-b: CCL64 Cells Orthogonal Assay for Cherry Picks,"TGF-b is a main component in the TGF-b signaling pathway which plays diverse roles in cellular and development pathways. TGF-b is the mediated by the transcription factors Smads. Although the Smad-dependent pathway is the primary canonical TGF-b signaling node, TGF-b1 can also activate alternative signaling pathways, including those involving MAPK (ERK, JNK and p38). This interaction may mediate or enhance Smad-dependent responses, or can exert Smad-independent effects. The complexity of this signaling casc",2,National Center for Advancing Translational Sciences (NCATS),tgfb-smad3-f1-cherrypick-ccl64-caga-gfp,20130720,"2199,3800,3820,3832,4605,4882,5153,5712,6245,7547,7594,8616,8975,10662,14161,26695,27647,32875,42640,43795,56909,58953,67238,67275,67277,71060,72402,72438,72512,77955,81124,82533,91378,91467,95307,99927,100520,122737,122815,148870,150655,156816,160386,161167,182791,203396,209651,221121,233768,237305,240350,242436,242571,247955,252247,253602,255329,260557,261769,262540,264006,264884,265036,265940,266923,268953,269050,270669,270853,274159,275098,275781,276233,277056,280101,280899,282274,282594,282697,286701,2","842825,843472,845245,845300,846190,846209,846246,846887,847082,848647,849093,850269,852129,855645,855836,856525,857211,857671,858172,858770,858798,860222,860470,860681,861415,861918,862581,862958,863133,865658,3712293,3712781,3712953,3713133,3714949,3715390,3716166,3716457,4241241,4241466,4242143,4242820,4243116,4243255,4245327,4248346,4248488,4248779,4251800,4251843,4254529,4254847,4255465,4255516,4256056,4257571,4257617,4257655,4258273,4259769,4260224,4260492,4261036,4261086,4262188,4262411,4262547,426333",4088,NULL,AAL68976,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P84022,NULL
720535,2,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen for Cherry Picks,"TGF-b is a main component in the TGF-b signaling pathway which plays diverse roles in cellular and development pathways. TGF-b is mediated by transcription factors called ""Smads"". Although the Smad-dependent pathway is the primary canonical TGF-b signaling mode, TGF-b1 can also activate alternative signaling pathways, including those involving MAPK (ERK, JNK and p38). This interaction may mediate or enhance Smad-dependent responses, or can exert Smad-independent effects. The complexity of this signaling cas",2,National Center for Advancing Translational Sciences (NCATS),tgfb-smad3-f1-cherrypick-hepg2-caga-cytotox,20130720,"2199,3800,3820,3832,4605,4882,5153,5712,6245,7547,7594,8616,8975,10662,14161,26695,27647,32875,42640,43795,56909,58953,67238,67275,67277,71060,72402,72438,72512,77955,81124,82533,91378,91467,95307,99927,100520,122737,122815,148870,150655,156816,160386,161167,182791,203396,209651,221121,233768,237305,240350,242436,242571,247955,252247,253602,255329,260557,261769,262540,264006,264884,265036,265940,266923,268953,269050,270669,270853,274159,275098,275781,276233,277056,280101,280899,282274,282594,282697,286701,2","842825,843472,845245,845300,846190,846209,846246,846887,847082,848647,849093,850269,852129,855645,855836,856525,857211,857671,858172,858770,858798,860222,860470,860681,861415,861918,862581,862958,863133,865658,3712293,3712781,3712953,3713133,3714949,3715390,3716166,3716457,4241241,4241466,4242143,4242820,4243116,4243255,4245327,4248346,4248488,4248779,4251800,4251843,4254529,4254847,4255465,4255516,4256056,4257571,4257617,4257655,4258273,4259769,4260224,4260492,4261036,4261086,4262188,4262411,4262547,426333",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
720496,2,qHTS for Inhibitors of Polymerase Iota: Confirmatory Assay for Cherry-picked Compounds,"DNA polymerases, such as polymerase iota (Pol iota), are involved in DNA repair. Pol iota specifically plays an important role in translesion synthesis, where the normal high-fidelity DNA polymerases cannot proceed and DNA synthesis stalls. It has been reported that human Pol iota may be up-regulated in a number of human cancers and specifically during the progression of breast cancer, indicating that Pol iota's activities within normal living cells must be tightly regulated. Thus, while Pol eta and most li",2,National Center for Advancing Translational Sciences (NCATS),pol-iota-ases-set-p1-selec,20130709,"3197,4212,4971,5923,6024,6047,6293,6842,7085,8323,8408,9922,10168,10603,14169,14313,14710,18834,22650,30923,32875,40304,49659,62770,66541,66671,67062,67065,68106,68207,72512,72571,73677,75583,80175,80417,80458,83156,83851,85517,92993,96506,96927,97167,100058,122815,125322,131349,174343,188677,213329,219926,224275,224560,227197,230133,235240,235574,235598,237490,240739,244989,246666,248874,252682,254021,254859,262093,263534,264630,265898,267286,268237,270505,272529,274108,275098,276685,277512,278675,279596,2","842352,843770,844210,845995,846098,847187,848304,848612,851427,855879,856108,856662,856717,857194,857345,857486,857522,857795,858569,860922,861705,862070,863066,863170,863306,863408,865081,865306,865879,3711664,3711831,3711852,3712105,3712171,3712200,3712249,3712251,3712270,3712386,3712399,3712480,3712622,3714133,3715042,3715091,3715212,3715229,3715412,3715781,3717399,3717535,3717601,4240544,4242102,4242272,4243236,4243472,4244309,4244801,4245926,4251081,4251194,4251253,4251604,4256349,4258200,4258396,42592",11201,NULL,NP_009126,Governmental Organizations|NIH Initiatives,23056190,0,10.1371/journal.pone.0045032,2.7.7.7,Q9UNA4,NULL
720652,2,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,"National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|__|_Assay Overview:_|__|_Nuclear steroid hormone receptors are involved in many biological processes including inflammatory responses, cell proliferation, and apoptosis.  Environmental factors or compounds disrupting these nuclear receptor pathways and gene expression may promote susceptibility to immunotoxicant",2,National Center for Advancing Translational Sciences (NCATS),ROR432,20131017,"11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,370,379,398,403,447,460,527,612,650,660,700,701,702,713,753,785,795,864,887,896,904,931,949,957,967,978,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1309,1318,1483,1486,1491,1493,1732,1752,1775,1923,1983,1988,1989,2078,2087,2153,2155,2202,2244,2256,2265,2268,2272,2286,2331,2347,2355,2365,2391,2406,2478,2482,2519,2537,2554,2576,2662,2708,2720,2727,2730,2756,2758,2767,2788,2879,2950,2955,2969,3017,3026,3035,30","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
720537,2,qHTS for Inhibitors of TGF-b: Hit Validation in HepG2 Cells using COP promoter,"TGF-b is a main component in the TGF-b signaling pathway which plays diverse roles in cellular and development pathways. TGF-b is the mediated by the transcription factors Smads. Although the Smad-dependent pathway is the primary canonical TGF-b signaling node, TGF-b1 can also activate alternative signaling pathways, including those involving MAPK (ERK, JNK and p38). This interaction may mediate or enhance Smad-dependent responses, or can exert Smad-independent effects. The complexity of this signaling casc",2,National Center for Advancing Translational Sciences (NCATS),tgfb-smad3-f1-cherrypick- hepg2-cop-gfp,20130813,"2199,3800,3820,3832,4605,4882,5153,5712,6245,7547,7594,8616,8975,10662,14161,26695,27647,32875,42640,43795,56909,58953,67238,67275,67277,71060,72402,72438,72512,77955,81124,82533,91378,91467,95307,99927,100520,122737,122815,148870,150655,156816,160386,161167,182791,203396,209651,221121,233768,237305,240350,242436,242571,247955,252247,253602,255329,260557,261769,262540,264006,264884,265036,265940,266923,268953,269050,270669,270853,274159,275098,275781,276233,277056,280101,280899,282274,282594,282697,286701,2","842825,843472,845245,845300,846190,846209,846246,846887,847082,848647,849093,850269,852129,855645,855836,856525,857211,857671,858172,858770,858798,860222,860470,860681,861415,861918,862581,862958,863133,865658,3712293,3712781,3712953,3713133,3714949,3715390,3716166,3716457,4241241,4241466,4242143,4242820,4243116,4243255,4245327,4248346,4248488,4248779,4251800,4251843,4254529,4254847,4255465,4255516,4256056,4257571,4257617,4257655,4258273,4259769,4260224,4260492,4261036,4261086,4262188,4262411,4262547,426333",4088,NULL,AAL68976,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,P84022,NULL
720513,2,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_Dose_CherryPick_Activity_Set6,"Keywords: GCN5,flag PGC1a adenovirus, acetyl transferase, SIRT1 deacetylase, Alphascreen, acetylation, inflammation, diabetes_|__|_Assay Overview: The close relationship between PGC-1a acetylation and metabolic diseases suggests the possibility the discovery of chemical probes that manipulate the acetylation level would introduce new therapeutic applications in those diseases.  Our primary goal is to discover chemical compounds that can modulate PGC1a acetylation levels to protect against age-associated dis",31,Broad Institute,2139-01_Activator_Dose_CherryPick_Activity_Set6,20130716,"2199,3902,4115,4211,4472,4506,4641,4993,5323,6197,7436,8549,9363,20345,21436,28718,57469,62389,64983,66541,69550,73293,78442,122737,126941,165528,216284,219756,223708,224644,230761,231744,233577,233768,234165,235453,235529,236075,239702,240061,242889,247533,248803,257424,259196,260644,267330,270402,270574,273896,278573,279787,285844,289159,306328,328145,328154,330435,348206,354677,373692,399618,404470,404472,419818,432905,441362,447912,449459,551351,565664,597363,604599,604621,613364,617293,618112,619280,62","842202,842503,842652,842730,842742,842778,842842,842874,842906,843344,843392,843757,843976,844003,844311,844346,844372,844436,844709,844782,844831,845253,845511,845693,846051,846438,846596,846647,846886,847511,847589,847697,847745,847911,847927,848061,848239,848396,848559,849112,849116,849170,849776,849781,849972,850032,850072,850208,850302,850381,850845,850880,850895,850945,851250,851304,851312,851374,851631,851657,851689,851986,852080,852119,852152,852158,852341,852494,852701,852712,852833,853273,853409,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
720514,2,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_Dose_CherryPick_Activity,"Keywords: GCN5,flag PGC1a adenovirus, acetyl transferase, SIRT1 deacetylase, Alphascreen, acetylation, inflammation, diabetes_|__|_Assay Overview: The close relationship between PGC-1a acetylation and metabolic diseases suggests the possibility the discovery of chemical probes that manipulate the acetylation level would introduce new therapeutic applications in those diseases.  Our primary goal is to discover chemical compounds that can modulate PGC1a acetylation levels to protect against age-associated dis",31,Broad Institute,2139-01_Inhibitor_Dose_CherryPick_Activity,20130716,"2199,3902,4115,4211,4472,4506,4641,4993,5323,6197,7436,8549,9363,20345,21436,28718,57469,62389,64983,66541,69550,73293,78442,122737,126941,165528,216284,219756,223708,224644,230761,231744,233577,233768,234165,235453,235529,236075,239702,240061,242889,247533,248803,257424,259196,260644,267330,270402,270574,273896,278573,279787,285844,289159,306328,328145,328154,330435,348206,354677,373692,399618,404470,404472,419818,432905,441362,447912,449459,551351,565664,597363,604599,604621,613364,617293,618112,619280,62","842202,842503,842652,842730,842742,842778,842842,842874,842906,843344,843392,843757,843976,844003,844311,844346,844372,844436,844709,844782,844831,845253,845511,845693,846051,846438,846596,846647,846886,847511,847589,847697,847745,847911,847927,848061,848239,848396,848559,849112,849116,849170,849776,849781,849972,850032,850072,850208,850302,850381,850845,850880,850895,850945,851250,851304,851312,851374,851631,851657,851689,851986,852080,852119,852152,852158,852341,852494,852701,852712,852833,853273,853409,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
720524,2,Nrf2 qHTS screen for inhibitors: Nrf2 A549 ARE-Fluc Confirmation Assay for Hit Validation,"Nrf2 is a transcription factor that maintains cellular redox homoestasis and protects cells from xenobiotics [1, 2]. Nrf2 binds to the antioxidant response element (ARE) to induce gene expression of a broad spectrum of genes that encode for antioxidants. Hence this Nrf2 pathway provides a first line of defense against stress caused by exposure to radiation, electrophiles, and xenobiotics. In many cancers it has been found that tumor cells manipulate the Nrf2 pathway for their survival against cytotoxic chem",2,National Center for Advancing Translational Sciences (NCATS),nrf2-f2-buglite,20130718,"1821,2199,2471,2569,3197,3370,3373,3384,3640,3641,3800,3832,3879,4112,4159,4605,4749,4894,4895,5153,5303,5614,5743,5744,5748,5753,5754,5755,5834,5877,6062,6114,6185,6197,6245,6741,6842,9279,9427,9782,10063,15478,16623,16888,20279,20469,24360,24466,25050,26133,31307,47508,51703,53277,54368,72402,72438,72512,73549,78545,80263,82498,91430,93149,94330,95069,95573,97265,99927,122723,152215,156816,159917,167683,174343,224001,225484,231422,233768,239596,243725,243849,247839,250948,253602,255762,260550,260976,26171","842526,842939,843683,844423,844482,844547,845318,845384,846220,847393,848028,848239,848536,848607,848734,848966,849061,849912,851321,853048,853098,853519,855532,855547,855549,855645,855810,855836,856030,856330,856949,857195,857389,857793,858016,858068,858151,859170,859461,861121,861351,861528,861945,861959,862424,862630,862638,862725,862811,862844,863423,865680,3711739,3714359,3714493,3714755,3714791,3715727,3716076,3716390,3716421,3717484,3717602,4240766,4240844,4240903,4241408,4242629,4242881,4243143,4243",4780,NULL,NP_001138884,Governmental Organizations|NIH Initiatives,"16959974,18692501",0,10.1053/j.gastro.2008.06.082|10.1126/science.1133427,NULL,Q16236,NULL
720540,2,qHTS for Inhibitors of the Phosphatase Activity of Eya2: Confirmatory Assay for Cherry-picked Compounds,"The Eya protein family is an essential co-activator of the Six1 transcription factor. Six1 is a developmental gene that is abnormally re-expressed in a large percentage of breast cancers. This over-expression plays a causal role in the initiation and metastatic development of breast cancers. The Eya family of protein is also found to contain a unique HAD phosphatase domain with protein tyrosine phosphatase activity which can potentially play a role in Six1-mediated breast tumorigenesis. Recently, Eya2 is fo",2,National Center for Advancing Translational Sciences (NCATS),eya2-six1-f2-cherrypick,20130720,"403,1489,2794,3468,3568,3702,3815,4139,4375,4485,5291,6053,6706,7589,9305,9363,14749,16414,16888,19604,21796,26248,27582,31553,31772,38853,41206,61336,63204,66068,67954,68939,71018,81124,82917,83650,86911,87247,91731,94388,95307,98136,98148,99051,107794,115824,124496,159917,176170,219274,219926,220284,224068,224895,224930,225181,227197,244118,246666,247668,248874,251983,255686,256073,256312,260314,260550,265594,267862,272529,273436,273769,274104,274108,274127,274337,277054,277067,277468,278037,278718,279589","842321,842532,842819,844586,845995,847875,849591,850759,851548,852004,852804,853199,853477,855680,855829,857451,861034,861480,862176,862356,862796,865118,3711479,3713285,3713366,3713430,3713780,3714059,3714126,3715878,3716728,4240600,4242820,4243274,4243465,4244208,4244262,4247581,4249141,4249468,4249540,4249753,4250073,4250429,4252061,4255294,4255861,4257657,4258072,4259634,4259639,4259997,4260267,4262635,4263755,4264898,4265306,4265790,7965363,7966526,7966862,7966923,7967771,7969166,7969414,7969817,796990",2139,NULL,NP_005235,Governmental Organizations|NIH Initiatives,22820394,0,10.1177/1087057112453936,3.1.3.48,O00167,NULL
720541,2,qHTS for Inhibitors of the Phosphatase Activity of Eya2: Carboxyl-terminal binding protein (CtBP) Counterscreen for Cherry-picked Compounds,"The Eya protein family is an essential co-activator of the Six1 transcription factor. Six1 is a developmental gene that is abnormally re-expressed in a large percentage of breast cancers. This over-expression plays a causal role in the initiation and metastatic development of breast cancers. The Eya family of protein is also found to contain a unique HAD phosphatase domain with protein tyrosine phosphatase activity which can potentially play a role in Six1-mediated breast tumorigenesis. Recently, Eya2 is fo",2,National Center for Advancing Translational Sciences (NCATS),Eya2-six1-f2-CtBP,20130720,"403,1489,2794,3468,3568,3702,3815,4139,4375,4485,5291,6053,6706,7589,9305,9363,14749,16414,16888,19604,21796,26248,27582,31553,31772,38853,41206,61336,63204,66068,67954,68939,71018,81124,82917,83650,86911,87247,91731,94388,95307,98136,98148,99051,107794,115824,124496,159917,176170,219274,219926,220284,224068,224895,224930,225181,227197,244118,246666,247668,248874,251983,255686,256073,256312,260314,260550,265594,267862,272529,273436,273769,274104,274108,274127,274337,277054,277067,277468,278037,278718,279589","842321,842532,842819,844586,845995,847875,849591,850759,851548,852004,852804,853199,853477,855680,855829,857451,861034,861480,862176,862356,862796,865118,3711479,3713285,3713366,3713430,3713780,3714059,3714126,3715878,3716728,4240600,4242820,4243274,4243465,4244208,4244262,4247581,4249141,4249468,4249540,4249753,4250073,4250429,4252061,4255294,4255861,4257657,4258072,4259634,4259639,4259997,4260267,4262635,4263755,4264898,4265306,4265790,7965363,7966526,7966862,7966923,7967771,7969166,7969414,7969817,796990",1487,NULL,Q13363,Governmental Organizations|NIH Initiatives,22820394,0,10.1177/1087057112453936,1.1.1.-,Q13363,NULL
720523,2,Nrf2 qHTS screen for inhibitors: A549 ARE-Fluc Cytotoxicity Counterscreen for Hit Validation,"Nrf2 is a transcription factor that maintains cellular redox homoestasis and protects cells from xenobiotics [1, 2]. Nrf2 binds to the antioxidant response element (ARE) to induce gene expression of a broad spectrum of genes that encode for antioxidants. Hence this Nrf2 pathway provides a first line of defense against stress caused by exposure to radiation, electrophiles, and xenobiotics. In many cancers it has been found that tumor cells manipulate the Nrf2 pathway for their survival against cytotoxic chem",2,National Center for Advancing Translational Sciences (NCATS),nrf2-f2-cytotox,20130718,"1821,2199,2471,2569,3197,3370,3373,3384,3640,3641,3800,3832,3879,4112,4159,4605,4749,4894,4895,5153,5303,5614,5743,5744,5748,5753,5754,5755,5834,5877,6062,6114,6185,6197,6245,6741,6842,9279,9427,9782,10063,15478,16623,16888,20279,20469,24360,24466,25050,26133,31307,47508,51703,53277,54368,72402,72438,72512,73549,78545,80263,82498,91430,93149,94330,95069,95573,97265,99927,122723,152215,156816,159917,167683,174343,224001,225484,231422,233768,239596,243725,243849,247839,250948,253602,255762,260550,260976,26171","842526,842939,843683,844423,844482,844547,845318,845384,846220,847393,848028,848239,848536,848607,848734,848966,849061,849912,851321,853048,853098,853519,855532,855547,855549,855645,855810,855836,856030,856330,856949,857195,857389,857793,858016,858068,858151,859170,859461,861121,861351,861528,861945,861959,862424,862630,862638,862725,862811,862844,863423,865680,3711739,3714359,3714493,3714755,3714791,3715727,3716076,3716390,3716421,3717484,3717602,4240766,4240844,4240903,4241408,4242629,4242881,4243143,4243",NULL,Toxicity,NULL,Governmental Organizations|NIH Initiatives,"16959974,18692501",0,10.1053/j.gastro.2008.06.082|10.1126/science.1133427,NULL,NULL,NULL
720538,2,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,"Lysosomal storage diseases (LSDs) are caused by genetic mutations in genes encoding proteins important for normal lysosomal function.  In affected patients, symptoms are usually not manifested unless the mutations result in more than 90% reduction of enzymatic activity of a specific lysosomal enzyme. Lysosomal dysfunction can be prevented and the disease process may be arrested and/or significantly reversed if the enzyme activity is increased above the critical threshold (~10%) [1,2]. Small molecules could ",2,National Center for Advancing Translational Sciences (NCATS),asa1-v2,20130725,"119,138,178,199,237,247,249,275,286,289,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,1820","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616,90340617",410,NULL,BAH11167,Governmental Organizations|NIH Initiatives,"1348043,18095864,18339182",0,10.1007/bf00219337|10.1111/j.1651-2227.2008.00648.x|10.1515/bc.2008.009,NULL,BAH11167,NULL
720522,2,Nrf2 qHTS screen for inhibitors: Purified Fluc Biochemical Counterscreen for Hit Validation,"Nrf2 is a transcription factor that maintains cellular redox homoestasis and protects cells from xenobiotics [1, 2]. Nrf2 binds to the antioxidant response element (ARE) to induce gene expression of a broad spectrum of genes that encode for antioxidants. Hence this Nrf2 pathway provides a first line of defense against stress caused by exposure to radiation, electrophiles, and xenobiotics. In many cancers it has been found that tumor cells manipulate the Nrf2 pathway for their survival against cytotoxic chem",2,National Center for Advancing Translational Sciences (NCATS),nrf2-f2-fluc,20130718,"1821,2199,2471,2569,3197,3370,3373,3384,3640,3641,3800,3832,3879,4112,4159,4605,4749,4894,4895,5153,5303,5614,5743,5744,5748,5753,5754,5755,5834,5877,6062,6114,6185,6197,6245,6741,6842,9279,9427,9782,10063,15478,16623,16888,20279,20469,24360,24466,25050,26133,31307,47508,51703,53277,54368,72402,72438,72512,73549,78545,80263,82498,91430,93149,94330,95069,95573,97265,99927,122723,152215,156816,159917,167683,174343,224001,225484,231422,233768,239596,243725,243849,247839,250948,253602,255762,260550,260976,26171","842526,842939,843683,844423,844482,844547,845318,845384,846220,847393,848028,848239,848536,848607,848734,848966,849061,849912,851321,853048,853098,853519,855532,855547,855549,855645,855810,855836,856030,856330,856949,857195,857389,857793,858016,858068,858151,859170,859461,861121,861351,861528,861945,861959,862424,862630,862638,862725,862811,862844,863423,865680,3711739,3714359,3714493,3714755,3714791,3715727,3716076,3716390,3716421,3717484,3717602,4240766,4240844,4240903,4241408,4242629,4242881,4243143,4243",NULL,Biochemical,ABM67533,Governmental Organizations|NIH Initiatives,"16959974,18692501",0,10.1053/j.gastro.2008.06.082|10.1126/science.1133427,NULL,ABM67533,NULL
720569,2,qHTS of Trypanosoma Brucei Inhibitors: Confirmatory Assay for Cherry-picked Compounds,"Members of the Trypanosomatidae family of parasitic protozoans cause a spectrum of diseases throughout the tropical and subtropical world. Sleeping sickness, caused by two subspecies of Trypanosoma brucei, is endemic to areas of sub-Saharan Africa, while Chagas' disease, a manifestation of Trypanosoma cruzi infection, is prevalent throughout Central and South America. In addition, many species of Leishmania are responsible for a range of cutaneous and visceral diseases, causing ulcers, destructive lesions a",2,National Center for Advancing Translational Sciences (NCATS),TbPyK-f2,20130813,"2064,2268,3194,7573,7619,8507,10603,16955,20992,37534,68485,76567,85517,85555,86926,94986,96672,96967,97410,99844,100519,181167,219296,220284,222515,222761,225407,234827,236184,236275,236589,236794,238781,241808,243251,243574,245097,247304,247652,248597,250583,254021,261066,262395,263521,263522,264630,267286,267626,268524,269249,269257,269582,270378,275191,275263,276581,276685,281376,282598,282938,284471,288807,297961,304835,308654,313603,313614,314728,315063,319938,320930,322570,323616,324415,324518,327741","842400,842534,842605,843090,843966,844060,844223,844849,845056,845982,848247,848370,849645,850087,850352,850662,851590,852024,852341,852826,853234,853276,853478,856093,856503,856627,856656,857499,858047,858258,858303,858812,859661,860907,861120,862225,864015,864052,864518,865277,865482,865589,865860,865874,3711717,3712030,3712084,3712150,3712884,3713011,3713060,3716553,3717524,3717542,3717898,3717903,4241367,4241399,4241466,4241904,4242649,4244856,4245118,4245610,4245916,4247670,4250067,4250086,4250263,4251",NULL,NULL,AAX80043,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAX80043,NULL
720501,2,qHTS for Inhibitors of Polymerase Kappa: Confirmatory Assay for Cherry-picked Compounds,"The processing and repair of DNA inter-strand crosslinks (ICL) in eukaryotic cells are extremely complex, potentially involving multiple DNA repair and damage tolerance pathways, including homologous recombination, nucleotide excision repair, translesion synthesis (TLS), and cell cycle checkpoints. In some repair models, the dually-incised strand possesses sufficient mobility that a DNA polymerase can strand displace the nucleotide patch that is 5' to the lesion, then replicate past the ICL site to complete",2,National Center for Advancing Translational Sciences (NCATS),pol-kappa-ases-set-p1_selec,20130709,"3197,4212,6683,6842,7085,8323,8408,10168,14169,14313,14710,31475,32875,62770,66671,67062,67065,67074,68106,68207,72571,80175,80458,80629,85485,85517,92993,94104,96506,96927,97167,97509,105671,112939,122734,125322,139991,150655,213329,219926,224560,227197,235240,235574,235598,239578,240646,247668,248874,252682,254859,264630,268237,269582,270505,275253,277512,278675,280615,280616,280618,281416,313614,317587,319089,320930,321186,331140,335352,360404,368865,371509,377971,378196,379559,381594,382447,386018,38651","855879,857345,857588,857868,861705,865879,4242102,4254995,4256018,4259217,7971429,7974131,7974348,7975446,7977855,14720891,14724300,14724712,14725275,14729412,14729514,14729515,14730237,14730322,14730936,14732465,14737522,14740573,14740840,14740923,14741773,14743503,14745409,14745443,14746772,14746975,16953239,17385789,17385974,17388495,17401661,17403457,17403487,17408998,17410781,17413990,17415263,17415796,17416013,17416093,17431724,17431860,17431927,17432329,17432420,17432859,17434007,17434033,17503807,17",51426,NULL,NP_057302,Governmental Organizations|NIH Initiatives,23056190,0,10.1371/journal.pone.0045032,2.7.7.7,Q9UBT6,NULL
720573,2,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),"Parkin is an E3 ubiquitin ligase localized in the cytosol of cells expressed in many tissues, including brain, skeletal muscle, heart and liver tissues.  One hour after stress induction by mitochondrial uncouplers (which mimic mitochondria damage by decreasing the mitochondrial inner membrane electrochemical gradient that is used to produce ATP), Parkin translocates from the cytosol to mitochondria in many cultured cell types, including neurons and HeLa cells [1].  Administration of other mitochondrial pois",2,National Center for Advancing Translational Sciences (NCATS),ParkinXPR-LOPAC-fluc,20130814,"119,138,178,199,237,247,249,275,286,289,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,1820","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616,90340617",5071,NULL,BAA25751,Governmental Organizations|NIH Initiatives,"19029340,20547844,23018994",0,10.1038/nmeth.2170|10.1073/pnas.0914569107|10.1083/jcb.200809125,NULL,BAA25751,NULL
720584,2,qHTS of Trypanosoma Brucei Inhibitors: Orthogonal Assay for Cherry-picked Compounds,"Members of the Trypanosomatidae family of parasitic protozoans cause a spectrum of diseases throughout the tropical and subtropical world. Sleeping sickness, caused by two subspecies of Trypanosoma brucei, is endemic to areas of sub-Saharan Africa, while Chagas' disease, a manifestation of Trypanosoma cruzi infection, is prevalent throughout Central and South America. In addition, many species of Leishmania are responsible for a range of cutaneous and visceral diseases, causing ulcers, destructive lesions a",2,National Center for Advancing Translational Sciences (NCATS),TbPyK-f2-adpglo,20130822,"2064,2268,3194,7573,7619,8507,10603,16955,20992,37534,68485,76567,85517,85555,86926,94986,96672,96967,97410,99844,100519,181167,219296,220284,222515,222761,225407,234827,236184,236275,236589,236794,238781,241808,243251,243574,245097,247304,247652,248597,250583,254021,261066,262395,263521,263522,264630,267286,267626,268524,269249,269257,269582,270378,275191,275263,276581,276685,281376,282598,282938,284471,288807,297961,304835,308654,313603,313614,314728,315063,319938,320930,322570,323616,324415,324518,327741","842400,842534,842605,843090,843966,844060,844223,844849,845056,845982,848247,848370,849645,850087,850352,850662,851590,852024,852341,852826,853234,853276,853478,856093,856503,856627,856656,857499,858047,858258,858303,858812,859661,860907,861120,862225,864015,864052,864518,865277,865482,865589,865860,865874,3711717,3712030,3712084,3712150,3712884,3713011,3713060,3716553,3717524,3717542,3717898,3717903,4241367,4241399,4241466,4241904,4242649,4244856,4245118,4245610,4245916,4247670,4250067,4250086,4250263,4251",NULL,NULL,AAX80043,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAX80043,NULL
720498,2,qHTS Assay for the Inhibitors of FEN1: Confirmatory Assay for Cherry-picked Compounds,"The major human flap endonuclease FEN1 is an efficient structure-specific enzyme that recognizes and cleaves a 5'-unannealed DNA flap. It belongs to the RAD2 family nucleases, which are involved in DNA metabolism and are highly conserved in prokaryotes and eukaryotes. FEN1 is a key enzyme in DNA replication, repair and maintenance of genomic stability. 5'-flap removal by FEN1 is critical for Okazaki fragment processing during lagging strand DNA synthesis, long-patch base excision repair (LP BER), and regula",2,National Center for Advancing Translational Sciences (NCATS),fen1-ases-set-p1_selected,20130716,"3197,3634,4212,4971,6047,6293,6683,6701,8321,8323,8408,9305,10168,10603,14169,14710,18834,22650,23533,32875,38853,40304,43640,47508,60063,62770,67062,67065,67485,68106,68207,73024,73677,75583,76357,77917,83156,83851,85517,97167,97688,100058,108155,112939,122815,124496,125322,145758,149800,150655,174343,176170,182785,182791,185146,188677,213329,219926,227197,231363,232570,233538,235598,245581,246666,247351,257702,258841,259213,263534,264630,265436,265522,266432,272112,272269,274108,276191,278675,281355,28137","846098,852091,852615,855879,857194,857319,857795,857966,858569,861947,862346,862604,862910,3711664,4241310,4241391,4242272,4245784,4250541,4258396,4259318,4260569,7967796,7968423,7969338,7969625,7971429,7972392,7972659,7973721,7974229,7975124,7975176,8139902,8139971,11532916,14720806,14722136,14722375,14724300,14727580,14727861,14728391,14731349,14731723,14732338,14732615,14733092,14734093,14735143,14735407,14735408,14737088,14737782,14737910,14739565,14742355,14742430,14745194,14745211,14745409,14745573,14",2237,NULL,NP_004102,Governmental Organizations|NIH Initiatives,21062821,0,10.1093/nar/gkq1082,3.1.-.-,P39748,NULL
720559,2,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,"The A-beta peptide is produced by the processing of the amyloid precursor protein (APP) by two proteases, beta and gamma secretases [1, 2]. These enzymatic processes generate multiple A-beta isoforms, most notably A-beta40 and A-beta42, and these isoforms are major constituents of amyloid plaques found in the brain regions of AD patients. A-beta42 is regarded as the most amyloidogenic form due to its hydrophobicity; however, precisely how A-beta42 induces neurotoxicity is unclear. To understand further this",2,National Center for Advancing Translational Sciences (NCATS),Abeta-yeast-LOPAC,20130806,"119,138,178,199,237,247,249,275,286,289,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,1820","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616,90340617",351,Toxicity,P05067,Governmental Organizations|NIH Initiatives,"10531052,10591213",0,10.1038/990107|10.1126/science.286.5440.735,NULL,P05067,NULL
720572,2,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),"Parkin is an E3 ubiquitin ligase localized in the cytosol of cells expressed in many tissues, including brain, skeletal muscle, heart and liver tissues.  One hour after stress induction by mitochondrial uncouplers (which mimic mitochondria damage by decreasing the mitochondrial inner membrane electrochemical gradient that is used to produce ATP), Parkin translocates from the cytosol to mitochondria in many cultured cell types, including neurons and HeLa cells [1].  Administration of other mitochondrial pois",2,National Center for Advancing Translational Sciences (NCATS),ParkinXPR-LOPAC-NLuc,20130814,"119,138,178,199,237,247,249,275,286,289,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,1820","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616,90340617",5071,NULL,BAA25751,Governmental Organizations|NIH Initiatives,"19029340,20547844,23018994",0,10.1038/nmeth.2170|10.1073/pnas.0914569107|10.1083/jcb.200809125,NULL,BAA25751,NULL
720575,2,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV):  Confirmation Assay for Cherry-picked Compounds,"Hepatitis C virus (HCV) infects about 200 million people in the world. Many infected people progress to chronic liver disease including cirrhosis with a risk of developing liver cancer. To date, there is no effective vaccine for hepatitis C. Current therapy based on interferon is only effective in about half of the patients and is associated with significant adverse effects. The fraction of people with HCV who can complete a successful treatment is estimated to be no more than 10 percent. Recent development",2,National Center for Advancing Translational Sciences (NCATS),hcv-replication-f1-2luc,20130815,"6741,8975,9283,10829,13195,13266,42640,50248,70848,82498,92806,197690,227530,231867,245079,248206,253602,257940,259513,259932,270995,273034,276258,276294,328144,377877,384400,389753,391131,436059,517348,571869,601428,624750,630988,645037,645969,646236,649143,649384,649589,651078,651192,651338,651357,652435,653126,653216,654534,656070,657306,658425,658668,658734,659872,659904,660572,661087,661336,662595,663466,663896,664212,665110,665670,665899,666697,666991,667087,667380,676047,687985,704682,710698,712598,7","842762,843666,844956,846141,846750,846989,847191,848734,848874,848895,849923,850293,850596,850687,851928,853415,857065,857319,857389,858563,858597,859273,859785,860029,860940,861345,862243,862974,863328,863857,864423,864658,865443,865730,865827,866121,3711225,3711742,3711761,3711875,3712877,3713679,3713837,3717003,3717484,3717529,3717810,4240761,4240983,4241033,4241526,4241879,4242876,4243046,4243143,4243806,4243897,4244220,4245437,4246922,4247205,4247500,4247541,4248927,4249626,4249927,4250276,4251763,4252",NULL,NULL,BAJ07247,Governmental Organizations|NIH Initiatives,23836237,0,10.1038/nm.3183,NULL,BAJ07247,NULL
720576,2,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV):  Cytotoxicity  Counterscreen for Cherry-picked Compounds,"Hepatitis C virus (HCV) infects about 200 million people in the world. Many infected people progress to chronic liver disease including cirrhosis with a risk of developing liver cancer. To date, there is no effective vaccine for hepatitis C. Current therapy based on interferon is only effective in about half of the patients and is associated with significant adverse effects. The fraction of people with HCV who can complete a successful treatment is estimated to be no more than 10 percent. Recent development",2,National Center for Advancing Translational Sciences (NCATS),hcv-replication-f1-2atp,20130815,"6741,8975,9283,10829,13195,13266,42640,50248,70848,82498,92806,197690,227530,231867,245079,248206,253602,257940,259513,259932,270995,273034,276258,276294,328144,377877,384400,389753,391131,436059,517348,571869,601428,624750,630988,645037,645969,646236,649143,649384,649589,651078,651192,651338,651357,652435,653126,653216,654534,656070,657306,658425,658668,658734,659872,659904,660572,661087,661336,662595,663466,663896,664212,665110,665670,665899,666697,666991,667087,667380,676047,687985,704682,710698,712598,7","842762,843666,844956,846141,846750,846989,847191,848734,848874,848895,849923,850293,850596,850687,851928,853415,857065,857319,857389,858563,858597,859273,859785,860029,860940,861345,862243,862974,863328,863857,864423,864658,865443,865730,865827,866121,3711225,3711742,3711761,3711875,3712877,3713679,3713837,3717003,3717484,3717529,3717810,4240761,4240983,4241033,4241526,4241879,4242876,4243046,4243143,4243806,4243897,4244220,4245437,4246922,4247205,4247500,4247541,4248927,4249626,4249927,4250276,4251763,4252",NULL,Toxicity,NULL,Governmental Organizations|NIH Initiatives,23836237,0,10.1038/nm.3183,NULL,NULL,NULL
720591,2,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_Dose_CherryPick_Activity_Set5,"Keywords: SirT-5, NAD-dependent desuccinylase and demalonylase, succinyl lysine modification, malonyl lysine modification, transcriptional and metabolic regulation._|__|_Assay Overview: This work aims to develop a high-throughput assay to find/screen for specific inhibitors of SirT-5 which can be used to study the biological function of SirT-5.  This includes the function of two novel SirT-5 protein post-translational modifications, lysine succinylation and malonylation._|__|_Expected Outcome: This assay ut",31,Broad Institute,7044-01_Inhibitor_Dose_CherryPick_Activity_Set5,20130827,"10168,10653,63441,66856,71014,95050,99749,134453,139369,221107,221162,223570,226671,227967,239538,240009,252682,266835,304923,307173,308468,342202,412741,519684,531951,555301,559927,581843,599759,600567,613179,613677,614315,617491,645434,646764,647036,647582,648080,648213,648620,650104,650129,650135,650479,650534,651822,652112,652467,652779,652985,653185,654775,654798,657880,658972,659792,664699,665032,666813,669311,670756,671565,679638,680129,699701,706601,713796,715695,722483,727274,727650,727889,730978,7","842766,843156,843465,844438,844706,845718,847695,847726,848055,848111,849333,849614,849957,850262,850464,850655,852162,852185,855879,856523,857542,857624,858479,858653,863447,863776,865554,3713477,3713515,3713907,3716705,4243531,4245222,4246895,4247108,4247757,4247936,4248778,4249639,4250762,4255550,4259098,4259139,4259247,4259747,4261396,4261835,4262901,4265420,7964808,7965512,7966519,7967038,7969539,7971401,7971898,7972807,7972947,7974933,7975343,7975727,14721193,14721217,14721457,14721465,14721696,147226",23408,Biochemical,Q9NXA8,NIH Initiatives,"21151122,22076378",0,10.1038/nchembio.495|10.1126/science.1207861,2.3.1.-,Q9NXA8,NULL
720503,2,qHTS for Inhibitors of WRN Helicase: BLM Helicase Counterscreen for WRN Inhibitors,"Inhibition of DNA repair is proposed as a strategy for combating cancer. Synthetic lethality is an approach that exploits preexisting DNA repair deficiencies in certain tumors to develop inhibitors of DNA repair pathways that compensate for the tumor-associated DNA repair deficiency. Because helicases play critical roles in the DNA damage response and in DNA repair, particularly in actively dividing and replicating cells, characterization of synthetic lethal relationships of DNA helicases may be of value in",2,National Center for Advancing Translational Sciences (NCATS),WRN-helicase-BLM-f1,20130709,"3197,4212,6047,6842,7141,32875,49659,62770,83851,125322,151582,219926,222761,225421,227197,230132,235240,235598,236065,236584,237102,237490,248466,248894,254021,254824,263521,264630,265898,267626,268499,268649,268807,268953,269582,274108,275191,276685,282594,291363,314728,317587,319846,331140,333459,335352,348896,360404,367851,376179,378196,379559,381594,382447,386517,388993,421105,427839,429575,429643,432465,432873,434797,445027,496451,540335,557197,602926,645041,646522,649290,651779,654283,658024,659329,6","842767,843770,844210,846897,849302,851690,856673,857486,857522,857981,861273,861471,861705,862800,863306,863408,863840,3713060,3714133,3714388,3717399,3717577,4241419,4243236,4243472,4245703,4245926,4258396,4259932,4260569,4260677,4262953,4264440,7969625,7972893,7974348,7975003,7975176,7975612,7976138,11532916,14718751,14720780,14720803,14722136,14724300,14726494,14727398,14727861,14728076,14728200,14729217,14729238,14730425,14730721,14730783,14731723,14732338,14732383,14732902,14733025,14733092,14733837,14",641,NULL,NP_000048,Governmental Organizations|NIH Initiatives,NULL,0,NULL,3.6.4.12,P54132,NULL
720497,2,qHTS for Inhibitors of WRN Helicase: Confirmatory Assay for Cherry-picked Compounds.,"Inhibition of DNA repair is proposed as a strategy for combating cancer. Synthetic lethality is an approach that exploits preexisting DNA repair deficiencies in certain tumors to develop inhibitors of DNA repair pathways that compensate for the tumor-associated DNA repair deficiency. Because helicases play critical roles in the DNA damage response and in DNA repair, particularly in actively dividing and replicating cells, characterization of synthetic lethal relationships of DNA helicases may be of value in",2,National Center for Advancing Translational Sciences (NCATS),WRN-helicase-f1-selec,20130709,"3197,4212,6047,6842,7141,32875,49659,62770,83851,125322,151582,219926,222761,225421,227197,230132,235240,235598,236065,236584,237102,237490,248466,248894,254021,254824,263521,264630,265898,267626,268499,268649,268807,268953,269582,274108,275191,276685,282594,291363,314728,317587,319846,331140,333459,335352,348896,360404,367851,376179,378196,379559,381594,382447,386517,388993,421105,427839,429575,429643,432465,432873,434797,445027,496451,540335,557197,602926,645041,646522,649290,651779,654283,658024,659329,6","842767,843770,844210,846897,849302,851690,856673,857486,857522,857981,861273,861471,861705,862800,863306,863408,863840,3713060,3714133,3714388,3717399,3717577,4241419,4243236,4243472,4245703,4245926,4258396,4259932,4260569,4260677,4262953,4264440,7969625,7972893,7974348,7975003,7975176,7975612,7976138,11532916,14718751,14720780,14720803,14722136,14724300,14726494,14727398,14727861,14728076,14728200,14729217,14729238,14730425,14730721,14730783,14731723,14732338,14732383,14732902,14733025,14733092,14733837,14",7486,NULL,AAC63361,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAC63361,NULL
720519,2,qHTS for Inhibitors of Cell Surface uPA Generation: Confirmatory Assay for Cherry-picked Compounds,"The overall objective of this project is to perform a quantitative high throughput screen (qHTS) to identify novel compounds that inhibit the generation of cell surface urokinase activity. The urokinase plasminogen activator (uPA) is one of the two primary endogenous systems that mediate plasminogen activation into plasmin. Members of this system, including uPA and its receptor (uPAR), are overexpressed in several malignant tumors. This system plays a major role in adhesion, migration, invasion and metastas",2,National Center for Advancing Translational Sciences (NCATS),upa-mem-PA-U2_LF,20130718,"335,1892,2181,3690,4612,6769,6842,17134,31772,40235,57469,69602,71399,95240,100492,108667,114961,167972,224264,238991,240843,246357,261413,261536,288336,324088,373871,379950,399616,404470,404472,428373,442437,452029,455821,462454,496073,573345,584360,618993,628002,640114,644835,646843,647809,647878,657287,658900,663861,665344,667476,667493,671866,679950,680195,700577,702539,706052,714032,719590,736267,752131,752353,755367,756704,765638,768298,772318,774802,776184,776639,785958,789929,792601,792632,799090,81","842566,844516,845957,855754,857546,862627,864094,865810,3712293,3712587,3715637,3715693,3716134,3716951,4260737,4264733,7965208,7965410,7965483,7965572,7965861,7966233,7966325,7966564,7966675,7966744,7966961,7967266,7968167,7968320,7968378,7968631,7969164,7969288,7969632,7969648,7969686,7969976,7970138,7970164,7970291,7970424,7970460,7970475,7970517,7970825,7970935,7971768,7973996,7976693,7977775,11533006,14718882,14721161,14721361,14723131,14723554,14724759,14728576,14729390,14729979,14732096,14732562,1473",5328,NULL,NP_002649,Governmental Organizations|NIH Initiatives,19377967,0,10.1007/978-1-60327-003-8_7,3.4.21.73,P00749,NULL
720658,1,Fluorescence polarization-based biochemical high throughput confirmation assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute_|_Assay Provider: Ben Cravatt, The Scripps Research Institute_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R01 DA033760_|_Grant Proposal PI: Ben Cravatt, The Scripps Research Institute_|_External Assay ID: ABHD4_INH_FP_1536_3X%INH CRUN_|__|_Name: Fluorescence polarization-based biochemical high throughput confi",5,The Scripps Research Institute Molecular Screening Center,ABHD4_INH_FP_1536_3X%INH CRUN,20131018,"1369,2215,2794,3396,3728,4212,5154,6099,6293,6683,6824,6825,6842,6868,7141,7421,7564,7573,8321,8323,8478,8816,9305,9922,10603,11106,11951,14710,16955,19379,22324,26248,26964,31280,32875,40586,62770,65324,66671,66672,66732,67074,68207,68485,70837,72512,72571,72725,73024,74491,75583,77258,80417,83851,85485,85895,87615,87935,93572,95223,96506,96673,97167,97688,99342,99844,101486,112939,113052,128355,131411,152086,161385,164676,174343,176170,182785,199391,202512,213331,216328,220284,221193,222091,222515,222761,","844076,845056,846670,846693,847214,848113,850858,850965,851690,852150,852707,855540,855570,855593,855609,855650,855680,855713,855829,856223,856589,857091,857212,857243,857297,857633,858170,858398,858859,859022,859133,859668,859770,860462,860897,861717,861740,862009,862254,862514,862594,863328,865268,865806,3712028,3714633,3715155,3716071,3716517,4245502,4247173,4251852,4254737,4255077,4255552,4255584,4255813,4257742,4257849,4259227,4259563,4259931,4259959,4260302,4261439,4261558,4261587,4261901,4262275,4264",105501,Biochemical,NP_598837,NIH Initiatives,"14634025,16605240,16818490,18429637,18446159,6726229,7126608",0,10.1016/0005-2760(82)90352-6|10.1021/bi060163l|10.1021/cr0782067|10.1038/nrd2553|10.1074/jbc.m306642200|10.1074/jbc.m604660200|10.1111/j.1471-4159.1984.tb12750.x,3.1.1.-,Q8VD66,NULL
720518,2,qHTS for Inhibitors of Cell Surface uPA Generation: Wild-type Protective Antigen (WT-PrAg) Counterscreen for Cherry-picked Compounds,"The overall objective of this project is to perform a quantitative high throughput screen (qHTS) to identify novel compounds that inhibit the generation of cell surface urokinase activity. The urokinase plasminogen activator (uPA) is one of the two primary endogenous systems that mediate plasminogen activation into plasmin. Members of this system, including uPA and its receptor (uPAR), are over expressed in several malignant tumors. This system plays a major role in adhesion, migration, invasion and metasta",2,National Center for Advancing Translational Sciences (NCATS),upa-mem-PA-WT_LF,20130717,"335,1892,2181,3690,4612,6769,6842,17134,31772,40235,57469,69602,71399,95240,100492,108667,114961,167972,224264,238991,240843,246357,261413,261536,288336,324088,373871,379950,399616,404470,404472,428373,442437,452029,455821,462454,496073,573345,584360,618993,628002,640114,644835,646843,647809,647878,657287,658900,663861,665344,667476,667493,671866,679950,680195,700577,702539,706052,714032,719590,736267,752131,752353,755367,756704,765638,768298,772318,774802,776184,776639,785958,789929,792601,792632,799090,81","842566,844516,845957,855754,857546,862627,864094,865810,3712293,3712587,3715637,3715693,3716134,3716951,4260737,4264733,7965208,7965410,7965483,7965572,7965861,7966233,7966325,7966564,7966675,7966744,7966961,7967266,7968167,7968320,7968378,7968631,7969164,7969288,7969632,7969648,7969686,7969976,7970138,7970164,7970291,7970424,7970460,7970475,7970517,7970825,7970935,7971768,7973996,7976693,7977775,11533006,14718882,14721161,14721361,14723131,14723554,14724759,14728576,14729390,14729979,14732096,14732562,1473",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,19377967,0,10.1007/978-1-60327-003-8_7,NULL,NULL,NULL
720632,2,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_Dose_CherryPick_Activity,"Keywords: Caspase 6, inhibitors, allosteric inhibitors, neurodegenerative disease_|__|__|_Assay Overview:_|_An assay was set up to monitor cleavage of of a fluorescent labeled peptide caspase susbtrate, Rhodamine 110, bis-(N-CBZ-L-Valyl-L-Glutamyl-L-Isoleucyl-L-Aspartic Acid Amide) (Z-VEID-R110). This caspase substrate is a derivative of the fluorophore rhodamine 110 (R110). Peptides are covalently linked to each of the amino groups on R110, which suppresses the fluorescence of the dye. When the peptides ar",31,Broad Institute,7052-01_Inhibitor_Dose_CherryPick_Activity,20130907,"86,4140,4813,5668,6084,6099,6868,9305,10709,19910,30923,38853,43231,60758,65303,66671,66672,67062,67074,71209,72571,73677,80444,80709,81423,85517,97167,103148,112939,185484,199799,219642,224275,224641,224810,224922,225906,235224,235551,235811,236064,237126,239930,244159,244633,245742,245928,247351,254722,254897,254944,260644,262391,265580,265661,269970,270995,271216,272361,278033,278810,279589,281376,281416,286554,291363,307686,313614,313619,316368,317587,317843,320930,321186,322539,323009,324140,349435,359","842874,855839,855961,858402,862121,864852,4241599,4242057,4242383,4242820,4245063,4245110,4247296,4249077,4250593,4251575,4256630,4259887,4262116,4263634,4264896,4265048,7967180,7969301,7971289,7971719,7972339,7973467,7975973,7977298,8139902,8139971,11532939,14722652,14723527,14727792,14730491,14730512,14733920,14734620,14734897,14736173,14736285,14739765,14744747,14744989,14745958,16952410,17388038,17401891,17413496,17431642,17431724,17433751,17504207,17504892,17506805,17507890,17507894,17508878,17512875,1",839,Biochemical,AAH04460,NIH Initiatives,NULL,0,NULL,NULL,P55212,NULL
720499,2,qHTS for Inhibitors of WRN Helicase: Thiazole Orange DNA Binding Counterscreen,"Inhibition of DNA repair is proposed as a strategy for combating cancer. Synthetic lethality is an approach that exploits preexisting DNA repair deficiencies in certain tumors to develop inhibitors of DNA repair pathways that compensate for the tumor-associated DNA repair deficiency. Because helicases play critical roles in the DNA damage response and in DNA repair, particularly in actively dividing and replicating cells, characterization of synthetic lethal relationships of DNA helicases may be of value in",2,National Center for Advancing Translational Sciences (NCATS),WRN-helicase-DNA-binding-f1,20130709,"3197,4212,6047,6842,7141,32875,49659,62770,83851,125322,151582,219926,222761,225421,227197,230132,235240,235598,236065,236584,237102,237490,248466,248894,254021,254824,263521,264630,265898,267626,268499,268649,268807,268953,269582,274108,275191,276685,282594,291363,314728,317587,319846,331140,333459,335352,348896,360404,367851,376179,378196,379559,381594,382447,386517,388993,421105,427839,429575,429643,432465,432873,434797,445027,496451,540335,557197,602926,645041,646522,649290,651779,654283,658024,659329,6","842767,843770,844210,846897,849302,851690,856673,857486,857522,857981,861273,861471,861705,862800,863306,863408,863840,3713060,3714133,3714388,3717399,3717577,4241419,4243236,4243472,4245703,4245926,4258396,4259932,4260569,4260677,4262953,4264440,7969625,7972893,7974348,7975003,7975176,7975612,7976138,11532916,14718751,14720780,14720803,14722136,14724300,14726494,14727398,14727861,14728076,14728200,14729217,14729238,14730425,14730721,14730783,14731723,14732338,14732383,14732902,14733025,14733092,14733837,14",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
720697,2,Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 2144-02_Inhibitor_Dose_CherryPick_Activity_Set2,"Keywords:  microRNA, miR-122, HCV, hepatoma Huh7_|__|__|_Assay Overview:  This assay tests for general mammalian cytotoxicity in a HEK293T cell line._|__|__|_Expected Outcome: Cytotoxicity would exhibit loss of signal as compared to neutral control wells.",31,Broad Institute,2144-02_Inhibitor_Dose_CherryPick_Activity_Set2,20131029,"5712,20231,20279,68363,80727,237195,254021,255329,306655,331342,348206,364824,401019,570353,644740,645981,646905,647738,649030,649478,650075,651054,651531,651738,653945,659078,659917,659940,660098,660434,662261,662619,663005,663048,663170,664962,665846,666575,666959,666972,667000,667108,678309,684592,688004,700862,714397,733165,750693,756939,759367,772256,779573,785909,787549,788410,798222,804847,805251,833065,836479,847813,849844,869163,869467,877422,882221,901979,907037,944701,951880,955142,971803,972880,","842476,843678,844578,845395,846634,847665,848599,849066,849261,851376,857720,858464,858611,858789,858862,859133,860987,861371,861727,861777,861826,861947,863710,864604,865321,865698,865711,865739,865848,3714761,3716869,4241510,4241547,4241611,4242974,4243407,4243664,4245273,4245463,4245617,4246159,4246732,4250565,4251140,4251800,4254508,4254899,4255741,4256499,4258250,4258769,4260748,4262159,4263485,4263793,4264531,4264774,4264952,7972164,7972489,7972933,7973071,7973704,7974583,7975045,7975962,7976428,79777",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
720597,2,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_Dose_CherryPick_Activity_Set6,"Keywords: SirT-5, NAD-dependent desuccinylase and demalonylase, succinyl lysine modification, malonyl lysine modification, transcriptional and metabolic regulation._|__|_Assay Overview: This work aims to develop a high-throughput assay to find/screen for specific inhibitors of SirT-5 which can be used to study the biological function of SirT-5.  This includes the function of two novel SirT-5 protein post-translational modifications, lysine succinylation and malonylation._|__|_Expected Outcome: This assay ut",31,Broad Institute,7044-01_Inhibitor_Dose_CherryPick_Activity_Set6,20130903,"718839,894153,894334,1071831,1349287,2254332,2969267,2980588,2980971,6484308,6622937,6729223,6729388,6729401,6730545,22581731,23748715,23806115,44202278,44202678,44202690,44202879,44246565,44483368,44483456,44483542,44483618,44483689,44484021,44484307,44484581,44484634,44484741,44484772,44484793,44484871,44485293,44485490,44485551,44485650,44486070,44486377,44486452,44486465,44486524,44486658,44486731,44487235,44487302,44487347,44487673,44487677,44487722,44487866,44487888,44487891,44487904,44487933,44487978","85789764,85789858,85789944,85790021,85790095,85790434,85790725,85791011,85791073,85791180,85791213,85791234,85791313,85791739,85791938,85792002,85792102,85792527,85792840,85792917,85792930,85792990,85793125,85793200,85793709,85793777,85793823,85794151,85794155,85794201,85794346,85794370,85794373,85794387,85794416,85794462,85794500,85794648,85794710,85794736,85794998,85795175,85795185,85795526,85795558,85795687,85795896,85795951,85795999,85796040,85796090,85796109,85796215,85796267,85796524,85796620,85796722",23408,Biochemical,Q9NXA8,NIH Initiatives,"21151122,22076378",0,10.1038/nchembio.495|10.1126/science.1207861,2.3.1.-,Q9NXA8,NULL
720517,2,qHTS for Inhibitors of Cell Surface uPA Generation: FP59 Counterscreen for Cherry-picked Compounds,"The overall objective of this project is to perform a quantitative high throughput screen (qHTS) to identify novel compounds that inhibit the generation of cell surface urokinase activity. The urokinase plasminogen activator (uPA) is one of the two primary endogenous systems that mediate plasminogen activation into plasmin. Members of this system, including uPA and its receptor (uPAR), are over expressed in several malignant tumors. This system plays a major role in adhesion, migration, invasion and metasta",2,National Center for Advancing Translational Sciences (NCATS),upa-mem-PA-WT_FP59,20130717,"335,1892,2181,3690,4612,6769,6842,17134,31772,40235,57469,69602,71399,95240,100492,108667,114961,167972,224264,238991,240843,246357,261413,261536,288336,324088,373871,379950,399616,404470,404472,428373,442437,452029,455821,462454,496073,573345,584360,618993,628002,640114,644835,646843,647809,647878,657287,658900,663861,665344,667476,667493,671866,679950,680195,700577,702539,706052,714032,719590,736267,752131,752353,755367,756704,765638,768298,772318,774802,776184,776639,785958,789929,792601,792632,799090,81","842566,844516,845957,855754,857546,862627,864094,865810,3712293,3712587,3715637,3715693,3716134,3716951,4260737,4264733,7965208,7965410,7965483,7965572,7965861,7966233,7966325,7966564,7966675,7966744,7966961,7967266,7968167,7968320,7968378,7968631,7969164,7969288,7969632,7969648,7969686,7969976,7970138,7970164,7970291,7970424,7970460,7970475,7970517,7970825,7970935,7971768,7973996,7976693,7977775,11533006,14718882,14721161,14721361,14723131,14723554,14724759,14728576,14729390,14729979,14732096,14732562,1473",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,19377967,0,10.1007/978-1-60327-003-8_7,NULL,NULL,NULL
720650,2,C. difficile toxins: Counterscreen in absence of substrate UDPG Measured in Biochemical System Using Plate Reader - 7074-02_Inhibitor_Dose_CherryPick_Activity,"Keywords: Clostridium difficile, toxin, virulence factors, TcdB, glycohydrolase, glucosyltransferase, uridine 5'-diphosphoglucuronic acid trisodium salt, glucose, EnzyChrom Glucose Assay Kit, non-specific inhibitors_|__|__|_Assay Overview:  The goal of this assay is to identify non-specific inhibitors to the coupled glucose oxidase/peroxidase kit (EnzyChrome Glucose Assay Kit, BioAssay Systems) used in a primary screen and retest at dose for inhibitors of C. difficile toxin B (TcdB) (AIDs 652162 and 720512)",31,Broad Institute,7074-02_Inhibitor_Dose_CherryPick_Activity,20131017,"1535,1983,4212,8765,10212,11972,52884,68094,72303,72323,72705,76819,79394,84572,96970,98192,98760,223470,223471,223840,229942,231835,232092,236664,237795,238099,239840,240699,242962,247486,252116,254454,254722,258436,261123,262310,265789,265904,266321,266629,266699,266913,267389,269248,272596,276244,277054,278808,279631,279650,279790,283716,287640,296474,306966,310764,324415,333139,333459,341818,376349,380572,385386,432873,432905,434797,458828,540240,542899,544979,556948,576570,596995,606772,608484,617669,6","842291,855593,857319,857461,857837,858863,860219,863447,3712368,3712613,3715357,4240686,4243487,4243749,4243761,4247757,4251530,4252055,4257031,4257471,4262073,7965143,7965289,7965645,7966727,7966896,7967094,7967248,7967925,7968269,7968488,7968777,7968783,7968950,7969856,7969885,7969984,7970618,7970781,7971180,7971463,7971638,7971744,7971937,7972433,7973632,7976009,14719349,14724839,14724844,14728955,14732316,14733295,14735238,14736580,14738287,14738288,14740266,14740992,14741623,14741636,14743644,14744194,",NULL,Biochemical,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
720690,2,Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 2144-02_Activator_Dose_CherryPick_Activity,"Keywords:  microRNA, miR-122, HCV, hepatoma Huh7_|__|_Assay Overview:  This assay tests for general mammalian cytotoxicity in a HEK293T cell line._|__|_Expected Outcome: Cytotoxicity would exhibit loss of signal as compared to neutral control wells.",31,Broad Institute,2144-02_Activator_Dose_CherryPick_Activity,20131028,"5712,20231,20279,68363,80727,237195,254021,255329,306655,331342,348206,364824,401019,570353,644740,645981,646905,647738,649030,649478,650075,651054,651531,651738,653945,659078,659917,659940,660098,660434,662261,662619,663005,663048,663170,664962,665846,666575,666959,666972,667000,667108,678309,684592,688004,700862,714397,733165,750693,756939,759367,772256,779573,785909,787549,788410,798222,804847,805251,833065,836479,847813,849844,869163,869467,877422,882221,901979,907037,944701,951880,955142,971803,972880,","842476,843678,844578,845395,846634,847665,848599,849066,849261,851376,857720,858464,858611,858789,858862,859133,860987,861371,861727,861777,861826,861947,863710,864604,865321,865698,865711,865739,865848,3714761,3716869,4241510,4241547,4241611,4242974,4243407,4243664,4245273,4245463,4245617,4246159,4246732,4250565,4251140,4251800,4254508,4254899,4255741,4256499,4258250,4258769,4260748,4262159,4263485,4263793,4264531,4264774,4264952,7972164,7972489,7972933,7973071,7973704,7974583,7975045,7975962,7976428,79777",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
720512,2,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_Dose_CherryPick_Activity,"Keywords: Clostridium difficile, toxin, virulence factors, TcdB, glycohydrolase, glucosyltransferase, uridine 5'-diphosphoglucuronic acid trisodium salt, glucose_|__|_Assay Overview:  The goal of this assay is to identify inhibitors to the C. difficile toxin B (TcdB), specifically to residues 1-549 that encodes the glycohydrolase and glucosyltransferase substrate binding and enzymatic domains.  Recombinant TcdB (expressed and purified from Bacillus megaterium) was assayed for glycohydrolase activity in the ",31,Broad Institute,7074-01_Inhibitor_Dose_CherryPick_Activity,20130926,"1535,1983,4212,8765,10212,11972,52884,68094,72303,72323,72705,76819,79394,84572,96970,98192,98760,223470,223471,223840,229942,231835,232092,236664,237795,238099,239840,240699,242962,247486,252116,254454,254722,258436,261123,262310,265789,265904,266321,266629,266699,266913,267389,269248,272596,276244,277054,278808,279631,279650,279790,283716,287640,296474,306966,310764,324415,333139,333459,341818,376349,380572,385386,432873,432905,434797,458828,540240,542899,544979,556948,576570,596995,606772,608484,617669,6","842291,855593,857319,857461,857837,858863,860219,863447,3712368,3712613,3715357,4240686,4243487,4243749,4243761,4247757,4251530,4252055,4257031,4257471,4262073,7965143,7965289,7965645,7966727,7966896,7967094,7967248,7967925,7968269,7968488,7968777,7968783,7968950,7969856,7969885,7969984,7970618,7970781,7971180,7971463,7971638,7971744,7971937,7972433,7973632,7976009,14719349,14724839,14724844,14728955,14732316,14733295,14735238,14736580,14738287,14738288,14740266,14740992,14741623,14741636,14743644,14744194,",4914074,Biochemical,YP_001087135,NIH Initiatives,NULL,0,NULL,NULL,YP_001087135,NULL
720491,2,HEK293 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-01_Inhibitor_Dose_CherryPick_Activity_Set2,"Keywords: Cytotoxicity Assay, cytotoxicity panel, HEK293_|__|__|_Assay Overview: The assay uses wild-type HEK293T cells from ATCC to counter screen for cytotoxicity at the same concentrations used to confirm compound activity in the primary screen._|__|_Expected Outcome: Compounds identified as hits will be toxic to cells at a compound concentration less than 10 uM. Activity in the assay leads to a reduction in cellular ATP levels which correlates with a decreased luminescence signal from the read reagent (",31,Broad Institute,7071-01_Inhibitor_Dose_CherryPick_Activity_Set2,20130701,"2474,63430,92163,558750,645541,645615,651983,652572,654294,655697,658117,665044,669781,692222,708636,721490,724119,773463,797087,800395,800756,833617,862679,872143,875397,875560,880674,891334,966816,967284,971121,991071,993512,1103777,1246653,1254616,1288168,1290900,1291981,1292253,1294250,1294866,1304063,1304174,1305458,1308454,1308688,1309768,1313016,1315019,1324355,1346587,1355632,1368283,1445469,1493952,1506500,1848903,1997013,2036865,2081728,2084777,2175488,2179404,2210360,2224487,2232159,2235946,22376","843260,843323,849489,849924,850061,851701,853056,856759,863788,4241016,4244867,4249163,4251428,4255287,4257711,4262509,4265313,7976261,7977524,7977663,11532855,14720798,14721120,14724098,14735139,14735614,14735996,14736543,14737767,14737815,14737821,14740443,16953010,16953177,17388109,17408203,17408964,17411939,17412397,17412514,17413128,17414156,17414830,17432577,17433598,17433638,17433754,17433794,17433830,17505592,17506614,17513006,17514066,22402115,22403081,22404035,22405554,22405735,22406780,22409230,2",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
720710,1,Break-induced replication repair of damaged forks induces genomic duplications in human cells,"Title: Break-induced replication repair of damaged forks induces genomic duplications in human cells_|__|_Abstract: In budding yeast, one-ended DNA double-strand breaks (DSBs) and damaged replication forks are repaired by break-induced replication (BIR), a homologous recombination pathway that requires the Pol32 subunit of DNA polymerase delta. DNA replication stress is prevalent in cancer, but BIR has not been characterized in mammals. In a cyclin E overexpression model of DNA replication stress, POLD3, th",62,VTT Technical Research Centre of Finland (CSMA),U2-OS-cyclinE-oncogene-DNA,20140114,NULL,"164221658,164221659,164221660,164221661,164221662,164221663,164221664,164221665,164221666,164221667,164221668,164221669,164221670,164221671,164221672,164221673,164221674,164221675,164221676,164221677,164221678,164221679,164221680,164221681,164221682,164221683,164221684,164221685,164221686,164221687,164221688,164221689,164221690,164221691,164221692,164221693,164221694,164221695,164221696,164221697,164221698,164221699,164221700,164221701,164221702,164221703,164221704,164221705,164221706,164221707,164221708,16","25,43,86,103,142,143,324,328,472,545,546,580,602,604,641,648,664,672,675,867,890,902,987,990,997,1017,1022,1026,1032,1054,1105,1106,1107,1111,1112,1149,1161,1387,1407,1408,1453,1454,1490,1642,1643,1647,1649,1663,1677,1729,1736,1763,1786,1788,1789,1791,1854,1877,1890,1950,2006,2067,2068,2069,2071,2072,2073,2074,2145,2146,2175,2176,2177,2178,2187,2188,2189,2237,2272,2309,2537,2547,2648,2735,2765,2794,2810,2956,2965,2966,2967,2968,3006,3007,3008,3009,3012,3013,3014,3018,3065,3066,3070,3146,3148,3151,3159,3162,",RNAi,NULL,Chemical Vendors,24310611,1,10.1126/science.1243211,NULL,NULL,NULL
720646,2,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-04_Inhibitor_Dose_CherryPick_Activity,"Keywords: _|_fibroblast growth factor (FGF), FGF22, FGF7, label-free Thermal Shift_|__|_Assay Overview:_|_A fluorescence-based thermal shift assay will be used to identify small molecule binders to FGF22.  This label-free approach is based on the principal of ligand-induced thermodynamic stabilization of proteins.  Changes in protein thermal stability can be induced by ligand binding, and these changes can be measured using an environmentally-sensitive fluorescent dye._|_Recombinant FGF22 is reconstituted i",31,Broad Institute,7012-04_Inhibitor_Dose_CherryPick_Activity,20131017,"1369,4788,4813,6890,68485,73677,78027,81268,95746,185484,185848,188323,201986,220929,221849,227518,230939,231437,238773,241899,243794,245533,261711,266734,286824,292351,307505,308950,310649,322494,342111,360219,376353,547574,564212,596204,649072,649089,698230,703254,707038,744384,751726,751906,755435,757946,759399,763210,763432,773093,774367,776591,778234,779647,787366,787560,790714,795488,839541,857262,888893,895866,901922,910973,935396,968625,972160,982708,984297,998046,1017937,1069065,1072991,1074696,107","846678,846696,4259169,4262687,7964792,7966523,7966653,7966855,14719362,14723446,14723466,14723502,14728506,14728611,14731834,14732503,14735492,14736405,14737550,14742889,14744734,14745037,17403270,17407237,17410476,17410688,17410881,17412318,17412625,17414396,17432431,17432653,17432703,17504086,17504768,17505003,17505920,17506987,17507234,17507322,17508168,17508512,17508666,17508708,17509142,17509557,17509732,17510336,17510789,17510997,17512160,17512229,17512733,17512797,17513728,17514557,17515020,17515891,",27006,Biochemical,NP_065688,NIH Initiatives,NULL,0,NULL,NULL,Q9HCT0,NULL
720589,2,HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_CherryPick_Activity_Set3,"Keywords:  Cytotoxicity Assay, luminescence, CellTiter-Glo, HepG2_|__|__|_Assay Overview: The cytotoxcity assay uses wild-type HepG2 cells from ATCC test for cytotoxicity.  The assay measures cellular ATP levels as a surrogate marker of cell viability with Pekin-Elmer CellTiter-Glo. Compound are tested at the same concentrations used in the primary assay._|__|__|_Expected Outcome: Compounds identified as actives were toxic to cells at a compound concentration less than 10 uM. Activity in the assay leads to ",31,Broad Institute,7071-02_Inhibitor_Dose_CherryPick_Activity_Set3,20130827,"1201,2361,2722,3598,3832,3879,4605,4993,5790,6185,6253,6256,9444,15478,17201,20345,22650,24466,25050,38777,54368,72139,74566,100596,101486,112939,126941,138252,147157,165528,220696,227456,238958,253289,253632,255887,257272,257275,262649,264884,269792,271216,274159,276294,279596,280522,280859,288101,295538,297344,300574,300942,310860,319846,328780,332767,332902,332905,334409,343097,346831,352429,367209,381371,384525,392613,396813,404406,407582,407583,415629,432465,434381,561606,580554,642384,657255,659499,69","855693,855854,858142,3715220,7964597,7967913,11533017,14734720,14737051,14740409,14744729,17401927,17408110,17409296,17432621,17432887,17433042,17433084,17433112,17433326,17433744,17433965,17503946,17504037,17504309,17504723,17505317,17506284,17506412,17506562,17507468,17508295,17508598,17509052,17510018,17510592,17510599,17510643,17510816,17511469,17511733,17512703,17513719,17513902,17513936,17514747,17514926,17515894,17516523,17516538,17516572,17517358,22400544,22400821,22401225,22402497,22402911,22403461",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
720588,2,HEK293 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-01_Inhibitor_Dose_CherryPick_Activity_Set3,"Keywords: Cytotoxicity Assay, luminescence, CellTiter-Glo, HEK293_|__|__|_Assay Overview: The assay uses HEK293T cells obtained from ATCC to test for cytotoxicity at the same concentrations used to confirm compound activity in the primary screen. Compounds are added to cells and incubated for 72 hours.  Cellular ATP levels are measured as a surrogate for cell viability using the luminescence reagent, CellTiter-Glo (Promega)._|__|_Expected Outcome: Compounds identified as hits will be toxic to cells at a com",31,Broad Institute,7071-01_Inhibitor_Dose_CherryPick_Activity_Set3,20130827,"1201,2361,2722,3598,3832,3879,4605,4993,5790,6185,6253,6256,9444,15478,17201,20345,22650,24466,25050,38777,54368,72139,74566,100596,101486,112939,126941,138252,147157,165528,220696,227456,238958,253289,253632,255887,257272,257275,262649,264884,269792,271216,274159,276294,279596,280522,280859,288101,295538,297344,300574,300942,310860,319846,328780,332767,332902,332905,334409,343097,346831,352429,367209,381371,384525,392613,396813,404406,407582,407583,415629,432465,434381,561606,580554,642384,657255,659499,69","855693,855854,858142,3715220,7964597,7967913,11533017,14734720,14737051,14740409,14744729,17401927,17408110,17409296,17432621,17432887,17433042,17433084,17433112,17433326,17433744,17433965,17503946,17504037,17504309,17504723,17505317,17506284,17506412,17506562,17507468,17508295,17508598,17509052,17510018,17510592,17510599,17510643,17510816,17511469,17511733,17512703,17513719,17513902,17513936,17514747,17514926,17515894,17516523,17516538,17516572,17517358,22400544,22400821,22401225,22402497,22402911,22403461",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
743255,2,Inhibitors of USP1/UAF1: Primary Screen,"Deubiquitinating enzymes (DUBs) are a class of enzymes that can cleave isopeptide bond formed between the C-terminal carboxylate of ubiquitin and a lysine side-chain amino group on the target protein. Among them, ubiquitin specific proteases (USPs) constitute the largest DUB family. Human USPs are emerging as promising targets for pharmacological intervention because of their connection to a number of human diseases, including prostate, colon and breast cancer (1, 2), pediatric acute lymphoblastic leukemia ",2,National Center for Advancing Translational Sciences (NCATS),usp1-uaf1-p1,20140116,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",7398,NULL,AAH18745,Governmental Organizations|NIH Initiatives,"12917691,15996926,16951176,17558397",0,10.1038/nature01802|10.1038/ncb1601|10.1158/0008-5472.can-06-1374,NULL,AAH18745,NULL
743266,2,qHTS for PTHR1 Agonists: Primary Screen,"The goal of the proposed studies is to discover new compounds that act as potent agonists on the parathyroid hormone receptor type-1 (PTHR1).  The PTHR1 plays critical roles in maintaining blood calcium and phosphate levels, as well as in controlling bone remodeling.  PTHR1 agonists could thus be useful for treating diseases such as hypoparathyroidism and osteoporosis.  In the former disease, an agonist drug would help maintain normal blood calcium and phosphate levels under conditions of parathyroid hormon",2,National Center for Advancing Translational Sciences (NCATS),pthr-p1,20190730,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",5745,NULL,NP_001171673,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,Q03431,NULL
743279,1,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,"Inflammasomes are a set of intracellular multi-protein complexes that enable autocatalytic activation of inflammatory caspases and drive the innate immune response to counter harmful agents.  Inflammasomes have been shown to contribute to the pathology of multiple autoinflammatory and autoimmune diseases, such as the Cryopryrin-Associated Periodic Syndrome (CAPS) and Chronic Obstructive Pulmonary Disease (COPD).  Patients with CAPS exhibit excessive production of IL-1B and IL-18 due to a gain-of-function mu",2,National Center for Advancing Translational Sciences (NCATS),Inflammasome- IL-1B -p1,20140213,"6,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,597,637,660,698,701,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1176,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,168","842121,842122,842123,842124,842125,842126,842127,842128,842129,842130,842131,842133,842134,842136,842137,842138,842139,842140,842141,842142,842143,842145,842146,842147,842148,842149,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842169,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842186,842187,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842198,842199,842200,842201,842202,8",3553,NULL,NP_000567,Governmental Organizations|NIH Initiatives,"22390695,22819042",0,10.1016/j.immuni.2012.04.013|10.2174/138161212800166077,NULL,P01584,NULL
743035,2,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Androgen receptor (AR), a nuclear hormone receptor, plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Endocrine disrupting chemica",58,Tox21,ARN311,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",367,NULL,AAI32976,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,AAI32976,NULL
743069,2,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Estrogen receptor (ER), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. Two subtypes of ER, ER-alpha and ER-bet",58,Tox21,ERN433,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",2099,NULL,AEP43755,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,P03372,NULL
743222,2,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The vitamin D receptor (VDR), a member of nuclear hormone receptor superfamily, plays a critical role in calcium homeostasis and bone metabolism. It is also involved in ce",58,Tox21,VDRA122,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",7421,NULL,BAH02291,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,BAH02291,NULL
743036,2,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Androgen receptor (AR), a nuclear hormone receptor, plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Endocrine disrupting chemica",58,Tox21,ARA345,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",367,NULL,AAI32976,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,AAI32976,NULL
743094,2,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely P,58,Tox21,PPARGA972,20140821,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",5468,NULL,BAH02283,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,BAH02283,NULL
743191,2,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely P,58,Tox21,PPARGN135,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",5468,NULL,BAH02283,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,BAH02283,NULL
743202,2,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Oxidative stress has been implicated in the pathogenesis of a variety of diseases ranging from cancer to neurodegeneration. The antioxidant response element (ARE) signalin,58,Tox21,ARE998,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",4780,NULL,NP_006155,Governmental Organizations,22551509,0,10.1289/ehp.1104709,NULL,Q16236,NULL
743075,2,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Estrogen receptor (ER), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. Two subtypes of ER, ER-alpha and ER-bet",58,Tox21,ERA553,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",2099,NULL,AEP43755,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,P03372,NULL
743223,2,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The vitamin D receptor (VDR), a member of nuclear hormone receptor superfamily, plays a critical role in calcium homeostasis and bone metabolism. It is also involved in ce",58,Tox21,VDRN244,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",7421,NULL,BAH02291,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,BAH02291,NULL
743215,2,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely P,58,Tox21,PPARDN875,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",5467,NULL,BAH02282,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,BAH02282,NULL
743217,2,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The farnesoid-X-receptor (FXR), a nuclear hormone receptor, is highly expressed in liver, intestine, kidney and adrenal cortex. Natural ligands of FXR are the bile acids (",58,Tox21,FXRN812,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",9971,NULL,ADZ17382,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,ADZ17382,NULL
743212,2,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely P,58,Tox21,PPARDA851,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",5467,NULL,BAH02282,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,BAH02282,NULL
743220,2,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The farnesoid-X-receptor (FXR), a nuclear hormone receptor, is highly expressed in liver, intestine, kidney and adrenal cortex. Natural ligands of FXR are the bile acids (",58,Tox21,FXRA481,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",9971,NULL,ADZ17382,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,ADZ17382,NULL
743210,2,qHTS assay for small molecule activators of the heat shock response signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Various chemicals, environmental and physiological stress conditions may lead to the activation of heat shock response/ unfolded protein response (HSR/UPR). There are thre",58,Tox21,HSE273,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",3315,NULL,NP_001531,Governmental Organizations,NULL,0,NULL,NULL,P04792,NULL
743287,1,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,"Keywords: Insulin, glucose-dependent insulin secretion, type 2 diabetes, Gaussia Luciferase, reporter gene_|__|_Assay Overview: The assay uses a rat Beta Cell line (INS-1E) engineered to contain a Gaussia luciferase reporter.  Beta-cell lines expressing this construct co-secrete luciferase and insulin in close correlation._|__|__|__|_Expected Outcome: Compounds that cause an increase in insulin secretion result in an increase in luminescence.  Active hits are determined as wells with luminesncent signal fou",31,Broad Institute,7055-01_Activator_SinglePoint_HTS_Activity,20140224,"13,40,72,109,119,127,191,243,253,255,299,300,311,314,335,379,460,499,525,547,564,588,597,660,698,727,745,774,802,803,892,896,904,931,932,936,942,949,957,978,996,1001,1002,1017,1018,1030,1066,1088,1123,1174,1183,1233,1292,1302,1326,1340,1345,1365,1369,1401,1474,1480,1483,1486,1491,1492,1493,1535,1539,1570,1609,1639,1646,1676,1687,1689,1727,1738,1742,1761,1794,1795,1814,1832,1853,1864,1882,1890,1917,1982,1983,1988,1989,1995,2002,2018,2048,2064,2073,2078,2108,2151,2153,2181,2196,2199,2206,2215,2236,2240,2247,2","842123,842124,842128,842136,842146,842150,842153,842161,842166,842168,842173,842180,842181,842182,842184,842189,842192,842202,842204,842217,842220,842223,842225,842229,842237,842238,842240,842252,842256,842259,842267,842268,842275,842279,842280,842285,842287,842294,842296,842300,842306,842313,842314,842317,842336,842337,842338,842342,842344,842348,842349,842368,842371,842375,842376,842388,842389,842392,842395,842396,842400,842411,842419,842421,842423,842426,842433,842435,842439,842440,842445,842452,842456,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
743397,1,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: CaV 1.3, L-type Ca2+ channels, Calcium dependent inactivation, CDI, FRET_|__|__|_Assay Overview:_|_Interactions between ICDI and IQ domains of CaV1.3 channels attenuate the strength of Ca2+ feedback_|_inhibition of the opening of these channels (i.e., they reduce CDI). Thus, disrupters of this interaction could_|_strengthen CDI, offering a selective inhibitor of CaV1.3 versus other CaV1 (L-type) channels. The heart of the_|_primary assay is a stable cell line expressing fluorophore-tagged IQ and I",31,Broad Institute,7081-01_Inhibitor_SinglePoint_HTS_Activity,20140408,"6,19,86,109,119,127,137,185,191,229,255,289,298,303,314,323,338,366,460,464,487,546,547,564,588,597,637,698,727,745,774,864,892,896,899,903,904,932,936,938,949,992,1002,1018,1046,1047,1088,1101,1123,1174,1183,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1401,1474,1480,1486,1489,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,1727,1732,1738,1742,1761,1775,1794,1795,1810,1814,1820,1826,1832,1853,1858,1864,1890,1892,1893,1917,1981,1982,1985,1986,1988,198","842121,842122,842123,842124,842127,842131,842134,842138,842139,842141,842143,842145,842146,842147,842150,842151,842152,842153,842154,842155,842157,842159,842163,842164,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842199,842200,842201,842202,842203,842204,842205,842208,842209,842210,842214,842216,842217,842218,842219,842220,842221,842223,842224,842225,842226,842228,842229,842230,842232,842233,842237,842238,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
743398,1,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,"Keywords: iPS cells, neural progenitor, TCF/LEF reporter system, Wnt3a_|__|__|_Assay Overview:_|_The canonical Wnt signaling pathway regulation is thought to be critical in in several disorders, including bipolar disorder and schizophrenia as well as in embryonic brain development and adult neurogenesis.  Signaling through the Wnt  pathway leads to the accumulation and nuclear translocation of a-catenin, and the transcriptional activation of genes with promoters containing TCF/LEF response elements that bin",31,Broad Institute,2161-01_Activator_SinglePoint_HTS_Activity,20140408,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1","842121,842122,842123,842124,842126,842127,842134,842138,842139,842146,842147,842150,842153,842155,842157,842162,842165,842166,842168,842170,842173,842174,842178,842179,842180,842181,842184,842187,842189,842192,842194,842199,842201,842202,842203,842204,842205,842209,842210,842213,842216,842219,842220,842224,842225,842230,842238,842240,842241,842242,842243,842244,842246,842247,842251,842252,842254,842256,842259,842261,842262,842265,842266,842267,842271,842274,842275,842276,842283,842288,842291,842293,842295,8",NULL,Cell-based,NULL,NIH Initiatives,"19303846,21095567,21407814",0,10.1016/j.cell.2008.12.044|10.1016/j.chembiol.2010.08.012|10.1371/journal.pone.0017540,NULL,NULL,NULL
743238,1,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,"Keywords: X-Chromosome reactivation, Gene dosage, lncRNA_|__|_Assay Overview:_|_High content imaging assay (GFP)_|_In the mammalian female, nearly all genes on one of the two X chromosomes are transcriptionally silenced by X chromosome inactivation (XCI), the mechanism of dosage compensation that equalizes gene expression in XX females and XY males. In the inner cell mass of peri-implantation embryos, however, the inactivated X chromosome can be reactivated. In this assay, we aim to identify small molecule ",31,Broad Institute,7015-01_Activator_SinglePoint_HTS_Activity_Set2,20131220,"6,19,86,109,119,127,137,185,191,229,255,289,298,303,314,323,338,460,464,487,546,547,564,588,597,637,698,727,745,774,864,892,896,899,903,904,932,936,938,949,992,1002,1018,1046,1047,1088,1101,1123,1174,1183,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1401,1474,1480,1486,1489,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,1651,1676,1678,1688,1689,1727,1732,1738,1742,1761,1775,1794,1795,1810,1814,1820,1826,1832,1853,1858,1864,1890,1892,1893,1917,1981,1982,1985,1986,1988,1989,19","842542,843841,844106,844352,844626,844770,844896,845022,845076,845498,845584,845627,845654,846004,846063,846270,846411,846585,846713,846740,846758,846912,846937,847531,847627,847692,847820,848003,848292,848432,848433,849185,849634,849792,850102,850702,850804,851347,851380,851387,851390,851506,851653,851898,852225,852427,853220,853326,853607,855511,855514,855516,855518,855526,855528,855530,855534,855540,855542,855544,855548,855549,855552,855555,855560,855570,855572,855574,855575,855576,855580,855583,855591,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
743247,1,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: AH1F cells, HBSS, PBS, fluorescence, FN, ECM_|__|__|_Assay Overview:_|_The deposition of Fibronectin (FN) is well known to be cell-dependent, as molecules at the cell surface serve to bind and arrange FN into a fibrillar mesh. This primary screening assay for identification of inhibitors of FN fibrillogenesis is fibroblast-based, as this is a cell type known to deposit large quantities of FN into the extracellular matrix (ECM). The assay measures fluorescence intensity from added Al488-FN, which h",31,Broad Institute,7059-01_Inhibitor_SinglePoint_HTS_Activity,20140113,"19,86,109,119,127,137,185,191,229,255,289,298,303,314,323,338,460,464,487,525,546,547,564,588,597,637,698,727,745,774,864,892,896,899,903,904,932,936,938,949,992,1002,1018,1046,1047,1088,1101,1123,1174,1183,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1401,1474,1480,1486,1489,1492,1493,1535,1539,1546,1570,1609,1639,1646,1651,1676,1678,1688,1689,1727,1732,1738,1742,1761,1775,1795,1810,1814,1820,1826,1832,1853,1858,1864,1890,1892,1893,1917,1981,1985,1986,1988,1989,1995,2005,2018,","842121,842122,842127,842134,842138,842139,842147,842151,842153,842155,842157,842159,842162,842164,842165,842170,842173,842174,842178,842179,842192,842194,842199,842201,842203,842205,842208,842209,842210,842213,842216,842218,842219,842223,842224,842229,842230,842238,842240,842241,842242,842244,842246,842248,842251,842254,842255,842261,842262,842266,842267,842274,842275,842276,842287,842288,842291,842293,842294,842295,842303,842305,842308,842313,842314,842315,842316,842318,842320,842321,842322,842323,842324,8",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
743126,1,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Michael H. Gelb, University of Washington_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number R37HL036235_|_Grant Proposal PI: Michael H. Gelb, University of Washington_|_External Assay ID: HGIII-SPLA2_INH_QFRET_1536_1X%INH PRUN_|__|_Name: QFRET-based biochemical high throughput primary assay to identify inhibito",5,The Scripps Research Institute Molecular Screening Center,HGIII-SPLA2_INH_QFRET_1536_1X%INH PRUN,20131125,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1050,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",50487,Biochemical,EAW59941,NIH Initiatives,"10713052,18405237,19541351,23624557",0,10.1016/j.jaci.2009.04.035|10.1038/ni.2586|10.1074/jbc.275.11.7492|10.1146/annurev.biochem.76.062405.154007,NULL,EAW59941,NULL
743269,1,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: Ohio State University_|_Assay Provider: Mamuka Kvaratskhelia, Ohio State University_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R01 AI081581_|_Grant Proposal PI: Mamuka Kvaratskhelia, Ohio State University_|_External Assay ID: LEDGF-p75_INH_TRFRET_1536_1X%INH PRUN_|__|_Name: TRFRET-based biochemical primary high throughput screening assay to identif",5,The Scripps Research Institute Molecular Screening Center,LEDGF-p75_INH_TRFRET_1536_1X%INH PRUN,20140131,"6,13,19,40,72,86,109,119,127,137,174,185,190,191,204,229,243,253,255,289,298,299,300,303,311,314,323,335,338,366,379,441,460,464,487,499,525,546,547,564,588,596,597,637,660,698,727,745,774,802,803,864,892,896,899,903,904,931,932,936,938,942,949,957,978,992,995,996,1001,1002,1017,1018,1030,1046,1047,1050,1066,1088,1101,1123,1150,1174,1183,1201,1233,1245,1292,1302,1309,1318,1326,1329,1330,1340,1345,1359,1365,1367,1369,1400,1401,1474,1480,1483,1486,1489,1491,1492,1493,1535,1539,1546,1570,1609,1639,1643,1646,16","842121,842122,842123,842124,842125,842126,842127,842128,842129,842131,842134,842136,842137,842138,842139,842140,842141,842143,842145,842146,842147,842148,842150,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842165,842166,842167,842168,842170,842171,842172,842173,842174,842178,842179,842180,842181,842182,842183,842184,842188,842189,842190,842191,842192,842193,842194,842195,842196,842197,842199,842200,842201,842202,842203,842204,842205,842206,842208,842209,842210,842211,8",11168,Biochemical,"AAC83551,AAF25870",NIH Initiatives,"16482214,18227187,18801737,19638533,20118915,20473303,21771857,22437836,22535962,22664975",0,10.1038/nature08784|10.1038/nchembio.370|10.1038/sj.emboj.7601005|10.1074/jbc.m112.347534|10.1074/jbc.m112.354373|10.1074/jbc.m805843200|10.1093/nar/gkr581|10.1124/mol.109.058883|10.1128/aac.00717-12|10.1128/aac.01228-07,NULL,"AAC83551,O75475",NULL
743445,1,"Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2","Keywords:_|_H3K36, histone methyltransferase, cancer, multiple myeloma, NSD2 small molecule inhibitors, histone-modifying, t(4;14) chromosomal translocation, AlphaScreen_|__|_Assay Overview:_|_The NSD2 methyltransferase reaction is designed to monitor the lysine methylation of a 16-amino acid biotinylated peptide  (Ac-RLARRGGVKRISGLI[K-Ahx-Biot]amide) (H4 peptide).  NSD2 transfers a methyl group from S-adenosylmethionine (SAM) to the lysine residue of the H4 peptide.  The enzyme reaction is allowed to proce",31,Broad Institute,7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2,20140410,"127,191,255,314,366,525,949,1002,1050,1309,1326,1369,1400,1486,1492,1535,1539,1639,1643,1651,1689,1742,1810,1814,1821,1853,1890,1972,1988,2048,2064,2078,2240,2242,2256,2268,2314,2336,2348,2363,2372,2541,2569,2717,2722,2741,2748,2795,2817,2833,2854,2871,2890,2904,2999,3003,3026,3039,3092,3165,3197,3286,3333,3346,3351,3370,3381,3384,3475,3476,3687,3784,3786,3787,3800,3820,3877,4011,4045,4053,4112,4121,4159,4212,4309,4448,4487,4491,4497,4537,4619,4632,4679,4692,4731,4780,4813,4865,4871,4878,4879,4882,4895,4928","842121,842122,842123,842125,842126,842127,842128,842129,842131,842136,842138,842139,842140,842141,842143,842145,842148,842150,842151,842152,842155,842159,842162,842163,842164,842165,842168,842170,842173,842174,842178,842179,842182,842183,842184,842188,842189,842190,842191,842192,842194,842199,842200,842203,842205,842208,842209,842210,842212,842213,842214,842216,842219,842220,842221,842223,842224,842225,842226,842228,842229,842231,842232,842233,842234,842235,842236,842237,842240,842241,842242,842243,842244,8",7468,Biochemical,NP_001035889,NIH Initiatives,NULL,0,NULL,2.1.1.356,O96028,NULL
743014,2,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_DNA repair pathways play a critical role in cellular homeostasis by repairing DNA damage induced by endogenous processes and xenobiotics. Isogenic chicken DT40 cell lines ,58,Tox21,DT40657,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,Toxicity,NULL,Governmental Organizations,21538559,0,10.1002/em.20656,NULL,NULL,NULL
743012,2,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_DNA repair pathways play a critical role in cellular homeostasis by repairing DNA damage induced by endogenous processes and xenobiotics. Isogenic chicken DT40 cell lines ,58,Tox21,DT40653,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,Toxicity,NULL,Governmental Organizations,21538559,0,10.1002/em.20656,NULL,NULL,NULL
743015,2,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_DNA repair pathways play a critical role in cellular homeostasis by repairing DNA damage induced by endogenous processes and xenobiotics. Isogenic chicken DT40 cell lines ,58,Tox21,DT40100,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,Toxicity,NULL,Governmental Organizations,21538559,0,10.1002/em.20656,NULL,NULL,NULL
743064,2,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular s",58,Tox21,TRV455,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,NULL,NULL
743065,2,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular s",58,Tox21,TRN186,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",24831,NULL,NP_001257783,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,NP_001257783,NULL
743083,2,qHTS assay to identify aromatase inhibitors,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Endocrine disrupting chemicals (EDCs) interfere with the biosynthesis and normal functions of steroid hormones including estrogen and androgen in the body. Aromatase catal,58,Tox21,AROA258,20140905,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",1588,NULL,EAW77416,Governmental Organizations,NULL,0,NULL,NULL,P11511,NULL
743079,2,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Estrogen receptor (ER), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. Endocrine disrupting chemicals (EDCs) a",58,Tox21,BG1A409,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",2099,NULL,AEP43755,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,P03372,NULL
743042,2,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Androgen receptor (AR), a nuclear hormone receptor, plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Endocrine disrupting chemica",58,Tox21,MDAN828,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",367,NULL,AAI32976,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,AAI32976,NULL
743080,2,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Estrogen receptor (ER), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. Endocrine disrupting chemicals (EDCs) a",58,Tox21,BG1N143,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",2099,NULL,AEP43755,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,P03372,NULL
743084,2,qHTS assay to identify aromatase inhibitors - cell viability counter screen,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Endocrine disrupting chemicals (EDCs) interfere with the biosynthesis and normal functions of steroid hormones including estrogen and androgen in the body. Aromatase catal,58,Tox21,AROV112,20140821,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,NULL,0,NULL,NULL,NULL,NULL
743033,2,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Androgen receptor (AR), a nuclear hormone receptor, plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Endocrine disrupting chemica",58,Tox21,ARV616,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,NULL,NULL
743074,2,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Estrogen receptor (ER), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. Two subtypes of ER, ER-alpha and ER-bet",58,Tox21,ERV270,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,NULL,NULL
743086,2,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay overview:_|__|_The Aryl hydrocarbon Receptor (AhR), a member of the family of basic helix-loop-helix transcription factors, is crucial to adaptive responses to environmental changes. AhR",58,Tox21,AHR684,20140821,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,NULL,0,NULL,NULL,NULL,NULL
743081,2,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Estrogen receptor (ER), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. Endocrine disrupting chemicals (EDCs) a",58,Tox21,BG1V992,20140821,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,NULL,NULL
743085,2,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay overview:_|__|_The Aryl hydrocarbon Receptor (AhR), a member of the family of basic helix-loop-helix transcription factors, is crucial to adaptive responses to environmental changes. AhR",58,Tox21,AHR848,20140821,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",196,NULL,EAL24281,Governmental Organizations,NULL,0,NULL,NULL,P35869,NULL
743194,2,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely P,58,Tox21,PPARGV841,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",NULL,NULL,NULL,Governmental Organizations,NULL,0,NULL,NULL,NULL,NULL
743225,2,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The vitamin D receptor (VDR), a member of nuclear hormone receptor superfamily, plays a critical role in calcium homeostasis and bone metabolism. It is also involved in ce",58,Tox21,VDRV271,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",NULL,NULL,NULL,Governmental Organizations,NULL,0,NULL,NULL,NULL,NULL
743041,2,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Androgen receptor (AR), a nuclear hormone receptor, plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Endocrine disrupting chemica",58,Tox21,MDAV150,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",NULL,NULL,NULL,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,NULL,NULL
743213,2,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely P,58,Tox21,PPARDV688,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",NULL,NULL,NULL,Governmental Organizations,NULL,0,NULL,NULL,NULL,NULL
743218,2,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The farnesoid-X-receptor (FXR), a nuclear hormone receptor, is highly expressed in liver, intestine, kidney and adrenal cortex. Natural ligands of FXR are the bile acids (",58,Tox21,FXRV164,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",NULL,NULL,NULL,Governmental Organizations,NULL,0,NULL,NULL,NULL,NULL
743211,2,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely P,58,Tox21,PPARDV813,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",NULL,NULL,NULL,Governmental Organizations,NULL,0,NULL,NULL,NULL,NULL
743224,2,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The vitamin D receptor (VDR), a member of nuclear hormone receptor superfamily, plays a critical role in calcium homeostasis and bone metabolism. It is also involved in ce",58,Tox21,VDRV930,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",NULL,NULL,NULL,Governmental Organizations,NULL,0,NULL,NULL,NULL,NULL
743209,2,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Various chemicals, environmental and physiological stress conditions may lead to the activation of heat shock response/ unfolded protein response (HSR/UPR). There are thre",58,Tox21,HSE724,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",NULL,NULL,NULL,Governmental Organizations,NULL,0,NULL,NULL,NULL,NULL
743221,2,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The farnesoid-X-receptor (FXR), a nuclear hormone receptor, is highly expressed in liver, intestine, kidney and adrenal cortex. Natural ligands of FXR are the bile acids (",58,Tox21,FXRV189,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",NULL,NULL,NULL,Governmental Organizations,NULL,0,NULL,NULL,NULL,NULL
743203,2,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Oxidative stress has been implicated in the pathogenesis of a variety of diseases ranging from cancer to neurodegeneration. The antioxidant response element (ARE) signalin,58,Tox21,ARE579,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",NULL,NULL,NULL,Governmental Organizations,NULL,0,NULL,NULL,NULL,NULL
743066,2,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular s",58,Tox21,TRA145,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",24831,NULL,NP_001257783,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,NP_001257783,NULL
743040,2,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Androgen receptor (AR), a nuclear hormone receptor, plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Endocrine disrupting chemica",58,Tox21,MDAA427,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",367,NULL,AAI32976,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,AAI32976,NULL
743093,1,Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of viability of late stage Plasmodium falciparum gametocytes,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: Don Gardiner, Queensland Institute of Medical Research_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1R21NS075609-01_|_Grant Proposal PI: Don Gardiner_|_External Assay ID: GAMETOCYTE_INH_LUMI_1536_1X%INH PRUN_|__|_Name: Luminescence-based primary cell-based high throughput screening assay to ident",5,The Scripps Research Institute Molecular Screening Center,GAMETOCYTE_INH_LUMI_1536_1X%INH PRUN,20140205,"127,191,366,1309,1369,1486,1492,1539,1639,1853,2256,2265,2722,3003,3787,4487,4619,4632,4731,4788,4895,4937,4938,5155,5267,5338,5382,5383,6051,6099,6129,6292,6634,6701,6706,6724,6731,6796,6821,6825,6872,7038,7087,7113,7135,7184,7226,7337,7340,7423,7547,7560,7564,7566,7571,8321,8395,8407,8572,8616,8660,8694,8737,8743,8796,9013,9189,9212,9340,9498,10208,10211,10212,10227,10737,10788,10816,10855,11106,11107,11332,11829,11886,11913,11942,12086,12138,12446,12856,12870,12884,12888,13067,13271,13283,13399,13659,137","842123,842124,842126,842127,842137,842139,842140,842141,842143,842145,842146,842147,842151,842152,842153,842154,842155,842156,842157,842159,842161,842162,842163,842164,842166,842167,842168,842173,842174,842181,842184,842188,842190,842196,842200,842202,842203,842208,842210,842211,842214,842220,842221,842222,842225,842226,842228,842229,842232,842233,842237,842241,842246,842247,842248,842256,842257,842259,842261,842263,842265,842266,842267,842270,842272,842277,842285,842286,842292,842294,842296,842298,842300,8",NULL,Cell-based,NULL,NIH Initiatives,"17408673,18801976,21311579,22305225",0,10.1016/j.ijpara.2007.02.007|10.1016/s0140-6736(12)60034-8|10.1126/science.321.5896.1620b|10.1371/journal.pmed.1000406,NULL,NULL,NULL
743121,1,Druggable Genome siRNA Screen for Enhancers of Camptothecin in MDA-MB-231 Breast Cancer Cells,"Camptothecin, a specific topoisomerase I inhibitor is a potent anticancer drug, especially against solid tumors. This agent produces well-characterized double-strand breaks upon collision of replication forks with topoisomerase I cleavage complexes. In an attempt to improve its efficacy, we conducted a synthetic lethal siRNA screening using a library that targets nearly 7000 human genes. Depletion of ATR, the main transducer of replication stress-induced DNA damage response exacerbated cytotoxic response to",2,National Center for Advancing Translational Sciences (NCATS),CPT-TOP1-RNAI,20140721,NULL,"164351727,164351729,164351730,164351734,164351737,164351738,164351740,164351759,164351760,164351761,164351764,164351766,164351767,164351793,164351795,164351798,164351801,164351805,164351807,164351809,164351812,164351813,164351814,164351818,164351819,164351821,164351822,164351824,164351825,164351827,164351830,164351831,164351835,164351838,164351840,164351841,164351843,164351845,164351846,164351848,164351854,164351858,164351859,164351860,164351874,164351877,164351881,164351882,164351907,164351909,164351910,16","1,2,12,13,18,19,20,21,22,23,24,25,27,31,32,33,34,35,37,38,39,40,41,43,47,48,49,51,52,53,54,55,56,81,86,87,90,91,92,93,94,100,101,102,103,104,107,108,109,111,112,113,114,115,117,118,123,124,125,126,127,128,130,131,132,133,134,135,136,140,142,143,146,147,148,150,151,152,153,154,155,156,157,158,163,165,166,173,174,175,177,178,181,182,183,185,186,187,189,190,191,196,197,199,203,204,205,207,208,210,212,214,215,216,217,218,219,220,221,222,223,224,225,226,229,231,238,239,240,241,242,245,246,247,248,249,250,251,262",RNAi,NULL,Governmental Organizations|NIH Initiatives,NULL,1,NULL,NULL,NULL,NULL
743454,1,RNAi screen for vorinostat resistance genes - Primary Screen,Assay description will be published shortly and manuscript citation added here.,68,"Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre",vorinostat-resistance-genes-primary-screen,20160302,NULL,"56478465,56478467,56478468,56478471,56478474,56478482,56478483,56478485,56478487,56478490,56478493,56478503,56478510,56478513,56478514,56478519,56478524,56478525,56478526,56478534,56478536,56478542,56478543,56478546,56478547,56478550,56478551,56478553,56478554,56478561,56478566,56478568,56478572,56478573,56478574,56478577,56478578,56478580,56478581,56478582,56478584,56478587,56478590,56478591,56478592,56478594,56478596,56478597,56478598,56478599,56478600,56478602,56478604,56478606,56478608,56478615,56478616","1,2,9,10,12,13,14,15,16,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,43,47,48,49,50,51,52,53,54,55,56,58,59,60,70,71,72,81,86,87,88,89,90,91,92,93,94,95,97,98,100,101,102,103,104,105,107,108,109,111,112,113,114,115,116,117,118,119,120,123,124,125,126,127,128,130,131,132,133,134,135,136,140,141,142,143,146,147,148,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,173,174,175,176,177,178,181,182,183,185,186,187,189,190,191,196,197,199,202,203,204,205,207,208,21",RNAi,NULL,Research and Development,25977774,1,10.1038/sdata.2014.17,NULL,NULL,NULL
743288,2,qHTS assay for cell viability of HEK293 cells,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI) is a homogeneous method to determine the number of viable cells in culture based on quantitation ",2,National Center for Advancing Translational Sciences (NCATS),NRV786,20140226,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,21543282,0,10.1289/ehp.1002952,NULL,NULL,NULL
743244,2,qHTS Assay for Identifying Gametocytocidal Compounds,"Malaria cases and deaths have dropped 50% in 29 countries since 2000 due to the combined effects of long-lasting insecticidal bednets, indoor residual spraying, and artemisinin-based combination therapies (ACTs). This success has raised hopes for malaria eradication and consequently stimulated interest in developing new reagents that block gametocyte transmission such as novel and safe gametocytocidal drugs. However, previous drug development efforts have focused primarily on the asexual parasites that caus",2,National Center for Advancing Translational Sciences (NCATS),MALG0567,20131230,"51,119,138,178,180,190,196,199,204,227,237,240,244,247,249,263,275,286,289,308,311,323,338,370,379,401,403,444,460,462,464,471,535,546,547,564,588,594,612,614,650,681,700,712,727,750,753,774,785,787,791,798,838,863,864,876,887,892,896,903,904,931,936,938,951,967,978,985,994,996,999,1004,1018,1030,1045,1046,1050,1053,1054,1057,1066,1080,1102,1103,1110,1123,1140,1150,1174,1175,1176,1183,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329","11111072,11112768,11112778,11113545,11113817,11113845,11113932,11113953,11114010,11114025,11114100,11114141,11114146,11114151,11114202,11114209,11114246,11114298,26747277,26748498,26753179,26753243,26753282,26755036,26755749,26756784,26757998,29215388,50103983,50107499,50111708,50111715,50112875,50112887,50112903,50112924,50112939,50112942,50112950,50113171,50125861,85736407,90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,23454872,0,10.1016/j.molbiopara.2013.02.005,NULL,NULL,NULL
743292,2,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI) is a homogeneous method to determine the number of viable cells in culture based on quantitation ",2,National Center for Advancing Translational Sciences (NCATS),P53V80,20140227,"6,11,13,51,66,174,177,180,196,227,240,241,243,244,261,263,289,299,300,311,323,335,342,370,379,398,403,447,460,527,568,612,650,660,671,679,700,701,702,713,727,753,785,795,864,887,896,904,931,949,957,967,978,985,991,992,995,996,1004,1017,1030,1046,1049,1057,1123,1140,1176,1183,1188,1254,1309,1318,1480,1483,1486,1489,1491,1493,1674,1727,1730,1732,1744,1752,1775,1923,1982,1983,1986,1988,1989,2078,2087,2126,2153,2154,2155,2202,2206,2244,2256,2265,2266,2268,2272,2286,2314,2319,2328,2331,2345,2347,2355,2365,2391,2","17388662,17388663,17388664,17388665,17388666,17388667,17388668,17388669,17388670,17388671,17388672,17388673,17388674,17388675,17388676,17388677,17388678,17388679,17388680,17388681,17388682,17388683,17388684,17388685,17388686,17388687,17388688,17388689,17388690,17388691,17388692,17388693,17388694,17388695,17388696,17388697,17388698,17388699,17388700,17388701,17388702,17388703,17388704,17388705,17388706,17388707,17388708,17388709,17388710,17388711,17388712,17388713,17388714,17388715,17388716,17388717,17388718",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
743449,1,HTS for YAP1 pathway inhibitors in DLD1 colon cancer cell line measuring mRNA levels of CTGF Measured in Cell-Based System Using RT-PCR - 7098-01_Inhibitor_SinglePoint_HTS_Activity,"Keywords: Yes Associated Protein 1, YAP1, transcription modulator, cancer, CTGF, DLD colon cancer cell line, qPCR_|__|_Assay Overview:  The transcriptional modulator Yes Associated Protein 1 (YAP1) has been implicated in several cancer phenotypes and studies of YAP1 implicate it as a promising target for cancer therapies.  However, there are no known selective inhibitors to the YAP1 pathway.  In order to better understand the role of YAP1 in cancer progression, a screen to identify selective inhibitors was ",31,Broad Institute,7098-01_Inhibitor_SinglePoint_HTS_Activity,20140411,"44202015,44202036,44202308,44202309,44202340,44202400,44202405,44202472,44202481,44202494,44202535,44202559,44202565,44202587,44202620,44202677,44202705,44202720,44202732,44202749,44202778,44202848,44202857,44202862,44202929,44202942,44202947,44202962,44246537,44483401,44483413,44483481,44483488,44483502,44483503,44483516,44483591,44483619,44483650,44483663,44483668,44483712,44483732,44483776,44483782,44483808,44483822,44483826,44483891,44483908,44483914,44483970,44483971,44483978,44484000,44484004,44484012","85789800,85789814,85789883,85789890,85789904,85789905,85789918,85789994,85790022,85790053,85790067,85790073,85790118,85790139,85790183,85790189,85790215,85790229,85790233,85790300,85790317,85790323,85790379,85790380,85790387,85790411,85790415,85790455,85790490,85790512,85790531,85790537,85790538,85790574,85790589,85790596,85790662,85790666,85790696,85790760,85790766,85790774,85790805,85790910,85790935,85790936,85790945,85790955,85790971,85790984,85790989,85791005,85791039,85791045,85791055,85791062,85791070",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
743063,3,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Androgen receptor (AR), a nuclear hormone receptor, plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Endocrine disrupting chemica",58,Tox21,ARN170,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",367,NULL,AAI32976,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,AAI32976,NULL
743346,2,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),"Plasmodium falciparum is a virulent malarial parasite that kills 1-2 million people worldwide each year. Transmitted by mosquitoes, the sporozoite form of the parasite enters the blood stream to infect hepatocytes, where they become merozoites that infect red blood cells (erythrocytes). Within erythrocytes, merozoites begin a 72-hour cycle of growth and division, after which the parasite is released to infect new red blood cells. Gametocytes, which form within erythrocytes as well, circulate in the bloodstr",2,National Center for Advancing Translational Sciences (NCATS),MMmipe4dd2-2,20140328,"248,401,425,444,471,564,572,573,581,681,709,774,827,896,936,938,967,1046,1102,1123,1156,1236,1253,1345,1401,1645,1744,1839,1935,1973,1981,1983,2019,2044,2051,2083,2092,2123,2130,2145,2153,2154,2157,2159,2161,2170,2187,2196,2230,2244,2264,2265,2267,2327,2351,2353,2369,2370,2375,2381,2390,2404,2405,2442,2449,2466,2467,2471,2478,2518,2520,2531,2532,2536,2547,2548,2563,2567,2576,2577,2578,2585,2662,2678,2703,2708,2713,2717,2719,2720,2722,2725,2749,2754,2763,2764,2767,2771,2777,2787,2794,2796,2800,2801,2803,2812","11111456,11112129,11112211,11112213,11112219,11112307,11112548,11112564,11112607,11112680,11112745,11112778,11112834,11112878,11112956,11113072,11113505,11113545,11113631,11113642,11113845,11113910,11113990,11114022,11114028,11114076,11114097,11114116,11114134,11114151,11114155,11114156,11114166,11114218,11114221,11114244,11114251,11114262,11114267,11114278,11114298,26747834,26747886,26748547,26748940,26748966,26748996,26749175,26749194,26750026,26751695,26752069,26752783,26753052,26753178,26753179,26753224",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,18579783,0,10.1073/pnas.0802982105,NULL,NULL,NULL
743219,3,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Oxidative stress has been implicated in the pathogenesis of a variety of diseases ranging from cancer to neurodegeneration. The antioxidant response element (ARE) signalin,58,Tox21,ARE591,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",4780,NULL,NP_006155,Governmental Organizations,22551509,0,10.1289/ehp.1104709,NULL,Q16236,NULL
743344,2,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,"Plasmodium falciparum is a virulent malarial parasite that kills 1-2 million people worldwide each year. Transmitted by mosquitoes, the sporozoite form of the parasite enters the blood stream to infect hepatocytes, where they become merozoites that infect red blood cells (erythrocytes). Within erythrocytes, merozoites begin a 72-hour cycle of growth and division, after which the parasite is released to infect new red blood cells. Gametocytes, which form within erythrocytes as well, circulate in the bloodstr",2,National Center for Advancing Translational Sciences (NCATS),MMmipe43d7,20140328,"248,401,425,444,471,564,572,573,581,681,709,774,827,896,936,938,967,1046,1102,1123,1156,1236,1253,1345,1401,1645,1744,1839,1935,1973,1981,1983,2019,2044,2051,2083,2092,2123,2130,2145,2153,2154,2157,2159,2161,2170,2187,2196,2230,2244,2264,2265,2267,2327,2351,2353,2369,2370,2375,2381,2390,2404,2405,2442,2449,2466,2467,2471,2478,2518,2520,2531,2532,2536,2547,2548,2563,2567,2576,2577,2578,2585,2662,2678,2703,2708,2713,2717,2719,2720,2722,2725,2749,2754,2763,2764,2767,2771,2777,2787,2794,2796,2800,2801,2803,2812","11111456,11112129,11112211,11112213,11112219,11112307,11112548,11112564,11112607,11112680,11112745,11112778,11112834,11112878,11112956,11113072,11113505,11113545,11113631,11113642,11113845,11113910,11113990,11114022,11114028,11114076,11114097,11114116,11114134,11114151,11114155,11114156,11114166,11114218,11114221,11114244,11114251,11114262,11114267,11114278,11114298,26747834,26747886,26748547,26748940,26748966,26748996,26749175,26749194,26750026,26751695,26752069,26752783,26753052,26753178,26753179,26753224",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,18579783,0,10.1073/pnas.0802982105,NULL,NULL,NULL
743345,2,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,"Plasmodium falciparum is a virulent malarial parasite that kills 1-2 million people worldwide each year. Transmitted by mosquitoes, the sporozoite form of the parasite enters the blood stream to infect hepatocytes, where they become merozoites that infect red blood cells (erythrocytes). Within erythrocytes, merozoites begin a 72-hour cycle of growth and division, after which the parasite is released to infect new red blood cells. Gametocytes, which form within erythrocytes as well, circulate in the bloodstr",2,National Center for Advancing Translational Sciences (NCATS),MMmipe4dd2,20140328,"248,401,425,444,471,564,572,573,581,681,709,774,827,896,936,938,967,1046,1102,1123,1156,1236,1253,1345,1401,1645,1744,1839,1935,1973,1981,1983,2019,2044,2051,2083,2092,2123,2130,2145,2153,2154,2157,2159,2161,2170,2187,2196,2230,2244,2264,2265,2267,2327,2351,2353,2369,2370,2375,2381,2390,2404,2405,2442,2449,2466,2467,2471,2478,2518,2520,2531,2532,2536,2547,2548,2563,2567,2576,2577,2578,2585,2662,2678,2703,2708,2713,2717,2719,2720,2722,2725,2749,2754,2763,2764,2767,2771,2777,2787,2794,2796,2800,2801,2803,2812","11111456,11112129,11112211,11112213,11112219,11112307,11112548,11112564,11112607,11112680,11112745,11112778,11112834,11112878,11112956,11113072,11113505,11113545,11113631,11113642,11113845,11113910,11113990,11114022,11114028,11114076,11114097,11114116,11114134,11114151,11114155,11114156,11114166,11114218,11114221,11114244,11114251,11114262,11114267,11114278,11114298,26747834,26747886,26748547,26748940,26748966,26748996,26749175,26749194,26750026,26751695,26752069,26752783,26753052,26753178,26753179,26753224",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,18579783,0,10.1073/pnas.0802982105,NULL,NULL,NULL
743347,2,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,"Plasmodium falciparum is a virulent malarial parasite that kills 1-2 million people worldwide each year. Transmitted by mosquitoes, the sporozoite form of the parasite enters the blood stream to infect hepatocytes, where they become merozoites that infect red blood cells (erythrocytes). Within erythrocytes, merozoites begin a 72-hour cycle of growth and division, after which the parasite is released to infect new red blood cells. Gametocytes, which form within erythrocytes as well, circulate in the bloodstr",2,National Center for Advancing Translational Sciences (NCATS),MMmipe4hb3,20140328,"248,401,425,444,471,564,572,573,581,681,709,774,827,896,936,938,967,1046,1102,1123,1156,1236,1253,1345,1401,1645,1744,1839,1935,1973,1981,1983,2019,2044,2051,2083,2092,2123,2130,2145,2153,2154,2157,2159,2161,2170,2187,2196,2230,2244,2264,2265,2267,2327,2351,2353,2369,2370,2375,2381,2390,2404,2405,2442,2449,2466,2467,2471,2478,2518,2520,2531,2532,2536,2547,2548,2563,2567,2576,2577,2578,2585,2662,2678,2703,2708,2713,2717,2719,2720,2722,2725,2749,2754,2763,2764,2767,2771,2777,2787,2794,2796,2800,2801,2803,2812","11111456,11112129,11112211,11112213,11112219,11112307,11112548,11112564,11112607,11112680,11112745,11112778,11112834,11112878,11112956,11113072,11113505,11113545,11113631,11113642,11113845,11113910,11113990,11114022,11114028,11114076,11114097,11114116,11114134,11114151,11114155,11114156,11114166,11114218,11114221,11114244,11114251,11114262,11114267,11114278,11114298,26747834,26747886,26748547,26748940,26748966,26748996,26749175,26749194,26750026,26751695,26752069,26752783,26753052,26753178,26753179,26753224",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,18579783,0,10.1073/pnas.0802982105,NULL,NULL,NULL
743078,3,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Estrogen receptor (ER), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. Two subtypes of ER, ER-alpha and ER-bet",58,Tox21,ERN743,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",2099,NULL,AEP43755,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,P03372,NULL
743199,3,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely P,58,Tox21,PPARGN781,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",5468,NULL,BAH02283,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,BAH02283,NULL
743067,3,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Thyroid receptor (TR), a nuclear hormone receptor, plays an important role in development, proliferation, differentiation, metabolism, brain function, and cardiovascular s",58,Tox21,TRN190,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",24831,NULL,NP_001257783,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,NP_001257783,NULL
743139,3,qHTS assay to identify aromatase inhibitors: Summary,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Endocrine disrupting chemicals (EDCs) interfere with the biosynthesis and normal functions of steroid hormones including estrogen and androgen in the body. Aromatase catal,58,Tox21,AROS634,20140821,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",1588,NULL,EAW77416,Governmental Organizations,NULL,0,NULL,NULL,P11511,NULL
743020,2,Counterscreen:CMV reporter Measured in Cell-Based System Using Plate Reader - 7054-04_Inhibitor_Dose_DryPowder_Activity,"Keywords: ovarian cancer, Pax8, luciferase, SteadyGlo, HEK293 cells, CMV_|__|_Assay Overview:_|_A cellular assay that measures Pax8 activity using a Luciferase-based reporter of a well characterized PAX8 transcriptional target, thyroperoxidase (TPO), was used in the primary assay. This assay determines if any active compounds in the PAX8 assay impact the expression of unrelated luciferase reporter, CMV. Cells were treated with compound and controls for 24 hours.  Following compound treatment, CMV promoter a",31,Broad Institute,7054-04_Inhibitor_Dose_DryPowder_Activity,20140205,"1795,2020,2361,2363,2833,2942,3598,3728,3800,3832,3879,4491,4882,5043,5100,5153,5303,5311,6167,6185,10607,15478,20345,29893,31316,40586,52884,60699,62770,72402,72810,72813,73427,81403,91467,93572,99844,99927,100037,100064,100158,101486,107346,114961,122815,131182,138252,151582,161167,176158,182785,200953,203396,217907,220401,233874,234636,236584,240739,242436,253602,256331,256646,257278,266923,274159,276294,276685,279596,280101,280899,282415,282594,282598,289018,289100,290355,295538,299645,300567,303610,310","844866,849093,851517,855609,858166,861918,864737,4241190,4242957,4252027,7970050,7970999,7977862,11533017,14719120,14720977,14721813,14727378,14727617,14729694,14731075,14731796,14732218,14733191,14733294,14734720,14735928,14736914,14737460,14739792,14745672,16953511,17387062,17387367,17401429,17402854,17403358,17407962,17410182,17410361,17411973,17412676,17415149,17431463,17431966,17432349,17432511,17432587,17432668,17432774,17432820,17432833,17432999,17433401,17433499,17433561,17503730,17503836,17504222,1",NULL,Cell-based,NULL,NIH Initiatives,"21746896,998701",0,10.1016/0002-9394(76)90060-x|10.1073/pnas.1109363108,NULL,NULL,NULL
743077,3,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Estrogen receptor (ER), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. Two subtypes of ER, ER-alpha and ER-bet",58,Tox21,ERA362,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",2099,NULL,AEP43755,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,P03372,NULL
743226,3,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely P,58,Tox21,PPARDN146,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",5467,NULL,BAH02282,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,BAH02282,NULL
743240,3,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The farnesoid-X-receptor (FXR), a nuclear hormone receptor, is highly expressed in liver, intestine, kidney and adrenal cortex. Natural ligands of FXR are the bile acids (",58,Tox21,FXRN519,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",9971,NULL,ADZ17382,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,ADZ17382,NULL
743242,3,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The vitamin D receptor (VDR), a member of nuclear hormone receptor superfamily, plays a critical role in calcium homeostasis and bone metabolism. It is also involved in ce",58,Tox21,VDRN803,20140905,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",7421,NULL,BAH02291,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,BAH02291,NULL
743054,3,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Androgen receptor (AR), a nuclear hormone receptor, plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Endocrine disrupting chemica",58,Tox21,MDAN535,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",367,NULL,AAI32976,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,AAI32976,NULL
743140,3,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely P,58,Tox21,PPARGA506,20140821,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",5468,NULL,BAH02283,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,BAH02283,NULL
743053,3,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Androgen receptor (AR), a nuclear hormone receptor, plays a critical role in AR-dependent prostate cancer and other androgen related diseases. Endocrine disrupting chemica",58,Tox21,ARA168,20140820,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",367,NULL,AAI32976,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,AAI32976,NULL
743091,3,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Estrogen receptor (ER), a nuclear hormone receptor, plays an important role in development, metabolic homeostasis and reproduction. Endocrine disrupting chemicals (EDCs) a",58,Tox21,BG1N735,20140821,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",2099,NULL,AEP43755,Governmental Organizations,21543282,0,10.1289/ehp.1002952,NULL,P03372,NULL
743122,3,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The Aryl hydrocarbon Receptor (AhR), a member of the family of basic helix-loop-helix transcription factors, is crucial to adaptive responses to environmental changes. AhR",58,Tox21,AHR641,20140821,"4,6,11,13,33,34,51,66,72,79,107,119,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,614,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,876,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,994,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1053,1054,10","144203552,144203553,144203554,144203555,144203556,144203557,144203558,144203559,144203560,144203561,144203562,144203563,144203564,144203565,144203566,144203567,144203568,144203569,144203570,144203571,144203572,144203573,144203574,144203575,144203576,144203577,144203578,144203579,144203580,144203581,144203582,144203583,144203584,144203585,144203586,144203587,144203588,144203589,144203590,144203591,144203592,144203593,144203594,144203595,144203596,144203597,144203598,144203599,144203600,144203601,144203602,14",196,NULL,EAL24281,Governmental Organizations,NULL,0,NULL,NULL,P35869,NULL
743228,3,qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_Various chemicals, environmental and physiological stress conditions may lead to the activation of heat shock response/ unfolded protein response (HSR/UPR). There are thre",58,Tox21,HSE158,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",3315,NULL,NP_001531,Governmental Organizations,22551509,0,10.1289/ehp.1104709,NULL,P04792,NULL
743227,3,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors of the nuclear receptor superfamily with three distinct subtypes namely P,58,Tox21,PPARDA158,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",5467,NULL,BAH02282,Governmental Organizations,22551509,0,10.1289/ehp.1104709,NULL,BAH02282,NULL
743241,3,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The vitamin D receptor (VDR), a member of nuclear hormone receptor superfamily, plays a critical role in calcium homeostasis and bone metabolism. It is also involved in ce",58,Tox21,VDRA806,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",7421,NULL,BAH02291,Governmental Organizations,22551509,0,10.1289/ehp.1104709,NULL,BAH02291,NULL
743239,3,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,"U.S. Tox21 Program_|__|_National Center for Advancing Translational Sciences [NCATS]_|_NIH Chemical Genomics Center [NCGC]_|_U.S. Environmental Protection Agency [EPA]_|_National Institutes of Environmental Health Sciences [NIEHS]_|_National Toxicology Program [NTP]_|_U.S. Food and Drug Administration [FDA]_|__|_Tox21 Assay Overview:_|__|_The farnesoid-X-receptor (FXR), a nuclear hormone receptor, is highly expressed in liver, intestine, kidney and adrenal cortex. Natural ligands of FXR are the bile acids (",58,Tox21,FXRA272,20140821,"4,6,11,13,33,34,51,66,72,79,107,135,174,176,177,178,179,180,190,196,204,227,240,241,243,244,247,261,262,263,264,289,299,300,307,308,311,323,325,326,335,338,342,356,370,379,385,398,403,447,454,460,464,525,527,541,546,564,568,588,594,597,612,650,660,671,674,679,681,700,701,702,712,713,727,743,750,753,757,774,785,791,795,798,802,803,807,811,863,864,867,875,887,892,896,904,931,936,938,949,957,967,970,971,978,980,985,991,992,995,996,997,998,999,1004,1017,1018,1030,1031,1046,1049,1050,1054,1057,1060,1066,1080,109","144205501,144206117,144206325,144206326,144206328,144206329,144206330,144206333,144206369,144206371,144206375,144206376,144206379,144206380,144206382,144206383,144206384,144206385,144206386,144206389,144206390,144206392,144206393,144206395,144206396,144206397,144206398,144206399,144206400,144206401,144206403,144206405,144206411,144206412,144206414,144206415,144206418,144206419,144206420,144206423,144206425,144206427,144206428,144206430,144206431,144206432,144206433,144206434,144206435,144206437,144206438,14",9971,NULL,ADZ17382,Governmental Organizations,22551509,0,10.1289/ehp.1104709,NULL,ADZ17382,NULL
743021,2,PAX8: non-specific cytotoxicity Measured in Cell-Based System Using Plate Reader - 7054-05_Inhibitor_Dose_DryPowder_Activity,"Keywords: ovarian cancer, Pax8, luciferase, CellTiterGlo, RMG-1 cells, cytotoxicity_|__|_Assay Overview:_|_A cellular assay that measures Pax8 activity using a Luciferase-based reporter of a well characterized PAX8 transcriptional target, thyroperoxidase (TPO), was used in the primary assay. That assay scores a compound as active when there is a decrease in luciferase signal. This assay measures cell viability via the surrogate measurement of cellular ATP.  It is known from knockdown studies that reduced le",31,Broad Institute,7054-05_Inhibitor_Dose_DryPowder_Activity,20140205,"1795,2020,2361,2363,2833,2942,3598,3728,3800,3832,3879,4491,4882,5043,5100,5153,5303,5311,6167,6185,10607,15478,20345,29893,31316,40586,52884,60699,62770,72402,72810,72813,73427,81403,91467,93572,99844,99927,100037,100064,100158,101486,107346,114961,122815,131182,138252,151582,161167,176158,182785,200953,203396,217907,220401,233874,234636,236584,240739,242436,253602,256331,256646,257278,266923,274159,276294,276685,279596,280101,280899,282415,282594,282598,289018,289100,290355,295538,299645,300567,303610,310","844866,849093,851517,855609,858166,861918,864737,4241190,4242957,4252027,7970050,7970999,7977862,11533017,14719120,14720977,14721813,14727378,14727617,14729694,14731075,14731796,14732218,14733191,14733294,14734720,14735928,14736914,14737460,14739792,14745672,16953511,17387062,17387367,17401429,17402854,17403358,17407962,17410182,17410361,17411973,17412676,17415149,17431463,17431966,17432349,17432511,17432587,17432668,17432774,17432820,17432833,17432999,17433401,17433499,17433561,17503730,17503836,17504222,1",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,21746896,0,10.1073/pnas.1109363108,NULL,NULL,NULL
743032,1,Luminescence-based cell-based high throughput confirmation assay to identify agonists of the DAF-12 from the parasite H. contortus (hcDAF-12),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: David Mangelsdorf, UT Southwestern_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: U19 DK062434_|_Grant Proposal PI: David Mangelsdorf, UT Southwestern_|_External Assay ID: HCDAF12_ACT_LUMI_1536_3X%ACT CRUN_|__|_Name: Luminescence-based cell-based high throughput confirmation assay to identify agoni",5,The Scripps Research Institute Molecular Screening Center,HCDAF12_ACT_LUMI_1536_3X%ACT CRUN,20131108,"2048,2361,3820,5311,5934,6035,6731,6772,6842,7087,8341,8366,8562,8615,9181,13977,14161,14358,15799,18311,21477,24239,24674,28561,28914,32875,33334,36851,37560,39164,42725,65752,65758,66532,67476,70840,72512,72835,77215,77793,79416,80123,80946,81124,85307,95301,95745,95753,95754,95915,96102,96737,96845,98136,98589,100239,100434,100596,107537,128355,134450,137292,139887,147157,150655,158632,162928,201136,219325,220147,220319,220696,222169,223034,223396,225534,226774,230513,232851,234249,234605,236968,237061,2","842268,842291,842317,842387,842443,842516,842578,842584,842657,842782,842811,843864,844101,844138,844221,844348,844372,844714,845346,845880,846063,846149,846550,846839,846898,846996,847089,847098,847307,847491,848033,848097,848261,848269,848360,848719,848738,849115,849434,849826,850312,850336,850349,850358,850439,850546,850673,851040,851113,851320,851331,851723,852113,852925,853383,853726,856033,856103,856285,856813,856987,857665,857817,857840,857901,857961,857983,858006,858153,858216,858230,858546,858603,8",181263,Cell-based,NP_001024547,NIH Initiatives,"10859169,14527330,15084461,16051528,16529801,16709466,17163670,19497877,4366476",0,10.1016/j.arr.2005.03.006|10.1016/j.cell.2006.01.037|10.1016/j.pt.2006.05.004|10.1021/cb600173t|10.1073/pnas.0904064106|10.1146/annurev.phyto.41.052102.104023|10.1242/dev.01068,NULL,G5EFF5,NULL
743027,1,Counterscreen for agonists of the DAF-12 from the parasite H.contortus (hcDAF-12): Luminescence-based cell-based screening assay to identify agonists of the Liver-X-Receptor (LXR).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Affiliation: The Scripps Research Institute, TSRI_|_Assay Provider: David Mangelsdorf, UT Southwestern_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: U19 DK062434_|_Grant Proposal PI: David Mangelsdorf, UT Southwestern_|_External Assay ID: LXR_ACT_LUMI_1536_3X%ACT for hcDAF-12 AG_|__|_Name: Counterscreen for agonists of the daf-12 abnormal Dauer Formation: Luminesc",5,The Scripps Research Institute Molecular Screening Center,LXR_ACT_LUMI_1536_3X%ACT for hcDAF-12 AG,20131108,"2048,2361,3820,5311,5934,6035,6731,6772,6842,7087,8341,8366,8562,8615,9181,13977,14161,14358,15799,18311,21477,24239,24674,28561,28914,32875,33334,36851,37560,39164,42725,65752,65758,66532,67476,70840,72512,72835,77215,77793,79416,80123,80946,81124,85307,95301,95745,95753,95754,95915,96102,96737,96845,98136,98589,100239,100434,100596,107537,128355,134450,137292,139887,147157,150655,158632,162928,201136,219325,220147,220319,220696,222169,223034,223396,225534,226774,230513,232851,234249,234605,236968,237061,2","842268,842291,842317,842387,842443,842516,842578,842584,842657,842782,842811,843864,844101,844138,844221,844348,844372,844714,845346,845880,846063,846149,846550,846839,846898,846996,847089,847098,847307,847491,848033,848097,848261,848269,848360,848719,848738,849115,849434,849826,850312,850336,850349,850358,850439,850546,850673,851040,851113,851320,851331,851723,852113,852925,853383,853726,856033,856103,856285,856813,856987,857665,857817,857840,857901,857961,857983,858006,858153,858216,858230,858546,858603,8",7376,Cell-based,NP_009052,NIH Initiatives,"10859169,14527330,15084461,16051528,16529801,16709466,17163670,19497877,4366476",0,10.1016/j.arr.2005.03.006|10.1016/j.cell.2006.01.037|10.1016/j.pt.2006.05.004|10.1021/cb600173t|10.1073/pnas.0904064106|10.1146/annurev.phyto.41.052102.104023|10.1242/dev.01068,NULL,P55055,NULL
743261,1,Fluorescence-based biochemical high throughput confirmation assay to identify inhibitors of phospholipase C isozymes (PLC-B3),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute_|_Assay Provider: Qisheng Zhang, University of North Carolina at Chapel Hill_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R01GM098894_|_Grant Proposal PI: Qisheng Zhang, University of North Carolina at Chapel Hill_|_External Assay ID: PLCB3_INH_QFRET_1536_3X%INH CRUN_|__|_Name: Fluorescence-based biochemical hi",5,The Scripps Research Institute Molecular Screening Center,PLCB3_INH_QFRET_1536_3X%INH CRUN,20140320,"1651,2762,2833,3640,4021,4421,4770,5404,5831,6000,6108,6763,11693,21396,21810,26106,26120,27647,28912,46428,52885,56209,60877,60934,65327,69448,70349,72810,73249,75583,83055,83213,87533,92199,92387,96256,96307,97167,97509,97857,98642,98778,99844,100089,158550,163121,186169,189710,219862,221159,222169,222680,223673,224388,224497,224621,224703,224936,227775,231841,234636,235729,236386,238759,239462,239491,240350,240739,241137,242429,245150,247157,254021,254471,254984,256039,256561,256617,257522,260992,261765,","842317,842341,842612,842721,842785,842933,843166,843287,843329,843505,843543,843652,843677,843682,843699,844245,844273,844283,844504,844811,845049,845050,845093,845222,845470,845483,845515,845549,845847,846079,846222,846270,846374,846673,846779,846782,846792,847416,847479,847506,847595,847637,847676,848072,848133,848514,848665,849027,849088,849419,849509,849537,849558,849594,849833,849853,850075,850080,850176,850317,850368,850452,850520,850573,850791,850825,850854,851007,851063,851077,851081,851115,851199,8",5331,Biochemical,AAI42682,NIH Initiatives,"15684042,16402909,17086182,17130835,17403917,17429106,18493969,19074886,1963096,20179606,20426766,20590620,20833646,21266572,2147038,21550986,7763279,8396627,8738291",0,10.1002/hipo.20443|10.1007/bf00167177|10.1016/0006-2952(95)00050-a|10.1038/ng1918|10.1038/sj.onc.1210115|10.1074/jbc.m110.191783|10.1074/jbc.m111.231993|10.1093/brain/awq238|10.1093/carcin/bgm078|10.1095/biolreprod43.4.704|10.1097/fjc.0b013e3181d8bec5|10.1111/j.1476-5381.2010.00795.x|10.1124/dmd.106.014498|10.1124/mol.105.011007|10.1146/annurev.pharmtox.46.120604.141223|10.1158/0008-5472.can-08-1181|10.2174/138945010791591331,NULL,Q01970,NULL
743051,1,Counterscreen for agonists of the daf-12 abnormal Dauer Formation: Luminescence-based cell-based screening assay to identify agonists of the Liver-X-Receptor (LXR),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: UT Southwestern_|_Assay Provider: David Mangelsdorf, UT Southwestern_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: U19 DK062434_|_Grant Proposal Pi: David Mangelsdorf, UT Southwestern_|_External Assay ID: LXR_ACT_LUMI_1536_3X%ACT CSRUN_|__|_Name: Counterscreen for agonists of the daf-12 abnormal Dauer Formation: Luminescence-based cell-based screening assay to",5,The Scripps Research Institute Molecular Screening Center,LXR_ACT_LUMI_1536_3X%ACT CSRUN,20131112,"2048,3608,3687,4309,4409,5311,6702,7340,8341,8615,8691,9181,12856,20085,33334,34920,36851,37560,39164,39508,42725,65752,66532,66721,68497,70052,71545,72279,72835,72838,73101,76075,76105,77793,88881,90600,93107,94408,94832,95301,95472,95707,95754,96102,96103,96854,96943,98778,99178,100239,101259,110635,136419,137292,147157,170221,182638,201136,216328,219760,219761,220319,220696,221714,222927,223220,224802,225534,226548,228624,229323,230513,231739,233068,234005,234605,234714,236184,236188,236425,236968,237071","842180,842267,842268,842332,842387,842443,842578,842858,843431,844138,844246,844372,845144,845517,845582,846040,846615,846637,846767,846839,846926,847222,847328,847491,847547,847888,848139,848261,848399,848719,848927,849148,849826,849836,849959,849961,850015,850191,850312,850358,850491,850803,851331,851723,851759,851992,852113,852169,852263,852820,853252,853383,853615,853726,855738,856033,856274,856587,856604,856615,856954,857045,857583,857865,858153,858166,858189,858520,859672,859766,859946,860128,860337,8",7376,Cell-based,NP_009052,NIH Initiatives,"10859169,14527330,15084461,16051528,16529801,16709466,17163670,19497877,4366476",0,10.1016/j.arr.2005.03.006|10.1016/j.cell.2006.01.037|10.1016/j.pt.2006.05.004|10.1021/cb600173t|10.1073/pnas.0904064106|10.1146/annurev.phyto.41.052102.104023|10.1242/dev.01068,NULL,P55055,NULL
743258,1,Counterscreen for inhibitors of phospholipase C isozymes (PLC-B3): Fluorescence-based biochemical high throughput assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1),"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: The Scripps Research Institute_|_Assay Provider: Qisheng Zhang, University of North Carolina at Chapel Hill_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: R01GM098894_|_Grant Proposal PI: Qisheng Zhang, University of North Carolina at Chapel Hill_|_External Assay ID: PLCG1_INH_QFRET_1536_3X%INH CSRUN for PLCB3 INH_|__|_Name: Counterscreen for ",5,The Scripps Research Institute Molecular Screening Center,PLCG1_INH_QFRET_1536_3X%INH CSRUN for PLCB3 INH,20140128,"1651,2762,2833,3640,4021,4421,4770,5404,5831,6000,6108,6763,11693,21396,21810,26106,26120,27647,28912,46428,52885,56209,60877,60934,65327,69448,70349,72810,73249,75583,83055,83213,87533,92199,92387,96256,96307,97167,97509,97857,98642,98778,99844,100089,158550,163121,186169,189710,219862,221159,222169,222680,223673,224388,224497,224621,224703,224936,227775,231841,234636,235729,236386,238759,239462,239491,240350,240739,241137,242429,245150,247157,254021,254471,254984,256039,256561,256617,257522,260992,261765,","842317,842341,842612,842721,842785,842933,843166,843287,843329,843505,843543,843652,843677,843682,843699,844245,844273,844283,844504,844811,845049,845050,845093,845222,845470,845483,845515,845549,845847,846079,846222,846270,846374,846673,846779,846782,846792,847416,847479,847506,847595,847637,847676,848072,848133,848514,848665,849027,849088,849419,849509,849537,849558,849594,849833,849853,850075,850080,850176,850317,850368,850452,850520,850573,850791,850825,850854,851007,851063,851077,851081,851115,851199,8",5335,Biochemical,AAI36467,NIH Initiatives,"15684042,16402909,17086182,17130835,17403917,17429106,18493969,19074886,1963096,20179606,20426766,20590620,20833646,21266572,2147038,21550986,7763279,8396627,8738291",0,10.1002/hipo.20443|10.1007/bf00167177|10.1016/0006-2952(95)00050-a|10.1038/ng1918|10.1038/sj.onc.1210115|10.1074/jbc.m110.191783|10.1074/jbc.m111.231993|10.1093/brain/awq238|10.1093/carcin/bgm078|10.1095/biolreprod43.4.704|10.1097/fjc.0b013e3181d8bec5|10.1111/j.1476-5381.2010.00795.x|10.1124/dmd.106.014498|10.1124/mol.105.011007|10.1146/annurev.pharmtox.46.120604.141223|10.1158/0008-5472.can-08-1181|10.2174/138945010791591331,NULL,AAI36467,NULL
743050,1,Luminescence-based cell-based high throughput confirmation assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center_|_Affiliation: UT Southwestern_|_Assay Provider: David Mangelsdorf, UT Southwestern_|_Network: Molecular Library Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: U19 DK062434_|_Grant Proposal Pi: David Mangelsdorf, UT Southwestern_|_External Assay ID: HGDAF12_ACT_LUMI_1536_3X%ACT CRUN_|__|_Name: Luminescence-based cell-based high throughput confirmation assay to identify agonists of the DAF-12 from the par",5,The Scripps Research Institute Molecular Screening Center,HGDAF12_ACT_LUMI_1536_3X%ACT CRUN,20131112,"2048,3608,3687,4309,4409,5311,6702,7340,8341,8615,8691,9181,12856,20085,33334,34920,36851,37560,39164,39508,42725,65752,66532,66721,68497,70052,71545,72279,72835,72838,73101,76075,76105,77793,88881,90600,93107,94408,94832,95301,95472,95707,95754,96102,96103,96854,96943,98778,99178,100239,101259,110635,136419,137292,147157,170221,182638,201136,216328,219760,219761,220319,220696,221714,222927,223220,224802,225534,226548,228624,229323,230513,231739,233068,234005,234605,234714,236184,236188,236425,236968,237071","842180,842267,842268,842332,842387,842443,842578,842858,843431,844138,844246,844372,845144,845517,845582,846040,846615,846637,846767,846839,846926,847222,847328,847491,847547,847888,848139,848261,848399,848719,848927,849148,849826,849836,849959,849961,850015,850191,850312,850358,850491,850803,851331,851723,851759,851992,852113,852169,852263,852820,853252,853383,853615,853726,855738,856033,856274,856587,856604,856615,856954,857045,857583,857865,858153,858166,858189,858520,859672,859766,859946,860128,860337,8",181263,Cell-based,NP_001024547,NIH Initiatives,"10859169,14527330,15084461,16051528,16529801,16709466,17163670,19497877,4366476",0,10.1016/j.arr.2005.03.006|10.1016/j.cell.2006.01.037|10.1016/j.pt.2006.05.004|10.1021/cb600173t|10.1073/pnas.0904064106|10.1146/annurev.phyto.41.052102.104023|10.1242/dev.01068,NULL,G5EFF5,NULL
743417,2,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_Dose_DryPowder_Activity_Set2,"Keywords:  osteoporosis, Schnurri-3, kappa recognition component_|__|_Assay Overview:_|__|_This is a novel physiologically relevant cell-based approach to identify inhibitors of Schnurri-3 (Shn3), a potent and essential regulator of adult bone formation._|__|_This screen will identify specific compounds that target the 3'UTR of Shn3 to post-transcriptionally regulate its mRNA to reduce Shn3 protein levels. This assay uses a SV40 large T antigen-transformed osteoblast cell line (Clone20-Shn3FFL) that maintai",31,Broad Institute,2134-01_Inhibitor_Dose_DryPowder_Activity_Set2,20140410,"1400,2199,2247,3197,4477,5396,5404,5405,5745,6084,6197,6769,12498,14169,23205,31316,33144,52167,53232,62882,67059,71821,72438,77865,81400,89341,91378,91467,91754,98652,100475,107346,130606,148673,148870,156816,176406,179617,203396,225126,226441,226752,233768,234636,235262,236584,240061,240350,243093,245742,246952,253602,254984,255329,255762,260976,263434,268239,268760,268762,268975,270378,270787,271216,272334,272378,272529,272568,275903,288760,298116,299645,310900,310951,315406,327044,328132,328138,328144,3","842204,842762,843298,844482,844525,844737,845300,847146,847393,847836,848536,851085,851321,852129,852303,852388,852701,852911,855514,855836,856091,856196,856251,856521,856525,856536,857195,857372,857621,857655,857671,857885,858068,858151,858220,858389,858611,858889,859630,859637,860183,861001,861006,861817,862514,862638,863149,863423,863619,863659,864658,864787,865957,3711304,3711988,3712502,3712888,3713133,3713760,3714089,3714469,3714582,3714634,3715971,3716076,3716675,3716687,3716773,3717335,3717519,42404",NULL,Cell-based,NULL,NIH Initiatives,NULL,0,NULL,NULL,NULL,NULL
743256,1,Counterscreen for exosite inhibitors of ADAM17: Fluorescence resonance energy transfer (FRET)-based biochemical high throughput screening assay to identify inhibitors of ADAM10,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: Torrey Pines Institute for Molecular Sciences (TPIMS)_|_Assay Provider: Dmitriy Minond, Torrey Pines Institute for Molecular Sciences (TPIMS)_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA033985-01_|_Grant Proposal PI: Dmitriy Minond, Torrey Pines Institute for Molecular Sciences (TPIMS)_|_External Assay ID: ADAM10_INH_QFRET_1536_3X%I",5,The Scripps Research Institute Molecular Screening Center,ADAM10_INH_QFRET_1536_3X%INH CSRUN for ADAM17 INH,20140117,"2020,3800,4871,5482,8425,15284,16623,68995,70799,73057,73677,74181,95099,95168,96256,97124,97509,98136,119031,124052,131673,167666,199161,211017,222490,224144,224183,224388,228946,230045,230221,230444,232682,235740,236330,236534,237046,239491,242048,242474,245556,248413,251739,251922,252028,254471,256561,259513,261765,263564,267726,276216,283102,289413,290626,293175,297153,297427,298620,313606,315872,327073,330513,342576,345002,363396,381388,388993,393650,406563,406791,443958,447912,480767,519685,585895,589","842317,842868,843731,843886,844515,845255,846627,847554,847836,848499,849049,849327,849389,849398,849501,849677,850097,850569,850578,850590,850777,851187,852277,852285,852397,852514,853654,856533,857270,857486,857690,858484,858687,858818,858905,858966,859101,859198,859287,859571,859872,860254,860346,860736,860804,860867,861237,862481,862816,862865,862893,863229,863431,863731,864069,864172,864302,864420,864511,864900,865129,865498,865967,3711210,3711246,3711317,3712168,3712412,3712554,3712996,3713202,3714375",102,Biochemical,AAC51766,NIH Initiatives,"15688065,16627988,20136654,20184396,20197081,20459566,20549373,20849079,21175594,21203579,21236490,21752713,21906355",0,10.1007/s00508-010-1373-6|10.1016/j.bbcan.2010.02.002|10.1016/j.it.2011.05.005|10.1016/j.molimm.2010.12.005|10.1021/pr100556z|10.1038/nrm1548|10.1111/j.1365-2249.2010.04298.x|10.1111/j.1365-2559.2010.03494.x|10.1111/j.1742-4658.2010.07566.x|10.1186/1559-0275-8-9|10.1371/journal.pbio.1000563|10.3109/10409231003628015|10.4161/cbt.5.6.2707,NULL,O14672,NULL
743286,2,qHTS for Inhibitors of PI5P4K: Confirmation in Primary Assay,"Phosphatidylinositol (PI) signaling has been shown to impact a large and diverse set of cellular processes including proliferation, survival, and growth; their dysregulation is common in cancer and other diseases. Recently, PI5P has been shown to regulate the tumor suppressor ING2. In addition to finding PI5P, we discovered the type II phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) family (alpha, beta, gamma isoforms) that catalyze the conversion of PI5P to PI(4,5)P2. Alternatively, PI(4,5)P2 can also b",2,National Center for Advancing Translational Sciences (NCATS),pi5p4k-f10-cherrypick-dpi,20140219,"1330,3698,3883,54900,62413,67062,67065,73024,79394,79493,80946,165348,176406,202918,235598,246783,248874,254824,264524,269257,279801,285479,293820,302853,327591,328138,334410,336746,399616,399618,436659,542822,555682,564213,566975,616832,619328,619526,641184,644215,645041,645252,646272,647655,647948,648581,649218,649585,649614,650604,651061,651960,652817,653996,654318,654359,654622,654636,654825,654955,655496,655908,655953,657862,658113,658227,658360,659580,659878,661093,661849,664552,664636,664696,665229,6","842767,842974,843966,845311,847187,847214,848175,849466,850302,851427,851725,851766,852213,852341,852849,853301,856503,856755,856869,857497,858235,858353,858569,859791,861273,863171,863306,863382,863444,863974,864518,865081,865482,865589,865860,3711485,3711555,3711813,3711921,3711936,3712176,3712386,3712399,3712622,3712945,3713064,3713572,3714094,3714926,3715073,3715091,3715229,3715273,3716545,3716652,3717747,3717855,3717951,4240696,4240909,4245411,4246988,4248518,4249564,4250152,4250961,4251803,4252082,425",5305,NULL,P48426,Governmental Organizations|NIH Initiatives,NULL,0,NULL,2.7.1.149,P48426,NULL
743257,1,QFRET-based biochemical high throughput confirmation assay to identify exosite inhibitors of ADAM17,"Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)_|_Center Affiliation: Torrey Pines Institute for Molecular Sciences (TPIMS)_|_Assay Provider: Dmitriy Minond, Torrey Pines Institute for Molecular Sciences (TPIMS)_|_Network: Molecular Libraries Probe Production Centers Network (MLPCN)_|_Grant Proposal Number: 1 R03 DA033985-01_|_Grant Proposal PI: Dmitriy Minond, Torrey Pines Institute for Molecular Sciences (TPIMS)_|_External Assay ID: ADAM17_INH_QFRET_1536_3X%I",5,The Scripps Research Institute Molecular Screening Center,ADAM17_INH_QFRET_1536_3X%INH CRUN,20140117,"2020,3800,4871,5482,8425,15284,16623,68995,70799,73057,73677,74181,95099,95168,96256,97124,97509,98136,119031,124052,131673,167666,199161,211017,222490,224144,224183,224388,228946,230045,230221,230444,232682,235740,236330,236534,237046,239491,242048,242474,245556,248413,251739,251922,252028,254471,256561,259513,261765,263564,267726,276216,283102,289413,290626,293175,297153,297427,298620,313606,315872,327073,330513,342576,345002,363396,381388,388993,393650,406563,406791,443958,447912,480767,519685,585895,589","842317,842868,843731,843886,844515,845255,846627,847554,847836,848499,849049,849327,849389,849398,849501,849677,850097,850569,850578,850590,850777,851187,852277,852285,852397,852514,853654,856533,857270,857486,857690,858484,858687,858818,858905,858966,859101,859198,859287,859571,859872,860254,860346,860736,860804,860867,861237,862481,862816,862865,862893,863229,863431,863731,864069,864172,864302,864420,864511,864900,865129,865498,865967,3711210,3711246,3711317,3712168,3712412,3712554,3712996,3713202,3714375",6868,Biochemical,NP_003174,NIH Initiatives,"15688065,16627988,20136654,20184396,20197081,20459566,20549373,20849079,21175594,21203579,21236490,21752713,21906355",0,10.1007/s00508-010-1373-6|10.1016/j.bbcan.2010.02.002|10.1016/j.it.2011.05.005|10.1016/j.molimm.2010.12.005|10.1021/pr100556z|10.1038/nrm1548|10.1111/j.1365-2249.2010.04298.x|10.1111/j.1365-2559.2010.03494.x|10.1111/j.1742-4658.2010.07566.x|10.1186/1559-0275-8-9|10.1371/journal.pbio.1000563|10.3109/10409231003628015|10.4161/cbt.5.6.2707,3.4.24.86,P78536,NULL
743262,2,qHTS of GLP-1 Receptor Agonists: Hit Validation,"The overall goal of this project was to develop a novel assay for discovering small molecule ligands for class B1 G protein-coupled receptors (GPCRs). Very few agonists (or inverse agonists) with generally weak activity for this entire group of physiologically important receptors are known to date. To establish proof-of-principle that this critical bottleneck can be overcome with a suitable screening approach, our studies focused on the class B1 receptor for glucagon-like peptide-1 (GLP-1R), a potential the",2,National Center for Advancing Translational Sciences (NCATS),glp1r-agonist-f1-cherrypick,20140122,"938,2082,2083,2337,2755,3016,3108,3333,3394,3671,4041,5319,5502,5723,5816,5957,6084,6825,7902,8395,10635,10680,10781,11310,11767,12035,13450,22860,31244,32995,33741,36755,38370,47936,54765,55483,56801,66359,68363,68647,69503,71486,71616,71986,72344,78537,79858,90473,101430,122077,123606,150311,193949,219862,220996,222757,223613,223733,226756,227464,231442,234265,237046,237624,239745,240893,241406,241897,241901,245525,246230,246231,251365,279644,286701,317451,317587,322406,325003,347328,429249,440990,534612,","842249,842792,842914,843146,843215,843275,844105,844316,844590,844909,845777,846313,846612,846917,847362,847531,848183,848424,848460,848666,848985,849007,849019,849685,849950,850063,850182,850589,850897,850898,851560,851885,851930,852024,852731,852972,852979,853672,855720,856255,856324,856426,856704,856803,856849,856880,856885,856998,857187,857374,857565,857645,857694,857715,857783,858369,858443,858451,858684,858978,859148,859305,859331,859501,859687,859793,860068,860136,860353,860609,860679,860742,860821,8",2740,NULL,AAB64013,Governmental Organizations|NIH Initiatives,NULL,0,NULL,NULL,AAB64013,NULL
743044,2,SA9-PAX8: cytotoxicity NIHOVCAR3 Measured in Cell-Based System Using Plate Reader - 7054-11_Inhibitor_Dose_DryPowder_Activity,"Keywords: ovarian cancer, Pax8, luciferase, CellTiterGlo, NIHOVCAR3 cells, cytotoxicity_|__|_Assay Overview:_|_A cellular assay that measures Pax8 activity using a Luciferase-based reporter of a well characterized PAX8 transcriptional target, thyroperoxidase (TPO), was used in the primary assay. That assay scores a compound as active when there is a decrease in luciferase signal. This assay measures cell viability via the surrogate measurement of cellular ATP.  It is known from knockdown studies that reduce",31,Broad Institute,7054-11_Inhibitor_Dose_DryPowder_Activity,20140205,"161167,220401,289100,759347,764129,1004945,1101639,1371654,1390454,1602833,2003702,2141470,2183861,2275330,2294766,2313776,2439490,2526122,2848041,2871851,3129244,3129248,3146306,3163459,3245634,3746921,3840152,4905301,4974547,5062711,5080792,5350189,5738109,6184113,6227479,6236643,6351925,6458680,6710578,7202555,7208394,7208865,8195301,8259799,8271986,8272034,9116001,9550406,9551034,9552079,12006187,15944722,16028005,16193502,16314235,16338356,16446988,16453200,16808745,16808764,20920611,20959061,20959105,","85790285,85792258,85792388,85793280,85793335,85793432,85793709,85793938,85794270,85794589,85795144,85795175,85795185,85795421,85797502,85797536,85797649,85797706,85797915,85798007,85798077,85798450,85798985,85798995,85799028,85799282,85799724,85799757,85800281,85800391,85800397,85800737,85800812,85801349,85801925,85802255,85802367,85802394,85802667,85802741,85803063,85803790,85803792,85803973,85804015,85804092,85804191,85804240,85804262,85804575,85804608,85804669,85804695,85804725,85804747,85804815,85805095",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,21746896,0,10.1073/pnas.1109363108,NULL,NULL,NULL
743205,2,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,"Glucokinase (GCK) is a glucose sensor in hepatocytes and pancreatic beta-cells.  Hepatic GCK is regulated by glucokinase regulatory protein (GKRP), which is predominantly localized to the liver.  GKRP binds to GCK inhibiting its activity in the fasting state while in the presence of glucose the GKRP is displaced.  There is an additional layer of regulation by fructose 1-phosphate and fructose 6-phosphate, which inhibit and enhance the GCK-GKRP interaction, respectively.  GCK plays a role in glucose homeosta",2,National Center for Advancing Translational Sciences (NCATS),GCK003,20131212,"119,138,178,199,237,247,249,275,286,289,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,1820","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616,90340617","2645,2646",NULL,"NP_000153,NP_001477",Governmental Organizations|NIH Initiatives,NULL,0,NULL,2.7.1.1,"P35557,Q14397",NULL
743207,2,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,"Glucokinase (GCK) is a glucose sensor in hepatocytes and pancreatic beta-cells.  Hepatic GCK is regulated by glucokinase regulatory protein (GKRP), which is predominantly localized to the liver.  GKRP binds to GCK inhibiting its activity in the fasting state while in the presence of glucose the GKRP is displaced.  There is an additional layer of regulation by fructose 1-phosphate and fructose 6-phosphate, which inhibit and enhance the GCK-GKRP interaction, respectively.  GCK plays a role in glucose homeosta",2,National Center for Advancing Translational Sciences (NCATS),GCK001,20131212,"119,138,178,199,237,247,249,275,286,289,401,444,462,471,535,546,547,564,650,681,774,785,787,838,896,903,951,1045,1046,1066,1102,1103,1123,1150,1207,1215,1216,1218,1219,1220,1221,1222,1225,1228,1229,1232,1233,1234,1237,1238,1240,1241,1242,1245,1256,1316,1317,1318,1329,1330,1337,1340,1342,1345,1346,1352,1354,1359,1365,1366,1367,1374,1390,1456,1474,1534,1551,1564,1574,1607,1609,1641,1645,1647,1649,1676,1678,1683,1694,1697,1701,1719,1720,1725,1727,1730,1734,1738,1742,1745,1774,1775,1779,1793,1794,1795,1809,1820","90340560,90340561,90340562,90340563,90340564,90340565,90340566,90340567,90340568,90340569,90340570,90340571,90340572,90340573,90340574,90340575,90340576,90340577,90340578,90340579,90340580,90340581,90340582,90340583,90340584,90340585,90340586,90340587,90340589,90340590,90340591,90340592,90340593,90340594,90340595,90340596,90340597,90340598,90340599,90340600,90340601,90340602,90340603,90340604,90340605,90340606,90340607,90340608,90340609,90340610,90340611,90340612,90340613,90340614,90340615,90340616,90340617","2645,2646",NULL,"NP_000153,NP_001477",Governmental Organizations|NIH Initiatives,NULL,0,NULL,2.7.1.1,"P35557,Q14397",NULL
743285,2,qHTS for Inhibitors of PI5P4K: ADP-Glo counter assay,"Phosphatidylinositol (PI) signaling has been shown to impact a large and diverse set of cellular processes including proliferation, survival, and growth; their dysregulation is common in cancer and other diseases. Recently, PI5P has been shown to regulate the tumor suppressor ING2. In addition to finding PI5P, we discovered the type II phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) family (alpha, beta, gamma isoforms) that catalyze the conversion of PI5P to PI(4,5)P2. Alternatively, PI(4,5)P2 can also b",2,National Center for Advancing Translational Sciences (NCATS),pi5p4k-counter-f11,20140226,"1330,3698,3883,54900,62413,67062,67065,73024,79394,79493,80946,165348,176406,202918,235598,246783,248874,254824,264524,269257,279801,285479,293820,302853,327591,328138,334410,336746,399616,399618,436659,542822,555682,564213,566975,616832,619328,619526,641184,644215,645041,645252,646272,647655,647948,648581,649218,649585,649614,650604,651061,651960,652817,653996,654318,654359,654622,654636,654825,654955,655496,655908,655953,657862,658113,658227,658360,659580,659878,661093,661849,664552,664636,664696,665229,6","842767,842974,843966,845311,847187,847214,848175,849466,850302,851427,851725,851766,852213,852341,852849,853301,856503,856755,856869,857497,858235,858353,858569,859791,861273,863171,863306,863382,863444,863974,864518,865081,865482,865589,865860,3711485,3711555,3711813,3711921,3711936,3712176,3712386,3712399,3712622,3712945,3713064,3713572,3714094,3714926,3715073,3715091,3715229,3715273,3716545,3716652,3717747,3717855,3717951,4240696,4240909,4245411,4246988,4248518,4249564,4250152,4250961,4251803,4252082,425",NULL,NULL,NULL,Governmental Organizations|NIH Initiatives,23326584,0,10.1371/journal.pone.0054127,NULL,NULL,NULL
743043,2,SA10 PAX8: cytotoxicity IGROV1 Measured in Cell-Based System Using Plate Reader - 7054-12_Inhibitor_Dose_DryPowder_Activity,"Keywords: ovarian cancer, Pax8, luciferase, CellTiterGlo, IGROV1 cells, cytotoxicity_|__|_Assay Overview:_|_A cellular assay that measures Pax8 activity using a Luciferase-based reporter of a well characterized PAX8 transcriptional target, thyroperoxidase (TPO), was used in the primary assay. That assay scores a compound as active when there is a decrease in luciferase signal. This assay measures cell viability via the surrogate measurement of cellular ATP.  It is known from knockdown studies that reduced l",31,Broad Institute,7054-12_Inhibitor_Dose_DryPowder_Activity,20140205,"161167,220401,289100,759347,764129,1004945,1101639,1371654,1390454,1602833,2003702,2141470,2183861,2275330,2294766,2313776,2439490,2526122,2848041,2871851,3129244,3129248,3146306,3163459,3245634,3746921,3840152,4905301,4974547,5062711,5080792,5350189,5738109,6184113,6227479,6236643,6351925,6458680,6710578,7202555,7208394,7208865,8195301,8259799,8271986,8272034,9116001,9550406,9551034,9552079,12006187,15944722,16028005,16193502,16314235,16338356,16446988,16453200,16808745,16808764,20920611,20959061,20959105,","85790285,85792258,85792388,85793280,85793335,85793432,85793709,85793938,85794270,85794589,85795144,85795175,85795185,85795421,85797502,85797536,85797649,85797706,85797915,85798007,85798077,85798450,85798985,85798995,85799028,85799282,85799724,85799757,85800281,85800391,85800397,85800737,85800812,85801349,85801925,85802255,85802367,85802394,85802667,85802741,85803063,85803790,85803792,85803973,85804015,85804092,85804191,85804240,85804262,85804575,85804608,85804669,85804695,85804725,85804747,85804815,85805095",NULL,"Cell-based,Toxicity",NULL,NIH Initiatives,21746896,0,10.1073/pnas.1109363108,NULL,NULL,NULL
